{"idB": "1316175_12_item1_p0_s0", "idA": "1316175_11_item1_p0_s0", "sentA": "Unless the context otherwise requires, we use the terms Anthera Pharmaceuticals, Anthera, we, us, the Company and our in this report to refer to Anthera Pharmaceuticals, Inc. and its sole subsidiary.", "sentB": "Unless the context otherwise requires, we use the terms \"Anthera Pharmaceuticals,\" \"Anthera,\" \"we,\" \"us,\" \"the Company\" and \"our\" in this report to refer to Anthera Pharmaceuticals, Inc. and its subsidiaries.", "type": 2, "words": ["<tag1>", "Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "Anthera", "Pharmaceuticals,", "Anthera,", "we,", "us,", "the", "Company", "and", "our", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "sole", "subsidiary.", "<tag2>", "Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "\"Anthera", "Pharmaceuticals,\"", "\"Anthera,\"", "\"we,\"", "\"us,\"", "\"the", "Company\"", "and", "\"our\"", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries.", "<tag3>"], "wordsA": ["Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "Anthera", "Pharmaceuticals,", "Anthera,", "we,", "us,", "the", "Company", "and", "our", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "sole", "subsidiary."], "wordsB": ["Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "\"Anthera", "Pharmaceuticals,\"", "\"Anthera,\"", "\"we,\"", "\"us,\"", "\"the", "Company\"", "and", "\"our\"", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p90_s2", "idA": "1316175_11_item1_p102_s0", "sentA": "Among all patients treated with varespladib, median sPLA 2 concentration decreased by 86.7% from baseline to week eight, as compared to 4.8% in the placebo group (p 0.0001).", "sentB": "At the end of the study sPLA 2 levels were reduced by 6.4% in the atorvastatin only arm and by 78.5% in the varespladib plus atorvastatin arm (p 0.0001).", "type": 2, "words": ["<tag1>", "Among", "all", "patients", "treated", "with", "varespladib,", "median", "sPLA", "2", "concentration", "decreased", "by", "86.7%", "from", "baseline", "to", "week", "eight,", "as", "compared", "to", "4.8%", "in", "the", "placebo", "group", "(p", "0.0001).", "<tag2>", "At", "the", "end", "of", "the", "study", "sPLA", "2", "levels", "were", "reduced", "by", "6.4%", "in", "the", "atorvastatin", "only", "arm", "and", "by", "78.5%", "in", "the", "varespladib", "plus", "atorvastatin", "arm", "(p", "0.0001).", "<tag3>"], "wordsA": ["Among", "all", "patients", "treated", "with", "varespladib,", "median", "sPLA", "2", "concentration", "decreased", "by", "86.7%", "from", "baseline", "to", "week", "eight,", "as", "compared", "to", "4.8%", "in", "the", "placebo", "group", "(p", "0.0001)."], "wordsB": ["At", "the", "end", "of", "the", "study", "sPLA", "2", "levels", "were", "reduced", "by", "6.4%", "in", "the", "atorvastatin", "only", "arm", "and", "by", "78.5%", "in", "the", "varespladib", "plus", "atorvastatin", "arm", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p90_s3", "idA": "1316175_11_item1_p102_s0", "sentA": "Among all patients treated with varespladib, median sPLA 2 concentration decreased by 86.7% from baseline to week eight, as compared to 4.8% in the placebo group (p 0.0001).", "sentB": "At the 16-week time-point in the FRANCIS clinical study sPLA2 levels were reduced by 12.1% in the atorvastatin only arm and by 62.0% in the varespladib plus atorvastatin arm (p 0.0001).", "type": 2, "words": ["<tag1>", "Among", "all", "patients", "treated", "with", "varespladib,", "median", "sPLA", "2", "concentration", "decreased", "by", "86.7%", "from", "baseline", "to", "week", "eight,", "as", "compared", "to", "4.8%", "in", "the", "placebo", "group", "(p", "0.0001).", "<tag2>", "At", "the", "16-week", "time-point", "in", "the", "FRANCIS", "clinical", "study", "sPLA2", "levels", "were", "reduced", "by", "12.1%", "in", "the", "atorvastatin", "only", "arm", "and", "by", "62.0%", "in", "the", "varespladib", "plus", "atorvastatin", "arm", "(p", "0.0001).", "<tag3>"], "wordsA": ["Among", "all", "patients", "treated", "with", "varespladib,", "median", "sPLA", "2", "concentration", "decreased", "by", "86.7%", "from", "baseline", "to", "week", "eight,", "as", "compared", "to", "4.8%", "in", "the", "placebo", "group", "(p", "0.0001)."], "wordsB": ["At", "the", "16-week", "time-point", "in", "the", "FRANCIS", "clinical", "study", "sPLA2", "levels", "were", "reduced", "by", "12.1%", "in", "the", "atorvastatin", "only", "arm", "and", "by", "62.0%", "in", "the", "varespladib", "plus", "atorvastatin", "arm", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p118_s0", "idA": "1316175_11_item1_p118_s0", "sentA": "Eli Lilly and Shionogi Co., Ltd. previously conducted a series of clinical studies evaluating varespladib and A-001 in various inflammatory conditions.", "sentB": "Eli Lilly and Shionogi Co., Ltd. previously conducted a series of clinical studies evaluating varespladib and varespladib sodium in various inflammatory conditions.", "type": 2, "words": ["<tag1>", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "previously", "conducted", "a", "series", "of", "clinical", "studies", "evaluating", "varespladib", "and", "A-001", "in", "various", "inflammatory", "conditions.", "<tag2>", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "previously", "conducted", "a", "series", "of", "clinical", "studies", "evaluating", "varespladib", "and", "varespladib", "sodium", "in", "various", "inflammatory", "conditions.", "<tag3>"], "wordsA": ["Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "previously", "conducted", "a", "series", "of", "clinical", "studies", "evaluating", "varespladib", "and", "A-001", "in", "various", "inflammatory", "conditions."], "wordsB": ["Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "previously", "conducted", "a", "series", "of", "clinical", "studies", "evaluating", "varespladib", "and", "varespladib", "sodium", "in", "various", "inflammatory", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p118_s1", "idA": "1316175_11_item1_p118_s1", "sentA": "In total, at least 17 Phase 1 and Phase 2 clinical studies evaluated varespladib and A-001 as a treatment in sepsis, rheumatoid arthritis, asthma and ulcerative colitis, an inflammatory bowel disease.", "sentB": "In total, at least 17 Phase 1 and Phase 2 clinical studies evaluated varespladib and varespladib sodium as a treatment in sepsis, rheumatoid arthritis, asthma and ulcerative colitis, an inflammatory bowel disease.", "type": 2, "words": ["<tag1>", "In", "total,", "at", "least", "17", "Phase", "1", "and", "Phase", "2", "clinical", "studies", "evaluated", "varespladib", "and", "A-001", "as", "a", "treatment", "in", "sepsis,", "rheumatoid", "arthritis,", "asthma", "and", "ulcerative", "colitis,", "an", "inflammatory", "bowel", "disease.", "<tag2>", "In", "total,", "at", "least", "17", "Phase", "1", "and", "Phase", "2", "clinical", "studies", "evaluated", "varespladib", "and", "varespladib", "sodium", "as", "a", "treatment", "in", "sepsis,", "rheumatoid", "arthritis,", "asthma", "and", "ulcerative", "colitis,", "an", "inflammatory", "bowel", "disease.", "<tag3>"], "wordsA": ["In", "total,", "at", "least", "17", "Phase", "1", "and", "Phase", "2", "clinical", "studies", "evaluated", "varespladib", "and", "A-001", "as", "a", "treatment", "in", "sepsis,", "rheumatoid", "arthritis,", "asthma", "and", "ulcerative", "colitis,", "an", "inflammatory", "bowel", "disease."], "wordsB": ["In", "total,", "at", "least", "17", "Phase", "1", "and", "Phase", "2", "clinical", "studies", "evaluated", "varespladib", "and", "varespladib", "sodium", "as", "a", "treatment", "in", "sepsis,", "rheumatoid", "arthritis,", "asthma", "and", "ulcerative", "colitis,", "an", "inflammatory", "bowel", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p118_s2", "idA": "1316175_11_item1_p118_s2", "sentA": "Results from these studies provide a large body of safety data for varespladib and A-001 with more than 1,000 healthy volunteers and subjects receiving treatment.", "sentB": "Results from these studies provide a large body of safety data for varespladib and varespladib sodium with more than 1,000 healthy volunteers and subjects receiving treatment.", "type": 2, "words": ["<tag1>", "Results", "from", "these", "studies", "provide", "a", "large", "body", "of", "safety", "data", "for", "varespladib", "and", "A-001", "with", "more", "than", "1,000", "healthy", "volunteers", "and", "subjects", "receiving", "treatment.", "<tag2>", "Results", "from", "these", "studies", "provide", "a", "large", "body", "of", "safety", "data", "for", "varespladib", "and", "varespladib", "sodium", "with", "more", "than", "1,000", "healthy", "volunteers", "and", "subjects", "receiving", "treatment.", "<tag3>"], "wordsA": ["Results", "from", "these", "studies", "provide", "a", "large", "body", "of", "safety", "data", "for", "varespladib", "and", "A-001", "with", "more", "than", "1,000", "healthy", "volunteers", "and", "subjects", "receiving", "treatment."], "wordsB": ["Results", "from", "these", "studies", "provide", "a", "large", "body", "of", "safety", "data", "for", "varespladib", "and", "varespladib", "sodium", "with", "more", "than", "1,000", "healthy", "volunteers", "and", "subjects", "receiving", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p11_s0", "idA": "1316175_11_item1_p11_s0", "sentA": "The American Heart Association defines acute coronary syndrome as any group of clinical symptoms related to acute myocardial ischemia, including unstable angina, or UA.", "sentB": "Our first product candidate, varespladib (an oral prodrug of varespladib sodium), is a broad-spectrum inhibitor of sPLA 2 enzymes, including type IIa, V and X. The American Heart Association defines acute coronary syndrome as any group of clinical symptoms related to acute myocardial ischemia, including unstable angina, or UA.", "type": 2, "words": ["<tag1>", "The", "American", "Heart", "Association", "defines", "acute", "coronary", "syndrome", "as", "any", "group", "of", "clinical", "symptoms", "related", "to", "acute", "myocardial", "ischemia,", "including", "unstable", "angina,", "or", "UA.", "<tag2>", "Our", "first", "product", "candidate,", "varespladib", "(an", "oral", "prodrug", "of", "varespladib", "sodium),", "is", "a", "broad-spectrum", "inhibitor", "of", "sPLA", "2", "enzymes,", "including", "type", "IIa,", "V", "and", "X.", "The", "American", "Heart", "Association", "defines", "acute", "coronary", "syndrome", "as", "any", "group", "of", "clinical", "symptoms", "related", "to", "acute", "myocardial", "ischemia,", "including", "unstable", "angina,", "or", "UA.", "<tag3>"], "wordsA": ["The", "American", "Heart", "Association", "defines", "acute", "coronary", "syndrome", "as", "any", "group", "of", "clinical", "symptoms", "related", "to", "acute", "myocardial", "ischemia,", "including", "unstable", "angina,", "or", "UA."], "wordsB": ["Our", "first", "product", "candidate,", "varespladib", "(an", "oral", "prodrug", "of", "varespladib", "sodium),", "is", "a", "broad-spectrum", "inhibitor", "of", "sPLA", "2", "enzymes,", "including", "type", "IIa,", "V", "and", "X.", "The", "American", "Heart", "Association", "defines", "acute", "coronary", "syndrome", "as", "any", "group", "of", "clinical", "symptoms", "related", "to", "acute", "myocardial", "ischemia,", "including", "unstable", "angina,", "or", "UA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p120_s0", "idA": "1316175_11_item1_p120_s0", "sentA": "Approximately 150 preclinical pharmacology and toxicology studies have been completed with varespladib and A-001, including two-year rat and mouse carcinogenicity studies, one-year primate study and three-month rat study in combination with Lipitor (atorvastatin).", "sentB": "Approximately 150 preclinical pharmacology and toxicology studies have been completed with varespladib and varespladib sodium, including two-year rat and mouse carcinogenicity studies, one-year primate study and three-month rat study in combination with Lipitor (atorvastatin).", "type": 2, "words": ["<tag1>", "Approximately", "150", "preclinical", "pharmacology", "and", "toxicology", "studies", "have", "been", "completed", "with", "varespladib", "and", "A-001,", "including", "two-year", "rat", "and", "mouse", "carcinogenicity", "studies,", "one-year", "primate", "study", "and", "three-month", "rat", "study", "in", "combination", "with", "Lipitor", "(atorvastatin).", "<tag2>", "Approximately", "150", "preclinical", "pharmacology", "and", "toxicology", "studies", "have", "been", "completed", "with", "varespladib", "and", "varespladib", "sodium,", "including", "two-year", "rat", "and", "mouse", "carcinogenicity", "studies,", "one-year", "primate", "study", "and", "three-month", "rat", "study", "in", "combination", "with", "Lipitor", "(atorvastatin).", "<tag3>"], "wordsA": ["Approximately", "150", "preclinical", "pharmacology", "and", "toxicology", "studies", "have", "been", "completed", "with", "varespladib", "and", "A-001,", "including", "two-year", "rat", "and", "mouse", "carcinogenicity", "studies,", "one-year", "primate", "study", "and", "three-month", "rat", "study", "in", "combination", "with", "Lipitor", "(atorvastatin)."], "wordsB": ["Approximately", "150", "preclinical", "pharmacology", "and", "toxicology", "studies", "have", "been", "completed", "with", "varespladib", "and", "varespladib", "sodium,", "including", "two-year", "rat", "and", "mouse", "carcinogenicity", "studies,", "one-year", "primate", "study", "and", "three-month", "rat", "study", "in", "combination", "with", "Lipitor", "(atorvastatin)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p121_s0", "idA": "1316175_11_item1_p121_s0", "sentA": "A-623 is a peptibody antagonist of the BAFF cytokine that is initially being developed as a treatment for lupus.", "sentB": "Blisibimod is a peptibody antagonist of the BAFF cytokine that is initially being developed as a treatment for lupus.", "type": 2, "words": ["<tag1>", "A-623", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus.", "<tag2>", "Blisibimod", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus.", "<tag3>"], "wordsA": ["A-623", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus."], "wordsB": ["Blisibimod", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p124_s0", "idA": "1316175_11_item1_p124_s0", "sentA": "Two randomized, dose-ranging, placebo-controlled Phase 1 clinical studies for A-623 in 104 lupus patients have already been completed.", "sentB": "Two randomized, dose-ranging, placebo-controlled Phase 1 clinical studies for blisibimod in 104 lupus patients have already been completed.", "type": 2, "words": ["<tag1>", "Two", "randomized,", "dose-ranging,", "placebo-controlled", "Phase", "1", "clinical", "studies", "for", "A-623", "in", "104", "lupus", "patients", "have", "already", "been", "completed.", "<tag2>", "Two", "randomized,", "dose-ranging,", "placebo-controlled", "Phase", "1", "clinical", "studies", "for", "blisibimod", "in", "104", "lupus", "patients", "have", "already", "been", "completed.", "<tag3>"], "wordsA": ["Two", "randomized,", "dose-ranging,", "placebo-controlled", "Phase", "1", "clinical", "studies", "for", "A-623", "in", "104", "lupus", "patients", "have", "already", "been", "completed."], "wordsB": ["Two", "randomized,", "dose-ranging,", "placebo-controlled", "Phase", "1", "clinical", "studies", "for", "blisibimod", "in", "104", "lupus", "patients", "have", "already", "been", "completed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p116_s2", "idA": "1316175_11_item1_p124_s1", "sentA": "Results from these studies demonstrated A-623 generated anti-BAFF activity and showed statistically significant reductions in B-cells of 50-70% (p 0.001) in lupus patients across multiple subcutaneous and intravenous formulations.", "sentB": "However, the results showed statistically significant reductions of sPLA 2 as early as 18 hours post-PCI procedure, which persisted throughout the five days of dosing (-93.0%, p 0.001).", "type": 2, "words": ["<tag1>", "Results", "from", "these", "studies", "demonstrated", "A-623", "generated", "anti-BAFF", "activity", "and", "showed", "statistically", "significant", "reductions", "in", "B-cells", "of", "50-70%", "(p", "0.001)", "in", "lupus", "patients", "across", "multiple", "subcutaneous", "and", "intravenous", "formulations.", "<tag2>", "However,", "the", "results", "showed", "statistically", "significant", "reductions", "of", "sPLA", "2", "as", "early", "as", "18", "hours", "post-PCI", "procedure,", "which", "persisted", "throughout", "the", "five", "days", "of", "dosing", "(-93.0%,", "p", "0.001).", "<tag3>"], "wordsA": ["Results", "from", "these", "studies", "demonstrated", "A-623", "generated", "anti-BAFF", "activity", "and", "showed", "statistically", "significant", "reductions", "in", "B-cells", "of", "50-70%", "(p", "0.001)", "in", "lupus", "patients", "across", "multiple", "subcutaneous", "and", "intravenous", "formulations."], "wordsB": ["However,", "the", "results", "showed", "statistically", "significant", "reductions", "of", "sPLA", "2", "as", "early", "as", "18", "hours", "post-PCI", "procedure,", "which", "persisted", "throughout", "the", "five", "days", "of", "dosing", "(-93.0%,", "p", "0.001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p124_s1", "idA": "1316175_11_item1_p124_s1", "sentA": "Results from these studies demonstrated A-623 generated anti-BAFF activity and showed statistically significant reductions in B-cells of 50-70% (p 0.001) in lupus patients across multiple subcutaneous and intravenous formulations.", "sentB": "Results from these studies demonstrated blisibimod generated anti-BAFF activity and showed statistically significant reductions in B-cells of 50-70% (p 0.001) in lupus patients across multiple subcutaneous and intravenous formulations.", "type": 2, "words": ["<tag1>", "Results", "from", "these", "studies", "demonstrated", "A-623", "generated", "anti-BAFF", "activity", "and", "showed", "statistically", "significant", "reductions", "in", "B-cells", "of", "50-70%", "(p", "0.001)", "in", "lupus", "patients", "across", "multiple", "subcutaneous", "and", "intravenous", "formulations.", "<tag2>", "Results", "from", "these", "studies", "demonstrated", "blisibimod", "generated", "anti-BAFF", "activity", "and", "showed", "statistically", "significant", "reductions", "in", "B-cells", "of", "50-70%", "(p", "0.001)", "in", "lupus", "patients", "across", "multiple", "subcutaneous", "and", "intravenous", "formulations.", "<tag3>"], "wordsA": ["Results", "from", "these", "studies", "demonstrated", "A-623", "generated", "anti-BAFF", "activity", "and", "showed", "statistically", "significant", "reductions", "in", "B-cells", "of", "50-70%", "(p", "0.001)", "in", "lupus", "patients", "across", "multiple", "subcutaneous", "and", "intravenous", "formulations."], "wordsB": ["Results", "from", "these", "studies", "demonstrated", "blisibimod", "generated", "anti-BAFF", "activity", "and", "showed", "statistically", "significant", "reductions", "in", "B-cells", "of", "50-70%", "(p", "0.001)", "in", "lupus", "patients", "across", "multiple", "subcutaneous", "and", "intravenous", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p125_s0", "idA": "1316175_11_item1_p125_s0", "sentA": "After successfully reactivating our Investigational New Drug Application, or IND, we initiated a Phase 2b clinical study with A-623 for the treatment of lupus in July 2010 called PEARL-SC.", "sentB": "In 2009, after successfully reactivating our Investigational New Drug Application, or IND, we initiated a Phase 2b clinical study with blisibimod for the treatment of lupus in July 2010 called PEARL-SC.", "type": 2, "words": ["<tag1>", "After", "successfully", "reactivating", "our", "Investigational", "New", "Drug", "Application,", "or", "IND,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "with", "A-623", "for", "the", "treatment", "of", "lupus", "in", "July", "2010", "called", "PEARL-SC.", "<tag2>", "In", "2009,", "after", "successfully", "reactivating", "our", "Investigational", "New", "Drug", "Application,", "or", "IND,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "for", "the", "treatment", "of", "lupus", "in", "July", "2010", "called", "PEARL-SC.", "<tag3>"], "wordsA": ["After", "successfully", "reactivating", "our", "Investigational", "New", "Drug", "Application,", "or", "IND,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "with", "A-623", "for", "the", "treatment", "of", "lupus", "in", "July", "2010", "called", "PEARL-SC."], "wordsB": ["In", "2009,", "after", "successfully", "reactivating", "our", "Investigational", "New", "Drug", "Application,", "or", "IND,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "for", "the", "treatment", "of", "lupus", "in", "July", "2010", "called", "PEARL-SC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p125_s2", "idA": "1316175_11_item1_p125_s1", "sentA": "We may also study A-623 in other B-cell mediated autoimmune diseases such as Sj gren s Syndrome or orphan indications such as myasthenia gravis and pemphigus.", "sentB": "We may also study blisibimod in other B-cell mediated autoimmune diseases such as vasculitis, Sj gren's Syndrome or orphan indications such as myasthenia gravis and pemphigus.", "type": 2, "words": ["<tag1>", "We", "may", "also", "study", "A-623", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "Sj", "gren", "s", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus.", "<tag2>", "We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus.", "<tag3>"], "wordsA": ["We", "may", "also", "study", "A-623", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "Sj", "gren", "s", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus."], "wordsB": ["We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p126_s0", "idA": "1316175_11_item1_p126_s0", "sentA": "We are actively pursuing a partnership with major pharmaceutical companies to develop and commercialize A-623.", "sentB": "We continue to actively pursue a partnership with major pharmaceutical companies to develop and commercialize blisibimod.", "type": 2, "words": ["<tag1>", "We", "are", "actively", "pursuing", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "A-623.", "<tag2>", "We", "continue", "to", "actively", "pursue", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "blisibimod.", "<tag3>"], "wordsA": ["We", "are", "actively", "pursuing", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "A-623."], "wordsB": ["We", "continue", "to", "actively", "pursue", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p127_s0", "idA": "1316175_11_item1_p127_s0", "sentA": "We intend to advance the development of our BAFF targeting molecule, A-623, a selective peptibody, to exploit its broad clinical utility in autoimmune diseases.", "sentB": "We intend to advance the development of our BAFF targeting molecule, blisibimod, a selective peptibody, to exploit its broad clinical utility in autoimmune diseases.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "advance", "the", "development", "of", "our", "BAFF", "targeting", "molecule,", "A-623,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "clinical", "utility", "in", "autoimmune", "diseases.", "<tag2>", "We", "intend", "to", "advance", "the", "development", "of", "our", "BAFF", "targeting", "molecule,", "blisibimod,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "clinical", "utility", "in", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["We", "intend", "to", "advance", "the", "development", "of", "our", "BAFF", "targeting", "molecule,", "A-623,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "clinical", "utility", "in", "autoimmune", "diseases."], "wordsB": ["We", "intend", "to", "advance", "the", "development", "of", "our", "BAFF", "targeting", "molecule,", "blisibimod,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "clinical", "utility", "in", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p127_s1", "idA": "1316175_11_item1_p127_s1", "sentA": "A-623, as a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture versus antibodies that are produced in mammalian cell culture.", "sentB": "Blisibimod, as a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture versus antibodies that are produced in mammalian cell culture.", "type": 2, "words": ["<tag1>", "A-623,", "as", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "versus", "antibodies", "that", "are", "produced", "in", "mammalian", "cell", "culture.", "<tag2>", "Blisibimod,", "as", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "versus", "antibodies", "that", "are", "produced", "in", "mammalian", "cell", "culture.", "<tag3>"], "wordsA": ["A-623,", "as", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "versus", "antibodies", "that", "are", "produced", "in", "mammalian", "cell", "culture."], "wordsB": ["Blisibimod,", "as", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "versus", "antibodies", "that", "are", "produced", "in", "mammalian", "cell", "culture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p127_s2", "idA": "1316175_11_item1_p127_s2", "sentA": "In addition, A-623 offers a number of potential differentiations over other anti-BAFF compounds, as well as other novel B-cell directed therapies, including:", "sentB": "In addition, blisibimod offers a number of potential differentiations over other anti-BAFF compounds, as well as other novel B-cell directed therapies, including:", "type": 2, "words": ["<tag1>", "In", "addition,", "A-623", "offers", "a", "number", "of", "potential", "differentiations", "over", "other", "anti-BAFF", "compounds,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies,", "including:", "<tag2>", "In", "addition,", "blisibimod", "offers", "a", "number", "of", "potential", "differentiations", "over", "other", "anti-BAFF", "compounds,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies,", "including:", "<tag3>"], "wordsA": ["In", "addition,", "A-623", "offers", "a", "number", "of", "potential", "differentiations", "over", "other", "anti-BAFF", "compounds,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies,", "including:"], "wordsB": ["In", "addition,", "blisibimod", "offers", "a", "number", "of", "potential", "differentiations", "over", "other", "anti-BAFF", "compounds,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p11_s1", "idA": "1316175_11_item1_p12_s0", "sentA": "Varespladib, when combined with Lipitor (atorvastatin), is one of only a few therapeutics in development with the potential to offer a unique and synergistic treatment approach targeting inflammation, elevated lipid levels and atherosclerosis as part of physician-directed standard of care.", "sentB": "Varespladib, when combined with Lipitor (atorvastatin), is one of only a few therapeutics in development with the potential to offer a unique and synergistic treatment approach targeting systemic inflammation, elevated lipid levels and the inflammatory path of atherosclerosis as part of physician-directed standard of care.", "type": 2, "words": ["<tag1>", "Varespladib,", "when", "combined", "with", "Lipitor", "(atorvastatin),", "is", "one", "of", "only", "a", "few", "therapeutics", "in", "development", "with", "the", "potential", "to", "offer", "a", "unique", "and", "synergistic", "treatment", "approach", "targeting", "inflammation,", "elevated", "lipid", "levels", "and", "atherosclerosis", "as", "part", "of", "physician-directed", "standard", "of", "care.", "<tag2>", "Varespladib,", "when", "combined", "with", "Lipitor", "(atorvastatin),", "is", "one", "of", "only", "a", "few", "therapeutics", "in", "development", "with", "the", "potential", "to", "offer", "a", "unique", "and", "synergistic", "treatment", "approach", "targeting", "systemic", "inflammation,", "elevated", "lipid", "levels", "and", "the", "inflammatory", "path", "of", "atherosclerosis", "as", "part", "of", "physician-directed", "standard", "of", "care.", "<tag3>"], "wordsA": ["Varespladib,", "when", "combined", "with", "Lipitor", "(atorvastatin),", "is", "one", "of", "only", "a", "few", "therapeutics", "in", "development", "with", "the", "potential", "to", "offer", "a", "unique", "and", "synergistic", "treatment", "approach", "targeting", "inflammation,", "elevated", "lipid", "levels", "and", "atherosclerosis", "as", "part", "of", "physician-directed", "standard", "of", "care."], "wordsB": ["Varespladib,", "when", "combined", "with", "Lipitor", "(atorvastatin),", "is", "one", "of", "only", "a", "few", "therapeutics", "in", "development", "with", "the", "potential", "to", "offer", "a", "unique", "and", "synergistic", "treatment", "approach", "targeting", "systemic", "inflammation,", "elevated", "lipid", "levels", "and", "the", "inflammatory", "path", "of", "atherosclerosis", "as", "part", "of", "physician-directed", "standard", "of", "care."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p17_s1", "idA": "1316175_11_item1_p131_s0", "sentA": "Patients with active lupus may have a broad range of symptoms related to the inflammation.", "sentB": "Results from a standard mouse model of edema demonstrated that topically administered varespladib was equivalent to the marketed immunosuppressant Elidel in resolving inflammation.", "type": 2, "words": ["<tag1>", "Patients", "with", "active", "lupus", "may", "have", "a", "broad", "range", "of", "symptoms", "related", "to", "the", "inflammation.", "<tag2>", "Results", "from", "a", "standard", "mouse", "model", "of", "edema", "demonstrated", "that", "topically", "administered", "varespladib", "was", "equivalent", "to", "the", "marketed", "immunosuppressant", "Elidel", "in", "resolving", "inflammation.", "<tag3>"], "wordsA": ["Patients", "with", "active", "lupus", "may", "have", "a", "broad", "range", "of", "symptoms", "related", "to", "the", "inflammation."], "wordsB": ["Results", "from", "a", "standard", "mouse", "model", "of", "edema", "demonstrated", "that", "topically", "administered", "varespladib", "was", "equivalent", "to", "the", "marketed", "immunosuppressant", "Elidel", "in", "resolving", "inflammation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p134_s0", "idA": "1316175_11_item1_p133_s1", "sentA": "PEARL-SC is a randomized, placebo-controlled, phase 2b clinical study which may enroll up to 600 patients in approximately 90 centers worldwide.", "sentB": "PEARL-SC is a randomized, placebo-controlled, Phase 2b study which enrolled 547 patients in 11 countries at 72 clinical sites.", "type": 2, "words": ["<tag1>", "PEARL-SC", "is", "a", "randomized,", "placebo-controlled,", "phase", "2b", "clinical", "study", "which", "may", "enroll", "up", "to", "600", "patients", "in", "approximately", "90", "centers", "worldwide.", "<tag2>", "PEARL-SC", "is", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites.", "<tag3>"], "wordsA": ["PEARL-SC", "is", "a", "randomized,", "placebo-controlled,", "phase", "2b", "clinical", "study", "which", "may", "enroll", "up", "to", "600", "patients", "in", "approximately", "90", "centers", "worldwide."], "wordsB": ["PEARL-SC", "is", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p134_s1", "idA": "1316175_11_item1_p133_s2", "sentA": "Subjects will be randomized into three active subcutaneous treatment arms and one placebo treatment arm for a minimum of 24 weeks.", "sentB": "Subjects were randomized into three active subcutaneous treatment arms and one placebo treatment arm for a minimum of 24 weeks and a maximum of 52 weeks.", "type": 2, "words": ["<tag1>", "Subjects", "will", "be", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks.", "<tag2>", "Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks.", "<tag3>"], "wordsA": ["Subjects", "will", "be", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks."], "wordsB": ["Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p135_s0", "idA": "1316175_11_item1_p133_s3", "sentA": "The primary endpoint of the PEARL-SC study will be clinical improvement at 24 weeks in responder rates of a composite systemic lupus erythematosus responder index, or SRI, in the pooled treatment arms versus placebo.", "sentB": "The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in a SLE responder index a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI improvement of five (5) points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two new BILAG B organ domain flares.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "will", "be", "clinical", "improvement", "at", "24", "weeks", "in", "responder", "rates", "of", "a", "composite", "systemic", "lupus", "erythematosus", "responder", "index,", "or", "SRI,", "in", "the", "pooled", "treatment", "arms", "versus", "placebo.", "<tag2>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "will", "be", "clinical", "improvement", "at", "24", "weeks", "in", "responder", "rates", "of", "a", "composite", "systemic", "lupus", "erythematosus", "responder", "index,", "or", "SRI,", "in", "the", "pooled", "treatment", "arms", "versus", "placebo."], "wordsB": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p137_s1", "idA": "1316175_11_item1_p134_s0", "sentA": "Initially we intend to randomize only 540 patients.", "sentB": "The open-label extension study is already underway and enrolling patients.", "type": 2, "words": ["<tag1>", "Initially", "we", "intend", "to", "randomize", "only", "540", "patients.", "<tag2>", "The", "open-label", "extension", "study", "is", "already", "underway", "and", "enrolling", "patients.", "<tag3>"], "wordsA": ["Initially", "we", "intend", "to", "randomize", "only", "540", "patients."], "wordsB": ["The", "open-label", "extension", "study", "is", "already", "underway", "and", "enrolling", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p13_s1", "idA": "1316175_11_item1_p135_s1", "sentA": "Patient enrollment in the study was temporarily suspended and dosing was discontinued in patients who were enrolled in the study while we conducted an analysis of the problem.", "sentB": "In March 2012, we closed enrollment in the study and informed all investigators to remove patients from therapy based on the recommendation from an independent data safety monitoring board.", "type": 2, "words": ["<tag1>", "Patient", "enrollment", "in", "the", "study", "was", "temporarily", "suspended", "and", "dosing", "was", "discontinued", "in", "patients", "who", "were", "enrolled", "in", "the", "study", "while", "we", "conducted", "an", "analysis", "of", "the", "problem.", "<tag2>", "In", "March", "2012,", "we", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "based", "on", "the", "recommendation", "from", "an", "independent", "data", "safety", "monitoring", "board.", "<tag3>"], "wordsA": ["Patient", "enrollment", "in", "the", "study", "was", "temporarily", "suspended", "and", "dosing", "was", "discontinued", "in", "patients", "who", "were", "enrolled", "in", "the", "study", "while", "we", "conducted", "an", "analysis", "of", "the", "problem."], "wordsB": ["In", "March", "2012,", "we", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "based", "on", "the", "recommendation", "from", "an", "independent", "data", "safety", "monitoring", "board."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p133_s1", "idA": "1316175_11_item1_p135_s4", "sentA": "Shipping logistics were modified and we reinitiated enrollment in PEARL-SC and dosing in January 2011.", "sentB": "Enrollment in PEARL-SC is now complete.", "type": 2, "words": ["<tag1>", "Shipping", "logistics", "were", "modified", "and", "we", "reinitiated", "enrollment", "in", "PEARL-SC", "and", "dosing", "in", "January", "2011.", "<tag2>", "Enrollment", "in", "PEARL-SC", "is", "now", "complete.", "<tag3>"], "wordsA": ["Shipping", "logistics", "were", "modified", "and", "we", "reinitiated", "enrollment", "in", "PEARL-SC", "and", "dosing", "in", "January", "2011."], "wordsB": ["Enrollment", "in", "PEARL-SC", "is", "now", "complete."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p140_s1", "idA": "1316175_11_item1_p135_s4", "sentA": "Shipping logistics were modified and we reinitiated enrollment in PEARL-SC and dosing in January 2011.", "sentB": "After informing the US FDA and a thorough inspection of all product vials, the study was re-opened for enrollment in January of 2011.", "type": 2, "words": ["<tag1>", "Shipping", "logistics", "were", "modified", "and", "we", "reinitiated", "enrollment", "in", "PEARL-SC", "and", "dosing", "in", "January", "2011.", "<tag2>", "After", "informing", "the", "US", "FDA", "and", "a", "thorough", "inspection", "of", "all", "product", "vials,", "the", "study", "was", "re-opened", "for", "enrollment", "in", "January", "of", "2011.", "<tag3>"], "wordsA": ["Shipping", "logistics", "were", "modified", "and", "we", "reinitiated", "enrollment", "in", "PEARL-SC", "and", "dosing", "in", "January", "2011."], "wordsB": ["After", "informing", "the", "US", "FDA", "and", "a", "thorough", "inspection", "of", "all", "product", "vials,", "the", "study", "was", "re-opened", "for", "enrollment", "in", "January", "of", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p138_s3", "idA": "1316175_11_item1_p136_s3", "sentA": "We believe we now have sufficient clinical material, both placebo and A-623, to dose up to 540 patients for a minimum of six months in the PEARL-SC study.", "sentB": "With the completion of the last batch of blisibimod in 2011, we believe we now have sufficient clinical material, both placebo and blisibimod, to complete dosing on the PEARL-SC study.", "type": 2, "words": ["<tag1>", "We", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "A-623,", "to", "dose", "up", "to", "540", "patients", "for", "a", "minimum", "of", "six", "months", "in", "the", "PEARL-SC", "study.", "<tag2>", "With", "the", "completion", "of", "the", "last", "batch", "of", "blisibimod", "in", "2011,", "we", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "blisibimod,", "to", "complete", "dosing", "on", "the", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["We", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "A-623,", "to", "dose", "up", "to", "540", "patients", "for", "a", "minimum", "of", "six", "months", "in", "the", "PEARL-SC", "study."], "wordsB": ["With", "the", "completion", "of", "the", "last", "batch", "of", "blisibimod", "in", "2011,", "we", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "blisibimod,", "to", "complete", "dosing", "on", "the", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p139_s0", "idA": "1316175_11_item1_p138_s0", "sentA": "The following chart outlines the basic manufacturing steps required for the production of A-623.", "sentB": "The following chart outlines the basic manufacturing steps required for the production of blisibimod.", "type": 2, "words": ["<tag1>", "The", "following", "chart", "outlines", "the", "basic", "manufacturing", "steps", "required", "for", "the", "production", "of", "A-623.", "<tag2>", "The", "following", "chart", "outlines", "the", "basic", "manufacturing", "steps", "required", "for", "the", "production", "of", "blisibimod.", "<tag3>"], "wordsA": ["The", "following", "chart", "outlines", "the", "basic", "manufacturing", "steps", "required", "for", "the", "production", "of", "A-623."], "wordsB": ["The", "following", "chart", "outlines", "the", "basic", "manufacturing", "steps", "required", "for", "the", "production", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p125_s1", "idA": "1316175_11_item1_p139_s2", "sentA": "Patients enrolled in this study will be randomized into three active treatment arms and one placebo arm.", "sentB": "Enrollment in this study is now complete (N=547) and we anticipate completing the study in 2012.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "this", "study", "will", "be", "randomized", "into", "three", "active", "treatment", "arms", "and", "one", "placebo", "arm.", "<tag2>", "Enrollment", "in", "this", "study", "is", "now", "complete", "(N=547)", "and", "we", "anticipate", "completing", "the", "study", "in", "2012.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "this", "study", "will", "be", "randomized", "into", "three", "active", "treatment", "arms", "and", "one", "placebo", "arm."], "wordsB": ["Enrollment", "in", "this", "study", "is", "now", "complete", "(N=547)", "and", "we", "anticipate", "completing", "the", "study", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p141_s1", "idA": "1316175_11_item1_p139_s3", "sentA": "Subsequent to this clearance, the FDA requested additional information regarding characterization and qualification of the manufactured vials of A-623.", "sentB": "Subsequent to this clearance, the FDA requested additional information regarding characterization and qualification of the manufactured vials of blisibimod.", "type": 2, "words": ["<tag1>", "Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "A-623.", "<tag2>", "Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "blisibimod.", "<tag3>"], "wordsA": ["Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "A-623."], "wordsB": ["Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p138_s2", "idA": "1316175_11_item1_p139_s5", "sentA": "Neither of these changes are considered material to the conduct of the PEARL-SC study.", "sentB": "Data from our first 3,000 liter manufacturing campaign was submitted to the US FDA, and after having received no comments from the US FDA, product from this batch was released for use in the PEARL-SC study.", "type": 2, "words": ["<tag1>", "Neither", "of", "these", "changes", "are", "considered", "material", "to", "the", "conduct", "of", "the", "PEARL-SC", "study.", "<tag2>", "Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "US", "FDA,", "and", "after", "having", "received", "no", "comments", "from", "the", "US", "FDA,", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["Neither", "of", "these", "changes", "are", "considered", "material", "to", "the", "conduct", "of", "the", "PEARL-SC", "study."], "wordsB": ["Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "US", "FDA,", "and", "after", "having", "received", "no", "comments", "from", "the", "US", "FDA,", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p143_s0", "idA": "1316175_11_item1_p139_s5", "sentA": "Neither of these changes are considered material to the conduct of the PEARL-SC study.", "sentB": "Enrollment in the PEARL-SC study is completed.", "type": 2, "words": ["<tag1>", "Neither", "of", "these", "changes", "are", "considered", "material", "to", "the", "conduct", "of", "the", "PEARL-SC", "study.", "<tag2>", "Enrollment", "in", "the", "PEARL-SC", "study", "is", "completed.", "<tag3>"], "wordsA": ["Neither", "of", "these", "changes", "are", "considered", "material", "to", "the", "conduct", "of", "the", "PEARL-SC", "study."], "wordsB": ["Enrollment", "in", "the", "PEARL-SC", "study", "is", "completed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p141_s4", "idA": "1316175_11_item1_p139_s6", "sentA": "The FDA also recommended we submit to the IND analytical and comparability data from our recently completed manufacturing lot of A-623 vials and a comparability proposal for purposes of soliciting their input prior to implementation.", "sentB": "The FDA also recommended we submit to the IND various analytical and comparability data from our recently completed manufacturing lot of blisibimod and a comparability proposal for purposes of soliciting their input prior to implementation.", "type": 2, "words": ["<tag1>", "The", "FDA", "also", "recommended", "we", "submit", "to", "the", "IND", "analytical", "and", "comparability", "data", "from", "our", "recently", "completed", "manufacturing", "lot", "of", "A-623", "vials", "and", "a", "comparability", "proposal", "for", "purposes", "of", "soliciting", "their", "input", "prior", "to", "implementation.", "<tag2>", "The", "FDA", "also", "recommended", "we", "submit", "to", "the", "IND", "various", "analytical", "and", "comparability", "data", "from", "our", "recently", "completed", "manufacturing", "lot", "of", "blisibimod", "and", "a", "comparability", "proposal", "for", "purposes", "of", "soliciting", "their", "input", "prior", "to", "implementation.", "<tag3>"], "wordsA": ["The", "FDA", "also", "recommended", "we", "submit", "to", "the", "IND", "analytical", "and", "comparability", "data", "from", "our", "recently", "completed", "manufacturing", "lot", "of", "A-623", "vials", "and", "a", "comparability", "proposal", "for", "purposes", "of", "soliciting", "their", "input", "prior", "to", "implementation."], "wordsB": ["The", "FDA", "also", "recommended", "we", "submit", "to", "the", "IND", "various", "analytical", "and", "comparability", "data", "from", "our", "recently", "completed", "manufacturing", "lot", "of", "blisibimod", "and", "a", "comparability", "proposal", "for", "purposes", "of", "soliciting", "their", "input", "prior", "to", "implementation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p144_s0", "idA": "1316175_11_item1_p141_s0", "sentA": "Prior to our in-licensing of A-623, Amgen completed two Phase 1 clinical studies of A-623 in lupus patients to evaluate the safety and pharmacokinetics of single and multiple doses of the drug using intravenous and subcutaneous formulations.", "sentB": "Prior to our in-licensing of blisibimod, Amgen completed two Phase 1 clinical studies of blisibimod in lupus patients to evaluate the safety and pharmacokinetics of single and multiple doses of the drug using intravenous and subcutaneous formulations.", "type": 2, "words": ["<tag1>", "Prior", "to", "our", "in-licensing", "of", "A-623,", "Amgen", "completed", "two", "Phase", "1", "clinical", "studies", "of", "A-623", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations.", "<tag2>", "Prior", "to", "our", "in-licensing", "of", "blisibimod,", "Amgen", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations.", "<tag3>"], "wordsA": ["Prior", "to", "our", "in-licensing", "of", "A-623,", "Amgen", "completed", "two", "Phase", "1", "clinical", "studies", "of", "A-623", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations."], "wordsB": ["Prior", "to", "our", "in-licensing", "of", "blisibimod,", "Amgen", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p144_s2", "idA": "1316175_11_item1_p141_s2", "sentA": "In Amgen s pre-Phase 1 clinical study, individual B-cell subsets, such as mature na ve B-cells, activated B-cells and memory B-cells, all therapeutic targets for A-623, were quantified in order to characterize the specific B-cell subset abnormalities associated with lupus.", "sentB": "In Amgen's pre-Phase 1 clinical study, individual B-cell subsets, such as mature na ve B-cells, activated B-cells and memory B-cells, all therapeutic targets for blisibimod, were quantified in order to characterize the specific B-cell subset abnormalities associated with lupus.", "type": 2, "words": ["<tag1>", "In", "Amgen", "s", "pre-Phase", "1", "clinical", "study,", "individual", "B-cell", "subsets,", "such", "as", "mature", "na", "ve", "B-cells,", "activated", "B-cells", "and", "memory", "B-cells,", "all", "therapeutic", "targets", "for", "A-623,", "were", "quantified", "in", "order", "to", "characterize", "the", "specific", "B-cell", "subset", "abnormalities", "associated", "with", "lupus.", "<tag2>", "In", "Amgen's", "pre-Phase", "1", "clinical", "study,", "individual", "B-cell", "subsets,", "such", "as", "mature", "na", "ve", "B-cells,", "activated", "B-cells", "and", "memory", "B-cells,", "all", "therapeutic", "targets", "for", "blisibimod,", "were", "quantified", "in", "order", "to", "characterize", "the", "specific", "B-cell", "subset", "abnormalities", "associated", "with", "lupus.", "<tag3>"], "wordsA": ["In", "Amgen", "s", "pre-Phase", "1", "clinical", "study,", "individual", "B-cell", "subsets,", "such", "as", "mature", "na", "ve", "B-cells,", "activated", "B-cells", "and", "memory", "B-cells,", "all", "therapeutic", "targets", "for", "A-623,", "were", "quantified", "in", "order", "to", "characterize", "the", "specific", "B-cell", "subset", "abnormalities", "associated", "with", "lupus."], "wordsB": ["In", "Amgen's", "pre-Phase", "1", "clinical", "study,", "individual", "B-cell", "subsets,", "such", "as", "mature", "na", "ve", "B-cells,", "activated", "B-cells", "and", "memory", "B-cells,", "all", "therapeutic", "targets", "for", "blisibimod,", "were", "quantified", "in", "order", "to", "characterize", "the", "specific", "B-cell", "subset", "abnormalities", "associated", "with", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p145_s0", "idA": "1316175_11_item1_p142_s0", "sentA": "The randomized, placebo-controlled, dose-escalation Phase 1a clinical study evaluated A-623 as a single intravenous or subcutaneous therapy among 56 lupus patients.", "sentB": "The randomized, placebo-controlled, dose-escalation Phase 1a clinical study evaluated blisibimod as a single intravenous or subcutaneous therapy among 56 lupus patients.", "type": 2, "words": ["<tag1>", "The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "A-623", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "56", "lupus", "patients.", "<tag2>", "The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "blisibimod", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "56", "lupus", "patients.", "<tag3>"], "wordsA": ["The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "A-623", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "56", "lupus", "patients."], "wordsB": ["The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "blisibimod", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "56", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p146_s0", "idA": "1316175_11_item1_p143_s0", "sentA": "The primary endpoint was to assess the safety and tolerability of single dose administrations of A-623.", "sentB": "The primary endpoint was to assess the safety and tolerability of single dose administrations of blisibimod.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "single", "dose", "administrations", "of", "A-623.", "<tag2>", "The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "single", "dose", "administrations", "of", "blisibimod.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "single", "dose", "administrations", "of", "A-623."], "wordsB": ["The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "single", "dose", "administrations", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p146_s1", "idA": "1316175_11_item1_p143_s1", "sentA": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of A-623.", "sentB": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of blisibimod.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "A-623.", "<tag2>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "A-623."], "wordsB": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p146_s2", "idA": "1316175_11_item1_p143_s2", "sentA": "Results from this clinical study indicated the safety and tolerability of A-623 administered as single dose of intravenous or subcutaneous was comparable to placebo.", "sentB": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as single dose of intravenous or subcutaneous was comparable to placebo.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "A-623", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo.", "<tag2>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo.", "<tag3>"], "wordsA": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "A-623", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo."], "wordsB": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p146_s3", "idA": "1316175_11_item1_p143_s3", "sentA": "Single doses of A-623 exhibited linear pharmacokinetics after both intravenous and subcutaneous administration.", "sentB": "Single doses of blisibimod exhibited linear pharmacokinetics after both intravenous and subcutaneous administration.", "type": 2, "words": ["<tag1>", "Single", "doses", "of", "A-623", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag2>", "Single", "doses", "of", "blisibimod", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag3>"], "wordsA": ["Single", "doses", "of", "A-623", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "wordsB": ["Single", "doses", "of", "blisibimod", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p146_s4", "idA": "1316175_11_item1_p143_s4", "sentA": "There were comparable adverse events between the A-623 and placebo groups with no deaths reported.", "sentB": "There were comparable adverse events between the blisibimod and placebo groups with no deaths reported.", "type": 2, "words": ["<tag1>", "There", "were", "comparable", "adverse", "events", "between", "the", "A-623", "and", "placebo", "groups", "with", "no", "deaths", "reported.", "<tag2>", "There", "were", "comparable", "adverse", "events", "between", "the", "blisibimod", "and", "placebo", "groups", "with", "no", "deaths", "reported.", "<tag3>"], "wordsA": ["There", "were", "comparable", "adverse", "events", "between", "the", "A-623", "and", "placebo", "groups", "with", "no", "deaths", "reported."], "wordsB": ["There", "were", "comparable", "adverse", "events", "between", "the", "blisibimod", "and", "placebo", "groups", "with", "no", "deaths", "reported."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p148_s0", "idA": "1316175_11_item1_p145_s0", "sentA": "A-623 was evaluated in a randomized, placebo-controlled, multi-dose Phase 1b clinical study as an intravenous or subcutaneous therapy among 63 lupus patients.", "sentB": "Blisibimod was evaluated in a randomized, placebo-controlled, multi-dose Phase 1b clinical study as an intravenous or subcutaneous therapy among 63 lupus patients.", "type": 2, "words": ["<tag1>", "A-623", "was", "evaluated", "in", "a", "randomized,", "placebo-controlled,", "multi-dose", "Phase", "1b", "clinical", "study", "as", "an", "intravenous", "or", "subcutaneous", "therapy", "among", "63", "lupus", "patients.", "<tag2>", "Blisibimod", "was", "evaluated", "in", "a", "randomized,", "placebo-controlled,", "multi-dose", "Phase", "1b", "clinical", "study", "as", "an", "intravenous", "or", "subcutaneous", "therapy", "among", "63", "lupus", "patients.", "<tag3>"], "wordsA": ["A-623", "was", "evaluated", "in", "a", "randomized,", "placebo-controlled,", "multi-dose", "Phase", "1b", "clinical", "study", "as", "an", "intravenous", "or", "subcutaneous", "therapy", "among", "63", "lupus", "patients."], "wordsB": ["Blisibimod", "was", "evaluated", "in", "a", "randomized,", "placebo-controlled,", "multi-dose", "Phase", "1b", "clinical", "study", "as", "an", "intravenous", "or", "subcutaneous", "therapy", "among", "63", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p149_s0", "idA": "1316175_11_item1_p145_s1", "sentA": "The intravenous dose was 6 mg/kg, and subcutaneous doses included 0.3, 1 and 3 mg/kg.", "sentB": "subcutaneous doses included 0.3, 1 and 3 mg/kg.", "type": 2, "words": ["<tag1>", "The", "intravenous", "dose", "was", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg.", "<tag2>", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg.", "<tag3>"], "wordsA": ["The", "intravenous", "dose", "was", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg."], "wordsB": ["subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p149_s1", "idA": "1316175_11_item1_p145_s2", "sentA": "Patients received their doses of A-623 or placebo once-weekly for four weeks.", "sentB": "Patients received their doses of blisibimod or placebo once-weekly for four weeks.", "type": 2, "words": ["<tag1>", "Patients", "received", "their", "doses", "of", "A-623", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag2>", "Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag3>"], "wordsA": ["Patients", "received", "their", "doses", "of", "A-623", "or", "placebo", "once-weekly", "for", "four", "weeks."], "wordsB": ["Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p149_s2", "idA": "1316175_11_item1_p145_s3", "sentA": "The primary endpoint was to assess the safety and tolerability of multiple dose administrations of A-623.", "sentB": "The primary endpoint was to assess the safety and tolerability of multiple dose administrations of blisibimod.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "multiple", "dose", "administrations", "of", "A-623.", "<tag2>", "The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "multiple", "dose", "administrations", "of", "blisibimod.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "multiple", "dose", "administrations", "of", "A-623."], "wordsB": ["The", "primary", "endpoint", "was", "to", "assess", "the", "safety", "and", "tolerability", "of", "multiple", "dose", "administrations", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p149_s3", "idA": "1316175_11_item1_p145_s4", "sentA": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of A-623 after multiple doses.", "sentB": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of blisibimod after multiple doses.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "A-623", "after", "multiple", "doses.", "<tag2>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod", "after", "multiple", "doses.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "A-623", "after", "multiple", "doses."], "wordsB": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod", "after", "multiple", "doses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p149_s4", "idA": "1316175_11_item1_p145_s5", "sentA": "Results showed that multiple doses of A-623 exhibited dose-proportional pharmacokinetics after both intravenous and subcutaneous administration.", "sentB": "Results showed that multiple doses of blisibimod exhibited dose-proportional pharmacokinetics after both intravenous and subcutaneous administration.", "type": 2, "words": ["<tag1>", "Results", "showed", "that", "multiple", "doses", "of", "A-623", "exhibited", "dose-proportional", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag2>", "Results", "showed", "that", "multiple", "doses", "of", "blisibimod", "exhibited", "dose-proportional", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag3>"], "wordsA": ["Results", "showed", "that", "multiple", "doses", "of", "A-623", "exhibited", "dose-proportional", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "wordsB": ["Results", "showed", "that", "multiple", "doses", "of", "blisibimod", "exhibited", "dose-proportional", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p150_s1", "idA": "1316175_11_item1_p146_s1", "sentA": "Results demonstrated that A-623 selectively modulates certain B-cell subsets and induced trends toward normalizing the B-cell abnormalities that were observed in lupus patients in the pre-Phase 1 clinical study.", "sentB": "Results demonstrated that blisibimod selectively modulates certain B-cell subsets and induced trends toward normalizing the B-cell abnormalities that were observed in lupus patients in the pre-Phase 1 clinical study.", "type": 2, "words": ["<tag1>", "Results", "demonstrated", "that", "A-623", "selectively", "modulates", "certain", "B-cell", "subsets", "and", "induced", "trends", "toward", "normalizing", "the", "B-cell", "abnormalities", "that", "were", "observed", "in", "lupus", "patients", "in", "the", "pre-Phase", "1", "clinical", "study.", "<tag2>", "Results", "demonstrated", "that", "blisibimod", "selectively", "modulates", "certain", "B-cell", "subsets", "and", "induced", "trends", "toward", "normalizing", "the", "B-cell", "abnormalities", "that", "were", "observed", "in", "lupus", "patients", "in", "the", "pre-Phase", "1", "clinical", "study.", "<tag3>"], "wordsA": ["Results", "demonstrated", "that", "A-623", "selectively", "modulates", "certain", "B-cell", "subsets", "and", "induced", "trends", "toward", "normalizing", "the", "B-cell", "abnormalities", "that", "were", "observed", "in", "lupus", "patients", "in", "the", "pre-Phase", "1", "clinical", "study."], "wordsB": ["Results", "demonstrated", "that", "blisibimod", "selectively", "modulates", "certain", "B-cell", "subsets", "and", "induced", "trends", "toward", "normalizing", "the", "B-cell", "abnormalities", "that", "were", "observed", "in", "lupus", "patients", "in", "the", "pre-Phase", "1", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p151_s0", "idA": "1316175_11_item1_p147_s0", "sentA": "Results indicated that the tolerability of A-623 administered as multiple doses of intravenous or subcutaneous administration was generally comparable to placebo.", "sentB": "Results indicated that the tolerability of blisibimod administered as multiple doses of intravenous or subcutaneous administration was generally comparable to placebo.", "type": 2, "words": ["<tag1>", "Results", "indicated", "that", "the", "tolerability", "of", "A-623", "administered", "as", "multiple", "doses", "of", "intravenous", "or", "subcutaneous", "administration", "was", "generally", "comparable", "to", "placebo.", "<tag2>", "Results", "indicated", "that", "the", "tolerability", "of", "blisibimod", "administered", "as", "multiple", "doses", "of", "intravenous", "or", "subcutaneous", "administration", "was", "generally", "comparable", "to", "placebo.", "<tag3>"], "wordsA": ["Results", "indicated", "that", "the", "tolerability", "of", "A-623", "administered", "as", "multiple", "doses", "of", "intravenous", "or", "subcutaneous", "administration", "was", "generally", "comparable", "to", "placebo."], "wordsB": ["Results", "indicated", "that", "the", "tolerability", "of", "blisibimod", "administered", "as", "multiple", "doses", "of", "intravenous", "or", "subcutaneous", "administration", "was", "generally", "comparable", "to", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p151_s1", "idA": "1316175_11_item1_p147_s1", "sentA": "There were no deaths reported between the A-623 and placebo groups.", "sentB": "There were no deaths reported between the blisibimod and placebo groups.", "type": 2, "words": ["<tag1>", "There", "were", "no", "deaths", "reported", "between", "the", "A-623", "and", "placebo", "groups.", "<tag2>", "There", "were", "no", "deaths", "reported", "between", "the", "blisibimod", "and", "placebo", "groups.", "<tag3>"], "wordsA": ["There", "were", "no", "deaths", "reported", "between", "the", "A-623", "and", "placebo", "groups."], "wordsB": ["There", "were", "no", "deaths", "reported", "between", "the", "blisibimod", "and", "placebo", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p152_s1", "idA": "1316175_11_item1_p148_s1", "sentA": "Based on these results and published data from competitor studies, we initiated a Phase 2b clinical study evaluating A-623 in lupus patients during the second half of 2010.", "sentB": "Based on these results and published data from competitor studies, we initiated a Phase 2b clinical study evaluating blisibimod in lupus patients during the second half of 2010.", "type": 2, "words": ["<tag1>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "A-623", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010.", "<tag2>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010.", "<tag3>"], "wordsA": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "A-623", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010."], "wordsB": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p153_s0", "idA": "1316175_11_item1_p149_s0", "sentA": "A-001 is an intravenously administered, potent, broad-spectrum inhibitor of sPLA 2 , including forms IIa, V and X. A-001 will be evaluated in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease in at-risk patients.", "sentB": "Varespladib sodium is an intravenously administered, potent, broad-spectrum inhibitor of sPLA 2 , including forms IIa, V and X. Varespladib is being evaluated for the prevention of acute chest syndrome associated with sickle cell disease in at-risk patients.", "type": 2, "words": ["<tag1>", "A-001", "is", "an", "intravenously", "administered,", "potent,", "broad-spectrum", "inhibitor", "of", "sPLA", "2", ",", "including", "forms", "IIa,", "V", "and", "X.", "A-001", "will", "be", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients.", "<tag2>", "Varespladib", "sodium", "is", "an", "intravenously", "administered,", "potent,", "broad-spectrum", "inhibitor", "of", "sPLA", "2", ",", "including", "forms", "IIa,", "V", "and", "X.", "Varespladib", "is", "being", "evaluated", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients.", "<tag3>"], "wordsA": ["A-001", "is", "an", "intravenously", "administered,", "potent,", "broad-spectrum", "inhibitor", "of", "sPLA", "2", ",", "including", "forms", "IIa,", "V", "and", "X.", "A-001", "will", "be", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients."], "wordsB": ["Varespladib", "sodium", "is", "an", "intravenously", "administered,", "potent,", "broad-spectrum", "inhibitor", "of", "sPLA", "2", ",", "including", "forms", "IIa,", "V", "and", "X.", "Varespladib", "is", "being", "evaluated", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p13_s0", "idA": "1316175_11_item1_p14_s0", "sentA": "Based on the successful results of our completed Phase 2b clinical study, we initiated a Phase 3 clinical study, VISTA-16, in patients with acute coronary syndrome in June 2010.", "sentB": "Based on the successful results of our completed Phase 2b, FRANCIS, clinical study, we initiated enrollment in a Phase 3 clinical study, VISTA-16, in patients with acute coronary syndrome in June 2010.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b", "clinical", "study,", "we", "initiated", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010.", "<tag2>", "Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b,", "FRANCIS,", "clinical", "study,", "we", "initiated", "enrollment", "in", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010.", "<tag3>"], "wordsA": ["Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b", "clinical", "study,", "we", "initiated", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010."], "wordsB": ["Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b,", "FRANCIS,", "clinical", "study,", "we", "initiated", "enrollment", "in", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p154_s0", "idA": "1316175_11_item1_p150_s0", "sentA": "The FDA granted orphan drug and fast-track designation for A-001 for the prevention of acute chest syndrome in at-risk patients.", "sentB": "The FDA granted orphan drug and fast-track designation for varespladib sodium for the prevention of acute chest syndrome in at-risk patients.", "type": 2, "words": ["<tag1>", "The", "FDA", "granted", "orphan", "drug", "and", "fast-track", "designation", "for", "A-001", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "in", "at-risk", "patients.", "<tag2>", "The", "FDA", "granted", "orphan", "drug", "and", "fast-track", "designation", "for", "varespladib", "sodium", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "in", "at-risk", "patients.", "<tag3>"], "wordsA": ["The", "FDA", "granted", "orphan", "drug", "and", "fast-track", "designation", "for", "A-001", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "in", "at-risk", "patients."], "wordsB": ["The", "FDA", "granted", "orphan", "drug", "and", "fast-track", "designation", "for", "varespladib", "sodium", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "in", "at-risk", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p154_s2", "idA": "1316175_11_item1_p150_s2", "sentA": "We also licensed A-001 from Eli Lilly and Shionogi Co., Ltd. in July 2006.", "sentB": "We also licensed varespladib sodium from Eli Lilly and Shionogi Co., Ltd. in July 2006.", "type": 2, "words": ["<tag1>", "We", "also", "licensed", "A-001", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006.", "<tag2>", "We", "also", "licensed", "varespladib", "sodium", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006.", "<tag3>"], "wordsA": ["We", "also", "licensed", "A-001", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006."], "wordsB": ["We", "also", "licensed", "varespladib", "sodium", "from", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p14_s0", "idA": "1316175_11_item1_p15_s0", "sentA": "Our second product candidate, varespladib sodium, A-001, is an intravenously administered inhibitor of sPLA 2 ,which we are planning to evaluate in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease.", "sentB": "Our second product candidate, varespladib sodium, is an intravenously administered inhibitor of sPLA 2 ,which we may evaluate in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease.", "type": 2, "words": ["<tag1>", "Our", "second", "product", "candidate,", "varespladib", "sodium,", "A-001,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "are", "planning", "to", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "Our", "second", "product", "candidate,", "varespladib", "sodium,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "may", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag3>"], "wordsA": ["Our", "second", "product", "candidate,", "varespladib", "sodium,", "A-001,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "are", "planning", "to", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["Our", "second", "product", "candidate,", "varespladib", "sodium,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "may", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p164_s1", "idA": "1316175_11_item1_p161_s0", "sentA": "Patients will be randomized to receive a continuous infusion of A-001 or placebo for 48 hours after randomization.", "sentB": "Patients will be randomized to receive a continuous infusion of varespladib sodium or placebo for 48 hours after randomization.", "type": 2, "words": ["<tag1>", "Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "A-001", "or", "placebo", "for", "48", "hours", "after", "randomization.", "<tag2>", "Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "varespladib", "sodium", "or", "placebo", "for", "48", "hours", "after", "randomization.", "<tag3>"], "wordsA": ["Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "A-001", "or", "placebo", "for", "48", "hours", "after", "randomization."], "wordsB": ["Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "varespladib", "sodium", "or", "placebo", "for", "48", "hours", "after", "randomization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p165_s1", "idA": "1316175_11_item1_p161_s2", "sentA": "This study represents a unique treatment approach for a small, orphan designated indication.", "sentB": "This study represents a unique treatment approach for a small, orphan indication.", "type": 2, "words": ["<tag1>", "This", "study", "represents", "a", "unique", "treatment", "approach", "for", "a", "small,", "orphan", "designated", "indication.", "<tag2>", "This", "study", "represents", "a", "unique", "treatment", "approach", "for", "a", "small,", "orphan", "indication.", "<tag3>"], "wordsA": ["This", "study", "represents", "a", "unique", "treatment", "approach", "for", "a", "small,", "orphan", "designated", "indication."], "wordsB": ["This", "study", "represents", "a", "unique", "treatment", "approach", "for", "a", "small,", "orphan", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p169_s0", "idA": "1316175_11_item1_p163_s0", "sentA": "In January 2007, we initiated a randomized, double-blind, placebo-controlled Phase 2 clinical study to assess the safety and tolerability of escalating doses of A-001 therapy when administered as a 48-hour continuous infusion.", "sentB": "In January 2007, we initiated a randomized, double-blind, placebo-controlled Phase 2 clinical study to assess the safety and tolerability of escalating doses of varespladib sodium when administered as a 48-hour continuous infusion.", "type": 2, "words": ["<tag1>", "In", "January", "2007,", "we", "initiated", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2", "clinical", "study", "to", "assess", "the", "safety", "and", "tolerability", "of", "escalating", "doses", "of", "A-001", "therapy", "when", "administered", "as", "a", "48-hour", "continuous", "infusion.", "<tag2>", "In", "January", "2007,", "we", "initiated", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2", "clinical", "study", "to", "assess", "the", "safety", "and", "tolerability", "of", "escalating", "doses", "of", "varespladib", "sodium", "when", "administered", "as", "a", "48-hour", "continuous", "infusion.", "<tag3>"], "wordsA": ["In", "January", "2007,", "we", "initiated", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2", "clinical", "study", "to", "assess", "the", "safety", "and", "tolerability", "of", "escalating", "doses", "of", "A-001", "therapy", "when", "administered", "as", "a", "48-hour", "continuous", "infusion."], "wordsB": ["In", "January", "2007,", "we", "initiated", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2", "clinical", "study", "to", "assess", "the", "safety", "and", "tolerability", "of", "escalating", "doses", "of", "varespladib", "sodium", "when", "administered", "as", "a", "48-hour", "continuous", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p170_s0", "idA": "1316175_11_item1_p163_s1", "sentA": "The clinical study was designed to enroll up to 75 patients across approximately 30 sites in the United States.", "sentB": "30 sites in the United States.", "type": 2, "words": ["<tag1>", "The", "clinical", "study", "was", "designed", "to", "enroll", "up", "to", "75", "patients", "across", "approximately", "30", "sites", "in", "the", "United", "States.", "<tag2>", "30", "sites", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["The", "clinical", "study", "was", "designed", "to", "enroll", "up", "to", "75", "patients", "across", "approximately", "30", "sites", "in", "the", "United", "States."], "wordsB": ["30", "sites", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p170_s1", "idA": "1316175_11_item1_p164_s0", "sentA": "fever and serum sPLA 2 concentration level greater than 50 mg/mL.", "sentB": "This clinical study enrolls hospitalized sickle cell disease patients at risk for acute chest syndrome on the basis of VOC, fever and serum sPLA 2 concentration level greater than 50 mg/mL.", "type": 2, "words": ["<tag1>", "fever", "and", "serum", "sPLA", "2", "concentration", "level", "greater", "than", "50", "mg/mL.", "<tag2>", "This", "clinical", "study", "enrolls", "hospitalized", "sickle", "cell", "disease", "patients", "at", "risk", "for", "acute", "chest", "syndrome", "on", "the", "basis", "of", "VOC,", "fever", "and", "serum", "sPLA", "2", "concentration", "level", "greater", "than", "50", "mg/mL.", "<tag3>"], "wordsA": ["fever", "and", "serum", "sPLA", "2", "concentration", "level", "greater", "than", "50", "mg/mL."], "wordsB": ["This", "clinical", "study", "enrolls", "hospitalized", "sickle", "cell", "disease", "patients", "at", "risk", "for", "acute", "chest", "syndrome", "on", "the", "basis", "of", "VOC,", "fever", "and", "serum", "sPLA", "2", "concentration", "level", "greater", "than", "50", "mg/mL."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p171_s0", "idA": "1316175_11_item1_p166_s0", "sentA": "The first group of patients was randomized 2:1 to receive low dose A-001 or placebo as a 48-hour continuous infusion.", "sentB": "The first group of patients was randomized 2:1 to receive low dose varespladib sodium or placebo as a 48-hour continuous infusion.", "type": 2, "words": ["<tag1>", "The", "first", "group", "of", "patients", "was", "randomized", "2:1", "to", "receive", "low", "dose", "A-001", "or", "placebo", "as", "a", "48-hour", "continuous", "infusion.", "<tag2>", "The", "first", "group", "of", "patients", "was", "randomized", "2:1", "to", "receive", "low", "dose", "varespladib", "sodium", "or", "placebo", "as", "a", "48-hour", "continuous", "infusion.", "<tag3>"], "wordsA": ["The", "first", "group", "of", "patients", "was", "randomized", "2:1", "to", "receive", "low", "dose", "A-001", "or", "placebo", "as", "a", "48-hour", "continuous", "infusion."], "wordsB": ["The", "first", "group", "of", "patients", "was", "randomized", "2:1", "to", "receive", "low", "dose", "varespladib", "sodium", "or", "placebo", "as", "a", "48-hour", "continuous", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p171_s3", "idA": "1316175_11_item1_p166_s3", "sentA": "Interim results indicated serum levels of A-001 when dosed at 55 ig/kg/hr reduced sPLA 2 activity levels by more than 80% from baseline within 48 hours.", "sentB": "Interim results indicated serum levels of varespladib sodium when dosed at 55 ig/kg/hr reduced sPLA 2 activity levels by more than 80% from baseline within 48 hours.", "type": 2, "words": ["<tag1>", "Interim", "results", "indicated", "serum", "levels", "of", "A-001", "when", "dosed", "at", "55", "ig/kg/hr", "reduced", "sPLA", "2", "activity", "levels", "by", "more", "than", "80%", "from", "baseline", "within", "48", "hours.", "<tag2>", "Interim", "results", "indicated", "serum", "levels", "of", "varespladib", "sodium", "when", "dosed", "at", "55", "ig/kg/hr", "reduced", "sPLA", "2", "activity", "levels", "by", "more", "than", "80%", "from", "baseline", "within", "48", "hours.", "<tag3>"], "wordsA": ["Interim", "results", "indicated", "serum", "levels", "of", "A-001", "when", "dosed", "at", "55", "ig/kg/hr", "reduced", "sPLA", "2", "activity", "levels", "by", "more", "than", "80%", "from", "baseline", "within", "48", "hours."], "wordsB": ["Interim", "results", "indicated", "serum", "levels", "of", "varespladib", "sodium", "when", "dosed", "at", "55", "ig/kg/hr", "reduced", "sPLA", "2", "activity", "levels", "by", "more", "than", "80%", "from", "baseline", "within", "48", "hours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p171_s7", "idA": "1316175_11_item1_p166_s7", "sentA": "We believe that the data suggests A-001 can suppress sPLA 2 at levels that may prevent the complication of acute chest syndrome associated with sickle cell disease.", "sentB": "We believe that the data suggests varespladib sodium can suppress sPLA 2 at levels that may prevent the complication of acute chest syndrome associated with sickle cell disease.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "data", "suggests", "A-001", "can", "suppress", "sPLA", "2", "at", "levels", "that", "may", "prevent", "the", "complication", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "We", "believe", "that", "the", "data", "suggests", "varespladib", "sodium", "can", "suppress", "sPLA", "2", "at", "levels", "that", "may", "prevent", "the", "complication", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "data", "suggests", "A-001", "can", "suppress", "sPLA", "2", "at", "levels", "that", "may", "prevent", "the", "complication", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["We", "believe", "that", "the", "data", "suggests", "varespladib", "sodium", "can", "suppress", "sPLA", "2", "at", "levels", "that", "may", "prevent", "the", "complication", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p3_s3", "idA": "1316175_11_item1_p166_s7", "sentA": "We believe that the data suggests A-001 can suppress sPLA 2 at levels that may prevent the complication of acute chest syndrome associated with sickle cell disease.", "sentB": "We believe that the DSMB's decision was based on the belief that the risk profile of the drug would not outweigh any benefit.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "data", "suggests", "A-001", "can", "suppress", "sPLA", "2", "at", "levels", "that", "may", "prevent", "the", "complication", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "We", "believe", "that", "the", "DSMB's", "decision", "was", "based", "on", "the", "belief", "that", "the", "risk", "profile", "of", "the", "drug", "would", "not", "outweigh", "any", "benefit.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "data", "suggests", "A-001", "can", "suppress", "sPLA", "2", "at", "levels", "that", "may", "prevent", "the", "complication", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["We", "believe", "that", "the", "DSMB's", "decision", "was", "based", "on", "the", "belief", "that", "the", "risk", "profile", "of", "the", "drug", "would", "not", "outweigh", "any", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p172_s0", "idA": "1316175_11_item1_p167_s0", "sentA": "Reductions of sPLA 2 activity from baseline and incidence of acute chest syndrome (including placebo patients and patients receiving A-001).", "sentB": "Reductions of sPLA 2 activity from baseline and incidence of acute chest syndrome (including placebo patients and patients receiving varespladib sodium.", "type": 2, "words": ["<tag1>", "Reductions", "of", "sPLA", "2", "activity", "from", "baseline", "and", "incidence", "of", "acute", "chest", "syndrome", "(including", "placebo", "patients", "and", "patients", "receiving", "A-001).", "<tag2>", "Reductions", "of", "sPLA", "2", "activity", "from", "baseline", "and", "incidence", "of", "acute", "chest", "syndrome", "(including", "placebo", "patients", "and", "patients", "receiving", "varespladib", "sodium.", "<tag3>"], "wordsA": ["Reductions", "of", "sPLA", "2", "activity", "from", "baseline", "and", "incidence", "of", "acute", "chest", "syndrome", "(including", "placebo", "patients", "and", "patients", "receiving", "A-001)."], "wordsB": ["Reductions", "of", "sPLA", "2", "activity", "from", "baseline", "and", "incidence", "of", "acute", "chest", "syndrome", "(including", "placebo", "patients", "and", "patients", "receiving", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p173_s0", "idA": "1316175_11_item1_p168_s0", "sentA": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.", "sentB": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including autoimmune diseases.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "cardiovascular", "and", "autoimmune", "diseases.", "<tag2>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "cardiovascular", "and", "autoimmune", "diseases."], "wordsB": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p173_s1", "idA": "1316175_11_item1_p168_s1", "sentA": "To achieve these objectives, we intend to initially focus on:", "sentB": "To achieve these objectives, we intend to initially focus on the following activities.", "type": 2, "words": ["<tag1>", "To", "achieve", "these", "objectives,", "we", "intend", "to", "initially", "focus", "on:", "<tag2>", "To", "achieve", "these", "objectives,", "we", "intend", "to", "initially", "focus", "on", "the", "following", "activities.", "<tag3>"], "wordsA": ["To", "achieve", "these", "objectives,", "we", "intend", "to", "initially", "focus", "on:"], "wordsB": ["To", "achieve", "these", "objectives,", "we", "intend", "to", "initially", "focus", "on", "the", "following", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p174_s0", "idA": "1316175_11_item1_p171_s0", "sentA": "We are advancing the development of A-623 to exploit the broad potential clinical utility of BAFF antagonism.", "sentB": "We are advancing the development of blisibimod to exploit the broad potential clinical utility of BAFF antagonism.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "A-623", "to", "exploit", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism.", "<tag2>", "We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "exploit", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "A-623", "to", "exploit", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism."], "wordsB": ["We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "exploit", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p136_s2", "idA": "1316175_11_item1_p171_s1", "sentA": "We have initiated the Phase 2b clinical study known as PEARL-SC in lupus patients.", "sentB": "Elevations in these B-cells have been associated with an increased risk of disease activity in lupus patients.", "type": 2, "words": ["<tag1>", "We", "have", "initiated", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag2>", "Elevations", "in", "these", "B-cells", "have", "been", "associated", "with", "an", "increased", "risk", "of", "disease", "activity", "in", "lupus", "patients.", "<tag3>"], "wordsA": ["We", "have", "initiated", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "wordsB": ["Elevations", "in", "these", "B-cells", "have", "been", "associated", "with", "an", "increased", "risk", "of", "disease", "activity", "in", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p174_s1", "idA": "1316175_11_item1_p171_s1", "sentA": "We have initiated the Phase 2b clinical study known as PEARL-SC in lupus patients.", "sentB": "We have completed enrollment in the Phase 2b clinical study known as PEARL-SC in lupus patients.", "type": 2, "words": ["<tag1>", "We", "have", "initiated", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag2>", "We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag3>"], "wordsA": ["We", "have", "initiated", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "wordsB": ["We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p174_s2", "idA": "1316175_11_item1_p171_s2", "sentA": "We may opportunistically enter into collaborations with third parties for development of this compound in lupus or in other B-cell mediated diseases, such as multiple sclerosis, rheumatoid arthritis or Sj gren s Syndrome, that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "sentB": "We may opportunistically enter into collaborations with third parties for development of this compound in lupus or in other B-cell mediated diseases, such as multiple sclerosis, rheumatoid arthritis or Sj gren's Syndrome, that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "multiple", "sclerosis,", "rheumatoid", "arthritis", "or", "Sj", "gren", "s", "Syndrome,", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "multiple", "sclerosis,", "rheumatoid", "arthritis", "or", "Sj", "gren's", "Syndrome,", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "multiple", "sclerosis,", "rheumatoid", "arthritis", "or", "Sj", "gren", "s", "Syndrome,", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "multiple", "sclerosis,", "rheumatoid", "arthritis", "or", "Sj", "gren's", "Syndrome,", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p15_s1", "idA": "1316175_11_item1_p172_s1", "sentA": "Given that there are currently no approved drugs for the prevention of acute chest syndrome associated with sickle cell disease, we have received orphan drug designation and fast track status from the FDA for A-001.", "sentB": "Given that there are currently no approved drugs for the prevention of acute chest syndrome associated with sickle cell disease, we have received orphan drug designation and fast track status from the FDA for varespladib sodium.", "type": 2, "words": ["<tag1>", "Given", "that", "there", "are", "currently", "no", "approved", "drugs", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "we", "have", "received", "orphan", "drug", "designation", "and", "fast", "track", "status", "from", "the", "FDA", "for", "A-001.", "<tag2>", "Given", "that", "there", "are", "currently", "no", "approved", "drugs", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "we", "have", "received", "orphan", "drug", "designation", "and", "fast", "track", "status", "from", "the", "FDA", "for", "varespladib", "sodium.", "<tag3>"], "wordsA": ["Given", "that", "there", "are", "currently", "no", "approved", "drugs", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "we", "have", "received", "orphan", "drug", "designation", "and", "fast", "track", "status", "from", "the", "FDA", "for", "A-001."], "wordsB": ["Given", "that", "there", "are", "currently", "no", "approved", "drugs", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "we", "have", "received", "orphan", "drug", "designation", "and", "fast", "track", "status", "from", "the", "FDA", "for", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p49_s2", "idA": "1316175_11_item1_p174_s2", "sentA": "Additionally, we believe that we can apply our sPLA 2 expertise to develop novel therapeutics for a number of chronic diseases.", "sentB": "Based on the DSMB recommendation we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "type": 2, "words": ["<tag1>", "Additionally,", "we", "believe", "that", "we", "can", "apply", "our", "sPLA", "2", "expertise", "to", "develop", "novel", "therapeutics", "for", "a", "number", "of", "chronic", "diseases.", "<tag2>", "Based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag3>"], "wordsA": ["Additionally,", "we", "believe", "that", "we", "can", "apply", "our", "sPLA", "2", "expertise", "to", "develop", "novel", "therapeutics", "for", "a", "number", "of", "chronic", "diseases."], "wordsB": ["Based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p176_s0", "idA": "1316175_11_item1_p177_s0", "sentA": "Our primary product candidates are focused on either the acute care setting in the hospital or highly-specialized physician segments, such as rheumatologists.", "sentB": "Our primary product candidate is focused on highly-specialized physician segments, such as rheumatologists.", "type": 2, "words": ["<tag1>", "Our", "primary", "product", "candidates", "are", "focused", "on", "either", "the", "acute", "care", "setting", "in", "the", "hospital", "or", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists.", "<tag2>", "Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists.", "<tag3>"], "wordsA": ["Our", "primary", "product", "candidates", "are", "focused", "on", "either", "the", "acute", "care", "setting", "in", "the", "hospital", "or", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists."], "wordsB": ["Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p16_s2", "idA": "1316175_11_item1_p17_s2", "sentA": "Our lead candidate within the series, A-003, is chemically distinct from A-001 and varespladib and has shown increased potency against the target enzymes and higher drug exposure after dosing in preclinical studies.", "sentB": "Our lead candidate within the series, A-003, is chemically distinct from varespladib sodium and varespladib and has shown increased potency against the target enzymes and higher drug exposure after dosing in preclinical studies.", "type": 2, "words": ["<tag1>", "Our", "lead", "candidate", "within", "the", "series,", "A-003,", "is", "chemically", "distinct", "from", "A-001", "and", "varespladib", "and", "has", "shown", "increased", "potency", "against", "the", "target", "enzymes", "and", "higher", "drug", "exposure", "after", "dosing", "in", "preclinical", "studies.", "<tag2>", "Our", "lead", "candidate", "within", "the", "series,", "A-003,", "is", "chemically", "distinct", "from", "varespladib", "sodium", "and", "varespladib", "and", "has", "shown", "increased", "potency", "against", "the", "target", "enzymes", "and", "higher", "drug", "exposure", "after", "dosing", "in", "preclinical", "studies.", "<tag3>"], "wordsA": ["Our", "lead", "candidate", "within", "the", "series,", "A-003,", "is", "chemically", "distinct", "from", "A-001", "and", "varespladib", "and", "has", "shown", "increased", "potency", "against", "the", "target", "enzymes", "and", "higher", "drug", "exposure", "after", "dosing", "in", "preclinical", "studies."], "wordsB": ["Our", "lead", "candidate", "within", "the", "series,", "A-003,", "is", "chemically", "distinct", "from", "varespladib", "sodium", "and", "varespladib", "and", "has", "shown", "increased", "potency", "against", "the", "target", "enzymes", "and", "higher", "drug", "exposure", "after", "dosing", "in", "preclinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p181_s1", "idA": "1316175_11_item1_p188_s0", "sentA": "Benlysta is currently under review with the FDA and, if approved, would be the first novel therapy in the last fifty years.", "sentB": "It is the first novel therapy approved in the last fifty years.", "type": 2, "words": ["<tag1>", "Benlysta", "is", "currently", "under", "review", "with", "the", "FDA", "and,", "if", "approved,", "would", "be", "the", "first", "novel", "therapy", "in", "the", "last", "fifty", "years.", "<tag2>", "It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "fifty", "years.", "<tag3>"], "wordsA": ["Benlysta", "is", "currently", "under", "review", "with", "the", "FDA", "and,", "if", "approved,", "would", "be", "the", "first", "novel", "therapy", "in", "the", "last", "fifty", "years."], "wordsB": ["It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "fifty", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p17_s0", "idA": "1316175_11_item1_p18_s0", "sentA": "We have explored the use of our varespladib and A-001 sPLA 2 inhibitors as both topical and inhalation therapies in animal models for the treatment of atopic dermatitis and asthma, respectively.", "sentB": "We have explored the use of our varespladib and varespladib sodium sPLA 2 inhibitors as both topical and inhalation therapies in animal models for the treatment of atopic dermatitis and asthma, respectively.", "type": 2, "words": ["<tag1>", "We", "have", "explored", "the", "use", "of", "our", "varespladib", "and", "A-001", "sPLA", "2", "inhibitors", "as", "both", "topical", "and", "inhalation", "therapies", "in", "animal", "models", "for", "the", "treatment", "of", "atopic", "dermatitis", "and", "asthma,", "respectively.", "<tag2>", "We", "have", "explored", "the", "use", "of", "our", "varespladib", "and", "varespladib", "sodium", "sPLA", "2", "inhibitors", "as", "both", "topical", "and", "inhalation", "therapies", "in", "animal", "models", "for", "the", "treatment", "of", "atopic", "dermatitis", "and", "asthma,", "respectively.", "<tag3>"], "wordsA": ["We", "have", "explored", "the", "use", "of", "our", "varespladib", "and", "A-001", "sPLA", "2", "inhibitors", "as", "both", "topical", "and", "inhalation", "therapies", "in", "animal", "models", "for", "the", "treatment", "of", "atopic", "dermatitis", "and", "asthma,", "respectively."], "wordsB": ["We", "have", "explored", "the", "use", "of", "our", "varespladib", "and", "varespladib", "sodium", "sPLA", "2", "inhibitors", "as", "both", "topical", "and", "inhalation", "therapies", "in", "animal", "models", "for", "the", "treatment", "of", "atopic", "dermatitis", "and", "asthma,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p181_s0", "idA": "1316175_11_item1_p190_s0", "sentA": "Several new biological agents under development have targeted BAFF (or BLyS) and other B-cell related pathways for the treatment of lupus.", "sentB": "Human Genome Sciences, Inc.'s and partner GlaxoSmithKline plc's Benlysta (belimumab) was approved in 2011 by the FDA for the treatment of lupus.", "type": 2, "words": ["<tag1>", "Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(or", "BLyS)", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Human", "Genome", "Sciences,", "Inc.'s", "and", "partner", "GlaxoSmithKline", "plc's", "Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(or", "BLyS)", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Human", "Genome", "Sciences,", "Inc.'s", "and", "partner", "GlaxoSmithKline", "plc's", "Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p184_s0", "idA": "1316175_11_item1_p190_s2", "sentA": "We believe that A-623 may offer potential differentiation from these agents, including demonstrated dosing flexibility with both subcutaneous and intravenous delivery; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; its smaller size as compared to a full antibody, which may confer differentiating pharmacokinetic and pharmacodynamic characteristics; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen, which may also confer potential manufacturing advantages with lower cost of goods based on a bacterial fermentation manufacturing process.", "sentB": "intravenous delivery; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; its smaller size as compared to a full antibody, which may confer differentiating pharmacokinetic and pharmacodynamic characteristics; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen, which may also confer potential manufacturing advantages with lower cost of goods based on a bacterial fermentation manufacturing process.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "A-623", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process.", "<tag2>", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process.", "<tag3>"], "wordsA": ["We", "believe", "that", "A-623", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process."], "wordsB": ["intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p38_s0", "idA": "1316175_11_item1_p190_s2", "sentA": "We believe that A-623 may offer potential differentiation from these agents, including demonstrated dosing flexibility with both subcutaneous and intravenous delivery; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; its smaller size as compared to a full antibody, which may confer differentiating pharmacokinetic and pharmacodynamic characteristics; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen, which may also confer potential manufacturing advantages with lower cost of goods based on a bacterial fermentation manufacturing process.", "sentB": "convenient, at-home, patient-administered subcutaneous dosing with a range of dosing frequencies including monthly and weekly; the ability to inhibit the activity of both membrane-bound and soluble BAFF; a Phase 2 clinical design which utilizes more stringent restrictions to background medication, a shorter time-point to the primary endpoint, and requiring larger disease reduction in the SELENA/SLEDAI clinical efficacy measurement tool; and a novel molecular structure, which may confer differentiating pharmacokinetic and pharmacodynamic characteristics, potentially providing efficacy and dosing benefits, as well as manufacturing benefits and lower cost of goods based on a bacterial fermentation manufacturing process; and multiple binding domains achieve highest reported affinity for inhibition of BAFF.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "A-623", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process.", "<tag2>", "convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "a", "Phase", "2", "clinical", "design", "which", "utilizes", "more", "stringent", "restrictions", "to", "background", "medication,", "a", "shorter", "time-point", "to", "the", "primary", "endpoint,", "and", "requiring", "larger", "disease", "reduction", "in", "the", "SELENA/SLEDAI", "clinical", "efficacy", "measurement", "tool;", "and", "a", "novel", "molecular", "structure,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics,", "potentially", "providing", "efficacy", "and", "dosing", "benefits,", "as", "well", "as", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF.", "<tag3>"], "wordsA": ["We", "believe", "that", "A-623", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process."], "wordsB": ["convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "a", "Phase", "2", "clinical", "design", "which", "utilizes", "more", "stringent", "restrictions", "to", "background", "medication,", "a", "shorter", "time-point", "to", "the", "primary", "endpoint,", "and", "requiring", "larger", "disease", "reduction", "in", "the", "SELENA/SLEDAI", "clinical", "efficacy", "measurement", "tool;", "and", "a", "novel", "molecular", "structure,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics,", "potentially", "providing", "efficacy", "and", "dosing", "benefits,", "as", "well", "as", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p187_s0", "idA": "1316175_11_item1_p194_s0", "sentA": "operate our business without infringing the patents and proprietary rights of third parties.", "sentB": "obtain and maintain patent and other proprietary protection for the technology, inventions and improvements we consider important to our business; defend our patents; preserve the confidentiality of our trade secrets; and operate our business without infringing the patents and proprietary rights of third parties.", "type": 2, "words": ["<tag1>", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties.", "<tag2>", "obtain", "and", "maintain", "patent", "and", "other", "proprietary", "protection", "for", "the", "technology,", "inventions", "and", "improvements", "we", "consider", "important", "to", "our", "business;", "defend", "our", "patents;", "preserve", "the", "confidentiality", "of", "our", "trade", "secrets;", "and", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties.", "<tag3>"], "wordsA": ["operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties."], "wordsB": ["obtain", "and", "maintain", "patent", "and", "other", "proprietary", "protection", "for", "the", "technology,", "inventions", "and", "improvements", "we", "consider", "important", "to", "our", "business;", "defend", "our", "patents;", "preserve", "the", "confidentiality", "of", "our", "trade", "secrets;", "and", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p213_s0", "idA": "1316175_11_item1_p194_s0", "sentA": "operate our business without infringing the patents and proprietary rights of third parties.", "sentB": "We are aware of two families of third party United States patents and pending foreign applications that contain broad claims related to BLyS or BAFF binding polypeptides.", "type": 2, "words": ["<tag1>", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties.", "<tag2>", "We", "are", "aware", "of", "two", "families", "of", "third", "party", "United", "States", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides.", "<tag3>"], "wordsA": ["operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties."], "wordsB": ["We", "are", "aware", "of", "two", "families", "of", "third", "party", "United", "States", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p188_s0", "idA": "1316175_11_item1_p195_s0", "sentA": "As of the date of this report, our licensed varespladib and A-001 patent portfolio includes:", "sentB": "As of the date of this report, our licensed varespladib and varespladib sodium patent portfolio includes:", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "licensed", "varespladib", "and", "A-001", "patent", "portfolio", "includes:", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "our", "licensed", "varespladib", "and", "varespladib", "sodium", "patent", "portfolio", "includes:", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "licensed", "varespladib", "and", "A-001", "patent", "portfolio", "includes:"], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "our", "licensed", "varespladib", "and", "varespladib", "sodium", "patent", "portfolio", "includes:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p189_s0", "idA": "1316175_11_item1_p196_s0", "sentA": "Three pending non-EP foreign patent applications in Brazil, Japan and Thailand.", "sentB": "13 U.S. patents; One pending U.S. non-provisional patent application; Six European, or EP, patents, each validated in one or more of Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, the Netherlands, Portugal, Spain, Sweden, Switzerland and the United Kingdom; 20 non-EP foreign patents in Argentina, Australia, Brazil, Canada, China, Finland, India, Malaysia, Mexico, the Philippines, South Korea, Taiwan and Turkey; and Two pending non-EP foreign patent applications in Brazil and Thailand.", "type": 2, "words": ["<tag1>", "Three", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Japan", "and", "Thailand.", "<tag2>", "13", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application;", "Six", "European,", "or", "EP,", "patents,", "each", "validated", "in", "one", "or", "more", "of", "Austria,", "Belgium,", "Denmark,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Liechtenstein,", "Luxembourg,", "the", "Netherlands,", "Portugal,", "Spain,", "Sweden,", "Switzerland", "and", "the", "United", "Kingdom;", "20", "non-EP", "foreign", "patents", "in", "Argentina,", "Australia,", "Brazil,", "Canada,", "China,", "Finland,", "India,", "Malaysia,", "Mexico,", "the", "Philippines,", "South", "Korea,", "Taiwan", "and", "Turkey;", "and", "Two", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil", "and", "Thailand.", "<tag3>"], "wordsA": ["Three", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Japan", "and", "Thailand."], "wordsB": ["13", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application;", "Six", "European,", "or", "EP,", "patents,", "each", "validated", "in", "one", "or", "more", "of", "Austria,", "Belgium,", "Denmark,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Liechtenstein,", "Luxembourg,", "the", "Netherlands,", "Portugal,", "Spain,", "Sweden,", "Switzerland", "and", "the", "United", "Kingdom;", "20", "non-EP", "foreign", "patents", "in", "Argentina,", "Australia,", "Brazil,", "Canada,", "China,", "Finland,", "India,", "Malaysia,", "Mexico,", "the", "Philippines,", "South", "Korea,", "Taiwan", "and", "Turkey;", "and", "Two", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil", "and", "Thailand."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p191_s0", "idA": "1316175_11_item1_p198_s0", "sentA": "The patents and applications described above contain claims directed to varespladib and A-001 compositions of matter and to various methods of making and using varespladib and A-001, including methods of treating various inflammatory conditions.", "sentB": "The patents and applications described above contain claims directed to varespladib and varespladib sodium compositions of matter and to various methods of making and using varespladib and varespladib sodium, including methods of treating various inflammatory conditions.", "type": 2, "words": ["<tag1>", "The", "patents", "and", "applications", "described", "above", "contain", "claims", "directed", "to", "varespladib", "and", "A-001", "compositions", "of", "matter", "and", "to", "various", "methods", "of", "making", "and", "using", "varespladib", "and", "A-001,", "including", "methods", "of", "treating", "various", "inflammatory", "conditions.", "<tag2>", "The", "patents", "and", "applications", "described", "above", "contain", "claims", "directed", "to", "varespladib", "and", "varespladib", "sodium", "compositions", "of", "matter", "and", "to", "various", "methods", "of", "making", "and", "using", "varespladib", "and", "varespladib", "sodium,", "including", "methods", "of", "treating", "various", "inflammatory", "conditions.", "<tag3>"], "wordsA": ["The", "patents", "and", "applications", "described", "above", "contain", "claims", "directed", "to", "varespladib", "and", "A-001", "compositions", "of", "matter", "and", "to", "various", "methods", "of", "making", "and", "using", "varespladib", "and", "A-001,", "including", "methods", "of", "treating", "various", "inflammatory", "conditions."], "wordsB": ["The", "patents", "and", "applications", "described", "above", "contain", "claims", "directed", "to", "varespladib", "and", "varespladib", "sodium", "compositions", "of", "matter", "and", "to", "various", "methods", "of", "making", "and", "using", "varespladib", "and", "varespladib", "sodium,", "including", "methods", "of", "treating", "various", "inflammatory", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p191_s2", "idA": "1316175_11_item1_p198_s2", "sentA": "The primary U.S. composition of matter patent for varespladib and A-00l currently expires in August 2014.", "sentB": "The primary U.S. composition of matter patent for varespladib and varespladib sodium currently expires in August 2014.", "type": 2, "words": ["<tag1>", "The", "primary", "U.S.", "composition", "of", "matter", "patent", "for", "varespladib", "and", "A-00l", "currently", "expires", "in", "August", "2014.", "<tag2>", "The", "primary", "U.S.", "composition", "of", "matter", "patent", "for", "varespladib", "and", "varespladib", "sodium", "currently", "expires", "in", "August", "2014.", "<tag3>"], "wordsA": ["The", "primary", "U.S.", "composition", "of", "matter", "patent", "for", "varespladib", "and", "A-00l", "currently", "expires", "in", "August", "2014."], "wordsB": ["The", "primary", "U.S.", "composition", "of", "matter", "patent", "for", "varespladib", "and", "varespladib", "sodium", "currently", "expires", "in", "August", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p209_s1", "idA": "1316175_11_item1_p198_s3", "sentA": "This patent is expected to be eligible for a Hatch-Waxman term restoration of up to five years, which could extend the expiration date to August 2019.", "sentB": "One of the U.S. patents is expected to be eligible for a Hatch-Waxman term restoration of up to five years, which could extend the expiration date to May 2027.", "type": 2, "words": ["<tag1>", "This", "patent", "is", "expected", "to", "be", "eligible", "for", "a", "Hatch-Waxman", "term", "restoration", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "August", "2019.", "<tag2>", "One", "of", "the", "U.S.", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Hatch-Waxman", "term", "restoration", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027.", "<tag3>"], "wordsA": ["This", "patent", "is", "expected", "to", "be", "eligible", "for", "a", "Hatch-Waxman", "term", "restoration", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "August", "2019."], "wordsB": ["One", "of", "the", "U.S.", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Hatch-Waxman", "term", "restoration", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p18_s0", "idA": "1316175_11_item1_p19_s0", "sentA": "In a sheep model of allergen-induced asthma, inhaled A-001 demonstrated an improvement in lung function similar to inhaled steroids.", "sentB": "allergen-induced asthma, inhaled varespladib sodium demonstrated an improvement in lung function similar to inhaled steroids.", "type": 2, "words": ["<tag1>", "In", "a", "sheep", "model", "of", "allergen-induced", "asthma,", "inhaled", "A-001", "demonstrated", "an", "improvement", "in", "lung", "function", "similar", "to", "inhaled", "steroids.", "<tag2>", "allergen-induced", "asthma,", "inhaled", "varespladib", "sodium", "demonstrated", "an", "improvement", "in", "lung", "function", "similar", "to", "inhaled", "steroids.", "<tag3>"], "wordsA": ["In", "a", "sheep", "model", "of", "allergen-induced", "asthma,", "inhaled", "A-001", "demonstrated", "an", "improvement", "in", "lung", "function", "similar", "to", "inhaled", "steroids."], "wordsB": ["allergen-induced", "asthma,", "inhaled", "varespladib", "sodium", "demonstrated", "an", "improvement", "in", "lung", "function", "similar", "to", "inhaled", "steroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p1_s0", "idA": "1316175_11_item1_p1_s0", "sentA": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.", "sentB": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation.", "type": 2, "words": ["<tag1>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "cardiovascular", "and", "autoimmune", "diseases.", "<tag2>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation.", "<tag3>"], "wordsA": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "cardiovascular", "and", "autoimmune", "diseases."], "wordsB": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p1_s1", "idA": "1316175_11_item1_p1_s1", "sentA": "We currently have one Phase 3 clinical program, varespladib, and two Phase 2 clinical programs, A-623 and A-001.", "sentB": "We currently have one Phase 2 clinical program, blisibimod.", "type": 2, "words": ["<tag1>", "We", "currently", "have", "one", "Phase", "3", "clinical", "program,", "varespladib,", "and", "two", "Phase", "2", "clinical", "programs,", "A-623", "and", "A-001.", "<tag2>", "We", "currently", "have", "one", "Phase", "2", "clinical", "program,", "blisibimod.", "<tag3>"], "wordsA": ["We", "currently", "have", "one", "Phase", "3", "clinical", "program,", "varespladib,", "and", "two", "Phase", "2", "clinical", "programs,", "A-623", "and", "A-001."], "wordsB": ["We", "currently", "have", "one", "Phase", "2", "clinical", "program,", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p193_s0", "idA": "1316175_11_item1_p200_s0", "sentA": "As of the date of this report, our internally developed varespladib and A-001 patent portfolio includes:", "sentB": "As of the date of this report, our internally developed varespladib and varespladib sodium patent portfolio includes:", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "internally", "developed", "varespladib", "and", "A-001", "patent", "portfolio", "includes:", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "our", "internally", "developed", "varespladib", "and", "varespladib", "sodium", "patent", "portfolio", "includes:", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "internally", "developed", "varespladib", "and", "A-001", "patent", "portfolio", "includes:"], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "our", "internally", "developed", "varespladib", "and", "varespladib", "sodium", "patent", "portfolio", "includes:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p194_s0", "idA": "1316175_11_item1_p201_s0", "sentA": "National phase applications in the European Patent Office, the Eurasian Patent Organization and 17 other countries (Australia, Brazil, Canada, China, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, The Philippines, Singapore, South Africa, South Korea and Vietnam).", "sentB": "Pending national phase applications arising from a fourth PCT application in the European Patent Office, the Eurasian Patent Organization and 19 other countries; and Pending national phase applications arising from a fifth PCT application in the European Patent Office, Brazil, Canada, China, India and Japan.", "type": 2, "words": ["<tag1>", "National", "phase", "applications", "in", "the", "European", "Patent", "Office,", "the", "Eurasian", "Patent", "Organization", "and", "17", "other", "countries", "(Australia,", "Brazil,", "Canada,", "China,", "Hong", "Kong,", "India,", "Indonesia,", "Israel,", "Japan,", "Malaysia,", "Mexico,", "New", "Zealand,", "The", "Philippines,", "Singapore,", "South", "Africa,", "South", "Korea", "and", "Vietnam).", "<tag2>", "Pending", "national", "phase", "applications", "arising", "from", "a", "fourth", "PCT", "application", "in", "the", "European", "Patent", "Office,", "the", "Eurasian", "Patent", "Organization", "and", "19", "other", "countries;", "and", "Pending", "national", "phase", "applications", "arising", "from", "a", "fifth", "PCT", "application", "in", "the", "European", "Patent", "Office,", "Brazil,", "Canada,", "China,", "India", "and", "Japan.", "<tag3>"], "wordsA": ["National", "phase", "applications", "in", "the", "European", "Patent", "Office,", "the", "Eurasian", "Patent", "Organization", "and", "17", "other", "countries", "(Australia,", "Brazil,", "Canada,", "China,", "Hong", "Kong,", "India,", "Indonesia,", "Israel,", "Japan,", "Malaysia,", "Mexico,", "New", "Zealand,", "The", "Philippines,", "Singapore,", "South", "Africa,", "South", "Korea", "and", "Vietnam)."], "wordsB": ["Pending", "national", "phase", "applications", "arising", "from", "a", "fourth", "PCT", "application", "in", "the", "European", "Patent", "Office,", "the", "Eurasian", "Patent", "Organization", "and", "19", "other", "countries;", "and", "Pending", "national", "phase", "applications", "arising", "from", "a", "fifth", "PCT", "application", "in", "the", "European", "Patent", "Office,", "Brazil,", "Canada,", "China,", "India", "and", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p195_s0", "idA": "1316175_11_item1_p202_s0", "sentA": "We own, and therefore hold all worldwide rights in and to, these patent applications, which contain claims directed to varespladib and A-001 compositions of matter and methods of treating various cardiovascular indications.", "sentB": "We own, and therefore hold all worldwide rights in and to, these patent applications, which contain claims directed to varespladib and varespladib sodium compositions of matter and methods of treating various cardiovascular indications.", "type": 2, "words": ["<tag1>", "We", "own,", "and", "therefore", "hold", "all", "worldwide", "rights", "in", "and", "to,", "these", "patent", "applications,", "which", "contain", "claims", "directed", "to", "varespladib", "and", "A-001", "compositions", "of", "matter", "and", "methods", "of", "treating", "various", "cardiovascular", "indications.", "<tag2>", "We", "own,", "and", "therefore", "hold", "all", "worldwide", "rights", "in", "and", "to,", "these", "patent", "applications,", "which", "contain", "claims", "directed", "to", "varespladib", "and", "varespladib", "sodium", "compositions", "of", "matter", "and", "methods", "of", "treating", "various", "cardiovascular", "indications.", "<tag3>"], "wordsA": ["We", "own,", "and", "therefore", "hold", "all", "worldwide", "rights", "in", "and", "to,", "these", "patent", "applications,", "which", "contain", "claims", "directed", "to", "varespladib", "and", "A-001", "compositions", "of", "matter", "and", "methods", "of", "treating", "various", "cardiovascular", "indications."], "wordsB": ["We", "own,", "and", "therefore", "hold", "all", "worldwide", "rights", "in", "and", "to,", "these", "patent", "applications,", "which", "contain", "claims", "directed", "to", "varespladib", "and", "varespladib", "sodium", "compositions", "of", "matter", "and", "methods", "of", "treating", "various", "cardiovascular", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p196_s0", "idA": "1316175_11_item1_p203_s0", "sentA": "Several of the pending U.S. and non-U.S. patent applications include disclosure relating to the combination of varespladib and A-001 with various cardiovascular drugs, including statins.", "sentB": "Several of the pending U.S. and non-U.S. patent applications include disclosure relating to the combination of varespladib and varespladib sodium with various cardiovascular drugs, including statins.", "type": 2, "words": ["<tag1>", "Several", "of", "the", "pending", "U.S.", "and", "non-U.S.", "patent", "applications", "include", "disclosure", "relating", "to", "the", "combination", "of", "varespladib", "and", "A-001", "with", "various", "cardiovascular", "drugs,", "including", "statins.", "<tag2>", "Several", "of", "the", "pending", "U.S.", "and", "non-U.S.", "patent", "applications", "include", "disclosure", "relating", "to", "the", "combination", "of", "varespladib", "and", "varespladib", "sodium", "with", "various", "cardiovascular", "drugs,", "including", "statins.", "<tag3>"], "wordsA": ["Several", "of", "the", "pending", "U.S.", "and", "non-U.S.", "patent", "applications", "include", "disclosure", "relating", "to", "the", "combination", "of", "varespladib", "and", "A-001", "with", "various", "cardiovascular", "drugs,", "including", "statins."], "wordsB": ["Several", "of", "the", "pending", "U.S.", "and", "non-U.S.", "patent", "applications", "include", "disclosure", "relating", "to", "the", "combination", "of", "varespladib", "and", "varespladib", "sodium", "with", "various", "cardiovascular", "drugs,", "including", "statins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p198_s0", "idA": "1316175_11_item1_p205_s0", "sentA": "One pending non-EP foreign patent application in Brazil (also listed above as covering varespladib and A-001).", "sentB": "Two U.S. patents; One pending U.S. non-provisional patent application (also listed above as covering varespladib and varespladib sodium); Five EP patents (two also listed above as covering varespladib and varespladib sodium), each validated in one or more of Albania, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, the Netherlands, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland and the United Kingdom; 14 non-EP foreign patents (six also listed above as covering varespladib and varespladib sodium) in Argentina, Australia, Canada, China, India, Mexico, South Korea and Taiwan; and One pending non-EP foreign patent application in Brazil (also listed above as covering varespladib and varespladib sodium).", "type": 2, "words": ["<tag1>", "One", "pending", "non-EP", "foreign", "patent", "application", "in", "Brazil", "(also", "listed", "above", "as", "covering", "varespladib", "and", "A-001).", "<tag2>", "Two", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application", "(also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium);", "Five", "EP", "patents", "(two", "also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium),", "each", "validated", "in", "one", "or", "more", "of", "Albania,", "Austria,", "Belgium,", "Denmark,", "Finland,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Latvia,", "Liechtenstein,", "Lithuania,", "Luxembourg,", "the", "Netherlands,", "Portugal,", "Romania,", "Slovenia,", "Spain,", "Sweden,", "Switzerland", "and", "the", "United", "Kingdom;", "14", "non-EP", "foreign", "patents", "(six", "also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium)", "in", "Argentina,", "Australia,", "Canada,", "China,", "India,", "Mexico,", "South", "Korea", "and", "Taiwan;", "and", "One", "pending", "non-EP", "foreign", "patent", "application", "in", "Brazil", "(also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium).", "<tag3>"], "wordsA": ["One", "pending", "non-EP", "foreign", "patent", "application", "in", "Brazil", "(also", "listed", "above", "as", "covering", "varespladib", "and", "A-001)."], "wordsB": ["Two", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application", "(also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium);", "Five", "EP", "patents", "(two", "also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium),", "each", "validated", "in", "one", "or", "more", "of", "Albania,", "Austria,", "Belgium,", "Denmark,", "Finland,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Latvia,", "Liechtenstein,", "Lithuania,", "Luxembourg,", "the", "Netherlands,", "Portugal,", "Romania,", "Slovenia,", "Spain,", "Sweden,", "Switzerland", "and", "the", "United", "Kingdom;", "14", "non-EP", "foreign", "patents", "(six", "also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium)", "in", "Argentina,", "Australia,", "Canada,", "China,", "India,", "Mexico,", "South", "Korea", "and", "Taiwan;", "and", "One", "pending", "non-EP", "foreign", "patent", "application", "in", "Brazil", "(also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p202_s0", "idA": "1316175_11_item1_p205_s0", "sentA": "One pending non-EP foreign patent application in Brazil (also listed above as covering varespladib and A-001).", "sentB": "National phase applications arising from a second PCT application in Japan and Singapore (both also listed above as covering varespladib and varespladib sodium); and National phase application arising from a third PCT application in Japan (also above as covering varespladib and varespladib sodium).", "type": 2, "words": ["<tag1>", "One", "pending", "non-EP", "foreign", "patent", "application", "in", "Brazil", "(also", "listed", "above", "as", "covering", "varespladib", "and", "A-001).", "<tag2>", "National", "phase", "applications", "arising", "from", "a", "second", "PCT", "application", "in", "Japan", "and", "Singapore", "(both", "also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium);", "and", "National", "phase", "application", "arising", "from", "a", "third", "PCT", "application", "in", "Japan", "(also", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium).", "<tag3>"], "wordsA": ["One", "pending", "non-EP", "foreign", "patent", "application", "in", "Brazil", "(also", "listed", "above", "as", "covering", "varespladib", "and", "A-001)."], "wordsB": ["National", "phase", "applications", "arising", "from", "a", "second", "PCT", "application", "in", "Japan", "and", "Singapore", "(both", "also", "listed", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium);", "and", "National", "phase", "application", "arising", "from", "a", "third", "PCT", "application", "in", "Japan", "(also", "above", "as", "covering", "varespladib", "and", "varespladib", "sodium)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p204_s0", "idA": "1316175_11_item1_p211_s0", "sentA": "As of the date of this report, our new sPLA 2 compound patent portfolio includes over 30 licensed U.S. patents, one pending U.S. non-provisional patent application, three EP patents, one pending EP patent application, four non-EP foreign patents, and one pending non-EP foreign patent application not listed above as covering A-001, varespladib or A-003.", "sentB": "As of the date of this report, our new sPLA 2 compound patent portfolio includes 28 licensed U.S. patents and two EP patents not listed above as covering varespladib sodium, varespladib or A-003.", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "new", "sPLA", "2", "compound", "patent", "portfolio", "includes", "over", "30", "licensed", "U.S.", "patents,", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "three", "EP", "patents,", "one", "pending", "EP", "patent", "application,", "four", "non-EP", "foreign", "patents,", "and", "one", "pending", "non-EP", "foreign", "patent", "application", "not", "listed", "above", "as", "covering", "A-001,", "varespladib", "or", "A-003.", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "our", "new", "sPLA", "2", "compound", "patent", "portfolio", "includes", "28", "licensed", "U.S.", "patents", "and", "two", "EP", "patents", "not", "listed", "above", "as", "covering", "varespladib", "sodium,", "varespladib", "or", "A-003.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "new", "sPLA", "2", "compound", "patent", "portfolio", "includes", "over", "30", "licensed", "U.S.", "patents,", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "three", "EP", "patents,", "one", "pending", "EP", "patent", "application,", "four", "non-EP", "foreign", "patents,", "and", "one", "pending", "non-EP", "foreign", "patent", "application", "not", "listed", "above", "as", "covering", "A-001,", "varespladib", "or", "A-003."], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "our", "new", "sPLA", "2", "compound", "patent", "portfolio", "includes", "28", "licensed", "U.S.", "patents", "and", "two", "EP", "patents", "not", "listed", "above", "as", "covering", "varespladib", "sodium,", "varespladib", "or", "A-003."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p206_s0", "idA": "1316175_11_item1_p213_s0", "sentA": "As of the date of this report, our A-623 patent portfolio includes:", "sentB": "As of the date of this report, our blisibimod patent portfolio includes:", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "A-623", "patent", "portfolio", "includes:", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "A-623", "patent", "portfolio", "includes:"], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p207_s0", "idA": "1316175_11_item1_p214_s0", "sentA": "13 pending non-EP foreign patent applications in Brazil, Bulgaria, Canada, China, the Czech Republic, Hong Kong, Hungary, Israel, Mexico, Norway, Poland, Serbia and Slovakia.", "sentB": "Two U.S. patents; One pending U.S. non-provisional patent application; One EP patent validated in Albania, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Monaco, the Netherlands, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom; Two pending EP patent applications; Thirteen non-EP foreign patents in Australia, China, Estonia, Eurasia (validated in all nine Eurasian countries), Hong Kong, Japan, New Zealand, the Philippines, Singapore, South Korea and South Africa; and Twelve pending non-EP foreign patent applications in Brazil, Bulgaria, China, the Czech Republic, Hong Kong, Hungary, Israel, Mexico, Norway, Poland, Serbia and Slovakia.", "type": 2, "words": ["<tag1>", "13", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "Canada,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia", "and", "Slovakia.", "<tag2>", "Two", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application;", "One", "EP", "patent", "validated", "in", "Albania,", "Austria,", "Belgium,", "Cyprus,", "Denmark,", "Finland,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Latvia,", "Liechtenstein,", "Lithuania,", "Luxembourg,", "Monaco,", "the", "Netherlands,", "Portugal,", "Romania,", "Slovenia,", "Spain,", "Sweden,", "Switzerland,", "Turkey", "and", "the", "United", "Kingdom;", "Two", "pending", "EP", "patent", "applications;", "Thirteen", "non-EP", "foreign", "patents", "in", "Australia,", "China,", "Estonia,", "Eurasia", "(validated", "in", "all", "nine", "Eurasian", "countries),", "Hong", "Kong,", "Japan,", "New", "Zealand,", "the", "Philippines,", "Singapore,", "South", "Korea", "and", "South", "Africa;", "and", "Twelve", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia", "and", "Slovakia.", "<tag3>"], "wordsA": ["13", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "Canada,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia", "and", "Slovakia."], "wordsB": ["Two", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application;", "One", "EP", "patent", "validated", "in", "Albania,", "Austria,", "Belgium,", "Cyprus,", "Denmark,", "Finland,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Latvia,", "Liechtenstein,", "Lithuania,", "Luxembourg,", "Monaco,", "the", "Netherlands,", "Portugal,", "Romania,", "Slovenia,", "Spain,", "Sweden,", "Switzerland,", "Turkey", "and", "the", "United", "Kingdom;", "Two", "pending", "EP", "patent", "applications;", "Thirteen", "non-EP", "foreign", "patents", "in", "Australia,", "China,", "Estonia,", "Eurasia", "(validated", "in", "all", "nine", "Eurasian", "countries),", "Hong", "Kong,", "Japan,", "New", "Zealand,", "the", "Philippines,", "Singapore,", "South", "Korea", "and", "South", "Africa;", "and", "Twelve", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia", "and", "Slovakia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p214_s0", "idA": "1316175_11_item1_p221_s0", "sentA": "Depending upon the timing, duration and specifics of FDA approval of varespladib, A-623, A-001, A-003 or one or more new sPLA 2 compounds, one or more of the U.S. patents listed above may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act.", "sentB": "Depending upon the timing, duration and specifics of FDA approval of varespladib, blisibimod, varespladib sodium, A-003 or one or more new sPLA 2 compounds, one or more of the U.S. patents listed above may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act.", "type": 2, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "varespladib,", "A-623,", "A-001,", "A-003", "or", "one", "or", "more", "new", "sPLA", "2", "compounds,", "one", "or", "more", "of", "the", "U.S.", "patents", "listed", "above", "may", "be", "eligible", "for", "limited", "patent", "term", "restoration", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act.", "<tag2>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "varespladib,", "blisibimod,", "varespladib", "sodium,", "A-003", "or", "one", "or", "more", "new", "sPLA", "2", "compounds,", "one", "or", "more", "of", "the", "U.S.", "patents", "listed", "above", "may", "be", "eligible", "for", "limited", "patent", "term", "restoration", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "varespladib,", "A-623,", "A-001,", "A-003", "or", "one", "or", "more", "new", "sPLA", "2", "compounds,", "one", "or", "more", "of", "the", "U.S.", "patents", "listed", "above", "may", "be", "eligible", "for", "limited", "patent", "term", "restoration", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act."], "wordsB": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "varespladib,", "blisibimod,", "varespladib", "sodium,", "A-003", "or", "one", "or", "more", "new", "sPLA", "2", "compounds,", "one", "or", "more", "of", "the", "U.S.", "patents", "listed", "above", "may", "be", "eligible", "for", "limited", "patent", "term", "restoration", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p221_s0", "idA": "1316175_11_item1_p228_s0", "sentA": "Under the agreement, we obtained exclusive rights to (i) use licensed patent rights and know-how to identify and develop sPLA 2 inhibitors, (ii) develop, make, have made, use, import, offer for sale and sell licensed compounds and pharmaceutical formulations thereof, including varespladib, A-001, A-003 and other sPLA 2 inhibitors and (iii) grant sublicenses.", "sentB": "Under the agreement, we obtained exclusive rights to (i) use licensed patent rights and know-how to identify and develop sPLA 2 inhibitors, (ii) develop, make, have made, use, import, offer for sale and sell licensed compounds and pharmaceutical formulations thereof, including varespladib, varespladib sodium, A-003 and other sPLA 2 inhibitors and (iii) grant sublicenses.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "to", "(i)", "use", "licensed", "patent", "rights", "and", "know-how", "to", "identify", "and", "develop", "sPLA", "2", "inhibitors,", "(ii)", "develop,", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale", "and", "sell", "licensed", "compounds", "and", "pharmaceutical", "formulations", "thereof,", "including", "varespladib,", "A-001,", "A-003", "and", "other", "sPLA", "2", "inhibitors", "and", "(iii)", "grant", "sublicenses.", "<tag2>", "Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "to", "(i)", "use", "licensed", "patent", "rights", "and", "know-how", "to", "identify", "and", "develop", "sPLA", "2", "inhibitors,", "(ii)", "develop,", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale", "and", "sell", "licensed", "compounds", "and", "pharmaceutical", "formulations", "thereof,", "including", "varespladib,", "varespladib", "sodium,", "A-003", "and", "other", "sPLA", "2", "inhibitors", "and", "(iii)", "grant", "sublicenses.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "to", "(i)", "use", "licensed", "patent", "rights", "and", "know-how", "to", "identify", "and", "develop", "sPLA", "2", "inhibitors,", "(ii)", "develop,", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale", "and", "sell", "licensed", "compounds", "and", "pharmaceutical", "formulations", "thereof,", "including", "varespladib,", "A-001,", "A-003", "and", "other", "sPLA", "2", "inhibitors", "and", "(iii)", "grant", "sublicenses."], "wordsB": ["Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "to", "(i)", "use", "licensed", "patent", "rights", "and", "know-how", "to", "identify", "and", "develop", "sPLA", "2", "inhibitors,", "(ii)", "develop,", "make,", "have", "made,", "use,", "import,", "offer", "for", "sale", "and", "sell", "licensed", "compounds", "and", "pharmaceutical", "formulations", "thereof,", "including", "varespladib,", "varespladib", "sodium,", "A-003", "and", "other", "sPLA", "2", "inhibitors", "and", "(iii)", "grant", "sublicenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p22_s1", "idA": "1316175_11_item1_p22_s1", "sentA": "In published studies and our own clinical studies, significant elevations in sPLA 2 activity and mass have been seen from 24 hours to two weeks following an acute coronary syndrome and can persist for up to an additional 12 weeks thereafter.", "sentB": "In published studies and our own clinical studies, significant elevations in sPLA 2 activity and mass have been seen from 24 hours to two weeks following an event constituting acute coronary syndrome and can persist for up to an additional 12 weeks thereafter.", "type": 2, "words": ["<tag1>", "In", "published", "studies", "and", "our", "own", "clinical", "studies,", "significant", "elevations", "in", "sPLA", "2", "activity", "and", "mass", "have", "been", "seen", "from", "24", "hours", "to", "two", "weeks", "following", "an", "acute", "coronary", "syndrome", "and", "can", "persist", "for", "up", "to", "an", "additional", "12", "weeks", "thereafter.", "<tag2>", "In", "published", "studies", "and", "our", "own", "clinical", "studies,", "significant", "elevations", "in", "sPLA", "2", "activity", "and", "mass", "have", "been", "seen", "from", "24", "hours", "to", "two", "weeks", "following", "an", "event", "constituting", "acute", "coronary", "syndrome", "and", "can", "persist", "for", "up", "to", "an", "additional", "12", "weeks", "thereafter.", "<tag3>"], "wordsA": ["In", "published", "studies", "and", "our", "own", "clinical", "studies,", "significant", "elevations", "in", "sPLA", "2", "activity", "and", "mass", "have", "been", "seen", "from", "24", "hours", "to", "two", "weeks", "following", "an", "acute", "coronary", "syndrome", "and", "can", "persist", "for", "up", "to", "an", "additional", "12", "weeks", "thereafter."], "wordsB": ["In", "published", "studies", "and", "our", "own", "clinical", "studies,", "significant", "elevations", "in", "sPLA", "2", "activity", "and", "mass", "have", "been", "seen", "from", "24", "hours", "to", "two", "weeks", "following", "an", "event", "constituting", "acute", "coronary", "syndrome", "and", "can", "persist", "for", "up", "to", "an", "additional", "12", "weeks", "thereafter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p222_s1", "idA": "1316175_11_item1_p230_s0", "sentA": "by Shionogi Co., Ltd. prior to the agreement remained under the control of Shionogi Co., Ltd. Licensed patent rights that were not classified as core remained under the control of Eli Lilly and Shionogi Co., Ltd.", "sentB": "All core patents prosecuted and maintained by Shionogi Co., Ltd. prior to the agreement remained under the control of Shionogi Co., Ltd. Licensed patent rights that were not classified as core remained under the control of Eli Lilly and Shionogi Co., Ltd.", "type": 2, "words": ["<tag1>", "by", "Shionogi", "Co.,", "Ltd.", "prior", "to", "the", "agreement", "remained", "under", "the", "control", "of", "Shionogi", "Co.,", "Ltd.", "Licensed", "patent", "rights", "that", "were", "not", "classified", "as", "core", "remained", "under", "the", "control", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag2>", "All", "core", "patents", "prosecuted", "and", "maintained", "by", "Shionogi", "Co.,", "Ltd.", "prior", "to", "the", "agreement", "remained", "under", "the", "control", "of", "Shionogi", "Co.,", "Ltd.", "Licensed", "patent", "rights", "that", "were", "not", "classified", "as", "core", "remained", "under", "the", "control", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag3>"], "wordsA": ["by", "Shionogi", "Co.,", "Ltd.", "prior", "to", "the", "agreement", "remained", "under", "the", "control", "of", "Shionogi", "Co.,", "Ltd.", "Licensed", "patent", "rights", "that", "were", "not", "classified", "as", "core", "remained", "under", "the", "control", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "wordsB": ["All", "core", "patents", "prosecuted", "and", "maintained", "by", "Shionogi", "Co.,", "Ltd.", "prior", "to", "the", "agreement", "remained", "under", "the", "control", "of", "Shionogi", "Co.,", "Ltd.", "Licensed", "patent", "rights", "that", "were", "not", "classified", "as", "core", "remained", "under", "the", "control", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p223_s4", "idA": "1316175_11_item1_p231_s4", "sentA": "For A-001, we are required to pay up to $3.0 million upon achievement of certain clinical development milestones and up to $25.0 million upon achievement of certain approval and post-approval sales milestones.", "sentB": "For varespladib sodium, we are required to pay up to $3.0 million upon achievement of certain clinical development milestones and up to $25.0 million upon achievement of certain approval and post-approval sales milestones.", "type": 2, "words": ["<tag1>", "For", "A-001,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones.", "<tag2>", "For", "varespladib", "sodium,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones.", "<tag3>"], "wordsA": ["For", "A-001,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones."], "wordsB": ["For", "varespladib", "sodium,", "we", "are", "required", "to", "pay", "up", "to", "$3.0", "million", "upon", "achievement", "of", "certain", "clinical", "development", "milestones", "and", "up", "to", "$25.0", "million", "upon", "achievement", "of", "certain", "approval", "and", "post-approval", "sales", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p225_s0", "idA": "1316175_11_item1_p233_s0", "sentA": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to A-623, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "type": 2, "words": ["<tag1>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "A-623,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag3>"], "wordsA": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "A-623,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p226_s0", "idA": "1316175_11_item1_p234_s0", "sentA": "Under the agreement, we obtained exclusive rights under the licensed patents and know-how to research, develop, make, have made, use, sell, offer for sale and import pharmaceutical products containing A-623, as well as the right to grant sublicenses.", "sentB": "Under the agreement, we obtained exclusive rights under the licensed patents and know-how to research, develop, make, have made, use, sell, offer for sale and import pharmaceutical products containing blisibimod, as well as the right to grant sublicenses.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "A-623,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses.", "<tag2>", "Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "A-623,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses."], "wordsB": ["Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p226_s2", "idA": "1316175_11_item1_p234_s2", "sentA": "During the period of the agreement, we are responsible for the filing, prosecution, defense and maintenance of all exclusively licensed A-623 patents and applications.", "sentB": "During the period of the agreement, we are responsible for the filing, prosecution, defense and maintenance of all exclusively licensed blisibimod patents and applications.", "type": 2, "words": ["<tag1>", "During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "A-623", "patents", "and", "applications.", "<tag2>", "During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "blisibimod", "patents", "and", "applications.", "<tag3>"], "wordsA": ["During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "A-623", "patents", "and", "applications."], "wordsB": ["During", "the", "period", "of", "the", "agreement,", "we", "are", "responsible", "for", "the", "filing,", "prosecution,", "defense", "and", "maintenance", "of", "all", "exclusively", "licensed", "blisibimod", "patents", "and", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p213_s3", "idA": "1316175_11_item1_p234_s3", "sentA": "Amgen retains the right to review all documents relating to said filing, prosecution, defense and maintenance, and we are required to incorporate all reasonable comments or suggestions that Amgen makes with regard to these documents.", "sentB": "There is no assurance that a court would find in our favor on questions of infringement or validity, and we could incur substantial costs in litigation if we are required to defend against patent suits brought by third parties or if we initiate these suits.", "type": 2, "words": ["<tag1>", "Amgen", "retains", "the", "right", "to", "review", "all", "documents", "relating", "to", "said", "filing,", "prosecution,", "defense", "and", "maintenance,", "and", "we", "are", "required", "to", "incorporate", "all", "reasonable", "comments", "or", "suggestions", "that", "Amgen", "makes", "with", "regard", "to", "these", "documents.", "<tag2>", "There", "is", "no", "assurance", "that", "a", "court", "would", "find", "in", "our", "favor", "on", "questions", "of", "infringement", "or", "validity,", "and", "we", "could", "incur", "substantial", "costs", "in", "litigation", "if", "we", "are", "required", "to", "defend", "against", "patent", "suits", "brought", "by", "third", "parties", "or", "if", "we", "initiate", "these", "suits.", "<tag3>"], "wordsA": ["Amgen", "retains", "the", "right", "to", "review", "all", "documents", "relating", "to", "said", "filing,", "prosecution,", "defense", "and", "maintenance,", "and", "we", "are", "required", "to", "incorporate", "all", "reasonable", "comments", "or", "suggestions", "that", "Amgen", "makes", "with", "regard", "to", "these", "documents."], "wordsB": ["There", "is", "no", "assurance", "that", "a", "court", "would", "find", "in", "our", "favor", "on", "questions", "of", "infringement", "or", "validity,", "and", "we", "could", "incur", "substantial", "costs", "in", "litigation", "if", "we", "are", "required", "to", "defend", "against", "patent", "suits", "brought", "by", "third", "parties", "or", "if", "we", "initiate", "these", "suits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p227_s1", "idA": "1316175_11_item1_p235_s1", "sentA": "Similarly, we are prohibited during the term of the agreement from clinically developing or commercializing any molecule other than A-623 that modulates BAFF as the primary intended therapeutic mechanism of action.", "sentB": "Similarly, we are prohibited during the term of the agreement from clinically developing or commercializing any molecule other than blisibimod that modulates BAFF as the primary intended therapeutic mechanism of action.", "type": 2, "words": ["<tag1>", "Similarly,", "we", "are", "prohibited", "during", "the", "term", "of", "the", "agreement", "from", "clinically", "developing", "or", "commercializing", "any", "molecule", "other", "than", "A-623", "that", "modulates", "BAFF", "as", "the", "primary", "intended", "therapeutic", "mechanism", "of", "action.", "<tag2>", "Similarly,", "we", "are", "prohibited", "during", "the", "term", "of", "the", "agreement", "from", "clinically", "developing", "or", "commercializing", "any", "molecule", "other", "than", "blisibimod", "that", "modulates", "BAFF", "as", "the", "primary", "intended", "therapeutic", "mechanism", "of", "action.", "<tag3>"], "wordsA": ["Similarly,", "we", "are", "prohibited", "during", "the", "term", "of", "the", "agreement", "from", "clinically", "developing", "or", "commercializing", "any", "molecule", "other", "than", "A-623", "that", "modulates", "BAFF", "as", "the", "primary", "intended", "therapeutic", "mechanism", "of", "action."], "wordsB": ["Similarly,", "we", "are", "prohibited", "during", "the", "term", "of", "the", "agreement", "from", "clinically", "developing", "or", "commercializing", "any", "molecule", "other", "than", "blisibimod", "that", "modulates", "BAFF", "as", "the", "primary", "intended", "therapeutic", "mechanism", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p228_s1", "idA": "1316175_11_item1_p236_s1", "sentA": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon initiation of the first Phase 3 clinical study for any A-623 formulation.", "sentB": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon initiation of the first Phase 3 clinical study for any blisibimod formulation.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "A-623", "formulation.", "<tag2>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "A-623", "formulation."], "wordsB": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p228_s4", "idA": "1316175_11_item1_p237_s0", "sentA": "and end upon the later of 10 years from the date of first commercial sale in that country or the expiration date of the last valid claim of a licensed patent that covers the manufacture, use or sale, offer to sell or import of the product.", "sentB": "Our royalty payment obligations for a particular product in a particular country begin on the date of the first commercial sale of the licensed product in that country, and end upon the later of 10 years from the date of first commercial sale in that country or the expiration date of the last valid claim of a licensed patent that covers the manufacture, use or sale, offer to sell or import of the product.", "type": 2, "words": ["<tag1>", "and", "end", "upon", "the", "later", "of", "10", "years", "from", "the", "date", "of", "first", "commercial", "sale", "in", "that", "country", "or", "the", "expiration", "date", "of", "the", "last", "valid", "claim", "of", "a", "licensed", "patent", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell", "or", "import", "of", "the", "product.", "<tag2>", "Our", "royalty", "payment", "obligations", "for", "a", "particular", "product", "in", "a", "particular", "country", "begin", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "licensed", "product", "in", "that", "country,", "and", "end", "upon", "the", "later", "of", "10", "years", "from", "the", "date", "of", "first", "commercial", "sale", "in", "that", "country", "or", "the", "expiration", "date", "of", "the", "last", "valid", "claim", "of", "a", "licensed", "patent", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell", "or", "import", "of", "the", "product.", "<tag3>"], "wordsA": ["and", "end", "upon", "the", "later", "of", "10", "years", "from", "the", "date", "of", "first", "commercial", "sale", "in", "that", "country", "or", "the", "expiration", "date", "of", "the", "last", "valid", "claim", "of", "a", "licensed", "patent", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell", "or", "import", "of", "the", "product."], "wordsB": ["Our", "royalty", "payment", "obligations", "for", "a", "particular", "product", "in", "a", "particular", "country", "begin", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "licensed", "product", "in", "that", "country,", "and", "end", "upon", "the", "later", "of", "10", "years", "from", "the", "date", "of", "first", "commercial", "sale", "in", "that", "country", "or", "the", "expiration", "date", "of", "the", "last", "valid", "claim", "of", "a", "licensed", "patent", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell", "or", "import", "of", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p231_s3", "idA": "1316175_11_item1_p240_s3", "sentA": "In selected therapeutic areas where we feel that any approved products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, acute care and orphan indications such as acute coronary syndrome and acute chest syndrome associated with sickle cell disease, we may seek to commercialize these product candidates alone.", "sentB": "In selected therapeutic areas where we feel that any approved products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we may seek to commercialize these product candidates alone.", "type": 2, "words": ["<tag1>", "In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "acute", "care", "and", "orphan", "indications", "such", "as", "acute", "coronary", "syndrome", "and", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "we", "may", "seek", "to", "commercialize", "these", "product", "candidates", "alone.", "<tag2>", "In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "these", "product", "candidates", "alone.", "<tag3>"], "wordsA": ["In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "acute", "care", "and", "orphan", "indications", "such", "as", "acute", "coronary", "syndrome", "and", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "we", "may", "seek", "to", "commercialize", "these", "product", "candidates", "alone."], "wordsB": ["In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "these", "product", "candidates", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p232_s0", "idA": "1316175_11_item1_p240_s4", "sentA": "In therapeutic areas that require a large sales force selling to a large and diverse prescribing population, such as chronic indications such as CAD, we currently plan to partner with third parties to commercialize our product candidates while retaining rights to co-promote our products to a select audience of high prescribing physicians in the United States, thereby supplementing or enhancing the efforts of a commercial partner.", "sentB": "commercialize our product candidates while retaining rights to co-promote our products to a select audience of high prescribing physicians in the United States, thereby supplementing or enhancing the efforts of a commercial partner.", "type": 2, "words": ["<tag1>", "In", "therapeutic", "areas", "that", "require", "a", "large", "sales", "force", "selling", "to", "a", "large", "and", "diverse", "prescribing", "population,", "such", "as", "chronic", "indications", "such", "as", "CAD,", "we", "currently", "plan", "to", "partner", "with", "third", "parties", "to", "commercialize", "our", "product", "candidates", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner.", "<tag2>", "commercialize", "our", "product", "candidates", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner.", "<tag3>"], "wordsA": ["In", "therapeutic", "areas", "that", "require", "a", "large", "sales", "force", "selling", "to", "a", "large", "and", "diverse", "prescribing", "population,", "such", "as", "chronic", "indications", "such", "as", "CAD,", "we", "currently", "plan", "to", "partner", "with", "third", "parties", "to", "commercialize", "our", "product", "candidates", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner."], "wordsB": ["commercialize", "our", "product", "candidates", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p235_s0", "idA": "1316175_11_item1_p245_s0", "sentA": "We intend to build the commercial infrastructure necessary to bring varespladib, A-623 and A-001 to market alone or in collaboration with a co-development or co-promotion partner.", "sentB": "We intend to build the commercial infrastructure necessary to bring our product candidates to market alone or in collaboration with a co-development or co-promotion partner.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "varespladib,", "A-623", "and", "A-001", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner.", "<tag2>", "We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidates", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner.", "<tag3>"], "wordsA": ["We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "varespladib,", "A-623", "and", "A-001", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner."], "wordsB": ["We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidates", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p236_s0", "idA": "1316175_11_item1_p246_s0", "sentA": "such as those we are developing.", "sentB": "Government authorities in the United States at the federal, state and local level and other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing.", "type": 2, "words": ["<tag1>", "such", "as", "those", "we", "are", "developing.", "<tag2>", "Government", "authorities", "in", "the", "United", "States", "at", "the", "federal,", "state", "and", "local", "level", "and", "other", "countries,", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing,", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag3>"], "wordsA": ["such", "as", "those", "we", "are", "developing."], "wordsB": ["Government", "authorities", "in", "the", "United", "States", "at", "the", "federal,", "state", "and", "local", "level", "and", "other", "countries,", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing,", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p236_s1", "idA": "1316175_11_item1_p246_s1", "sentA": "Our product candidates must be approved by the FDA through the new drug application, or NDA, process, and our biological product candidate, A-623, must be approved by the FDA through the biologics license application, or BLA, process before they may legally be marketed in the United States.", "sentB": "Our product candidates must be approved by the FDA through the new drug application, or NDA, process, and our biological product candidate, blisibimod, must be approved by the FDA through the biologics license application, or BLA, process before they may legally be marketed in the United States.", "type": 2, "words": ["<tag1>", "Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process,", "and", "our", "biological", "product", "candidate,", "A-623,", "must", "be", "approved", "by", "the", "FDA", "through", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States.", "<tag2>", "Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process,", "and", "our", "biological", "product", "candidate,", "blisibimod,", "must", "be", "approved", "by", "the", "FDA", "through", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process,", "and", "our", "biological", "product", "candidate,", "A-623,", "must", "be", "approved", "by", "the", "FDA", "through", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States."], "wordsB": ["Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process,", "and", "our", "biological", "product", "candidate,", "blisibimod,", "must", "be", "approved", "by", "the", "FDA", "through", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p55_s3", "idA": "1316175_11_item1_p251_s2", "sentA": "An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part of the IND.", "sentB": "These studies do not include the incidence of unstable angina as part of the composite end point.", "type": 2, "words": ["<tag1>", "An", "IND", "sponsor", "must", "submit", "the", "results", "of", "the", "preclinical", "tests,", "together", "with", "manufacturing", "information,", "analytical", "data", "and", "any", "available", "clinical", "data", "or", "literature,", "to", "the", "FDA", "as", "part", "of", "the", "IND.", "<tag2>", "These", "studies", "do", "not", "include", "the", "incidence", "of", "unstable", "angina", "as", "part", "of", "the", "composite", "end", "point.", "<tag3>"], "wordsA": ["An", "IND", "sponsor", "must", "submit", "the", "results", "of", "the", "preclinical", "tests,", "together", "with", "manufacturing", "information,", "analytical", "data", "and", "any", "available", "clinical", "data", "or", "literature,", "to", "the", "FDA", "as", "part", "of", "the", "IND."], "wordsB": ["These", "studies", "do", "not", "include", "the", "incidence", "of", "unstable", "angina", "as", "part", "of", "the", "composite", "end", "point."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p247_s0", "idA": "1316175_11_item1_p256_s1", "sentA": "In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.", "sentB": "for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.", "type": 2, "words": ["<tag1>", "In", "the", "case", "of", "some", "products", "for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients.", "<tag2>", "for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients.", "<tag3>"], "wordsA": ["In", "the", "case", "of", "some", "products", "for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients."], "wordsB": ["for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p213_s5", "idA": "1316175_11_item1_p259_s1", "sentA": "Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all.", "sentB": "Such a license may not be available on commercially acceptable terms, if at all.", "type": 2, "words": ["<tag1>", "Phase", "1,", "Phase", "2", "and", "Phase", "3", "testing", "may", "not", "be", "completed", "successfully", "within", "any", "specified", "period,", "if", "at", "all.", "<tag2>", "Such", "a", "license", "may", "not", "be", "available", "on", "commercially", "acceptable", "terms,", "if", "at", "all.", "<tag3>"], "wordsA": ["Phase", "1,", "Phase", "2", "and", "Phase", "3", "testing", "may", "not", "be", "completed", "successfully", "within", "any", "specified", "period,", "if", "at", "all."], "wordsB": ["Such", "a", "license", "may", "not", "be", "available", "on", "commercially", "acceptable", "terms,", "if", "at", "all."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p3_s4", "idA": "1316175_11_item1_p25_s2", "sentA": "As a result, LDL-C remains in circulation longer and has a greater tendency to deposit in the artery wall.", "sentB": "As a result, we have closed enrollment in the study and informed all investigators to remove patients from therapy immediately.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "LDL-C", "remains", "in", "circulation", "longer", "and", "has", "a", "greater", "tendency", "to", "deposit", "in", "the", "artery", "wall.", "<tag2>", "As", "a", "result,", "we", "have", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "immediately.", "<tag3>"], "wordsA": ["As", "a", "result,", "LDL-C", "remains", "in", "circulation", "longer", "and", "has", "a", "greater", "tendency", "to", "deposit", "in", "the", "artery", "wall."], "wordsB": ["As", "a", "result,", "we", "have", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "immediately."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p239_s0", "idA": "1316175_11_item1_p261_s0", "sentA": "The results of product development, preclinical studies and clinical studies, along with descriptions of the manufacturing process, analytical tests conducted on the drug or biological product, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA for a new drug or BLA for a biological product, requesting approval to market the product.", "sentB": "completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices regulations; submission to the FDA of an IND, which must become effective before human clinical studies may begin; performance of adequate and well-controlled human clinical studies according to Good Clinical Practices, or GCP, to establish the safety and efficacy of the proposed drug or biological product for its intended use; submission to the FDA of an NDA for a new drug or BLA for a biological product; satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biological product is produced to assess compliance with cGMP; and FDA review and approval of the NDA or BLA.", "type": 2, "words": ["<tag1>", "The", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "studies,", "along", "with", "descriptions", "of", "the", "manufacturing", "process,", "analytical", "tests", "conducted", "on", "the", "drug", "or", "biological", "product,", "proposed", "labeling", "and", "other", "relevant", "information,", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "for", "a", "new", "drug", "or", "BLA", "for", "a", "biological", "product,", "requesting", "approval", "to", "market", "the", "product.", "<tag2>", "completion", "of", "preclinical", "laboratory", "tests,", "animal", "studies", "and", "formulation", "studies", "according", "to", "Good", "Laboratory", "Practices", "regulations;", "submission", "to", "the", "FDA", "of", "an", "IND,", "which", "must", "become", "effective", "before", "human", "clinical", "studies", "may", "begin;", "performance", "of", "adequate", "and", "well-controlled", "human", "clinical", "studies", "according", "to", "Good", "Clinical", "Practices,", "or", "GCP,", "to", "establish", "the", "safety", "and", "efficacy", "of", "the", "proposed", "drug", "or", "biological", "product", "for", "its", "intended", "use;", "submission", "to", "the", "FDA", "of", "an", "NDA", "for", "a", "new", "drug", "or", "BLA", "for", "a", "biological", "product;", "satisfactory", "completion", "of", "an", "FDA", "inspection", "of", "the", "manufacturing", "facility", "or", "facilities", "at", "which", "the", "drug", "or", "biological", "product", "is", "produced", "to", "assess", "compliance", "with", "cGMP;", "and", "FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA.", "<tag3>"], "wordsA": ["The", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "studies,", "along", "with", "descriptions", "of", "the", "manufacturing", "process,", "analytical", "tests", "conducted", "on", "the", "drug", "or", "biological", "product,", "proposed", "labeling", "and", "other", "relevant", "information,", "are", "submitted", "to", "the", "FDA", "as", "part", "of", "an", "NDA", "for", "a", "new", "drug", "or", "BLA", "for", "a", "biological", "product,", "requesting", "approval", "to", "market", "the", "product."], "wordsB": ["completion", "of", "preclinical", "laboratory", "tests,", "animal", "studies", "and", "formulation", "studies", "according", "to", "Good", "Laboratory", "Practices", "regulations;", "submission", "to", "the", "FDA", "of", "an", "IND,", "which", "must", "become", "effective", "before", "human", "clinical", "studies", "may", "begin;", "performance", "of", "adequate", "and", "well-controlled", "human", "clinical", "studies", "according", "to", "Good", "Clinical", "Practices,", "or", "GCP,", "to", "establish", "the", "safety", "and", "efficacy", "of", "the", "proposed", "drug", "or", "biological", "product", "for", "its", "intended", "use;", "submission", "to", "the", "FDA", "of", "an", "NDA", "for", "a", "new", "drug", "or", "BLA", "for", "a", "biological", "product;", "satisfactory", "completion", "of", "an", "FDA", "inspection", "of", "the", "manufacturing", "facility", "or", "facilities", "at", "which", "the", "drug", "or", "biological", "product", "is", "produced", "to", "assess", "compliance", "with", "cGMP;", "and", "FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p256_s1", "idA": "1316175_11_item1_p266_s0", "sentA": "processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.", "sentB": "The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.", "type": 2, "words": ["<tag1>", "processes", "and", "facilities", "are", "in", "compliance", "with", "cGMP", "requirements", "and", "adequate", "to", "assure", "consistent", "production", "of", "the", "product", "within", "required", "specifications.", "<tag2>", "The", "FDA", "will", "not", "approve", "an", "application", "unless", "it", "determines", "that", "the", "manufacturing", "processes", "and", "facilities", "are", "in", "compliance", "with", "cGMP", "requirements", "and", "adequate", "to", "assure", "consistent", "production", "of", "the", "product", "within", "required", "specifications.", "<tag3>"], "wordsA": ["processes", "and", "facilities", "are", "in", "compliance", "with", "cGMP", "requirements", "and", "adequate", "to", "assure", "consistent", "production", "of", "the", "product", "within", "required", "specifications."], "wordsB": ["The", "FDA", "will", "not", "approve", "an", "application", "unless", "it", "determines", "that", "the", "manufacturing", "processes", "and", "facilities", "are", "in", "compliance", "with", "cGMP", "requirements", "and", "adequate", "to", "assure", "consistent", "production", "of", "the", "product", "within", "required", "specifications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p261_s0", "idA": "1316175_11_item1_p272_s0", "sentA": "The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity.", "sentB": "within the United States to the first applicant to gain approval of an NDA for a new chemical entity.", "type": 2, "words": ["<tag1>", "The", "FDCA", "provides", "a", "five-year", "period", "of", "non-patent", "marketing", "exclusivity", "within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity.", "<tag2>", "within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity.", "<tag3>"], "wordsA": ["The", "FDCA", "provides", "a", "five-year", "period", "of", "non-patent", "marketing", "exclusivity", "within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity."], "wordsB": ["within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p3_s2", "idA": "1316175_11_item1_p272_s1", "sentA": "A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance.", "sentB": "According to the DSMB, the chief reason is the inability of VISTA-16 to detect a statistically significant benefit of the drug on the prespecified primary and secondary endpoints even if the trial continues to its scheduled termination.", "type": 2, "words": ["<tag1>", "A", "drug", "is", "a", "new", "chemical", "entity", "if", "the", "FDA", "has", "not", "previously", "approved", "any", "other", "new", "drug", "containing", "the", "same", "active", "moiety,", "which", "is", "the", "molecule", "or", "ion", "responsible", "for", "the", "action", "of", "the", "drug", "substance.", "<tag2>", "According", "to", "the", "DSMB,", "the", "chief", "reason", "is", "the", "inability", "of", "VISTA-16", "to", "detect", "a", "statistically", "significant", "benefit", "of", "the", "drug", "on", "the", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continues", "to", "its", "scheduled", "termination.", "<tag3>"], "wordsA": ["A", "drug", "is", "a", "new", "chemical", "entity", "if", "the", "FDA", "has", "not", "previously", "approved", "any", "other", "new", "drug", "containing", "the", "same", "active", "moiety,", "which", "is", "the", "molecule", "or", "ion", "responsible", "for", "the", "action", "of", "the", "drug", "substance."], "wordsB": ["According", "to", "the", "DSMB,", "the", "chief", "reason", "is", "the", "inability", "of", "VISTA-16", "to", "detect", "a", "statistically", "significant", "benefit", "of", "the", "drug", "on", "the", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continues", "to", "its", "scheduled", "termination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p261_s6", "idA": "1316175_11_item1_p273_s0", "sentA": "will not delay the submission or approval of a full NDA.", "sentB": "Five-year and three-year exclusivity will not delay the submission or approval of a full NDA.", "type": 2, "words": ["<tag1>", "will", "not", "delay", "the", "submission", "or", "approval", "of", "a", "full", "NDA.", "<tag2>", "Five-year", "and", "three-year", "exclusivity", "will", "not", "delay", "the", "submission", "or", "approval", "of", "a", "full", "NDA.", "<tag3>"], "wordsA": ["will", "not", "delay", "the", "submission", "or", "approval", "of", "a", "full", "NDA."], "wordsB": ["Five-year", "and", "three-year", "exclusivity", "will", "not", "delay", "the", "submission", "or", "approval", "of", "a", "full", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p263_s2", "idA": "1316175_11_item1_p275_s2", "sentA": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued Written Request for such a study.", "sentB": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued \"Written Request\" for such a study.", "type": 2, "words": ["<tag1>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study.", "<tag2>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "\"Written", "Request\"", "for", "such", "a", "study.", "<tag3>"], "wordsA": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study."], "wordsB": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "\"Written", "Request\"", "for", "such", "a", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p213_s1", "idA": "1316175_11_item1_p27_s2", "sentA": "Based on our clinical studies, we believe that our sPLA 2 inhibitor, varespladib, can be distinguished from other PLA 2 enzyme inhibitors such as those targeted at inhibiting Lp-PLA 2 because varespladib treatment:", "sentB": "Based on our analyses, if these patents were asserted against us, we do not believe that blisibimod would be found to infringe any valid claim of these patents.", "type": 2, "words": ["<tag1>", "Based", "on", "our", "clinical", "studies,", "we", "believe", "that", "our", "sPLA", "2", "inhibitor,", "varespladib,", "can", "be", "distinguished", "from", "other", "PLA", "2", "enzyme", "inhibitors", "such", "as", "those", "targeted", "at", "inhibiting", "Lp-PLA", "2", "because", "varespladib", "treatment:", "<tag2>", "Based", "on", "our", "analyses,", "if", "these", "patents", "were", "asserted", "against", "us,", "we", "do", "not", "believe", "that", "blisibimod", "would", "be", "found", "to", "infringe", "any", "valid", "claim", "of", "these", "patents.", "<tag3>"], "wordsA": ["Based", "on", "our", "clinical", "studies,", "we", "believe", "that", "our", "sPLA", "2", "inhibitor,", "varespladib,", "can", "be", "distinguished", "from", "other", "PLA", "2", "enzyme", "inhibitors", "such", "as", "those", "targeted", "at", "inhibiting", "Lp-PLA", "2", "because", "varespladib", "treatment:"], "wordsB": ["Based", "on", "our", "analyses,", "if", "these", "patents", "were", "asserted", "against", "us,", "we", "do", "not", "believe", "that", "blisibimod", "would", "be", "found", "to", "infringe", "any", "valid", "claim", "of", "these", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p270_s1", "idA": "1316175_11_item1_p283_s0", "sentA": "significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products.", "sentB": "A fast track product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products.", "type": 2, "words": ["<tag1>", "significant", "improvement", "in", "the", "treatment,", "diagnosis", "or", "prevention", "of", "a", "disease", "compared", "to", "marketed", "products.", "<tag2>", "A", "fast", "track", "product", "is", "eligible", "for", "priority", "review", "if", "it", "has", "the", "potential", "to", "provide", "safe", "and", "effective", "therapy", "where", "no", "satisfactory", "alternative", "therapy", "exists", "or", "a", "significant", "improvement", "in", "the", "treatment,", "diagnosis", "or", "prevention", "of", "a", "disease", "compared", "to", "marketed", "products.", "<tag3>"], "wordsA": ["significant", "improvement", "in", "the", "treatment,", "diagnosis", "or", "prevention", "of", "a", "disease", "compared", "to", "marketed", "products."], "wordsB": ["A", "fast", "track", "product", "is", "eligible", "for", "priority", "review", "if", "it", "has", "the", "potential", "to", "provide", "safe", "and", "effective", "therapy", "where", "no", "satisfactory", "alternative", "therapy", "exists", "or", "a", "significant", "improvement", "in", "the", "treatment,", "diagnosis", "or", "prevention", "of", "a", "disease", "compared", "to", "marketed", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p272_s0", "idA": "1316175_11_item1_p285_s0", "sentA": "We have been granted fast track designation for our product candidate, A-001, for the prevention of acute chest syndrome associated with sickle cell disease in at-risk patients.", "sentB": "We have been granted fast track designation for our product candidate, varespladib sodium, for the prevention of acute chest syndrome associated with sickle cell disease in at-risk patients.", "type": 2, "words": ["<tag1>", "We", "have", "been", "granted", "fast", "track", "designation", "for", "our", "product", "candidate,", "A-001,", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients.", "<tag2>", "We", "have", "been", "granted", "fast", "track", "designation", "for", "our", "product", "candidate,", "varespladib", "sodium,", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "fast", "track", "designation", "for", "our", "product", "candidate,", "A-001,", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients."], "wordsB": ["We", "have", "been", "granted", "fast", "track", "designation", "for", "our", "product", "candidate,", "varespladib", "sodium,", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease", "in", "at-risk", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p272_s1", "idA": "1316175_11_item1_p285_s1", "sentA": "Even though we have received fast track designation for A-001, the FDA may later decide that A-001 no longer meets the conditions for qualification.", "sentB": "Even though we have received fast track designation for varespladib sodium, the FDA may later decide that varespladib sodium no longer meets the conditions for qualification.", "type": 2, "words": ["<tag1>", "Even", "though", "we", "have", "received", "fast", "track", "designation", "for", "A-001,", "the", "FDA", "may", "later", "decide", "that", "A-001", "no", "longer", "meets", "the", "conditions", "for", "qualification.", "<tag2>", "Even", "though", "we", "have", "received", "fast", "track", "designation", "for", "varespladib", "sodium,", "the", "FDA", "may", "later", "decide", "that", "varespladib", "sodium", "no", "longer", "meets", "the", "conditions", "for", "qualification.", "<tag3>"], "wordsA": ["Even", "though", "we", "have", "received", "fast", "track", "designation", "for", "A-001,", "the", "FDA", "may", "later", "decide", "that", "A-001", "no", "longer", "meets", "the", "conditions", "for", "qualification."], "wordsB": ["Even", "though", "we", "have", "received", "fast", "track", "designation", "for", "varespladib", "sodium,", "the", "FDA", "may", "later", "decide", "that", "varespladib", "sodium", "no", "longer", "meets", "the", "conditions", "for", "qualification."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p275_s0", "idA": "1316175_11_item1_p287_s2", "sentA": "Further, manufacturers of drugs and biological products must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance.", "sentB": "products must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance.", "type": 2, "words": ["<tag1>", "Further,", "manufacturers", "of", "drugs", "and", "biological", "products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance.", "<tag2>", "products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance.", "<tag3>"], "wordsA": ["Further,", "manufacturers", "of", "drugs", "and", "biological", "products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance."], "wordsB": ["products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p28_s0", "idA": "1316175_11_item1_p28_s0", "sentA": "reduces plaque volume and aneurysms in standard rodent models of atherosclerosis and has demonstrated synergistic reductions of plaque volume in standard rodent models of atherosclerosis when used in combination with statins.", "sentB": "lowers circulating small, dense and pro-atherogenic, or plaque-building LDL-C particles, while Lp-PLA 2 inhibition has not demonstrated similar effects; and reduces plaque volume and aneurysms in standard rodent models of atherosclerosis and has demonstrated synergistic reductions of plaque volume in standard rodent models of atherosclerosis when used in combination with statins.", "type": 2, "words": ["<tag1>", "reduces", "plaque", "volume", "and", "aneurysms", "in", "standard", "rodent", "models", "of", "atherosclerosis", "and", "has", "demonstrated", "synergistic", "reductions", "of", "plaque", "volume", "in", "standard", "rodent", "models", "of", "atherosclerosis", "when", "used", "in", "combination", "with", "statins.", "<tag2>", "lowers", "circulating", "small,", "dense", "and", "pro-atherogenic,", "or", "plaque-building", "LDL-C", "particles,", "while", "Lp-PLA", "2", "inhibition", "has", "not", "demonstrated", "similar", "effects;", "and", "reduces", "plaque", "volume", "and", "aneurysms", "in", "standard", "rodent", "models", "of", "atherosclerosis", "and", "has", "demonstrated", "synergistic", "reductions", "of", "plaque", "volume", "in", "standard", "rodent", "models", "of", "atherosclerosis", "when", "used", "in", "combination", "with", "statins.", "<tag3>"], "wordsA": ["reduces", "plaque", "volume", "and", "aneurysms", "in", "standard", "rodent", "models", "of", "atherosclerosis", "and", "has", "demonstrated", "synergistic", "reductions", "of", "plaque", "volume", "in", "standard", "rodent", "models", "of", "atherosclerosis", "when", "used", "in", "combination", "with", "statins."], "wordsB": ["lowers", "circulating", "small,", "dense", "and", "pro-atherogenic,", "or", "plaque-building", "LDL-C", "particles,", "while", "Lp-PLA", "2", "inhibition", "has", "not", "demonstrated", "similar", "effects;", "and", "reduces", "plaque", "volume", "and", "aneurysms", "in", "standard", "rodent", "models", "of", "atherosclerosis", "and", "has", "demonstrated", "synergistic", "reductions", "of", "plaque", "volume", "in", "standard", "rodent", "models", "of", "atherosclerosis", "when", "used", "in", "combination", "with", "statins."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p283_s0", "idA": "1316175_11_item1_p294_s2", "sentA": "Additionally, the new law expands the clinical study registry so that sponsors of all clinical studies, except for Phase 1 clinical studies, are required to submit certain clinical study information for inclusion in the clinical study registry data bank.", "sentB": "are required to submit certain clinical study information for inclusion in the clinical study registry data bank.", "type": 2, "words": ["<tag1>", "Additionally,", "the", "new", "law", "expands", "the", "clinical", "study", "registry", "so", "that", "sponsors", "of", "all", "clinical", "studies,", "except", "for", "Phase", "1", "clinical", "studies,", "are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank.", "<tag2>", "are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank.", "<tag3>"], "wordsA": ["Additionally,", "the", "new", "law", "expands", "the", "clinical", "study", "registry", "so", "that", "sponsors", "of", "all", "clinical", "studies,", "except", "for", "Phase", "1", "clinical", "studies,", "are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank."], "wordsB": ["are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p288_s3", "idA": "1316175_11_item1_p299_s3", "sentA": "Within 90 days of receiving the reference member state s assessment report, each concerned member state must decide whether to approve the assessment report and related materials.", "sentB": "Within 90 days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials.", "type": 2, "words": ["<tag1>", "Within", "90", "days", "of", "receiving", "the", "reference", "member", "state", "s", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials.", "<tag2>", "Within", "90", "days", "of", "receiving", "the", "reference", "member", "state's", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials.", "<tag3>"], "wordsA": ["Within", "90", "days", "of", "receiving", "the", "reference", "member", "state", "s", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials."], "wordsB": ["Within", "90", "days", "of", "receiving", "the", "reference", "member", "state's", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p1_s2", "idA": "1316175_11_item1_p2_s0", "sentA": "Two of our product candidates, varespladib and A-001, are designed to inhibit a novel enzyme target known as secretory phospholipase A 2 , or sPLA 2 .", "sentB": "Two of our product candidates, varespladib and varespladib sodium, are designed to inhibit a novel enzyme target known as secretory phospholipase A 2 , or sPLA 2 .", "type": 2, "words": ["<tag1>", "Two", "of", "our", "product", "candidates,", "varespladib", "and", "A-001,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ".", "<tag2>", "Two", "of", "our", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ".", "<tag3>"], "wordsA": ["Two", "of", "our", "product", "candidates,", "varespladib", "and", "A-001,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", "."], "wordsB": ["Two", "of", "our", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p290_s0", "idA": "1316175_11_item1_p300_s7", "sentA": "It is time consuming and expensive for us to seek reimbursement from third-party payors.", "sentB": "consuming and expensive for us to seek reimbursement from third-party payors.", "type": 2, "words": ["<tag1>", "It", "is", "time", "consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors.", "<tag2>", "consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors.", "<tag3>"], "wordsA": ["It", "is", "time", "consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors."], "wordsB": ["consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p291_s2", "idA": "1316175_11_item1_p301_s2", "sentA": "Effective October 1, 2010, the Health Care Reform Law revises the definition of average manufacturer price for reporting purposes, which could increase the amount of Medicaid drug rebates to states once the provision is effective.", "sentB": "Effective October 1, 2010, the Health Care Reform Law revises the definition of \"average manufacturer price\" for reporting purposes, which could increase the amount of Medicaid drug rebates to states once the provision is effective.", "type": 2, "words": ["<tag1>", "Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective.", "<tag2>", "Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "\"average", "manufacturer", "price\"", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective.", "<tag3>"], "wordsA": ["Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective."], "wordsB": ["Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "\"average", "manufacturer", "price\"", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p213_s4", "idA": "1316175_11_item1_p301_s4", "sentA": "Substantial new provisions affecting compliance also have been enacted, which may require us to modify our business practices with healthcare practitioners.", "sentB": "If third party patents are determined to be valid and construed to cover blisibimod, the development and commercialization of this program could be affected, subjecting us to potential liability for damages and in addition may require us to obtain a license to continue marketing the affected product.", "type": 2, "words": ["<tag1>", "Substantial", "new", "provisions", "affecting", "compliance", "also", "have", "been", "enacted,", "which", "may", "require", "us", "to", "modify", "our", "business", "practices", "with", "healthcare", "practitioners.", "<tag2>", "If", "third", "party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "in", "addition", "may", "require", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product.", "<tag3>"], "wordsA": ["Substantial", "new", "provisions", "affecting", "compliance", "also", "have", "been", "enacted,", "which", "may", "require", "us", "to", "modify", "our", "business", "practices", "with", "healthcare", "practitioners."], "wordsB": ["If", "third", "party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "in", "addition", "may", "require", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p296_s1", "idA": "1316175_11_item1_p307_s0", "sentA": "healthcare, the increasing influence of managed care organizations, and additional legislative proposals.", "sentB": "We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations, and additional legislative proposals.", "type": 2, "words": ["<tag1>", "healthcare,", "the", "increasing", "influence", "of", "managed", "care", "organizations,", "and", "additional", "legislative", "proposals.", "<tag2>", "We", "expect", "that", "the", "pharmaceutical", "industry", "will", "experience", "pricing", "pressures", "due", "to", "the", "trend", "toward", "managed", "healthcare,", "the", "increasing", "influence", "of", "managed", "care", "organizations,", "and", "additional", "legislative", "proposals.", "<tag3>"], "wordsA": ["healthcare,", "the", "increasing", "influence", "of", "managed", "care", "organizations,", "and", "additional", "legislative", "proposals."], "wordsB": ["We", "expect", "that", "the", "pharmaceutical", "industry", "will", "experience", "pricing", "pressures", "due", "to", "the", "trend", "toward", "managed", "healthcare,", "the", "increasing", "influence", "of", "managed", "care", "organizations,", "and", "additional", "legislative", "proposals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p167_s0", "idA": "1316175_11_item1_p307_s1", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "While data continues to be made available to us, and while we continue to assess these data, based on the DSMB recommendation to stop the VISTA-16 study for varespladib, we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "type": 2, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "to", "stop", "the", "VISTA-16", "study", "for", "varespladib,", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "to", "stop", "the", "VISTA-16", "study", "for", "varespladib,", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p19_s0", "idA": "1316175_11_item1_p307_s1", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "While data continues to be made available to us, and while we continue to assess these data, based on the DSMB recommendation to stop the VISTA-16 study for varespladib, we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "type": 2, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "to", "stop", "the", "VISTA-16", "study", "for", "varespladib,", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "to", "stop", "the", "VISTA-16", "study", "for", "varespladib,", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p297_s0", "idA": "1316175_11_item1_p307_s1", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "type": 2, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p4_s0", "idA": "1316175_11_item1_p307_s1", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "While data continues to be made available to us, and while we continue to assess these data, based on the DSMB recommendation we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "type": 2, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p80_s0", "idA": "1316175_11_item1_p307_s1", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "While data continues to be made available to us, and while we continue to assess these data, based on the DSMB recommendation we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "type": 2, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["While", "data", "continues", "to", "be", "made", "available", "to", "us,", "and", "while", "we", "continue", "to", "assess", "these", "data,", "based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p30_s0", "idA": "1316175_11_item1_p30_s0", "sentA": "Sickle cell disease is a genetic disorder which leads to the structural alteration, or sickling, of otherwise healthy red blood cells.", "sentB": "Sickle cell disease is a genetic disorder which leads to the structural alteration, or \"sickling,\" of otherwise healthy red blood cells.", "type": 2, "words": ["<tag1>", "Sickle", "cell", "disease", "is", "a", "genetic", "disorder", "which", "leads", "to", "the", "structural", "alteration,", "or", "sickling,", "of", "otherwise", "healthy", "red", "blood", "cells.", "<tag2>", "Sickle", "cell", "disease", "is", "a", "genetic", "disorder", "which", "leads", "to", "the", "structural", "alteration,", "or", "\"sickling,\"", "of", "otherwise", "healthy", "red", "blood", "cells.", "<tag3>"], "wordsA": ["Sickle", "cell", "disease", "is", "a", "genetic", "disorder", "which", "leads", "to", "the", "structural", "alteration,", "or", "sickling,", "of", "otherwise", "healthy", "red", "blood", "cells."], "wordsB": ["Sickle", "cell", "disease", "is", "a", "genetic", "disorder", "which", "leads", "to", "the", "structural", "alteration,", "or", "\"sickling,\"", "of", "otherwise", "healthy", "red", "blood", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p302_s0", "idA": "1316175_11_item1_p312_s0", "sentA": "As of December 31, 2010, we had 25 employees, eight of whom hold an M.D., Ph.D. or Pharm.", "sentB": "As of December 31, 2011, we had 38 employees, eight of whom hold an M.D., Ph.D. or Pharm.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2010,", "we", "had", "25", "employees,", "eight", "of", "whom", "hold", "an", "M.D.,", "Ph.D.", "or", "Pharm.", "<tag2>", "As", "of", "December", "31,", "2011,", "we", "had", "38", "employees,", "eight", "of", "whom", "hold", "an", "M.D.,", "Ph.D.", "or", "Pharm.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2010,", "we", "had", "25", "employees,", "eight", "of", "whom", "hold", "an", "M.D.,", "Ph.D.", "or", "Pharm."], "wordsB": ["As", "of", "December", "31,", "2011,", "we", "had", "38", "employees,", "eight", "of", "whom", "hold", "an", "M.D.,", "Ph.D.", "or", "Pharm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p305_s0", "idA": "1316175_11_item1_p315_s0", "sentA": "Through a link on the Investors section of our website (under SEC Filings in the Financial Information section), we make available, free of charge, the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.", "sentB": "Through a link on the \"Investors\" section of our website (under \"SEC Filings\" in the \"Financial Information\" section), we make available, free of charge, the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.", "type": 2, "words": ["<tag1>", "Through", "a", "link", "on", "the", "Investors", "section", "of", "our", "website", "(under", "SEC", "Filings", "in", "the", "Financial", "Information", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act.", "<tag2>", "Through", "a", "link", "on", "the", "\"Investors\"", "section", "of", "our", "website", "(under", "\"SEC", "Filings\"", "in", "the", "\"Financial", "Information\"", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act.", "<tag3>"], "wordsA": ["Through", "a", "link", "on", "the", "Investors", "section", "of", "our", "website", "(under", "SEC", "Filings", "in", "the", "Financial", "Information", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act."], "wordsB": ["Through", "a", "link", "on", "the", "\"Investors\"", "section", "of", "our", "website", "(under", "\"SEC", "Filings\"", "in", "the", "\"Financial", "Information\"", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p33_s2", "idA": "1316175_11_item1_p33_s2", "sentA": "We are advancing the development of our BAFF inhibitor molecule, A-623, a selective peptibody, to exploit its broad potential clinical utility in autoimmune diseases.", "sentB": "We are advancing the development of our BAFF inhibitor molecule, blisibimod, a selective peptibody, to exploit its broad potential clinical utility in autoimmune diseases.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "our", "BAFF", "inhibitor", "molecule,", "A-623,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "autoimmune", "diseases.", "<tag2>", "We", "are", "advancing", "the", "development", "of", "our", "BAFF", "inhibitor", "molecule,", "blisibimod,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "our", "BAFF", "inhibitor", "molecule,", "A-623,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "autoimmune", "diseases."], "wordsB": ["We", "are", "advancing", "the", "development", "of", "our", "BAFF", "inhibitor", "molecule,", "blisibimod,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p35_s0", "idA": "1316175_11_item1_p34_s1", "sentA": "We have worldwide rights to A-623 in all potential indications.", "sentB": "We have worldwide rights to blisibimod in all potential indications.", "type": 2, "words": ["<tag1>", "We", "have", "worldwide", "rights", "to", "A-623", "in", "all", "potential", "indications.", "<tag2>", "We", "have", "worldwide", "rights", "to", "blisibimod", "in", "all", "potential", "indications.", "<tag3>"], "wordsA": ["We", "have", "worldwide", "rights", "to", "A-623", "in", "all", "potential", "indications."], "wordsB": ["We", "have", "worldwide", "rights", "to", "blisibimod", "in", "all", "potential", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p35_s1", "idA": "1316175_11_item1_p35_s0", "sentA": "We have initiated PEARL-SC, the Phase 2b clinical study of A-623, for the treatment of Systemic Lupus Erythematosus (lupus).", "sentB": "We have initiated PEARL-SC, the Phase 2b clinical study of blisibimod, for the treatment of Systemic Lupus Erythematosus (lupus).", "type": 2, "words": ["<tag1>", "We", "have", "initiated", "PEARL-SC,", "the", "Phase", "2b", "clinical", "study", "of", "A-623,", "for", "the", "treatment", "of", "Systemic", "Lupus", "Erythematosus", "(lupus).", "<tag2>", "We", "have", "initiated", "PEARL-SC,", "the", "Phase", "2b", "clinical", "study", "of", "blisibimod,", "for", "the", "treatment", "of", "Systemic", "Lupus", "Erythematosus", "(lupus).", "<tag3>"], "wordsA": ["We", "have", "initiated", "PEARL-SC,", "the", "Phase", "2b", "clinical", "study", "of", "A-623,", "for", "the", "treatment", "of", "Systemic", "Lupus", "Erythematosus", "(lupus)."], "wordsB": ["We", "have", "initiated", "PEARL-SC,", "the", "Phase", "2b", "clinical", "study", "of", "blisibimod,", "for", "the", "treatment", "of", "Systemic", "Lupus", "Erythematosus", "(lupus)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p37_s0", "idA": "1316175_11_item1_p37_s0", "sentA": "A-623 demonstrates anti-BAFF activity and has shown statistically significant reductions in B-cells in two Phase 1 clinical studies in patients with lupus.", "sentB": "Blisibimod demonstrates anti-BAFF activity and has shown statistically significant reductions in B-cells in two Phase 1 clinical studies in patients with lupus.", "type": 2, "words": ["<tag1>", "A-623", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus.", "<tag2>", "Blisibimod", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus.", "<tag3>"], "wordsA": ["A-623", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus."], "wordsB": ["Blisibimod", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p37_s1", "idA": "1316175_11_item1_p37_s1", "sentA": "We believe A-623 may offer a number of potential differentiations over other BAFF antagonists, as well as other novel B-cell directed therapies including:", "sentB": "We believe blisibimod may offer a number of potential differentiations over the currently marketed BAFF antagonist, Benlysta, as well as other novel B-cell directed therapies including:", "type": 2, "words": ["<tag1>", "We", "believe", "A-623", "may", "offer", "a", "number", "of", "potential", "differentiations", "over", "other", "BAFF", "antagonists,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:", "<tag2>", "We", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "differentiations", "over", "the", "currently", "marketed", "BAFF", "antagonist,", "Benlysta,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:", "<tag3>"], "wordsA": ["We", "believe", "A-623", "may", "offer", "a", "number", "of", "potential", "differentiations", "over", "other", "BAFF", "antagonists,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:"], "wordsB": ["We", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "differentiations", "over", "the", "currently", "marketed", "BAFF", "antagonist,", "Benlysta,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p128_s0", "idA": "1316175_11_item1_p38_s0", "sentA": "multiple binding domains achieve highest reported affinity for inhibition of BAFF.", "sentB": "convenient, at-home, patient-administered subcutaneous dosing with a range of dosing frequencies including monthly and weekly; ability to inhibit the activity of both membrane-bound and soluble BAFF, which may confer differentiating pharmacodynamic characteristics; non-glycosylated peptibody that is produced in a bacterial fermentation manufacturing process, which may reduce the potential to be immunogenic and may provide manufacturing benefits and lower cost of goods; and multiple binding domains achieve highest reported affinity for inhibition of BAFF.", "type": 2, "words": ["<tag1>", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF.", "<tag2>", "convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF,", "which", "may", "confer", "differentiating", "pharmacodynamic", "characteristics;", "non-glycosylated", "peptibody", "that", "is", "produced", "in", "a", "bacterial", "fermentation", "manufacturing", "process,", "which", "may", "reduce", "the", "potential", "to", "be", "immunogenic", "and", "may", "provide", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF.", "<tag3>"], "wordsA": ["multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF."], "wordsB": ["convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF,", "which", "may", "confer", "differentiating", "pharmacodynamic", "characteristics;", "non-glycosylated", "peptibody", "that", "is", "produced", "in", "a", "bacterial", "fermentation", "manufacturing", "process,", "which", "may", "reduce", "the", "potential", "to", "be", "immunogenic", "and", "may", "provide", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p39_s1", "idA": "1316175_11_item1_p39_s1", "sentA": "Our current product development programs are listed in the table below.", "sentB": "Our current product development programs are listed in the table below and can be found online at clinicaltrials.gov .", "type": 2, "words": ["<tag1>", "Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below.", "<tag2>", "Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below", "and", "can", "be", "found", "online", "at", "clinicaltrials.gov", ".", "<tag3>"], "wordsA": ["Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below."], "wordsB": ["Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below", "and", "can", "be", "found", "online", "at", "clinicaltrials.gov", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p2_s1", "idA": "1316175_11_item1_p3_s1", "sentA": "In addition, A-623, a phase 2 product candidate, targets elevated levels of B-lymphocyte stimulator, or BLyS, also known as B-cell Activating Factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, lupus nephritis, or LN, rheumatoid arthritis, multiple sclerosis, Sj gren s Syndrome, Graves Disease and others.", "sentB": "In addition, blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS, also known as B-cell Activating Factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, lupus nephritis, or LN, vasculitis, rheumatoid arthritis, multiple sclerosis, Sj gren's Syndrome, Graves' Disease and others.", "type": 2, "words": ["<tag1>", "In", "addition,", "A-623,", "a", "phase", "2", "product", "candidate,", "targets", "elevated", "levels", "of", "B-lymphocyte", "stimulator,", "or", "BLyS,", "also", "known", "as", "B-cell", "Activating", "Factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "or", "lupus,", "lupus", "nephritis,", "or", "LN,", "rheumatoid", "arthritis,", "multiple", "sclerosis,", "Sj", "gren", "s", "Syndrome,", "Graves", "Disease", "and", "others.", "<tag2>", "In", "addition,", "blisibimod", "targets", "elevated", "levels", "of", "B-lymphocyte", "stimulator,", "or", "BLyS,", "also", "known", "as", "B-cell", "Activating", "Factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "or", "lupus,", "lupus", "nephritis,", "or", "LN,", "vasculitis,", "rheumatoid", "arthritis,", "multiple", "sclerosis,", "Sj", "gren's", "Syndrome,", "Graves'", "Disease", "and", "others.", "<tag3>"], "wordsA": ["In", "addition,", "A-623,", "a", "phase", "2", "product", "candidate,", "targets", "elevated", "levels", "of", "B-lymphocyte", "stimulator,", "or", "BLyS,", "also", "known", "as", "B-cell", "Activating", "Factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "or", "lupus,", "lupus", "nephritis,", "or", "LN,", "rheumatoid", "arthritis,", "multiple", "sclerosis,", "Sj", "gren", "s", "Syndrome,", "Graves", "Disease", "and", "others."], "wordsB": ["In", "addition,", "blisibimod", "targets", "elevated", "levels", "of", "B-lymphocyte", "stimulator,", "or", "BLyS,", "also", "known", "as", "B-cell", "Activating", "Factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "or", "lupus,", "lupus", "nephritis,", "or", "LN,", "vasculitis,", "rheumatoid", "arthritis,", "multiple", "sclerosis,", "Sj", "gren's", "Syndrome,", "Graves'", "Disease", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p40_s0", "idA": "1316175_11_item1_p40_s0", "sentA": "We have historically spent a significant portion of our capital resources on research and development.", "sentB": "We have historically spent a significant portion of our resources on research and development.", "type": 2, "words": ["<tag1>", "We", "have", "historically", "spent", "a", "significant", "portion", "of", "our", "capital", "resources", "on", "research", "and", "development.", "<tag2>", "We", "have", "historically", "spent", "a", "significant", "portion", "of", "our", "resources", "on", "research", "and", "development.", "<tag3>"], "wordsA": ["We", "have", "historically", "spent", "a", "significant", "portion", "of", "our", "capital", "resources", "on", "research", "and", "development."], "wordsB": ["We", "have", "historically", "spent", "a", "significant", "portion", "of", "our", "resources", "on", "research", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p40_s1", "idA": "1316175_11_item1_p40_s1", "sentA": "Our research and development expenses were $29.5, $8.4 and $10.9 million for the years ended December 31, 2010, 2009 and 2008, respectively.", "sentB": "Our research and development expenses were $85.3, $29.5, and $8.4 million for the years ended December 31, 2011, 2010, and 2009, respectively.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "expenses", "were", "$29.5,", "$8.4", "and", "$10.9", "million", "for", "the", "years", "ended", "December", "31,", "2010,", "2009", "and", "2008,", "respectively.", "<tag2>", "Our", "research", "and", "development", "expenses", "were", "$85.3,", "$29.5,", "and", "$8.4", "million", "for", "the", "years", "ended", "December", "31,", "2011,", "2010,", "and", "2009,", "respectively.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "expenses", "were", "$29.5,", "$8.4", "and", "$10.9", "million", "for", "the", "years", "ended", "December", "31,", "2010,", "2009", "and", "2008,", "respectively."], "wordsB": ["Our", "research", "and", "development", "expenses", "were", "$85.3,", "$29.5,", "and", "$8.4", "million", "for", "the", "years", "ended", "December", "31,", "2011,", "2010,", "and", "2009,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p41_s0", "idA": "1316175_11_item1_p41_s0", "sentA": "Varespladib is an orally administered pro-drug of A-001, which is a broad-spectrum, once-daily inhibitor of the IIa, V and X iso-forms of the sPLA 2 enzyme that has demonstrated potent anti-inflammatory, lipid-lowering and lipid-modulating treatment effects in multiple clinical studies.", "sentB": "Varespladib is an orally administered pro-drug of varespladib sodium, which is a broad-spectrum, once-daily inhibitor of the IIa, V and X iso-forms of the sPLA 2 enzyme that has demonstrated potent anti-inflammatory, lipid-lowering and lipid-modulating treatment effects in multiple clinical studies.", "type": 2, "words": ["<tag1>", "Varespladib", "is", "an", "orally", "administered", "pro-drug", "of", "A-001,", "which", "is", "a", "broad-spectrum,", "once-daily", "inhibitor", "of", "the", "IIa,", "V", "and", "X", "iso-forms", "of", "the", "sPLA", "2", "enzyme", "that", "has", "demonstrated", "potent", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "treatment", "effects", "in", "multiple", "clinical", "studies.", "<tag2>", "Varespladib", "is", "an", "orally", "administered", "pro-drug", "of", "varespladib", "sodium,", "which", "is", "a", "broad-spectrum,", "once-daily", "inhibitor", "of", "the", "IIa,", "V", "and", "X", "iso-forms", "of", "the", "sPLA", "2", "enzyme", "that", "has", "demonstrated", "potent", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "treatment", "effects", "in", "multiple", "clinical", "studies.", "<tag3>"], "wordsA": ["Varespladib", "is", "an", "orally", "administered", "pro-drug", "of", "A-001,", "which", "is", "a", "broad-spectrum,", "once-daily", "inhibitor", "of", "the", "IIa,", "V", "and", "X", "iso-forms", "of", "the", "sPLA", "2", "enzyme", "that", "has", "demonstrated", "potent", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "treatment", "effects", "in", "multiple", "clinical", "studies."], "wordsB": ["Varespladib", "is", "an", "orally", "administered", "pro-drug", "of", "varespladib", "sodium,", "which", "is", "a", "broad-spectrum,", "once-daily", "inhibitor", "of", "the", "IIa,", "V", "and", "X", "iso-forms", "of", "the", "sPLA", "2", "enzyme", "that", "has", "demonstrated", "potent", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "treatment", "effects", "in", "multiple", "clinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p42_s0", "idA": "1316175_11_item1_p42_s0", "sentA": "evaluate varespladib in combination with atorvastatin therapy, specifically Lipitor, for the short-term (16-week) treatment of acute coronary syndrome.", "sentB": "We commenced the Phase 3 VISTA-16 study to evaluate varespladib in combination with atorvastatin therapy, for the short-term (16-week) treatment of acute coronary syndrome.", "type": 2, "words": ["<tag1>", "evaluate", "varespladib", "in", "combination", "with", "atorvastatin", "therapy,", "specifically", "Lipitor,", "for", "the", "short-term", "(16-week)", "treatment", "of", "acute", "coronary", "syndrome.", "<tag2>", "We", "commenced", "the", "Phase", "3", "VISTA-16", "study", "to", "evaluate", "varespladib", "in", "combination", "with", "atorvastatin", "therapy,", "for", "the", "short-term", "(16-week)", "treatment", "of", "acute", "coronary", "syndrome.", "<tag3>"], "wordsA": ["evaluate", "varespladib", "in", "combination", "with", "atorvastatin", "therapy,", "specifically", "Lipitor,", "for", "the", "short-term", "(16-week)", "treatment", "of", "acute", "coronary", "syndrome."], "wordsB": ["We", "commenced", "the", "Phase", "3", "VISTA-16", "study", "to", "evaluate", "varespladib", "in", "combination", "with", "atorvastatin", "therapy,", "for", "the", "short-term", "(16-week)", "treatment", "of", "acute", "coronary", "syndrome."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p47_s0", "idA": "1316175_11_item1_p46_s0", "sentA": "Varespladib has been studied in combination with Lipitor (atorvastatin) in a Phase 2b clinical study in acute coronary syndrome patients and two earlier Phase 2 clinical studies in stable CAD patients, the majority of whom were on various statin therapies.", "sentB": "Varespladib has been studied in combination with Lipitor (atorvastatin) in our Phase 2b clinical study, FRANCIS, in acute coronary syndrome patients and two earlier Phase 2 clinical studies, PLASMA and PLASMA-2, in stable CAD patients, the majority of whom were on various statin therapies.", "type": 2, "words": ["<tag1>", "Varespladib", "has", "been", "studied", "in", "combination", "with", "Lipitor", "(atorvastatin)", "in", "a", "Phase", "2b", "clinical", "study", "in", "acute", "coronary", "syndrome", "patients", "and", "two", "earlier", "Phase", "2", "clinical", "studies", "in", "stable", "CAD", "patients,", "the", "majority", "of", "whom", "were", "on", "various", "statin", "therapies.", "<tag2>", "Varespladib", "has", "been", "studied", "in", "combination", "with", "Lipitor", "(atorvastatin)", "in", "our", "Phase", "2b", "clinical", "study,", "FRANCIS,", "in", "acute", "coronary", "syndrome", "patients", "and", "two", "earlier", "Phase", "2", "clinical", "studies,", "PLASMA", "and", "PLASMA-2,", "in", "stable", "CAD", "patients,", "the", "majority", "of", "whom", "were", "on", "various", "statin", "therapies.", "<tag3>"], "wordsA": ["Varespladib", "has", "been", "studied", "in", "combination", "with", "Lipitor", "(atorvastatin)", "in", "a", "Phase", "2b", "clinical", "study", "in", "acute", "coronary", "syndrome", "patients", "and", "two", "earlier", "Phase", "2", "clinical", "studies", "in", "stable", "CAD", "patients,", "the", "majority", "of", "whom", "were", "on", "various", "statin", "therapies."], "wordsB": ["Varespladib", "has", "been", "studied", "in", "combination", "with", "Lipitor", "(atorvastatin)", "in", "our", "Phase", "2b", "clinical", "study,", "FRANCIS,", "in", "acute", "coronary", "syndrome", "patients", "and", "two", "earlier", "Phase", "2", "clinical", "studies,", "PLASMA", "and", "PLASMA-2,", "in", "stable", "CAD", "patients,", "the", "majority", "of", "whom", "were", "on", "various", "statin", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p48_s1", "idA": "1316175_11_item1_p47_s1", "sentA": "We originally licensed our sPLA 2 inhibitor portfolio, including varespladib and A-001, from Eli Lilly Company, or Eli Lilly, and Shionogi Co., Ltd. in July 2006.", "sentB": "We originally licensed our sPLA 2 inhibitor portfolio, including varespladib and varespladib sodium, from Eli Lilly Company, or Eli Lilly, and Shionogi Co., Ltd. in July 2006.", "type": 2, "words": ["<tag1>", "We", "originally", "licensed", "our", "sPLA", "2", "inhibitor", "portfolio,", "including", "varespladib", "and", "A-001,", "from", "Eli", "Lilly", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006.", "<tag2>", "We", "originally", "licensed", "our", "sPLA", "2", "inhibitor", "portfolio,", "including", "varespladib", "and", "varespladib", "sodium,", "from", "Eli", "Lilly", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006.", "<tag3>"], "wordsA": ["We", "originally", "licensed", "our", "sPLA", "2", "inhibitor", "portfolio,", "including", "varespladib", "and", "A-001,", "from", "Eli", "Lilly", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006."], "wordsB": ["We", "originally", "licensed", "our", "sPLA", "2", "inhibitor", "portfolio,", "including", "varespladib", "and", "varespladib", "sodium,", "from", "Eli", "Lilly", "Company,", "or", "Eli", "Lilly,", "and", "Shionogi", "Co.,", "Ltd.", "in", "July", "2006."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p50_s0", "idA": "1316175_11_item1_p48_s0", "sentA": "According to the American Heart Association, over 18 million people in the United States have experienced an acute coronary syndrome and an estimated 1.5 million Americans will have a new or recurrent heart attack.", "sentB": "According to the American Heart Association, over 18 million people in the United States have experienced a cardiac event that constitutes acute coronary syndrome and an estimated 1.5 million Americans will have a new or recurrent heart attack.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Heart", "Association,", "over", "18", "million", "people", "in", "the", "United", "States", "have", "experienced", "an", "acute", "coronary", "syndrome", "and", "an", "estimated", "1.5", "million", "Americans", "will", "have", "a", "new", "or", "recurrent", "heart", "attack.", "<tag2>", "According", "to", "the", "American", "Heart", "Association,", "over", "18", "million", "people", "in", "the", "United", "States", "have", "experienced", "a", "cardiac", "event", "that", "constitutes", "acute", "coronary", "syndrome", "and", "an", "estimated", "1.5", "million", "Americans", "will", "have", "a", "new", "or", "recurrent", "heart", "attack.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Heart", "Association,", "over", "18", "million", "people", "in", "the", "United", "States", "have", "experienced", "an", "acute", "coronary", "syndrome", "and", "an", "estimated", "1.5", "million", "Americans", "will", "have", "a", "new", "or", "recurrent", "heart", "attack."], "wordsB": ["According", "to", "the", "American", "Heart", "Association,", "over", "18", "million", "people", "in", "the", "United", "States", "have", "experienced", "a", "cardiac", "event", "that", "constitutes", "acute", "coronary", "syndrome", "and", "an", "estimated", "1.5", "million", "Americans", "will", "have", "a", "new", "or", "recurrent", "heart", "attack."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p52_s0", "idA": "1316175_11_item1_p49_s2", "sentA": "These numbers are expected to increase given an aging population, as well as the rising epidemics of diabetes and obesity, two conditions known to increase the risk of acute coronary syndrome.", "sentB": "to increase given an aging population, as well as the rising epidemics of diabetes and obesity, two conditions known to increase the risk of acute coronary syndrome.", "type": 2, "words": ["<tag1>", "These", "numbers", "are", "expected", "to", "increase", "given", "an", "aging", "population,", "as", "well", "as", "the", "rising", "epidemics", "of", "diabetes", "and", "obesity,", "two", "conditions", "known", "to", "increase", "the", "risk", "of", "acute", "coronary", "syndrome.", "<tag2>", "to", "increase", "given", "an", "aging", "population,", "as", "well", "as", "the", "rising", "epidemics", "of", "diabetes", "and", "obesity,", "two", "conditions", "known", "to", "increase", "the", "risk", "of", "acute", "coronary", "syndrome.", "<tag3>"], "wordsA": ["These", "numbers", "are", "expected", "to", "increase", "given", "an", "aging", "population,", "as", "well", "as", "the", "rising", "epidemics", "of", "diabetes", "and", "obesity,", "two", "conditions", "known", "to", "increase", "the", "risk", "of", "acute", "coronary", "syndrome."], "wordsB": ["to", "increase", "given", "an", "aging", "population,", "as", "well", "as", "the", "rising", "epidemics", "of", "diabetes", "and", "obesity,", "two", "conditions", "known", "to", "increase", "the", "risk", "of", "acute", "coronary", "syndrome."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p140_s3", "idA": "1316175_11_item1_p4_s0", "sentA": "We were incorporated in Delaware in 2004.", "sentB": "Appropriate changes were incorporated and there have been no further reports of broken vials.", "type": 2, "words": ["<tag1>", "We", "were", "incorporated", "in", "Delaware", "in", "2004.", "<tag2>", "Appropriate", "changes", "were", "incorporated", "and", "there", "have", "been", "no", "further", "reports", "of", "broken", "vials.", "<tag3>"], "wordsA": ["We", "were", "incorporated", "in", "Delaware", "in", "2004."], "wordsB": ["Appropriate", "changes", "were", "incorporated", "and", "there", "have", "been", "no", "further", "reports", "of", "broken", "vials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p55_s1", "idA": "1316175_11_item1_p52_s1", "sentA": "Large clinical outcome studies such as MIRACL and PROVE-IT have previously reported, and data from our own FRANCIS Phase 2b clinical study supports, the 16-week rate of secondary MACE in acute coronary syndrome patients to be between 6.1% and 14.8%.", "sentB": "Large clinical outcome studies such as MIRACL and PROVE-IT have previously reported, and data from our own FRANCIS Phase 2b clinical study supports, the 16-week placebo rate of secondary MACE in acute coronary syndrome patients to be between 6.1% and 14.8%.", "type": 2, "words": ["<tag1>", "Large", "clinical", "outcome", "studies", "such", "as", "MIRACL", "and", "PROVE-IT", "have", "previously", "reported,", "and", "data", "from", "our", "own", "FRANCIS", "Phase", "2b", "clinical", "study", "supports,", "the", "16-week", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "6.1%", "and", "14.8%.", "<tag2>", "Large", "clinical", "outcome", "studies", "such", "as", "MIRACL", "and", "PROVE-IT", "have", "previously", "reported,", "and", "data", "from", "our", "own", "FRANCIS", "Phase", "2b", "clinical", "study", "supports,", "the", "16-week", "placebo", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "6.1%", "and", "14.8%.", "<tag3>"], "wordsA": ["Large", "clinical", "outcome", "studies", "such", "as", "MIRACL", "and", "PROVE-IT", "have", "previously", "reported,", "and", "data", "from", "our", "own", "FRANCIS", "Phase", "2b", "clinical", "study", "supports,", "the", "16-week", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "6.1%", "and", "14.8%."], "wordsB": ["Large", "clinical", "outcome", "studies", "such", "as", "MIRACL", "and", "PROVE-IT", "have", "previously", "reported,", "and", "data", "from", "our", "own", "FRANCIS", "Phase", "2b", "clinical", "study", "supports,", "the", "16-week", "placebo", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "6.1%", "and", "14.8%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p55_s2", "idA": "1316175_11_item1_p52_s1", "sentA": "Large clinical outcome studies such as MIRACL and PROVE-IT have previously reported, and data from our own FRANCIS Phase 2b clinical study supports, the 16-week rate of secondary MACE in acute coronary syndrome patients to be between 6.1% and 14.8%.", "sentB": "Recent published clinical studies involving anti-platelet and anti-coagulant therapies in ACS patients including PLATO, APPRAISE-2 TRA-CER and ATLAS-ACS have reported 16-week placebo rate of secondary MACE in acute coronary syndrome patients to be between approximately 4.5% and 8.0%.", "type": 2, "words": ["<tag1>", "Large", "clinical", "outcome", "studies", "such", "as", "MIRACL", "and", "PROVE-IT", "have", "previously", "reported,", "and", "data", "from", "our", "own", "FRANCIS", "Phase", "2b", "clinical", "study", "supports,", "the", "16-week", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "6.1%", "and", "14.8%.", "<tag2>", "Recent", "published", "clinical", "studies", "involving", "anti-platelet", "and", "anti-coagulant", "therapies", "in", "ACS", "patients", "including", "PLATO,", "APPRAISE-2", "TRA-CER", "and", "ATLAS-ACS", "have", "reported", "16-week", "placebo", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "approximately", "4.5%", "and", "8.0%.", "<tag3>"], "wordsA": ["Large", "clinical", "outcome", "studies", "such", "as", "MIRACL", "and", "PROVE-IT", "have", "previously", "reported,", "and", "data", "from", "our", "own", "FRANCIS", "Phase", "2b", "clinical", "study", "supports,", "the", "16-week", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "6.1%", "and", "14.8%."], "wordsB": ["Recent", "published", "clinical", "studies", "involving", "anti-platelet", "and", "anti-coagulant", "therapies", "in", "ACS", "patients", "including", "PLATO,", "APPRAISE-2", "TRA-CER", "and", "ATLAS-ACS", "have", "reported", "16-week", "placebo", "rate", "of", "secondary", "MACE", "in", "acute", "coronary", "syndrome", "patients", "to", "be", "between", "approximately", "4.5%", "and", "8.0%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p58_s1", "idA": "1316175_11_item1_p57_s1", "sentA": "It has been correlated with adverse cardiovascular outcomes in multiple clinical studies.", "sentB": "In numerous clinical studies with a variety of therapeutic interventions, reductions in CRP have been correlated with reductions in subsequent MACE.", "type": 2, "words": ["<tag1>", "It", "has", "been", "correlated", "with", "adverse", "cardiovascular", "outcomes", "in", "multiple", "clinical", "studies.", "<tag2>", "In", "numerous", "clinical", "studies", "with", "a", "variety", "of", "therapeutic", "interventions,", "reductions", "in", "CRP", "have", "been", "correlated", "with", "reductions", "in", "subsequent", "MACE.", "<tag3>"], "wordsA": ["It", "has", "been", "correlated", "with", "adverse", "cardiovascular", "outcomes", "in", "multiple", "clinical", "studies."], "wordsB": ["In", "numerous", "clinical", "studies", "with", "a", "variety", "of", "therapeutic", "interventions,", "reductions", "in", "CRP", "have", "been", "correlated", "with", "reductions", "in", "subsequent", "MACE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p136_s1", "idA": "1316175_11_item1_p63_s0", "sentA": "More recently, in 2005, the New England Journal of Medicine published data from the PROVE-IT study.", "sentB": "After analysis by an independent statistician, data from the ongoing PEARL-SC study indicated that weekly and monthly subcutaneous doses of blisibimod resulted in statistically significant reductions of B-cells.", "type": 2, "words": ["<tag1>", "More", "recently,", "in", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study.", "<tag2>", "After", "analysis", "by", "an", "independent", "statistician,", "data", "from", "the", "ongoing", "PEARL-SC", "study", "indicated", "that", "weekly", "and", "monthly", "subcutaneous", "doses", "of", "blisibimod", "resulted", "in", "statistically", "significant", "reductions", "of", "B-cells.", "<tag3>"], "wordsA": ["More", "recently,", "in", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study."], "wordsB": ["After", "analysis", "by", "an", "independent", "statistician,", "data", "from", "the", "ongoing", "PEARL-SC", "study", "indicated", "that", "weekly", "and", "monthly", "subcutaneous", "doses", "of", "blisibimod", "resulted", "in", "statistically", "significant", "reductions", "of", "B-cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p65_s0", "idA": "1316175_11_item1_p63_s0", "sentA": "More recently, in 2005, the New England Journal of Medicine published data from the PROVE-IT study.", "sentB": "In 2005, the New England Journal of Medicine published data from the PROVE-IT study.", "type": 2, "words": ["<tag1>", "More", "recently,", "in", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study.", "<tag2>", "In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study.", "<tag3>"], "wordsA": ["More", "recently,", "in", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study."], "wordsB": ["In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p166_s1", "idA": "1316175_11_item1_p65_s2", "sentA": "As a result, the lipid treatment guidelines have been revised to establish more aggressive LDL-C treatment goals over time.", "sentB": "As a result, the Company has closed enrollment in the study and informed all investigators to remove patients from therapy immediately.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "the", "lipid", "treatment", "guidelines", "have", "been", "revised", "to", "establish", "more", "aggressive", "LDL-C", "treatment", "goals", "over", "time.", "<tag2>", "As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "immediately.", "<tag3>"], "wordsA": ["As", "a", "result,", "the", "lipid", "treatment", "guidelines", "have", "been", "revised", "to", "establish", "more", "aggressive", "LDL-C", "treatment", "goals", "over", "time."], "wordsB": ["As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy", "immediately."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p49_s1", "idA": "1316175_11_item1_p65_s2", "sentA": "As a result, the lipid treatment guidelines have been revised to establish more aggressive LDL-C treatment goals over time.", "sentB": "As a result, the Company has closed enrollment in the study and informed all investigators to remove patients from therapy.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "the", "lipid", "treatment", "guidelines", "have", "been", "revised", "to", "establish", "more", "aggressive", "LDL-C", "treatment", "goals", "over", "time.", "<tag2>", "As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy.", "<tag3>"], "wordsA": ["As", "a", "result,", "the", "lipid", "treatment", "guidelines", "have", "been", "revised", "to", "establish", "more", "aggressive", "LDL-C", "treatment", "goals", "over", "time."], "wordsB": ["As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p79_s2", "idA": "1316175_11_item1_p65_s2", "sentA": "As a result, the lipid treatment guidelines have been revised to establish more aggressive LDL-C treatment goals over time.", "sentB": "As a result, the Company has closed enrollment in the study and informed all investigators to remove patients from therapy.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "the", "lipid", "treatment", "guidelines", "have", "been", "revised", "to", "establish", "more", "aggressive", "LDL-C", "treatment", "goals", "over", "time.", "<tag2>", "As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy.", "<tag3>"], "wordsA": ["As", "a", "result,", "the", "lipid", "treatment", "guidelines", "have", "been", "revised", "to", "establish", "more", "aggressive", "LDL-C", "treatment", "goals", "over", "time."], "wordsB": ["As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p68_s0", "idA": "1316175_11_item1_p66_s0", "sentA": "Patients enrolled in our FRANCIS Phase 2b clinical study and our planned Phase 3 acute coronary syndrome study represent high-risk patients as defined by the NCEP.", "sentB": "Patients enrolled in our FRANCIS Phase 2b clinical study and our Phase 3 acute coronary syndrome study represent high-risk patients as defined by the NCEP.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "planned", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP.", "<tag2>", "Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "planned", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP."], "wordsB": ["Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p42_s2", "idA": "1316175_11_item1_p71_s2", "sentA": "We reached agreement with the FDA on all aspects of the VISTA-16 study protocol, including patient inclusion/exclusion criteria, study size, statistical considerations, efficacy endpoints, study duration, randomization and lipid management strategies.", "sentB": "During 2011, we revised operational aspects of our SPA and received agreement from the FDA on June 29, 2011.", "type": 2, "words": ["<tag1>", "We", "reached", "agreement", "with", "the", "FDA", "on", "all", "aspects", "of", "the", "VISTA-16", "study", "protocol,", "including", "patient", "inclusion/exclusion", "criteria,", "study", "size,", "statistical", "considerations,", "efficacy", "endpoints,", "study", "duration,", "randomization", "and", "lipid", "management", "strategies.", "<tag2>", "During", "2011,", "we", "revised", "operational", "aspects", "of", "our", "SPA", "and", "received", "agreement", "from", "the", "FDA", "on", "June", "29,", "2011.", "<tag3>"], "wordsA": ["We", "reached", "agreement", "with", "the", "FDA", "on", "all", "aspects", "of", "the", "VISTA-16", "study", "protocol,", "including", "patient", "inclusion/exclusion", "criteria,", "study", "size,", "statistical", "considerations,", "efficacy", "endpoints,", "study", "duration,", "randomization", "and", "lipid", "management", "strategies."], "wordsB": ["During", "2011,", "we", "revised", "operational", "aspects", "of", "our", "SPA", "and", "received", "agreement", "from", "the", "FDA", "on", "June", "29,", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p77_s0", "idA": "1316175_11_item1_p72_s0", "sentA": "An independent DSMB will continually evaluate the performance of the VISTA-16 study over time to ensure patient safety.", "sentB": "Since the beginning of the VISTA-16 clinical study, the DSMB has met six (6) times to review all available patient safety and outcome data.", "type": 2, "words": ["<tag1>", "An", "independent", "DSMB", "will", "continually", "evaluate", "the", "performance", "of", "the", "VISTA-16", "study", "over", "time", "to", "ensure", "patient", "safety.", "<tag2>", "Since", "the", "beginning", "of", "the", "VISTA-16", "clinical", "study,", "the", "DSMB", "has", "met", "six", "(6)", "times", "to", "review", "all", "available", "patient", "safety", "and", "outcome", "data.", "<tag3>"], "wordsA": ["An", "independent", "DSMB", "will", "continually", "evaluate", "the", "performance", "of", "the", "VISTA-16", "study", "over", "time", "to", "ensure", "patient", "safety."], "wordsB": ["Since", "the", "beginning", "of", "the", "VISTA-16", "clinical", "study,", "the", "DSMB", "has", "met", "six", "(6)", "times", "to", "review", "all", "available", "patient", "safety", "and", "outcome", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p78_s0", "idA": "1316175_11_item1_p72_s0", "sentA": "An independent DSMB will continually evaluate the performance of the VISTA-16 study over time to ensure patient safety.", "sentB": "On March 9, 2012, the DSMB recommended stopping the VISTA-16 study due to a lack efficacy that could not be reasonably overcome in the remainder of the trial.", "type": 2, "words": ["<tag1>", "An", "independent", "DSMB", "will", "continually", "evaluate", "the", "performance", "of", "the", "VISTA-16", "study", "over", "time", "to", "ensure", "patient", "safety.", "<tag2>", "On", "March", "9,", "2012,", "the", "DSMB", "recommended", "stopping", "the", "VISTA-16", "study", "due", "to", "a", "lack", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial.", "<tag3>"], "wordsA": ["An", "independent", "DSMB", "will", "continually", "evaluate", "the", "performance", "of", "the", "VISTA-16", "study", "over", "time", "to", "ensure", "patient", "safety."], "wordsB": ["On", "March", "9,", "2012,", "the", "DSMB", "recommended", "stopping", "the", "VISTA-16", "study", "due", "to", "a", "lack", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p76_s0", "idA": "1316175_11_item1_p72_s1", "sentA": "In addition, after a minimum of 1,000 patients have been enrolled in the VISTA-16 study, an independent statistician not involved with the conduct of the VISTA-16 study will conduct a biomarker analysis to ensure patient levels of inflammation, as measured by sPLA 2 , CRP and IL-6, and lipid profiles, as measured by LDL-C, have met pre-specified reductions versus placebo at various time-points.", "sentB": "After a minimum of 1,000 patients were enrolled in the VISTA-16 study, an independent statistician not involved with the conduct of the VISTA-16 study conducted a biomarker analysis to ensure patient levels of inflammation, as measured by sPLA 2 , CRP and IL-6, and lipid levels, as measured by LDL-C, had met pre-specified reductions versus placebo at various time-points.", "type": 2, "words": ["<tag1>", "In", "addition,", "after", "a", "minimum", "of", "1,000", "patients", "have", "been", "enrolled", "in", "the", "VISTA-16", "study,", "an", "independent", "statistician", "not", "involved", "with", "the", "conduct", "of", "the", "VISTA-16", "study", "will", "conduct", "a", "biomarker", "analysis", "to", "ensure", "patient", "levels", "of", "inflammation,", "as", "measured", "by", "sPLA", "2", ",", "CRP", "and", "IL-6,", "and", "lipid", "profiles,", "as", "measured", "by", "LDL-C,", "have", "met", "pre-specified", "reductions", "versus", "placebo", "at", "various", "time-points.", "<tag2>", "After", "a", "minimum", "of", "1,000", "patients", "were", "enrolled", "in", "the", "VISTA-16", "study,", "an", "independent", "statistician", "not", "involved", "with", "the", "conduct", "of", "the", "VISTA-16", "study", "conducted", "a", "biomarker", "analysis", "to", "ensure", "patient", "levels", "of", "inflammation,", "as", "measured", "by", "sPLA", "2", ",", "CRP", "and", "IL-6,", "and", "lipid", "levels,", "as", "measured", "by", "LDL-C,", "had", "met", "pre-specified", "reductions", "versus", "placebo", "at", "various", "time-points.", "<tag3>"], "wordsA": ["In", "addition,", "after", "a", "minimum", "of", "1,000", "patients", "have", "been", "enrolled", "in", "the", "VISTA-16", "study,", "an", "independent", "statistician", "not", "involved", "with", "the", "conduct", "of", "the", "VISTA-16", "study", "will", "conduct", "a", "biomarker", "analysis", "to", "ensure", "patient", "levels", "of", "inflammation,", "as", "measured", "by", "sPLA", "2", ",", "CRP", "and", "IL-6,", "and", "lipid", "profiles,", "as", "measured", "by", "LDL-C,", "have", "met", "pre-specified", "reductions", "versus", "placebo", "at", "various", "time-points."], "wordsB": ["After", "a", "minimum", "of", "1,000", "patients", "were", "enrolled", "in", "the", "VISTA-16", "study,", "an", "independent", "statistician", "not", "involved", "with", "the", "conduct", "of", "the", "VISTA-16", "study", "conducted", "a", "biomarker", "analysis", "to", "ensure", "patient", "levels", "of", "inflammation,", "as", "measured", "by", "sPLA", "2", ",", "CRP", "and", "IL-6,", "and", "lipid", "levels,", "as", "measured", "by", "LDL-C,", "had", "met", "pre-specified", "reductions", "versus", "placebo", "at", "various", "time-points."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p76_s1", "idA": "1316175_11_item1_p72_s2", "sentA": "These markers of inflammation and lipid profiles are established in the clinical community and pharmaceutical industry as independent predictors of cardiovascular risk and, if positive, will provide additional validation of our previous findings from the FRANCIS Phase 2b clinical study.", "sentB": "These markers of inflammation and lipid levels are established in the clinical community and pharmaceutical industry as independent predictors of cardiovascular risk.", "type": 2, "words": ["<tag1>", "These", "markers", "of", "inflammation", "and", "lipid", "profiles", "are", "established", "in", "the", "clinical", "community", "and", "pharmaceutical", "industry", "as", "independent", "predictors", "of", "cardiovascular", "risk", "and,", "if", "positive,", "will", "provide", "additional", "validation", "of", "our", "previous", "findings", "from", "the", "FRANCIS", "Phase", "2b", "clinical", "study.", "<tag2>", "These", "markers", "of", "inflammation", "and", "lipid", "levels", "are", "established", "in", "the", "clinical", "community", "and", "pharmaceutical", "industry", "as", "independent", "predictors", "of", "cardiovascular", "risk.", "<tag3>"], "wordsA": ["These", "markers", "of", "inflammation", "and", "lipid", "profiles", "are", "established", "in", "the", "clinical", "community", "and", "pharmaceutical", "industry", "as", "independent", "predictors", "of", "cardiovascular", "risk", "and,", "if", "positive,", "will", "provide", "additional", "validation", "of", "our", "previous", "findings", "from", "the", "FRANCIS", "Phase", "2b", "clinical", "study."], "wordsB": ["These", "markers", "of", "inflammation", "and", "lipid", "levels", "are", "established", "in", "the", "clinical", "community", "and", "pharmaceutical", "industry", "as", "independent", "predictors", "of", "cardiovascular", "risk."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p76_s2", "idA": "1316175_11_item1_p72_s2", "sentA": "These markers of inflammation and lipid profiles are established in the clinical community and pharmaceutical industry as independent predictors of cardiovascular risk and, if positive, will provide additional validation of our previous findings from the FRANCIS Phase 2b clinical study.", "sentB": "The intention of this biomarker analysis was to ensure results observed in the VISTA-16 were consistent with findings from the FRANCIS Phase 2b clinical study.", "type": 2, "words": ["<tag1>", "These", "markers", "of", "inflammation", "and", "lipid", "profiles", "are", "established", "in", "the", "clinical", "community", "and", "pharmaceutical", "industry", "as", "independent", "predictors", "of", "cardiovascular", "risk", "and,", "if", "positive,", "will", "provide", "additional", "validation", "of", "our", "previous", "findings", "from", "the", "FRANCIS", "Phase", "2b", "clinical", "study.", "<tag2>", "The", "intention", "of", "this", "biomarker", "analysis", "was", "to", "ensure", "results", "observed", "in", "the", "VISTA-16", "were", "consistent", "with", "findings", "from", "the", "FRANCIS", "Phase", "2b", "clinical", "study.", "<tag3>"], "wordsA": ["These", "markers", "of", "inflammation", "and", "lipid", "profiles", "are", "established", "in", "the", "clinical", "community", "and", "pharmaceutical", "industry", "as", "independent", "predictors", "of", "cardiovascular", "risk", "and,", "if", "positive,", "will", "provide", "additional", "validation", "of", "our", "previous", "findings", "from", "the", "FRANCIS", "Phase", "2b", "clinical", "study."], "wordsB": ["The", "intention", "of", "this", "biomarker", "analysis", "was", "to", "ensure", "results", "observed", "in", "the", "VISTA-16", "were", "consistent", "with", "findings", "from", "the", "FRANCIS", "Phase", "2b", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p76_s3", "idA": "1316175_11_item1_p72_s3", "sentA": "At the same time, the independent DSMB will review all clinical data from the VISTA-16 study to ensure no emergent adverse safety signals.", "sentB": "At the end of this analysis, the independent statistician recommended continuation of the VISTA-16 study based on a pre-specified algorithm.", "type": 2, "words": ["<tag1>", "At", "the", "same", "time,", "the", "independent", "DSMB", "will", "review", "all", "clinical", "data", "from", "the", "VISTA-16", "study", "to", "ensure", "no", "emergent", "adverse", "safety", "signals.", "<tag2>", "At", "the", "end", "of", "this", "analysis,", "the", "independent", "statistician", "recommended", "continuation", "of", "the", "VISTA-16", "study", "based", "on", "a", "pre-specified", "algorithm.", "<tag3>"], "wordsA": ["At", "the", "same", "time,", "the", "independent", "DSMB", "will", "review", "all", "clinical", "data", "from", "the", "VISTA-16", "study", "to", "ensure", "no", "emergent", "adverse", "safety", "signals."], "wordsB": ["At", "the", "end", "of", "this", "analysis,", "the", "independent", "statistician", "recommended", "continuation", "of", "the", "VISTA-16", "study", "based", "on", "a", "pre-specified", "algorithm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p140_s0", "idA": "1316175_11_item1_p73_s0", "sentA": "In June 2010, we initiated enrollment in the VISTA-16 clinical study.", "sentB": "In November 2010, we suspended enrollment in the PEARL-SC clinical study after reports of broken vials at clinical sites.", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study.", "<tag2>", "In", "November", "2010,", "we", "suspended", "enrollment", "in", "the", "PEARL-SC", "clinical", "study", "after", "reports", "of", "broken", "vials", "at", "clinical", "sites.", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study."], "wordsB": ["In", "November", "2010,", "we", "suspended", "enrollment", "in", "the", "PEARL-SC", "clinical", "study", "after", "reports", "of", "broken", "vials", "at", "clinical", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p166_s0", "idA": "1316175_11_item1_p73_s0", "sentA": "In June 2010, we initiated enrollment in the VISTA-16 clinical study.", "sentB": "On March 9, 2012, an independent data safety monitoring board recommended stopping the Company's VISTA-16 clinical study for varespladib due to a lack efficacy that could not be reasonably overcome in the remainder of the trial.", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study.", "<tag2>", "On", "March", "9,", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial.", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study."], "wordsB": ["On", "March", "9,", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p166_s3", "idA": "1316175_11_item1_p73_s0", "sentA": "In June 2010, we initiated enrollment in the VISTA-16 clinical study.", "sentB": "The Company has also closed enrollment in its IMPACTS-2 clinical study for varespladib sodium.", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study.", "<tag2>", "The", "Company", "has", "also", "closed", "enrollment", "in", "its", "IMPACTS-2", "clinical", "study", "for", "varespladib", "sodium.", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study."], "wordsB": ["The", "Company", "has", "also", "closed", "enrollment", "in", "its", "IMPACTS-2", "clinical", "study", "for", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p3_s5", "idA": "1316175_11_item1_p73_s0", "sentA": "In June 2010, we initiated enrollment in the VISTA-16 clinical study.", "sentB": "We have also closed enrollment in our IMPACTS-2 clinical study for varespladib sodium.", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study.", "<tag2>", "We", "have", "also", "closed", "enrollment", "in", "our", "IMPACTS-2", "clinical", "study", "for", "varespladib", "sodium.", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study."], "wordsB": ["We", "have", "also", "closed", "enrollment", "in", "our", "IMPACTS-2", "clinical", "study", "for", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p49_s0", "idA": "1316175_11_item1_p73_s0", "sentA": "In June 2010, we initiated enrollment in the VISTA-16 clinical study.", "sentB": "In March 2012, an independent data safety monitoring board recommended stopping the Company's VISTA-16 clinical study for varespladib due to a lack of efficacy that could not be reasonably overcome in the remainder of the trial.", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study.", "<tag2>", "In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial.", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study."], "wordsB": ["In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p55_s4", "idA": "1316175_11_item1_p73_s0", "sentA": "In June 2010, we initiated enrollment in the VISTA-16 clinical study.", "sentB": "Unstable angina, included as a component of the MACE endpoint in the VISTA-16 clinical study, represented approximately 30% of the total MACE at 16 weeks in the FRANCIS clinical study with varespladib.", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study.", "<tag2>", "Unstable", "angina,", "included", "as", "a", "component", "of", "the", "MACE", "endpoint", "in", "the", "VISTA-16", "clinical", "study,", "represented", "approximately", "30%", "of", "the", "total", "MACE", "at", "16", "weeks", "in", "the", "FRANCIS", "clinical", "study", "with", "varespladib.", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "initiated", "enrollment", "in", "the", "VISTA-16", "clinical", "study."], "wordsB": ["Unstable", "angina,", "included", "as", "a", "component", "of", "the", "MACE", "endpoint", "in", "the", "VISTA-16", "clinical", "study,", "represented", "approximately", "30%", "of", "the", "total", "MACE", "at", "16", "weeks", "in", "the", "FRANCIS", "clinical", "study", "with", "varespladib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p72_s2", "idA": "1316175_11_item1_p73_s2", "sentA": "We anticipate the study will be conducted in up to 15 countries and up to 500 centers.", "sentB": "The study was conducted in up to 17 countries and up to 500 centers.", "type": 2, "words": ["<tag1>", "We", "anticipate", "the", "study", "will", "be", "conducted", "in", "up", "to", "15", "countries", "and", "up", "to", "500", "centers.", "<tag2>", "The", "study", "was", "conducted", "in", "up", "to", "17", "countries", "and", "up", "to", "500", "centers.", "<tag3>"], "wordsA": ["We", "anticipate", "the", "study", "will", "be", "conducted", "in", "up", "to", "15", "countries", "and", "up", "to", "500", "centers."], "wordsB": ["The", "study", "was", "conducted", "in", "up", "to", "17", "countries", "and", "up", "to", "500", "centers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p73_s0", "idA": "1316175_11_item1_p77_s0", "sentA": "The primary endpoint of the VISTA-16 study is to determine whether 16 weeks of once-daily treatment with varespladib plus a dose of Lipitor (atorvastatin) is superior to placebo plus Lipitor (atorvastatin) in the time to the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or documented UA with objective evidence of ischemia requiring hospitalization as defined by recent FDA draft guidance.", "sentB": "The primary endpoint of the VISTA-16 study was to determine whether 16 weeks of once-daily treatment with varespladib plus a dose of Lipitor (atorvastatin) is superior to placebo plus Lipitor (atorvastatin) in the time to the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or documented UA with objective evidence of ischemia requiring hospitalization as defined by recent FDA draft guidance.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "VISTA-16", "study", "is", "to", "determine", "whether", "16", "weeks", "of", "once-daily", "treatment", "with", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization", "as", "defined", "by", "recent", "FDA", "draft", "guidance.", "<tag2>", "The", "primary", "endpoint", "of", "the", "VISTA-16", "study", "was", "to", "determine", "whether", "16", "weeks", "of", "once-daily", "treatment", "with", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization", "as", "defined", "by", "recent", "FDA", "draft", "guidance.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "VISTA-16", "study", "is", "to", "determine", "whether", "16", "weeks", "of", "once-daily", "treatment", "with", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization", "as", "defined", "by", "recent", "FDA", "draft", "guidance."], "wordsB": ["The", "primary", "endpoint", "of", "the", "VISTA-16", "study", "was", "to", "determine", "whether", "16", "weeks", "of", "once-daily", "treatment", "with", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization", "as", "defined", "by", "recent", "FDA", "draft", "guidance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p3_s0", "idA": "1316175_11_item1_p78_s1", "sentA": "The VISTA-16 clinical study endpoint definitions conform to these guidelines.", "sentB": "On March 9, 2012, an independent data safety monitoring board (DSMB) recommended stopping the Company's VISTA-16 clinical study for varespladib.", "type": 2, "words": ["<tag1>", "The", "VISTA-16", "clinical", "study", "endpoint", "definitions", "conform", "to", "these", "guidelines.", "<tag2>", "On", "March", "9,", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "(DSMB)", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib.", "<tag3>"], "wordsA": ["The", "VISTA-16", "clinical", "study", "endpoint", "definitions", "conform", "to", "these", "guidelines."], "wordsB": ["On", "March", "9,", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "(DSMB)", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p75_s0", "idA": "1316175_11_item1_p79_s0", "sentA": "A secondary endpoint for the VISTA-16 study is to determine whether varespladib plus a dose of Lipitor (atorvastatin) is superior to placebo plus Lipitor (atorvastatin) in the time to the first occurrence of the combined endpoint of all cause mortality, non-fatal myocardial infarction, non-fatal stroke or documented UA with objective evidence of ischemia requiring hospitalization.", "sentB": "A secondary endpoint for the VISTA-16 study was to determine whether varespladib plus a dose of Lipitor (atorvastatin) is superior to placebo plus Lipitor (atorvastatin) as measured in the time to the first occurrence of the combined endpoint of all cause mortality, non-fatal myocardial infarction, non-fatal stroke or documented UA with objective evidence of ischemia requiring hospitalization.", "type": 2, "words": ["<tag1>", "A", "secondary", "endpoint", "for", "the", "VISTA-16", "study", "is", "to", "determine", "whether", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "all", "cause", "mortality,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization.", "<tag2>", "A", "secondary", "endpoint", "for", "the", "VISTA-16", "study", "was", "to", "determine", "whether", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "as", "measured", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "all", "cause", "mortality,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization.", "<tag3>"], "wordsA": ["A", "secondary", "endpoint", "for", "the", "VISTA-16", "study", "is", "to", "determine", "whether", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "all", "cause", "mortality,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization."], "wordsB": ["A", "secondary", "endpoint", "for", "the", "VISTA-16", "study", "was", "to", "determine", "whether", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "as", "measured", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "all", "cause", "mortality,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p164_s0", "idA": "1316175_11_item1_p80_s0", "sentA": "In July 2008, we initiated a randomized, double-blind, placebo-controlled Phase 2b clinical study that enrolled 625 acute coronary syndrome patients across 35 centers in three countries.", "sentB": "In January 2012, we initiated a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical study that will enroll up to 150 patients with sickle cell disease who are at an elevated risk of developing acute chest syndrome as a result of fever, VOC and CRP 5.0 mg/L at the time of hospitalization.", "type": 2, "words": ["<tag1>", "In", "July", "2008,", "we", "initiated", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2b", "clinical", "study", "that", "enrolled", "625", "acute", "coronary", "syndrome", "patients", "across", "35", "centers", "in", "three", "countries.", "<tag2>", "In", "January", "2012,", "we", "initiated", "a", "multinational,", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2b", "clinical", "study", "that", "will", "enroll", "up", "to", "150", "patients", "with", "sickle", "cell", "disease", "who", "are", "at", "an", "elevated", "risk", "of", "developing", "acute", "chest", "syndrome", "as", "a", "result", "of", "fever,", "VOC", "and", "CRP", "5.0", "mg/L", "at", "the", "time", "of", "hospitalization.", "<tag3>"], "wordsA": ["In", "July", "2008,", "we", "initiated", "a", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2b", "clinical", "study", "that", "enrolled", "625", "acute", "coronary", "syndrome", "patients", "across", "35", "centers", "in", "three", "countries."], "wordsB": ["In", "January", "2012,", "we", "initiated", "a", "multinational,", "randomized,", "double-blind,", "placebo-controlled", "Phase", "2b", "clinical", "study", "that", "will", "enroll", "up", "to", "150", "patients", "with", "sickle", "cell", "disease", "who", "are", "at", "an", "elevated", "risk", "of", "developing", "acute", "chest", "syndrome", "as", "a", "result", "of", "fever,", "VOC", "and", "CRP", "5.0", "mg/L", "at", "the", "time", "of", "hospitalization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p81_s1", "idA": "1316175_11_item1_p80_s1", "sentA": "Given the drug s combined anti-inflammatory, lipid-lowering and lipid-modulating effects, we evaluated the effects of varespladib in acute coronary syndrome patients with high levels of inflammation and dislipidemia.", "sentB": "Given the drug's combined anti-inflammatory, lipid-lowering and lipid-modulating effects, we evaluated the effects of varespladib in acute coronary syndrome patients with high levels of inflammation and dyslipidemia.", "type": 2, "words": ["<tag1>", "Given", "the", "drug", "s", "combined", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "effects,", "we", "evaluated", "the", "effects", "of", "varespladib", "in", "acute", "coronary", "syndrome", "patients", "with", "high", "levels", "of", "inflammation", "and", "dislipidemia.", "<tag2>", "Given", "the", "drug's", "combined", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "effects,", "we", "evaluated", "the", "effects", "of", "varespladib", "in", "acute", "coronary", "syndrome", "patients", "with", "high", "levels", "of", "inflammation", "and", "dyslipidemia.", "<tag3>"], "wordsA": ["Given", "the", "drug", "s", "combined", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "effects,", "we", "evaluated", "the", "effects", "of", "varespladib", "in", "acute", "coronary", "syndrome", "patients", "with", "high", "levels", "of", "inflammation", "and", "dislipidemia."], "wordsB": ["Given", "the", "drug's", "combined", "anti-inflammatory,", "lipid-lowering", "and", "lipid-modulating", "effects,", "we", "evaluated", "the", "effects", "of", "varespladib", "in", "acute", "coronary", "syndrome", "patients", "with", "high", "levels", "of", "inflammation", "and", "dyslipidemia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p86_s0", "idA": "1316175_11_item1_p85_s0", "sentA": "the occurrence of secondary MACE (for purposes of this clinical study, all-cause mortality, non-fatal myocardial infarction, documented UA requiring urgent hospitalization, revascularization occurring 60 days post the index event or non-fatal stroke).", "sentB": "changes in established markers of inflammation such as sPLA 2 , CRP and IL-6; and the occurrence of secondary MACE (for purposes of this clinical study, all-cause mortality, non-fatal myocardial infarction, documented UA requiring urgent hospitalization, revascularization occurring 60 days post the index event or non-fatal stroke).", "type": 2, "words": ["<tag1>", "the", "occurrence", "of", "secondary", "MACE", "(for", "purposes", "of", "this", "clinical", "study,", "all-cause", "mortality,", "non-fatal", "myocardial", "infarction,", "documented", "UA", "requiring", "urgent", "hospitalization,", "revascularization", "occurring", "60", "days", "post", "the", "index", "event", "or", "non-fatal", "stroke).", "<tag2>", "changes", "in", "established", "markers", "of", "inflammation", "such", "as", "sPLA", "2", ",", "CRP", "and", "IL-6;", "and", "the", "occurrence", "of", "secondary", "MACE", "(for", "purposes", "of", "this", "clinical", "study,", "all-cause", "mortality,", "non-fatal", "myocardial", "infarction,", "documented", "UA", "requiring", "urgent", "hospitalization,", "revascularization", "occurring", "60", "days", "post", "the", "index", "event", "or", "non-fatal", "stroke).", "<tag3>"], "wordsA": ["the", "occurrence", "of", "secondary", "MACE", "(for", "purposes", "of", "this", "clinical", "study,", "all-cause", "mortality,", "non-fatal", "myocardial", "infarction,", "documented", "UA", "requiring", "urgent", "hospitalization,", "revascularization", "occurring", "60", "days", "post", "the", "index", "event", "or", "non-fatal", "stroke)."], "wordsB": ["changes", "in", "established", "markers", "of", "inflammation", "such", "as", "sPLA", "2", ",", "CRP", "and", "IL-6;", "and", "the", "occurrence", "of", "secondary", "MACE", "(for", "purposes", "of", "this", "clinical", "study,", "all-cause", "mortality,", "non-fatal", "myocardial", "infarction,", "documented", "UA", "requiring", "urgent", "hospitalization,", "revascularization", "occurring", "60", "days", "post", "the", "index", "event", "or", "non-fatal", "stroke)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p88_s0", "idA": "1316175_11_item1_p87_s0", "sentA": "A statistically significant difference was observed in LDL-C reduction from baseline as early as two weeks after treatment.", "sentB": "observed in LDL-C reduction from baseline as early as two weeks after treatment.", "type": 2, "words": ["<tag1>", "A", "statistically", "significant", "difference", "was", "observed", "in", "LDL-C", "reduction", "from", "baseline", "as", "early", "as", "two", "weeks", "after", "treatment.", "<tag2>", "observed", "in", "LDL-C", "reduction", "from", "baseline", "as", "early", "as", "two", "weeks", "after", "treatment.", "<tag3>"], "wordsA": ["A", "statistically", "significant", "difference", "was", "observed", "in", "LDL-C", "reduction", "from", "baseline", "as", "early", "as", "two", "weeks", "after", "treatment."], "wordsB": ["observed", "in", "LDL-C", "reduction", "from", "baseline", "as", "early", "as", "two", "weeks", "after", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p90_s0", "idA": "1316175_11_item1_p89_s0", "sentA": "sPLA 2 concentration was statistically significantly reduced from the earliest time point of two weeks through the 16-week time point (p 0.0001) as compared to high-dose statin (80 mg Lipitor (atorvastatin)) therapy alone.", "sentB": "sPLA 2 concentrations were statistically significantly reduced from the earliest time point of two weeks through the 16-week time point (p 0.0001) as compared to high-dose statin atorvastatin (80mg) therapy alone.", "type": 2, "words": ["<tag1>", "sPLA", "2", "concentration", "was", "statistically", "significantly", "reduced", "from", "the", "earliest", "time", "point", "of", "two", "weeks", "through", "the", "16-week", "time", "point", "(p", "0.0001)", "as", "compared", "to", "high-dose", "statin", "(80", "mg", "Lipitor", "(atorvastatin))", "therapy", "alone.", "<tag2>", "sPLA", "2", "concentrations", "were", "statistically", "significantly", "reduced", "from", "the", "earliest", "time", "point", "of", "two", "weeks", "through", "the", "16-week", "time", "point", "(p", "0.0001)", "as", "compared", "to", "high-dose", "statin", "atorvastatin", "(80mg)", "therapy", "alone.", "<tag3>"], "wordsA": ["sPLA", "2", "concentration", "was", "statistically", "significantly", "reduced", "from", "the", "earliest", "time", "point", "of", "two", "weeks", "through", "the", "16-week", "time", "point", "(p", "0.0001)", "as", "compared", "to", "high-dose", "statin", "(80", "mg", "Lipitor", "(atorvastatin))", "therapy", "alone."], "wordsB": ["sPLA", "2", "concentrations", "were", "statistically", "significantly", "reduced", "from", "the", "earliest", "time", "point", "of", "two", "weeks", "through", "the", "16-week", "time", "point", "(p", "0.0001)", "as", "compared", "to", "high-dose", "statin", "atorvastatin", "(80mg)", "therapy", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p136_s3", "idA": "1316175_11_item1_p89_s1", "sentA": "While our first sPLA 2 measurement in this clinical study occurred at two weeks, data from previous clinical studies utilizing varespladib or A-001 demonstrated reductions in sPLA 2 as early as two days following treatment.", "sentB": "These findings are consistent with data from previous clinical studies of blisibimod.", "type": 2, "words": ["<tag1>", "While", "our", "first", "sPLA", "2", "measurement", "in", "this", "clinical", "study", "occurred", "at", "two", "weeks,", "data", "from", "previous", "clinical", "studies", "utilizing", "varespladib", "or", "A-001", "demonstrated", "reductions", "in", "sPLA", "2", "as", "early", "as", "two", "days", "following", "treatment.", "<tag2>", "These", "findings", "are", "consistent", "with", "data", "from", "previous", "clinical", "studies", "of", "blisibimod.", "<tag3>"], "wordsA": ["While", "our", "first", "sPLA", "2", "measurement", "in", "this", "clinical", "study", "occurred", "at", "two", "weeks,", "data", "from", "previous", "clinical", "studies", "utilizing", "varespladib", "or", "A-001", "demonstrated", "reductions", "in", "sPLA", "2", "as", "early", "as", "two", "days", "following", "treatment."], "wordsB": ["These", "findings", "are", "consistent", "with", "data", "from", "previous", "clinical", "studies", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p90_s1", "idA": "1316175_11_item1_p89_s1", "sentA": "While our first sPLA 2 measurement in this clinical study occurred at two weeks, data from previous clinical studies utilizing varespladib or A-001 demonstrated reductions in sPLA 2 as early as two days following treatment.", "sentB": "While our first sPLA 2 measurement in this clinical study occurred at two weeks, data from previous clinical studies utilizing varespladib or varespladib sodium demonstrated reductions in sPLA 2 as early as two days following treatment.", "type": 2, "words": ["<tag1>", "While", "our", "first", "sPLA", "2", "measurement", "in", "this", "clinical", "study", "occurred", "at", "two", "weeks,", "data", "from", "previous", "clinical", "studies", "utilizing", "varespladib", "or", "A-001", "demonstrated", "reductions", "in", "sPLA", "2", "as", "early", "as", "two", "days", "following", "treatment.", "<tag2>", "While", "our", "first", "sPLA", "2", "measurement", "in", "this", "clinical", "study", "occurred", "at", "two", "weeks,", "data", "from", "previous", "clinical", "studies", "utilizing", "varespladib", "or", "varespladib", "sodium", "demonstrated", "reductions", "in", "sPLA", "2", "as", "early", "as", "two", "days", "following", "treatment.", "<tag3>"], "wordsA": ["While", "our", "first", "sPLA", "2", "measurement", "in", "this", "clinical", "study", "occurred", "at", "two", "weeks,", "data", "from", "previous", "clinical", "studies", "utilizing", "varespladib", "or", "A-001", "demonstrated", "reductions", "in", "sPLA", "2", "as", "early", "as", "two", "days", "following", "treatment."], "wordsB": ["While", "our", "first", "sPLA", "2", "measurement", "in", "this", "clinical", "study", "occurred", "at", "two", "weeks,", "data", "from", "previous", "clinical", "studies", "utilizing", "varespladib", "or", "varespladib", "sodium", "demonstrated", "reductions", "in", "sPLA", "2", "as", "early", "as", "two", "days", "following", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p136_s0", "idA": "1316175_11_item1_p95_s0", "sentA": "We also conducted an exploratory analysis of MACE in the clinical study.", "sentB": "In November 2011, we completed an interim biomarker analysis of changes in B-Cells in patients enrolled in the PEARL-SC clinical study.", "type": 2, "words": ["<tag1>", "We", "also", "conducted", "an", "exploratory", "analysis", "of", "MACE", "in", "the", "clinical", "study.", "<tag2>", "In", "November", "2011,", "we", "completed", "an", "interim", "biomarker", "analysis", "of", "changes", "in", "B-Cells", "in", "patients", "enrolled", "in", "the", "PEARL-SC", "clinical", "study.", "<tag3>"], "wordsA": ["We", "also", "conducted", "an", "exploratory", "analysis", "of", "MACE", "in", "the", "clinical", "study."], "wordsB": ["In", "November", "2011,", "we", "completed", "an", "interim", "biomarker", "analysis", "of", "changes", "in", "B-Cells", "in", "patients", "enrolled", "in", "the", "PEARL-SC", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_12_item1_p96_s3", "idA": "1316175_11_item1_p95_s3", "sentA": "While the MACE analysis was not designed to demonstrate any statistical differences between the two treatment groups, we believe that the results are encouraging and has helped us to design our VISTA-16 study.", "sentB": "While the MACE analysis was not designed to demonstrate any statistical differences between the two treatment groups, we believed these results to be encouraging and provide guidance on the appropriate design of the VISTA-16 study.", "type": 2, "words": ["<tag1>", "While", "the", "MACE", "analysis", "was", "not", "designed", "to", "demonstrate", "any", "statistical", "differences", "between", "the", "two", "treatment", "groups,", "we", "believe", "that", "the", "results", "are", "encouraging", "and", "has", "helped", "us", "to", "design", "our", "VISTA-16", "study.", "<tag2>", "While", "the", "MACE", "analysis", "was", "not", "designed", "to", "demonstrate", "any", "statistical", "differences", "between", "the", "two", "treatment", "groups,", "we", "believed", "these", "results", "to", "be", "encouraging", "and", "provide", "guidance", "on", "the", "appropriate", "design", "of", "the", "VISTA-16", "study.", "<tag3>"], "wordsA": ["While", "the", "MACE", "analysis", "was", "not", "designed", "to", "demonstrate", "any", "statistical", "differences", "between", "the", "two", "treatment", "groups,", "we", "believe", "that", "the", "results", "are", "encouraging", "and", "has", "helped", "us", "to", "design", "our", "VISTA-16", "study."], "wordsB": ["While", "the", "MACE", "analysis", "was", "not", "designed", "to", "demonstrate", "any", "statistical", "differences", "between", "the", "two", "treatment", "groups,", "we", "believed", "these", "results", "to", "be", "encouraging", "and", "provide", "guidance", "on", "the", "appropriate", "design", "of", "the", "VISTA-16", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p0_s0", "idA": "1316175_12_item1_p0_s0", "sentA": "Unless the context otherwise requires, we use the terms \"Anthera Pharmaceuticals,\" \"Anthera,\" \"we,\" \"us,\" \"the Company\" and \"our\" in this report to refer to Anthera Pharmaceuticals, Inc. and its subsidiaries.", "sentB": "Unless the context otherwise requires, we use the terms Anthera Pharmaceuticals, Anthera, we, us, the Company and our in this report to refer to Anthera Pharmaceuticals, Inc. and its subsidiaries.", "type": 2, "words": ["<tag1>", "Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "\"Anthera", "Pharmaceuticals,\"", "\"Anthera,\"", "\"we,\"", "\"us,\"", "\"the", "Company\"", "and", "\"our\"", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries.", "<tag2>", "Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "Anthera", "Pharmaceuticals,", "Anthera,", "we,", "us,", "the", "Company", "and", "our", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries.", "<tag3>"], "wordsA": ["Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "\"Anthera", "Pharmaceuticals,\"", "\"Anthera,\"", "\"we,\"", "\"us,\"", "\"the", "Company\"", "and", "\"our\"", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries."], "wordsB": ["Unless", "the", "context", "otherwise", "requires,", "we", "use", "the", "terms", "Anthera", "Pharmaceuticals,", "Anthera,", "we,", "us,", "the", "Company", "and", "our", "in", "this", "report", "to", "refer", "to", "Anthera", "Pharmaceuticals,", "Inc.", "and", "its", "subsidiaries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p0_s1", "idA": "1316175_12_item1_p0_s1", "sentA": "This report also contains trademarks, services marks and trade names of other businesses that are the property of their respective holders.", "sentB": "We use various trademarks, service marks and trade names in our business, including without limitation Anthera Pharmaceuticals and Anthera.", "type": 2, "words": ["<tag1>", "This", "report", "also", "contains", "trademarks,", "services", "marks", "and", "trade", "names", "of", "other", "businesses", "that", "are", "the", "property", "of", "their", "respective", "holders.", "<tag2>", "We", "use", "various", "trademarks,", "service", "marks", "and", "trade", "names", "in", "our", "business,", "including", "without", "limitation", "Anthera", "Pharmaceuticals", "and", "Anthera.", "<tag3>"], "wordsA": ["This", "report", "also", "contains", "trademarks,", "services", "marks", "and", "trade", "names", "of", "other", "businesses", "that", "are", "the", "property", "of", "their", "respective", "holders."], "wordsB": ["We", "use", "various", "trademarks,", "service", "marks", "and", "trade", "names", "in", "our", "business,", "including", "without", "limitation", "Anthera", "Pharmaceuticals", "and", "Anthera."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p85_s3", "idA": "1316175_12_item1_p103_s1", "sentA": "Median sPLA 2 concentration decreased among the varespladib groups in a dose-dependent manner.", "sentB": "We believe that this orphan approach will further differentiate blisibimod from other anti-BAFF molecules in a capital-efficient manner.", "type": 2, "words": ["<tag1>", "Median", "sPLA", "2", "concentration", "decreased", "among", "the", "varespladib", "groups", "in", "a", "dose-dependent", "manner.", "<tag2>", "We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules", "in", "a", "capital-efficient", "manner.", "<tag3>"], "wordsA": ["Median", "sPLA", "2", "concentration", "decreased", "among", "the", "varespladib", "groups", "in", "a", "dose-dependent", "manner."], "wordsB": ["We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules", "in", "a", "capital-efficient", "manner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p49_s2", "idA": "1316175_12_item1_p107_s1", "sentA": "The clinical study, conducted in the United States, involved 13 clinical sites.", "sentB": "In Asia, assuming similar prevalence rates as the United States, IgAN is estimated to affect over 500,000 people annually.", "type": 2, "words": ["<tag1>", "The", "clinical", "study,", "conducted", "in", "the", "United", "States,", "involved", "13", "clinical", "sites.", "<tag2>", "In", "Asia,", "assuming", "similar", "prevalence", "rates", "as", "the", "United", "States,", "IgAN", "is", "estimated", "to", "affect", "over", "500,000", "people", "annually.", "<tag3>"], "wordsA": ["The", "clinical", "study,", "conducted", "in", "the", "United", "States,", "involved", "13", "clinical", "sites."], "wordsB": ["In", "Asia,", "assuming", "similar", "prevalence", "rates", "as", "the", "United", "States,", "IgAN", "is", "estimated", "to", "affect", "over", "500,000", "people", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p15_s1", "idA": "1316175_12_item1_p108_s0", "sentA": "The primary endpoint of the clinical study was a comparison between once-daily doses of varespladib and placebo in changes in sPLA 2 concentration at week eight.", "sentB": "The primary endpoint of the PEARL-SC study was a clinical improvement in the Systemic Lupus Erythematosus responder index, or SRI-5, at week 24 for the pooled blisibimod dose groups versus pooled placebo groups.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "clinical", "study", "was", "a", "comparison", "between", "once-daily", "doses", "of", "varespladib", "and", "placebo", "in", "changes", "in", "sPLA", "2", "concentration", "at", "week", "eight.", "<tag2>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "in", "the", "Systemic", "Lupus", "Erythematosus", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "blisibimod", "dose", "groups", "versus", "pooled", "placebo", "groups.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "clinical", "study", "was", "a", "comparison", "between", "once-daily", "doses", "of", "varespladib", "and", "placebo", "in", "changes", "in", "sPLA", "2", "concentration", "at", "week", "eight."], "wordsB": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "in", "the", "Systemic", "Lupus", "Erythematosus", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "blisibimod", "dose", "groups", "versus", "pooled", "placebo", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p52_s0", "idA": "1316175_12_item1_p108_s0", "sentA": "The primary endpoint of the clinical study was a comparison between once-daily doses of varespladib and placebo in changes in sPLA 2 concentration at week eight.", "sentB": "The primary endpoint of the PEARL-SC study was a clinical improvement at the SLE responder index, or SRI-5, at week 24 for the pooled bisibimod dose groups versus placebo groups.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "clinical", "study", "was", "a", "comparison", "between", "once-daily", "doses", "of", "varespladib", "and", "placebo", "in", "changes", "in", "sPLA", "2", "concentration", "at", "week", "eight.", "<tag2>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "SLE", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "bisibimod", "dose", "groups", "versus", "placebo", "groups.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "clinical", "study", "was", "a", "comparison", "between", "once-daily", "doses", "of", "varespladib", "and", "placebo", "in", "changes", "in", "sPLA", "2", "concentration", "at", "week", "eight."], "wordsB": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "SLE", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "bisibimod", "dose", "groups", "versus", "placebo", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p24_s1", "idA": "1316175_12_item1_p111_s0", "sentA": "As was observed in the first clinical study, there were statistically significant reductions from baseline to week eight in total cholesterol and non-HDL cholesterol in the overall clinical study population treated with varespladib.", "sentB": "In all three (3) studies, statistically significant reductions in total B-cells were observed in patients treated with blisibimod versus those treated with placebo due to its mechanism of BAFF inhibition.", "type": 2, "words": ["<tag1>", "As", "was", "observed", "in", "the", "first", "clinical", "study,", "there", "were", "statistically", "significant", "reductions", "from", "baseline", "to", "week", "eight", "in", "total", "cholesterol", "and", "non-HDL", "cholesterol", "in", "the", "overall", "clinical", "study", "population", "treated", "with", "varespladib.", "<tag2>", "In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag3>"], "wordsA": ["As", "was", "observed", "in", "the", "first", "clinical", "study,", "there", "were", "statistically", "significant", "reductions", "from", "baseline", "to", "week", "eight", "in", "total", "cholesterol", "and", "non-HDL", "cholesterol", "in", "the", "overall", "clinical", "study", "population", "treated", "with", "varespladib."], "wordsB": ["In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p11_s0", "idA": "1316175_12_item1_p121_s0", "sentA": "Blisibimod is a peptibody antagonist of the BAFF cytokine that is initially being developed as a treatment for lupus.", "sentB": "Blisibimod (also referred to as A-623) is a peptibody antagonist of the BAFF cytokine that we are developing as a treatment for systemic lupus erythematosus, or lupus and IgAN.", "type": 2, "words": ["<tag1>", "Blisibimod", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus.", "<tag2>", "Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "we", "are", "developing", "as", "a", "treatment", "for", "systemic", "lupus", "erythematosus,", "or", "lupus", "and", "IgAN.", "<tag3>"], "wordsA": ["Blisibimod", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus."], "wordsB": ["Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "we", "are", "developing", "as", "a", "treatment", "for", "systemic", "lupus", "erythematosus,", "or", "lupus", "and", "IgAN."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s5", "idA": "1316175_12_item1_p121_s0", "sentA": "Blisibimod is a peptibody antagonist of the BAFF cytokine that is initially being developed as a treatment for lupus.", "sentB": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "type": 2, "words": ["<tag1>", "Blisibimod", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus.", "<tag2>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["Blisibimod", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "is", "initially", "being", "developed", "as", "a", "treatment", "for", "lupus."], "wordsB": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p12_s0", "idA": "1316175_12_item1_p122_s0", "sentA": "BLyS, also known as B-cell activating factor, or BAFF, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells.", "sentB": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells.", "type": 2, "words": ["<tag1>", "BLyS,", "also", "known", "as", "B-cell", "activating", "factor,", "or", "BAFF,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells.", "<tag2>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells.", "<tag3>"], "wordsA": ["BLyS,", "also", "known", "as", "B-cell", "activating", "factor,", "or", "BAFF,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells."], "wordsB": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p2_s0", "idA": "1316175_12_item1_p122_s0", "sentA": "BLyS, also known as B-cell activating factor, or BAFF, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells.", "sentB": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells.", "type": 2, "words": ["<tag1>", "BLyS,", "also", "known", "as", "B-cell", "activating", "factor,", "or", "BAFF,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells.", "<tag2>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells.", "<tag3>"], "wordsA": ["BLyS,", "also", "known", "as", "B-cell", "activating", "factor,", "or", "BAFF,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells."], "wordsB": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p15_s0", "idA": "1316175_12_item1_p125_s0", "sentA": "In 2009, after successfully reactivating our Investigational New Drug Application, or IND, we initiated a Phase 2b clinical study with blisibimod for the treatment of lupus in July 2010 called PEARL-SC.", "sentB": "In April of 2012 we completed a Phase 2b clinical study, called PEARL-SC, with blisibimod for the treatment of patients with seropositive markers of lupus and active disease defined as SELENA-SLEDAI score of greater than 6.", "type": 2, "words": ["<tag1>", "In", "2009,", "after", "successfully", "reactivating", "our", "Investigational", "New", "Drug", "Application,", "or", "IND,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "for", "the", "treatment", "of", "lupus", "in", "July", "2010", "called", "PEARL-SC.", "<tag2>", "In", "April", "of", "2012", "we", "completed", "a", "Phase", "2b", "clinical", "study,", "called", "PEARL-SC,", "with", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6.", "<tag3>"], "wordsA": ["In", "2009,", "after", "successfully", "reactivating", "our", "Investigational", "New", "Drug", "Application,", "or", "IND,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "for", "the", "treatment", "of", "lupus", "in", "July", "2010", "called", "PEARL-SC."], "wordsB": ["In", "April", "of", "2012", "we", "completed", "a", "Phase", "2b", "clinical", "study,", "called", "PEARL-SC,", "with", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p56_s1", "idA": "1316175_12_item1_p125_s1", "sentA": "Enrollment in this study is now complete (N=547) and we anticipate completing the study in 2012.", "sentB": "The open-label extension study completed enrollment in 2012 and we anticipate completing patient dosing in this safety and efficacy study in 2013.", "type": 2, "words": ["<tag1>", "Enrollment", "in", "this", "study", "is", "now", "complete", "(N=547)", "and", "we", "anticipate", "completing", "the", "study", "in", "2012.", "<tag2>", "The", "open-label", "extension", "study", "completed", "enrollment", "in", "2012", "and", "we", "anticipate", "completing", "patient", "dosing", "in", "this", "safety", "and", "efficacy", "study", "in", "2013.", "<tag3>"], "wordsA": ["Enrollment", "in", "this", "study", "is", "now", "complete", "(N=547)", "and", "we", "anticipate", "completing", "the", "study", "in", "2012."], "wordsB": ["The", "open-label", "extension", "study", "completed", "enrollment", "in", "2012", "and", "we", "anticipate", "completing", "patient", "dosing", "in", "this", "safety", "and", "efficacy", "study", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p33_s0", "idA": "1316175_12_item1_p125_s2", "sentA": "We may also study blisibimod in other B-cell mediated autoimmune diseases such as vasculitis, Sj gren's Syndrome or orphan indications such as myasthenia gravis and pemphigus.", "sentB": "In 2013 we will begin to study blisibimod in patients with B-cell mediated autoimmune diseases such as IgA nephropathy (Berger s disease).", "type": 2, "words": ["<tag1>", "We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus.", "<tag2>", "In", "2013", "we", "will", "begin", "to", "study", "blisibimod", "in", "patients", "with", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease).", "<tag3>"], "wordsA": ["We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus."], "wordsB": ["In", "2013", "we", "will", "begin", "to", "study", "blisibimod", "in", "patients", "with", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s6", "idA": "1316175_12_item1_p125_s2", "sentA": "We may also study blisibimod in other B-cell mediated autoimmune diseases such as vasculitis, Sj gren's Syndrome or orphan indications such as myasthenia gravis and pemphigus.", "sentB": "We believe data from the BRIGHT-SC clinical study may provide information for other B-cell mediated kidney orphan diseases such as idiopathic membranous glomerulonephritis and lupus nephritis.", "type": 2, "words": ["<tag1>", "We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus.", "<tag2>", "We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "idiopathic", "membranous", "glomerulonephritis", "and", "lupus", "nephritis.", "<tag3>"], "wordsA": ["We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus."], "wordsB": ["We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "idiopathic", "membranous", "glomerulonephritis", "and", "lupus", "nephritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p67_s1", "idA": "1316175_12_item1_p125_s2", "sentA": "We may also study blisibimod in other B-cell mediated autoimmune diseases such as vasculitis, Sj gren's Syndrome or orphan indications such as myasthenia gravis and pemphigus.", "sentB": "We believe data from the BRIGHT-SC clinical study may provide information for other B-cell mediated kidney orphan diseases such as lupus nephritis and idiopathic membranous glomerulonephritis.", "type": 2, "words": ["<tag1>", "We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus.", "<tag2>", "We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "lupus", "nephritis", "and", "idiopathic", "membranous", "glomerulonephritis.", "<tag3>"], "wordsA": ["We", "may", "also", "study", "blisibimod", "in", "other", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "vasculitis,", "Sj", "gren's", "Syndrome", "or", "orphan", "indications", "such", "as", "myasthenia", "gravis", "and", "pemphigus."], "wordsB": ["We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "lupus", "nephritis", "and", "idiopathic", "membranous", "glomerulonephritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p64_s1", "idA": "1316175_12_item1_p126_s0", "sentA": "We continue to actively pursue a partnership with major pharmaceutical companies to develop and commercialize blisibimod.", "sentB": "We are actively pursuing various partnerships with major pharmaceutical and biotech companies to develop and commercialize blisibimod for both lupus and additional indications.", "type": 2, "words": ["<tag1>", "We", "continue", "to", "actively", "pursue", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "blisibimod.", "<tag2>", "We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "additional", "indications.", "<tag3>"], "wordsA": ["We", "continue", "to", "actively", "pursue", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "blisibimod."], "wordsB": ["We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "additional", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p9_s1", "idA": "1316175_12_item1_p126_s0", "sentA": "We continue to actively pursue a partnership with major pharmaceutical companies to develop and commercialize blisibimod.", "sentB": "We are actively pursuing various partnerships with major pharmaceutical and biotech companies to develop and commercialize blisibimod for both lupus and additional indications.", "type": 2, "words": ["<tag1>", "We", "continue", "to", "actively", "pursue", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "blisibimod.", "<tag2>", "We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "additional", "indications.", "<tag3>"], "wordsA": ["We", "continue", "to", "actively", "pursue", "a", "partnership", "with", "major", "pharmaceutical", "companies", "to", "develop", "and", "commercialize", "blisibimod."], "wordsB": ["We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "additional", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p3_s2", "idA": "1316175_12_item1_p127_s0", "sentA": "We intend to advance the development of our BAFF targeting molecule, blisibimod, a selective peptibody, to exploit its broad clinical utility in autoimmune diseases.", "sentB": "We intend to advance the clinical development of our BAFF inhibitor, blisibimod, to exploit its broad potential clinical utility in a number of autoimmune diseases.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "advance", "the", "development", "of", "our", "BAFF", "targeting", "molecule,", "blisibimod,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "clinical", "utility", "in", "autoimmune", "diseases.", "<tag2>", "We", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["We", "intend", "to", "advance", "the", "development", "of", "our", "BAFF", "targeting", "molecule,", "blisibimod,", "a", "selective", "peptibody,", "to", "exploit", "its", "broad", "clinical", "utility", "in", "autoimmune", "diseases."], "wordsB": ["We", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p3_s3", "idA": "1316175_12_item1_p127_s1", "sentA": "Blisibimod, as a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture versus antibodies that are produced in mammalian cell culture.", "sentB": "Blisibimod, a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture which contrasts with antibody therapeutics that are typically manufactured in mammalian cell culture.", "type": 2, "words": ["<tag1>", "Blisibimod,", "as", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "versus", "antibodies", "that", "are", "produced", "in", "mammalian", "cell", "culture.", "<tag2>", "Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "which", "contrasts", "with", "antibody", "therapeutics", "that", "are", "typically", "manufactured", "in", "mammalian", "cell", "culture.", "<tag3>"], "wordsA": ["Blisibimod,", "as", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "versus", "antibodies", "that", "are", "produced", "in", "mammalian", "cell", "culture."], "wordsB": ["Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "which", "contrasts", "with", "antibody", "therapeutics", "that", "are", "typically", "manufactured", "in", "mammalian", "cell", "culture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p36_s1", "idA": "1316175_12_item1_p129_s1", "sentA": "Lupus can affect any part of the body, but especially the skin, heart, brain, lungs, joints and the kidneys.", "sentB": "IgA nephropathy may occur when excessive plasma B-cells express excessive amounts of abnormal IgA and this immunogenic protein is deposited in the kidneys.", "type": 2, "words": ["<tag1>", "Lupus", "can", "affect", "any", "part", "of", "the", "body,", "but", "especially", "the", "skin,", "heart,", "brain,", "lungs,", "joints", "and", "the", "kidneys.", "<tag2>", "IgA", "nephropathy", "may", "occur", "when", "excessive", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "this", "immunogenic", "protein", "is", "deposited", "in", "the", "kidneys.", "<tag3>"], "wordsA": ["Lupus", "can", "affect", "any", "part", "of", "the", "body,", "but", "especially", "the", "skin,", "heart,", "brain,", "lungs,", "joints", "and", "the", "kidneys."], "wordsB": ["IgA", "nephropathy", "may", "occur", "when", "excessive", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "this", "immunogenic", "protein", "is", "deposited", "in", "the", "kidneys."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p46_s0", "idA": "1316175_12_item1_p129_s1", "sentA": "Lupus can affect any part of the body, but especially the skin, heart, brain, lungs, joints and the kidneys.", "sentB": "IgA nephropathy occurs when too much of this protein, especially aberrant and immunogenic forms of IgA, is deposited in the kidneys.", "type": 2, "words": ["<tag1>", "Lupus", "can", "affect", "any", "part", "of", "the", "body,", "but", "especially", "the", "skin,", "heart,", "brain,", "lungs,", "joints", "and", "the", "kidneys.", "<tag2>", "IgA", "nephropathy", "occurs", "when", "too", "much", "of", "this", "protein,", "especially", "aberrant", "and", "immunogenic", "forms", "of", "IgA,", "is", "deposited", "in", "the", "kidneys.", "<tag3>"], "wordsA": ["Lupus", "can", "affect", "any", "part", "of", "the", "body,", "but", "especially", "the", "skin,", "heart,", "brain,", "lungs,", "joints", "and", "the", "kidneys."], "wordsB": ["IgA", "nephropathy", "occurs", "when", "too", "much", "of", "this", "protein,", "especially", "aberrant", "and", "immunogenic", "forms", "of", "IgA,", "is", "deposited", "in", "the", "kidneys."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p43_s4", "idA": "1316175_12_item1_p131_s4", "sentA": "Lupus may also cause swollen joints and severe rash.", "sentB": "Lupus may also cause swollen joints, proteinuria and severe rash.", "type": 2, "words": ["<tag1>", "Lupus", "may", "also", "cause", "swollen", "joints", "and", "severe", "rash.", "<tag2>", "Lupus", "may", "also", "cause", "swollen", "joints,", "proteinuria", "and", "severe", "rash.", "<tag3>"], "wordsA": ["Lupus", "may", "also", "cause", "swollen", "joints", "and", "severe", "rash."], "wordsB": ["Lupus", "may", "also", "cause", "swollen", "joints,", "proteinuria", "and", "severe", "rash."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p12_s2", "idA": "1316175_12_item1_p131_s5", "sentA": "In addition, LN may lead to requiring kidney dialysis or transplantation.", "sentB": "However abnormal elevations of B-cells, often accompanied by elevations in BAFF, may lead to an over active immune response which may damage normal healthy tissues and organ systems.", "type": 2, "words": ["<tag1>", "In", "addition,", "LN", "may", "lead", "to", "requiring", "kidney", "dialysis", "or", "transplantation.", "<tag2>", "However", "abnormal", "elevations", "of", "B-cells,", "often", "accompanied", "by", "elevations", "in", "BAFF,", "may", "lead", "to", "an", "over", "active", "immune", "response", "which", "may", "damage", "normal", "healthy", "tissues", "and", "organ", "systems.", "<tag3>"], "wordsA": ["In", "addition,", "LN", "may", "lead", "to", "requiring", "kidney", "dialysis", "or", "transplantation."], "wordsB": ["However", "abnormal", "elevations", "of", "B-cells,", "often", "accompanied", "by", "elevations", "in", "BAFF,", "may", "lead", "to", "an", "over", "active", "immune", "response", "which", "may", "damage", "normal", "healthy", "tissues", "and", "organ", "systems."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p43_s5", "idA": "1316175_12_item1_p131_s5", "sentA": "In addition, LN may lead to requiring kidney dialysis or transplantation.", "sentB": "In addition, patients with lupus nephritis may require kidney dialysis or eventual transplantation.", "type": 2, "words": ["<tag1>", "In", "addition,", "LN", "may", "lead", "to", "requiring", "kidney", "dialysis", "or", "transplantation.", "<tag2>", "In", "addition,", "patients", "with", "lupus", "nephritis", "may", "require", "kidney", "dialysis", "or", "eventual", "transplantation.", "<tag3>"], "wordsA": ["In", "addition,", "LN", "may", "lead", "to", "requiring", "kidney", "dialysis", "or", "transplantation."], "wordsB": ["In", "addition,", "patients", "with", "lupus", "nephritis", "may", "require", "kidney", "dialysis", "or", "eventual", "transplantation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p13_s1", "idA": "1316175_12_item1_p132_s1", "sentA": "Evidence has emerged that over-expression of BAFF plays an important role in this disease process.", "sentB": "Evidence has emerged that over-expression of BAFF plays an important role in these disease processes.", "type": 2, "words": ["<tag1>", "Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "plays", "an", "important", "role", "in", "this", "disease", "process.", "<tag2>", "Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "plays", "an", "important", "role", "in", "these", "disease", "processes.", "<tag3>"], "wordsA": ["Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "plays", "an", "important", "role", "in", "this", "disease", "process."], "wordsB": ["Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "plays", "an", "important", "role", "in", "these", "disease", "processes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p34_s2", "idA": "1316175_12_item1_p132_s3", "sentA": "In addition, treatment of these same mice with BAFF antagonists appears to ameliorate the disease.", "sentB": "In Asia, routine urinalyses are often performed for school children, and renal biopsies are performed for any patients with asymptomatic hematuria, thus raising the reported prevalence of the disease.", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment", "of", "these", "same", "mice", "with", "BAFF", "antagonists", "appears", "to", "ameliorate", "the", "disease.", "<tag2>", "In", "Asia,", "routine", "urinalyses", "are", "often", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "any", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease.", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "of", "these", "same", "mice", "with", "BAFF", "antagonists", "appears", "to", "ameliorate", "the", "disease."], "wordsB": ["In", "Asia,", "routine", "urinalyses", "are", "often", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "any", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p44_s3", "idA": "1316175_12_item1_p132_s3", "sentA": "In addition, treatment of these same mice with BAFF antagonists appears to ameliorate the disease.", "sentB": "In addition, treatment of lupus-prone mice with blisibimod ameliorates the disease.", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment", "of", "these", "same", "mice", "with", "BAFF", "antagonists", "appears", "to", "ameliorate", "the", "disease.", "<tag2>", "In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease.", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "of", "these", "same", "mice", "with", "BAFF", "antagonists", "appears", "to", "ameliorate", "the", "disease."], "wordsB": ["In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p49_s3", "idA": "1316175_12_item1_p132_s3", "sentA": "In addition, treatment of these same mice with BAFF antagonists appears to ameliorate the disease.", "sentB": "In Asia, routine urinalyses are performed for school children, and renal biopsies are performed for patients with asymptomatic hematuria, thus raising the reported prevalence of the disease.", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment", "of", "these", "same", "mice", "with", "BAFF", "antagonists", "appears", "to", "ameliorate", "the", "disease.", "<tag2>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease.", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "of", "these", "same", "mice", "with", "BAFF", "antagonists", "appears", "to", "ameliorate", "the", "disease."], "wordsB": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p51_s0", "idA": "1316175_12_item1_p133_s0", "sentA": "Based on positive results among 104 patients in our Phase 1a and 1b clinical studies, we initiated a Phase 2b clinical study in lupus patients called PEARL-SC.", "sentB": "Based on positive results among 104 patients in our Phase 1a and 1b clinical studies, we initiated a Phase 2b clinical study in lupus patients called PEARL-SC in 2010, exploring three doses of blisibimod for the treatment of patients with seropositive markers of lupus and active disease defined as SELENA-SLEDAI score of greater than 6.", "type": 2, "words": ["<tag1>", "Based", "on", "positive", "results", "among", "104", "patients", "in", "our", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "patients", "called", "PEARL-SC.", "<tag2>", "Based", "on", "positive", "results", "among", "104", "patients", "in", "our", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "patients", "called", "PEARL-SC", "in", "2010,", "exploring", "three", "doses", "of", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6.", "<tag3>"], "wordsA": ["Based", "on", "positive", "results", "among", "104", "patients", "in", "our", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "patients", "called", "PEARL-SC."], "wordsB": ["Based", "on", "positive", "results", "among", "104", "patients", "in", "our", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "patients", "called", "PEARL-SC", "in", "2010,", "exploring", "three", "doses", "of", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p51_s1", "idA": "1316175_12_item1_p134_s0", "sentA": "PEARL-SC is a randomized, placebo-controlled, Phase 2b study which enrolled 547 patients in 11 countries at 72 clinical sites.", "sentB": "PEARL-SC was a randomized, placebo-controlled, Phase 2b study which enrolled 547 patients in 11 countries at 72 clinical sites.", "type": 2, "words": ["<tag1>", "PEARL-SC", "is", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites.", "<tag2>", "PEARL-SC", "was", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites.", "<tag3>"], "wordsA": ["PEARL-SC", "is", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites."], "wordsB": ["PEARL-SC", "was", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p20_s3", "idA": "1316175_12_item1_p134_s1", "sentA": "Subjects were randomized into three active subcutaneous treatment arms and one placebo treatment arm for a minimum of 24 weeks and a maximum of 52 weeks.", "sentB": "Graphs show data for blisibimod (200mg once-weekly) and treatment matched or pooled placebo administered subcutaneously for 24 weeks.", "type": 2, "words": ["<tag1>", "Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "treatment", "matched", "or", "pooled", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag3>"], "wordsA": ["Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "treatment", "matched", "or", "pooled", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p21_s3", "idA": "1316175_12_item1_p134_s1", "sentA": "Subjects were randomized into three active subcutaneous treatment arms and one placebo treatment arm for a minimum of 24 weeks and a maximum of 52 weeks.", "sentB": "Graph shows data for blisibimod (200mg once-weekly) and regimen matched placebo administered subcutaneously for 24 weeks .", "type": 2, "words": ["<tag1>", "Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks.", "<tag2>", "Graph", "shows", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks", ".", "<tag3>"], "wordsA": ["Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks."], "wordsB": ["Graph", "shows", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p27_s1", "idA": "1316175_12_item1_p134_s1", "sentA": "Subjects were randomized into three active subcutaneous treatment arms and one placebo treatment arm for a minimum of 24 weeks and a maximum of 52 weeks.", "sentB": "Graphs show data for blisibimod (average of all dose levels) and placebo administered subcutaneously for 24 weeks.", "type": 2, "words": ["<tag1>", "Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(average", "of", "all", "dose", "levels)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag3>"], "wordsA": ["Subjects", "were", "randomized", "into", "three", "active", "subcutaneous", "treatment", "arms", "and", "one", "placebo", "treatment", "arm", "for", "a", "minimum", "of", "24", "weeks", "and", "a", "maximum", "of", "52", "weeks."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(average", "of", "all", "dose", "levels)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p15_s2", "idA": "1316175_12_item1_p135_s0", "sentA": "The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in a SLE responder index a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI improvement of five (5) points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two new BILAG B organ domain flares.", "sentB": "SRI-5 is defined as a five-point improvement in the SELENA-SLEDAI score, no new BILAG A or two B scores, and no increase in a physician s global assessment of more than 0.3 points.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares.", "<tag2>", "SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "A", "or", "two", "B", "scores,", "and", "no", "increase", "in", "a", "physician", "s", "global", "assessment", "of", "more", "than", "0.3", "points.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares."], "wordsB": ["SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "A", "or", "two", "B", "scores,", "and", "no", "increase", "in", "a", "physician", "s", "global", "assessment", "of", "more", "than", "0.3", "points."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p20_s0", "idA": "1316175_12_item1_p135_s0", "sentA": "The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in a SLE responder index a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI improvement of five (5) points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two new BILAG B organ domain flares.", "sentB": "An SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, AND no new BILAG A or 2B organ domain scores, AND no worsening ( 0.3 increase) in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares.", "<tag2>", "An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares."], "wordsB": ["An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p21_s0", "idA": "1316175_12_item1_p135_s0", "sentA": "The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in a SLE responder index a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI improvement of five (5) points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two new BILAG B organ domain flares.", "sentB": "An SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, AND no new BILAG A or 2B organ domain scores, AND no worsening ( 0.3 increase) in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares.", "<tag2>", "An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares."], "wordsB": ["An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p23_s0", "idA": "1316175_12_item1_p135_s0", "sentA": "The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in a SLE responder index a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI improvement of five (5) points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two new BILAG B organ domain flares.", "sentB": "*SRI is defined as patients who respond to treatment and achieve a reduction in SELENA-SLEDAI equal to or greater than the number indicated, no new BILAG A or two B organ domain scores, and no increase in Physician's Global Assessment (PGA) of greater than 0.3 on a three point scale.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares.", "<tag2>", "*SRI", "is", "defined", "as", "patients", "who", "respond", "to", "treatment", "and", "achieve", "a", "reduction", "in", "SELENA-SLEDAI", "equal", "to", "or", "greater", "than", "the", "number", "indicated,", "no", "new", "BILAG", "A", "or", "two", "B", "organ", "domain", "scores,", "and", "no", "increase", "in", "Physician's", "Global", "Assessment", "(PGA)", "of", "greater", "than", "0.3", "on", "a", "three", "point", "scale.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares."], "wordsB": ["*SRI", "is", "defined", "as", "patients", "who", "respond", "to", "treatment", "and", "achieve", "a", "reduction", "in", "SELENA-SLEDAI", "equal", "to", "or", "greater", "than", "the", "number", "indicated,", "no", "new", "BILAG", "A", "or", "two", "B", "organ", "domain", "scores,", "and", "no", "increase", "in", "Physician's", "Global", "Assessment", "(PGA)", "of", "greater", "than", "0.3", "on", "a", "three", "point", "scale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p52_s1", "idA": "1316175_12_item1_p135_s0", "sentA": "The primary endpoint of the PEARL-SC study is clinical improvement at 24 weeks in a SLE responder index a composite responder index evaluating various patient and physician reported clinical disease activity including a SELENA/SLEDAI improvement of five (5) points or greater, no increase in a physician's global assessment of more than 0.3 points, with no new BILAG A or two new BILAG B organ domain flares.", "sentB": "SRI-5 is defined as a five-point improvement in the SELENA-SLEDAI score, no new BILAG A or two BILAG B scores, and no new increase in physician s global assessment of more than 0.3 points.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares.", "<tag2>", "SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "A", "or", "two", "BILAG", "B", "scores,", "and", "no", "new", "increase", "in", "physician", "s", "global", "assessment", "of", "more", "than", "0.3", "points.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "is", "clinical", "improvement", "at", "24", "weeks", "in", "a", "SLE", "responder", "index", "a", "composite", "responder", "index", "evaluating", "various", "patient", "and", "physician", "reported", "clinical", "disease", "activity", "including", "a", "SELENA/SLEDAI", "improvement", "of", "five", "(5)", "points", "or", "greater,", "no", "increase", "in", "a", "physician's", "global", "assessment", "of", "more", "than", "0.3", "points,", "with", "no", "new", "BILAG", "A", "or", "two", "new", "BILAG", "B", "organ", "domain", "flares."], "wordsB": ["SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "A", "or", "two", "BILAG", "B", "scores,", "and", "no", "new", "increase", "in", "physician", "s", "global", "assessment", "of", "more", "than", "0.3", "points."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p52_s2", "idA": "1316175_12_item1_p135_s1", "sentA": "Secondary endpoints will include safety, improvement in other clinical assessment scores, clinical response in patients with various baseline disease severities, resolution of fatigue, steroid utilization and time to flare.", "sentB": "Secondary endpoints included safety, improvement in other clinical assessment scores, and clinical response in patients with various baseline disease severities, resolution of fatigue, steroid utilization and time to flare.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "will", "include", "safety,", "improvement", "in", "other", "clinical", "assessment", "scores,", "clinical", "response", "in", "patients", "with", "various", "baseline", "disease", "severities,", "resolution", "of", "fatigue,", "steroid", "utilization", "and", "time", "to", "flare.", "<tag2>", "Secondary", "endpoints", "included", "safety,", "improvement", "in", "other", "clinical", "assessment", "scores,", "and", "clinical", "response", "in", "patients", "with", "various", "baseline", "disease", "severities,", "resolution", "of", "fatigue,", "steroid", "utilization", "and", "time", "to", "flare.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "will", "include", "safety,", "improvement", "in", "other", "clinical", "assessment", "scores,", "clinical", "response", "in", "patients", "with", "various", "baseline", "disease", "severities,", "resolution", "of", "fatigue,", "steroid", "utilization", "and", "time", "to", "flare."], "wordsB": ["Secondary", "endpoints", "included", "safety,", "improvement", "in", "other", "clinical", "assessment", "scores,", "and", "clinical", "response", "in", "patients", "with", "various", "baseline", "disease", "severities,", "resolution", "of", "fatigue,", "steroid", "utilization", "and", "time", "to", "flare."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p20_s1", "idA": "1316175_12_item1_p136_s0", "sentA": "In November 2011, we completed an interim biomarker analysis of changes in B-Cells in patients enrolled in the PEARL-SC clinical study.", "sentB": "Across all subjects enrolled in the PEARL-SC study, the percent of subjects achieving the SRI-5 at 24 weeks was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "type": 2, "words": ["<tag1>", "In", "November", "2011,", "we", "completed", "an", "interim", "biomarker", "analysis", "of", "changes", "in", "B-Cells", "in", "patients", "enrolled", "in", "the", "PEARL-SC", "clinical", "study.", "<tag2>", "Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag3>"], "wordsA": ["In", "November", "2011,", "we", "completed", "an", "interim", "biomarker", "analysis", "of", "changes", "in", "B-Cells", "in", "patients", "enrolled", "in", "the", "PEARL-SC", "clinical", "study."], "wordsB": ["Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p31_s1", "idA": "1316175_12_item1_p136_s0", "sentA": "In November 2011, we completed an interim biomarker analysis of changes in B-Cells in patients enrolled in the PEARL-SC clinical study.", "sentB": "At the meeting we presented the results of the PEARL-SC clinical study and our plans for Phase 3 registration studies in patients with active lupus who are receiving steroids.", "type": 2, "words": ["<tag1>", "In", "November", "2011,", "we", "completed", "an", "interim", "biomarker", "analysis", "of", "changes", "in", "B-Cells", "in", "patients", "enrolled", "in", "the", "PEARL-SC", "clinical", "study.", "<tag2>", "At", "the", "meeting", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus", "who", "are", "receiving", "steroids.", "<tag3>"], "wordsA": ["In", "November", "2011,", "we", "completed", "an", "interim", "biomarker", "analysis", "of", "changes", "in", "B-Cells", "in", "patients", "enrolled", "in", "the", "PEARL-SC", "clinical", "study."], "wordsB": ["At", "the", "meeting", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus", "who", "are", "receiving", "steroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p24_s2", "idA": "1316175_12_item1_p136_s2", "sentA": "Elevations in these B-cells have been associated with an increased risk of disease activity in lupus patients.", "sentB": "In addition, treatment with blisibimod was associated with significant improvements in lupus disease activity and lupus biomarkers, including anti-double-stranded DNA antibodies, urine protein content, or proteinuria, and complement components C3 and C4.", "type": 2, "words": ["<tag1>", "Elevations", "in", "these", "B-cells", "have", "been", "associated", "with", "an", "increased", "risk", "of", "disease", "activity", "in", "lupus", "patients.", "<tag2>", "In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-double-stranded", "DNA", "antibodies,", "urine", "protein", "content,", "or", "proteinuria,", "and", "complement", "components", "C3", "and", "C4.", "<tag3>"], "wordsA": ["Elevations", "in", "these", "B-cells", "have", "been", "associated", "with", "an", "increased", "risk", "of", "disease", "activity", "in", "lupus", "patients."], "wordsB": ["In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-double-stranded", "DNA", "antibodies,", "urine", "protein", "content,", "or", "proteinuria,", "and", "complement", "components", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p38_s3", "idA": "1316175_12_item1_p136_s3", "sentA": "These findings are consistent with data from previous clinical studies of blisibimod.", "sentB": "Significant reductions in plasma B-cells were observed in previous clinical studies of SLE patients with another BAFF inhibitor antibody, belimumab.", "type": 2, "words": ["<tag1>", "These", "findings", "are", "consistent", "with", "data", "from", "previous", "clinical", "studies", "of", "blisibimod.", "<tag2>", "Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "SLE", "patients", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab.", "<tag3>"], "wordsA": ["These", "findings", "are", "consistent", "with", "data", "from", "previous", "clinical", "studies", "of", "blisibimod."], "wordsB": ["Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "SLE", "patients", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p60_s3", "idA": "1316175_12_item1_p136_s3", "sentA": "These findings are consistent with data from previous clinical studies of blisibimod.", "sentB": "Significant reductions in plasma B-cells were observed in previous clinical studies of SLE patients with another BAFF inhibitor antibody, belimumab.", "type": 2, "words": ["<tag1>", "These", "findings", "are", "consistent", "with", "data", "from", "previous", "clinical", "studies", "of", "blisibimod.", "<tag2>", "Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "SLE", "patients", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab.", "<tag3>"], "wordsA": ["These", "findings", "are", "consistent", "with", "data", "from", "previous", "clinical", "studies", "of", "blisibimod."], "wordsB": ["Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "SLE", "patients", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p56_s0", "idA": "1316175_12_item1_p137_s0", "sentA": "Upon completion of PEARL-SC, patients may be invited to enroll in an open-label extension study in which patients will receive active study drug (blisibimod) for the primary objective of monitoring long-term safety.", "sentB": "Upon completion of PEARL-SC, patients were invited to enroll in an open-label extension study in which patients receive active study drug (blisibimod) for the primary objective of monitoring long-term safety.", "type": 2, "words": ["<tag1>", "Upon", "completion", "of", "PEARL-SC,", "patients", "may", "be", "invited", "to", "enroll", "in", "an", "open-label", "extension", "study", "in", "which", "patients", "will", "receive", "active", "study", "drug", "(blisibimod)", "for", "the", "primary", "objective", "of", "monitoring", "long-term", "safety.", "<tag2>", "Upon", "completion", "of", "PEARL-SC,", "patients", "were", "invited", "to", "enroll", "in", "an", "open-label", "extension", "study", "in", "which", "patients", "receive", "active", "study", "drug", "(blisibimod)", "for", "the", "primary", "objective", "of", "monitoring", "long-term", "safety.", "<tag3>"], "wordsA": ["Upon", "completion", "of", "PEARL-SC,", "patients", "may", "be", "invited", "to", "enroll", "in", "an", "open-label", "extension", "study", "in", "which", "patients", "will", "receive", "active", "study", "drug", "(blisibimod)", "for", "the", "primary", "objective", "of", "monitoring", "long-term", "safety."], "wordsB": ["Upon", "completion", "of", "PEARL-SC,", "patients", "were", "invited", "to", "enroll", "in", "an", "open-label", "extension", "study", "in", "which", "patients", "receive", "active", "study", "drug", "(blisibimod)", "for", "the", "primary", "objective", "of", "monitoring", "long-term", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p62_s0", "idA": "1316175_12_item1_p138_s0", "sentA": "In December 2011, we completed the technology transfer from Amgen and manufacturing scale up to 3,000 liters at our contract manufacturing organization, or CRO (Fujifilm Diosynth Bioservices or \"Fujifilm\").", "sentB": "In December 2011, we completed the technology transfer from Amgen Inc., or Amgen and manufacturing scale up to 3,000 liters at our contract manufacturing organization, or CMO (Fujifilm Diosynth Bioservices or Fujifilm ).", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CRO", "(Fujifilm", "Diosynth", "Bioservices", "or", "\"Fujifilm\").", "<tag2>", "In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices", "or", "Fujifilm", ").", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CRO", "(Fujifilm", "Diosynth", "Bioservices", "or", "\"Fujifilm\")."], "wordsB": ["In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices", "or", "Fujifilm", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p62_s1", "idA": "1316175_12_item1_p138_s1", "sentA": "Two (2) batches of blisibimod produced under US FDA good manufacturing procedures, or GMP, at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "sentB": "Two batches of blisibimod produced under U.S. and EU good manufacturing procedures, or GMPs, at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "type": 2, "words": ["<tag1>", "Two", "(2)", "batches", "of", "blisibimod", "produced", "under", "US", "FDA", "good", "manufacturing", "procedures,", "or", "GMP,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag2>", "Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures,", "or", "GMPs,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag3>"], "wordsA": ["Two", "(2)", "batches", "of", "blisibimod", "produced", "under", "US", "FDA", "good", "manufacturing", "procedures,", "or", "GMP,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "wordsB": ["Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures,", "or", "GMPs,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p62_s2", "idA": "1316175_12_item1_p138_s2", "sentA": "Data from our first 3,000 liter manufacturing campaign was submitted to the US FDA, and after having received no comments from the US FDA, product from this batch was released for use in the PEARL-SC study.", "sentB": "Data from our first 3,000 liter manufacturing campaign was submitted to the FDA, and product from this batch was released for use in the PEARL-SC and OLE studies.", "type": 2, "words": ["<tag1>", "Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "US", "FDA,", "and", "after", "having", "received", "no", "comments", "from", "the", "US", "FDA,", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "study.", "<tag2>", "Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "FDA,", "and", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "and", "OLE", "studies.", "<tag3>"], "wordsA": ["Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "US", "FDA,", "and", "after", "having", "received", "no", "comments", "from", "the", "US", "FDA,", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "study."], "wordsB": ["Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "FDA,", "and", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "and", "OLE", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p16_s0", "idA": "1316175_12_item1_p138_s3", "sentA": "With the completion of the last batch of blisibimod in 2011, we believe we now have sufficient clinical material, both placebo and blisibimod, to complete dosing on the PEARL-SC study.", "sentB": "In June and July of 2012 we announced results from the Phase 2b PEARL-SC study which we believe support the initiation of a differentiated Phase 3 registration plan utilizing the 200mg weekly dose of blisibimod in patients with active lupus, despite the concomitant use of corticosteroids.", "type": 2, "words": ["<tag1>", "With", "the", "completion", "of", "the", "last", "batch", "of", "blisibimod", "in", "2011,", "we", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "blisibimod,", "to", "complete", "dosing", "on", "the", "PEARL-SC", "study.", "<tag2>", "In", "June", "and", "July", "of", "2012", "we", "announced", "results", "from", "the", "Phase", "2b", "PEARL-SC", "study", "which", "we", "believe", "support", "the", "initiation", "of", "a", "differentiated", "Phase", "3", "registration", "plan", "utilizing", "the", "200mg", "weekly", "dose", "of", "blisibimod", "in", "patients", "with", "active", "lupus,", "despite", "the", "concomitant", "use", "of", "corticosteroids.", "<tag3>"], "wordsA": ["With", "the", "completion", "of", "the", "last", "batch", "of", "blisibimod", "in", "2011,", "we", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "blisibimod,", "to", "complete", "dosing", "on", "the", "PEARL-SC", "study."], "wordsB": ["In", "June", "and", "July", "of", "2012", "we", "announced", "results", "from", "the", "Phase", "2b", "PEARL-SC", "study", "which", "we", "believe", "support", "the", "initiation", "of", "a", "differentiated", "Phase", "3", "registration", "plan", "utilizing", "the", "200mg", "weekly", "dose", "of", "blisibimod", "in", "patients", "with", "active", "lupus,", "despite", "the", "concomitant", "use", "of", "corticosteroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p53_s0", "idA": "1316175_12_item1_p138_s3", "sentA": "With the completion of the last batch of blisibimod in 2011, we believe we now have sufficient clinical material, both placebo and blisibimod, to complete dosing on the PEARL-SC study.", "sentB": "In June and July 2012 we announced results from the Phase 2b PEARL-SC study which we believe support the initiation of a differentiated Phase 3 registration plan utilizing the 200mg weekly dose of blisibimod in patients with active lupus, despite the concomitant use of corticosteroids.", "type": 2, "words": ["<tag1>", "With", "the", "completion", "of", "the", "last", "batch", "of", "blisibimod", "in", "2011,", "we", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "blisibimod,", "to", "complete", "dosing", "on", "the", "PEARL-SC", "study.", "<tag2>", "In", "June", "and", "July", "2012", "we", "announced", "results", "from", "the", "Phase", "2b", "PEARL-SC", "study", "which", "we", "believe", "support", "the", "initiation", "of", "a", "differentiated", "Phase", "3", "registration", "plan", "utilizing", "the", "200mg", "weekly", "dose", "of", "blisibimod", "in", "patients", "with", "active", "lupus,", "despite", "the", "concomitant", "use", "of", "corticosteroids.", "<tag3>"], "wordsA": ["With", "the", "completion", "of", "the", "last", "batch", "of", "blisibimod", "in", "2011,", "we", "believe", "we", "now", "have", "sufficient", "clinical", "material,", "both", "placebo", "and", "blisibimod,", "to", "complete", "dosing", "on", "the", "PEARL-SC", "study."], "wordsB": ["In", "June", "and", "July", "2012", "we", "announced", "results", "from", "the", "Phase", "2b", "PEARL-SC", "study", "which", "we", "believe", "support", "the", "initiation", "of", "a", "differentiated", "Phase", "3", "registration", "plan", "utilizing", "the", "200mg", "weekly", "dose", "of", "blisibimod", "in", "patients", "with", "active", "lupus,", "despite", "the", "concomitant", "use", "of", "corticosteroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s4", "idA": "1316175_12_item1_p13_s0", "sentA": "Based on the successful results of our completed Phase 2b, FRANCIS, clinical study, we initiated enrollment in a Phase 3 clinical study, VISTA-16, in patients with acute coronary syndrome in June 2010.", "sentB": "Following an interim analysis of clinical data from the CHABLIS-SC1 study we plan to initiate patient enrollment in our second Phase 3 clinical study, CHABLIS-SC2.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b,", "FRANCIS,", "clinical", "study,", "we", "initiated", "enrollment", "in", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010.", "<tag2>", "Following", "an", "interim", "analysis", "of", "clinical", "data", "from", "the", "CHABLIS-SC1", "study", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "second", "Phase", "3", "clinical", "study,", "CHABLIS-SC2.", "<tag3>"], "wordsA": ["Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b,", "FRANCIS,", "clinical", "study,", "we", "initiated", "enrollment", "in", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010."], "wordsB": ["Following", "an", "interim", "analysis", "of", "clinical", "data", "from", "the", "CHABLIS-SC1", "study", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "second", "Phase", "3", "clinical", "study,", "CHABLIS-SC2."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p59_s0", "idA": "1316175_12_item1_p13_s0", "sentA": "Based on the successful results of our completed Phase 2b, FRANCIS, clinical study, we initiated enrollment in a Phase 3 clinical study, VISTA-16, in patients with acute coronary syndrome in June 2010.", "sentB": "Following our initial interim analysis of clinical data from the CHABLIS-SC1 study we plan to initiate patient enrollment in our second Phase 3 clinical study, CHABLIS-SC2.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b,", "FRANCIS,", "clinical", "study,", "we", "initiated", "enrollment", "in", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010.", "<tag2>", "Following", "our", "initial", "interim", "analysis", "of", "clinical", "data", "from", "the", "CHABLIS-SC1", "study", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "second", "Phase", "3", "clinical", "study,", "CHABLIS-SC2.", "<tag3>"], "wordsA": ["Based", "on", "the", "successful", "results", "of", "our", "completed", "Phase", "2b,", "FRANCIS,", "clinical", "study,", "we", "initiated", "enrollment", "in", "a", "Phase", "3", "clinical", "study,", "VISTA-16,", "in", "patients", "with", "acute", "coronary", "syndrome", "in", "June", "2010."], "wordsB": ["Following", "our", "initial", "interim", "analysis", "of", "clinical", "data", "from", "the", "CHABLIS-SC1", "study", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "second", "Phase", "3", "clinical", "study,", "CHABLIS-SC2."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p16_s1", "idA": "1316175_12_item1_p140_s0", "sentA": "In November 2010, we suspended enrollment in the PEARL-SC clinical study after reports of broken vials at clinical sites.", "sentB": "While the pre-specified primary efficacy endpoint in the PEARL-SC clinical study was not met due to an apparent lack of clinical efficacy in the two lowest dose groups, additional prospective data from the PEARL-SC study suggest consistent treatment benefits in the 200mg weekly dose group when utilizing higher thresholds of disease improvement, as measured by larger point reductions in SELENA-SLEDAI scoring index.", "type": 2, "words": ["<tag1>", "In", "November", "2010,", "we", "suspended", "enrollment", "in", "the", "PEARL-SC", "clinical", "study", "after", "reports", "of", "broken", "vials", "at", "clinical", "sites.", "<tag2>", "While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "an", "apparent", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lowest", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "SELENA-SLEDAI", "scoring", "index.", "<tag3>"], "wordsA": ["In", "November", "2010,", "we", "suspended", "enrollment", "in", "the", "PEARL-SC", "clinical", "study", "after", "reports", "of", "broken", "vials", "at", "clinical", "sites."], "wordsB": ["While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "an", "apparent", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lowest", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "SELENA-SLEDAI", "scoring", "index."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p30_s1", "idA": "1316175_12_item1_p141_s0", "sentA": "In July 2010, we received clearance from the FDA to begin recruitment of lupus patients into the PEARL-SC clinical study.", "sentB": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "type": 2, "words": ["<tag1>", "In", "July", "2010,", "we", "received", "clearance", "from", "the", "FDA", "to", "begin", "recruitment", "of", "lupus", "patients", "into", "the", "PEARL-SC", "clinical", "study.", "<tag2>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["In", "July", "2010,", "we", "received", "clearance", "from", "the", "FDA", "to", "begin", "recruitment", "of", "lupus", "patients", "into", "the", "PEARL-SC", "clinical", "study."], "wordsB": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p55_s2", "idA": "1316175_12_item1_p141_s0", "sentA": "In July 2010, we received clearance from the FDA to begin recruitment of lupus patients into the PEARL-SC clinical study.", "sentB": "Additional information and publications from the PEARL-SC clinical study can be found at www.anthera.com/studies_pearl-sc.asp.", "type": 2, "words": ["<tag1>", "In", "July", "2010,", "we", "received", "clearance", "from", "the", "FDA", "to", "begin", "recruitment", "of", "lupus", "patients", "into", "the", "PEARL-SC", "clinical", "study.", "<tag2>", "Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_pearl-sc.asp.", "<tag3>"], "wordsA": ["In", "July", "2010,", "we", "received", "clearance", "from", "the", "FDA", "to", "begin", "recruitment", "of", "lupus", "patients", "into", "the", "PEARL-SC", "clinical", "study."], "wordsB": ["Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_pearl-sc.asp."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p25_s1", "idA": "1316175_12_item1_p141_s1", "sentA": "Subsequent to this clearance, the FDA requested additional information regarding characterization and qualification of the manufactured vials of blisibimod.", "sentB": "Furthermore, the observed treatment-related decreases in proteinuria resulted in near normalization of the proteinuria to 1g/24hrs in those subjects receiving blisibimod.", "type": 2, "words": ["<tag1>", "Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "blisibimod.", "<tag2>", "Furthermore,", "the", "observed", "treatment-related", "decreases", "in", "proteinuria", "resulted", "in", "near", "normalization", "of", "the", "proteinuria", "to", "1g/24hrs", "in", "those", "subjects", "receiving", "blisibimod.", "<tag3>"], "wordsA": ["Subsequent", "to", "this", "clearance,", "the", "FDA", "requested", "additional", "information", "regarding", "characterization", "and", "qualification", "of", "the", "manufactured", "vials", "of", "blisibimod."], "wordsB": ["Furthermore,", "the", "observed", "treatment-related", "decreases", "in", "proteinuria", "resulted", "in", "near", "normalization", "of", "the", "proteinuria", "to", "1g/24hrs", "in", "those", "subjects", "receiving", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p24_s3", "idA": "1316175_12_item1_p141_s3", "sentA": "Neither of these changes are considered material to the conduct of the PEARL-SC study.", "sentB": "Details of the findings of these trials are provided in the Historical Clinical Studies section.", "type": 2, "words": ["<tag1>", "Neither", "of", "these", "changes", "are", "considered", "material", "to", "the", "conduct", "of", "the", "PEARL-SC", "study.", "<tag2>", "Details", "of", "the", "findings", "of", "these", "trials", "are", "provided", "in", "the", "Historical", "Clinical", "Studies", "section.", "<tag3>"], "wordsA": ["Neither", "of", "these", "changes", "are", "considered", "material", "to", "the", "conduct", "of", "the", "PEARL-SC", "study."], "wordsB": ["Details", "of", "the", "findings", "of", "these", "trials", "are", "provided", "in", "the", "Historical", "Clinical", "Studies", "section."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p66_s0", "idA": "1316175_12_item1_p141_s5", "sentA": "We submitted a response to the FDA in October 2010.", "sentB": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012 and to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting).", "type": 2, "words": ["<tag1>", "We", "submitted", "a", "response", "to", "the", "FDA", "in", "October", "2010.", "<tag2>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting).", "<tag3>"], "wordsA": ["We", "submitted", "a", "response", "to", "the", "FDA", "in", "October", "2010."], "wordsB": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p67_s0", "idA": "1316175_12_item1_p141_s5", "sentA": "We submitted a response to the FDA in October 2010.", "sentB": "We submitted an application to the FDA in January 2013 requesting orphan designation for the use of blisibimod as a treatment for IgAN.", "type": 2, "words": ["<tag1>", "We", "submitted", "a", "response", "to", "the", "FDA", "in", "October", "2010.", "<tag2>", "We", "submitted", "an", "application", "to", "the", "FDA", "in", "January", "2013", "requesting", "orphan", "designation", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgAN.", "<tag3>"], "wordsA": ["We", "submitted", "a", "response", "to", "the", "FDA", "in", "October", "2010."], "wordsB": ["We", "submitted", "an", "application", "to", "the", "FDA", "in", "January", "2013", "requesting", "orphan", "designation", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgAN."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s0", "idA": "1316175_12_item1_p146_s1", "sentA": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of blisibimod.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are currently planned to be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard-of-care for treatment of their disease.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "currently", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "currently", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p58_s0", "idA": "1316175_12_item1_p146_s1", "sentA": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of blisibimod.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p66_s2", "idA": "1316175_12_item1_p146_s1", "sentA": "Secondary endpoints were designed to assess the plasma pharmacokinetic profile and immunogenicity of blisibimod.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "were", "designed", "to", "assess", "the", "plasma", "pharmacokinetic", "profile", "and", "immunogenicity", "of", "blisibimod."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p21_s1", "idA": "1316175_12_item1_p146_s2", "sentA": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as single dose of intravenous or subcutaneous was comparable to placebo.", "sentB": "In a subgroup analysis of patients with severe lupus disease (SELENA SLEDAI 10 and receiving steroid at baseline, n=278), the percent of subjects achieving the SRI-5 was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo.", "<tag2>", "In", "a", "subgroup", "analysis", "of", "patients", "with", "severe", "lupus", "disease", "(SELENA", "SLEDAI", "10", "and", "receiving", "steroid", "at", "baseline,", "n=278),", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag3>"], "wordsA": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo."], "wordsB": ["In", "a", "subgroup", "analysis", "of", "patients", "with", "severe", "lupus", "disease", "(SELENA", "SLEDAI", "10", "and", "receiving", "steroid", "at", "baseline,", "n=278),", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p71_s2", "idA": "1316175_12_item1_p146_s2", "sentA": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as single dose of intravenous or subcutaneous was comparable to placebo.", "sentB": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as a single intravenous or subcutaneous dose was comparable to placebo.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo.", "<tag2>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "was", "comparable", "to", "placebo.", "<tag3>"], "wordsA": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "single", "dose", "of", "intravenous", "or", "subcutaneous", "was", "comparable", "to", "placebo."], "wordsB": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "was", "comparable", "to", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p64_s0", "idA": "1316175_12_item1_p146_s3", "sentA": "Single doses of blisibimod exhibited linear pharmacokinetics after both intravenous and subcutaneous administration.", "sentB": "The product is designed for patient at-home administration and is presented in pre-filled syringes for subcutaneous administration.", "type": 2, "words": ["<tag1>", "Single", "doses", "of", "blisibimod", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag2>", "The", "product", "is", "designed", "for", "patient", "at-home", "administration", "and", "is", "presented", "in", "pre-filled", "syringes", "for", "subcutaneous", "administration.", "<tag3>"], "wordsA": ["Single", "doses", "of", "blisibimod", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "wordsB": ["The", "product", "is", "designed", "for", "patient", "at-home", "administration", "and", "is", "presented", "in", "pre-filled", "syringes", "for", "subcutaneous", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p9_s0", "idA": "1316175_12_item1_p146_s3", "sentA": "Single doses of blisibimod exhibited linear pharmacokinetics after both intravenous and subcutaneous administration.", "sentB": "The blisibimod product is designed for at-home, self-administration and is presented as a pre-filled syringe for subcutaneous administration.", "type": 2, "words": ["<tag1>", "Single", "doses", "of", "blisibimod", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag2>", "The", "blisibimod", "product", "is", "designed", "for", "at-home,", "self-administration", "and", "is", "presented", "as", "a", "pre-filled", "syringe", "for", "subcutaneous", "administration.", "<tag3>"], "wordsA": ["Single", "doses", "of", "blisibimod", "exhibited", "linear", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "wordsB": ["The", "blisibimod", "product", "is", "designed", "for", "at-home,", "self-administration", "and", "is", "presented", "as", "a", "pre-filled", "syringe", "for", "subcutaneous", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p19_s1", "idA": "1316175_12_item1_p146_s4", "sentA": "There were comparable adverse events between the blisibimod and placebo groups with no deaths reported.", "sentB": "Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.", "type": 2, "words": ["<tag1>", "There", "were", "comparable", "adverse", "events", "between", "the", "blisibimod", "and", "placebo", "groups", "with", "no", "deaths", "reported.", "<tag2>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events.", "<tag3>"], "wordsA": ["There", "were", "comparable", "adverse", "events", "between", "the", "blisibimod", "and", "placebo", "groups", "with", "no", "deaths", "reported."], "wordsB": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p55_s1", "idA": "1316175_12_item1_p146_s4", "sentA": "There were comparable adverse events between the blisibimod and placebo groups with no deaths reported.", "sentB": "Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.", "type": 2, "words": ["<tag1>", "There", "were", "comparable", "adverse", "events", "between", "the", "blisibimod", "and", "placebo", "groups", "with", "no", "deaths", "reported.", "<tag2>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events.", "<tag3>"], "wordsA": ["There", "were", "comparable", "adverse", "events", "between", "the", "blisibimod", "and", "placebo", "groups", "with", "no", "deaths", "reported."], "wordsB": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p47_s0", "idA": "1316175_12_item1_p147_s0", "sentA": "The most common adverse events were nausea (15%), headache (10%), upper respiratory tract infection (10%) and diarrhea (8%).", "sentB": "The classic presentation (in 40-50% of the cases) of signs and symptoms in patients with IgAN is episodic frank hematuria which usually starts within a day or two of a non-specific upper respiratory tract infection or (less commonly) gastrointestinal or urinary infection.", "type": 2, "words": ["<tag1>", "The", "most", "common", "adverse", "events", "were", "nausea", "(15%),", "headache", "(10%),", "upper", "respiratory", "tract", "infection", "(10%)", "and", "diarrhea", "(8%).", "<tag2>", "The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgAN", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection.", "<tag3>"], "wordsA": ["The", "most", "common", "adverse", "events", "were", "nausea", "(15%),", "headache", "(10%),", "upper", "respiratory", "tract", "infection", "(10%)", "and", "diarrhea", "(8%)."], "wordsB": ["The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgAN", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p74_s1", "idA": "1316175_12_item1_p149_s0", "sentA": "subcutaneous doses included 0.3, 1 and 3 mg/kg.", "sentB": "The intravenous dose was 6 mg/kg, and subcutaneous doses included 0.3, 1 and 3 mg/kg.", "type": 2, "words": ["<tag1>", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg.", "<tag2>", "The", "intravenous", "dose", "was", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg.", "<tag3>"], "wordsA": ["subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg."], "wordsB": ["The", "intravenous", "dose", "was", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p19_s0", "idA": "1316175_12_item1_p149_s1", "sentA": "Patients received their doses of blisibimod or placebo once-weekly for four weeks.", "sentB": "All doses of blisibimod demonstrated consistent serological response including reductions of B-cells, double-stranded-DNA antibodies and improvement in complement levels.", "type": 2, "words": ["<tag1>", "Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag2>", "All", "doses", "of", "blisibimod", "demonstrated", "consistent", "serological", "response", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "improvement", "in", "complement", "levels.", "<tag3>"], "wordsA": ["Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks."], "wordsB": ["All", "doses", "of", "blisibimod", "demonstrated", "consistent", "serological", "response", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "improvement", "in", "complement", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s1", "idA": "1316175_12_item1_p149_s1", "sentA": "Patients received their doses of blisibimod or placebo once-weekly for four weeks.", "sentB": "Each study will randomize approximately 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "type": 2, "words": ["<tag1>", "Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag2>", "Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag3>"], "wordsA": ["Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks."], "wordsB": ["Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p55_s0", "idA": "1316175_12_item1_p149_s1", "sentA": "Patients received their doses of blisibimod or placebo once-weekly for four weeks.", "sentB": "All doses of blisibimod demonstrated consistent serological response including reductions of B-cells, ds-DNA antibodies and improvement in complement levels.", "type": 2, "words": ["<tag1>", "Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag2>", "All", "doses", "of", "blisibimod", "demonstrated", "consistent", "serological", "response", "including", "reductions", "of", "B-cells,", "ds-DNA", "antibodies", "and", "improvement", "in", "complement", "levels.", "<tag3>"], "wordsA": ["Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks."], "wordsB": ["All", "doses", "of", "blisibimod", "demonstrated", "consistent", "serological", "response", "including", "reductions", "of", "B-cells,", "ds-DNA", "antibodies", "and", "improvement", "in", "complement", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p58_s1", "idA": "1316175_12_item1_p149_s1", "sentA": "Patients received their doses of blisibimod or placebo once-weekly for four weeks.", "sentB": "Each study will randomize approximately 400 patients to receive either 200mg of blisibimod or placebo weekly for 52 weeks.", "type": 2, "words": ["<tag1>", "Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag2>", "Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "weekly", "for", "52", "weeks.", "<tag3>"], "wordsA": ["Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks."], "wordsB": ["Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "weekly", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p66_s3", "idA": "1316175_12_item1_p149_s1", "sentA": "Patients received their doses of blisibimod or placebo once-weekly for four weeks.", "sentB": "Each study will randomize approximately 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "type": 2, "words": ["<tag1>", "Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks.", "<tag2>", "Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag3>"], "wordsA": ["Patients", "received", "their", "doses", "of", "blisibimod", "or", "placebo", "once-weekly", "for", "four", "weeks."], "wordsB": ["Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p74_s6", "idA": "1316175_12_item1_p149_s5", "sentA": "Further, results demonstrated a dose-dependent decrease in total B-cells as early as 15 days of treatment, and total B-cell reduction (up to approximately 60-70% of baseline) reached its nadir after about 160 days of therapy.", "sentB": "Further, results demonstrated a significant decrease in total B-cells as early as 15 days of treatment, and total B-cell reduction (up to approximately 60-70% of baseline) reached its nadir after about 160 days of therapy.", "type": 2, "words": ["<tag1>", "Further,", "results", "demonstrated", "a", "dose-dependent", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "of", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy.", "<tag2>", "Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "of", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy.", "<tag3>"], "wordsA": ["Further,", "results", "demonstrated", "a", "dose-dependent", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "of", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy."], "wordsB": ["Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "of", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s0", "idA": "1316175_12_item1_p14_s0", "sentA": "Our second product candidate, varespladib sodium, is an intravenously administered inhibitor of sPLA 2 ,which we may evaluate in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease.", "sentB": "We plan to initiate patient enrollment in a Phase 2 proof-of-concept study for the treatment of IgA Nephropathy in 2013.", "type": 2, "words": ["<tag1>", "Our", "second", "product", "candidate,", "varespladib", "sodium,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "may", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013.", "<tag3>"], "wordsA": ["Our", "second", "product", "candidate,", "varespladib", "sodium,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "may", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s0", "idA": "1316175_12_item1_p14_s0", "sentA": "Our second product candidate, varespladib sodium, is an intravenously administered inhibitor of sPLA 2 ,which we may evaluate in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease.", "sentB": "In 2013 we plan to initiate patient enrollment in BRIGHT-SC, a Phase 2 proof-of-concept study for the treatment of IgA nephropathy, our first clinical study addressing an orphan indication for the treatment of renal disease.", "type": 2, "words": ["<tag1>", "Our", "second", "product", "candidate,", "varespladib", "sodium,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "may", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "In", "2013", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "BRIGHT-SC,", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "nephropathy,", "our", "first", "clinical", "study", "addressing", "an", "orphan", "indication", "for", "the", "treatment", "of", "renal", "disease.", "<tag3>"], "wordsA": ["Our", "second", "product", "candidate,", "varespladib", "sodium,", "is", "an", "intravenously", "administered", "inhibitor", "of", "sPLA", "2", ",which", "we", "may", "evaluate", "in", "a", "Phase", "2", "clinical", "study", "for", "the", "prevention", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["In", "2013", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "BRIGHT-SC,", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "nephropathy,", "our", "first", "clinical", "study", "addressing", "an", "orphan", "indication", "for", "the", "treatment", "of", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p30_s2", "idA": "1316175_12_item1_p152_s1", "sentA": "Based on these results and published data from competitor studies, we initiated a Phase 2b clinical study evaluating blisibimod in lupus patients during the second half of 2010.", "sentB": "We expect to complete dosing in this open label extension study during the first half of 2013.", "type": 2, "words": ["<tag1>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010.", "<tag2>", "We", "expect", "to", "complete", "dosing", "in", "this", "open", "label", "extension", "study", "during", "the", "first", "half", "of", "2013.", "<tag3>"], "wordsA": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010."], "wordsB": ["We", "expect", "to", "complete", "dosing", "in", "this", "open", "label", "extension", "study", "during", "the", "first", "half", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p30_s4", "idA": "1316175_12_item1_p152_s1", "sentA": "Based on these results and published data from competitor studies, we initiated a Phase 2b clinical study evaluating blisibimod in lupus patients during the second half of 2010.", "sentB": "Data from this study will be presented during the second half of 2013.", "type": 2, "words": ["<tag1>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010.", "<tag2>", "Data", "from", "this", "study", "will", "be", "presented", "during", "the", "second", "half", "of", "2013.", "<tag3>"], "wordsA": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010."], "wordsB": ["Data", "from", "this", "study", "will", "be", "presented", "during", "the", "second", "half", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p6_s1", "idA": "1316175_12_item1_p152_s1", "sentA": "Based on these results and published data from competitor studies, we initiated a Phase 2b clinical study evaluating blisibimod in lupus patients during the second half of 2010.", "sentB": "In 2012, we completed a Phase 2b clinical study named PEARL-SC, to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus.", "type": 2, "words": ["<tag1>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010.", "<tag2>", "In", "2012,", "we", "completed", "a", "Phase", "2b", "clinical", "study", "named", "PEARL-SC,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "subcutaneous", "blisibimod", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag3>"], "wordsA": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010."], "wordsB": ["In", "2012,", "we", "completed", "a", "Phase", "2b", "clinical", "study", "named", "PEARL-SC,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "subcutaneous", "blisibimod", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p76_s1", "idA": "1316175_12_item1_p152_s1", "sentA": "Based on these results and published data from competitor studies, we initiated a Phase 2b clinical study evaluating blisibimod in lupus patients during the second half of 2010.", "sentB": "Based on these results and published data from competitor studies, we conducted a Phase 2b clinical study evaluating blisibimod in lupus patients from the second half of 2010 to the third quarter of 2012.", "type": 2, "words": ["<tag1>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010.", "<tag2>", "Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "conducted", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "from", "the", "second", "half", "of", "2010", "to", "the", "third", "quarter", "of", "2012.", "<tag3>"], "wordsA": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "during", "the", "second", "half", "of", "2010."], "wordsB": ["Based", "on", "these", "results", "and", "published", "data", "from", "competitor", "studies,", "we", "conducted", "a", "Phase", "2b", "clinical", "study", "evaluating", "blisibimod", "in", "lupus", "patients", "from", "the", "second", "half", "of", "2010", "to", "the", "third", "quarter", "of", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p27_s0", "idA": "1316175_12_item1_p153_s1", "sentA": "Substantial scientific evidence implicates sPLA 2 activity in the development of acute chest syndrome associated with sickle cell disease, as well as other forms of acute lung injury.", "sentB": "With its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "type": 2, "words": ["<tag1>", "Substantial", "scientific", "evidence", "implicates", "sPLA", "2", "activity", "in", "the", "development", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "as", "well", "as", "other", "forms", "of", "acute", "lung", "injury.", "<tag2>", "With", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B", "cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag3>"], "wordsA": ["Substantial", "scientific", "evidence", "implicates", "sPLA", "2", "activity", "in", "the", "development", "of", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease,", "as", "well", "as", "other", "forms", "of", "acute", "lung", "injury."], "wordsB": ["With", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B", "cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p14_s2", "idA": "1316175_12_item1_p15_s0", "sentA": "Acute chest syndrome is a form of inflammation-induced lung failure and is the most common cause of death in patients with sickle cell disease.", "sentB": "IgAN is the most common form of primary glomerulonephritis throughout the world, although the U.S. prevalence is estimated at approximately 130,000 patients.", "type": 2, "words": ["<tag1>", "Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease.", "<tag2>", "IgAN", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "throughout", "the", "world,", "although", "the", "U.S.", "prevalence", "is", "estimated", "at", "approximately", "130,000", "patients.", "<tag3>"], "wordsA": ["Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease."], "wordsB": ["IgAN", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "throughout", "the", "world,", "although", "the", "U.S.", "prevalence", "is", "estimated", "at", "approximately", "130,000", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p45_s1", "idA": "1316175_12_item1_p15_s0", "sentA": "Acute chest syndrome is a form of inflammation-induced lung failure and is the most common cause of death in patients with sickle cell disease.", "sentB": "IgA Nephropathy (also known as IgA nephritis or Berger's disease) is a form of glomerulonephritis ( inflammation of the glomeruli of the kidney ) and leading cause of end stage renal disease.", "type": 2, "words": ["<tag1>", "Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease.", "<tag2>", "IgA", "Nephropathy", "(also", "known", "as", "IgA", "nephritis", "or", "Berger's", "disease)", "is", "a", "form", "of", "glomerulonephritis", "(", "inflammation", "of", "the", "glomeruli", "of", "the", "kidney", ")", "and", "leading", "cause", "of", "end", "stage", "renal", "disease.", "<tag3>"], "wordsA": ["Acute", "chest", "syndrome", "is", "a", "form", "of", "inflammation-induced", "lung", "failure", "and", "is", "the", "most", "common", "cause", "of", "death", "in", "patients", "with", "sickle", "cell", "disease."], "wordsB": ["IgA", "Nephropathy", "(also", "known", "as", "IgA", "nephritis", "or", "Berger's", "disease)", "is", "a", "form", "of", "glomerulonephritis", "(", "inflammation", "of", "the", "glomeruli", "of", "the", "kidney", ")", "and", "leading", "cause", "of", "end", "stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s2", "idA": "1316175_12_item1_p164_s1", "sentA": "Patients will be randomized to receive a continuous infusion of varespladib sodium or placebo for 48 hours after randomization.", "sentB": "Patients will receive high dose, 300mg weekly, blisibimod or placebo for 8 weeks, during the induction phase, followed by 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "type": 2, "words": ["<tag1>", "Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "varespladib", "sodium", "or", "placebo", "for", "48", "hours", "after", "randomization.", "<tag2>", "Patients", "will", "receive", "high", "dose,", "300mg", "weekly,", "blisibimod", "or", "placebo", "for", "8", "weeks,", "during", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag3>"], "wordsA": ["Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "varespladib", "sodium", "or", "placebo", "for", "48", "hours", "after", "randomization."], "wordsB": ["Patients", "will", "receive", "high", "dose,", "300mg", "weekly,", "blisibimod", "or", "placebo", "for", "8", "weeks,", "during", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s3", "idA": "1316175_12_item1_p164_s1", "sentA": "Patients will be randomized to receive a continuous infusion of varespladib sodium or placebo for 48 hours after randomization.", "sentB": "Patients will receive high dose, 300mg weekly, blisibimod or placebo for 8 weeks the induction phase, followed by 24 weeks of 200mg weekly blisibimod or placebo in the maintenance phase.", "type": 2, "words": ["<tag1>", "Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "varespladib", "sodium", "or", "placebo", "for", "48", "hours", "after", "randomization.", "<tag2>", "Patients", "will", "receive", "high", "dose,", "300mg", "weekly,", "blisibimod", "or", "placebo", "for", "8", "weeks", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo", "in", "the", "maintenance", "phase.", "<tag3>"], "wordsA": ["Patients", "will", "be", "randomized", "to", "receive", "a", "continuous", "infusion", "of", "varespladib", "sodium", "or", "placebo", "for", "48", "hours", "after", "randomization."], "wordsB": ["Patients", "will", "receive", "high", "dose,", "300mg", "weekly,", "blisibimod", "or", "placebo", "for", "8", "weeks", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo", "in", "the", "maintenance", "phase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s2", "idA": "1316175_12_item1_p165_s0", "sentA": "The primary endpoint of this study will be freedom from acute chest syndrome as determined by physician assessment and independent review of chest X-rays.", "sentB": "As agreed with the FDA, the primary endpoint of the Phase 3 studies will be clinical improvement in the SRI-8 response at 52 weeks.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays.", "<tag2>", "As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays."], "wordsB": ["As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s3", "idA": "1316175_12_item1_p165_s0", "sentA": "The primary endpoint of this study will be freedom from acute chest syndrome as determined by physician assessment and independent review of chest X-rays.", "sentB": "The primary endpoint of the BRIGHT-SC study will be improvements in proteinuria versus placebo after 32 weeks.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays.", "<tag2>", "The", "primary", "endpoint", "of", "the", "BRIGHT-SC", "study", "will", "be", "improvements", "in", "proteinuria", "versus", "placebo", "after", "32", "weeks.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays."], "wordsB": ["The", "primary", "endpoint", "of", "the", "BRIGHT-SC", "study", "will", "be", "improvements", "in", "proteinuria", "versus", "placebo", "after", "32", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p58_s2", "idA": "1316175_12_item1_p165_s0", "sentA": "The primary endpoint of this study will be freedom from acute chest syndrome as determined by physician assessment and independent review of chest X-rays.", "sentB": "As agreed with the FDA, the primary endpoint of the Phase 3 studies will be clinical improvement in the SRI-8 response at 52 weeks.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays.", "<tag2>", "As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays."], "wordsB": ["As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s4", "idA": "1316175_12_item1_p165_s0", "sentA": "The primary endpoint of this study will be freedom from acute chest syndrome as determined by physician assessment and independent review of chest X-rays.", "sentB": "The primary endpoint of the BRIGHT-SC study will be improvements in proteinuria versus placebo after completion of the maintenance phase of the study, or 32 weeks.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays.", "<tag2>", "The", "primary", "endpoint", "of", "the", "BRIGHT-SC", "study", "will", "be", "improvements", "in", "proteinuria", "versus", "placebo", "after", "completion", "of", "the", "maintenance", "phase", "of", "the", "study,", "or", "32", "weeks.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "will", "be", "freedom", "from", "acute", "chest", "syndrome", "as", "determined", "by", "physician", "assessment", "and", "independent", "review", "of", "chest", "X-rays."], "wordsB": ["The", "primary", "endpoint", "of", "the", "BRIGHT-SC", "study", "will", "be", "improvements", "in", "proteinuria", "versus", "placebo", "after", "completion", "of", "the", "maintenance", "phase", "of", "the", "study,", "or", "32", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p14_s0", "idA": "1316175_12_item1_p170_s0", "sentA": "30 sites in the United States.", "sentB": "According to the Journal of Arthritis and Rheumatism the prevalence of lupus is estimated to be between 50 and 150 per 100,000 in the United States.", "type": 2, "words": ["<tag1>", "30", "sites", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50", "and", "150", "per", "100,000", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["30", "sites", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50", "and", "150", "per", "100,000", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p34_s0", "idA": "1316175_12_item1_p170_s0", "sentA": "30 sites in the United States.", "sentB": "According to the National Organization for Rare Disorders (NORD) IgA nephropathy, an orphan indication is believed to affect approximately 130,000 people annually in the United States.", "type": 2, "words": ["<tag1>", "30", "sites", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "indication", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["30", "sites", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "indication", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p41_s0", "idA": "1316175_12_item1_p170_s0", "sentA": "30 sites in the United States.", "sentB": "According to the Journal of Arthritis and Rheumatism, the prevalence of lupus is estimated to be between 50-150 per 100,000 in the United States.", "type": 2, "words": ["<tag1>", "30", "sites", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["30", "sites", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p49_s0", "idA": "1316175_12_item1_p170_s0", "sentA": "30 sites in the United States.", "sentB": "There is also a striking geographic variation in the prevalence of IgAN throughout the world.", "type": 2, "words": ["<tag1>", "30", "sites", "in", "the", "United", "States.", "<tag2>", "There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgAN", "throughout", "the", "world.", "<tag3>"], "wordsA": ["30", "sites", "in", "the", "United", "States."], "wordsB": ["There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgAN", "throughout", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p49_s1", "idA": "1316175_12_item1_p170_s0", "sentA": "30 sites in the United States.", "sentB": "According to the National Organization for Rare Disorders (NORD) IgA nephropathy, an orphan disease is believed to affect approximately 130,000 people annually in the United States.", "type": 2, "words": ["<tag1>", "30", "sites", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["30", "sites", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s4", "idA": "1316175_12_item1_p171_s1", "sentA": "A pre-specified interim analysis was conducted in February 2009 after the 30th patient completed treatment to examine safety and adjust dosing schedules.", "sentB": "We plan to conduct an interim analysis after the eight-week induction phase to determine effects of blisibimod on proteinuria.", "type": 2, "words": ["<tag1>", "A", "pre-specified", "interim", "analysis", "was", "conducted", "in", "February", "2009", "after", "the", "30th", "patient", "completed", "treatment", "to", "examine", "safety", "and", "adjust", "dosing", "schedules.", "<tag2>", "We", "plan", "to", "conduct", "an", "interim", "analysis", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "on", "proteinuria.", "<tag3>"], "wordsA": ["A", "pre-specified", "interim", "analysis", "was", "conducted", "in", "February", "2009", "after", "the", "30th", "patient", "completed", "treatment", "to", "examine", "safety", "and", "adjust", "dosing", "schedules."], "wordsB": ["We", "plan", "to", "conduct", "an", "interim", "analysis", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "on", "proteinuria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p38_s4", "idA": "1316175_12_item1_p174_s1", "sentA": "We have completed enrollment in the Phase 2b clinical study known as PEARL-SC in lupus patients.", "sentB": "In our PEARL-SC Phase 2b study, significant reductions in total B-cells as well as significant improvements in proteinuria and increases in complement C3 were observed with blisibimod in lupus patients.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag2>", "In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients.", "<tag3>"], "wordsA": ["We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "wordsB": ["In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p74_s8", "idA": "1316175_12_item1_p174_s1", "sentA": "We have completed enrollment in the Phase 2b clinical study known as PEARL-SC in lupus patients.", "sentB": "Further analyses of B cell subsets found that na ve B cells and activated B cells were significantly decreased while memory B cells were transiently significantly increased following treatment with blisibimod, consistent with a correction of the B cell abnormalities reported in lupus patients.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag2>", "Further", "analyses", "of", "B", "cell", "subsets", "found", "that", "na", "ve", "B", "cells", "and", "activated", "B", "cells", "were", "significantly", "decreased", "while", "memory", "B", "cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B", "cell", "abnormalities", "reported", "in", "lupus", "patients.", "<tag3>"], "wordsA": ["We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "wordsB": ["Further", "analyses", "of", "B", "cell", "subsets", "found", "that", "na", "ve", "B", "cells", "and", "activated", "B", "cells", "were", "significantly", "decreased", "while", "memory", "B", "cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B", "cell", "abnormalities", "reported", "in", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p84_s1", "idA": "1316175_12_item1_p174_s1", "sentA": "We have completed enrollment in the Phase 2b clinical study known as PEARL-SC in lupus patients.", "sentB": "We have completed Phase 1 and Phase 2b clinical studies with blisibimod in lupus patients and plan to advance blisibimod into a Phase 3 registration program in 2013.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients.", "<tag2>", "We", "have", "completed", "Phase", "1", "and", "Phase", "2b", "clinical", "studies", "with", "blisibimod", "in", "lupus", "patients", "and", "plan", "to", "advance", "blisibimod", "into", "a", "Phase", "3", "registration", "program", "in", "2013.", "<tag3>"], "wordsA": ["We", "have", "completed", "enrollment", "in", "the", "Phase", "2b", "clinical", "study", "known", "as", "PEARL-SC", "in", "lupus", "patients."], "wordsB": ["We", "have", "completed", "Phase", "1", "and", "Phase", "2b", "clinical", "studies", "with", "blisibimod", "in", "lupus", "patients", "and", "plan", "to", "advance", "blisibimod", "into", "a", "Phase", "3", "registration", "program", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p84_s2", "idA": "1316175_12_item1_p174_s2", "sentA": "We may opportunistically enter into collaborations with third parties for development of this compound in lupus or in other B-cell mediated diseases, such as multiple sclerosis, rheumatoid arthritis or Sj gren's Syndrome, that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "sentB": "We may opportunistically enter into collaborations with third parties for development of this compound in lupus or in other B-cell mediated diseases, such as IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "multiple", "sclerosis,", "rheumatoid", "arthritis", "or", "Sj", "gren's", "Syndrome,", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "multiple", "sclerosis,", "rheumatoid", "arthritis", "or", "Sj", "gren's", "Syndrome,", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p88_s0", "idA": "1316175_12_item1_p176_s0", "sentA": "Our primary product candidate is focused on highly-specialized physician segments, such as rheumatologists.", "sentB": "Our primary product candidate is focused on highly-specialized physician segments, such as rheumatologists and nephrologists.", "type": 2, "words": ["<tag1>", "Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists.", "<tag2>", "Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists.", "<tag3>"], "wordsA": ["Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists."], "wordsB": ["Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p88_s1", "idA": "1316175_12_item1_p176_s1", "sentA": "We believe that we can build a small, focused sales force capable of marketing our products effectively in acute care and orphan indications such as acute coronary syndrome and acute chest syndrome associated with sickle cell disease.", "sentB": "We believe that we can build a small, focused sales force capable of marketing our products effectively in acute care and orphan indications.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "we", "can", "build", "a", "small,", "focused", "sales", "force", "capable", "of", "marketing", "our", "products", "effectively", "in", "acute", "care", "and", "orphan", "indications", "such", "as", "acute", "coronary", "syndrome", "and", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease.", "<tag2>", "We", "believe", "that", "we", "can", "build", "a", "small,", "focused", "sales", "force", "capable", "of", "marketing", "our", "products", "effectively", "in", "acute", "care", "and", "orphan", "indications.", "<tag3>"], "wordsA": ["We", "believe", "that", "we", "can", "build", "a", "small,", "focused", "sales", "force", "capable", "of", "marketing", "our", "products", "effectively", "in", "acute", "care", "and", "orphan", "indications", "such", "as", "acute", "coronary", "syndrome", "and", "acute", "chest", "syndrome", "associated", "with", "sickle", "cell", "disease."], "wordsB": ["We", "believe", "that", "we", "can", "build", "a", "small,", "focused", "sales", "force", "capable", "of", "marketing", "our", "products", "effectively", "in", "acute", "care", "and", "orphan", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p88_s2", "idA": "1316175_12_item1_p176_s2", "sentA": "In other chronic indications such as CAD, we intend to seek commercial collaborations with companies that have a large, dedicated sales force focused on general practitioners and cardiologists and we plan to seek commercialization partners for products in non-specialty and international markets.", "sentB": "In other chronic indications, we intend to seek commercial collaborations with companies that have a large, dedicated sales force focused on general practitioners and we plan to seek commercialization partners for products in non-specialty and international markets.", "type": 2, "words": ["<tag1>", "In", "other", "chronic", "indications", "such", "as", "CAD,", "we", "intend", "to", "seek", "commercial", "collaborations", "with", "companies", "that", "have", "a", "large,", "dedicated", "sales", "force", "focused", "on", "general", "practitioners", "and", "cardiologists", "and", "we", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "non-specialty", "and", "international", "markets.", "<tag2>", "In", "other", "chronic", "indications,", "we", "intend", "to", "seek", "commercial", "collaborations", "with", "companies", "that", "have", "a", "large,", "dedicated", "sales", "force", "focused", "on", "general", "practitioners", "and", "we", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "non-specialty", "and", "international", "markets.", "<tag3>"], "wordsA": ["In", "other", "chronic", "indications", "such", "as", "CAD,", "we", "intend", "to", "seek", "commercial", "collaborations", "with", "companies", "that", "have", "a", "large,", "dedicated", "sales", "force", "focused", "on", "general", "practitioners", "and", "cardiologists", "and", "we", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "non-specialty", "and", "international", "markets."], "wordsB": ["In", "other", "chronic", "indications,", "we", "intend", "to", "seek", "commercial", "collaborations", "with", "companies", "that", "have", "a", "large,", "dedicated", "sales", "force", "focused", "on", "general", "practitioners", "and", "we", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "non-specialty", "and", "international", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p90_s2", "idA": "1316175_12_item1_p178_s2", "sentA": "Our competitors' drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our product candidates.", "sentB": "Our competitors drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our product candidate obsolete or non-competitive before we can recover the expenses of developing and commercializing our product candidate.", "type": 2, "words": ["<tag1>", "Our", "competitors'", "drugs", "may", "be", "more", "effective,", "or", "more", "effectively", "marketed", "and", "sold,", "than", "any", "drug", "we", "may", "commercialize", "and", "may", "render", "our", "product", "candidates", "obsolete", "or", "non-competitive", "before", "we", "can", "recover", "the", "expenses", "of", "developing", "and", "commercializing", "any", "of", "our", "product", "candidates.", "<tag2>", "Our", "competitors", "drugs", "may", "be", "more", "effective,", "or", "more", "effectively", "marketed", "and", "sold,", "than", "any", "drug", "we", "may", "commercialize", "and", "may", "render", "our", "product", "candidate", "obsolete", "or", "non-competitive", "before", "we", "can", "recover", "the", "expenses", "of", "developing", "and", "commercializing", "our", "product", "candidate.", "<tag3>"], "wordsA": ["Our", "competitors'", "drugs", "may", "be", "more", "effective,", "or", "more", "effectively", "marketed", "and", "sold,", "than", "any", "drug", "we", "may", "commercialize", "and", "may", "render", "our", "product", "candidates", "obsolete", "or", "non-competitive", "before", "we", "can", "recover", "the", "expenses", "of", "developing", "and", "commercializing", "any", "of", "our", "product", "candidates."], "wordsB": ["Our", "competitors", "drugs", "may", "be", "more", "effective,", "or", "more", "effectively", "marketed", "and", "sold,", "than", "any", "drug", "we", "may", "commercialize", "and", "may", "render", "our", "product", "candidate", "obsolete", "or", "non-competitive", "before", "we", "can", "recover", "the", "expenses", "of", "developing", "and", "commercializing", "our", "product", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p91_s0", "idA": "1316175_12_item1_p181_s0", "sentA": "Human Genome Sciences, Inc.'s and partner GlaxoSmithKline plc's Benlysta (belimumab) was approved in 2011 by the FDA for the treatment of lupus.", "sentB": "Benlysta (belimumab) was approved in 2011 by the FDA for the treatment of lupus.", "type": 2, "words": ["<tag1>", "Human", "Genome", "Sciences,", "Inc.'s", "and", "partner", "GlaxoSmithKline", "plc's", "Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Human", "Genome", "Sciences,", "Inc.'s", "and", "partner", "GlaxoSmithKline", "plc's", "Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p91_s1", "idA": "1316175_12_item1_p181_s1", "sentA": "It is the first novel therapy approved in the last fifty years.", "sentB": "It is the first novel therapy approved in the last 50 years.", "type": 2, "words": ["<tag1>", "It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "fifty", "years.", "<tag2>", "It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years.", "<tag3>"], "wordsA": ["It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "fifty", "years."], "wordsB": ["It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p93_s1", "idA": "1316175_12_item1_p183_s1", "sentA": "These product candidates include Benlysta (belimumab) from Human Genome Sciences, Inc., LY2127399 from Eli Lilly and Company, atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc., as well as others acting via non B-cell mechanisms, such as Lupuzor from Cephalon.", "sentB": "These product candidates include Benlysta (belimumab) from Human Genome Sciences, Inc., tabalumab (LY2127399) from Eli Lilly and Company, atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc., as well as others acting via non B-cell mechanisms, such as Lupuzor from Cephalon.", "type": 2, "words": ["<tag1>", "These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "LY2127399", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon.", "<tag2>", "These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon.", "<tag3>"], "wordsA": ["These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "LY2127399", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon."], "wordsB": ["These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p93_s2", "idA": "1316175_12_item1_p184_s0", "sentA": "intravenous delivery; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; its smaller size as compared to a full antibody, which may confer differentiating pharmacokinetic and pharmacodynamic characteristics; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen, which may also confer potential manufacturing advantages with lower cost of goods based on a bacterial fermentation manufacturing process.", "sentB": "We believe that blisibimod may offer potential differentiation from these agents, including demonstrated dosing flexibility with both subcutaneous and intravenous delivery; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; the use of a bacterial expression platform which is expected to translate to lower manufacturing costs compared with therapeutic antibodies; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen.", "type": 2, "words": ["<tag1>", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process.", "<tag2>", "We", "believe", "that", "blisibimod", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "the", "use", "of", "a", "bacterial", "expression", "platform", "which", "is", "expected", "to", "translate", "to", "lower", "manufacturing", "costs", "compared", "with", "therapeutic", "antibodies;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen.", "<tag3>"], "wordsA": ["intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "its", "smaller", "size", "as", "compared", "to", "a", "full", "antibody,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen,", "which", "may", "also", "confer", "potential", "manufacturing", "advantages", "with", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process."], "wordsB": ["We", "believe", "that", "blisibimod", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "the", "use", "of", "a", "bacterial", "expression", "platform", "which", "is", "expected", "to", "translate", "to", "lower", "manufacturing", "costs", "compared", "with", "therapeutic", "antibodies;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p96_s0", "idA": "1316175_12_item1_p187_s0", "sentA": "obtain and maintain patent and other proprietary protection for the technology, inventions and improvements we consider important to our business; defend our patents; preserve the confidentiality of our trade secrets; and operate our business without infringing the patents and proprietary rights of third parties.", "sentB": "operate our business without infringing the patents and proprietary rights of third parties.", "type": 2, "words": ["<tag1>", "obtain", "and", "maintain", "patent", "and", "other", "proprietary", "protection", "for", "the", "technology,", "inventions", "and", "improvements", "we", "consider", "important", "to", "our", "business;", "defend", "our", "patents;", "preserve", "the", "confidentiality", "of", "our", "trade", "secrets;", "and", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties.", "<tag2>", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties.", "<tag3>"], "wordsA": ["obtain", "and", "maintain", "patent", "and", "other", "proprietary", "protection", "for", "the", "technology,", "inventions", "and", "improvements", "we", "consider", "important", "to", "our", "business;", "defend", "our", "patents;", "preserve", "the", "confidentiality", "of", "our", "trade", "secrets;", "and", "operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties."], "wordsB": ["operate", "our", "business", "without", "infringing", "the", "patents", "and", "proprietary", "rights", "of", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p1_s0", "idA": "1316175_12_item1_p1_s0", "sentA": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation.", "sentB": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.", "type": 2, "words": ["<tag1>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation.", "<tag2>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation."], "wordsB": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p77_s0", "idA": "1316175_12_item1_p1_s2", "sentA": "Two of our product candidates, varespladib and varespladib sodium, are designed to inhibit a novel enzyme target known as secretory phospholipase A 2 , or sPLA 2 .", "sentB": "Two of our former product candidates, varespladib and varespladib sodium, were designed to inhibit a novel enzyme target known as secretory phospholipase A 2 , or sPLA 2 .", "type": 2, "words": ["<tag1>", "Two", "of", "our", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ".", "<tag2>", "Two", "of", "our", "former", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "were", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ".", "<tag3>"], "wordsA": ["Two", "of", "our", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", "."], "wordsB": ["Two", "of", "our", "former", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "were", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p82_s0", "idA": "1316175_12_item1_p1_s2", "sentA": "Two of our product candidates, varespladib and varespladib sodium, are designed to inhibit a novel enzyme target known as secretory phospholipase A 2 , or sPLA 2 .", "sentB": "In connection with the termination of varespladib and varespladib sodium, we implemented an organizational restructuring plan in 2012 that lowered operating expenses through headcount reductions and the elimination of certain vendor activities.", "type": 2, "words": ["<tag1>", "Two", "of", "our", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", ".", "<tag2>", "In", "connection", "with", "the", "termination", "of", "varespladib", "and", "varespladib", "sodium,", "we", "implemented", "an", "organizational", "restructuring", "plan", "in", "2012", "that", "lowered", "operating", "expenses", "through", "headcount", "reductions", "and", "the", "elimination", "of", "certain", "vendor", "activities.", "<tag3>"], "wordsA": ["Two", "of", "our", "product", "candidates,", "varespladib", "and", "varespladib", "sodium,", "are", "designed", "to", "inhibit", "a", "novel", "enzyme", "target", "known", "as", "secretory", "phospholipase", "A", "2", ",", "or", "sPLA", "2", "."], "wordsB": ["In", "connection", "with", "the", "termination", "of", "varespladib", "and", "varespladib", "sodium,", "we", "implemented", "an", "organizational", "restructuring", "plan", "in", "2012", "that", "lowered", "operating", "expenses", "through", "headcount", "reductions", "and", "the", "elimination", "of", "certain", "vendor", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p98_s0", "idA": "1316175_12_item1_p207_s0", "sentA": "Two U.S. patents; One pending U.S. non-provisional patent application; One EP patent validated in Albania, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Monaco, the Netherlands, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom; Two pending EP patent applications; Thirteen non-EP foreign patents in Australia, China, Estonia, Eurasia (validated in all nine Eurasian countries), Hong Kong, Japan, New Zealand, the Philippines, Singapore, South Korea and South Africa; and Twelve pending non-EP foreign patent applications in Brazil, Bulgaria, China, the Czech Republic, Hong Kong, Hungary, Israel, Mexico, Norway, Poland, Serbia and Slovakia.", "sentB": "Eleven pending non-EP foreign patent applications in Brazil, Bulgaria, China, the Czech Republic, Hong Kong, Hungary, Israel, Mexico, Norway, Poland, Serbia, Montenegro and Slovakia.", "type": 2, "words": ["<tag1>", "Two", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application;", "One", "EP", "patent", "validated", "in", "Albania,", "Austria,", "Belgium,", "Cyprus,", "Denmark,", "Finland,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Latvia,", "Liechtenstein,", "Lithuania,", "Luxembourg,", "Monaco,", "the", "Netherlands,", "Portugal,", "Romania,", "Slovenia,", "Spain,", "Sweden,", "Switzerland,", "Turkey", "and", "the", "United", "Kingdom;", "Two", "pending", "EP", "patent", "applications;", "Thirteen", "non-EP", "foreign", "patents", "in", "Australia,", "China,", "Estonia,", "Eurasia", "(validated", "in", "all", "nine", "Eurasian", "countries),", "Hong", "Kong,", "Japan,", "New", "Zealand,", "the", "Philippines,", "Singapore,", "South", "Korea", "and", "South", "Africa;", "and", "Twelve", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia", "and", "Slovakia.", "<tag2>", "Eleven", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia,", "Montenegro", "and", "Slovakia.", "<tag3>"], "wordsA": ["Two", "U.S.", "patents;", "One", "pending", "U.S.", "non-provisional", "patent", "application;", "One", "EP", "patent", "validated", "in", "Albania,", "Austria,", "Belgium,", "Cyprus,", "Denmark,", "Finland,", "France,", "Germany,", "Greece,", "Ireland,", "Italy,", "Latvia,", "Liechtenstein,", "Lithuania,", "Luxembourg,", "Monaco,", "the", "Netherlands,", "Portugal,", "Romania,", "Slovenia,", "Spain,", "Sweden,", "Switzerland,", "Turkey", "and", "the", "United", "Kingdom;", "Two", "pending", "EP", "patent", "applications;", "Thirteen", "non-EP", "foreign", "patents", "in", "Australia,", "China,", "Estonia,", "Eurasia", "(validated", "in", "all", "nine", "Eurasian", "countries),", "Hong", "Kong,", "Japan,", "New", "Zealand,", "the", "Philippines,", "Singapore,", "South", "Korea", "and", "South", "Africa;", "and", "Twelve", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia", "and", "Slovakia."], "wordsB": ["Eleven", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia,", "Montenegro", "and", "Slovakia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p100_s0", "idA": "1316175_12_item1_p209_s0", "sentA": "The U.S. patents are currently scheduled to expire in May 2022.", "sentB": "The exclusively licensed U.S. patents are currently scheduled to expire in May 2022 and November 2023.", "type": 2, "words": ["<tag1>", "The", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag2>", "The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022", "and", "November", "2023.", "<tag3>"], "wordsA": ["The", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "wordsB": ["The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022", "and", "November", "2023."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p101_s4", "idA": "1316175_12_item1_p209_s0", "sentA": "The U.S. patents are currently scheduled to expire in May 2022.", "sentB": "The European patents are currently scheduled to expire in May 2022.", "type": 2, "words": ["<tag1>", "The", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag2>", "The", "European", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag3>"], "wordsA": ["The", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "wordsB": ["The", "European", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p101_s2", "idA": "1316175_12_item1_p209_s1", "sentA": "One of the U.S. patents is expected to be eligible for a Hatch-Waxman term restoration of up to five years, which could extend the expiration date to May 2027.", "sentB": "This could extend the expiration date of the U.S. Patent to May 2027 or November 2028, depending on which patent the term restoration is applied to.", "type": 2, "words": ["<tag1>", "One", "of", "the", "U.S.", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Hatch-Waxman", "term", "restoration", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027.", "<tag2>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag3>"], "wordsA": ["One", "of", "the", "U.S.", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Hatch-Waxman", "term", "restoration", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027."], "wordsB": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p101_s5", "idA": "1316175_12_item1_p209_s4", "sentA": "This patent is expected to be eligible for a Supplementary Protection Certificate of up to five years, which could extend the expiration date to May 2027.", "sentB": "One of these patents is expected to be eligible for a Supplementary Protection Certificate of up to five years, which could extend the expiration date to May 2027.", "type": 2, "words": ["<tag1>", "This", "patent", "is", "expected", "to", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027.", "<tag2>", "One", "of", "these", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027.", "<tag3>"], "wordsA": ["This", "patent", "is", "expected", "to", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027."], "wordsB": ["One", "of", "these", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p101_s0", "idA": "1316175_12_item1_p214_s0", "sentA": "Depending upon the timing, duration and specifics of FDA approval of varespladib, blisibimod, varespladib sodium, A-003 or one or more new sPLA 2 compounds, one or more of the U.S. patents listed above may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act.", "sentB": "Depending upon the timing, duration and specifics of FDA approval of blisibimod, one of these U.S. patents (or another patent issuing from a related patent application) is expected to be eligible for a patent term restoration of up to five years under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act.", "type": 2, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "varespladib,", "blisibimod,", "varespladib", "sodium,", "A-003", "or", "one", "or", "more", "new", "sPLA", "2", "compounds,", "one", "or", "more", "of", "the", "U.S.", "patents", "listed", "above", "may", "be", "eligible", "for", "limited", "patent", "term", "restoration", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act.", "<tag2>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "blisibimod,", "one", "of", "these", "U.S.", "patents", "(or", "another", "patent", "issuing", "from", "a", "related", "patent", "application)", "is", "expected", "to", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "varespladib,", "blisibimod,", "varespladib", "sodium,", "A-003", "or", "one", "or", "more", "new", "sPLA", "2", "compounds,", "one", "or", "more", "of", "the", "U.S.", "patents", "listed", "above", "may", "be", "eligible", "for", "limited", "patent", "term", "restoration", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act."], "wordsB": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "blisibimod,", "one", "of", "these", "U.S.", "patents", "(or", "another", "patent", "issuing", "from", "a", "related", "patent", "application)", "is", "expected", "to", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p112_s0", "idA": "1316175_12_item1_p220_s0", "sentA": "In July 2006, we entered into a license agreement with Eli Lilly and Shionogi Co., Ltd., pursuant to which we obtained an exclusive license in all countries except for Japan to certain technology and compounds relating to sPLA 2 inhibitors.", "sentB": "In July 2006, we entered into a license agreement with Eli Lilly and Company or Eli Lilly and Shionogi Co., Ltd., pursuant to which we obtained an exclusive license in all countries except for Japan to certain technology and compounds relating to sPLA 2 inhibitors.", "type": 2, "words": ["<tag1>", "In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "license", "in", "all", "countries", "except", "for", "Japan", "to", "certain", "technology", "and", "compounds", "relating", "to", "sPLA", "2", "inhibitors.", "<tag2>", "In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Company", "or", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "license", "in", "all", "countries", "except", "for", "Japan", "to", "certain", "technology", "and", "compounds", "relating", "to", "sPLA", "2", "inhibitors.", "<tag3>"], "wordsA": ["In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "license", "in", "all", "countries", "except", "for", "Japan", "to", "certain", "technology", "and", "compounds", "relating", "to", "sPLA", "2", "inhibitors."], "wordsB": ["In", "July", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Eli", "Lilly", "and", "Company", "or", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "license", "in", "all", "countries", "except", "for", "Japan", "to", "certain", "technology", "and", "compounds", "relating", "to", "sPLA", "2", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p115_s3", "idA": "1316175_12_item1_p222_s0", "sentA": "Upon entering into the license agreement, we assumed control of all prosecution and maintenance of core patents prosecuted and maintained by Eli Lilly prior to the agreement.", "sentB": "In August 2012, we provided notice of termination to Eli Lilly to terminate the license agreement.", "type": 2, "words": ["<tag1>", "Upon", "entering", "into", "the", "license", "agreement,", "we", "assumed", "control", "of", "all", "prosecution", "and", "maintenance", "of", "core", "patents", "prosecuted", "and", "maintained", "by", "Eli", "Lilly", "prior", "to", "the", "agreement.", "<tag2>", "In", "August", "2012,", "we", "provided", "notice", "of", "termination", "to", "Eli", "Lilly", "to", "terminate", "the", "license", "agreement.", "<tag3>"], "wordsA": ["Upon", "entering", "into", "the", "license", "agreement,", "we", "assumed", "control", "of", "all", "prosecution", "and", "maintenance", "of", "core", "patents", "prosecuted", "and", "maintained", "by", "Eli", "Lilly", "prior", "to", "the", "agreement."], "wordsB": ["In", "August", "2012,", "we", "provided", "notice", "of", "termination", "to", "Eli", "Lilly", "to", "terminate", "the", "license", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p82_s4", "idA": "1316175_12_item1_p222_s0", "sentA": "Upon entering into the license agreement, we assumed control of all prosecution and maintenance of core patents prosecuted and maintained by Eli Lilly prior to the agreement.", "sentB": "Therefore, we provided notice of termination to the collaborators in August 2012 to terminate the license agreement.", "type": 2, "words": ["<tag1>", "Upon", "entering", "into", "the", "license", "agreement,", "we", "assumed", "control", "of", "all", "prosecution", "and", "maintenance", "of", "core", "patents", "prosecuted", "and", "maintained", "by", "Eli", "Lilly", "prior", "to", "the", "agreement.", "<tag2>", "Therefore,", "we", "provided", "notice", "of", "termination", "to", "the", "collaborators", "in", "August", "2012", "to", "terminate", "the", "license", "agreement.", "<tag3>"], "wordsA": ["Upon", "entering", "into", "the", "license", "agreement,", "we", "assumed", "control", "of", "all", "prosecution", "and", "maintenance", "of", "core", "patents", "prosecuted", "and", "maintained", "by", "Eli", "Lilly", "prior", "to", "the", "agreement."], "wordsB": ["Therefore,", "we", "provided", "notice", "of", "termination", "to", "the", "collaborators", "in", "August", "2012", "to", "terminate", "the", "license", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p113_s2", "idA": "1316175_12_item1_p222_s1", "sentA": "All core patents prosecuted and maintained by Shionogi Co., Ltd. prior to the agreement remained under the control of Shionogi Co., Ltd. Licensed patent rights that were not classified as core remained under the control of Eli Lilly and Shionogi Co., Ltd.", "sentB": "Certain patents and applications within the licensed patent rights are defined as core patents.", "type": 2, "words": ["<tag1>", "All", "core", "patents", "prosecuted", "and", "maintained", "by", "Shionogi", "Co.,", "Ltd.", "prior", "to", "the", "agreement", "remained", "under", "the", "control", "of", "Shionogi", "Co.,", "Ltd.", "Licensed", "patent", "rights", "that", "were", "not", "classified", "as", "core", "remained", "under", "the", "control", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd.", "<tag2>", "Certain", "patents", "and", "applications", "within", "the", "licensed", "patent", "rights", "are", "defined", "as", "core", "patents.", "<tag3>"], "wordsA": ["All", "core", "patents", "prosecuted", "and", "maintained", "by", "Shionogi", "Co.,", "Ltd.", "prior", "to", "the", "agreement", "remained", "under", "the", "control", "of", "Shionogi", "Co.,", "Ltd.", "Licensed", "patent", "rights", "that", "were", "not", "classified", "as", "core", "remained", "under", "the", "control", "of", "Eli", "Lilly", "and", "Shionogi", "Co.,", "Ltd."], "wordsB": ["Certain", "patents", "and", "applications", "within", "the", "licensed", "patent", "rights", "are", "defined", "as", "core", "patents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p106_s0", "idA": "1316175_12_item1_p225_s0", "sentA": "relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "type": 2, "words": ["<tag1>", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag3>"], "wordsA": ["relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p26_s0", "idA": "1316175_12_item1_p225_s0", "sentA": "relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks.", "type": 2, "words": ["<tag1>", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag3>"], "wordsA": ["relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p109_s1", "idA": "1316175_12_item1_p228_s1", "sentA": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon initiation of the first Phase 3 clinical study for any blisibimod formulation.", "sentB": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon commencement of the first Phase 3 clinical study for any blisibimod formulation in the United States, European Union or Japan.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation.", "<tag2>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "initiation", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation."], "wordsB": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p82_s5", "idA": "1316175_12_item1_p229_s0", "sentA": "The license agreement will remain in effect until we elect to terminate, or until termination for material breach by either party or insolvency on our part.", "sentB": "The license agreement was effectively terminated in November 2012.", "type": 2, "words": ["<tag1>", "The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part.", "<tag2>", "The", "license", "agreement", "was", "effectively", "terminated", "in", "November", "2012.", "<tag3>"], "wordsA": ["The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part."], "wordsB": ["The", "license", "agreement", "was", "effectively", "terminated", "in", "November", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p38_s0", "idA": "1316175_12_item1_p22_s0", "sentA": "In cardiovascular diseases such as acute coronary syndrome, elevated levels of sPLA 2 mass and sPLA 2 activity have acute and chronic implications on disease progression and patient outcomes.", "sentB": "Similar to patients with other autoimmune diseases such as lupus, in IgA Nephropathy, elevated levels of BAFF are associated with the proliferation of B-cells and plasma B-cells which may contribute to the disease.", "type": 2, "words": ["<tag1>", "In", "cardiovascular", "diseases", "such", "as", "acute", "coronary", "syndrome,", "elevated", "levels", "of", "sPLA", "2", "mass", "and", "sPLA", "2", "activity", "have", "acute", "and", "chronic", "implications", "on", "disease", "progression", "and", "patient", "outcomes.", "<tag2>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "Nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "the", "proliferation", "of", "B-cells", "and", "plasma", "B-cells", "which", "may", "contribute", "to", "the", "disease.", "<tag3>"], "wordsA": ["In", "cardiovascular", "diseases", "such", "as", "acute", "coronary", "syndrome,", "elevated", "levels", "of", "sPLA", "2", "mass", "and", "sPLA", "2", "activity", "have", "acute", "and", "chronic", "implications", "on", "disease", "progression", "and", "patient", "outcomes."], "wordsB": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "Nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "the", "proliferation", "of", "B-cells", "and", "plasma", "B-cells", "which", "may", "contribute", "to", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p60_s0", "idA": "1316175_12_item1_p22_s0", "sentA": "In cardiovascular diseases such as acute coronary syndrome, elevated levels of sPLA 2 mass and sPLA 2 activity have acute and chronic implications on disease progression and patient outcomes.", "sentB": "Similar to patients with other autoimmune diseases such as lupus, in IgA Nephropathy, elevated levels of BAFF are associated with the proliferation of B-cells and plasma B-cells which may contribute to disease.", "type": 2, "words": ["<tag1>", "In", "cardiovascular", "diseases", "such", "as", "acute", "coronary", "syndrome,", "elevated", "levels", "of", "sPLA", "2", "mass", "and", "sPLA", "2", "activity", "have", "acute", "and", "chronic", "implications", "on", "disease", "progression", "and", "patient", "outcomes.", "<tag2>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "Nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "the", "proliferation", "of", "B-cells", "and", "plasma", "B-cells", "which", "may", "contribute", "to", "disease.", "<tag3>"], "wordsA": ["In", "cardiovascular", "diseases", "such", "as", "acute", "coronary", "syndrome,", "elevated", "levels", "of", "sPLA", "2", "mass", "and", "sPLA", "2", "activity", "have", "acute", "and", "chronic", "implications", "on", "disease", "progression", "and", "patient", "outcomes."], "wordsB": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "Nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "the", "proliferation", "of", "B-cells", "and", "plasma", "B-cells", "which", "may", "contribute", "to", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p116_s0", "idA": "1316175_12_item1_p230_s0", "sentA": "We currently rely on contract manufacturers to produce drug substances and drug products required for our clinical studies under cGMP with oversight by our internal managers.", "sentB": "We currently rely on contract manufacturers to produce drug substances and drug products required for our clinical studies under current Good Manufacturing Practice ( cGMP ) with oversight by our internal managers.", "type": 2, "words": ["<tag1>", "We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "cGMP", "with", "oversight", "by", "our", "internal", "managers.", "<tag2>", "We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "Good", "Manufacturing", "Practice", "(", "cGMP", ")", "with", "oversight", "by", "our", "internal", "managers.", "<tag3>"], "wordsA": ["We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "cGMP", "with", "oversight", "by", "our", "internal", "managers."], "wordsB": ["We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "Good", "Manufacturing", "Practice", "(", "cGMP", ")", "with", "oversight", "by", "our", "internal", "managers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s3", "idA": "1316175_12_item1_p230_s1", "sentA": "We plan to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our product candidates if and when approved for marketing by the FDA.", "sentB": "We plan to conduct periodic interim analyses during the course of the CHABLIS-SC1 study to ensure the accuracy of our estimates.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA.", "<tag2>", "We", "plan", "to", "conduct", "periodic", "interim", "analyses", "during", "the", "course", "of", "the", "CHABLIS-SC1", "study", "to", "ensure", "the", "accuracy", "of", "our", "estimates.", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA."], "wordsB": ["We", "plan", "to", "conduct", "periodic", "interim", "analyses", "during", "the", "course", "of", "the", "CHABLIS-SC1", "study", "to", "ensure", "the", "accuracy", "of", "our", "estimates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p58_s3", "idA": "1316175_12_item1_p230_s1", "sentA": "We plan to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our product candidates if and when approved for marketing by the FDA.", "sentB": "We plan to conduct periodic interim analyses during the course of the CHABLIS-SC1 study to ensure the accuracy of our estimates.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA.", "<tag2>", "We", "plan", "to", "conduct", "periodic", "interim", "analyses", "during", "the", "course", "of", "the", "CHABLIS-SC1", "study", "to", "ensure", "the", "accuracy", "of", "our", "estimates.", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA."], "wordsB": ["We", "plan", "to", "conduct", "periodic", "interim", "analyses", "during", "the", "course", "of", "the", "CHABLIS-SC1", "study", "to", "ensure", "the", "accuracy", "of", "our", "estimates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p117_s2", "idA": "1316175_12_item1_p231_s2", "sentA": "In order to commercialize any of our product candidates, we must develop these capabilities internally or through collaboration with third parties.", "sentB": "In order to commercialize our product candidate, we must develop these capabilities internally or through collaboration with third parties.", "type": 2, "words": ["<tag1>", "In", "order", "to", "commercialize", "any", "of", "our", "product", "candidates,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties.", "<tag2>", "In", "order", "to", "commercialize", "our", "product", "candidate,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties.", "<tag3>"], "wordsA": ["In", "order", "to", "commercialize", "any", "of", "our", "product", "candidates,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties."], "wordsB": ["In", "order", "to", "commercialize", "our", "product", "candidate,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p117_s3", "idA": "1316175_12_item1_p231_s3", "sentA": "In selected therapeutic areas where we feel that any approved products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we may seek to commercialize these product candidates alone.", "sentB": "In selected therapeutic areas where we feel that any approved products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we may seek to commercialize the product candidate alone.", "type": 2, "words": ["<tag1>", "In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "these", "product", "candidates", "alone.", "<tag2>", "In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "the", "product", "candidate", "alone.", "<tag3>"], "wordsA": ["In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "these", "product", "candidates", "alone."], "wordsB": ["In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "the", "product", "candidate", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p117_s4", "idA": "1316175_12_item1_p232_s0", "sentA": "commercialize our product candidates while retaining rights to co-promote our products to a select audience of high prescribing physicians in the United States, thereby supplementing or enhancing the efforts of a commercial partner.", "sentB": "In therapeutic areas that require a large sales force selling to a large and diverse prescribing population, we currently plan to partner with third parties to commercialize our product candidate while retaining rights to co-promote our products to a select audience of high prescribing physicians in the United States, thereby supplementing or enhancing the efforts of a commercial partner.", "type": 2, "words": ["<tag1>", "commercialize", "our", "product", "candidates", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner.", "<tag2>", "In", "therapeutic", "areas", "that", "require", "a", "large", "sales", "force", "selling", "to", "a", "large", "and", "diverse", "prescribing", "population,", "we", "currently", "plan", "to", "partner", "with", "third", "parties", "to", "commercialize", "our", "product", "candidate", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner.", "<tag3>"], "wordsA": ["commercialize", "our", "product", "candidates", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner."], "wordsB": ["In", "therapeutic", "areas", "that", "require", "a", "large", "sales", "force", "selling", "to", "a", "large", "and", "diverse", "prescribing", "population,", "we", "currently", "plan", "to", "partner", "with", "third", "parties", "to", "commercialize", "our", "product", "candidate", "while", "retaining", "rights", "to", "co-promote", "our", "products", "to", "a", "select", "audience", "of", "high", "prescribing", "physicians", "in", "the", "United", "States,", "thereby", "supplementing", "or", "enhancing", "the", "efforts", "of", "a", "commercial", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p115_s2", "idA": "1316175_12_item1_p234_s1", "sentA": "Therefore, we expect to utilize a specialized sales force in North America for the sales and marketing of product candidates that we may successfully develop.", "sentB": "Therefore, we do not expect to incur further payments to our collaborators.", "type": 2, "words": ["<tag1>", "Therefore,", "we", "expect", "to", "utilize", "a", "specialized", "sales", "force", "in", "North", "America", "for", "the", "sales", "and", "marketing", "of", "product", "candidates", "that", "we", "may", "successfully", "develop.", "<tag2>", "Therefore,", "we", "do", "not", "expect", "to", "incur", "further", "payments", "to", "our", "collaborators.", "<tag3>"], "wordsA": ["Therefore,", "we", "expect", "to", "utilize", "a", "specialized", "sales", "force", "in", "North", "America", "for", "the", "sales", "and", "marketing", "of", "product", "candidates", "that", "we", "may", "successfully", "develop."], "wordsB": ["Therefore,", "we", "do", "not", "expect", "to", "incur", "further", "payments", "to", "our", "collaborators."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p118_s0", "idA": "1316175_12_item1_p235_s0", "sentA": "We intend to build the commercial infrastructure necessary to bring our product candidates to market alone or in collaboration with a co-development or co-promotion partner.", "sentB": "We intend to build the commercial infrastructure necessary to bring our product candidate to market alone or in collaboration with a co-development or co-promotion partner.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidates", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner.", "<tag2>", "We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidate", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner.", "<tag3>"], "wordsA": ["We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidates", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner."], "wordsB": ["We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidate", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-promotion", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p63_s0", "idA": "1316175_12_item1_p235_s2", "sentA": "We may also choose to employ medical sales liaisons personnel to support the product.", "sentB": "We have successfully manufactured blisibimod at launch scale volumes and currently have sufficient inventory to support the CHABLIS-SC1 and BRIGHT-SC studies in 2013.", "type": 2, "words": ["<tag1>", "We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "the", "product.", "<tag2>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "currently", "have", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies", "in", "2013.", "<tag3>"], "wordsA": ["We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "the", "product."], "wordsB": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "currently", "have", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p123_s0", "idA": "1316175_12_item1_p240_s0", "sentA": "The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.", "sentB": "The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidate will be granted on a timely basis, if at all.", "type": 2, "words": ["<tag1>", "The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidates", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all.", "<tag2>", "The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidate", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all.", "<tag3>"], "wordsA": ["The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidates", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all."], "wordsB": ["The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidate", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p129_s1", "idA": "1316175_12_item1_p247_s0", "sentA": "for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.", "sentB": "In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.", "type": 2, "words": ["<tag1>", "for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients.", "<tag2>", "In", "the", "case", "of", "some", "products", "for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients.", "<tag3>"], "wordsA": ["for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients."], "wordsB": ["In", "the", "case", "of", "some", "products", "for", "severe", "or", "life-threatening", "diseases,", "especially", "when", "the", "product", "may", "be", "too", "inherently", "toxic", "to", "ethically", "administer", "to", "healthy", "volunteers,", "the", "initial", "human", "testing", "is", "often", "conducted", "in", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p133_s1", "idA": "1316175_12_item1_p250_s1", "sentA": "The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.", "sentB": "The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things; the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.", "type": 2, "words": ["<tag1>", "The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things,", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product.", "<tag2>", "The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things;", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product.", "<tag3>"], "wordsA": ["The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things,", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product."], "wordsB": ["The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things;", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p137_s1", "idA": "1316175_12_item1_p255_s0", "sentA": "The FDA reviews a BLA to determine, among other things, whether the product is safe, has an acceptable purity profile and is adequately potent, and whether its manufacturing meets standards designed to assure the product's continued identity, sterility, safety, purity and potency.", "sentB": "The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product s identity, strength, quality and purity.", "type": 2, "words": ["<tag1>", "The", "FDA", "reviews", "a", "BLA", "to", "determine,", "among", "other", "things,", "whether", "the", "product", "is", "safe,", "has", "an", "acceptable", "purity", "profile", "and", "is", "adequately", "potent,", "and", "whether", "its", "manufacturing", "meets", "standards", "designed", "to", "assure", "the", "product's", "continued", "identity,", "sterility,", "safety,", "purity", "and", "potency.", "<tag2>", "The", "FDA", "reviews", "an", "NDA", "to", "determine,", "among", "other", "things,", "whether", "a", "product", "is", "safe", "and", "effective", "for", "its", "intended", "use", "and", "whether", "its", "manufacturing", "is", "cGMP-compliant", "to", "assure", "and", "preserve", "the", "product", "s", "identity,", "strength,", "quality", "and", "purity.", "<tag3>"], "wordsA": ["The", "FDA", "reviews", "a", "BLA", "to", "determine,", "among", "other", "things,", "whether", "the", "product", "is", "safe,", "has", "an", "acceptable", "purity", "profile", "and", "is", "adequately", "potent,", "and", "whether", "its", "manufacturing", "meets", "standards", "designed", "to", "assure", "the", "product's", "continued", "identity,", "sterility,", "safety,", "purity", "and", "potency."], "wordsB": ["The", "FDA", "reviews", "an", "NDA", "to", "determine,", "among", "other", "things,", "whether", "a", "product", "is", "safe", "and", "effective", "for", "its", "intended", "use", "and", "whether", "its", "manufacturing", "is", "cGMP-compliant", "to", "assure", "and", "preserve", "the", "product", "s", "identity,", "strength,", "quality", "and", "purity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p143_s0", "idA": "1316175_12_item1_p261_s0", "sentA": "within the United States to the first applicant to gain approval of an NDA for a new chemical entity.", "sentB": "The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity.", "type": 2, "words": ["<tag1>", "within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity.", "<tag2>", "The", "FDCA", "provides", "a", "five-year", "period", "of", "non-patent", "marketing", "exclusivity", "within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity.", "<tag3>"], "wordsA": ["within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity."], "wordsB": ["The", "FDCA", "provides", "a", "five-year", "period", "of", "non-patent", "marketing", "exclusivity", "within", "the", "United", "States", "to", "the", "first", "applicant", "to", "gain", "approval", "of", "an", "NDA", "for", "a", "new", "chemical", "entity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p145_s2", "idA": "1316175_12_item1_p263_s2", "sentA": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued \"Written Request\" for such a study.", "sentB": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued Written Request for such a study.", "type": 2, "words": ["<tag1>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "\"Written", "Request\"", "for", "such", "a", "study.", "<tag2>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study.", "<tag3>"], "wordsA": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "\"Written", "Request\"", "for", "such", "a", "study."], "wordsB": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p122_s0", "idA": "1316175_12_item1_p264_s1", "sentA": "Orphan product designation must be requested before submitting an NDA or BLA.", "sentB": "FDA review and approval of the NDA or BLA.", "type": 2, "words": ["<tag1>", "Orphan", "product", "designation", "must", "be", "requested", "before", "submitting", "an", "NDA", "or", "BLA.", "<tag2>", "FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA.", "<tag3>"], "wordsA": ["Orphan", "product", "designation", "must", "be", "requested", "before", "submitting", "an", "NDA", "or", "BLA."], "wordsB": ["FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p154_s0", "idA": "1316175_12_item1_p266_s1", "sentA": "A product does not have to be designated as an orphan product to be eligible for the grant program.", "sentB": "The Food and Drug Administration Safety and Innovation Act (FDASIA) includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy.", "type": 2, "words": ["<tag1>", "A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program.", "<tag2>", "The", "Food", "and", "Drug", "Administration", "Safety", "and", "Innovation", "Act", "(FDASIA)", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag3>"], "wordsA": ["A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program."], "wordsB": ["The", "Food", "and", "Drug", "Administration", "Safety", "and", "Innovation", "Act", "(FDASIA)", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p155_s0", "idA": "1316175_12_item1_p268_s1", "sentA": "Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition.", "sentB": "The goal of this program is to expedite the development and review of a drug that is intended, alone or in combination with 1 or more other drugs, to treat a serious or life-threatening disease or condition if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on 1 or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.", "type": 2, "words": ["<tag1>", "Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition.", "<tag2>", "The", "goal", "of", "this", "program", "is", "to", "expedite", "the", "development", "and", "review", "of", "a", "drug", "that", "is", "intended,", "alone", "or", "in", "combination", "with", "1", "or", "more", "other", "drugs,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition", "if", "preliminary", "clinical", "evidence", "indicates", "that", "the", "drug", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "1", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development.", "<tag3>"], "wordsA": ["Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition."], "wordsB": ["The", "goal", "of", "this", "program", "is", "to", "expedite", "the", "development", "and", "review", "of", "a", "drug", "that", "is", "intended,", "alone", "or", "in", "combination", "with", "1", "or", "more", "other", "drugs,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition", "if", "preliminary", "clinical", "evidence", "indicates", "that", "the", "drug", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "1", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p69_s0", "idA": "1316175_12_item1_p270_s0", "sentA": "A fast track product may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.", "sentB": "The recent Food and Drug Administration and Innovation Act (FDASIA) provide a number of mechanisms intended to expedite the review and development of drugs for serious or life-threatening conditions.", "type": 2, "words": ["<tag1>", "A", "fast", "track", "product", "may", "also", "be", "eligible", "for", "other", "types", "of", "FDA", "programs", "intended", "to", "expedite", "development", "and", "review,", "such", "as", "priority", "review", "and", "accelerated", "approval.", "<tag2>", "The", "recent", "Food", "and", "Drug", "Administration", "and", "Innovation", "Act", "(FDASIA)", "provide", "a", "number", "of", "mechanisms", "intended", "to", "expedite", "the", "review", "and", "development", "of", "drugs", "for", "serious", "or", "life-threatening", "conditions.", "<tag3>"], "wordsA": ["A", "fast", "track", "product", "may", "also", "be", "eligible", "for", "other", "types", "of", "FDA", "programs", "intended", "to", "expedite", "development", "and", "review,", "such", "as", "priority", "review", "and", "accelerated", "approval."], "wordsB": ["The", "recent", "Food", "and", "Drug", "Administration", "and", "Innovation", "Act", "(FDASIA)", "provide", "a", "number", "of", "mechanisms", "intended", "to", "expedite", "the", "review", "and", "development", "of", "drugs", "for", "serious", "or", "life-threatening", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p157_s2", "idA": "1316175_12_item1_p275_s0", "sentA": "products must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance.", "sentB": "Further, manufacturers of drugs and biological products must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance.", "type": 2, "words": ["<tag1>", "products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance.", "<tag2>", "Further,", "manufacturers", "of", "drugs", "and", "biological", "products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance.", "<tag3>"], "wordsA": ["products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance."], "wordsB": ["Further,", "manufacturers", "of", "drugs", "and", "biological", "products", "must", "continue", "to", "comply", "with", "cGMP", "requirements,", "which", "are", "extensive", "and", "require", "considerable", "time,", "resources", "and", "ongoing", "investment", "to", "ensure", "compliance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p163_s2", "idA": "1316175_12_item1_p283_s0", "sentA": "are required to submit certain clinical study information for inclusion in the clinical study registry data bank.", "sentB": "Additionally, the new law expands the clinical study registry so that sponsors of all clinical studies, except for Phase 1 clinical studies, are required to submit certain clinical study information for inclusion in the clinical study registry data bank.", "type": 2, "words": ["<tag1>", "are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank.", "<tag2>", "Additionally,", "the", "new", "law", "expands", "the", "clinical", "study", "registry", "so", "that", "sponsors", "of", "all", "clinical", "studies,", "except", "for", "Phase", "1", "clinical", "studies,", "are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank.", "<tag3>"], "wordsA": ["are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank."], "wordsB": ["Additionally,", "the", "new", "law", "expands", "the", "clinical", "study", "registry", "so", "that", "sponsors", "of", "all", "clinical", "studies,", "except", "for", "Phase", "1", "clinical", "studies,", "are", "required", "to", "submit", "certain", "clinical", "study", "information", "for", "inclusion", "in", "the", "clinical", "study", "registry", "data", "bank."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p166_s1", "idA": "1316175_12_item1_p286_s1", "sentA": "European Union member states require both regulatory clearance by the national competent authority and a favorable ethics committee opinion prior to the commencement of a clinical study.", "sentB": "European Union member states require regulatory clearance by both the national competent authority and a favorable ethics committee opinion prior to the commencement of a clinical study.", "type": 2, "words": ["<tag1>", "European", "Union", "member", "states", "require", "both", "regulatory", "clearance", "by", "the", "national", "competent", "authority", "and", "a", "favorable", "ethics", "committee", "opinion", "prior", "to", "the", "commencement", "of", "a", "clinical", "study.", "<tag2>", "European", "Union", "member", "states", "require", "regulatory", "clearance", "by", "both", "the", "national", "competent", "authority", "and", "a", "favorable", "ethics", "committee", "opinion", "prior", "to", "the", "commencement", "of", "a", "clinical", "study.", "<tag3>"], "wordsA": ["European", "Union", "member", "states", "require", "both", "regulatory", "clearance", "by", "the", "national", "competent", "authority", "and", "a", "favorable", "ethics", "committee", "opinion", "prior", "to", "the", "commencement", "of", "a", "clinical", "study."], "wordsB": ["European", "Union", "member", "states", "require", "regulatory", "clearance", "by", "both", "the", "national", "competent", "authority", "and", "a", "favorable", "ethics", "committee", "opinion", "prior", "to", "the", "commencement", "of", "a", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p168_s3", "idA": "1316175_12_item1_p288_s3", "sentA": "Within 90 days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials.", "sentB": "Within 90 days of receiving the reference member state s assessment report, each concerned member state must decide whether to approve the assessment report and related materials.", "type": 2, "words": ["<tag1>", "Within", "90", "days", "of", "receiving", "the", "reference", "member", "state's", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials.", "<tag2>", "Within", "90", "days", "of", "receiving", "the", "reference", "member", "state", "s", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials.", "<tag3>"], "wordsA": ["Within", "90", "days", "of", "receiving", "the", "reference", "member", "state's", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials."], "wordsB": ["Within", "90", "days", "of", "receiving", "the", "reference", "member", "state", "s", "assessment", "report,", "each", "concerned", "member", "state", "must", "decide", "whether", "to", "approve", "the", "assessment", "report", "and", "related", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p169_s2", "idA": "1316175_12_item1_p289_s2", "sentA": "We anticipate third-party payors will provide reimbursement for our products.", "sentB": "We anticipate third-party payors will provide reimbursement for our product.", "type": 2, "words": ["<tag1>", "We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "products.", "<tag2>", "We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product.", "<tag3>"], "wordsA": ["We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "products."], "wordsB": ["We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p169_s6", "idA": "1316175_12_item1_p289_s6", "sentA": "Our product candidates may not be considered cost-effective.", "sentB": "Our product candidate may not be considered cost-effective.", "type": 2, "words": ["<tag1>", "Our", "product", "candidates", "may", "not", "be", "considered", "cost-effective.", "<tag2>", "Our", "product", "candidate", "may", "not", "be", "considered", "cost-effective.", "<tag3>"], "wordsA": ["Our", "product", "candidates", "may", "not", "be", "considered", "cost-effective."], "wordsB": ["Our", "product", "candidate", "may", "not", "be", "considered", "cost-effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p169_s7", "idA": "1316175_12_item1_p290_s0", "sentA": "consuming and expensive for us to seek reimbursement from third-party payors.", "sentB": "It is time consuming and expensive for us to seek reimbursement from third-party payors.", "type": 2, "words": ["<tag1>", "consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors.", "<tag2>", "It", "is", "time", "consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors.", "<tag3>"], "wordsA": ["consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors."], "wordsB": ["It", "is", "time", "consuming", "and", "expensive", "for", "us", "to", "seek", "reimbursement", "from", "third-party", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p169_s8", "idA": "1316175_12_item1_p290_s1", "sentA": "Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.", "sentB": "Reimbursement may not be available or sufficient to allow us to sell our product on a competitive and profitable basis.", "type": 2, "words": ["<tag1>", "Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "competitive", "and", "profitable", "basis.", "<tag2>", "Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "product", "on", "a", "competitive", "and", "profitable", "basis.", "<tag3>"], "wordsA": ["Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "competitive", "and", "profitable", "basis."], "wordsB": ["Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "product", "on", "a", "competitive", "and", "profitable", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p170_s2", "idA": "1316175_12_item1_p291_s2", "sentA": "Effective October 1, 2010, the Health Care Reform Law revises the definition of \"average manufacturer price\" for reporting purposes, which could increase the amount of Medicaid drug rebates to states once the provision is effective.", "sentB": "Effective October 1, 2010, the Health Care Reform Law revises the definition of average manufacturer price for reporting purposes, which could increase the amount of Medicaid drug rebates to states once the provision is effective.", "type": 2, "words": ["<tag1>", "Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "\"average", "manufacturer", "price\"", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective.", "<tag2>", "Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective.", "<tag3>"], "wordsA": ["Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "\"average", "manufacturer", "price\"", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective."], "wordsB": ["Effective", "October", "1,", "2010,", "the", "Health", "Care", "Reform", "Law", "revises", "the", "definition", "of", "average", "manufacturer", "price", "for", "reporting", "purposes,", "which", "could", "increase", "the", "amount", "of", "Medicaid", "drug", "rebates", "to", "states", "once", "the", "provision", "is", "effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p80_s0", "idA": "1316175_12_item1_p292_s6", "sentA": "Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee.", "sentB": "The same data reviewed by the DSMB were subsequently brought in-house and examined by a committee of medical and drug safety professionals.", "type": 2, "words": ["<tag1>", "Any", "formulary", "used", "by", "a", "Part", "D", "prescription", "drug", "plan", "must", "be", "developed", "and", "reviewed", "by", "a", "pharmacy", "and", "therapeutic", "committee.", "<tag2>", "The", "same", "data", "reviewed", "by", "the", "DSMB", "were", "subsequently", "brought", "in-house", "and", "examined", "by", "a", "committee", "of", "medical", "and", "drug", "safety", "professionals.", "<tag3>"], "wordsA": ["Any", "formulary", "used", "by", "a", "Part", "D", "prescription", "drug", "plan", "must", "be", "developed", "and", "reviewed", "by", "a", "pharmacy", "and", "therapeutic", "committee."], "wordsB": ["The", "same", "data", "reviewed", "by", "the", "DSMB", "were", "subsequently", "brought", "in-house", "and", "examined", "by", "a", "committee", "of", "medical", "and", "drug", "safety", "professionals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p174_s2", "idA": "1316175_12_item1_p297_s0", "sentA": "proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "type": 2, "words": ["<tag1>", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag3>"], "wordsA": ["proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p1_s1", "idA": "1316175_12_item1_p2_s1", "sentA": "In addition, blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS, also known as B-cell Activating Factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, lupus nephritis, or LN, vasculitis, rheumatoid arthritis, multiple sclerosis, Sj gren's Syndrome, Graves' Disease and others.", "sentB": "We currently have one Phase 3 ready product candidate, blisibimod, which targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.", "type": 2, "words": ["<tag1>", "In", "addition,", "blisibimod", "targets", "elevated", "levels", "of", "B-lymphocyte", "stimulator,", "or", "BLyS,", "also", "known", "as", "B-cell", "Activating", "Factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "or", "lupus,", "lupus", "nephritis,", "or", "LN,", "vasculitis,", "rheumatoid", "arthritis,", "multiple", "sclerosis,", "Sj", "gren's", "Syndrome,", "Graves'", "Disease", "and", "others.", "<tag2>", "We", "currently", "have", "one", "Phase", "3", "ready", "product", "candidate,", "blisibimod,", "which", "targets", "elevated", "levels", "of", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE),", "or", "lupus,", "Immunoglobin", "A", "nephropathy,", "or", "IgAN,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others.", "<tag3>"], "wordsA": ["In", "addition,", "blisibimod", "targets", "elevated", "levels", "of", "B-lymphocyte", "stimulator,", "or", "BLyS,", "also", "known", "as", "B-cell", "Activating", "Factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "or", "lupus,", "lupus", "nephritis,", "or", "LN,", "vasculitis,", "rheumatoid", "arthritis,", "multiple", "sclerosis,", "Sj", "gren's", "Syndrome,", "Graves'", "Disease", "and", "others."], "wordsB": ["We", "currently", "have", "one", "Phase", "3", "ready", "product", "candidate,", "blisibimod,", "which", "targets", "elevated", "levels", "of", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE),", "or", "lupus,", "Immunoglobin", "A", "nephropathy,", "or", "IgAN,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p178_s5", "idA": "1316175_12_item1_p301_s5", "sentA": "There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.", "sentB": "There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for our product.", "type": 2, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "any", "country", "that", "has", "price", "controls", "or", "reimbursement", "limitations", "for", "pharmaceutical", "products", "will", "allow", "favorable", "reimbursement", "and", "pricing", "arrangements", "for", "any", "of", "our", "products.", "<tag2>", "There", "can", "be", "no", "assurance", "that", "any", "country", "that", "has", "price", "controls", "or", "reimbursement", "limitations", "for", "pharmaceutical", "products", "will", "allow", "favorable", "reimbursement", "and", "pricing", "arrangements", "for", "our", "product.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "any", "country", "that", "has", "price", "controls", "or", "reimbursement", "limitations", "for", "pharmaceutical", "products", "will", "allow", "favorable", "reimbursement", "and", "pricing", "arrangements", "for", "any", "of", "our", "products."], "wordsB": ["There", "can", "be", "no", "assurance", "that", "any", "country", "that", "has", "price", "controls", "or", "reimbursement", "limitations", "for", "pharmaceutical", "products", "will", "allow", "favorable", "reimbursement", "and", "pricing", "arrangements", "for", "our", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p179_s0", "idA": "1316175_12_item1_p302_s0", "sentA": "As of December 31, 2011, we had 38 employees, eight of whom hold an M.D., Ph.D. or Pharm.", "sentB": "As of December 31, 2012, we had 23 employees.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2011,", "we", "had", "38", "employees,", "eight", "of", "whom", "hold", "an", "M.D.,", "Ph.D.", "or", "Pharm.", "<tag2>", "As", "of", "December", "31,", "2012,", "we", "had", "23", "employees.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2011,", "we", "had", "38", "employees,", "eight", "of", "whom", "hold", "an", "M.D.,", "Ph.D.", "or", "Pharm."], "wordsB": ["As", "of", "December", "31,", "2012,", "we", "had", "23", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p179_s1", "idA": "1316175_12_item1_p302_s1", "sentA": "D. All of our employees are engaged in administration, finance, clinical, regulatory and business development functions.", "sentB": "All of our employees are engaged in administration, finance, clinical, regulatory and business development functions.", "type": 2, "words": ["<tag1>", "D.", "All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "regulatory", "and", "business", "development", "functions.", "<tag2>", "All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "regulatory", "and", "business", "development", "functions.", "<tag3>"], "wordsA": ["D.", "All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "regulatory", "and", "business", "development", "functions."], "wordsB": ["All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "regulatory", "and", "business", "development", "functions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p182_s0", "idA": "1316175_12_item1_p305_s0", "sentA": "Through a link on the \"Investors\" section of our website (under \"SEC Filings\" in the \"Financial Information\" section), we make available, free of charge, the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.", "sentB": "Through a link on the Investors section of our website (under SEC Filings in the Financial Information section), we make available, free of charge, the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.", "type": 2, "words": ["<tag1>", "Through", "a", "link", "on", "the", "\"Investors\"", "section", "of", "our", "website", "(under", "\"SEC", "Filings\"", "in", "the", "\"Financial", "Information\"", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act.", "<tag2>", "Through", "a", "link", "on", "the", "Investors", "section", "of", "our", "website", "(under", "SEC", "Filings", "in", "the", "Financial", "Information", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act.", "<tag3>"], "wordsA": ["Through", "a", "link", "on", "the", "\"Investors\"", "section", "of", "our", "website", "(under", "\"SEC", "Filings\"", "in", "the", "\"Financial", "Information\"", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act."], "wordsB": ["Through", "a", "link", "on", "the", "Investors", "section", "of", "our", "website", "(under", "SEC", "Filings", "in", "the", "Financial", "Information", "section),", "we", "make", "available,", "free", "of", "charge,", "the", "following", "filings", "as", "soon", "as", "reasonably", "practicable", "after", "they", "are", "electronically", "filed", "with", "or", "furnished", "to", "the", "SEC:", "our", "Annual", "Reports", "on", "Form", "10-K;", "Quarterly", "Reports", "on", "Form", "10-Q;", "Current", "Reports", "on", "Form", "8-K;", "and", "any", "amendments", "to", "those", "reports", "filed", "or", "furnished", "pursuant", "to", "Section", "13(a)", "or", "15(d)", "of", "the", "Exchange", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p3_s1", "idA": "1316175_12_item1_p33_s1", "sentA": "The role of BAFF in lupus and rheumatoid arthritis has recently been validated in multiple clinical studies with other BAFF antagonists.", "sentB": "The potential role of BAFF inhibition and associated reductions in B-cell concentrations in lupus and rheumatoid arthritis has been validated in multiple clinical studies with blisibimod and other BAFF antagonists.", "type": 2, "words": ["<tag1>", "The", "role", "of", "BAFF", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "recently", "been", "validated", "in", "multiple", "clinical", "studies", "with", "other", "BAFF", "antagonists.", "<tag2>", "The", "potential", "role", "of", "BAFF", "inhibition", "and", "associated", "reductions", "in", "B-cell", "concentrations", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "been", "validated", "in", "multiple", "clinical", "studies", "with", "blisibimod", "and", "other", "BAFF", "antagonists.", "<tag3>"], "wordsA": ["The", "role", "of", "BAFF", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "recently", "been", "validated", "in", "multiple", "clinical", "studies", "with", "other", "BAFF", "antagonists."], "wordsB": ["The", "potential", "role", "of", "BAFF", "inhibition", "and", "associated", "reductions", "in", "B-cell", "concentrations", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "been", "validated", "in", "multiple", "clinical", "studies", "with", "blisibimod", "and", "other", "BAFF", "antagonists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p4_s0", "idA": "1316175_12_item1_p34_s0", "sentA": "A peptibody is a novel fusion protein that is distinct from an antibody.", "sentB": "A peptibody is a novel fusion protein that is distinct from an antibody with several potential advantages including ease of manufacture and relatively small molecular weight.", "type": 2, "words": ["<tag1>", "A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody.", "<tag2>", "A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody", "with", "several", "potential", "advantages", "including", "ease", "of", "manufacture", "and", "relatively", "small", "molecular", "weight.", "<tag3>"], "wordsA": ["A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody."], "wordsB": ["A", "peptibody", "is", "a", "novel", "fusion", "protein", "that", "is", "distinct", "from", "an", "antibody", "with", "several", "potential", "advantages", "including", "ease", "of", "manufacture", "and", "relatively", "small", "molecular", "weight."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p68_s0", "idA": "1316175_12_item1_p35_s1", "sentA": "We have initiated PEARL-SC, the Phase 2b clinical study of blisibimod, for the treatment of Systemic Lupus Erythematosus (lupus).", "sentB": "In 2014, we anticipate submitting an application to designate blisibimod as a breakthrough therapy in the treatment of IgAN.", "type": 2, "words": ["<tag1>", "We", "have", "initiated", "PEARL-SC,", "the", "Phase", "2b", "clinical", "study", "of", "blisibimod,", "for", "the", "treatment", "of", "Systemic", "Lupus", "Erythematosus", "(lupus).", "<tag2>", "In", "2014,", "we", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgAN.", "<tag3>"], "wordsA": ["We", "have", "initiated", "PEARL-SC,", "the", "Phase", "2b", "clinical", "study", "of", "blisibimod,", "for", "the", "treatment", "of", "Systemic", "Lupus", "Erythematosus", "(lupus)."], "wordsB": ["In", "2014,", "we", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgAN."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p7_s0", "idA": "1316175_12_item1_p36_s0", "sentA": "Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications and cardiovascular disease.", "sentB": "Lupus patients suffer from chronic autoimmune disease, where an inappropriate or abnormal immune response often leads to severe skin rash, fatigue, joint pain, major kidney complications and cardiovascular disease.", "type": 2, "words": ["<tag1>", "Lupus", "patients", "suffer", "from", "a", "chronic", "autoimmune", "disease,", "which", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "major", "organ", "complications", "and", "cardiovascular", "disease.", "<tag2>", "Lupus", "patients", "suffer", "from", "chronic", "autoimmune", "disease,", "where", "an", "inappropriate", "or", "abnormal", "immune", "response", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "major", "kidney", "complications", "and", "cardiovascular", "disease.", "<tag3>"], "wordsA": ["Lupus", "patients", "suffer", "from", "a", "chronic", "autoimmune", "disease,", "which", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "major", "organ", "complications", "and", "cardiovascular", "disease."], "wordsB": ["Lupus", "patients", "suffer", "from", "chronic", "autoimmune", "disease,", "where", "an", "inappropriate", "or", "abnormal", "immune", "response", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "major", "kidney", "complications", "and", "cardiovascular", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p24_s0", "idA": "1316175_12_item1_p37_s0", "sentA": "Blisibimod demonstrates anti-BAFF activity and has shown statistically significant reductions in B-cells in two Phase 1 clinical studies in patients with lupus.", "sentB": "To date, three (3) randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two (2) Phase 1 dose-ranging studies in which a total of 104 patients were randomized, and a Phase 2b dose-ranging clinical outcomes study in which 547 subjects were enrolled.", "type": 2, "words": ["<tag1>", "Blisibimod", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus.", "<tag2>", "To", "date,", "three", "(3)", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "(2)", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "randomized,", "and", "a", "Phase", "2b", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled.", "<tag3>"], "wordsA": ["Blisibimod", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus."], "wordsB": ["To", "date,", "three", "(3)", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "(2)", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "randomized,", "and", "a", "Phase", "2b", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p8_s2", "idA": "1316175_12_item1_p37_s0", "sentA": "Blisibimod demonstrates anti-BAFF activity and has shown statistically significant reductions in B-cells in two Phase 1 clinical studies in patients with lupus.", "sentB": "Anthera has successfully manufactured blisibimod at launch scale volumes and has sufficient inventory to support the CHABLIS-SC and BRIGHT-SC clinical studies in 2013.", "type": 2, "words": ["<tag1>", "Blisibimod", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus.", "<tag2>", "Anthera", "has", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "has", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC", "and", "BRIGHT-SC", "clinical", "studies", "in", "2013.", "<tag3>"], "wordsA": ["Blisibimod", "demonstrates", "anti-BAFF", "activity", "and", "has", "shown", "statistically", "significant", "reductions", "in", "B-cells", "in", "two", "Phase", "1", "clinical", "studies", "in", "patients", "with", "lupus."], "wordsB": ["Anthera", "has", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "has", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC", "and", "BRIGHT-SC", "clinical", "studies", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p28_s0", "idA": "1316175_12_item1_p37_s1", "sentA": "We believe blisibimod may offer a number of potential differentiations over the currently marketed BAFF antagonist, Benlysta, as well as other novel B-cell directed therapies including:", "sentB": "In addition, we believe blisibimod may offer a number of potential opportunities for differentiation versus the currently marketed BAFF antagonist, belimumab, as well as other novel B-cell directed therapies including:", "type": 2, "words": ["<tag1>", "We", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "differentiations", "over", "the", "currently", "marketed", "BAFF", "antagonist,", "Benlysta,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:", "<tag2>", "In", "addition,", "we", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist,", "belimumab,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:", "<tag3>"], "wordsA": ["We", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "differentiations", "over", "the", "currently", "marketed", "BAFF", "antagonist,", "Benlysta,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:"], "wordsB": ["In", "addition,", "we", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist,", "belimumab,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p29_s0", "idA": "1316175_12_item1_p38_s0", "sentA": "convenient, at-home, patient-administered subcutaneous dosing with a range of dosing frequencies including monthly and weekly; the ability to inhibit the activity of both membrane-bound and soluble BAFF; a Phase 2 clinical design which utilizes more stringent restrictions to background medication, a shorter time-point to the primary endpoint, and requiring larger disease reduction in the SELENA/SLEDAI clinical efficacy measurement tool; and a novel molecular structure, which may confer differentiating pharmacokinetic and pharmacodynamic characteristics, potentially providing efficacy and dosing benefits, as well as manufacturing benefits and lower cost of goods based on a bacterial fermentation manufacturing process; and multiple binding domains achieve highest reported affinity for inhibition of BAFF.", "sentB": "Manufacturing and peptibody design: Blisibimod represents a novel molecular structure, which confers manufacturing benefits and lower cost of goods based on a bacterial fermentation manufacturing process; and utilizes multiple binding sites to achieve highest reported affinity for inhibition of BAFF.", "type": 2, "words": ["<tag1>", "convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "a", "Phase", "2", "clinical", "design", "which", "utilizes", "more", "stringent", "restrictions", "to", "background", "medication,", "a", "shorter", "time-point", "to", "the", "primary", "endpoint,", "and", "requiring", "larger", "disease", "reduction", "in", "the", "SELENA/SLEDAI", "clinical", "efficacy", "measurement", "tool;", "and", "a", "novel", "molecular", "structure,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics,", "potentially", "providing", "efficacy", "and", "dosing", "benefits,", "as", "well", "as", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF.", "<tag2>", "Manufacturing", "and", "peptibody", "design:", "Blisibimod", "represents", "a", "novel", "molecular", "structure,", "which", "confers", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process;", "and", "utilizes", "multiple", "binding", "sites", "to", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF.", "<tag3>"], "wordsA": ["convenient,", "at-home,", "patient-administered", "subcutaneous", "dosing", "with", "a", "range", "of", "dosing", "frequencies", "including", "monthly", "and", "weekly;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "a", "Phase", "2", "clinical", "design", "which", "utilizes", "more", "stringent", "restrictions", "to", "background", "medication,", "a", "shorter", "time-point", "to", "the", "primary", "endpoint,", "and", "requiring", "larger", "disease", "reduction", "in", "the", "SELENA/SLEDAI", "clinical", "efficacy", "measurement", "tool;", "and", "a", "novel", "molecular", "structure,", "which", "may", "confer", "differentiating", "pharmacokinetic", "and", "pharmacodynamic", "characteristics,", "potentially", "providing", "efficacy", "and", "dosing", "benefits,", "as", "well", "as", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process;", "and", "multiple", "binding", "domains", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF."], "wordsB": ["Manufacturing", "and", "peptibody", "design:", "Blisibimod", "represents", "a", "novel", "molecular", "structure,", "which", "confers", "manufacturing", "benefits", "and", "lower", "cost", "of", "goods", "based", "on", "a", "bacterial", "fermentation", "manufacturing", "process;", "and", "utilizes", "multiple", "binding", "sites", "to", "achieve", "highest", "reported", "affinity", "for", "inhibition", "of", "BAFF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p82_s2", "idA": "1316175_12_item1_p39_s0", "sentA": "We have focused our product development programs on anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases for which we believe that current treatments are either inadequate or non-existent.", "sentB": "We have reallocated our remaining resources to other potential development programs and product portfolio efforts.", "type": 2, "words": ["<tag1>", "We", "have", "focused", "our", "product", "development", "programs", "on", "anti-inflammatory", "therapeutics", "for", "cardiovascular", "diseases,", "lupus", "and", "other", "serious", "diseases", "for", "which", "we", "believe", "that", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag2>", "We", "have", "reallocated", "our", "remaining", "resources", "to", "other", "potential", "development", "programs", "and", "product", "portfolio", "efforts.", "<tag3>"], "wordsA": ["We", "have", "focused", "our", "product", "development", "programs", "on", "anti-inflammatory", "therapeutics", "for", "cardiovascular", "diseases,", "lupus", "and", "other", "serious", "diseases", "for", "which", "we", "believe", "that", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "wordsB": ["We", "have", "reallocated", "our", "remaining", "resources", "to", "other", "potential", "development", "programs", "and", "product", "portfolio", "efforts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p8_s0", "idA": "1316175_12_item1_p39_s0", "sentA": "We have focused our product development programs on anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases for which we believe that current treatments are either inadequate or non-existent.", "sentB": "Our product development programs are focused on blisibimod and its use as therapeutic treatments for lupus and other serious autoimmune diseases for which we believe current treatments are either inadequate or non-existent.", "type": 2, "words": ["<tag1>", "We", "have", "focused", "our", "product", "development", "programs", "on", "anti-inflammatory", "therapeutics", "for", "cardiovascular", "diseases,", "lupus", "and", "other", "serious", "diseases", "for", "which", "we", "believe", "that", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag2>", "Our", "product", "development", "programs", "are", "focused", "on", "blisibimod", "and", "its", "use", "as", "therapeutic", "treatments", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag3>"], "wordsA": ["We", "have", "focused", "our", "product", "development", "programs", "on", "anti-inflammatory", "therapeutics", "for", "cardiovascular", "diseases,", "lupus", "and", "other", "serious", "diseases", "for", "which", "we", "believe", "that", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "wordsB": ["Our", "product", "development", "programs", "are", "focused", "on", "blisibimod", "and", "its", "use", "as", "therapeutic", "treatments", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p56_s2", "idA": "1316175_12_item1_p39_s1", "sentA": "Our current product development programs are listed in the table below and can be found online at clinicaltrials.gov .", "sentB": "Additional information about the OLE clinical study can be found at www.anthera.com/studies_open-label-extension-study.asp.", "type": 2, "words": ["<tag1>", "Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below", "and", "can", "be", "found", "online", "at", "clinicaltrials.gov", ".", "<tag2>", "Additional", "information", "about", "the", "OLE", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_open-label-extension-study.asp.", "<tag3>"], "wordsA": ["Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below", "and", "can", "be", "found", "online", "at", "clinicaltrials.gov", "."], "wordsB": ["Additional", "information", "about", "the", "OLE", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_open-label-extension-study.asp."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s6", "idA": "1316175_12_item1_p39_s1", "sentA": "Our current product development programs are listed in the table below and can be found online at clinicaltrials.gov .", "sentB": "Additional information about the BRIGHT-SC clinical study can be found at www.anthera.com/studies_bright-sc.asp.", "type": 2, "words": ["<tag1>", "Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below", "and", "can", "be", "found", "online", "at", "clinicaltrials.gov", ".", "<tag2>", "Additional", "information", "about", "the", "BRIGHT-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_bright-sc.asp.", "<tag3>"], "wordsA": ["Our", "current", "product", "development", "programs", "are", "listed", "in", "the", "table", "below", "and", "can", "be", "found", "online", "at", "clinicaltrials.gov", "."], "wordsB": ["Additional", "information", "about", "the", "BRIGHT-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_bright-sc.asp."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p79_s1", "idA": "1316175_12_item1_p3_s2", "sentA": "According to the DSMB, the chief reason is the inability of VISTA-16 to detect a statistically significant benefit of the drug on the prespecified primary and secondary endpoints even if the trial continues to its scheduled termination.", "sentB": "The study was prematurely terminated by the DSMB because of the inability of VISTA-16 to detect a statistically significant benefit of the drug on the prespecified primary and secondary endpoints even if the trial continued to its scheduled termination with the proposed expanded sample size.", "type": 2, "words": ["<tag1>", "According", "to", "the", "DSMB,", "the", "chief", "reason", "is", "the", "inability", "of", "VISTA-16", "to", "detect", "a", "statistically", "significant", "benefit", "of", "the", "drug", "on", "the", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continues", "to", "its", "scheduled", "termination.", "<tag2>", "The", "study", "was", "prematurely", "terminated", "by", "the", "DSMB", "because", "of", "the", "inability", "of", "VISTA-16", "to", "detect", "a", "statistically", "significant", "benefit", "of", "the", "drug", "on", "the", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continued", "to", "its", "scheduled", "termination", "with", "the", "proposed", "expanded", "sample", "size.", "<tag3>"], "wordsA": ["According", "to", "the", "DSMB,", "the", "chief", "reason", "is", "the", "inability", "of", "VISTA-16", "to", "detect", "a", "statistically", "significant", "benefit", "of", "the", "drug", "on", "the", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continues", "to", "its", "scheduled", "termination."], "wordsB": ["The", "study", "was", "prematurely", "terminated", "by", "the", "DSMB", "because", "of", "the", "inability", "of", "VISTA-16", "to", "detect", "a", "statistically", "significant", "benefit", "of", "the", "drug", "on", "the", "prespecified", "primary", "and", "secondary", "endpoints", "even", "if", "the", "trial", "continued", "to", "its", "scheduled", "termination", "with", "the", "proposed", "expanded", "sample", "size."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p31_s2", "idA": "1316175_12_item1_p3_s5", "sentA": "We have also closed enrollment in our IMPACTS-2 clinical study for varespladib sodium.", "sentB": "As a result of this meeting we plan to initiate patient enrollment in our initial Phase 3 CHABLIS-SC1 clinical study in 2013.", "type": 2, "words": ["<tag1>", "We", "have", "also", "closed", "enrollment", "in", "our", "IMPACTS-2", "clinical", "study", "for", "varespladib", "sodium.", "<tag2>", "As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "initial", "Phase", "3", "CHABLIS-SC1", "clinical", "study", "in", "2013.", "<tag3>"], "wordsA": ["We", "have", "also", "closed", "enrollment", "in", "our", "IMPACTS-2", "clinical", "study", "for", "varespladib", "sodium."], "wordsB": ["As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "initial", "Phase", "3", "CHABLIS-SC1", "clinical", "study", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p81_s3", "idA": "1316175_12_item1_p42_s1", "sentA": "We have an agreement with the FDA on a Special Protocol Assessment, or SPA for the VISTA-16 study.", "sentB": "Additional details about the VISTA-16 study can be found at www.anthera.com/studies_vista-16.asp.", "type": 2, "words": ["<tag1>", "We", "have", "an", "agreement", "with", "the", "FDA", "on", "a", "Special", "Protocol", "Assessment,", "or", "SPA", "for", "the", "VISTA-16", "study.", "<tag2>", "Additional", "details", "about", "the", "VISTA-16", "study", "can", "be", "found", "at", "www.anthera.com/studies_vista-16.asp.", "<tag3>"], "wordsA": ["We", "have", "an", "agreement", "with", "the", "FDA", "on", "a", "Special", "Protocol", "Assessment,", "or", "SPA", "for", "the", "VISTA-16", "study."], "wordsB": ["Additional", "details", "about", "the", "VISTA-16", "study", "can", "be", "found", "at", "www.anthera.com/studies_vista-16.asp."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p53_s1", "idA": "1316175_12_item1_p49_s0", "sentA": "In March 2012, an independent data safety monitoring board recommended stopping the Company's VISTA-16 clinical study for varespladib due to a lack of efficacy that could not be reasonably overcome in the remainder of the trial.", "sentB": "While the pre-specified primary efficacy endpoint in the PEARL-SC clinical study was not met due to a lack of clinical efficacy in the two lower dose groups, additional prospective data from the PEARL-SC study suggest consistent treatment benefits in the 200mg weekly dose group when utilizing higher thresholds of disease improvement, as measured by larger point reductions in the SELENA-SLEDAI scoring index.", "type": 2, "words": ["<tag1>", "In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial.", "<tag2>", "While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "a", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lower", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "the", "SELENA-SLEDAI", "scoring", "index.", "<tag3>"], "wordsA": ["In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial."], "wordsB": ["While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "a", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lower", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "the", "SELENA-SLEDAI", "scoring", "index."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p79_s0", "idA": "1316175_12_item1_p49_s0", "sentA": "In March 2012, an independent data safety monitoring board recommended stopping the Company's VISTA-16 clinical study for varespladib due to a lack of efficacy that could not be reasonably overcome in the remainder of the trial.", "sentB": "In March 2012, an independent data safety monitoring board (DSMB) recommended stopping the VISTA-16 clinical study for varespladib due to a lack of efficacy that could not be reasonably overcome in the remainder of the trial.", "type": 2, "words": ["<tag1>", "In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial.", "<tag2>", "In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "(DSMB)", "recommended", "stopping", "the", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial.", "<tag3>"], "wordsA": ["In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "recommended", "stopping", "the", "Company's", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial."], "wordsB": ["In", "March", "2012,", "an", "independent", "data", "safety", "monitoring", "board", "(DSMB)", "recommended", "stopping", "the", "VISTA-16", "clinical", "study", "for", "varespladib", "due", "to", "a", "lack", "of", "efficacy", "that", "could", "not", "be", "reasonably", "overcome", "in", "the", "remainder", "of", "the", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p57_s1", "idA": "1316175_12_item1_p49_s1", "sentA": "As a result, the Company has closed enrollment in the study and informed all investigators to remove patients from therapy.", "sentB": "As a result of this meeting we plan to initiate patient enrollment in the initial Phase 3 CHABLIS-SC1 study in 2013.", "type": 2, "words": ["<tag1>", "As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy.", "<tag2>", "As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "2013.", "<tag3>"], "wordsA": ["As", "a", "result,", "the", "Company", "has", "closed", "enrollment", "in", "the", "study", "and", "informed", "all", "investigators", "to", "remove", "patients", "from", "therapy."], "wordsB": ["As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p115_s1", "idA": "1316175_12_item1_p49_s2", "sentA": "Based on the DSMB recommendation we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "sentB": "Based on the recommendation of the DSMB in March 2012 to terminate the VISTA-16 study of varespladib, we do not expect to engage in any further development activities of our sPLA 2 portfolio, including varespladib and varespladib sodium.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag2>", "Based", "on", "the", "recommendation", "of", "the", "DSMB", "in", "March", "2012", "to", "terminate", "the", "VISTA-16", "study", "of", "varespladib,", "we", "do", "not", "expect", "to", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio,", "including", "varespladib", "and", "varespladib", "sodium.", "<tag3>"], "wordsA": ["Based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "wordsB": ["Based", "on", "the", "recommendation", "of", "the", "DSMB", "in", "March", "2012", "to", "terminate", "the", "VISTA-16", "study", "of", "varespladib,", "we", "do", "not", "expect", "to", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio,", "including", "varespladib", "and", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p82_s3", "idA": "1316175_12_item1_p49_s2", "sentA": "Based on the DSMB recommendation we expect that we will not engage in any further development activities of our sPLA 2 portfolio.", "sentB": "Based on the recommendation of the DSMB, we do not expect to engage in any further development activities of varespladib and varespladib sodium.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio.", "<tag2>", "Based", "on", "the", "recommendation", "of", "the", "DSMB,", "we", "do", "not", "expect", "to", "engage", "in", "any", "further", "development", "activities", "of", "varespladib", "and", "varespladib", "sodium.", "<tag3>"], "wordsA": ["Based", "on", "the", "DSMB", "recommendation", "we", "expect", "that", "we", "will", "not", "engage", "in", "any", "further", "development", "activities", "of", "our", "sPLA", "2", "portfolio."], "wordsB": ["Based", "on", "the", "recommendation", "of", "the", "DSMB,", "we", "do", "not", "expect", "to", "engage", "in", "any", "further", "development", "activities", "of", "varespladib", "and", "varespladib", "sodium."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p60_s4", "idA": "1316175_12_item1_p52_s0", "sentA": "to increase given an aging population, as well as the rising epidemics of diabetes and obesity, two conditions known to increase the risk of acute coronary syndrome.", "sentB": "In our PEARL-SC Phase 2b study, significant reductions in total B-cells as well as significant improvements in proteinuria and increases in complement C3, biomarkers known to be correlated with severity of kidney injury, were observed with blisibimod in SLE patients.", "type": 2, "words": ["<tag1>", "to", "increase", "given", "an", "aging", "population,", "as", "well", "as", "the", "rising", "epidemics", "of", "diabetes", "and", "obesity,", "two", "conditions", "known", "to", "increase", "the", "risk", "of", "acute", "coronary", "syndrome.", "<tag2>", "In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3,", "biomarkers", "known", "to", "be", "correlated", "with", "severity", "of", "kidney", "injury,", "were", "observed", "with", "blisibimod", "in", "SLE", "patients.", "<tag3>"], "wordsA": ["to", "increase", "given", "an", "aging", "population,", "as", "well", "as", "the", "rising", "epidemics", "of", "diabetes", "and", "obesity,", "two", "conditions", "known", "to", "increase", "the", "risk", "of", "acute", "coronary", "syndrome."], "wordsB": ["In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3,", "biomarkers", "known", "to", "be", "correlated", "with", "severity", "of", "kidney", "injury,", "were", "observed", "with", "blisibimod", "in", "SLE", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p2_s1", "idA": "1316175_12_item1_p55_s3", "sentA": "These studies do not include the incidence of unstable angina as part of the composite end point.", "sentB": "B-cells are a vital part of the human immune system producing natural antibody responses to invading pathogens such as viruses.", "type": 2, "words": ["<tag1>", "These", "studies", "do", "not", "include", "the", "incidence", "of", "unstable", "angina", "as", "part", "of", "the", "composite", "end", "point.", "<tag2>", "B-cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses.", "<tag3>"], "wordsA": ["These", "studies", "do", "not", "include", "the", "incidence", "of", "unstable", "angina", "as", "part", "of", "the", "composite", "end", "point."], "wordsB": ["B-cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p3_s0", "idA": "1316175_12_item1_p58_s1", "sentA": "In numerous clinical studies with a variety of therapeutic interventions, reductions in CRP have been correlated with reductions in subsequent MACE.", "sentB": "Abnormal elevations in BAFF and B-cells have been correlated with several autoimmune diseases.", "type": 2, "words": ["<tag1>", "In", "numerous", "clinical", "studies", "with", "a", "variety", "of", "therapeutic", "interventions,", "reductions", "in", "CRP", "have", "been", "correlated", "with", "reductions", "in", "subsequent", "MACE.", "<tag2>", "Abnormal", "elevations", "in", "BAFF", "and", "B-cells", "have", "been", "correlated", "with", "several", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["In", "numerous", "clinical", "studies", "with", "a", "variety", "of", "therapeutic", "interventions,", "reductions", "in", "CRP", "have", "been", "correlated", "with", "reductions", "in", "subsequent", "MACE."], "wordsB": ["Abnormal", "elevations", "in", "BAFF", "and", "B-cells", "have", "been", "correlated", "with", "several", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p38_s5", "idA": "1316175_12_item1_p61_s0", "sentA": "Statins reduce the level of CRP and other markers of inflammation in patients with stable CAD.", "sentB": "We believe inhibition of BAFF may reduce proliferative B-cells and plasma B-cells, reduce serum levels of IgA and therefore reduce progressive renal damage in patients with IgAN.", "type": 2, "words": ["<tag1>", "Statins", "reduce", "the", "level", "of", "CRP", "and", "other", "markers", "of", "inflammation", "in", "patients", "with", "stable", "CAD.", "<tag2>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN.", "<tag3>"], "wordsA": ["Statins", "reduce", "the", "level", "of", "CRP", "and", "other", "markers", "of", "inflammation", "in", "patients", "with", "stable", "CAD."], "wordsB": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p60_s5", "idA": "1316175_12_item1_p61_s0", "sentA": "Statins reduce the level of CRP and other markers of inflammation in patients with stable CAD.", "sentB": "We believe inhibition of BAFF may reduce proliferative B-cells and plasma B-cells, reduce serum levels of IgA and therefore reduce progressive renal damage in patients with IgAN.", "type": 2, "words": ["<tag1>", "Statins", "reduce", "the", "level", "of", "CRP", "and", "other", "markers", "of", "inflammation", "in", "patients", "with", "stable", "CAD.", "<tag2>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN.", "<tag3>"], "wordsA": ["Statins", "reduce", "the", "level", "of", "CRP", "and", "other", "markers", "of", "inflammation", "in", "patients", "with", "stable", "CAD."], "wordsB": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p37_s0", "idA": "1316175_12_item1_p65_s0", "sentA": "In 2005, the New England Journal of Medicine published data from the PROVE-IT study.", "sentB": "According to the New England Journal of Medicine, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life, and a large number of cases eventually progress to renal failure.", "type": 2, "words": ["<tag1>", "In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study.", "<tag2>", "According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life,", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag3>"], "wordsA": ["In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study."], "wordsB": ["According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life,", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p48_s0", "idA": "1316175_12_item1_p65_s0", "sentA": "In 2005, the New England Journal of Medicine published data from the PROVE-IT study.", "sentB": "According to the New England Journal of Medicine, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life and a large number of cases eventually progress to renal failure.", "type": 2, "words": ["<tag1>", "In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study.", "<tag2>", "According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag3>"], "wordsA": ["In", "2005,", "the", "New", "England", "Journal", "of", "Medicine", "published", "data", "from", "the", "PROVE-IT", "study."], "wordsB": ["According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p18_s1", "idA": "1316175_12_item1_p68_s0", "sentA": "Patients enrolled in our FRANCIS Phase 2b clinical study and our Phase 3 acute coronary syndrome study represent high-risk patients as defined by the NCEP.", "sentB": "In this subgroup, which we plan to enroll in our Phase 3 CHABLIS-SC studies, separation of clinical response occurred as early as week eight and numerical differences were observed beyond week 24.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP.", "<tag2>", "In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP."], "wordsB": ["In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p54_s1", "idA": "1316175_12_item1_p68_s0", "sentA": "Patients enrolled in our FRANCIS Phase 2b clinical study and our Phase 3 acute coronary syndrome study represent high-risk patients as defined by the NCEP.", "sentB": "In this subgroup, which we plan to enroll in our Phase 3 CHABLIS-SC studies, separation of clinical response occurred as early as week eight and numerical differences were observed beyond week 24.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP.", "<tag2>", "In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP."], "wordsB": ["In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p85_s1", "idA": "1316175_12_item1_p68_s0", "sentA": "Patients enrolled in our FRANCIS Phase 2b clinical study and our Phase 3 acute coronary syndrome study represent high-risk patients as defined by the NCEP.", "sentB": "We intend to build an orphan path upon the secondary data we collected from our Phase 2b PEARL-SC study and recently published renal effects of Benlysta.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP.", "<tag2>", "We", "intend", "to", "build", "an", "orphan", "path", "upon", "the", "secondary", "data", "we", "collected", "from", "our", "Phase", "2b", "PEARL-SC", "study", "and", "recently", "published", "renal", "effects", "of", "Benlysta.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "our", "FRANCIS", "Phase", "2b", "clinical", "study", "and", "our", "Phase", "3", "acute", "coronary", "syndrome", "study", "represent", "high-risk", "patients", "as", "defined", "by", "the", "NCEP."], "wordsB": ["We", "intend", "to", "build", "an", "orphan", "path", "upon", "the", "secondary", "data", "we", "collected", "from", "our", "Phase", "2b", "PEARL-SC", "study", "and", "recently", "published", "renal", "effects", "of", "Benlysta."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p10_s0", "idA": "1316175_12_item1_p6_s1", "sentA": "Our current development plans are focused on acute treatment and orphan indications that may provide an accelerated and cost-efficient path to regulatory approval and commercialization.", "sentB": "Our current development plans include the phase 3 development of blisibimod for lupus and a focus on orphan indications, which may provide an accelerated and cost-efficient path to regulatory approval and commercialization both in the United States and Asia.", "type": 2, "words": ["<tag1>", "Our", "current", "development", "plans", "are", "focused", "on", "acute", "treatment", "and", "orphan", "indications", "that", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization.", "<tag2>", "Our", "current", "development", "plans", "include", "the", "phase", "3", "development", "of", "blisibimod", "for", "lupus", "and", "a", "focus", "on", "orphan", "indications,", "which", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization", "both", "in", "the", "United", "States", "and", "Asia.", "<tag3>"], "wordsA": ["Our", "current", "development", "plans", "are", "focused", "on", "acute", "treatment", "and", "orphan", "indications", "that", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization."], "wordsB": ["Our", "current", "development", "plans", "include", "the", "phase", "3", "development", "of", "blisibimod", "for", "lupus", "and", "a", "focus", "on", "orphan", "indications,", "which", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization", "both", "in", "the", "United", "States", "and", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p10_s1", "idA": "1316175_12_item1_p6_s2", "sentA": "We believe that certain of these markets can be commercialized through a limited specialty sales force.", "sentB": "We believe that certain of these markets and product opportunities for blisibimod can be commercialized through utilization of a limited specialty sales force targeting a small set of clinical specialists.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "certain", "of", "these", "markets", "can", "be", "commercialized", "through", "a", "limited", "specialty", "sales", "force.", "<tag2>", "We", "believe", "that", "certain", "of", "these", "markets", "and", "product", "opportunities", "for", "blisibimod", "can", "be", "commercialized", "through", "utilization", "of", "a", "limited", "specialty", "sales", "force", "targeting", "a", "small", "set", "of", "clinical", "specialists.", "<tag3>"], "wordsA": ["We", "believe", "that", "certain", "of", "these", "markets", "can", "be", "commercialized", "through", "a", "limited", "specialty", "sales", "force."], "wordsB": ["We", "believe", "that", "certain", "of", "these", "markets", "and", "product", "opportunities", "for", "blisibimod", "can", "be", "commercialized", "through", "utilization", "of", "a", "limited", "specialty", "sales", "force", "targeting", "a", "small", "set", "of", "clinical", "specialists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p10_s2", "idA": "1316175_12_item1_p6_s3", "sentA": "In addition, we believe that our product candidates can also address market opportunities in chronic indications and we may seek development and commercialization partners to address chronic, non-specialty and international markets.", "sentB": "In addition, we believe blisibimod may address market opportunities in chronic indications such as lupus and to maximize these opportunities we may seek development and commercialization partners to address non-specialty and international markets.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "believe", "that", "our", "product", "candidates", "can", "also", "address", "market", "opportunities", "in", "chronic", "indications", "and", "we", "may", "seek", "development", "and", "commercialization", "partners", "to", "address", "chronic,", "non-specialty", "and", "international", "markets.", "<tag2>", "In", "addition,", "we", "believe", "blisibimod", "may", "address", "market", "opportunities", "in", "chronic", "indications", "such", "as", "lupus", "and", "to", "maximize", "these", "opportunities", "we", "may", "seek", "development", "and", "commercialization", "partners", "to", "address", "non-specialty", "and", "international", "markets.", "<tag3>"], "wordsA": ["In", "addition,", "we", "believe", "that", "our", "product", "candidates", "can", "also", "address", "market", "opportunities", "in", "chronic", "indications", "and", "we", "may", "seek", "development", "and", "commercialization", "partners", "to", "address", "chronic,", "non-specialty", "and", "international", "markets."], "wordsB": ["In", "addition,", "we", "believe", "blisibimod", "may", "address", "market", "opportunities", "in", "chronic", "indications", "such", "as", "lupus", "and", "to", "maximize", "these", "opportunities", "we", "may", "seek", "development", "and", "commercialization", "partners", "to", "address", "non-specialty", "and", "international", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p86_s2", "idA": "1316175_12_item1_p6_s3", "sentA": "In addition, we believe that our product candidates can also address market opportunities in chronic indications and we may seek development and commercialization partners to address chronic, non-specialty and international markets.", "sentB": "In addition, we believe successful outcomes in the BRIGHT-SC study will support future lifecycle expansion for blisibimod.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "believe", "that", "our", "product", "candidates", "can", "also", "address", "market", "opportunities", "in", "chronic", "indications", "and", "we", "may", "seek", "development", "and", "commercialization", "partners", "to", "address", "chronic,", "non-specialty", "and", "international", "markets.", "<tag2>", "In", "addition,", "we", "believe", "successful", "outcomes", "in", "the", "BRIGHT-SC", "study", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod.", "<tag3>"], "wordsA": ["In", "addition,", "we", "believe", "that", "our", "product", "candidates", "can", "also", "address", "market", "opportunities", "in", "chronic", "indications", "and", "we", "may", "seek", "development", "and", "commercialization", "partners", "to", "address", "chronic,", "non-specialty", "and", "international", "markets."], "wordsB": ["In", "addition,", "we", "believe", "successful", "outcomes", "in", "the", "BRIGHT-SC", "study", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p38_s1", "idA": "1316175_12_item1_p70_s1", "sentA": "The study randomized patients with relatively normal levels of LDL-C, but elevated levels of inflammation based on CRP, to statin or placebo therapy.", "sentB": "In patients with IgAN, levels of BAFF are significantly higher than in healthy patients.", "type": 2, "words": ["<tag1>", "The", "study", "randomized", "patients", "with", "relatively", "normal", "levels", "of", "LDL-C,", "but", "elevated", "levels", "of", "inflammation", "based", "on", "CRP,", "to", "statin", "or", "placebo", "therapy.", "<tag2>", "In", "patients", "with", "IgAN,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients.", "<tag3>"], "wordsA": ["The", "study", "randomized", "patients", "with", "relatively", "normal", "levels", "of", "LDL-C,", "but", "elevated", "levels", "of", "inflammation", "based", "on", "CRP,", "to", "statin", "or", "placebo", "therapy."], "wordsB": ["In", "patients", "with", "IgAN,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p60_s1", "idA": "1316175_12_item1_p70_s1", "sentA": "The study randomized patients with relatively normal levels of LDL-C, but elevated levels of inflammation based on CRP, to statin or placebo therapy.", "sentB": "In patients with IgAN, levels of BAFF are significantly higher than in healthy patients.", "type": 2, "words": ["<tag1>", "The", "study", "randomized", "patients", "with", "relatively", "normal", "levels", "of", "LDL-C,", "but", "elevated", "levels", "of", "inflammation", "based", "on", "CRP,", "to", "statin", "or", "placebo", "therapy.", "<tag2>", "In", "patients", "with", "IgAN,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients.", "<tag3>"], "wordsA": ["The", "study", "randomized", "patients", "with", "relatively", "normal", "levels", "of", "LDL-C,", "but", "elevated", "levels", "of", "inflammation", "based", "on", "CRP,", "to", "statin", "or", "placebo", "therapy."], "wordsB": ["In", "patients", "with", "IgAN,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p31_s0", "idA": "1316175_12_item1_p71_s0", "sentA": "In 2008, based on the results from Phase 2 stable CAD studies, as discussed below, we met with the FDA to discuss the next steps of clinical development of varespladib during our end of Phase 2 meeting.", "sentB": "During the third quarter of 2012 we met with the U.S. Food and Drug Administration, or FDA, at an end of phase 2 meeting.", "type": 2, "words": ["<tag1>", "In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting.", "<tag2>", "During", "the", "third", "quarter", "of", "2012", "we", "met", "with", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "at", "an", "end", "of", "phase", "2", "meeting.", "<tag3>"], "wordsA": ["In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting."], "wordsB": ["During", "the", "third", "quarter", "of", "2012", "we", "met", "with", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "at", "an", "end", "of", "phase", "2", "meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p32_s5", "idA": "1316175_12_item1_p71_s0", "sentA": "In 2008, based on the results from Phase 2 stable CAD studies, as discussed below, we met with the FDA to discuss the next steps of clinical development of varespladib during our end of Phase 2 meeting.", "sentB": "Based on significant improvements in renal disease biomarkers such as proteinuria, C3 and C4 observed with blisibimod, in 2013 we plan to meet with the FDA to discuss and finalize the enrollment criteria of the CHABLIS-SC2 clinical study in an effort to include patients diagnosed with or without glomerulonephritis.", "type": 2, "words": ["<tag1>", "In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting.", "<tag2>", "Based", "on", "significant", "improvements", "in", "renal", "disease", "biomarkers", "such", "as", "proteinuria,", "C3", "and", "C4", "observed", "with", "blisibimod,", "in", "2013", "we", "plan", "to", "meet", "with", "the", "FDA", "to", "discuss", "and", "finalize", "the", "enrollment", "criteria", "of", "the", "CHABLIS-SC2", "clinical", "study", "in", "an", "effort", "to", "include", "patients", "diagnosed", "with", "or", "without", "glomerulonephritis.", "<tag3>"], "wordsA": ["In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting."], "wordsB": ["Based", "on", "significant", "improvements", "in", "renal", "disease", "biomarkers", "such", "as", "proteinuria,", "C3", "and", "C4", "observed", "with", "blisibimod,", "in", "2013", "we", "plan", "to", "meet", "with", "the", "FDA", "to", "discuss", "and", "finalize", "the", "enrollment", "criteria", "of", "the", "CHABLIS-SC2", "clinical", "study", "in", "an", "effort", "to", "include", "patients", "diagnosed", "with", "or", "without", "glomerulonephritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p57_s0", "idA": "1316175_12_item1_p71_s0", "sentA": "In 2008, based on the results from Phase 2 stable CAD studies, as discussed below, we met with the FDA to discuss the next steps of clinical development of varespladib during our end of Phase 2 meeting.", "sentB": "In the third quarter of 2012 at an end of Phase 2 meeting with the FDA, we presented the results of the PEARL-SC clinical study and our plans for Phase 3 registration studies in patients with active lupus.", "type": 2, "words": ["<tag1>", "In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting.", "<tag2>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "end", "of", "Phase", "2", "meeting", "with", "the", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag3>"], "wordsA": ["In", "2008,", "based", "on", "the", "results", "from", "Phase", "2", "stable", "CAD", "studies,", "as", "discussed", "below,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "next", "steps", "of", "clinical", "development", "of", "varespladib", "during", "our", "end", "of", "Phase", "2", "meeting."], "wordsB": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "end", "of", "Phase", "2", "meeting", "with", "the", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p81_s1", "idA": "1316175_12_item1_p73_s0", "sentA": "The primary endpoint of the VISTA-16 study was to determine whether 16 weeks of once-daily treatment with varespladib plus a dose of Lipitor (atorvastatin) is superior to placebo plus Lipitor (atorvastatin) in the time to the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or documented UA with objective evidence of ischemia requiring hospitalization as defined by recent FDA draft guidance.", "sentB": "At the time of study termination the hazard ratio for the primary endpoint (time to first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring hospitalization) was 1.244 (p=0.155).", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "VISTA-16", "study", "was", "to", "determine", "whether", "16", "weeks", "of", "once-daily", "treatment", "with", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization", "as", "defined", "by", "recent", "FDA", "draft", "guidance.", "<tag2>", "At", "the", "time", "of", "study", "termination", "the", "hazard", "ratio", "for", "the", "primary", "endpoint", "(time", "to", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke,", "or", "documented", "unstable", "angina", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization)", "was", "1.244", "(p=0.155).", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "VISTA-16", "study", "was", "to", "determine", "whether", "16", "weeks", "of", "once-daily", "treatment", "with", "varespladib", "plus", "a", "dose", "of", "Lipitor", "(atorvastatin)", "is", "superior", "to", "placebo", "plus", "Lipitor", "(atorvastatin)", "in", "the", "time", "to", "the", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke", "or", "documented", "UA", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization", "as", "defined", "by", "recent", "FDA", "draft", "guidance."], "wordsB": ["At", "the", "time", "of", "study", "termination", "the", "hazard", "ratio", "for", "the", "primary", "endpoint", "(time", "to", "first", "occurrence", "of", "the", "combined", "endpoint", "of", "cardiovascular", "death,", "non-fatal", "myocardial", "infarction,", "non-fatal", "stroke,", "or", "documented", "unstable", "angina", "with", "objective", "evidence", "of", "ischemia", "requiring", "hospitalization)", "was", "1.244", "(p=0.155)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p81_s2", "idA": "1316175_12_item1_p75_s2", "sentA": "Additionally, the time to multiple occurrences of any non-fatal component of the composite primary endpoint will also be explored.", "sentB": "This is primarily driven by the increased occurrence of non-fatal myocardial infarction, a single component of the composite primary endpoint: HR 1.686 p=0.009.", "type": 2, "words": ["<tag1>", "Additionally,", "the", "time", "to", "multiple", "occurrences", "of", "any", "non-fatal", "component", "of", "the", "composite", "primary", "endpoint", "will", "also", "be", "explored.", "<tag2>", "This", "is", "primarily", "driven", "by", "the", "increased", "occurrence", "of", "non-fatal", "myocardial", "infarction,", "a", "single", "component", "of", "the", "composite", "primary", "endpoint:", "HR", "1.686", "p=0.009.", "<tag3>"], "wordsA": ["Additionally,", "the", "time", "to", "multiple", "occurrences", "of", "any", "non-fatal", "component", "of", "the", "composite", "primary", "endpoint", "will", "also", "be", "explored."], "wordsB": ["This", "is", "primarily", "driven", "by", "the", "increased", "occurrence", "of", "non-fatal", "myocardial", "infarction,", "a", "single", "component", "of", "the", "composite", "primary", "endpoint:", "HR", "1.686", "p=0.009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p47_s1", "idA": "1316175_12_item1_p7_s3", "sentA": "All of these circumstances can cause significant damage to cells and tissues, leading to a range of inflammatory disorders, such as cardiovascular and autoimmune diseases.", "sentB": "All of these infections have in common the activation of mucosal defenses and hence IgA antibody production.", "type": 2, "words": ["<tag1>", "All", "of", "these", "circumstances", "can", "cause", "significant", "damage", "to", "cells", "and", "tissues,", "leading", "to", "a", "range", "of", "inflammatory", "disorders,", "such", "as", "cardiovascular", "and", "autoimmune", "diseases.", "<tag2>", "All", "of", "these", "infections", "have", "in", "common", "the", "activation", "of", "mucosal", "defenses", "and", "hence", "IgA", "antibody", "production.", "<tag3>"], "wordsA": ["All", "of", "these", "circumstances", "can", "cause", "significant", "damage", "to", "cells", "and", "tissues,", "leading", "to", "a", "range", "of", "inflammatory", "disorders,", "such", "as", "cardiovascular", "and", "autoimmune", "diseases."], "wordsB": ["All", "of", "these", "infections", "have", "in", "common", "the", "activation", "of", "mucosal", "defenses", "and", "hence", "IgA", "antibody", "production."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p39_s1", "idA": "1316175_12_item1_p81_s3", "sentA": "The clinical study randomized all patients to a minimum of 24 weeks of treatment with either 500 mg once-daily of varespladib or placebo in combination with 80 mg Lipitor (atorvastatin) and physician-directed standard of care.", "sentB": "The BRIGHT-SC study will enroll approximately 48 patients with biopsy-proven IgAN who have proteinuria greater than 1 gram per 24 hours and are receiving standard of care.", "type": 2, "words": ["<tag1>", "The", "clinical", "study", "randomized", "all", "patients", "to", "a", "minimum", "of", "24", "weeks", "of", "treatment", "with", "either", "500", "mg", "once-daily", "of", "varespladib", "or", "placebo", "in", "combination", "with", "80", "mg", "Lipitor", "(atorvastatin)", "and", "physician-directed", "standard", "of", "care.", "<tag2>", "The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "1", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care.", "<tag3>"], "wordsA": ["The", "clinical", "study", "randomized", "all", "patients", "to", "a", "minimum", "of", "24", "weeks", "of", "treatment", "with", "either", "500", "mg", "once-daily", "of", "varespladib", "or", "placebo", "in", "combination", "with", "80", "mg", "Lipitor", "(atorvastatin)", "and", "physician-directed", "standard", "of", "care."], "wordsB": ["The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "1", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p61_s2", "idA": "1316175_12_item1_p81_s3", "sentA": "The clinical study randomized all patients to a minimum of 24 weeks of treatment with either 500 mg once-daily of varespladib or placebo in combination with 80 mg Lipitor (atorvastatin) and physician-directed standard of care.", "sentB": "The BRIGHT-SC study will enroll approximately 48 patients with biopsy-proven IgAN who have proteinuria greater than one gram per 24 hours and are receiving standard of care.", "type": 2, "words": ["<tag1>", "The", "clinical", "study", "randomized", "all", "patients", "to", "a", "minimum", "of", "24", "weeks", "of", "treatment", "with", "either", "500", "mg", "once-daily", "of", "varespladib", "or", "placebo", "in", "combination", "with", "80", "mg", "Lipitor", "(atorvastatin)", "and", "physician-directed", "standard", "of", "care.", "<tag2>", "The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care.", "<tag3>"], "wordsA": ["The", "clinical", "study", "randomized", "all", "patients", "to", "a", "minimum", "of", "24", "weeks", "of", "treatment", "with", "either", "500", "mg", "once-daily", "of", "varespladib", "or", "placebo", "in", "combination", "with", "80", "mg", "Lipitor", "(atorvastatin)", "and", "physician-directed", "standard", "of", "care."], "wordsB": ["The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p30_s0", "idA": "1316175_12_item1_p83_s1", "sentA": "All patients who completed the clinical study received a final evaluation.", "sentB": "As part of the PEARL-SC clinical study program, patients who completed the study were eligible to enroll in an open label extension study.", "type": 2, "words": ["<tag1>", "All", "patients", "who", "completed", "the", "clinical", "study", "received", "a", "final", "evaluation.", "<tag2>", "As", "part", "of", "the", "PEARL-SC", "clinical", "study", "program,", "patients", "who", "completed", "the", "study", "were", "eligible", "to", "enroll", "in", "an", "open", "label", "extension", "study.", "<tag3>"], "wordsA": ["All", "patients", "who", "completed", "the", "clinical", "study", "received", "a", "final", "evaluation."], "wordsB": ["As", "part", "of", "the", "PEARL-SC", "clinical", "study", "program,", "patients", "who", "completed", "the", "study", "were", "eligible", "to", "enroll", "in", "an", "open", "label", "extension", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p22_s0", "idA": "1316175_12_item1_p91_s0", "sentA": "In addition, treatment-related reductions in CRP and IL-6 levels were also greater in varespladib treated patients compared to those treated with placebo at all time points in the clinical study.", "sentB": "The following table shows the N values at the different time points in the graph above.", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment-related", "reductions", "in", "CRP", "and", "IL-6", "levels", "were", "also", "greater", "in", "varespladib", "treated", "patients", "compared", "to", "those", "treated", "with", "placebo", "at", "all", "time", "points", "in", "the", "clinical", "study.", "<tag2>", "The", "following", "table", "shows", "the", "N", "values", "at", "the", "different", "time", "points", "in", "the", "graph", "above.", "<tag3>"], "wordsA": ["In", "addition,", "treatment-related", "reductions", "in", "CRP", "and", "IL-6", "levels", "were", "also", "greater", "in", "varespladib", "treated", "patients", "compared", "to", "those", "treated", "with", "placebo", "at", "all", "time", "points", "in", "the", "clinical", "study."], "wordsB": ["The", "following", "table", "shows", "the", "N", "values", "at", "the", "different", "time", "points", "in", "the", "graph", "above."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_13_item1_p51_s3", "idA": "1316175_12_item1_p97_s2", "sentA": "In total, 485 total patients completed six months of treatment, with 167 subjects completing 40 weeks and 70 completing 44 weeks.", "sentB": "All patients completed the PEARL-SC study when the final enrolled patient completed six months of therapy.", "type": 2, "words": ["<tag1>", "In", "total,", "485", "total", "patients", "completed", "six", "months", "of", "treatment,", "with", "167", "subjects", "completing", "40", "weeks", "and", "70", "completing", "44", "weeks.", "<tag2>", "All", "patients", "completed", "the", "PEARL-SC", "study", "when", "the", "final", "enrolled", "patient", "completed", "six", "months", "of", "therapy.", "<tag3>"], "wordsA": ["In", "total,", "485", "total", "patients", "completed", "six", "months", "of", "treatment,", "with", "167", "subjects", "completing", "40", "weeks", "and", "70", "completing", "44", "weeks."], "wordsB": ["All", "patients", "completed", "the", "PEARL-SC", "study", "when", "the", "final", "enrolled", "patient", "completed", "six", "months", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p119_s2", "idA": "1316175_13_item1_p101_s2", "sentA": "This could extend the expiration date of the U.S. Patent to May 2027 or November 2028, depending on which patent the term restoration is applied to.", "sentB": "This could extend the expiration date of the U.S. Patent to as late as May 2027 or November 2028, depending on which patent the term restoration is applied to.", "type": 2, "words": ["<tag1>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag2>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag3>"], "wordsA": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "wordsB": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p119_s4", "idA": "1316175_13_item1_p101_s4", "sentA": "The European patents are currently scheduled to expire in May 2022.", "sentB": "The EP patents are currently scheduled to expire in May 2022.", "type": 2, "words": ["<tag1>", "The", "European", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag2>", "The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag3>"], "wordsA": ["The", "European", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "wordsB": ["The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p120_s1", "idA": "1316175_13_item1_p102_s1", "sentA": "A non-provisional patent application is examined by the U.S. Patent Office, or USPTO, and can mature into a patent once the USPTO determines that the claimed invention meets the standards for patentability.", "sentB": "A non-provisional patent application is examined by the United States Patent and Trademark Office, or USPTO, and can mature into a patent once the USPTO determines that the claimed invention meets the standards for patentability.", "type": 2, "words": ["<tag1>", "A", "non-provisional", "patent", "application", "is", "examined", "by", "the", "U.S.", "Patent", "Office,", "or", "USPTO,", "and", "can", "mature", "into", "a", "patent", "once", "the", "USPTO", "determines", "that", "the", "claimed", "invention", "meets", "the", "standards", "for", "patentability.", "<tag2>", "A", "non-provisional", "patent", "application", "is", "examined", "by", "the", "United", "States", "Patent", "and", "Trademark", "Office,", "or", "USPTO,", "and", "can", "mature", "into", "a", "patent", "once", "the", "USPTO", "determines", "that", "the", "claimed", "invention", "meets", "the", "standards", "for", "patentability.", "<tag3>"], "wordsA": ["A", "non-provisional", "patent", "application", "is", "examined", "by", "the", "U.S.", "Patent", "Office,", "or", "USPTO,", "and", "can", "mature", "into", "a", "patent", "once", "the", "USPTO", "determines", "that", "the", "claimed", "invention", "meets", "the", "standards", "for", "patentability."], "wordsB": ["A", "non-provisional", "patent", "application", "is", "examined", "by", "the", "United", "States", "Patent", "and", "Trademark", "Office,", "or", "USPTO,", "and", "can", "mature", "into", "a", "patent", "once", "the", "USPTO", "determines", "that", "the", "claimed", "invention", "meets", "the", "standards", "for", "patentability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p123_s0", "idA": "1316175_13_item1_p105_s0", "sentA": "We are aware of two families of third party United States patents and pending foreign applications that contain broad claims related to BLyS or BAFF binding polypeptides.", "sentB": "We are aware of two families of third-party U.S. patents and pending foreign applications that contain broad claims related to BLyS or BAFF binding polypeptides.", "type": 2, "words": ["<tag1>", "We", "are", "aware", "of", "two", "families", "of", "third", "party", "United", "States", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides.", "<tag2>", "We", "are", "aware", "of", "two", "families", "of", "third-party", "U.S.", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides.", "<tag3>"], "wordsA": ["We", "are", "aware", "of", "two", "families", "of", "third", "party", "United", "States", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides."], "wordsB": ["We", "are", "aware", "of", "two", "families", "of", "third-party", "U.S.", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p123_s2", "idA": "1316175_13_item1_p105_s2", "sentA": "If we were to challenge the validity of any issued United States patent in court, we would need to overcome the presumption of validity that attaches to every United States patent by presenting clear and convincing evidence as to the invalidity of the patent s claims.", "sentB": "If we were to challenge the validity of any issued U.S. patent in court, we would need to overcome the presumption of validity that attaches to every U.S. patent by presenting clear and convincing evidence as to the invalidity of the patent s claims.", "type": 2, "words": ["<tag1>", "If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "United", "States", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "United", "States", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims.", "<tag2>", "If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "U.S.", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "U.S.", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims.", "<tag3>"], "wordsA": ["If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "United", "States", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "United", "States", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims."], "wordsB": ["If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "U.S.", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "U.S.", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p123_s4", "idA": "1316175_13_item1_p105_s4", "sentA": "If third party patents are determined to be valid and construed to cover blisibimod, the development and commercialization of this program could be affected, subjecting us to potential liability for damages and in addition may require us to obtain a license to continue marketing the affected product.", "sentB": "If third-party patents are determined to be valid and construed to cover blisibimod, the development and commercialization of this program could be affected, subjecting us to potential liability for damages and possibly requiring us to obtain a license to continue marketing the affected product.", "type": 2, "words": ["<tag1>", "If", "third", "party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "in", "addition", "may", "require", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product.", "<tag2>", "If", "third-party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "possibly", "requiring", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product.", "<tag3>"], "wordsA": ["If", "third", "party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "in", "addition", "may", "require", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product."], "wordsB": ["If", "third-party", "patents", "are", "determined", "to", "be", "valid", "and", "construed", "to", "cover", "blisibimod,", "the", "development", "and", "commercialization", "of", "this", "program", "could", "be", "affected,", "subjecting", "us", "to", "potential", "liability", "for", "damages", "and", "possibly", "requiring", "us", "to", "obtain", "a", "license", "to", "continue", "marketing", "the", "affected", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p104_s1", "idA": "1316175_13_item1_p108_s1", "sentA": "Similarly, we are prohibited during the term of the agreement from clinically developing or commercializing any molecule other than blisibimod that modulates BAFF as the primary intended therapeutic mechanism of action.", "sentB": "The proposed mechanism of action of blisibimod in this disease is to decrease survival of the disease-causing multiple myeloma cells.", "type": 2, "words": ["<tag1>", "Similarly,", "we", "are", "prohibited", "during", "the", "term", "of", "the", "agreement", "from", "clinically", "developing", "or", "commercializing", "any", "molecule", "other", "than", "blisibimod", "that", "modulates", "BAFF", "as", "the", "primary", "intended", "therapeutic", "mechanism", "of", "action.", "<tag2>", "The", "proposed", "mechanism", "of", "action", "of", "blisibimod", "in", "this", "disease", "is", "to", "decrease", "survival", "of", "the", "disease-causing", "multiple", "myeloma", "cells.", "<tag3>"], "wordsA": ["Similarly,", "we", "are", "prohibited", "during", "the", "term", "of", "the", "agreement", "from", "clinically", "developing", "or", "commercializing", "any", "molecule", "other", "than", "blisibimod", "that", "modulates", "BAFF", "as", "the", "primary", "intended", "therapeutic", "mechanism", "of", "action."], "wordsB": ["The", "proposed", "mechanism", "of", "action", "of", "blisibimod", "in", "this", "disease", "is", "to", "decrease", "survival", "of", "the", "disease-causing", "multiple", "myeloma", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p15_s1", "idA": "1316175_13_item1_p10_s0", "sentA": "Our current development plans include the phase 3 development of blisibimod for lupus and a focus on orphan indications, which may provide an accelerated and cost-efficient path to regulatory approval and commercialization both in the United States and Asia.", "sentB": "These indications provide multiple commercial potentials for blisibimod and may provide an accelerated and cost-efficient path to regulatory approval and commercialization.", "type": 2, "words": ["<tag1>", "Our", "current", "development", "plans", "include", "the", "phase", "3", "development", "of", "blisibimod", "for", "lupus", "and", "a", "focus", "on", "orphan", "indications,", "which", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization", "both", "in", "the", "United", "States", "and", "Asia.", "<tag2>", "These", "indications", "provide", "multiple", "commercial", "potentials", "for", "blisibimod", "and", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization.", "<tag3>"], "wordsA": ["Our", "current", "development", "plans", "include", "the", "phase", "3", "development", "of", "blisibimod", "for", "lupus", "and", "a", "focus", "on", "orphan", "indications,", "which", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization", "both", "in", "the", "United", "States", "and", "Asia."], "wordsB": ["These", "indications", "provide", "multiple", "commercial", "potentials", "for", "blisibimod", "and", "may", "provide", "an", "accelerated", "and", "cost-efficient", "path", "to", "regulatory", "approval", "and", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p131_s2", "idA": "1316175_13_item1_p10_s1", "sentA": "We believe that certain of these markets and product opportunities for blisibimod can be commercialized through utilization of a limited specialty sales force targeting a small set of clinical specialists.", "sentB": "We believe that our safety procedures for handling and disposing of these materials comply in all material respects with the standards prescribed by local, state and federal regulations.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "certain", "of", "these", "markets", "and", "product", "opportunities", "for", "blisibimod", "can", "be", "commercialized", "through", "utilization", "of", "a", "limited", "specialty", "sales", "force", "targeting", "a", "small", "set", "of", "clinical", "specialists.", "<tag2>", "We", "believe", "that", "our", "safety", "procedures", "for", "handling", "and", "disposing", "of", "these", "materials", "comply", "in", "all", "material", "respects", "with", "the", "standards", "prescribed", "by", "local,", "state", "and", "federal", "regulations.", "<tag3>"], "wordsA": ["We", "believe", "that", "certain", "of", "these", "markets", "and", "product", "opportunities", "for", "blisibimod", "can", "be", "commercialized", "through", "utilization", "of", "a", "limited", "specialty", "sales", "force", "targeting", "a", "small", "set", "of", "clinical", "specialists."], "wordsB": ["We", "believe", "that", "our", "safety", "procedures", "for", "handling", "and", "disposing", "of", "these", "materials", "comply", "in", "all", "material", "respects", "with", "the", "standards", "prescribed", "by", "local,", "state", "and", "federal", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p127_s0", "idA": "1316175_13_item1_p114_s0", "sentA": "Upon entering into the license agreement, we assumed control of all prosecution and maintenance of core patents prosecuted and maintained by Eli Lilly prior to the agreement.", "sentB": "Pursuant to the terms of the license agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "type": 2, "words": ["<tag1>", "Upon", "entering", "into", "the", "license", "agreement,", "we", "assumed", "control", "of", "all", "prosecution", "and", "maintenance", "of", "core", "patents", "prosecuted", "and", "maintained", "by", "Eli", "Lilly", "prior", "to", "the", "agreement.", "<tag2>", "Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag3>"], "wordsA": ["Upon", "entering", "into", "the", "license", "agreement,", "we", "assumed", "control", "of", "all", "prosecution", "and", "maintenance", "of", "core", "patents", "prosecuted", "and", "maintained", "by", "Eli", "Lilly", "prior", "to", "the", "agreement."], "wordsB": ["Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p130_s0", "idA": "1316175_13_item1_p116_s0", "sentA": "We currently rely on contract manufacturers to produce drug substances and drug products required for our clinical studies under current Good Manufacturing Practice ( cGMP ) with oversight by our internal managers.", "sentB": "Our contract manufacturers obtain the raw materials for the drug substances and drug products required for our clinical studies from a variety of sources.", "type": 2, "words": ["<tag1>", "We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "Good", "Manufacturing", "Practice", "(", "cGMP", ")", "with", "oversight", "by", "our", "internal", "managers.", "<tag2>", "Our", "contract", "manufacturers", "obtain", "the", "raw", "materials", "for", "the", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "from", "a", "variety", "of", "sources.", "<tag3>"], "wordsA": ["We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "Good", "Manufacturing", "Practice", "(", "cGMP", ")", "with", "oversight", "by", "our", "internal", "managers."], "wordsB": ["Our", "contract", "manufacturers", "obtain", "the", "raw", "materials", "for", "the", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "from", "a", "variety", "of", "sources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p134_s0", "idA": "1316175_13_item1_p119_s0", "sentA": "Government authorities in the United States at the federal, state and local level and other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing.", "sentB": "Government authorities in the United States at the federal, state and local level and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing.", "type": 2, "words": ["<tag1>", "Government", "authorities", "in", "the", "United", "States", "at", "the", "federal,", "state", "and", "local", "level", "and", "other", "countries,", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing,", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag2>", "Government", "authorities", "in", "the", "United", "States", "at", "the", "federal,", "state", "and", "local", "level", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing,", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing.", "<tag3>"], "wordsA": ["Government", "authorities", "in", "the", "United", "States", "at", "the", "federal,", "state", "and", "local", "level", "and", "other", "countries,", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing,", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "wordsB": ["Government", "authorities", "in", "the", "United", "States", "at", "the", "federal,", "state", "and", "local", "level", "and", "other", "countries", "extensively", "regulate,", "among", "other", "things,", "the", "research,", "development,", "testing,", "manufacture,", "quality", "control,", "approval,", "labeling,", "packaging,", "storage,", "record-keeping,", "promotion,", "advertising,", "distribution,", "marketing,", "export", "and", "import", "of", "products", "such", "as", "those", "we", "are", "developing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p16_s0", "idA": "1316175_13_item1_p11_s0", "sentA": "Blisibimod (also referred to as A-623) is a peptibody antagonist of the BAFF cytokine that we are developing as a treatment for systemic lupus erythematosus, or lupus and IgAN.", "sentB": "Blisibimod (also referred to as A-623) is a peptibody antagonist of the BAFF cytokine, also known as B-cell activating factor, which was initially developed as treatment for patients with severe systemic lupus.", "type": 2, "words": ["<tag1>", "Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "we", "are", "developing", "as", "a", "treatment", "for", "systemic", "lupus", "erythematosus,", "or", "lupus", "and", "IgAN.", "<tag2>", "Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine,", "also", "known", "as", "B-cell", "activating", "factor,", "which", "was", "initially", "developed", "as", "treatment", "for", "patients", "with", "severe", "systemic", "lupus.", "<tag3>"], "wordsA": ["Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine", "that", "we", "are", "developing", "as", "a", "treatment", "for", "systemic", "lupus", "erythematosus,", "or", "lupus", "and", "IgAN."], "wordsB": ["Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine,", "also", "known", "as", "B-cell", "activating", "factor,", "which", "was", "initially", "developed", "as", "treatment", "for", "patients", "with", "severe", "systemic", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p66_s1", "idA": "1316175_13_item1_p125_s2", "sentA": "In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin.", "sentB": "This submission incorporated feedback from both the initial meetings with the FDA and PMDA and included a second clinical study protocol, BRILLIANT-SC1.", "type": 2, "words": ["<tag1>", "In", "such", "a", "case,", "the", "IND", "sponsor", "and", "the", "FDA", "must", "resolve", "any", "outstanding", "concerns", "before", "the", "clinical", "study", "can", "begin.", "<tag2>", "This", "submission", "incorporated", "feedback", "from", "both", "the", "initial", "meetings", "with", "the", "FDA", "and", "PMDA", "and", "included", "a", "second", "clinical", "study", "protocol,", "BRILLIANT-SC1.", "<tag3>"], "wordsA": ["In", "such", "a", "case,", "the", "IND", "sponsor", "and", "the", "FDA", "must", "resolve", "any", "outstanding", "concerns", "before", "the", "clinical", "study", "can", "begin."], "wordsB": ["This", "submission", "incorporated", "feedback", "from", "both", "the", "initial", "meetings", "with", "the", "FDA", "and", "PMDA", "and", "included", "a", "second", "clinical", "study", "protocol,", "BRILLIANT-SC1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p90_s1", "idA": "1316175_13_item1_p125_s2", "sentA": "In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin.", "sentB": "This IND incorporated feedback from both the initial meetings with the FDA and PMDA and included a second clinical study protocol, BRILLIANT-SC1.", "type": 2, "words": ["<tag1>", "In", "such", "a", "case,", "the", "IND", "sponsor", "and", "the", "FDA", "must", "resolve", "any", "outstanding", "concerns", "before", "the", "clinical", "study", "can", "begin.", "<tag2>", "This", "IND", "incorporated", "feedback", "from", "both", "the", "initial", "meetings", "with", "the", "FDA", "and", "PMDA", "and", "included", "a", "second", "clinical", "study", "protocol,", "BRILLIANT-SC1.", "<tag3>"], "wordsA": ["In", "such", "a", "case,", "the", "IND", "sponsor", "and", "the", "FDA", "must", "resolve", "any", "outstanding", "concerns", "before", "the", "clinical", "study", "can", "begin."], "wordsB": ["This", "IND", "incorporated", "feedback", "from", "both", "the", "initial", "meetings", "with", "the", "FDA", "and", "PMDA", "and", "included", "a", "second", "clinical", "study", "protocol,", "BRILLIANT-SC1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p17_s0", "idA": "1316175_13_item1_p12_s0", "sentA": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells.", "sentB": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells and plasma cells.", "type": 2, "words": ["<tag1>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells.", "<tag2>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells", "and", "plasma", "cells.", "<tag3>"], "wordsA": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells."], "wordsB": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells", "and", "plasma", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p18_s1", "idA": "1316175_13_item1_p12_s2", "sentA": "However abnormal elevations of B-cells, often accompanied by elevations in BAFF, may lead to an over active immune response which may damage normal healthy tissues and organ systems.", "sentB": "However, abnormal elevations of B-cells and plasma cells, often accompanied by elevations in BAFF, may lead to an overactive immune response, including an increased production of immunogloblulins, which may damage normal healthy tissues and organ systems.", "type": 2, "words": ["<tag1>", "However", "abnormal", "elevations", "of", "B-cells,", "often", "accompanied", "by", "elevations", "in", "BAFF,", "may", "lead", "to", "an", "over", "active", "immune", "response", "which", "may", "damage", "normal", "healthy", "tissues", "and", "organ", "systems.", "<tag2>", "However,", "abnormal", "elevations", "of", "B-cells", "and", "plasma", "cells,", "often", "accompanied", "by", "elevations", "in", "BAFF,", "may", "lead", "to", "an", "overactive", "immune", "response,", "including", "an", "increased", "production", "of", "immunogloblulins,", "which", "may", "damage", "normal", "healthy", "tissues", "and", "organ", "systems.", "<tag3>"], "wordsA": ["However", "abnormal", "elevations", "of", "B-cells,", "often", "accompanied", "by", "elevations", "in", "BAFF,", "may", "lead", "to", "an", "over", "active", "immune", "response", "which", "may", "damage", "normal", "healthy", "tissues", "and", "organ", "systems."], "wordsB": ["However,", "abnormal", "elevations", "of", "B-cells", "and", "plasma", "cells,", "often", "accompanied", "by", "elevations", "in", "BAFF,", "may", "lead", "to", "an", "overactive", "immune", "response,", "including", "an", "increased", "production", "of", "immunogloblulins,", "which", "may", "damage", "normal", "healthy", "tissues", "and", "organ", "systems."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p148_s1", "idA": "1316175_13_item1_p133_s1", "sentA": "The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things; the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.", "sentB": "The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product.", "type": 2, "words": ["<tag1>", "The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things;", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product.", "<tag2>", "The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things,", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product.", "<tag3>"], "wordsA": ["The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things;", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product."], "wordsB": ["The", "manufacturing", "process", "must", "be", "capable", "of", "consistently", "producing", "quality", "batches", "of", "the", "product", "candidate", "and,", "among", "other", "things,", "the", "manufacturer", "must", "develop", "methods", "for", "testing", "the", "identity,", "strength,", "quality", "and", "purity", "of", "the", "final", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p89_s5", "idA": "1316175_13_item1_p139_s4", "sentA": "The complete response letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA.", "sentB": "The statistical analysis plan for CHALIS SC-1 has been amended to reflect advice received from the FDA.", "type": 2, "words": ["<tag1>", "The", "complete", "response", "letter", "usually", "describes", "all", "of", "the", "specific", "deficiencies", "in", "the", "NDA", "or", "BLA", "identified", "by", "the", "FDA.", "<tag2>", "The", "statistical", "analysis", "plan", "for", "CHALIS", "SC-1", "has", "been", "amended", "to", "reflect", "advice", "received", "from", "the", "FDA.", "<tag3>"], "wordsA": ["The", "complete", "response", "letter", "usually", "describes", "all", "of", "the", "specific", "deficiencies", "in", "the", "NDA", "or", "BLA", "identified", "by", "the", "FDA."], "wordsB": ["The", "statistical", "analysis", "plan", "for", "CHALIS", "SC-1", "has", "been", "amended", "to", "reflect", "advice", "received", "from", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p71_s0", "idA": "1316175_13_item1_p13_s3", "sentA": "In preclinical studies in mice that develop lupus-like disease, BAFF is known to be elevated, and treatment with blisibimod improves outcomes and survival.", "sentB": "BAFF is known to be elevated in patients with multiple myeloma, and the BCMA receptor (or B-cell Maturation Antigen receptor) which binds to BAFF and a proliferation-inducing ligand (or APRIL) and increases survival of plasma cells is also expressed on multiple myeloma cells.", "type": 2, "words": ["<tag1>", "In", "preclinical", "studies", "in", "mice", "that", "develop", "lupus-like", "disease,", "BAFF", "is", "known", "to", "be", "elevated,", "and", "treatment", "with", "blisibimod", "improves", "outcomes", "and", "survival.", "<tag2>", "BAFF", "is", "known", "to", "be", "elevated", "in", "patients", "with", "multiple", "myeloma,", "and", "the", "BCMA", "receptor", "(or", "B-cell", "Maturation", "Antigen", "receptor)", "which", "binds", "to", "BAFF", "and", "a", "proliferation-inducing", "ligand", "(or", "APRIL)", "and", "increases", "survival", "of", "plasma", "cells", "is", "also", "expressed", "on", "multiple", "myeloma", "cells.", "<tag3>"], "wordsA": ["In", "preclinical", "studies", "in", "mice", "that", "develop", "lupus-like", "disease,", "BAFF", "is", "known", "to", "be", "elevated,", "and", "treatment", "with", "blisibimod", "improves", "outcomes", "and", "survival."], "wordsB": ["BAFF", "is", "known", "to", "be", "elevated", "in", "patients", "with", "multiple", "myeloma,", "and", "the", "BCMA", "receptor", "(or", "B-cell", "Maturation", "Antigen", "receptor)", "which", "binds", "to", "BAFF", "and", "a", "proliferation-inducing", "ligand", "(or", "APRIL)", "and", "increases", "survival", "of", "plasma", "cells", "is", "also", "expressed", "on", "multiple", "myeloma", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p19_s4", "idA": "1316175_13_item1_p13_s4", "sentA": "Similarly, in IgAN, mice that over-express BAFF develop a fatal nephropathy associated with IgA.", "sentB": "Similarly, in IgA nephropathy, mice that over-express BAFF develop a fatal nephropathy associated with elevated Immunoglobulin A, or IgA.", "type": 2, "words": ["<tag1>", "Similarly,", "in", "IgAN,", "mice", "that", "over-express", "BAFF", "develop", "a", "fatal", "nephropathy", "associated", "with", "IgA.", "<tag2>", "Similarly,", "in", "IgA", "nephropathy,", "mice", "that", "over-express", "BAFF", "develop", "a", "fatal", "nephropathy", "associated", "with", "elevated", "Immunoglobulin", "A,", "or", "IgA.", "<tag3>"], "wordsA": ["Similarly,", "in", "IgAN,", "mice", "that", "over-express", "BAFF", "develop", "a", "fatal", "nephropathy", "associated", "with", "IgA."], "wordsB": ["Similarly,", "in", "IgA", "nephropathy,", "mice", "that", "over-express", "BAFF", "develop", "a", "fatal", "nephropathy", "associated", "with", "elevated", "Immunoglobulin", "A,", "or", "IgA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p68_s1", "idA": "1316175_13_item1_p145_s0", "sentA": "Pediatric exclusivity is another type of exclusivity in the United States.", "sentB": "Approximately 100,000 patients are believed to have multiple myeloma in the United States.", "type": 2, "words": ["<tag1>", "Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States.", "<tag2>", "Approximately", "100,000", "patients", "are", "believed", "to", "have", "multiple", "myeloma", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States."], "wordsB": ["Approximately", "100,000", "patients", "are", "believed", "to", "have", "multiple", "myeloma", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p74_s4", "idA": "1316175_13_item1_p145_s0", "sentA": "Pediatric exclusivity is another type of exclusivity in the United States.", "sentB": "The Alliance for Lupus Research reports up to 1.5 million people have lupus in the United States.", "type": 2, "words": ["<tag1>", "Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States.", "<tag2>", "The", "Alliance", "for", "Lupus", "Research", "reports", "up", "to", "1.5", "million", "people", "have", "lupus", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States."], "wordsB": ["The", "Alliance", "for", "Lupus", "Research", "reports", "up", "to", "1.5", "million", "people", "have", "lupus", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p74_s5", "idA": "1316175_13_item1_p145_s0", "sentA": "Pediatric exclusivity is another type of exclusivity in the United States.", "sentB": "It is estimated that approximately 10% of people with lupus are treated in the United States.", "type": 2, "words": ["<tag1>", "Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States.", "<tag2>", "It", "is", "estimated", "that", "approximately", "10%", "of", "people", "with", "lupus", "are", "treated", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States."], "wordsB": ["It", "is", "estimated", "that", "approximately", "10%", "of", "people", "with", "lupus", "are", "treated", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p3_s0", "idA": "1316175_13_item1_p145_s3", "sentA": "The current pediatric exclusivity provision was reauthorized in September 2007.", "sentB": "We were incorporated as a Delaware corporation in September 2004.", "type": 2, "words": ["<tag1>", "The", "current", "pediatric", "exclusivity", "provision", "was", "reauthorized", "in", "September", "2007.", "<tag2>", "We", "were", "incorporated", "as", "a", "Delaware", "corporation", "in", "September", "2004.", "<tag3>"], "wordsA": ["The", "current", "pediatric", "exclusivity", "provision", "was", "reauthorized", "in", "September", "2007."], "wordsB": ["We", "were", "incorporated", "as", "a", "Delaware", "corporation", "in", "September", "2004."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p21_s0", "idA": "1316175_13_item1_p14_s2", "sentA": "IgAN is the most common form of primary glomerulonephritis throughout the world, although the U.S. prevalence is estimated at approximately 130,000 patients.", "sentB": "IgA nephropathy is the most common form of primary glomerulonephritis throughout the world.", "type": 2, "words": ["<tag1>", "IgAN", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "throughout", "the", "world,", "although", "the", "U.S.", "prevalence", "is", "estimated", "at", "approximately", "130,000", "patients.", "<tag2>", "IgA", "nephropathy", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "throughout", "the", "world.", "<tag3>"], "wordsA": ["IgAN", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "throughout", "the", "world,", "although", "the", "U.S.", "prevalence", "is", "estimated", "at", "approximately", "130,000", "patients."], "wordsB": ["IgA", "nephropathy", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "throughout", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p21_s1", "idA": "1316175_13_item1_p14_s3", "sentA": "The prevalence of IgAN varies throughout the world, with the highest prevalence in Asia (Singapore, Japan, and Hong Kong), Australia, Finland, and southern Europe (20 to 40% of all glomerulnephritis).", "sentB": "The prevalence of IgA nephropathy varies throughout the world, with the highest prevalence in Asia (Singapore, Japan and China), Australia, Finland and southern Europe (20 to 40% of all glomerulonephritis).", "type": 2, "words": ["<tag1>", "The", "prevalence", "of", "IgAN", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan,", "and", "Hong", "Kong),", "Australia,", "Finland,", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulnephritis).", "<tag2>", "The", "prevalence", "of", "IgA", "nephropathy", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan", "and", "China),", "Australia,", "Finland", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulonephritis).", "<tag3>"], "wordsA": ["The", "prevalence", "of", "IgAN", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan,", "and", "Hong", "Kong),", "Australia,", "Finland,", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulnephritis)."], "wordsB": ["The", "prevalence", "of", "IgA", "nephropathy", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan", "and", "China),", "Australia,", "Finland", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulonephritis)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p169_s0", "idA": "1316175_13_item1_p154_s0", "sentA": "The Food and Drug Administration Safety and Innovation Act (FDASIA) includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy.", "sentB": "The FDASIA includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy.", "type": 2, "words": ["<tag1>", "The", "Food", "and", "Drug", "Administration", "Safety", "and", "Innovation", "Act", "(FDASIA)", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag2>", "The", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag3>"], "wordsA": ["The", "Food", "and", "Drug", "Administration", "Safety", "and", "Innovation", "Act", "(FDASIA)", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "wordsB": ["The", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p170_s0", "idA": "1316175_13_item1_p155_s0", "sentA": "The goal of this program is to expedite the development and review of a drug that is intended, alone or in combination with 1 or more other drugs, to treat a serious or life-threatening disease or condition if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on 1 or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.", "sentB": "The goal of this program is to expedite the development and review of a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.", "type": 2, "words": ["<tag1>", "The", "goal", "of", "this", "program", "is", "to", "expedite", "the", "development", "and", "review", "of", "a", "drug", "that", "is", "intended,", "alone", "or", "in", "combination", "with", "1", "or", "more", "other", "drugs,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition", "if", "preliminary", "clinical", "evidence", "indicates", "that", "the", "drug", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "1", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development.", "<tag2>", "The", "goal", "of", "this", "program", "is", "to", "expedite", "the", "development", "and", "review", "of", "a", "drug", "that", "is", "intended,", "alone", "or", "in", "combination", "with", "one", "or", "more", "other", "drugs,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition", "if", "preliminary", "clinical", "evidence", "indicates", "that", "the", "drug", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "one", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development.", "<tag3>"], "wordsA": ["The", "goal", "of", "this", "program", "is", "to", "expedite", "the", "development", "and", "review", "of", "a", "drug", "that", "is", "intended,", "alone", "or", "in", "combination", "with", "1", "or", "more", "other", "drugs,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition", "if", "preliminary", "clinical", "evidence", "indicates", "that", "the", "drug", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "1", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development."], "wordsB": ["The", "goal", "of", "this", "program", "is", "to", "expedite", "the", "development", "and", "review", "of", "a", "drug", "that", "is", "intended,", "alone", "or", "in", "combination", "with", "one", "or", "more", "other", "drugs,", "to", "treat", "a", "serious", "or", "life-threatening", "disease", "or", "condition", "if", "preliminary", "clinical", "evidence", "indicates", "that", "the", "drug", "may", "demonstrate", "substantial", "improvement", "over", "existing", "therapies", "on", "one", "or", "more", "clinically", "significant", "endpoints,", "such", "as", "substantial", "treatment", "effects", "observed", "early", "in", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p89_s3", "idA": "1316175_13_item1_p15_s0", "sentA": "In April of 2012 we completed a Phase 2b clinical study, called PEARL-SC, with blisibimod for the treatment of patients with seropositive markers of lupus and active disease defined as SELENA-SLEDAI score of greater than 6.", "sentB": "The second Phase 3 study, CHABLIS SC-2, includes modifications to enrich for the enrollment of patients with lupus and nephritis.", "type": 2, "words": ["<tag1>", "In", "April", "of", "2012", "we", "completed", "a", "Phase", "2b", "clinical", "study,", "called", "PEARL-SC,", "with", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6.", "<tag2>", "The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis.", "<tag3>"], "wordsA": ["In", "April", "of", "2012", "we", "completed", "a", "Phase", "2b", "clinical", "study,", "called", "PEARL-SC,", "with", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6."], "wordsB": ["The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s2", "idA": "1316175_13_item1_p16_s1", "sentA": "While the pre-specified primary efficacy endpoint in the PEARL-SC clinical study was not met due to an apparent lack of clinical efficacy in the two lowest dose groups, additional prospective data from the PEARL-SC study suggest consistent treatment benefits in the 200mg weekly dose group when utilizing higher thresholds of disease improvement, as measured by larger point reductions in SELENA-SLEDAI scoring index.", "sentB": "The primary endpoint of this study was not met due to the lack of efficacy in the two lowest dose groups.", "type": 2, "words": ["<tag1>", "While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "an", "apparent", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lowest", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "SELENA-SLEDAI", "scoring", "index.", "<tag2>", "The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups.", "<tag3>"], "wordsA": ["While", "the", "pre-specified", "primary", "efficacy", "endpoint", "in", "the", "PEARL-SC", "clinical", "study", "was", "not", "met", "due", "to", "an", "apparent", "lack", "of", "clinical", "efficacy", "in", "the", "two", "lowest", "dose", "groups,", "additional", "prospective", "data", "from", "the", "PEARL-SC", "study", "suggest", "consistent", "treatment", "benefits", "in", "the", "200mg", "weekly", "dose", "group", "when", "utilizing", "higher", "thresholds", "of", "disease", "improvement,", "as", "measured", "by", "larger", "point", "reductions", "in", "SELENA-SLEDAI", "scoring", "index."], "wordsB": ["The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p194_s0", "idA": "1316175_13_item1_p179_s0", "sentA": "As of December 31, 2012, we had 23 employees.", "sentB": "As of December 31, 2013, we had 25 employees.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2012,", "we", "had", "23", "employees.", "<tag2>", "As", "of", "December", "31,", "2013,", "we", "had", "25", "employees.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2012,", "we", "had", "23", "employees."], "wordsB": ["As", "of", "December", "31,", "2013,", "we", "had", "25", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p130_s2", "idA": "1316175_13_item1_p180_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "We do not have in place long term supply agreements with respect to all of the components of any of our pharmaceutical systems, however, and are subject to the risk that we may not be able to procure all required components in adequate quantities with acceptable quality, within acceptable time frames or at reasonable cost.", "type": 2, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "We", "do", "not", "have", "in", "place", "long", "term", "supply", "agreements", "with", "respect", "to", "all", "of", "the", "components", "of", "any", "of", "our", "pharmaceutical", "systems,", "however,", "and", "are", "subject", "to", "the", "risk", "that", "we", "may", "not", "be", "able", "to", "procure", "all", "required", "components", "in", "adequate", "quantities", "with", "acceptable", "quality,", "within", "acceptable", "time", "frames", "or", "at", "reasonable", "cost.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["We", "do", "not", "have", "in", "place", "long", "term", "supply", "agreements", "with", "respect", "to", "all", "of", "the", "components", "of", "any", "of", "our", "pharmaceutical", "systems,", "however,", "and", "are", "subject", "to", "the", "risk", "that", "we", "may", "not", "be", "able", "to", "procure", "all", "required", "components", "in", "adequate", "quantities", "with", "acceptable", "quality,", "within", "acceptable", "time", "frames", "or", "at", "reasonable", "cost."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p131_s1", "idA": "1316175_13_item1_p180_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials.", "type": 2, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "Accordingly,", "we", "are", "subject", "to", "federal,", "state", "and", "local", "laws", "governing", "the", "use,", "handling", "and", "disposal", "of", "these", "materials.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["Accordingly,", "we", "are", "subject", "to", "federal,", "state", "and", "local", "laws", "governing", "the", "use,", "handling", "and", "disposal", "of", "these", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p196_s1", "idA": "1316175_13_item1_p180_s1", "sentA": "Therefore, we file periodic reports, proxy statements and other information with the SEC, which may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, NE, Washington, D.C. 20549 or by calling the SEC at 1-800-SEC-0330.", "sentB": "Therefore, we file periodic reports, proxy statements and other information with the Securities and Exchange Commission (SEC), which may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, NE, Washington, D.C. 20549 or by calling the SEC at 1-800-SEC-0330.", "type": 2, "words": ["<tag1>", "Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "SEC,", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330.", "<tag2>", "Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "Securities", "and", "Exchange", "Commission", "(SEC),", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330.", "<tag3>"], "wordsA": ["Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "SEC,", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330."], "wordsB": ["Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "Securities", "and", "Exchange", "Commission", "(SEC),", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p29_s0", "idA": "1316175_13_item1_p18_s0", "sentA": "Using a higher treatment threshold of an eight point reduction in the SELENA-SLEDAI, or an SRI-8 endpoint, in this enhanced subgroup population, the 200mg blisibimod treatment group demonstrated a 15.6% treatment difference compared to pooled placebo (41.7% versus 26.1%, p 0.05) and 31.1% treatment difference compare to treatment matched placebo (41.7% versus 10.6%, p 0.001) at 24 weeks.", "sentB": "Using a higher treatment threshold of an eight-point reduction in the SELENA-SLEDAI, or an SRI-8 endpoint, in this enhanced subgroup population, the 200mg blisibimod treatment group demonstrated a 15.6% treatment difference compared to pooled placebo (41.7% versus 26.1%, p 0.05) and 31.1% treatment difference compare to regimen-matched placebo (41.7% versus 10.6%, p 0.001) at 24 weeks.", "type": 2, "words": ["<tag1>", "Using", "a", "higher", "treatment", "threshold", "of", "an", "eight", "point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "treatment", "matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks.", "<tag2>", "Using", "a", "higher", "treatment", "threshold", "of", "an", "eight-point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "regimen-matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks.", "<tag3>"], "wordsA": ["Using", "a", "higher", "treatment", "threshold", "of", "an", "eight", "point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "treatment", "matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks."], "wordsB": ["Using", "a", "higher", "treatment", "threshold", "of", "an", "eight-point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "regimen-matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p29_s2", "idA": "1316175_13_item1_p18_s1", "sentA": "In this subgroup, which we plan to enroll in our Phase 3 CHABLIS-SC studies, separation of clinical response occurred as early as week eight and numerical differences were observed beyond week 24.", "sentB": "This severe subgroup is the population that we believe will benefit most from treatment with blisibimod, and is the population whom we are enrolling in our Phase 3 CHABLIS-SC studies.", "type": 2, "words": ["<tag1>", "In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24.", "<tag2>", "This", "severe", "subgroup", "is", "the", "population", "that", "we", "believe", "will", "benefit", "most", "from", "treatment", "with", "blisibimod,", "and", "is", "the", "population", "whom", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.", "<tag3>"], "wordsA": ["In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24."], "wordsB": ["This", "severe", "subgroup", "is", "the", "population", "that", "we", "believe", "will", "benefit", "most", "from", "treatment", "with", "blisibimod,", "and", "is", "the", "population", "whom", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p74_s7", "idA": "1316175_13_item1_p18_s1", "sentA": "In this subgroup, which we plan to enroll in our Phase 3 CHABLIS-SC studies, separation of clinical response occurred as early as week eight and numerical differences were observed beyond week 24.", "sentB": "Based on the results from our PERAL SC study, we believe patients in the moderate to severe disease categories, which approximate 30,000 to 40,000, are likely to benefit most from treatment with blisibimod and this is the population whom we are enrolling in our Phase 3 CHABLIS-SC studies..", "type": 2, "words": ["<tag1>", "In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24.", "<tag2>", "Based", "on", "the", "results", "from", "our", "PERAL", "SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "which", "approximate", "30,000", "to", "40,000,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "whom", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies..", "<tag3>"], "wordsA": ["In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24."], "wordsB": ["Based", "on", "the", "results", "from", "our", "PERAL", "SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "which", "approximate", "30,000", "to", "40,000,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "whom", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p37_s2", "idA": "1316175_13_item1_p19_s1", "sentA": "Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.", "sentB": "Blisibimod was safe and well-tolerated at all dose levels evaluated in this study, with no meaningful imbalances in serious adverse events or infections compared with placebo (see Table 2 in the next section).", "type": 2, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events.", "<tag2>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section).", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events."], "wordsB": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p39_s3", "idA": "1316175_13_item1_p19_s1", "sentA": "Blisibimod was safe and well-tolerated at all dose levels with no meaningful imbalances in serious adverse events.", "sentB": "Blisibimod was safe and well-tolerated at all dose levels through the PEARL-SC and OLE studies, with no associated increase in risk of severe infection (Table 2).", "type": 2, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events.", "<tag2>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "through", "the", "PEARL-SC", "and", "OLE", "studies,", "with", "no", "associated", "increase", "in", "risk", "of", "severe", "infection", "(Table", "2).", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events."], "wordsB": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "through", "the", "PEARL-SC", "and", "OLE", "studies,", "with", "no", "associated", "increase", "in", "risk", "of", "severe", "infection", "(Table", "2)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p1_s0", "idA": "1316175_13_item1_p1_s0", "sentA": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.", "sentB": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.", "type": 2, "words": ["<tag1>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "autoimmune", "diseases.", "<tag2>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation", "and", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "autoimmune", "diseases."], "wordsB": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation", "and", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p2_s0", "idA": "1316175_13_item1_p1_s1", "sentA": "We currently have one Phase 3 ready product candidate, blisibimod, which targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.", "sentB": "Our Phase 3 candidate, blisibimod, targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, (lupus), Immunoglobin A nephropathy (IgA nephropathy), lupus nephritis, vasculitis and others.", "type": 2, "words": ["<tag1>", "We", "currently", "have", "one", "Phase", "3", "ready", "product", "candidate,", "blisibimod,", "which", "targets", "elevated", "levels", "of", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE),", "or", "lupus,", "Immunoglobin", "A", "nephropathy,", "or", "IgAN,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others.", "<tag2>", "Our", "Phase", "3", "candidate,", "blisibimod,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "(lupus),", "Immunoglobin", "A", "nephropathy", "(IgA", "nephropathy),", "lupus", "nephritis,", "vasculitis", "and", "others.", "<tag3>"], "wordsA": ["We", "currently", "have", "one", "Phase", "3", "ready", "product", "candidate,", "blisibimod,", "which", "targets", "elevated", "levels", "of", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "associated", "with", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE),", "or", "lupus,", "Immunoglobin", "A", "nephropathy,", "or", "IgAN,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others."], "wordsB": ["Our", "Phase", "3", "candidate,", "blisibimod,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "(lupus),", "Immunoglobin", "A", "nephropathy", "(IgA", "nephropathy),", "lupus", "nephritis,", "vasculitis", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s3", "idA": "1316175_13_item1_p20_s1", "sentA": "Across all subjects enrolled in the PEARL-SC study, the percent of subjects achieving the SRI-5 at 24 weeks was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "sentB": "However, the primary endpoint SRI-5 responder rates were numerically higher in subjects receiving blisibimod 200mg weekly (QW) compared with pooled placebo, from Week 16 ( SRI 5 for blisibimod-placebo=8%, p= 0.14), through Week 24 ( SRI 5=8.2%, p=0.15), reaching statistical significance at Week 20 ( SRI 5=13.4%, p = 0.02, Figure 1).", "type": 2, "words": ["<tag1>", "Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag2>", "However,", "the", "primary", "endpoint", "SRI-5", "responder", "rates", "were", "numerically", "higher", "in", "subjects", "receiving", "blisibimod", "200mg", "weekly", "(QW)", "compared", "with", "pooled", "placebo,", "from", "Week", "16", "(", "SRI", "5", "for", "blisibimod-placebo=8%,", "p=", "0.14),", "through", "Week", "24", "(", "SRI", "5=8.2%,", "p=0.15),", "reaching", "statistical", "significance", "at", "Week", "20", "(", "SRI", "5=13.4%,", "p", "=", "0.02,", "Figure", "1).", "<tag3>"], "wordsA": ["Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "wordsB": ["However,", "the", "primary", "endpoint", "SRI-5", "responder", "rates", "were", "numerically", "higher", "in", "subjects", "receiving", "blisibimod", "200mg", "weekly", "(QW)", "compared", "with", "pooled", "placebo,", "from", "Week", "16", "(", "SRI", "5", "for", "blisibimod-placebo=8%,", "p=", "0.14),", "through", "Week", "24", "(", "SRI", "5=8.2%,", "p=0.15),", "reaching", "statistical", "significance", "at", "Week", "20", "(", "SRI", "5=13.4%,", "p", "=", "0.02,", "Figure", "1)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s4", "idA": "1316175_13_item1_p20_s1", "sentA": "Across all subjects enrolled in the PEARL-SC study, the percent of subjects achieving the SRI-5 at 24 weeks was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "sentB": "Treatment benefit was greater still when compared with the regimen-matched (QW) placebo.", "type": 2, "words": ["<tag1>", "Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag2>", "Treatment", "benefit", "was", "greater", "still", "when", "compared", "with", "the", "regimen-matched", "(QW)", "placebo.", "<tag3>"], "wordsA": ["Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "wordsB": ["Treatment", "benefit", "was", "greater", "still", "when", "compared", "with", "the", "regimen-matched", "(QW)", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p31_s0", "idA": "1316175_13_item1_p20_s3", "sentA": "Graphs show data for blisibimod (200mg once-weekly) and treatment matched or pooled placebo administered subcutaneously for 24 weeks.", "sentB": "Graphs show data for blisibimod (200mg QW) and treatment matched or pooled placebo administered subcutaneously for 24 weeks.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "treatment", "matched", "or", "pooled", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(200mg", "QW)", "and", "treatment", "matched", "or", "pooled", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "treatment", "matched", "or", "pooled", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(200mg", "QW)", "and", "treatment", "matched", "or", "pooled", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p30_s0", "idA": "1316175_13_item1_p21_s0", "sentA": "An SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, AND no new BILAG A or 2B organ domain scores, AND no worsening ( 0.3 increase) in Physician s Global Assessment.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, Washington DC, 2012 in Figure 1, an SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Washington", "DC,", "2012", "in", "Figure", "1,", "an", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Washington", "DC,", "2012", "in", "Figure", "1,", "an", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p32_s0", "idA": "1316175_13_item1_p21_s0", "sentA": "An SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, AND no new BILAG A or 2B organ domain scores, AND no worsening ( 0.3 increase) in Physician s Global Assessment.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, Washington DC, 2012 in Figure 2, a n SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Washington", "DC,", "2012", "in", "Figure", "2,", "a", "n", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["An", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "AND", "no", "new", "BILAG", "A", "or", "2B", "organ", "domain", "scores,", "AND", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Washington", "DC,", "2012", "in", "Figure", "2,", "a", "n", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s6", "idA": "1316175_13_item1_p21_s1", "sentA": "In a subgroup analysis of patients with severe lupus disease (SELENA SLEDAI 10 and receiving steroid at baseline, n=278), the percent of subjects achieving the SRI-5 was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "sentB": "Blisibimod was also effective in a subgroup of patients with severe lupus with baseline SELENA-SLEDAI 10 and receiving corticosteroids at any dose (n=278) utilizing more stringent response thresholds ( SRI-5=13.8%, p=0.18; SRI-7=28.9%, p=0.002; SRI-8=31.1%, p 0.001, Figure 2 and Table 1).", "type": 2, "words": ["<tag1>", "In", "a", "subgroup", "analysis", "of", "patients", "with", "severe", "lupus", "disease", "(SELENA", "SLEDAI", "10", "and", "receiving", "steroid", "at", "baseline,", "n=278),", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag2>", "Blisibimod", "was", "also", "effective", "in", "a", "subgroup", "of", "patients", "with", "severe", "lupus", "with", "baseline", "SELENA-SLEDAI", "10", "and", "receiving", "corticosteroids", "at", "any", "dose", "(n=278)", "utilizing", "more", "stringent", "response", "thresholds", "(", "SRI-5=13.8%,", "p=0.18;", "SRI-7=28.9%,", "p=0.002;", "SRI-8=31.1%,", "p", "0.001,", "Figure", "2", "and", "Table", "1).", "<tag3>"], "wordsA": ["In", "a", "subgroup", "analysis", "of", "patients", "with", "severe", "lupus", "disease", "(SELENA", "SLEDAI", "10", "and", "receiving", "steroid", "at", "baseline,", "n=278),", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "wordsB": ["Blisibimod", "was", "also", "effective", "in", "a", "subgroup", "of", "patients", "with", "severe", "lupus", "with", "baseline", "SELENA-SLEDAI", "10", "and", "receiving", "corticosteroids", "at", "any", "dose", "(n=278)", "utilizing", "more", "stringent", "response", "thresholds", "(", "SRI-5=13.8%,", "p=0.18;", "SRI-7=28.9%,", "p=0.002;", "SRI-8=31.1%,", "p", "0.001,", "Figure", "2", "and", "Table", "1)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p32_s3", "idA": "1316175_13_item1_p21_s3", "sentA": "Graph shows data for blisibimod (200mg once-weekly) and regimen matched placebo administered subcutaneously for 24 weeks .", "sentB": "Graph shows data for blisibimod (200mg QW) and regimen matched placebo administered subcutaneously for 24 weeks.", "type": 2, "words": ["<tag1>", "Graph", "shows", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks", ".", "<tag2>", "Graph", "shows", "data", "for", "blisibimod", "(200mg", "QW)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag3>"], "wordsA": ["Graph", "shows", "data", "for", "blisibimod", "(200mg", "once-weekly)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "."], "wordsB": ["Graph", "shows", "data", "for", "blisibimod", "(200mg", "QW)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p34_s0", "idA": "1316175_13_item1_p23_s0", "sentA": "*SRI is defined as patients who respond to treatment and achieve a reduction in SELENA-SLEDAI equal to or greater than the number indicated, no new BILAG A or two B organ domain scores, and no increase in Physician's Global Assessment (PGA) of greater than 0.3 on a three point scale.", "sentB": "SLE Responder Index (SRI) is defined as patients who respond to treatment and achieve a reduction in SELENA-SLEDAI equal to or greater than the number indicated, no new BILAG 1A or 2B organ domain scores, and no increase in Physician's Global Assessment (PGA) of greater than 0.3 on a three point scale.", "type": 2, "words": ["<tag1>", "*SRI", "is", "defined", "as", "patients", "who", "respond", "to", "treatment", "and", "achieve", "a", "reduction", "in", "SELENA-SLEDAI", "equal", "to", "or", "greater", "than", "the", "number", "indicated,", "no", "new", "BILAG", "A", "or", "two", "B", "organ", "domain", "scores,", "and", "no", "increase", "in", "Physician's", "Global", "Assessment", "(PGA)", "of", "greater", "than", "0.3", "on", "a", "three", "point", "scale.", "<tag2>", "SLE", "Responder", "Index", "(SRI)", "is", "defined", "as", "patients", "who", "respond", "to", "treatment", "and", "achieve", "a", "reduction", "in", "SELENA-SLEDAI", "equal", "to", "or", "greater", "than", "the", "number", "indicated,", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "increase", "in", "Physician's", "Global", "Assessment", "(PGA)", "of", "greater", "than", "0.3", "on", "a", "three", "point", "scale.", "<tag3>"], "wordsA": ["*SRI", "is", "defined", "as", "patients", "who", "respond", "to", "treatment", "and", "achieve", "a", "reduction", "in", "SELENA-SLEDAI", "equal", "to", "or", "greater", "than", "the", "number", "indicated,", "no", "new", "BILAG", "A", "or", "two", "B", "organ", "domain", "scores,", "and", "no", "increase", "in", "Physician's", "Global", "Assessment", "(PGA)", "of", "greater", "than", "0.3", "on", "a", "three", "point", "scale."], "wordsB": ["SLE", "Responder", "Index", "(SRI)", "is", "defined", "as", "patients", "who", "respond", "to", "treatment", "and", "achieve", "a", "reduction", "in", "SELENA-SLEDAI", "equal", "to", "or", "greater", "than", "the", "number", "indicated,", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "increase", "in", "Physician's", "Global", "Assessment", "(PGA)", "of", "greater", "than", "0.3", "on", "a", "three", "point", "scale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p22_s0", "idA": "1316175_13_item1_p24_s0", "sentA": "To date, three (3) randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two (2) Phase 1 dose-ranging studies in which a total of 104 patients were randomized, and a Phase 2b dose-ranging clinical outcomes study in which 547 subjects were enrolled.", "sentB": "To date, four randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC trial.", "type": 2, "words": ["<tag1>", "To", "date,", "three", "(3)", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "(2)", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "randomized,", "and", "a", "Phase", "2b", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled.", "<tag2>", "To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "trial.", "<tag3>"], "wordsA": ["To", "date,", "three", "(3)", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "(2)", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "randomized,", "and", "a", "Phase", "2b", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled."], "wordsB": ["To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p22_s1", "idA": "1316175_13_item1_p24_s1", "sentA": "In all three (3) studies, statistically significant reductions in total B-cells were observed in patients treated with blisibimod versus those treated with placebo due to its mechanism of BAFF inhibition.", "sentB": "As expected for a BAFF inhibitor, statistically significant reductions in total B-cells were observed in patients treated with blisibimod compared with placebo in all three of the placebo-controlled studies.", "type": 2, "words": ["<tag1>", "In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag2>", "As", "expected", "for", "a", "BAFF", "inhibitor,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "in", "all", "three", "of", "the", "placebo-controlled", "studies.", "<tag3>"], "wordsA": ["In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "wordsB": ["As", "expected", "for", "a", "BAFF", "inhibitor,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "in", "all", "three", "of", "the", "placebo-controlled", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p37_s0", "idA": "1316175_13_item1_p24_s1", "sentA": "In all three (3) studies, statistically significant reductions in total B-cells were observed in patients treated with blisibimod versus those treated with placebo due to its mechanism of BAFF inhibition.", "sentB": "In this study, statistically significant reductions in total B-cells were observed in patients treated with blisibimod compared with placebo due to its mechanism of BAFF inhibition.", "type": 2, "words": ["<tag1>", "In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag2>", "In", "this", "study,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag3>"], "wordsA": ["In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "wordsB": ["In", "this", "study,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p43_s0", "idA": "1316175_13_item1_p24_s1", "sentA": "In all three (3) studies, statistically significant reductions in total B-cells were observed in patients treated with blisibimod versus those treated with placebo due to its mechanism of BAFF inhibition.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 6, s ignificant reductions in immunoglobulins IgG and IgM were observed with blisibimod compared with placebo during the placebo-controlled PEARL-SC study.", "type": 2, "words": ["<tag1>", "In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "6,", "s", "ignificant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["In", "all", "three", "(3)", "studies,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "versus", "those", "treated", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "6,", "s", "ignificant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p37_s1", "idA": "1316175_13_item1_p24_s2", "sentA": "In addition, treatment with blisibimod was associated with significant improvements in lupus disease activity and lupus biomarkers, including anti-double-stranded DNA antibodies, urine protein content, or proteinuria, and complement components C3 and C4.", "sentB": "In addition, treatment with blisibimod was associated with significant improvements in lupus disease activity and lupus biomarkers, including anti-dsDNA antibodies, proteinuria, immunoglobulins including IgG and IgM, and complement components C3 and C4.", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-double-stranded", "DNA", "antibodies,", "urine", "protein", "content,", "or", "proteinuria,", "and", "complement", "components", "C3", "and", "C4.", "<tag2>", "In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-dsDNA", "antibodies,", "proteinuria,", "immunoglobulins", "including", "IgG", "and", "IgM,", "and", "complement", "components", "C3", "and", "C4.", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-double-stranded", "DNA", "antibodies,", "urine", "protein", "content,", "or", "proteinuria,", "and", "complement", "components", "C3", "and", "C4."], "wordsB": ["In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-dsDNA", "antibodies,", "proteinuria,", "immunoglobulins", "including", "IgG", "and", "IgM,", "and", "complement", "components", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p39_s2", "idA": "1316175_13_item1_p24_s2", "sentA": "In addition, treatment with blisibimod was associated with significant improvements in lupus disease activity and lupus biomarkers, including anti-double-stranded DNA antibodies, urine protein content, or proteinuria, and complement components C3 and C4.", "sentB": "In addition, the effects observed with blisibimod on peripheral B-cells, anti-dsDNA autoantibodies, and complement C3 and C4 and immunoglobulins IgG and IgM observed over 24 weeks of dosing in the PEARL-SC study were found to be durable over 52 weeks of therapy through the OLE study (Figures 5 and 6).", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-double-stranded", "DNA", "antibodies,", "urine", "protein", "content,", "or", "proteinuria,", "and", "complement", "components", "C3", "and", "C4.", "<tag2>", "In", "addition,", "the", "effects", "observed", "with", "blisibimod", "on", "peripheral", "B-cells,", "anti-dsDNA", "autoantibodies,", "and", "complement", "C3", "and", "C4", "and", "immunoglobulins", "IgG", "and", "IgM", "observed", "over", "24", "weeks", "of", "dosing", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "over", "52", "weeks", "of", "therapy", "through", "the", "OLE", "study", "(Figures", "5", "and", "6).", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "with", "blisibimod", "was", "associated", "with", "significant", "improvements", "in", "lupus", "disease", "activity", "and", "lupus", "biomarkers,", "including", "anti-double-stranded", "DNA", "antibodies,", "urine", "protein", "content,", "or", "proteinuria,", "and", "complement", "components", "C3", "and", "C4."], "wordsB": ["In", "addition,", "the", "effects", "observed", "with", "blisibimod", "on", "peripheral", "B-cells,", "anti-dsDNA", "autoantibodies,", "and", "complement", "C3", "and", "C4", "and", "immunoglobulins", "IgG", "and", "IgM", "observed", "over", "24", "weeks", "of", "dosing", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "over", "52", "weeks", "of", "therapy", "through", "the", "OLE", "study", "(Figures", "5", "and", "6)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p26_s1", "idA": "1316175_13_item1_p25_s0", "sentA": "In subjects with baseline urinary protein excretion equivalent to 1-6 g/24hrs, treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "sentB": "Compared with baseline, decreases in proteinuria were observed with blisibimod from Week 12 through Week 52 in the subgroup of subjects with proteinuria equivalent 1 g/24hr at enrollment (Figure 3).", "type": 2, "words": ["<tag1>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag2>", "Compared", "with", "baseline,", "decreases", "in", "proteinuria", "were", "observed", "with", "blisibimod", "from", "Week", "12", "through", "Week", "52", "in", "the", "subgroup", "of", "subjects", "with", "proteinuria", "equivalent", "1", "g/24hr", "at", "enrollment", "(Figure", "3).", "<tag3>"], "wordsA": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "wordsB": ["Compared", "with", "baseline,", "decreases", "in", "proteinuria", "were", "observed", "with", "blisibimod", "from", "Week", "12", "through", "Week", "52", "in", "the", "subgroup", "of", "subjects", "with", "proteinuria", "equivalent", "1", "g/24hr", "at", "enrollment", "(Figure", "3)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p26_s2", "idA": "1316175_13_item1_p25_s0", "sentA": "In subjects with baseline urinary protein excretion equivalent to 1-6 g/24hrs, treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "sentB": "Similarly, decreases in proteinuria were observed in subjects with proteinuria equivalent 0.5 g/24hr through Week 44.", "type": 2, "words": ["<tag1>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag2>", "Similarly,", "decreases", "in", "proteinuria", "were", "observed", "in", "subjects", "with", "proteinuria", "equivalent", "0.5", "g/24hr", "through", "Week", "44.", "<tag3>"], "wordsA": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "wordsB": ["Similarly,", "decreases", "in", "proteinuria", "were", "observed", "in", "subjects", "with", "proteinuria", "equivalent", "0.5", "g/24hr", "through", "Week", "44."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p26_s3", "idA": "1316175_13_item1_p25_s0", "sentA": "In subjects with baseline urinary protein excretion equivalent to 1-6 g/24hrs, treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "sentB": "Significantly greater reductions in proteinuria were also observed in a subgroup of subjects with active inflammation (ie low C3) and high anti-double-stranded DNA (anti-dsDNA) (Figure 3).", "type": 2, "words": ["<tag1>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag2>", "Significantly", "greater", "reductions", "in", "proteinuria", "were", "also", "observed", "in", "a", "subgroup", "of", "subjects", "with", "active", "inflammation", "(ie", "low", "C3)", "and", "high", "anti-double-stranded", "DNA", "(anti-dsDNA)", "(Figure", "3).", "<tag3>"], "wordsA": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "wordsB": ["Significantly", "greater", "reductions", "in", "proteinuria", "were", "also", "observed", "in", "a", "subgroup", "of", "subjects", "with", "active", "inflammation", "(ie", "low", "C3)", "and", "high", "anti-double-stranded", "DNA", "(anti-dsDNA)", "(Figure", "3)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p29_s3", "idA": "1316175_13_item1_p25_s0", "sentA": "In subjects with baseline urinary protein excretion equivalent to 1-6 g/24hrs, treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "sentB": "Significant and early decreases in proteinuria were also observed with blisibimod as early as Week 8 in subjects with baseline proteinuria equivalent 1g/24 hrs.", "type": 2, "words": ["<tag1>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag2>", "Significant", "and", "early", "decreases", "in", "proteinuria", "were", "also", "observed", "with", "blisibimod", "as", "early", "as", "Week", "8", "in", "subjects", "with", "baseline", "proteinuria", "equivalent", "1g/24", "hrs.", "<tag3>"], "wordsA": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6", "g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "wordsB": ["Significant", "and", "early", "decreases", "in", "proteinuria", "were", "also", "observed", "with", "blisibimod", "as", "early", "as", "Week", "8", "in", "subjects", "with", "baseline", "proteinuria", "equivalent", "1g/24", "hrs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p36_s2", "idA": "1316175_13_item1_p26_s0", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks.", "sentB": "Data are plotted for all pooled blisibimod dose levels as well as 200mg once-weekly and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "Data", "are", "plotted", "for", "all", "pooled", "blisibimod", "dose", "levels", "as", "well", "as", "200mg", "once-weekly", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["Data", "are", "plotted", "for", "all", "pooled", "blisibimod", "dose", "levels", "as", "well", "as", "200mg", "once-weekly", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p41_s1", "idA": "1316175_13_item1_p26_s0", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks.", "sentB": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p42_s1", "idA": "1316175_13_item1_p26_s0", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks.", "sentB": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p43_s3", "idA": "1316175_13_item1_p26_s0", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks.", "sentB": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p42_s0", "idA": "1316175_13_item1_p27_s0", "sentA": "With its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 5, w ith its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B-cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "type": 2, "words": ["<tag1>", "With", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B", "cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "5,", "w", "ith", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag3>"], "wordsA": ["With", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B", "cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "5,", "w", "ith", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p36_s0", "idA": "1316175_13_item1_p27_s1", "sentA": "Graphs show data for blisibimod (average of all dose levels) and placebo administered subcutaneously for 24 weeks.", "sentB": "Graphs show data from subgroups of patients defined by baseline proteinuria for blisibimod.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(average", "of", "all", "dose", "levels)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "Graphs", "show", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(average", "of", "all", "dose", "levels)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["Graphs", "show", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p46_s0", "idA": "1316175_13_item1_p28_s0", "sentA": "In addition, we believe blisibimod may offer a number of potential opportunities for differentiation versus the currently marketed BAFF antagonist, belimumab, as well as other novel B-cell directed therapies including:", "sentB": "We believe the CHABLIS development program for blisibimod may offer a number of potential opportunities for differentiation versus the currently marketed BAFF antagonist and other novel B-cell directed therapies, including:", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist,", "belimumab,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:", "<tag2>", "We", "believe", "the", "CHABLIS", "development", "program", "for", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist", "and", "other", "novel", "B-cell", "directed", "therapies,", "including:", "<tag3>"], "wordsA": ["In", "addition,", "we", "believe", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist,", "belimumab,", "as", "well", "as", "other", "novel", "B-cell", "directed", "therapies", "including:"], "wordsB": ["We", "believe", "the", "CHABLIS", "development", "program", "for", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist", "and", "other", "novel", "B-cell", "directed", "therapies,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p4_s0", "idA": "1316175_13_item1_p2_s0", "sentA": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells.", "sentB": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells.", "type": 2, "words": ["<tag1>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells.", "<tag2>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "multiple", "B-cell", "lineages", "as", "well", "as", "plasma", "cells.", "<tag3>"], "wordsA": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "B-cells."], "wordsB": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "multiple", "B-cell", "lineages", "as", "well", "as", "plasma", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p4_s1", "idA": "1316175_13_item1_p2_s1", "sentA": "B-cells are a vital part of the human immune system producing natural antibody responses to invading pathogens such as viruses.", "sentB": "B-cells and plasma cells are a vital part of the human immune system, producing natural antibody responses to invading pathogens such as viruses.", "type": 2, "words": ["<tag1>", "B-cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses.", "<tag2>", "B-cells", "and", "plasma", "cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system,", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses.", "<tag3>"], "wordsA": ["B-cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses."], "wordsB": ["B-cells", "and", "plasma", "cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system,", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p38_s0", "idA": "1316175_13_item1_p30_s0", "sentA": "As part of the PEARL-SC clinical study program, patients who completed the study were eligible to enroll in an open label extension study.", "sentB": "In order to evaluate longer-term safety of blisibimod, patients with lupus who completed the PEARL-SC study were able to participate in an OLE study in which they were treated with active drug (blisibimod).", "type": 2, "words": ["<tag1>", "As", "part", "of", "the", "PEARL-SC", "clinical", "study", "program,", "patients", "who", "completed", "the", "study", "were", "eligible", "to", "enroll", "in", "an", "open", "label", "extension", "study.", "<tag2>", "In", "order", "to", "evaluate", "longer-term", "safety", "of", "blisibimod,", "patients", "with", "lupus", "who", "completed", "the", "PEARL-SC", "study", "were", "able", "to", "participate", "in", "an", "OLE", "study", "in", "which", "they", "were", "treated", "with", "active", "drug", "(blisibimod).", "<tag3>"], "wordsA": ["As", "part", "of", "the", "PEARL-SC", "clinical", "study", "program,", "patients", "who", "completed", "the", "study", "were", "eligible", "to", "enroll", "in", "an", "open", "label", "extension", "study."], "wordsB": ["In", "order", "to", "evaluate", "longer-term", "safety", "of", "blisibimod,", "patients", "with", "lupus", "who", "completed", "the", "PEARL-SC", "study", "were", "able", "to", "participate", "in", "an", "OLE", "study", "in", "which", "they", "were", "treated", "with", "active", "drug", "(blisibimod)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p28_s0", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "In June of 2012 we completed dosing in the PEARL-SC study.", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p38_s1", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "The OLE study was opened in Q2 2012 and closed in Q2 2013 after subjects had completed a minimum of one year of continuous therapy with blisibimod.", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "The", "OLE", "study", "was", "opened", "in", "Q2", "2012", "and", "closed", "in", "Q2", "2013", "after", "subjects", "had", "completed", "a", "minimum", "of", "one", "year", "of", "continuous", "therapy", "with", "blisibimod.", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["The", "OLE", "study", "was", "opened", "in", "Q2", "2012", "and", "closed", "in", "Q2", "2013", "after", "subjects", "had", "completed", "a", "minimum", "of", "one", "year", "of", "continuous", "therapy", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p38_s3", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "In addition, a case report was published summarizing observations in a patient who was randomized to placebo in the PEARL-SC study then experienced a rapid improvement in serum cryoglobulins upon initiation of blisibimod therapy in the OLE study (Golima et al., Rheumatology , 2013).", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "In", "addition,", "a", "case", "report", "was", "published", "summarizing", "observations", "in", "a", "patient", "who", "was", "randomized", "to", "placebo", "in", "the", "PEARL-SC", "study", "then", "experienced", "a", "rapid", "improvement", "in", "serum", "cryoglobulins", "upon", "initiation", "of", "blisibimod", "therapy", "in", "the", "OLE", "study", "(Golima", "et", "al.,", "Rheumatology", ",", "2013).", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["In", "addition,", "a", "case", "report", "was", "published", "summarizing", "observations", "in", "a", "patient", "who", "was", "randomized", "to", "placebo", "in", "the", "PEARL-SC", "study", "then", "experienced", "a", "rapid", "improvement", "in", "serum", "cryoglobulins", "upon", "initiation", "of", "blisibimod", "therapy", "in", "the", "OLE", "study", "(Golima", "et", "al.,", "Rheumatology", ",", "2013)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p39_s0", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "The emerging data for the OLE study corroborate the effects of 24-week therapy with blisibimod observed in the PEARL-SC study.", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "The", "emerging", "data", "for", "the", "OLE", "study", "corroborate", "the", "effects", "of", "24-week", "therapy", "with", "blisibimod", "observed", "in", "the", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["The", "emerging", "data", "for", "the", "OLE", "study", "corroborate", "the", "effects", "of", "24-week", "therapy", "with", "blisibimod", "observed", "in", "the", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p41_s0", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013, in Figure 4, the significant improvements in proteinuria in patients with lupus randomized to blisibimod compared with placebo observed in the PEARL-SC study were found to be durable through their continuing exposure to blisibimod in the OLE study.", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study.", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p43_s1", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "These effects were found to be durable in subjects who continued to receive blisibimod through the OLE study.", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "These", "effects", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study.", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["These", "effects", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p48_s0", "idA": "1316175_13_item1_p30_s1", "sentA": "In the OLE study all patients, including those from the placebo arm of the PEARL-SC clinical study receive active therapy for a minimum of 12 months following their final dose in the PEARL-SC study.", "sentB": "A futility analysis of clinical study is planned to be conducted by an independent unblinded statistician in mid-2014 after a minimum of 100 subjects have completed 24 weeks of treatment to confirm the clinical and commercial assumptions of the design of this study.", "type": 2, "words": ["<tag1>", "In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study.", "<tag2>", "A", "futility", "analysis", "of", "clinical", "study", "is", "planned", "to", "be", "conducted", "by", "an", "independent", "unblinded", "statistician", "in", "mid-2014", "after", "a", "minimum", "of", "100", "subjects", "have", "completed", "24", "weeks", "of", "treatment", "to", "confirm", "the", "clinical", "and", "commercial", "assumptions", "of", "the", "design", "of", "this", "study.", "<tag3>"], "wordsA": ["In", "the", "OLE", "study", "all", "patients,", "including", "those", "from", "the", "placebo", "arm", "of", "the", "PEARL-SC", "clinical", "study", "receive", "active", "therapy", "for", "a", "minimum", "of", "12", "months", "following", "their", "final", "dose", "in", "the", "PEARL-SC", "study."], "wordsB": ["A", "futility", "analysis", "of", "clinical", "study", "is", "planned", "to", "be", "conducted", "by", "an", "independent", "unblinded", "statistician", "in", "mid-2014", "after", "a", "minimum", "of", "100", "subjects", "have", "completed", "24", "weeks", "of", "treatment", "to", "confirm", "the", "clinical", "and", "commercial", "assumptions", "of", "the", "design", "of", "this", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p50_s0", "idA": "1316175_13_item1_p30_s4", "sentA": "Data from this study will be presented during the second half of 2013.", "sentB": "We enrolled more than 100 patients prior to the end of 2013.", "type": 2, "words": ["<tag1>", "Data", "from", "this", "study", "will", "be", "presented", "during", "the", "second", "half", "of", "2013.", "<tag2>", "We", "enrolled", "more", "than", "100", "patients", "prior", "to", "the", "end", "of", "2013.", "<tag3>"], "wordsA": ["Data", "from", "this", "study", "will", "be", "presented", "during", "the", "second", "half", "of", "2013."], "wordsB": ["We", "enrolled", "more", "than", "100", "patients", "prior", "to", "the", "end", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p62_s1", "idA": "1316175_13_item1_p30_s4", "sentA": "Data from this study will be presented during the second half of 2013.", "sentB": "We initiated our BRIGHT-SC1 study in the second quarter of 2013.", "type": 2, "words": ["<tag1>", "Data", "from", "this", "study", "will", "be", "presented", "during", "the", "second", "half", "of", "2013.", "<tag2>", "We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag3>"], "wordsA": ["Data", "from", "this", "study", "will", "be", "presented", "during", "the", "second", "half", "of", "2013."], "wordsB": ["We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p45_s0", "idA": "1316175_13_item1_p32_s0", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are currently planned to be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard-of-care for treatment of their disease.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are multicenter, randomized, double-blind, placebo-controlled studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with seropositive, clinically active lupus (SELENA-SLEDAI 10) who continue to have active disease despite stable corticosteroid therapy for treatment of their disease.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "currently", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "seropositive,", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "continue", "to", "have", "active", "disease", "despite", "stable", "corticosteroid", "therapy", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "currently", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "seropositive,", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "continue", "to", "have", "active", "disease", "despite", "stable", "corticosteroid", "therapy", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p61_s0", "idA": "1316175_13_item1_p32_s0", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are currently planned to be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard-of-care for treatment of their disease.", "sentB": "The BRIGHT-SC1 study (Figure 10) is a Phase 2/3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "currently", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease.", "<tag2>", "The", "BRIGHT-SC1", "study", "(Figure", "10)", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "currently", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease."], "wordsB": ["The", "BRIGHT-SC1", "study", "(Figure", "10)", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p45_s1", "idA": "1316175_13_item1_p32_s1", "sentA": "Each study will randomize approximately 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "sentB": "Each study plans to randomize up to 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "type": 2, "words": ["<tag1>", "Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag2>", "Each", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag3>"], "wordsA": ["Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "wordsB": ["Each", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p50_s1", "idA": "1316175_13_item1_p32_s3", "sentA": "We plan to conduct periodic interim analyses during the course of the CHABLIS-SC1 study to ensure the accuracy of our estimates.", "sentB": "Continuing enrollment of the full 400 patients into the CHABLIS-SC1 trial is contingent on a positive outcome from this interim analysis.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "conduct", "periodic", "interim", "analyses", "during", "the", "course", "of", "the", "CHABLIS-SC1", "study", "to", "ensure", "the", "accuracy", "of", "our", "estimates.", "<tag2>", "Continuing", "enrollment", "of", "the", "full", "400", "patients", "into", "the", "CHABLIS-SC1", "trial", "is", "contingent", "on", "a", "positive", "outcome", "from", "this", "interim", "analysis.", "<tag3>"], "wordsA": ["We", "plan", "to", "conduct", "periodic", "interim", "analyses", "during", "the", "course", "of", "the", "CHABLIS-SC1", "study", "to", "ensure", "the", "accuracy", "of", "our", "estimates."], "wordsB": ["Continuing", "enrollment", "of", "the", "full", "400", "patients", "into", "the", "CHABLIS-SC1", "trial", "is", "contingent", "on", "a", "positive", "outcome", "from", "this", "interim", "analysis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p73_s1", "idA": "1316175_13_item1_p32_s5", "sentA": "Based on significant improvements in renal disease biomarkers such as proteinuria, C3 and C4 observed with blisibimod, in 2013 we plan to meet with the FDA to discuss and finalize the enrollment criteria of the CHABLIS-SC2 clinical study in an effort to include patients diagnosed with or without glomerulonephritis.", "sentB": "Additionally, we plan to seek advice on our clinical development plans in multiple myeloma with the Division of Hematology Products of the FDA in mid-2014.", "type": 2, "words": ["<tag1>", "Based", "on", "significant", "improvements", "in", "renal", "disease", "biomarkers", "such", "as", "proteinuria,", "C3", "and", "C4", "observed", "with", "blisibimod,", "in", "2013", "we", "plan", "to", "meet", "with", "the", "FDA", "to", "discuss", "and", "finalize", "the", "enrollment", "criteria", "of", "the", "CHABLIS-SC2", "clinical", "study", "in", "an", "effort", "to", "include", "patients", "diagnosed", "with", "or", "without", "glomerulonephritis.", "<tag2>", "Additionally,", "we", "plan", "to", "seek", "advice", "on", "our", "clinical", "development", "plans", "in", "multiple", "myeloma", "with", "the", "Division", "of", "Hematology", "Products", "of", "the", "FDA", "in", "mid-2014.", "<tag3>"], "wordsA": ["Based", "on", "significant", "improvements", "in", "renal", "disease", "biomarkers", "such", "as", "proteinuria,", "C3", "and", "C4", "observed", "with", "blisibimod,", "in", "2013", "we", "plan", "to", "meet", "with", "the", "FDA", "to", "discuss", "and", "finalize", "the", "enrollment", "criteria", "of", "the", "CHABLIS-SC2", "clinical", "study", "in", "an", "effort", "to", "include", "patients", "diagnosed", "with", "or", "without", "glomerulonephritis."], "wordsB": ["Additionally,", "we", "plan", "to", "seek", "advice", "on", "our", "clinical", "development", "plans", "in", "multiple", "myeloma", "with", "the", "Division", "of", "Hematology", "Products", "of", "the", "FDA", "in", "mid-2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p52_s0", "idA": "1316175_13_item1_p33_s0", "sentA": "In 2013 we will begin to study blisibimod in patients with B-cell mediated autoimmune diseases such as IgA nephropathy (Berger s disease).", "sentB": "We intend to study blisibimod in B-cell mediated autoimmune diseases such as IgA nephropathy (Berger s disease).", "type": 2, "words": ["<tag1>", "In", "2013", "we", "will", "begin", "to", "study", "blisibimod", "in", "patients", "with", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease).", "<tag2>", "We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease).", "<tag3>"], "wordsA": ["In", "2013", "we", "will", "begin", "to", "study", "blisibimod", "in", "patients", "with", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease)."], "wordsB": ["We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p67_s0", "idA": "1316175_13_item1_p33_s0", "sentA": "In 2013 we will begin to study blisibimod in patients with B-cell mediated autoimmune diseases such as IgA nephropathy (Berger s disease).", "sentB": "We intend to study blisibimod in B-cell mediated hematologic diseases such as multiple myeloma.", "type": 2, "words": ["<tag1>", "In", "2013", "we", "will", "begin", "to", "study", "blisibimod", "in", "patients", "with", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease).", "<tag2>", "We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "hematologic", "diseases", "such", "as", "multiple", "myeloma.", "<tag3>"], "wordsA": ["In", "2013", "we", "will", "begin", "to", "study", "blisibimod", "in", "patients", "with", "B-cell", "mediated", "autoimmune", "diseases", "such", "as", "IgA", "nephropathy", "(Berger", "s", "disease)."], "wordsB": ["We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "hematologic", "diseases", "such", "as", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p53_s1", "idA": "1316175_13_item1_p34_s1", "sentA": "In Asia, a similar prevalence to the U.S. would be estimated to affect over 500,000 people annually.", "sentB": "In Asia, a similar prevalence to the United States would be estimated to affect over 500,000 people annually.", "type": 2, "words": ["<tag1>", "In", "Asia,", "a", "similar", "prevalence", "to", "the", "U.S.", "would", "be", "estimated", "to", "affect", "over", "500,000", "people", "annually.", "<tag2>", "In", "Asia,", "a", "similar", "prevalence", "to", "the", "United", "States", "would", "be", "estimated", "to", "affect", "over", "500,000", "people", "annually.", "<tag3>"], "wordsA": ["In", "Asia,", "a", "similar", "prevalence", "to", "the", "U.S.", "would", "be", "estimated", "to", "affect", "over", "500,000", "people", "annually."], "wordsB": ["In", "Asia,", "a", "similar", "prevalence", "to", "the", "United", "States", "would", "be", "estimated", "to", "affect", "over", "500,000", "people", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p56_s0", "idA": "1316175_13_item1_p36_s1", "sentA": "IgA nephropathy may occur when excessive plasma B-cells express excessive amounts of abnormal IgA and this immunogenic protein is deposited in the kidneys.", "sentB": "IgA nephropathy may occur when plasma B-cells express excessive amounts of abnormal IgA and immune complexes containing this immunogenic protein are deposited in the kidneys.", "type": 2, "words": ["<tag1>", "IgA", "nephropathy", "may", "occur", "when", "excessive", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "this", "immunogenic", "protein", "is", "deposited", "in", "the", "kidneys.", "<tag2>", "IgA", "nephropathy", "may", "occur", "when", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "immune", "complexes", "containing", "this", "immunogenic", "protein", "are", "deposited", "in", "the", "kidneys.", "<tag3>"], "wordsA": ["IgA", "nephropathy", "may", "occur", "when", "excessive", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "this", "immunogenic", "protein", "is", "deposited", "in", "the", "kidneys."], "wordsB": ["IgA", "nephropathy", "may", "occur", "when", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "immune", "complexes", "containing", "this", "immunogenic", "protein", "are", "deposited", "in", "the", "kidneys."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p57_s0", "idA": "1316175_13_item1_p37_s0", "sentA": "According to the New England Journal of Medicine, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life, and a large number of cases eventually progress to renal failure.", "sentB": "According to a recent publication in the New England Journal of Medicine (Wyatt Julian, 2013), primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life, and a large number of cases eventually progress to renal failure.", "type": 2, "words": ["<tag1>", "According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life,", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag2>", "According", "to", "a", "recent", "publication", "in", "the", "New", "England", "Journal", "of", "Medicine", "(Wyatt", "Julian,", "2013),", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life,", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag3>"], "wordsA": ["According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life,", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "wordsB": ["According", "to", "a", "recent", "publication", "in", "the", "New", "England", "Journal", "of", "Medicine", "(Wyatt", "Julian,", "2013),", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life,", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p59_s1", "idA": "1316175_13_item1_p38_s1", "sentA": "In patients with IgAN, levels of BAFF are significantly higher than in healthy patients.", "sentB": "In patients with IgA nephropathy, levels of BAFF are significantly higher than in healthy patients.", "type": 2, "words": ["<tag1>", "In", "patients", "with", "IgAN,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients.", "<tag2>", "In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients.", "<tag3>"], "wordsA": ["In", "patients", "with", "IgAN,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients."], "wordsB": ["In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p60_s0", "idA": "1316175_13_item1_p38_s2", "sentA": "In IgAN, increased plasma B-cells express immunogenic IgA that forms immune complexes that deposit in renal tissue and lead to renal inflammation and damage that can progress to renal failure and end-stage renal disease.", "sentB": "In IgA nephropathy, increased plasma B-cells express immunogenic IgA that forms immune complexes that deposit in renal tissue and lead to renal inflammation and damage that can progress to renal failure and end-stage renal disease.", "type": 2, "words": ["<tag1>", "In", "IgAN,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease.", "<tag2>", "In", "IgA", "nephropathy,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease.", "<tag3>"], "wordsA": ["In", "IgAN,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease."], "wordsB": ["In", "IgA", "nephropathy,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p60_s1", "idA": "1316175_13_item1_p38_s3", "sentA": "Significant reductions in plasma B-cells were observed in previous clinical studies of SLE patients with another BAFF inhibitor antibody, belimumab.", "sentB": "Significant reductions in plasma B-cells were observed in previous clinical studies of patients with lupus with another BAFF inhibitor antibody, belimumab.", "type": 2, "words": ["<tag1>", "Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "SLE", "patients", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab.", "<tag2>", "Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "patients", "with", "lupus", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab.", "<tag3>"], "wordsA": ["Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "SLE", "patients", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab."], "wordsB": ["Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "patients", "with", "lupus", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p60_s3", "idA": "1316175_13_item1_p38_s5", "sentA": "We believe inhibition of BAFF may reduce proliferative B-cells and plasma B-cells, reduce serum levels of IgA and therefore reduce progressive renal damage in patients with IgAN.", "sentB": "We believe inhibition of BAFF may reduce proliferative B-cells and plasma B-cells, reduce serum levels of IgA and therefore reduce progressive renal damage in patients with IgA nephropathy.", "type": 2, "words": ["<tag1>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN.", "<tag2>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgAN."], "wordsB": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p50_s3", "idA": "1316175_13_item1_p39_s0", "sentA": "We plan to initiate patient enrollment in a Phase 2 proof-of-concept study for the treatment of IgA Nephropathy in 2013.", "sentB": "In addition to serving as a registration study for a potential lupus indication, we plan to include safety data from CHABLIS-SC1 in a potential IgA nephropathy marketing application for blisibimod.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013.", "<tag2>", "In", "addition", "to", "serving", "as", "a", "registration", "study", "for", "a", "potential", "lupus", "indication,", "we", "plan", "to", "include", "safety", "data", "from", "CHABLIS-SC1", "in", "a", "potential", "IgA", "nephropathy", "marketing", "application", "for", "blisibimod.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013."], "wordsB": ["In", "addition", "to", "serving", "as", "a", "registration", "study", "for", "a", "potential", "lupus", "indication,", "we", "plan", "to", "include", "safety", "data", "from", "CHABLIS-SC1", "in", "a", "potential", "IgA", "nephropathy", "marketing", "application", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p64_s3", "idA": "1316175_13_item1_p39_s0", "sentA": "We plan to initiate patient enrollment in a Phase 2 proof-of-concept study for the treatment of IgA Nephropathy in 2013.", "sentB": "Upon implementation of this new amendment it is our intention to use the BRIGHT-SC study as one of two studies necessary to support the marketing approval of blisibimod for the treatment of IgA nephropathy under the accelerated approval pathway (FDA Subpart E).", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013.", "<tag2>", "Upon", "implementation", "of", "this", "new", "amendment", "it", "is", "our", "intention", "to", "use", "the", "BRIGHT-SC", "study", "as", "one", "of", "two", "studies", "necessary", "to", "support", "the", "marketing", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy", "under", "the", "accelerated", "approval", "pathway", "(FDA", "Subpart", "E).", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013."], "wordsB": ["Upon", "implementation", "of", "this", "new", "amendment", "it", "is", "our", "intention", "to", "use", "the", "BRIGHT-SC", "study", "as", "one", "of", "two", "studies", "necessary", "to", "support", "the", "marketing", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy", "under", "the", "accelerated", "approval", "pathway", "(FDA", "Subpart", "E)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p65_s0", "idA": "1316175_13_item1_p39_s0", "sentA": "We plan to initiate patient enrollment in a Phase 2 proof-of-concept study for the treatment of IgA Nephropathy in 2013.", "sentB": "In June 2013, we met with the Japanese Pharmaceutical and Medical Devices Agency, or PMDA, to discuss the development of blisibimod for the treatment of IgA nephropathy in Japan.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013.", "<tag2>", "In", "June", "2013,", "we", "met", "with", "the", "Japanese", "Pharmaceutical", "and", "Medical", "Devices", "Agency,", "or", "PMDA,", "to", "discuss", "the", "development", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy", "in", "Japan.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013."], "wordsB": ["In", "June", "2013,", "we", "met", "with", "the", "Japanese", "Pharmaceutical", "and", "Medical", "Devices", "Agency,", "or", "PMDA,", "to", "discuss", "the", "development", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy", "in", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p65_s1", "idA": "1316175_13_item1_p39_s0", "sentA": "We plan to initiate patient enrollment in a Phase 2 proof-of-concept study for the treatment of IgA Nephropathy in 2013.", "sentB": "At this initial meeting, the PMDA agreed to consider a change in proteinuria as the basis for an initial approval of blisibimod for the treatment of IgA nephropathy.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013.", "<tag2>", "At", "this", "initial", "meeting,", "the", "PMDA", "agreed", "to", "consider", "a", "change", "in", "proteinuria", "as", "the", "basis", "for", "an", "initial", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "patient", "enrollment", "in", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "Nephropathy", "in", "2013."], "wordsB": ["At", "this", "initial", "meeting,", "the", "PMDA", "agreed", "to", "consider", "a", "change", "in", "proteinuria", "as", "the", "basis", "for", "an", "initial", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p64_s2", "idA": "1316175_13_item1_p39_s1", "sentA": "The BRIGHT-SC study will enroll approximately 48 patients with biopsy-proven IgAN who have proteinuria greater than 1 gram per 24 hours and are receiving standard of care.", "sentB": "The amendment serves to both transform BRIGHT-SC1 into a pivotal Phase 3 study and adjust its endpoints to paitents achieving less than 1 gram of proteinuria per 24 hours at 24 weeks.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "1", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care.", "<tag2>", "The", "amendment", "serves", "to", "both", "transform", "BRIGHT-SC1", "into", "a", "pivotal", "Phase", "3", "study", "and", "adjust", "its", "endpoints", "to", "paitents", "achieving", "less", "than", "1", "gram", "of", "proteinuria", "per", "24", "hours", "at", "24", "weeks.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "1", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care."], "wordsB": ["The", "amendment", "serves", "to", "both", "transform", "BRIGHT-SC1", "into", "a", "pivotal", "Phase", "3", "study", "and", "adjust", "its", "endpoints", "to", "paitents", "achieving", "less", "than", "1", "gram", "of", "proteinuria", "per", "24", "hours", "at", "24", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p63_s0", "idA": "1316175_13_item1_p39_s2", "sentA": "Patients will receive high dose, 300mg weekly, blisibimod or placebo for 8 weeks, during the induction phase, followed by 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "sentB": "Patients will receive 300mg weekly blisibimod or placebo subcutaneously during the first 8 weeks of therapy, the induction phase, followed by 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "type": 2, "words": ["<tag1>", "Patients", "will", "receive", "high", "dose,", "300mg", "weekly,", "blisibimod", "or", "placebo", "for", "8", "weeks,", "during", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag2>", "Patients", "will", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag3>"], "wordsA": ["Patients", "will", "receive", "high", "dose,", "300mg", "weekly,", "blisibimod", "or", "placebo", "for", "8", "weeks,", "during", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "wordsB": ["Patients", "will", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p39_s1", "idA": "1316175_13_item1_p39_s3", "sentA": "The primary endpoint of the BRIGHT-SC study will be improvements in proteinuria versus placebo after 32 weeks.", "sentB": "Specifically, the improvements in proteinuria observed in the subgroup of patients with abnormal proteinuria at enrollment (Figure 4), were maintained over 52 weeks of continuous blisibimod therapy.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BRIGHT-SC", "study", "will", "be", "improvements", "in", "proteinuria", "versus", "placebo", "after", "32", "weeks.", "<tag2>", "Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "(Figure", "4),", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BRIGHT-SC", "study", "will", "be", "improvements", "in", "proteinuria", "versus", "placebo", "after", "32", "weeks."], "wordsB": ["Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "(Figure", "4),", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p63_s1", "idA": "1316175_13_item1_p39_s4", "sentA": "We plan to conduct an interim analysis after the eight-week induction phase to determine effects of blisibimod on proteinuria.", "sentB": "When the first 48 patients have completed eight weeks of treatment we plan to conduct an interim analysis to determine the effect of blisibimod on proteinuria and other relevant renal biomarkers such as IgA and IgG levels.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "conduct", "an", "interim", "analysis", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "on", "proteinuria.", "<tag2>", "When", "the", "first", "48", "patients", "have", "completed", "eight", "weeks", "of", "treatment", "we", "plan", "to", "conduct", "an", "interim", "analysis", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "and", "other", "relevant", "renal", "biomarkers", "such", "as", "IgA", "and", "IgG", "levels.", "<tag3>"], "wordsA": ["We", "plan", "to", "conduct", "an", "interim", "analysis", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "on", "proteinuria."], "wordsB": ["When", "the", "first", "48", "patients", "have", "completed", "eight", "weeks", "of", "treatment", "we", "plan", "to", "conduct", "an", "interim", "analysis", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "and", "other", "relevant", "renal", "biomarkers", "such", "as", "IgA", "and", "IgG", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p73_s0", "idA": "1316175_13_item1_p39_s4", "sentA": "We plan to conduct an interim analysis after the eight-week induction phase to determine effects of blisibimod on proteinuria.", "sentB": "We plan to initiate a Phase 2 study in the second half of 2014 to evaluate the effects of blisibimod on survival, progression, and biomarkers in patients with relapsed or refractory multiple myeloma treated with at least one prior regimen.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "conduct", "an", "interim", "analysis", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "on", "proteinuria.", "<tag2>", "We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen.", "<tag3>"], "wordsA": ["We", "plan", "to", "conduct", "an", "interim", "analysis", "after", "the", "eight-week", "induction", "phase", "to", "determine", "effects", "of", "blisibimod", "on", "proteinuria."], "wordsB": ["We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p15_s0", "idA": "1316175_13_item1_p39_s5", "sentA": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "sentB": "We are currently evaluating additional plans for the development of blisibimod as a treatment for patients with multiple myeloma.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag2>", "We", "are", "currently", "evaluating", "additional", "plans", "for", "the", "development", "of", "blisibimod", "as", "a", "treatment", "for", "patients", "with", "multiple", "myeloma.", "<tag3>"], "wordsA": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "wordsB": ["We", "are", "currently", "evaluating", "additional", "plans", "for", "the", "development", "of", "blisibimod", "as", "a", "treatment", "for", "patients", "with", "multiple", "myeloma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p64_s0", "idA": "1316175_13_item1_p39_s5", "sentA": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "sentB": "In May 2013, we met with the FDA to discuss the blisibimod development program for IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag2>", "In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "wordsB": ["In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p66_s0", "idA": "1316175_13_item1_p39_s5", "sentA": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "sentB": "In December 2013, we submitted an Investigational New Drug application, or IND, to the Division of Cardiovascular and Renal Products of the FDA for the investigation of blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag2>", "In", "December", "2013,", "we", "submitted", "an", "Investigational", "New", "Drug", "application,", "or", "IND,", "to", "the", "Division", "of", "Cardiovascular", "and", "Renal", "Products", "of", "the", "FDA", "for", "the", "investigation", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "wordsB": ["In", "December", "2013,", "we", "submitted", "an", "Investigational", "New", "Drug", "application,", "or", "IND,", "to", "the", "Division", "of", "Cardiovascular", "and", "Renal", "Products", "of", "the", "FDA", "for", "the", "investigation", "of", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p88_s1", "idA": "1316175_13_item1_p39_s5", "sentA": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "sentB": "Additionally, in late 2013, we initiated activities for large-scale purification of our next batch of blisibimod with Fujifilim.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag2>", "Additionally,", "in", "late", "2013,", "we", "initiated", "activities", "for", "large-scale", "purification", "of", "our", "next", "batch", "of", "blisibimod", "with", "Fujifilim.", "<tag3>"], "wordsA": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "wordsB": ["Additionally,", "in", "late", "2013,", "we", "initiated", "activities", "for", "large-scale", "purification", "of", "our", "next", "batch", "of", "blisibimod", "with", "Fujifilim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p90_s0", "idA": "1316175_13_item1_p39_s5", "sentA": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "sentB": "An Investigational New Drug application, or IND, submitted to the Division of Cardiovascular and Renal Products of the FDA for the investigation of blisibimod in IgA nephropathy, is now in effect.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag2>", "An", "Investigational", "New", "Drug", "application,", "or", "IND,", "submitted", "to", "the", "Division", "of", "Cardiovascular", "and", "Renal", "Products", "of", "the", "FDA", "for", "the", "investigation", "of", "blisibimod", "in", "IgA", "nephropathy,", "is", "now", "in", "effect.", "<tag3>"], "wordsA": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "wordsB": ["An", "Investigational", "New", "Drug", "application,", "or", "IND,", "submitted", "to", "the", "Division", "of", "Cardiovascular", "and", "Renal", "Products", "of", "the", "FDA", "for", "the", "investigation", "of", "blisibimod", "in", "IgA", "nephropathy,", "is", "now", "in", "effect."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p90_s3", "idA": "1316175_13_item1_p39_s5", "sentA": "In 2013, we will submit an orphan designation application to the FDA for the use of blisibimod as a treatment for IgA nephropathy.", "sentB": "Among the discussion points with the FDA and later with the PMDA was the use of a substantial reduction in proteinuria to establish the efficacy of blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy.", "<tag2>", "Among", "the", "discussion", "points", "with", "the", "FDA", "and", "later", "with", "the", "PMDA", "was", "the", "use", "of", "a", "substantial", "reduction", "in", "proteinuria", "to", "establish", "the", "efficacy", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "2013,", "we", "will", "submit", "an", "orphan", "designation", "application", "to", "the", "FDA", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgA", "nephropathy."], "wordsB": ["Among", "the", "discussion", "points", "with", "the", "FDA", "and", "later", "with", "the", "PMDA", "was", "the", "use", "of", "a", "substantial", "reduction", "in", "proteinuria", "to", "establish", "the", "efficacy", "of", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p51_s1", "idA": "1316175_13_item1_p39_s6", "sentA": "We believe data from the BRIGHT-SC clinical study may provide information for other B-cell mediated kidney orphan diseases such as idiopathic membranous glomerulonephritis and lupus nephritis.", "sentB": "This study is planned to enroll patients with clinical diagnosis of lupus with or without renal disease, including patients with glomerulonephritis and patients who may have had a previous diagnosis of lupus nephritis.", "type": 2, "words": ["<tag1>", "We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "idiopathic", "membranous", "glomerulonephritis", "and", "lupus", "nephritis.", "<tag2>", "This", "study", "is", "planned", "to", "enroll", "patients", "with", "clinical", "diagnosis", "of", "lupus", "with", "or", "without", "renal", "disease,", "including", "patients", "with", "glomerulonephritis", "and", "patients", "who", "may", "have", "had", "a", "previous", "diagnosis", "of", "lupus", "nephritis.", "<tag3>"], "wordsA": ["We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "idiopathic", "membranous", "glomerulonephritis", "and", "lupus", "nephritis."], "wordsB": ["This", "study", "is", "planned", "to", "enroll", "patients", "with", "clinical", "diagnosis", "of", "lupus", "with", "or", "without", "renal", "disease,", "including", "patients", "with", "glomerulonephritis", "and", "patients", "who", "may", "have", "had", "a", "previous", "diagnosis", "of", "lupus", "nephritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p5_s0", "idA": "1316175_13_item1_p3_s0", "sentA": "Abnormal elevations in BAFF and B-cells have been correlated with several autoimmune diseases.", "sentB": "Abnormal elevations in BAFF, B-cells and plasma cells have been associated with several autoimmune diseases.", "type": 2, "words": ["<tag1>", "Abnormal", "elevations", "in", "BAFF", "and", "B-cells", "have", "been", "correlated", "with", "several", "autoimmune", "diseases.", "<tag2>", "Abnormal", "elevations", "in", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Abnormal", "elevations", "in", "BAFF", "and", "B-cells", "have", "been", "correlated", "with", "several", "autoimmune", "diseases."], "wordsB": ["Abnormal", "elevations", "in", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p6_s1", "idA": "1316175_13_item1_p3_s1", "sentA": "The potential role of BAFF inhibition and associated reductions in B-cell concentrations in lupus and rheumatoid arthritis has been validated in multiple clinical studies with blisibimod and other BAFF antagonists.", "sentB": "The potential role of BAFF inhibition and associated reductions in B-cell and plasma cell numbers in lupus and rheumatoid arthritis has been validated in multiple clinical studies with blisibimod and other BAFF antagonists.", "type": 2, "words": ["<tag1>", "The", "potential", "role", "of", "BAFF", "inhibition", "and", "associated", "reductions", "in", "B-cell", "concentrations", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "been", "validated", "in", "multiple", "clinical", "studies", "with", "blisibimod", "and", "other", "BAFF", "antagonists.", "<tag2>", "The", "potential", "role", "of", "BAFF", "inhibition", "and", "associated", "reductions", "in", "B-cell", "and", "plasma", "cell", "numbers", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "been", "validated", "in", "multiple", "clinical", "studies", "with", "blisibimod", "and", "other", "BAFF", "antagonists.", "<tag3>"], "wordsA": ["The", "potential", "role", "of", "BAFF", "inhibition", "and", "associated", "reductions", "in", "B-cell", "concentrations", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "been", "validated", "in", "multiple", "clinical", "studies", "with", "blisibimod", "and", "other", "BAFF", "antagonists."], "wordsB": ["The", "potential", "role", "of", "BAFF", "inhibition", "and", "associated", "reductions", "in", "B-cell", "and", "plasma", "cell", "numbers", "in", "lupus", "and", "rheumatoid", "arthritis", "has", "been", "validated", "in", "multiple", "clinical", "studies", "with", "blisibimod", "and", "other", "BAFF", "antagonists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p6_s2", "idA": "1316175_13_item1_p3_s2", "sentA": "We intend to advance the clinical development of our BAFF inhibitor, blisibimod, to exploit its broad potential clinical utility in a number of autoimmune diseases.", "sentB": "Based on data from our Phase 2b clinical study, we intend to advance the clinical development of our BAFF inhibitor, blisibimod, to exploit its potential clinical utility in a number of autoimmune diseases.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases.", "<tag2>", "Based", "on", "data", "from", "our", "Phase", "2b", "clinical", "study,", "we", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["We", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "broad", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases."], "wordsB": ["Based", "on", "data", "from", "our", "Phase", "2b", "clinical", "study,", "we", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p6_s3", "idA": "1316175_13_item1_p3_s3", "sentA": "Blisibimod, a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture which contrasts with antibody therapeutics that are typically manufactured in mammalian cell culture.", "sentB": "Blisibimod, a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture, as opposed to antibodies that are typically produced in mammalian cell culture.", "type": 2, "words": ["<tag1>", "Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "which", "contrasts", "with", "antibody", "therapeutics", "that", "are", "typically", "manufactured", "in", "mammalian", "cell", "culture.", "<tag2>", "Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture,", "as", "opposed", "to", "antibodies", "that", "are", "typically", "produced", "in", "mammalian", "cell", "culture.", "<tag3>"], "wordsA": ["Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "which", "contrasts", "with", "antibody", "therapeutics", "that", "are", "typically", "manufactured", "in", "mammalian", "cell", "culture."], "wordsB": ["Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture,", "as", "opposed", "to", "antibodies", "that", "are", "typically", "produced", "in", "mammalian", "cell", "culture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p93_s0", "idA": "1316175_13_item1_p3_s3", "sentA": "Blisibimod, a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture which contrasts with antibody therapeutics that are typically manufactured in mammalian cell culture.", "sentB": "Blisibimod, a peptibody directed against BAFF, was developed as an alternative to antibodies and is produced in Escherichia coli bacterial culture as opposed to antibodies that are typically produced in mammalian cell culture.", "type": 2, "words": ["<tag1>", "Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "which", "contrasts", "with", "antibody", "therapeutics", "that", "are", "typically", "manufactured", "in", "mammalian", "cell", "culture.", "<tag2>", "Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "as", "opposed", "to", "antibodies", "that", "are", "typically", "produced", "in", "mammalian", "cell", "culture.", "<tag3>"], "wordsA": ["Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "which", "contrasts", "with", "antibody", "therapeutics", "that", "are", "typically", "manufactured", "in", "mammalian", "cell", "culture."], "wordsB": ["Blisibimod,", "a", "peptibody", "directed", "against", "BAFF,", "was", "developed", "as", "an", "alternative", "to", "antibodies", "and", "is", "produced", "in", "Escherichia", "coli", "bacterial", "culture", "as", "opposed", "to", "antibodies", "that", "are", "typically", "produced", "in", "mammalian", "cell", "culture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p74_s2", "idA": "1316175_13_item1_p40_s2", "sentA": "The course of the disease is unpredictable, with periods of illness, called flares alternating with remission.", "sentB": "The course of the disease is unpredictable, with periods of illness, called flares, alternating with remission.", "type": 2, "words": ["<tag1>", "The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares", "alternating", "with", "remission.", "<tag2>", "The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares,", "alternating", "with", "remission.", "<tag3>"], "wordsA": ["The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares", "alternating", "with", "remission."], "wordsB": ["The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares,", "alternating", "with", "remission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p20_s0", "idA": "1316175_13_item1_p41_s0", "sentA": "According to the Journal of Arthritis and Rheumatism, the prevalence of lupus is estimated to be between 50-150 per 100,000 in the United States.", "sentB": "According to the Alliance for Lupus Research, it is estimated that up to 1.5 million people have lupus in the United States.", "type": 2, "words": ["<tag1>", "According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "Alliance", "for", "Lupus", "Research,", "it", "is", "estimated", "that", "up", "to", "1.5", "million", "people", "have", "lupus", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "Alliance", "for", "Lupus", "Research,", "it", "is", "estimated", "that", "up", "to", "1.5", "million", "people", "have", "lupus", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p68_s0", "idA": "1316175_13_item1_p41_s0", "sentA": "According to the Journal of Arthritis and Rheumatism, the prevalence of lupus is estimated to be between 50-150 per 100,000 in the United States.", "sentB": "According to the NORD, multiple myeloma is a rare disease that afflicted an estimated 21,700 new individuals in the United States in 2012.", "type": 2, "words": ["<tag1>", "According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "United", "States", "in", "2012.", "<tag3>"], "wordsA": ["According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "United", "States", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p84_s0", "idA": "1316175_13_item1_p41_s0", "sentA": "According to the Journal of Arthritis and Rheumatism, the prevalence of lupus is estimated to be between 50-150 per 100,000 in the United States.", "sentB": "According to NORD, multiple myeloma is a rare disease that afflicted an estimated 21,700 new individuals in the US in 2012.", "type": 2, "words": ["<tag1>", "According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States.", "<tag2>", "According", "to", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "US", "in", "2012.", "<tag3>"], "wordsA": ["According", "to", "the", "Journal", "of", "Arthritis", "and", "Rheumatism,", "the", "prevalence", "of", "lupus", "is", "estimated", "to", "be", "between", "50-150", "per", "100,000", "in", "the", "United", "States."], "wordsB": ["According", "to", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "US", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p76_s3", "idA": "1316175_13_item1_p43_s3", "sentA": "Lung inflammation causes shortness of breath.", "sentB": "Lung inflammation may cause shortness of breath.", "type": 2, "words": ["<tag1>", "Lung", "inflammation", "causes", "shortness", "of", "breath.", "<tag2>", "Lung", "inflammation", "may", "cause", "shortness", "of", "breath.", "<tag3>"], "wordsA": ["Lung", "inflammation", "causes", "shortness", "of", "breath."], "wordsB": ["Lung", "inflammation", "may", "cause", "shortness", "of", "breath."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p19_s0", "idA": "1316175_13_item1_p44_s0", "sentA": "Although the cause of lupus is still not completely understood, B-cell activation and autoantibody production are known to be central to the process.", "sentB": "Although the cause of lupus is still not completely understood, B-cell activation and autoantibody production from plasma cells are known to be central to the process.", "type": 2, "words": ["<tag1>", "Although", "the", "cause", "of", "lupus", "is", "still", "not", "completely", "understood,", "B-cell", "activation", "and", "autoantibody", "production", "are", "known", "to", "be", "central", "to", "the", "process.", "<tag2>", "Although", "the", "cause", "of", "lupus", "is", "still", "not", "completely", "understood,", "B-cell", "activation", "and", "autoantibody", "production", "from", "plasma", "cells", "are", "known", "to", "be", "central", "to", "the", "process.", "<tag3>"], "wordsA": ["Although", "the", "cause", "of", "lupus", "is", "still", "not", "completely", "understood,", "B-cell", "activation", "and", "autoantibody", "production", "are", "known", "to", "be", "central", "to", "the", "process."], "wordsB": ["Although", "the", "cause", "of", "lupus", "is", "still", "not", "completely", "understood,", "B-cell", "activation", "and", "autoantibody", "production", "from", "plasma", "cells", "are", "known", "to", "be", "central", "to", "the", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p80_s0", "idA": "1316175_13_item1_p47_s0", "sentA": "The classic presentation (in 40-50% of the cases) of signs and symptoms in patients with IgAN is episodic frank hematuria which usually starts within a day or two of a non-specific upper respiratory tract infection or (less commonly) gastrointestinal or urinary infection.", "sentB": "The classic presentation (in 40-50% of the cases) of signs and symptoms in patients with IgA nephropathy is episodic frank hematuria which usually starts within a day or two of a non-specific upper respiratory tract infection or (less commonly) gastrointestinal or urinary infection.", "type": 2, "words": ["<tag1>", "The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgAN", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection.", "<tag2>", "The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgA", "nephropathy", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection.", "<tag3>"], "wordsA": ["The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgAN", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection."], "wordsB": ["The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgA", "nephropathy", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p81_s0", "idA": "1316175_13_item1_p48_s0", "sentA": "According to the New England Journal of Medicine, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life and a large number of cases eventually progress to renal failure.", "sentB": "According to NORD, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life and a large number of cases eventually progress to renal failure.", "type": 2, "words": ["<tag1>", "According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag2>", "According", "to", "NORD,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag3>"], "wordsA": ["According", "to", "the", "New", "England", "Journal", "of", "Medicine,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "wordsB": ["According", "to", "NORD,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p104_s0", "idA": "1316175_13_item1_p49_s0", "sentA": "There is also a striking geographic variation in the prevalence of IgAN throughout the world.", "sentB": "Multiple myeloma is also a rare disease with clear unmet medical need.", "type": 2, "words": ["<tag1>", "There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgAN", "throughout", "the", "world.", "<tag2>", "Multiple", "myeloma", "is", "also", "a", "rare", "disease", "with", "clear", "unmet", "medical", "need.", "<tag3>"], "wordsA": ["There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgAN", "throughout", "the", "world."], "wordsB": ["Multiple", "myeloma", "is", "also", "a", "rare", "disease", "with", "clear", "unmet", "medical", "need."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p82_s0", "idA": "1316175_13_item1_p49_s0", "sentA": "There is also a striking geographic variation in the prevalence of IgAN throughout the world.", "sentB": "There is also a striking geographic variation in the prevalence of IgA nephropathy throughout the world.", "type": 2, "words": ["<tag1>", "There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgAN", "throughout", "the", "world.", "<tag2>", "There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgA", "nephropathy", "throughout", "the", "world.", "<tag3>"], "wordsA": ["There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgAN", "throughout", "the", "world."], "wordsB": ["There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgA", "nephropathy", "throughout", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p53_s0", "idA": "1316175_13_item1_p49_s1", "sentA": "According to the National Organization for Rare Disorders (NORD) IgA nephropathy, an orphan disease is believed to affect approximately 130,000 people annually in the United States.", "sentB": "According to the National Organization of Rare Disease, or NORD, IgA nephropathy, an orphan indication, is believed to affect approximately 130,000 people annually in the United States.", "type": 2, "words": ["<tag1>", "According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "National", "Organization", "of", "Rare", "Disease,", "or", "NORD,", "IgA", "nephropathy,", "an", "orphan", "indication,", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "National", "Organization", "of", "Rare", "Disease,", "or", "NORD,", "IgA", "nephropathy,", "an", "orphan", "indication,", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p82_s1", "idA": "1316175_13_item1_p49_s1", "sentA": "According to the National Organization for Rare Disorders (NORD) IgA nephropathy, an orphan disease is believed to affect approximately 130,000 people annually in the United States.", "sentB": "In the United States, IgA nephropathy is considered an orphan disease as it is believed to affect approximately 130,000 people annually, although this number might prove to be higher with more robust screening.", "type": 2, "words": ["<tag1>", "According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag2>", "In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually,", "although", "this", "number", "might", "prove", "to", "be", "higher", "with", "more", "robust", "screening.", "<tag3>"], "wordsA": ["According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "wordsB": ["In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually,", "although", "this", "number", "might", "prove", "to", "be", "higher", "with", "more", "robust", "screening."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p84_s1", "idA": "1316175_13_item1_p49_s1", "sentA": "According to the National Organization for Rare Disorders (NORD) IgA nephropathy, an orphan disease is believed to affect approximately 130,000 people annually in the United States.", "sentB": "Approximately 100,000 patients are believed to have multiple myeloma in the US.", "type": 2, "words": ["<tag1>", "According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag2>", "Approximately", "100,000", "patients", "are", "believed", "to", "have", "multiple", "myeloma", "in", "the", "US.", "<tag3>"], "wordsA": ["According", "to", "the", "National", "Organization", "for", "Rare", "Disorders", "(NORD)", "IgA", "nephropathy,", "an", "orphan", "disease", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "wordsB": ["Approximately", "100,000", "patients", "are", "believed", "to", "have", "multiple", "myeloma", "in", "the", "US."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p82_s3", "idA": "1316175_13_item1_p49_s2", "sentA": "In Asia, assuming similar prevalence rates as the United States, IgAN is estimated to affect over 500,000 people annually.", "sentB": "For example, in Japan, IgA nephropathy is estimated to affect over 350,000 people annually.", "type": 2, "words": ["<tag1>", "In", "Asia,", "assuming", "similar", "prevalence", "rates", "as", "the", "United", "States,", "IgAN", "is", "estimated", "to", "affect", "over", "500,000", "people", "annually.", "<tag2>", "For", "example,", "in", "Japan,", "IgA", "nephropathy", "is", "estimated", "to", "affect", "over", "350,000", "people", "annually.", "<tag3>"], "wordsA": ["In", "Asia,", "assuming", "similar", "prevalence", "rates", "as", "the", "United", "States,", "IgAN", "is", "estimated", "to", "affect", "over", "500,000", "people", "annually."], "wordsB": ["For", "example,", "in", "Japan,", "IgA", "nephropathy", "is", "estimated", "to", "affect", "over", "350,000", "people", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p70_s1", "idA": "1316175_13_item1_p49_s3", "sentA": "In Asia, routine urinalyses are performed for school children, and renal biopsies are performed for patients with asymptomatic hematuria, thus raising the reported prevalence of the disease.", "sentB": "Multiple myeloma typically presents during the 4th to 7th decades of a patient s life and has a median survival rate of 2-4 years for patients with Stage II - III disease.", "type": 2, "words": ["<tag1>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease.", "<tag2>", "Multiple", "myeloma", "typically", "presents", "during", "the", "4th", "to", "7th", "decades", "of", "a", "patient", "s", "life", "and", "has", "a", "median", "survival", "rate", "of", "2-4", "years", "for", "patients", "with", "Stage", "II", "-", "III", "disease.", "<tag3>"], "wordsA": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease."], "wordsB": ["Multiple", "myeloma", "typically", "presents", "during", "the", "4th", "to", "7th", "decades", "of", "a", "patient", "s", "life", "and", "has", "a", "median", "survival", "rate", "of", "2-4", "years", "for", "patients", "with", "Stage", "II", "-", "III", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p82_s2", "idA": "1316175_13_item1_p49_s3", "sentA": "In Asia, routine urinalyses are performed for school children, and renal biopsies are performed for patients with asymptomatic hematuria, thus raising the reported prevalence of the disease.", "sentB": "In Asia, routine urinalyses are performed for school children, and renal biopsies are performed for patients with asymptomatic hematuria and the reported prevalence of the disease is much higher.", "type": 2, "words": ["<tag1>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease.", "<tag2>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria", "and", "the", "reported", "prevalence", "of", "the", "disease", "is", "much", "higher.", "<tag3>"], "wordsA": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease."], "wordsB": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria", "and", "the", "reported", "prevalence", "of", "the", "disease", "is", "much", "higher."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p86_s1", "idA": "1316175_13_item1_p49_s3", "sentA": "In Asia, routine urinalyses are performed for school children, and renal biopsies are performed for patients with asymptomatic hematuria, thus raising the reported prevalence of the disease.", "sentB": "Multiple myeloma typically presents in during the 4th to 7th decades of a patient s life and has a median survival rate of 2-4 years for patients with Stage II - III disease.", "type": 2, "words": ["<tag1>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease.", "<tag2>", "Multiple", "myeloma", "typically", "presents", "in", "during", "the", "4th", "to", "7th", "decades", "of", "a", "patient", "s", "life", "and", "has", "a", "median", "survival", "rate", "of", "2-4", "years", "for", "patients", "with", "Stage", "II", "-", "III", "disease.", "<tag3>"], "wordsA": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease."], "wordsB": ["Multiple", "myeloma", "typically", "presents", "in", "during", "the", "4th", "to", "7th", "decades", "of", "a", "patient", "s", "life", "and", "has", "a", "median", "survival", "rate", "of", "2-4", "years", "for", "patients", "with", "Stage", "II", "-", "III", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p23_s0", "idA": "1316175_13_item1_p51_s0", "sentA": "Based on positive results among 104 patients in our Phase 1a and 1b clinical studies, we initiated a Phase 2b clinical study in lupus patients called PEARL-SC in 2010, exploring three doses of blisibimod for the treatment of patients with seropositive markers of lupus and active disease defined as SELENA-SLEDAI score of greater than 6.", "sentB": "Based on positive results among 104 lupus patients in our licensor s Phase 1a and 1b clinical studies, we conducted PEARL-SC, a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of various subcutaneous doses of blisibimod in patients with seropositive lupus and active disease defined as SELENA-SLEDAI 6 at enrollment, which ran from mid-2010 to April 2012.", "type": 2, "words": ["<tag1>", "Based", "on", "positive", "results", "among", "104", "patients", "in", "our", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "patients", "called", "PEARL-SC", "in", "2010,", "exploring", "three", "doses", "of", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6.", "<tag2>", "Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "our", "licensor", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "PEARL-SC,", "a", "Phase", "2b", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012.", "<tag3>"], "wordsA": ["Based", "on", "positive", "results", "among", "104", "patients", "in", "our", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "initiated", "a", "Phase", "2b", "clinical", "study", "in", "lupus", "patients", "called", "PEARL-SC", "in", "2010,", "exploring", "three", "doses", "of", "blisibimod", "for", "the", "treatment", "of", "patients", "with", "seropositive", "markers", "of", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "score", "of", "greater", "than", "6."], "wordsB": ["Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "our", "licensor", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "PEARL-SC,", "a", "Phase", "2b", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p23_s1", "idA": "1316175_13_item1_p51_s1", "sentA": "PEARL-SC was a randomized, placebo-controlled, Phase 2b study which enrolled 547 patients in 11 countries at 72 clinical sites.", "sentB": "The study enrolled 547 patients in 11 countries at 72 clinical sites.", "type": 2, "words": ["<tag1>", "PEARL-SC", "was", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites.", "<tag2>", "The", "study", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites.", "<tag3>"], "wordsA": ["PEARL-SC", "was", "a", "randomized,", "placebo-controlled,", "Phase", "2b", "study", "which", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites."], "wordsB": ["The", "study", "enrolled", "547", "patients", "in", "11", "countries", "at", "72", "clinical", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s0", "idA": "1316175_13_item1_p52_s0", "sentA": "The primary endpoint of the PEARL-SC study was a clinical improvement at the SLE responder index, or SRI-5, at week 24 for the pooled bisibimod dose groups versus placebo groups.", "sentB": "The primary endpoint of the PEARL-SC study was a clinical improvement at the lupus responder index, or SRI-5, at week 24 for the pooled blisibimod dose groups versus placebo groups.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "SLE", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "bisibimod", "dose", "groups", "versus", "placebo", "groups.", "<tag2>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "lupus", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "blisibimod", "dose", "groups", "versus", "placebo", "groups.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "SLE", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "bisibimod", "dose", "groups", "versus", "placebo", "groups."], "wordsB": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "lupus", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "blisibimod", "dose", "groups", "versus", "placebo", "groups."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p25_s1", "idA": "1316175_13_item1_p52_s1", "sentA": "SRI-5 is defined as a five-point improvement in the SELENA-SLEDAI score, no new BILAG A or two BILAG B scores, and no new increase in physician s global assessment of more than 0.3 points.", "sentB": "SRI-5 is defined as a five-point improvement in the SELENA-SLEDAI score, no new BILAG 1A or 2B scores, and no new increase in Physician s Global Assessment of more than 0.3 points.", "type": 2, "words": ["<tag1>", "SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "A", "or", "two", "BILAG", "B", "scores,", "and", "no", "new", "increase", "in", "physician", "s", "global", "assessment", "of", "more", "than", "0.3", "points.", "<tag2>", "SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "1A", "or", "2B", "scores,", "and", "no", "new", "increase", "in", "Physician", "s", "Global", "Assessment", "of", "more", "than", "0.3", "points.", "<tag3>"], "wordsA": ["SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "A", "or", "two", "BILAG", "B", "scores,", "and", "no", "new", "increase", "in", "physician", "s", "global", "assessment", "of", "more", "than", "0.3", "points."], "wordsB": ["SRI-5", "is", "defined", "as", "a", "five-point", "improvement", "in", "the", "SELENA-SLEDAI", "score,", "no", "new", "BILAG", "1A", "or", "2B", "scores,", "and", "no", "new", "increase", "in", "Physician", "s", "Global", "Assessment", "of", "more", "than", "0.3", "points."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p27_s0", "idA": "1316175_13_item1_p52_s2", "sentA": "Secondary endpoints included safety, improvement in other clinical assessment scores, and clinical response in patients with various baseline disease severities, resolution of fatigue, steroid utilization and time to flare.", "sentB": "Secondary endpoints included safety, improvements in variant forms of the SRI (e.g. defined by greater improvements in SELENA-SLEDAI), effects on clinical response in subgroup of patients with greater baseline disease severities, time to lupus disease flare, improvements in proteinuria, improvements in biomarkers of inflammation (e.g. anti-dsDNA, complement C3 and C4), and changes in B-cell counts.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "included", "safety,", "improvement", "in", "other", "clinical", "assessment", "scores,", "and", "clinical", "response", "in", "patients", "with", "various", "baseline", "disease", "severities,", "resolution", "of", "fatigue,", "steroid", "utilization", "and", "time", "to", "flare.", "<tag2>", "Secondary", "endpoints", "included", "safety,", "improvements", "in", "variant", "forms", "of", "the", "SRI", "(e.g.", "defined", "by", "greater", "improvements", "in", "SELENA-SLEDAI),", "effects", "on", "clinical", "response", "in", "subgroup", "of", "patients", "with", "greater", "baseline", "disease", "severities,", "time", "to", "lupus", "disease", "flare,", "improvements", "in", "proteinuria,", "improvements", "in", "biomarkers", "of", "inflammation", "(e.g.", "anti-dsDNA,", "complement", "C3", "and", "C4),", "and", "changes", "in", "B-cell", "counts.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "included", "safety,", "improvement", "in", "other", "clinical", "assessment", "scores,", "and", "clinical", "response", "in", "patients", "with", "various", "baseline", "disease", "severities,", "resolution", "of", "fatigue,", "steroid", "utilization", "and", "time", "to", "flare."], "wordsB": ["Secondary", "endpoints", "included", "safety,", "improvements", "in", "variant", "forms", "of", "the", "SRI", "(e.g.", "defined", "by", "greater", "improvements", "in", "SELENA-SLEDAI),", "effects", "on", "clinical", "response", "in", "subgroup", "of", "patients", "with", "greater", "baseline", "disease", "severities,", "time", "to", "lupus", "disease", "flare,", "improvements", "in", "proteinuria,", "improvements", "in", "biomarkers", "of", "inflammation", "(e.g.", "anti-dsDNA,", "complement", "C3", "and", "C4),", "and", "changes", "in", "B-cell", "counts."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p40_s0", "idA": "1316175_13_item1_p53_s0", "sentA": "In June and July 2012 we announced results from the Phase 2b PEARL-SC study which we believe support the initiation of a differentiated Phase 3 registration plan utilizing the 200mg weekly dose of blisibimod in patients with active lupus, despite the concomitant use of corticosteroids.", "sentB": "The data from the Phase 2 program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the Phase 2 study in patients with IgA nephropathy (BRIGHT-SC1).", "type": 2, "words": ["<tag1>", "In", "June", "and", "July", "2012", "we", "announced", "results", "from", "the", "Phase", "2b", "PEARL-SC", "study", "which", "we", "believe", "support", "the", "initiation", "of", "a", "differentiated", "Phase", "3", "registration", "plan", "utilizing", "the", "200mg", "weekly", "dose", "of", "blisibimod", "in", "patients", "with", "active", "lupus,", "despite", "the", "concomitant", "use", "of", "corticosteroids.", "<tag2>", "The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1).", "<tag3>"], "wordsA": ["In", "June", "and", "July", "2012", "we", "announced", "results", "from", "the", "Phase", "2b", "PEARL-SC", "study", "which", "we", "believe", "support", "the", "initiation", "of", "a", "differentiated", "Phase", "3", "registration", "plan", "utilizing", "the", "200mg", "weekly", "dose", "of", "blisibimod", "in", "patients", "with", "active", "lupus,", "despite", "the", "concomitant", "use", "of", "corticosteroids."], "wordsB": ["The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p29_s1", "idA": "1316175_13_item1_p54_s1", "sentA": "In this subgroup, which we plan to enroll in our Phase 3 CHABLIS-SC studies, separation of clinical response occurred as early as week eight and numerical differences were observed beyond week 24.", "sentB": "In this severe subgroup, separation of clinical response was evident as early as Week 8 and numerical improvements relative to placebo were maintained beyond Week 24.", "type": 2, "words": ["<tag1>", "In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24.", "<tag2>", "In", "this", "severe", "subgroup,", "separation", "of", "clinical", "response", "was", "evident", "as", "early", "as", "Week", "8", "and", "numerical", "improvements", "relative", "to", "placebo", "were", "maintained", "beyond", "Week", "24.", "<tag3>"], "wordsA": ["In", "this", "subgroup,", "which", "we", "plan", "to", "enroll", "in", "our", "Phase", "3", "CHABLIS-SC", "studies,", "separation", "of", "clinical", "response", "occurred", "as", "early", "as", "week", "eight", "and", "numerical", "differences", "were", "observed", "beyond", "week", "24."], "wordsB": ["In", "this", "severe", "subgroup,", "separation", "of", "clinical", "response", "was", "evident", "as", "early", "as", "Week", "8", "and", "numerical", "improvements", "relative", "to", "placebo", "were", "maintained", "beyond", "Week", "24."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p29_s6", "idA": "1316175_13_item1_p55_s2", "sentA": "Additional information and publications from the PEARL-SC clinical study can be found at www.anthera.com/studies_pearl-sc.asp.", "sentB": "Additional information and publications from the PEARL-SC clinical study can be found at www.anthera.com/studies_pearl-sc.htm.", "type": 2, "words": ["<tag1>", "Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_pearl-sc.asp.", "<tag2>", "Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_pearl-sc.htm.", "<tag3>"], "wordsA": ["Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_pearl-sc.asp."], "wordsB": ["Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_pearl-sc.htm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p40_s1", "idA": "1316175_13_item1_p56_s2", "sentA": "Additional information about the OLE clinical study can be found at www.anthera.com/studies_open-label-extension-study.asp.", "sentB": "Additional information for the OLE clinical studies can be found at www.anthera.com /studies_open-label-extension-study.htm.", "type": 2, "words": ["<tag1>", "Additional", "information", "about", "the", "OLE", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_open-label-extension-study.asp.", "<tag2>", "Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "www.anthera.com", "/studies_open-label-extension-study.htm.", "<tag3>"], "wordsA": ["Additional", "information", "about", "the", "OLE", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_open-label-extension-study.asp."], "wordsB": ["Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "www.anthera.com", "/studies_open-label-extension-study.htm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p44_s0", "idA": "1316175_13_item1_p57_s0", "sentA": "In the third quarter of 2012 at an end of Phase 2 meeting with the FDA, we presented the results of the PEARL-SC clinical study and our plans for Phase 3 registration studies in patients with active lupus.", "sentB": "In the third quarter of 2012 at an End of Phase 2 meeting with the United States Food and Drug Administration, or FDA, we presented the results of the PEARL-SC clinical study and our plans for Phase 3 registration studies in patients with active lupus.", "type": 2, "words": ["<tag1>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "end", "of", "Phase", "2", "meeting", "with", "the", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag2>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag3>"], "wordsA": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "end", "of", "Phase", "2", "meeting", "with", "the", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "wordsB": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p88_s2", "idA": "1316175_13_item1_p57_s0", "sentA": "In the third quarter of 2012 at an end of Phase 2 meeting with the FDA, we presented the results of the PEARL-SC clinical study and our plans for Phase 3 registration studies in patients with active lupus.", "sentB": "Final product from this product manufacturing campaign is expected to provide sufficient placebo and blisibimod syringes for completion of the CHABLIS-SC1 clinical study and the initiation of the second pivotal clinical study in patients with lupus.", "type": 2, "words": ["<tag1>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "end", "of", "Phase", "2", "meeting", "with", "the", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag2>", "Final", "product", "from", "this", "product", "manufacturing", "campaign", "is", "expected", "to", "provide", "sufficient", "placebo", "and", "blisibimod", "syringes", "for", "completion", "of", "the", "CHABLIS-SC1", "clinical", "study", "and", "the", "initiation", "of", "the", "second", "pivotal", "clinical", "study", "in", "patients", "with", "lupus.", "<tag3>"], "wordsA": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "end", "of", "Phase", "2", "meeting", "with", "the", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "wordsB": ["Final", "product", "from", "this", "product", "manufacturing", "campaign", "is", "expected", "to", "provide", "sufficient", "placebo", "and", "blisibimod", "syringes", "for", "completion", "of", "the", "CHABLIS-SC1", "clinical", "study", "and", "the", "initiation", "of", "the", "second", "pivotal", "clinical", "study", "in", "patients", "with", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p44_s1", "idA": "1316175_13_item1_p57_s1", "sentA": "As a result of this meeting we plan to initiate patient enrollment in the initial Phase 3 CHABLIS-SC1 study in 2013.", "sentB": "As a result of this meeting we initiated patient enrollment in the initial Phase 3 CHABLIS-SC1 (Figure 7) study in March 2013.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "2013.", "<tag2>", "As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "(Figure", "7)", "study", "in", "March", "2013.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "2013."], "wordsB": ["As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "(Figure", "7)", "study", "in", "March", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p64_s1", "idA": "1316175_13_item1_p57_s1", "sentA": "As a result of this meeting we plan to initiate patient enrollment in the initial Phase 3 CHABLIS-SC1 study in 2013.", "sentB": "As a result of feedback from the FDA on the potential use proteinuria as the endpoint for Subpart E approval for blisibimod, we have amended the BRIGHT-SC study endpoints during the fourth quarter of 2013.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "2013.", "<tag2>", "As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "meeting", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "2013."], "wordsB": ["As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p49_s0", "idA": "1316175_13_item1_p59_s0", "sentA": "Following our initial interim analysis of clinical data from the CHABLIS-SC1 study we plan to initiate patient enrollment in our second Phase 3 clinical study, CHABLIS-SC2.", "sentB": "Enrollment rates for the CHABLIS-SC1 study have exceeded our initial expectations.", "type": 2, "words": ["<tag1>", "Following", "our", "initial", "interim", "analysis", "of", "clinical", "data", "from", "the", "CHABLIS-SC1", "study", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "second", "Phase", "3", "clinical", "study,", "CHABLIS-SC2.", "<tag2>", "Enrollment", "rates", "for", "the", "CHABLIS-SC1", "study", "have", "exceeded", "our", "initial", "expectations.", "<tag3>"], "wordsA": ["Following", "our", "initial", "interim", "analysis", "of", "clinical", "data", "from", "the", "CHABLIS-SC1", "study", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "our", "second", "Phase", "3", "clinical", "study,", "CHABLIS-SC2."], "wordsB": ["Enrollment", "rates", "for", "the", "CHABLIS-SC1", "study", "have", "exceeded", "our", "initial", "expectations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p59_s0", "idA": "1316175_13_item1_p60_s0", "sentA": "Similar to patients with other autoimmune diseases such as lupus, in IgA Nephropathy, elevated levels of BAFF are associated with the proliferation of B-cells and plasma B-cells which may contribute to disease.", "sentB": "Similar to patients with other autoimmune diseases such as lupus, in IgA nephropathy, elevated levels of BAFF are associated with disease activity.", "type": 2, "words": ["<tag1>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "Nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "the", "proliferation", "of", "B-cells", "and", "plasma", "B-cells", "which", "may", "contribute", "to", "disease.", "<tag2>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "disease", "activity.", "<tag3>"], "wordsA": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "Nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "the", "proliferation", "of", "B-cells", "and", "plasma", "B-cells", "which", "may", "contribute", "to", "disease."], "wordsB": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "disease", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p88_s3", "idA": "1316175_13_item1_p61_s0", "sentA": "In 2013 we plan to initiate patient enrollment in BRIGHT-SC, a Phase 2 proof-of-concept study for the treatment of IgA nephropathy, our first clinical study addressing an orphan indication for the treatment of renal disease.", "sentB": "Furthermore, we plan to develop an auto injector strategy for the product presentation at launch in 2014.", "type": 2, "words": ["<tag1>", "In", "2013", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "BRIGHT-SC,", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "nephropathy,", "our", "first", "clinical", "study", "addressing", "an", "orphan", "indication", "for", "the", "treatment", "of", "renal", "disease.", "<tag2>", "Furthermore,", "we", "plan", "to", "develop", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation", "at", "launch", "in", "2014.", "<tag3>"], "wordsA": ["In", "2013", "we", "plan", "to", "initiate", "patient", "enrollment", "in", "BRIGHT-SC,", "a", "Phase", "2", "proof-of-concept", "study", "for", "the", "treatment", "of", "IgA", "nephropathy,", "our", "first", "clinical", "study", "addressing", "an", "orphan", "indication", "for", "the", "treatment", "of", "renal", "disease."], "wordsB": ["Furthermore,", "we", "plan", "to", "develop", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation", "at", "launch", "in", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p43_s2", "idA": "1316175_13_item1_p61_s1", "sentA": "BRIGHT-SC will serve as our initial proof of concept study for an eventual Phase 3 path in renal diseases with blisibimod.", "sentB": "The effects on immunoglobulins were not associated with infection risk, nor were alterations in white blood cells, monocytes, or neutrophils associated with blisibimod.", "type": 2, "words": ["<tag1>", "BRIGHT-SC", "will", "serve", "as", "our", "initial", "proof", "of", "concept", "study", "for", "an", "eventual", "Phase", "3", "path", "in", "renal", "diseases", "with", "blisibimod.", "<tag2>", "The", "effects", "on", "immunoglobulins", "were", "not", "associated", "with", "infection", "risk,", "nor", "were", "alterations", "in", "white", "blood", "cells,", "monocytes,", "or", "neutrophils", "associated", "with", "blisibimod.", "<tag3>"], "wordsA": ["BRIGHT-SC", "will", "serve", "as", "our", "initial", "proof", "of", "concept", "study", "for", "an", "eventual", "Phase", "3", "path", "in", "renal", "diseases", "with", "blisibimod."], "wordsB": ["The", "effects", "on", "immunoglobulins", "were", "not", "associated", "with", "infection", "risk,", "nor", "were", "alterations", "in", "white", "blood", "cells,", "monocytes,", "or", "neutrophils", "associated", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p62_s0", "idA": "1316175_13_item1_p61_s2", "sentA": "The BRIGHT-SC study will enroll approximately 48 patients with biopsy-proven IgAN who have proteinuria greater than one gram per 24 hours and are receiving standard of care.", "sentB": "Initially we intend to enroll up to 48 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care.", "<tag2>", "Initially", "we", "intend", "to", "enroll", "up", "to", "48", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "study", "will", "enroll", "approximately", "48", "patients", "with", "biopsy-proven", "IgAN", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "and", "are", "receiving", "standard", "of", "care."], "wordsB": ["Initially", "we", "intend", "to", "enroll", "up", "to", "48", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p50_s4", "idA": "1316175_13_item1_p61_s6", "sentA": "Additional information about the BRIGHT-SC clinical study can be found at www.anthera.com/studies_bright-sc.asp.", "sentB": "Additional information for the CHABLIS-SC1 clinical studies can be found at www.anthera.com/studies_chablis-sc1.htm.", "type": 2, "words": ["<tag1>", "Additional", "information", "about", "the", "BRIGHT-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_bright-sc.asp.", "<tag2>", "Additional", "information", "for", "the", "CHABLIS-SC1", "clinical", "studies", "can", "be", "found", "at", "www.anthera.com/studies_chablis-sc1.htm.", "<tag3>"], "wordsA": ["Additional", "information", "about", "the", "BRIGHT-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_bright-sc.asp."], "wordsB": ["Additional", "information", "for", "the", "CHABLIS-SC1", "clinical", "studies", "can", "be", "found", "at", "www.anthera.com/studies_chablis-sc1.htm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p87_s0", "idA": "1316175_13_item1_p62_s0", "sentA": "In December 2011, we completed the technology transfer from Amgen Inc., or Amgen and manufacturing scale up to 3,000 liters at our contract manufacturing organization, or CMO (Fujifilm Diosynth Bioservices or Fujifilm ).", "sentB": "In December 2011, we completed the manufacturing site transfer from Amgen Inc., or Amgen, to our contract manufacturing organization, or CMO (Fujifilm Diosynth Bioservices, or Fujifilm).", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices", "or", "Fujifilm", ").", "<tag2>", "In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices,", "or", "Fujifilm).", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices", "or", "Fujifilm", ")."], "wordsB": ["In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices,", "or", "Fujifilm)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p87_s1", "idA": "1316175_13_item1_p62_s0", "sentA": "In December 2011, we completed the technology transfer from Amgen Inc., or Amgen and manufacturing scale up to 3,000 liters at our contract manufacturing organization, or CMO (Fujifilm Diosynth Bioservices or Fujifilm ).", "sentB": "We also scaled up manufacturing from 300 liters up to 3,000 liters.", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices", "or", "Fujifilm", ").", "<tag2>", "We", "also", "scaled", "up", "manufacturing", "from", "300", "liters", "up", "to", "3,000", "liters.", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "completed", "the", "technology", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen", "and", "manufacturing", "scale", "up", "to", "3,000", "liters", "at", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices", "or", "Fujifilm", ")."], "wordsB": ["We", "also", "scaled", "up", "manufacturing", "from", "300", "liters", "up", "to", "3,000", "liters."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p38_s2", "idA": "1316175_13_item1_p62_s2", "sentA": "Data from our first 3,000 liter manufacturing campaign was submitted to the FDA, and product from this batch was released for use in the PEARL-SC and OLE studies.", "sentB": "Interim data from the combined PEARL-SC and OLE studies were presented at the 2013 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP).", "type": 2, "words": ["<tag1>", "Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "FDA,", "and", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "and", "OLE", "studies.", "<tag2>", "Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP).", "<tag3>"], "wordsA": ["Data", "from", "our", "first", "3,000", "liter", "manufacturing", "campaign", "was", "submitted", "to", "the", "FDA,", "and", "product", "from", "this", "batch", "was", "released", "for", "use", "in", "the", "PEARL-SC", "and", "OLE", "studies."], "wordsB": ["Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p13_s0", "idA": "1316175_13_item1_p63_s0", "sentA": "We have successfully manufactured blisibimod at launch scale volumes and currently have sufficient inventory to support the CHABLIS-SC1 and BRIGHT-SC studies in 2013.", "sentB": "We have successfully manufactured blisibimod at launch scale quantities.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "currently", "have", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies", "in", "2013.", "<tag2>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "quantities.", "<tag3>"], "wordsA": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "currently", "have", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies", "in", "2013."], "wordsB": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "quantities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p88_s0", "idA": "1316175_13_item1_p63_s0", "sentA": "We have successfully manufactured blisibimod at launch scale volumes and currently have sufficient inventory to support the CHABLIS-SC1 and BRIGHT-SC studies in 2013.", "sentB": "We have successfully manufactured blisibimod at launch scale volumes to support the CHABLIS-SC1 and BRIGHT-SC1 studies.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "currently", "have", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies", "in", "2013.", "<tag2>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC1", "studies.", "<tag3>"], "wordsA": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "and", "currently", "have", "sufficient", "inventory", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies", "in", "2013."], "wordsB": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC1", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p65_s2", "idA": "1316175_13_item1_p65_s0", "sentA": "The following chart outlines the basic manufacturing steps required for the production of blisibimod.", "sentB": "Additional discussions with the PMDA regarding development of blisibimod in Japan are planned for the second quarter of 2014.", "type": 2, "words": ["<tag1>", "The", "following", "chart", "outlines", "the", "basic", "manufacturing", "steps", "required", "for", "the", "production", "of", "blisibimod.", "<tag2>", "Additional", "discussions", "with", "the", "PMDA", "regarding", "development", "of", "blisibimod", "in", "Japan", "are", "planned", "for", "the", "second", "quarter", "of", "2014.", "<tag3>"], "wordsA": ["The", "following", "chart", "outlines", "the", "basic", "manufacturing", "steps", "required", "for", "the", "production", "of", "blisibimod."], "wordsB": ["Additional", "discussions", "with", "the", "PMDA", "regarding", "development", "of", "blisibimod", "in", "Japan", "are", "planned", "for", "the", "second", "quarter", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p51_s0", "idA": "1316175_13_item1_p66_s0", "sentA": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012 and to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting).", "sentB": "Following recent input from the FDA, we submitted a second pivotal study, CHABLIS-SC2, to the FDA in the first quarter of 2014.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting).", "<tag2>", "Following", "recent", "input", "from", "the", "FDA,", "we", "submitted", "a", "second", "pivotal", "study,", "CHABLIS-SC2,", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)."], "wordsB": ["Following", "recent", "input", "from", "the", "FDA,", "we", "submitted", "a", "second", "pivotal", "study,", "CHABLIS-SC2,", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p89_s0", "idA": "1316175_13_item1_p66_s0", "sentA": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012 and to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting).", "sentB": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012, to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting) and to the FDA in a follow-up advice procedure in the third quarter of 2013 (Type C request to which the FDA provided written responses in lieu of a meeting).", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting).", "<tag2>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012,", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)", "and", "to", "the", "FDA", "in", "a", "follow-up", "advice", "procedure", "in", "the", "third", "quarter", "of", "2013", "(Type", "C", "request", "to", "which", "the", "FDA", "provided", "written", "responses", "in", "lieu", "of", "a", "meeting).", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)."], "wordsB": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012,", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)", "and", "to", "the", "FDA", "in", "a", "follow-up", "advice", "procedure", "in", "the", "third", "quarter", "of", "2013", "(Type", "C", "request", "to", "which", "the", "FDA", "provided", "written", "responses", "in", "lieu", "of", "a", "meeting)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p89_s6", "idA": "1316175_13_item1_p66_s0", "sentA": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012 and to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting).", "sentB": "Amended CHALIS-SC1 and CHABLIS SC-2 protocols were submitted to the FDA in the first quarter of 2014.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting).", "<tag2>", "Amended", "CHALIS-SC1", "and", "CHABLIS", "SC-2", "protocols", "were", "submitted", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)."], "wordsB": ["Amended", "CHALIS-SC1", "and", "CHABLIS", "SC-2", "protocols", "were", "submitted", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p90_s2", "idA": "1316175_13_item1_p66_s0", "sentA": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012 and to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting).", "sentB": "The meeting with the FDA in May 2013 focused on the choice of primary endpoints for an approval in the post-marketing setting.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting).", "<tag2>", "The", "meeting", "with", "the", "FDA", "in", "May", "2013", "focused", "on", "the", "choice", "of", "primary", "endpoints", "for", "an", "approval", "in", "the", "post-marketing", "setting.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)."], "wordsB": ["The", "meeting", "with", "the", "FDA", "in", "May", "2013", "focused", "on", "the", "choice", "of", "primary", "endpoints", "for", "an", "approval", "in", "the", "post-marketing", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p90_s4", "idA": "1316175_13_item1_p66_s0", "sentA": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012 and to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting).", "sentB": "Additional feedback from FDA on the IgA nephropathy program is anticipated in the second quarter of 2014.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting).", "<tag2>", "Additional", "feedback", "from", "FDA", "on", "the", "IgA", "nephropathy", "program", "is", "anticipated", "in", "the", "second", "quarter", "of", "2014.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012", "and", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)."], "wordsB": ["Additional", "feedback", "from", "FDA", "on", "the", "IgA", "nephropathy", "program", "is", "anticipated", "in", "the", "second", "quarter", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p89_s2", "idA": "1316175_13_item1_p66_s2", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies of similar design intended to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "of", "similar", "design", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "SLE", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "of", "similar", "design", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p89_s4", "idA": "1316175_13_item1_p66_s3", "sentA": "Each study will randomize approximately 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "sentB": "Each study plans to randomize approximately 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "type": 2, "words": ["<tag1>", "Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag2>", "Each", "study", "plans", "to", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag3>"], "wordsA": ["Each", "study", "will", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "wordsB": ["Each", "study", "plans", "to", "randomize", "approximately", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p51_s2", "idA": "1316175_13_item1_p67_s0", "sentA": "We submitted an application to the FDA in January 2013 requesting orphan designation for the use of blisibimod as a treatment for IgAN.", "sentB": "It is anticipated that these two CHABLIS studies, along with long-term safety observations from the CHABLIS-Open-Label Extension Study will form the basis of approval for blisibimod as a treatment for lupus patients with active disease despite the use of steroids.", "type": 2, "words": ["<tag1>", "We", "submitted", "an", "application", "to", "the", "FDA", "in", "January", "2013", "requesting", "orphan", "designation", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgAN.", "<tag2>", "It", "is", "anticipated", "that", "these", "two", "CHABLIS", "studies,", "along", "with", "long-term", "safety", "observations", "from", "the", "CHABLIS-Open-Label", "Extension", "Study", "will", "form", "the", "basis", "of", "approval", "for", "blisibimod", "as", "a", "treatment", "for", "lupus", "patients", "with", "active", "disease", "despite", "the", "use", "of", "steroids.", "<tag3>"], "wordsA": ["We", "submitted", "an", "application", "to", "the", "FDA", "in", "January", "2013", "requesting", "orphan", "designation", "for", "the", "use", "of", "blisibimod", "as", "a", "treatment", "for", "IgAN."], "wordsB": ["It", "is", "anticipated", "that", "these", "two", "CHABLIS", "studies,", "along", "with", "long-term", "safety", "observations", "from", "the", "CHABLIS-Open-Label", "Extension", "Study", "will", "form", "the", "basis", "of", "approval", "for", "blisibimod", "as", "a", "treatment", "for", "lupus", "patients", "with", "active", "disease", "despite", "the", "use", "of", "steroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p2_s1", "idA": "1316175_13_item1_p67_s1", "sentA": "We believe data from the BRIGHT-SC clinical study may provide information for other B-cell mediated kidney orphan diseases such as lupus nephritis and idiopathic membranous glomerulonephritis.", "sentB": "Elevated BAFF is also reported in hematological diseases such as multiple myeloma and idiopathic thrombocytopenia purpura.", "type": 2, "words": ["<tag1>", "We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "lupus", "nephritis", "and", "idiopathic", "membranous", "glomerulonephritis.", "<tag2>", "Elevated", "BAFF", "is", "also", "reported", "in", "hematological", "diseases", "such", "as", "multiple", "myeloma", "and", "idiopathic", "thrombocytopenia", "purpura.", "<tag3>"], "wordsA": ["We", "believe", "data", "from", "the", "BRIGHT-SC", "clinical", "study", "may", "provide", "information", "for", "other", "B-cell", "mediated", "kidney", "orphan", "diseases", "such", "as", "lupus", "nephritis", "and", "idiopathic", "membranous", "glomerulonephritis."], "wordsB": ["Elevated", "BAFF", "is", "also", "reported", "in", "hematological", "diseases", "such", "as", "multiple", "myeloma", "and", "idiopathic", "thrombocytopenia", "purpura."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p91_s0", "idA": "1316175_13_item1_p68_s0", "sentA": "In 2014, we anticipate submitting an application to designate blisibimod as a breakthrough therapy in the treatment of IgAN.", "sentB": "We anticipate submitting an application to designate blisibimod as a breakthrough therapy in the treatment of IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "2014,", "we", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgAN.", "<tag2>", "We", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "2014,", "we", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgAN."], "wordsB": ["We", "anticipate", "submitting", "an", "application", "to", "designate", "blisibimod", "as", "a", "breakthrough", "therapy", "in", "the", "treatment", "of", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p92_s0", "idA": "1316175_13_item1_p69_s0", "sentA": "The recent Food and Drug Administration and Innovation Act (FDASIA) provide a number of mechanisms intended to expedite the review and development of drugs for serious or life-threatening conditions.", "sentB": "The recent Food and Drug Administration Safety and Innovation Act (FDASIA) provide a number of mechanisms intended to expedite the review and development of drugs for serious or life-threatening conditions.", "type": 2, "words": ["<tag1>", "The", "recent", "Food", "and", "Drug", "Administration", "and", "Innovation", "Act", "(FDASIA)", "provide", "a", "number", "of", "mechanisms", "intended", "to", "expedite", "the", "review", "and", "development", "of", "drugs", "for", "serious", "or", "life-threatening", "conditions.", "<tag2>", "The", "recent", "Food", "and", "Drug", "Administration", "Safety", "and", "Innovation", "Act", "(FDASIA)", "provide", "a", "number", "of", "mechanisms", "intended", "to", "expedite", "the", "review", "and", "development", "of", "drugs", "for", "serious", "or", "life-threatening", "conditions.", "<tag3>"], "wordsA": ["The", "recent", "Food", "and", "Drug", "Administration", "and", "Innovation", "Act", "(FDASIA)", "provide", "a", "number", "of", "mechanisms", "intended", "to", "expedite", "the", "review", "and", "development", "of", "drugs", "for", "serious", "or", "life-threatening", "conditions."], "wordsB": ["The", "recent", "Food", "and", "Drug", "Administration", "Safety", "and", "Innovation", "Act", "(FDASIA)", "provide", "a", "number", "of", "mechanisms", "intended", "to", "expedite", "the", "review", "and", "development", "of", "drugs", "for", "serious", "or", "life-threatening", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p9_s0", "idA": "1316175_13_item1_p6_s0", "sentA": "We have worldwide rights to blisibimod in all potential indications.", "sentB": "We have worldwide rights to blisibimod for all potential indications.", "type": 2, "words": ["<tag1>", "We", "have", "worldwide", "rights", "to", "blisibimod", "in", "all", "potential", "indications.", "<tag2>", "We", "have", "worldwide", "rights", "to", "blisibimod", "for", "all", "potential", "indications.", "<tag3>"], "wordsA": ["We", "have", "worldwide", "rights", "to", "blisibimod", "in", "all", "potential", "indications."], "wordsB": ["We", "have", "worldwide", "rights", "to", "blisibimod", "for", "all", "potential", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p10_s0", "idA": "1316175_13_item1_p6_s1", "sentA": "In 2012, we completed a Phase 2b clinical study named PEARL-SC, to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus.", "sentB": "In 2012, we completed the PEARL-SC Phase 2b clinical study, which evaluated the efficacy and safety of multiple doses of subcutaneous blisibimod versus placebo in patients with active and seropositive lupus.", "type": 2, "words": ["<tag1>", "In", "2012,", "we", "completed", "a", "Phase", "2b", "clinical", "study", "named", "PEARL-SC,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "subcutaneous", "blisibimod", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag2>", "In", "2012,", "we", "completed", "the", "PEARL-SC", "Phase", "2b", "clinical", "study,", "which", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag3>"], "wordsA": ["In", "2012,", "we", "completed", "a", "Phase", "2b", "clinical", "study", "named", "PEARL-SC,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "subcutaneous", "blisibimod", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "wordsB": ["In", "2012,", "we", "completed", "the", "PEARL-SC", "Phase", "2b", "clinical", "study,", "which", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p12_s1", "idA": "1316175_13_item1_p6_s1", "sentA": "In 2012, we completed a Phase 2b clinical study named PEARL-SC, to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus.", "sentB": "Our current plan includes continuing the ongoing CHABLIS-SC1 clinical study in patients with active lupus and the BRIGHT-SC1 clinical study in patients with IgA nephropathy, and evaluating the potential of blisibimod in additional autoimmune and hematological diseases through clinical and nonclinical investigations.", "type": 2, "words": ["<tag1>", "In", "2012,", "we", "completed", "a", "Phase", "2b", "clinical", "study", "named", "PEARL-SC,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "subcutaneous", "blisibimod", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag2>", "Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC1", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "additional", "autoimmune", "and", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations.", "<tag3>"], "wordsA": ["In", "2012,", "we", "completed", "a", "Phase", "2b", "clinical", "study", "named", "PEARL-SC,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "subcutaneous", "blisibimod", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "wordsB": ["Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC1", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "additional", "autoimmune", "and", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p93_s1", "idA": "1316175_13_item1_p70_s0", "sentA": "Prior to our in-licensing of blisibimod, Amgen completed two Phase 1 clinical studies of blisibimod in lupus patients to evaluate the safety and pharmacokinetics of single and multiple doses of the drug using intravenous and subcutaneous formulations.", "sentB": "Prior to our in-licensing of blisibimod, our licensor, Amgen, completed two Phase 1 clinical studies of blisibimod in lupus patients to evaluate the safety and pharmacokinetics of single and multiple doses of the drug using intravenous and subcutaneous formulations.", "type": 2, "words": ["<tag1>", "Prior", "to", "our", "in-licensing", "of", "blisibimod,", "Amgen", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations.", "<tag2>", "Prior", "to", "our", "in-licensing", "of", "blisibimod,", "our", "licensor,", "Amgen,", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations.", "<tag3>"], "wordsA": ["Prior", "to", "our", "in-licensing", "of", "blisibimod,", "Amgen", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations."], "wordsB": ["Prior", "to", "our", "in-licensing", "of", "blisibimod,", "our", "licensor,", "Amgen,", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p93_s3", "idA": "1316175_13_item1_p70_s2", "sentA": "Intravenous doses included 1, 3 and 6 mg/kg, and subcutaneous doses included 0.1, 0.3, 1 and 3 mg/kg.", "sentB": "Intravenous doses included 1, 3 and 6mg/kg, and subcutaneous doses included 0.1, 0.3, 1 and 3mg/kg.", "type": 2, "words": ["<tag1>", "Intravenous", "doses", "included", "1,", "3", "and", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.1,", "0.3,", "1", "and", "3", "mg/kg.", "<tag2>", "Intravenous", "doses", "included", "1,", "3", "and", "6mg/kg,", "and", "subcutaneous", "doses", "included", "0.1,", "0.3,", "1", "and", "3mg/kg.", "<tag3>"], "wordsA": ["Intravenous", "doses", "included", "1,", "3", "and", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.1,", "0.3,", "1", "and", "3", "mg/kg."], "wordsB": ["Intravenous", "doses", "included", "1,", "3", "and", "6mg/kg,", "and", "subcutaneous", "doses", "included", "0.1,", "0.3,", "1", "and", "3mg/kg."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p97_s1", "idA": "1316175_13_item1_p74_s1", "sentA": "The intravenous dose was 6 mg/kg, and subcutaneous doses included 0.3, 1 and 3 mg/kg.", "sentB": "The intravenous dose was 6mg/kg, and subcutaneous doses included 0.3, 1 and 3 mg/kg.", "type": 2, "words": ["<tag1>", "The", "intravenous", "dose", "was", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg.", "<tag2>", "The", "intravenous", "dose", "was", "6mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg.", "<tag3>"], "wordsA": ["The", "intravenous", "dose", "was", "6", "mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg."], "wordsB": ["The", "intravenous", "dose", "was", "6mg/kg,", "and", "subcutaneous", "doses", "included", "0.3,", "1", "and", "3", "mg/kg."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p97_s6", "idA": "1316175_13_item1_p74_s6", "sentA": "Further, results demonstrated a significant decrease in total B-cells as early as 15 days of treatment, and total B-cell reduction (up to approximately 60-70% of baseline) reached its nadir after about 160 days of therapy.", "sentB": "Further, results demonstrated a significant decrease in total B-cells as early as 15 days after beginning treatment, and total B-cell reduction (up to approximately 60-70% of baseline) reached its nadir after about 160 days of therapy.", "type": 2, "words": ["<tag1>", "Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "of", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy.", "<tag2>", "Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "after", "beginning", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy.", "<tag3>"], "wordsA": ["Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "of", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy."], "wordsB": ["Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "after", "beginning", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p97_s7", "idA": "1316175_13_item1_p74_s7", "sentA": "By six months after treatment, the B-cell populations had returned to baseline levels.", "sentB": "By six months after beginning treatment, the B-cell populations had returned to baseline levels.", "type": 2, "words": ["<tag1>", "By", "six", "months", "after", "treatment,", "the", "B-cell", "populations", "had", "returned", "to", "baseline", "levels.", "<tag2>", "By", "six", "months", "after", "beginning", "treatment,", "the", "B-cell", "populations", "had", "returned", "to", "baseline", "levels.", "<tag3>"], "wordsA": ["By", "six", "months", "after", "treatment,", "the", "B-cell", "populations", "had", "returned", "to", "baseline", "levels."], "wordsB": ["By", "six", "months", "after", "beginning", "treatment,", "the", "B-cell", "populations", "had", "returned", "to", "baseline", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p97_s8", "idA": "1316175_13_item1_p74_s8", "sentA": "Further analyses of B cell subsets found that na ve B cells and activated B cells were significantly decreased while memory B cells were transiently significantly increased following treatment with blisibimod, consistent with a correction of the B cell abnormalities reported in lupus patients.", "sentB": "Further analyses of B-cell subsets found that na ve B-cells and activated B-cells were significantly decreased while memory B-cells were transiently significantly increased following treatment with blisibimod, consistent with a correction of the B-cell abnormalities reported in lupus patients.", "type": 2, "words": ["<tag1>", "Further", "analyses", "of", "B", "cell", "subsets", "found", "that", "na", "ve", "B", "cells", "and", "activated", "B", "cells", "were", "significantly", "decreased", "while", "memory", "B", "cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B", "cell", "abnormalities", "reported", "in", "lupus", "patients.", "<tag2>", "Further", "analyses", "of", "B-cell", "subsets", "found", "that", "na", "ve", "B-cells", "and", "activated", "B-cells", "were", "significantly", "decreased", "while", "memory", "B-cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B-cell", "abnormalities", "reported", "in", "lupus", "patients.", "<tag3>"], "wordsA": ["Further", "analyses", "of", "B", "cell", "subsets", "found", "that", "na", "ve", "B", "cells", "and", "activated", "B", "cells", "were", "significantly", "decreased", "while", "memory", "B", "cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B", "cell", "abnormalities", "reported", "in", "lupus", "patients."], "wordsB": ["Further", "analyses", "of", "B-cell", "subsets", "found", "that", "na", "ve", "B-cells", "and", "activated", "B-cells", "were", "significantly", "decreased", "while", "memory", "B-cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B-cell", "abnormalities", "reported", "in", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p11_s0", "idA": "1316175_13_item1_p7_s0", "sentA": "Lupus patients suffer from chronic autoimmune disease, where an inappropriate or abnormal immune response often leads to severe skin rash, fatigue, joint pain, major kidney complications and cardiovascular disease.", "sentB": "Lupus patients suffer from a chronic autoimmune disease, where an inappropriate or abnormal immune response often leads to severe skin rash, fatigue, joint pain, ulceration, major kidney complications, including proteinuria, and cardiovascular disease.", "type": 2, "words": ["<tag1>", "Lupus", "patients", "suffer", "from", "chronic", "autoimmune", "disease,", "where", "an", "inappropriate", "or", "abnormal", "immune", "response", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "major", "kidney", "complications", "and", "cardiovascular", "disease.", "<tag2>", "Lupus", "patients", "suffer", "from", "a", "chronic", "autoimmune", "disease,", "where", "an", "inappropriate", "or", "abnormal", "immune", "response", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "ulceration,", "major", "kidney", "complications,", "including", "proteinuria,", "and", "cardiovascular", "disease.", "<tag3>"], "wordsA": ["Lupus", "patients", "suffer", "from", "chronic", "autoimmune", "disease,", "where", "an", "inappropriate", "or", "abnormal", "immune", "response", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "major", "kidney", "complications", "and", "cardiovascular", "disease."], "wordsB": ["Lupus", "patients", "suffer", "from", "a", "chronic", "autoimmune", "disease,", "where", "an", "inappropriate", "or", "abnormal", "immune", "response", "often", "leads", "to", "severe", "skin", "rash,", "fatigue,", "joint", "pain,", "ulceration,", "major", "kidney", "complications,", "including", "proteinuria,", "and", "cardiovascular", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p11_s1", "idA": "1316175_13_item1_p7_s1", "sentA": "Inhibition of BAFF is believed to reduce survival and subsequent elevations in B-cells leading to a reduction in severity of disease and resolution of Lupus symptoms.", "sentB": "Inhibition of BAFF is believed to reduce survival of B-cells and plasma cells and autoantibodies, leading to a reduction in severity of disease and resolution of lupus symptoms.", "type": 2, "words": ["<tag1>", "Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "and", "subsequent", "elevations", "in", "B-cells", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "Lupus", "symptoms.", "<tag2>", "Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "of", "B-cells", "and", "plasma", "cells", "and", "autoantibodies,", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "lupus", "symptoms.", "<tag3>"], "wordsA": ["Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "and", "subsequent", "elevations", "in", "B-cells", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "Lupus", "symptoms."], "wordsB": ["Inhibition", "of", "BAFF", "is", "believed", "to", "reduce", "survival", "of", "B-cells", "and", "plasma", "cells", "and", "autoantibodies,", "leading", "to", "a", "reduction", "in", "severity", "of", "disease", "and", "resolution", "of", "lupus", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p100_s0", "idA": "1316175_13_item1_p83_s0", "sentA": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including autoimmune diseases.", "sentB": "Our objective is to develop and commercialize our product candidate to treat serious diseases associated with inflammation, including autoimmune diseases and hematological malignancies.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases.", "<tag2>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidate", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "hematological", "malignancies.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases."], "wordsB": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidate", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "hematological", "malignancies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p101_s1", "idA": "1316175_13_item1_p84_s1", "sentA": "We have completed Phase 1 and Phase 2b clinical studies with blisibimod in lupus patients and plan to advance blisibimod into a Phase 3 registration program in 2013.", "sentB": "We have completed a Phase 2b clinical study with blisibimod in patients with lupus and plan to continue the advancement of blisibimod in a Phase 3 registration program in lupus and IgA nephropathy and a Phase 2 clinical development in multiple myeloma in 2014.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "Phase", "1", "and", "Phase", "2b", "clinical", "studies", "with", "blisibimod", "in", "lupus", "patients", "and", "plan", "to", "advance", "blisibimod", "into", "a", "Phase", "3", "registration", "program", "in", "2013.", "<tag2>", "We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "a", "Phase", "3", "registration", "program", "in", "lupus", "and", "IgA", "nephropathy", "and", "a", "Phase", "2", "clinical", "development", "in", "multiple", "myeloma", "in", "2014.", "<tag3>"], "wordsA": ["We", "have", "completed", "Phase", "1", "and", "Phase", "2b", "clinical", "studies", "with", "blisibimod", "in", "lupus", "patients", "and", "plan", "to", "advance", "blisibimod", "into", "a", "Phase", "3", "registration", "program", "in", "2013."], "wordsB": ["We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "a", "Phase", "3", "registration", "program", "in", "lupus", "and", "IgA", "nephropathy", "and", "a", "Phase", "2", "clinical", "development", "in", "multiple", "myeloma", "in", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p101_s2", "idA": "1316175_13_item1_p84_s2", "sentA": "We may opportunistically enter into collaborations with third parties for development of this compound in lupus or in other B-cell mediated diseases, such as IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "sentB": "We may opportunistically enter into collaborations with third parties for development of blisibimod in lupus or in other B-cell mediated diseases, such as IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "multiple", "myeloma,", "vasculitis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "this", "compound", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "vasculitis,", "rheumatoid", "arthritis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "multiple", "myeloma,", "vasculitis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p102_s2", "idA": "1316175_13_item1_p85_s2", "sentA": "The data will help us select an appropriate orphan path to supplement our approach in lupus.", "sentB": "It is anticipated that the data will help us select an appropriate orphan path to supplement our approach in lupus.", "type": 2, "words": ["<tag1>", "The", "data", "will", "help", "us", "select", "an", "appropriate", "orphan", "path", "to", "supplement", "our", "approach", "in", "lupus.", "<tag2>", "It", "is", "anticipated", "that", "the", "data", "will", "help", "us", "select", "an", "appropriate", "orphan", "path", "to", "supplement", "our", "approach", "in", "lupus.", "<tag3>"], "wordsA": ["The", "data", "will", "help", "us", "select", "an", "appropriate", "orphan", "path", "to", "supplement", "our", "approach", "in", "lupus."], "wordsB": ["It", "is", "anticipated", "that", "the", "data", "will", "help", "us", "select", "an", "appropriate", "orphan", "path", "to", "supplement", "our", "approach", "in", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p102_s3", "idA": "1316175_13_item1_p85_s3", "sentA": "We believe that this orphan approach will further differentiate blisibimod from other anti-BAFF molecules in a capital-efficient manner.", "sentB": "We believe that this orphan approach will further differentiate blisibimod from other anti-BAFF molecules.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules", "in", "a", "capital-efficient", "manner.", "<tag2>", "We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules", "in", "a", "capital-efficient", "manner."], "wordsB": ["We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p130_s1", "idA": "1316175_13_item1_p85_s3", "sentA": "We believe that this orphan approach will further differentiate blisibimod from other anti-BAFF molecules in a capital-efficient manner.", "sentB": "We believe that this will provide a sufficient supply of these raw materials and drug product to meet our needs for the foreseeable future.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules", "in", "a", "capital-efficient", "manner.", "<tag2>", "We", "believe", "that", "this", "will", "provide", "a", "sufficient", "supply", "of", "these", "raw", "materials", "and", "drug", "product", "to", "meet", "our", "needs", "for", "the", "foreseeable", "future.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules", "in", "a", "capital-efficient", "manner."], "wordsB": ["We", "believe", "that", "this", "will", "provide", "a", "sufficient", "supply", "of", "these", "raw", "materials", "and", "drug", "product", "to", "meet", "our", "needs", "for", "the", "foreseeable", "future."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p105_s0", "idA": "1316175_13_item1_p86_s0", "sentA": "The progression of patients with IgA nephropathy and lupus nephritis to end stage renal disease poses a considerable cost and societal burden.", "sentB": "The cost and societal burden of multiple myeloma are considerable as the disease typically presents during the 4 th to 7 th decades of a patient s life, and the median survival is 2-4 years for patients with Stage II - III disease.", "type": 2, "words": ["<tag1>", "The", "progression", "of", "patients", "with", "IgA", "nephropathy", "and", "lupus", "nephritis", "to", "end", "stage", "renal", "disease", "poses", "a", "considerable", "cost", "and", "societal", "burden.", "<tag2>", "The", "cost", "and", "societal", "burden", "of", "multiple", "myeloma", "are", "considerable", "as", "the", "disease", "typically", "presents", "during", "the", "4", "th", "to", "7", "th", "decades", "of", "a", "patient", "s", "life,", "and", "the", "median", "survival", "is", "2-4", "years", "for", "patients", "with", "Stage", "II", "-", "III", "disease.", "<tag3>"], "wordsA": ["The", "progression", "of", "patients", "with", "IgA", "nephropathy", "and", "lupus", "nephritis", "to", "end", "stage", "renal", "disease", "poses", "a", "considerable", "cost", "and", "societal", "burden."], "wordsB": ["The", "cost", "and", "societal", "burden", "of", "multiple", "myeloma", "are", "considerable", "as", "the", "disease", "typically", "presents", "during", "the", "4", "th", "to", "7", "th", "decades", "of", "a", "patient", "s", "life,", "and", "the", "median", "survival", "is", "2-4", "years", "for", "patients", "with", "Stage", "II", "-", "III", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p58_s0", "idA": "1316175_13_item1_p86_s0", "sentA": "The progression of patients with IgA nephropathy and lupus nephritis to end stage renal disease poses a considerable cost and societal burden.", "sentB": "Data for the cumulative renal survival rate observed from the time of renal biopsy until a diagnosis of end-stage renal disease in 1,012 patients with IgA Nephopathy (Presented by Moriyama and colleagues at the American Society of Nephrology, 2013).", "type": 2, "words": ["<tag1>", "The", "progression", "of", "patients", "with", "IgA", "nephropathy", "and", "lupus", "nephritis", "to", "end", "stage", "renal", "disease", "poses", "a", "considerable", "cost", "and", "societal", "burden.", "<tag2>", "Data", "for", "the", "cumulative", "renal", "survival", "rate", "observed", "from", "the", "time", "of", "renal", "biopsy", "until", "a", "diagnosis", "of", "end-stage", "renal", "disease", "in", "1,012", "patients", "with", "IgA", "Nephopathy", "(Presented", "by", "Moriyama", "and", "colleagues", "at", "the", "American", "Society", "of", "Nephrology,", "2013).", "<tag3>"], "wordsA": ["The", "progression", "of", "patients", "with", "IgA", "nephropathy", "and", "lupus", "nephritis", "to", "end", "stage", "renal", "disease", "poses", "a", "considerable", "cost", "and", "societal", "burden."], "wordsB": ["Data", "for", "the", "cumulative", "renal", "survival", "rate", "observed", "from", "the", "time", "of", "renal", "biopsy", "until", "a", "diagnosis", "of", "end-stage", "renal", "disease", "in", "1,012", "patients", "with", "IgA", "Nephopathy", "(Presented", "by", "Moriyama", "and", "colleagues", "at", "the", "American", "Society", "of", "Nephrology,", "2013)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p103_s2", "idA": "1316175_13_item1_p86_s2", "sentA": "In addition, we believe successful outcomes in the BRIGHT-SC study will support future lifecycle expansion for blisibimod.", "sentB": "In addition, we believe successful outcomes in our clinical studies targeting IgA nephropathy will support future lifecycle expansion for blisibimod.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "believe", "successful", "outcomes", "in", "the", "BRIGHT-SC", "study", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod.", "<tag2>", "In", "addition,", "we", "believe", "successful", "outcomes", "in", "our", "clinical", "studies", "targeting", "IgA", "nephropathy", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod.", "<tag3>"], "wordsA": ["In", "addition,", "we", "believe", "successful", "outcomes", "in", "the", "BRIGHT-SC", "study", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod."], "wordsB": ["In", "addition,", "we", "believe", "successful", "outcomes", "in", "our", "clinical", "studies", "targeting", "IgA", "nephropathy", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p50_s2", "idA": "1316175_13_item1_p86_s2", "sentA": "In addition, we believe successful outcomes in the BRIGHT-SC study will support future lifecycle expansion for blisibimod.", "sentB": "Regardless of the outcome of the interim analysis, all patients randomized into the CHABLIS-SC1 study will be allowed to complete the full 52 weeks of blinded treatment to provide additional safety and efficacy data for future regulatory filings for other potential indications for blisibimod.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "believe", "successful", "outcomes", "in", "the", "BRIGHT-SC", "study", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod.", "<tag2>", "Regardless", "of", "the", "outcome", "of", "the", "interim", "analysis,", "all", "patients", "randomized", "into", "the", "CHABLIS-SC1", "study", "will", "be", "allowed", "to", "complete", "the", "full", "52", "weeks", "of", "blinded", "treatment", "to", "provide", "additional", "safety", "and", "efficacy", "data", "for", "future", "regulatory", "filings", "for", "other", "potential", "indications", "for", "blisibimod.", "<tag3>"], "wordsA": ["In", "addition,", "we", "believe", "successful", "outcomes", "in", "the", "BRIGHT-SC", "study", "will", "support", "future", "lifecycle", "expansion", "for", "blisibimod."], "wordsB": ["Regardless", "of", "the", "outcome", "of", "the", "interim", "analysis,", "all", "patients", "randomized", "into", "the", "CHABLIS-SC1", "study", "will", "be", "allowed", "to", "complete", "the", "full", "52", "weeks", "of", "blinded", "treatment", "to", "provide", "additional", "safety", "and", "efficacy", "data", "for", "future", "regulatory", "filings", "for", "other", "potential", "indications", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p106_s0", "idA": "1316175_13_item1_p88_s0", "sentA": "Our primary product candidate is focused on highly-specialized physician segments, such as rheumatologists and nephrologists.", "sentB": "Our product candidate is focused on highly-specialized physician segments, such as rheumatologists and nephrologists.", "type": 2, "words": ["<tag1>", "Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists.", "<tag2>", "Our", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists.", "<tag3>"], "wordsA": ["Our", "primary", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists."], "wordsB": ["Our", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p107_s2", "idA": "1316175_13_item1_p89_s2", "sentA": "We believe that key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement.", "sentB": "We believe that key competitive factors that will affect the development and commercial success of our product candidate are efficacy, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidates", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement.", "<tag2>", "We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidate", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement.", "<tag3>"], "wordsA": ["We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidates", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement."], "wordsB": ["We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidate", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p12_s0", "idA": "1316175_13_item1_p8_s0", "sentA": "Our product development programs are focused on blisibimod and its use as therapeutic treatments for lupus and other serious autoimmune diseases for which we believe current treatments are either inadequate or non-existent.", "sentB": "Our product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which we believe current treatments are either inadequate or non-existent.", "type": 2, "words": ["<tag1>", "Our", "product", "development", "programs", "are", "focused", "on", "blisibimod", "and", "its", "use", "as", "therapeutic", "treatments", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag2>", "Our", "product", "development", "program", "is", "focused", "on", "development", "of", "blisibimod", "for", "use", "as", "a", "therapeutic", "treatment", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag3>"], "wordsA": ["Our", "product", "development", "programs", "are", "focused", "on", "blisibimod", "and", "its", "use", "as", "therapeutic", "treatments", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "wordsB": ["Our", "product", "development", "program", "is", "focused", "on", "development", "of", "blisibimod", "for", "use", "as", "a", "therapeutic", "treatment", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p131_s0", "idA": "1316175_13_item1_p8_s1", "sentA": "Our current plan includes commencing the CHABLIS-SC and BRIGHT-SC clinical studies, continuing the ongoing blisibimod open label extension safety and efficacy study, or OLE study, and investigating the structure of future clinical studies and research and development activities.", "sentB": "Our research and development activities involve the controlled use of potentially hazardous substances, including toxic chemical and biological materials.", "type": 2, "words": ["<tag1>", "Our", "current", "plan", "includes", "commencing", "the", "CHABLIS-SC", "and", "BRIGHT-SC", "clinical", "studies,", "continuing", "the", "ongoing", "blisibimod", "open", "label", "extension", "safety", "and", "efficacy", "study,", "or", "OLE", "study,", "and", "investigating", "the", "structure", "of", "future", "clinical", "studies", "and", "research", "and", "development", "activities.", "<tag2>", "Our", "research", "and", "development", "activities", "involve", "the", "controlled", "use", "of", "potentially", "hazardous", "substances,", "including", "toxic", "chemical", "and", "biological", "materials.", "<tag3>"], "wordsA": ["Our", "current", "plan", "includes", "commencing", "the", "CHABLIS-SC", "and", "BRIGHT-SC", "clinical", "studies,", "continuing", "the", "ongoing", "blisibimod", "open", "label", "extension", "safety", "and", "efficacy", "study,", "or", "OLE", "study,", "and", "investigating", "the", "structure", "of", "future", "clinical", "studies", "and", "research", "and", "development", "activities."], "wordsB": ["Our", "research", "and", "development", "activities", "involve", "the", "controlled", "use", "of", "potentially", "hazardous", "substances,", "including", "toxic", "chemical", "and", "biological", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p108_s0", "idA": "1316175_13_item1_p90_s0", "sentA": "Many of our potential competitors, including many of the organizations named below, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products.", "sentB": "Many of our potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products.", "type": 2, "words": ["<tag1>", "Many", "of", "our", "potential", "competitors,", "including", "many", "of", "the", "organizations", "named", "below,", "have", "substantially", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "significantly", "greater", "experience", "in", "the", "discovery", "and", "development", "of", "product", "candidates,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "of", "products", "and", "the", "commercialization", "of", "those", "products.", "<tag2>", "Many", "of", "our", "potential", "competitors", "have", "substantially", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "significantly", "greater", "experience", "in", "the", "discovery", "and", "development", "of", "product", "candidates,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "of", "products", "and", "the", "commercialization", "of", "those", "products.", "<tag3>"], "wordsA": ["Many", "of", "our", "potential", "competitors,", "including", "many", "of", "the", "organizations", "named", "below,", "have", "substantially", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "significantly", "greater", "experience", "in", "the", "discovery", "and", "development", "of", "product", "candidates,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "of", "products", "and", "the", "commercialization", "of", "those", "products."], "wordsB": ["Many", "of", "our", "potential", "competitors", "have", "substantially", "greater", "financial,", "technical", "and", "human", "resources", "than", "we", "do", "and", "significantly", "greater", "experience", "in", "the", "discovery", "and", "development", "of", "product", "candidates,", "obtaining", "FDA", "and", "other", "regulatory", "approvals", "of", "products", "and", "the", "commercialization", "of", "those", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p109_s0", "idA": "1316175_13_item1_p91_s0", "sentA": "Benlysta (belimumab) was approved in 2011 by the FDA for the treatment of lupus.", "sentB": "Human Genome Sciences, Inc. and partner GlaxoSmithKline plc (GSK) obtained FDA approval for Benlysta (belimumab) in 2011 for the treatment of lupus.", "type": 2, "words": ["<tag1>", "Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Human", "Genome", "Sciences,", "Inc.", "and", "partner", "GlaxoSmithKline", "plc", "(GSK)", "obtained", "FDA", "approval", "for", "Benlysta", "(belimumab)", "in", "2011", "for", "the", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Benlysta", "(belimumab)", "was", "approved", "in", "2011", "by", "the", "FDA", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Human", "Genome", "Sciences,", "Inc.", "and", "partner", "GlaxoSmithKline", "plc", "(GSK)", "obtained", "FDA", "approval", "for", "Benlysta", "(belimumab)", "in", "2011", "for", "the", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p109_s1", "idA": "1316175_13_item1_p91_s1", "sentA": "It is the first novel therapy approved in the last 50 years.", "sentB": "Benlysta , the first novel therapy approved in the last 50 years, was acquired by GSK in July 2012.", "type": 2, "words": ["<tag1>", "It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years.", "<tag2>", "Benlysta", ",", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years,", "was", "acquired", "by", "GSK", "in", "July", "2012.", "<tag3>"], "wordsA": ["It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years."], "wordsB": ["Benlysta", ",", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years,", "was", "acquired", "by", "GSK", "in", "July", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p71_s1", "idA": "1316175_13_item1_p91_s1", "sentA": "It is the first novel therapy approved in the last 50 years.", "sentB": "It is therefore not surprising that survival of patient-derived multiple myeloma cells is decreased in the presence of a BAFF inhibitor when administered on its own or in combination with steroid or lenalidomide.", "type": 2, "words": ["<tag1>", "It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years.", "<tag2>", "It", "is", "therefore", "not", "surprising", "that", "survival", "of", "patient-derived", "multiple", "myeloma", "cells", "is", "decreased", "in", "the", "presence", "of", "a", "BAFF", "inhibitor", "when", "administered", "on", "its", "own", "or", "in", "combination", "with", "steroid", "or", "lenalidomide.", "<tag3>"], "wordsA": ["It", "is", "the", "first", "novel", "therapy", "approved", "in", "the", "last", "50", "years."], "wordsB": ["It", "is", "therefore", "not", "surprising", "that", "survival", "of", "patient-derived", "multiple", "myeloma", "cells", "is", "decreased", "in", "the", "presence", "of", "a", "BAFF", "inhibitor", "when", "administered", "on", "its", "own", "or", "in", "combination", "with", "steroid", "or", "lenalidomide."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p110_s0", "idA": "1316175_13_item1_p92_s0", "sentA": "Current therapies such as non-steroidal anti-inflammatory drugs, or NSAIDs, corticosteroids and immunosuppressants generally act to hold back broadly the proliferation of many types of cells, including white blood cells.", "sentB": "Other current therapies such as non-steroidal anti-inflammatory drugs, or NSAIDs, corticosteroids, anti-malarials and immunosuppressants generally act to hold back broadly the proliferation of many types of cells, including white blood cells.", "type": 2, "words": ["<tag1>", "Current", "therapies", "such", "as", "non-steroidal", "anti-inflammatory", "drugs,", "or", "NSAIDs,", "corticosteroids", "and", "immunosuppressants", "generally", "act", "to", "hold", "back", "broadly", "the", "proliferation", "of", "many", "types", "of", "cells,", "including", "white", "blood", "cells.", "<tag2>", "Other", "current", "therapies", "such", "as", "non-steroidal", "anti-inflammatory", "drugs,", "or", "NSAIDs,", "corticosteroids,", "anti-malarials", "and", "immunosuppressants", "generally", "act", "to", "hold", "back", "broadly", "the", "proliferation", "of", "many", "types", "of", "cells,", "including", "white", "blood", "cells.", "<tag3>"], "wordsA": ["Current", "therapies", "such", "as", "non-steroidal", "anti-inflammatory", "drugs,", "or", "NSAIDs,", "corticosteroids", "and", "immunosuppressants", "generally", "act", "to", "hold", "back", "broadly", "the", "proliferation", "of", "many", "types", "of", "cells,", "including", "white", "blood", "cells."], "wordsB": ["Other", "current", "therapies", "such", "as", "non-steroidal", "anti-inflammatory", "drugs,", "or", "NSAIDs,", "corticosteroids,", "anti-malarials", "and", "immunosuppressants", "generally", "act", "to", "hold", "back", "broadly", "the", "proliferation", "of", "many", "types", "of", "cells,", "including", "white", "blood", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p110_s1", "idA": "1316175_13_item1_p92_s1", "sentA": "However, use of these agents is associated with significant adverse events and broad immune suppression.", "sentB": "However, use of these agents is often associated with limited efficacy or significant adverse events and broad immune suppression.", "type": 2, "words": ["<tag1>", "However,", "use", "of", "these", "agents", "is", "associated", "with", "significant", "adverse", "events", "and", "broad", "immune", "suppression.", "<tag2>", "However,", "use", "of", "these", "agents", "is", "often", "associated", "with", "limited", "efficacy", "or", "significant", "adverse", "events", "and", "broad", "immune", "suppression.", "<tag3>"], "wordsA": ["However,", "use", "of", "these", "agents", "is", "associated", "with", "significant", "adverse", "events", "and", "broad", "immune", "suppression."], "wordsB": ["However,", "use", "of", "these", "agents", "is", "often", "associated", "with", "limited", "efficacy", "or", "significant", "adverse", "events", "and", "broad", "immune", "suppression."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p69_s0", "idA": "1316175_13_item1_p92_s1", "sentA": "However, use of these agents is associated with significant adverse events and broad immune suppression.", "sentB": "Multiple myeloma is associated with over-production and altered function of cancerous forms of plasma cells in the bone marrow.", "type": 2, "words": ["<tag1>", "However,", "use", "of", "these", "agents", "is", "associated", "with", "significant", "adverse", "events", "and", "broad", "immune", "suppression.", "<tag2>", "Multiple", "myeloma", "is", "associated", "with", "over-production", "and", "altered", "function", "of", "cancerous", "forms", "of", "plasma", "cells", "in", "the", "bone", "marrow.", "<tag3>"], "wordsA": ["However,", "use", "of", "these", "agents", "is", "associated", "with", "significant", "adverse", "events", "and", "broad", "immune", "suppression."], "wordsB": ["Multiple", "myeloma", "is", "associated", "with", "over-production", "and", "altered", "function", "of", "cancerous", "forms", "of", "plasma", "cells", "in", "the", "bone", "marrow."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p85_s0", "idA": "1316175_13_item1_p92_s1", "sentA": "However, use of these agents is associated with significant adverse events and broad immune suppression.", "sentB": "Multiple myeloma is associated with over-production and altered function of cancerous forms of plasma cells in the bone marrow.", "type": 2, "words": ["<tag1>", "However,", "use", "of", "these", "agents", "is", "associated", "with", "significant", "adverse", "events", "and", "broad", "immune", "suppression.", "<tag2>", "Multiple", "myeloma", "is", "associated", "with", "over-production", "and", "altered", "function", "of", "cancerous", "forms", "of", "plasma", "cells", "in", "the", "bone", "marrow.", "<tag3>"], "wordsA": ["However,", "use", "of", "these", "agents", "is", "associated", "with", "significant", "adverse", "events", "and", "broad", "immune", "suppression."], "wordsB": ["Multiple", "myeloma", "is", "associated", "with", "over-production", "and", "altered", "function", "of", "cancerous", "forms", "of", "plasma", "cells", "in", "the", "bone", "marrow."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p111_s0", "idA": "1316175_13_item1_p93_s0", "sentA": "Several new biological agents under development have targeted BAFF (or BLyS) and other B-cell related pathways for the treatment of lupus.", "sentB": "Several new biological agents under development have targeted BAFF (like Benlysta ) and other B-cell related pathways for the treatment of lupus.", "type": 2, "words": ["<tag1>", "Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(or", "BLyS)", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(like", "Benlysta", ")", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(or", "BLyS)", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(like", "Benlysta", ")", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p111_s1", "idA": "1316175_13_item1_p93_s1", "sentA": "These product candidates include Benlysta (belimumab) from Human Genome Sciences, Inc., tabalumab (LY2127399) from Eli Lilly and Company, atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc., as well as others acting via non B-cell mechanisms, such as Lupuzor from Cephalon.", "sentB": "These product candidates include tabalumab (LY2127399) from Eli Lilly and Company, atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc.", "type": 2, "words": ["<tag1>", "These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon.", "<tag2>", "These", "product", "candidates", "include", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.", "<tag3>"], "wordsA": ["These", "product", "candidates", "include", "Benlysta", "(belimumab)", "from", "Human", "Genome", "Sciences,", "Inc.,", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.,", "as", "well", "as", "others", "acting", "via", "non", "B-cell", "mechanisms,", "such", "as", "Lupuzor", "from", "Cephalon."], "wordsB": ["These", "product", "candidates", "include", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p117_s1", "idA": "1316175_13_item1_p99_s1", "sentA": "In addition, we hold a non-exclusive worldwide license to one pending U.S. non-provisional patent application, one EP patent, one pending EP patent application, 14 non-EP foreign patents, and over 40 pending non-EP foreign patent applications relating to general peptibody compositions and formulations.", "sentB": "In addition, we hold a non-exclusive worldwide license to one pending U.S. non-provisional patent application, one EP patent, one pending EP patent application, and over 50 non-EP foreign patents and pending patent applications relating to general peptibody compositions and formulations.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "14", "non-EP", "foreign", "patents,", "and", "over", "40", "pending", "non-EP", "foreign", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations.", "<tag2>", "In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "and", "over", "50", "non-EP", "foreign", "patents", "and", "pending", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations.", "<tag3>"], "wordsA": ["In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "14", "non-EP", "foreign", "patents,", "and", "over", "40", "pending", "non-EP", "foreign", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations."], "wordsB": ["In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "and", "over", "50", "non-EP", "foreign", "patents", "and", "pending", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_14_item1_p14_s1", "idA": "1316175_13_item1_p9_s1", "sentA": "We are actively pursuing various partnerships with major pharmaceutical and biotech companies to develop and commercialize blisibimod for both lupus and additional indications.", "sentB": "We are actively pursuing various partnerships with major pharmaceutical and biotech companies to develop and commercialize blisibimod for both lupus and IgA nephropathy.", "type": 2, "words": ["<tag1>", "We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "additional", "indications.", "<tag2>", "We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "additional", "indications."], "wordsB": ["We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p101_s0", "idA": "1316175_14_item1_p100_s0", "sentA": "Our objective is to develop and commercialize our product candidate to treat serious diseases associated with inflammation, including autoimmune diseases and hematological malignancies.", "sentB": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including autoimmune diseases and enzyme replacement therapies.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidate", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "hematological", "malignancies.", "<tag2>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "enzyme", "replacement", "therapies.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidate", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "hematological", "malignancies."], "wordsB": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "enzyme", "replacement", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p102_s0", "idA": "1316175_14_item1_p101_s0", "sentA": "We are advancing the development of blisibimod to exploit the broad potential clinical utility of BAFF antagonism.", "sentB": "We are advancing the development of blisibimod to evaluate the broad potential clinical utility of BAFF antagonism.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "exploit", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism.", "<tag2>", "We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "evaluate", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "exploit", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism."], "wordsB": ["We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "evaluate", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p102_s1", "idA": "1316175_14_item1_p101_s1", "sentA": "We have completed a Phase 2b clinical study with blisibimod in patients with lupus and plan to continue the advancement of blisibimod in a Phase 3 registration program in lupus and IgA nephropathy and a Phase 2 clinical development in multiple myeloma in 2014.", "sentB": "We have completed a Phase 2b clinical study with blisibimod in patients with lupus and plan to continue the advancement of blisibimod in our ongoing Phase 3 registration program in lupus and development in IgA nephropathy in 2015.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "a", "Phase", "3", "registration", "program", "in", "lupus", "and", "IgA", "nephropathy", "and", "a", "Phase", "2", "clinical", "development", "in", "multiple", "myeloma", "in", "2014.", "<tag2>", "We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "our", "ongoing", "Phase", "3", "registration", "program", "in", "lupus", "and", "development", "in", "IgA", "nephropathy", "in", "2015.", "<tag3>"], "wordsA": ["We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "a", "Phase", "3", "registration", "program", "in", "lupus", "and", "IgA", "nephropathy", "and", "a", "Phase", "2", "clinical", "development", "in", "multiple", "myeloma", "in", "2014."], "wordsB": ["We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "our", "ongoing", "Phase", "3", "registration", "program", "in", "lupus", "and", "development", "in", "IgA", "nephropathy", "in", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p102_s2", "idA": "1316175_14_item1_p101_s1", "sentA": "We have completed a Phase 2b clinical study with blisibimod in patients with lupus and plan to continue the advancement of blisibimod in a Phase 3 registration program in lupus and IgA nephropathy and a Phase 2 clinical development in multiple myeloma in 2014.", "sentB": "We intend to initiate the development of liprotamase in a Phase 3 registration program in the second half of 2015 in patients with cystic fibrosis-related Exocrine Pancreatic Insufficiency.", "type": 2, "words": ["<tag1>", "We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "a", "Phase", "3", "registration", "program", "in", "lupus", "and", "IgA", "nephropathy", "and", "a", "Phase", "2", "clinical", "development", "in", "multiple", "myeloma", "in", "2014.", "<tag2>", "We", "intend", "to", "initiate", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "the", "second", "half", "of", "2015", "in", "patients", "with", "cystic", "fibrosis-related", "Exocrine", "Pancreatic", "Insufficiency.", "<tag3>"], "wordsA": ["We", "have", "completed", "a", "Phase", "2b", "clinical", "study", "with", "blisibimod", "in", "patients", "with", "lupus", "and", "plan", "to", "continue", "the", "advancement", "of", "blisibimod", "in", "a", "Phase", "3", "registration", "program", "in", "lupus", "and", "IgA", "nephropathy", "and", "a", "Phase", "2", "clinical", "development", "in", "multiple", "myeloma", "in", "2014."], "wordsB": ["We", "intend", "to", "initiate", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "the", "second", "half", "of", "2015", "in", "patients", "with", "cystic", "fibrosis-related", "Exocrine", "Pancreatic", "Insufficiency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p102_s3", "idA": "1316175_14_item1_p101_s2", "sentA": "We may opportunistically enter into collaborations with third parties for development of blisibimod in lupus or in other B-cell mediated diseases, such as IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others that may benefit from BAFF antagonism, including securing corporate partners whose capabilities complement ours.", "sentB": "We may opportunistically enter into collaborations with third parties for development of blisibimod in lupus or for the development of liprotamase, including securing corporate partners whose capabilities complement ours.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "multiple", "myeloma,", "vasculitis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "for", "the", "development", "of", "liprotamase,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "in", "other", "B-cell", "mediated", "diseases,", "such", "as", "IgA", "nephropathy,", "lupus", "nephritis,", "multiple", "myeloma,", "vasculitis,", "idiopathic", "thrombocytopenia", "purpura,", "and", "others", "that", "may", "benefit", "from", "BAFF", "antagonism,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "for", "the", "development", "of", "liprotamase,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s5", "idA": "1316175_14_item1_p102_s3", "sentA": "We believe that this orphan approach will further differentiate blisibimod from other anti-BAFF molecules.", "sentB": "Key secondary outcomes from the study, including SRI-8, reduction in the number of lupus flares and steroid use, are intended to further differentiate blisibimod from currently available therapies.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules.", "<tag2>", "Key", "secondary", "outcomes", "from", "the", "study,", "including", "SRI-8,", "reduction", "in", "the", "number", "of", "lupus", "flares", "and", "steroid", "use,", "are", "intended", "to", "further", "differentiate", "blisibimod", "from", "currently", "available", "therapies.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "orphan", "approach", "will", "further", "differentiate", "blisibimod", "from", "other", "anti-BAFF", "molecules."], "wordsB": ["Key", "secondary", "outcomes", "from", "the", "study,", "including", "SRI-8,", "reduction", "in", "the", "number", "of", "lupus", "flares", "and", "steroid", "use,", "are", "intended", "to", "further", "differentiate", "blisibimod", "from", "currently", "available", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p103_s0", "idA": "1316175_14_item1_p106_s0", "sentA": "Our product candidate is focused on highly-specialized physician segments, such as rheumatologists and nephrologists.", "sentB": "Our product candidates are focused on highly-specialized physician segments, such as rheumatologists, nephrologists and cystic fibrosis specialists.", "type": 2, "words": ["<tag1>", "Our", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists.", "<tag2>", "Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists,", "nephrologists", "and", "cystic", "fibrosis", "specialists.", "<tag3>"], "wordsA": ["Our", "product", "candidate", "is", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists", "and", "nephrologists."], "wordsB": ["Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists,", "nephrologists", "and", "cystic", "fibrosis", "specialists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p104_s3", "idA": "1316175_14_item1_p107_s2", "sentA": "We believe that key competitive factors that will affect the development and commercial success of our product candidate are efficacy, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement.", "sentB": "We believe that key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price and reimbursement.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidate", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement.", "<tag2>", "We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidates", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement.", "<tag3>"], "wordsA": ["We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidate", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement."], "wordsB": ["We", "believe", "that", "key", "competitive", "factors", "that", "will", "affect", "the", "development", "and", "commercial", "success", "of", "our", "product", "candidates", "are", "efficacy,", "safety", "and", "tolerability", "profile,", "reliability,", "convenience", "of", "dosing,", "price", "and", "reimbursement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p15_s0", "idA": "1316175_14_item1_p109_s0", "sentA": "Human Genome Sciences, Inc. and partner GlaxoSmithKline plc (GSK) obtained FDA approval for Benlysta (belimumab) in 2011 for the treatment of lupus.", "sentB": "Orally delivered porcine PERTs have been available for many years for the treatment of EPI.", "type": 2, "words": ["<tag1>", "Human", "Genome", "Sciences,", "Inc.", "and", "partner", "GlaxoSmithKline", "plc", "(GSK)", "obtained", "FDA", "approval", "for", "Benlysta", "(belimumab)", "in", "2011", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Orally", "delivered", "porcine", "PERTs", "have", "been", "available", "for", "many", "years", "for", "the", "treatment", "of", "EPI.", "<tag3>"], "wordsA": ["Human", "Genome", "Sciences,", "Inc.", "and", "partner", "GlaxoSmithKline", "plc", "(GSK)", "obtained", "FDA", "approval", "for", "Benlysta", "(belimumab)", "in", "2011", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Orally", "delivered", "porcine", "PERTs", "have", "been", "available", "for", "many", "years", "for", "the", "treatment", "of", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p15_s1", "idA": "1316175_14_item1_p109_s0", "sentA": "Human Genome Sciences, Inc. and partner GlaxoSmithKline plc (GSK) obtained FDA approval for Benlysta (belimumab) in 2011 for the treatment of lupus.", "sentB": "Unmet medical needs for the treatment of EPI remain.", "type": 2, "words": ["<tag1>", "Human", "Genome", "Sciences,", "Inc.", "and", "partner", "GlaxoSmithKline", "plc", "(GSK)", "obtained", "FDA", "approval", "for", "Benlysta", "(belimumab)", "in", "2011", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Unmet", "medical", "needs", "for", "the", "treatment", "of", "EPI", "remain.", "<tag3>"], "wordsA": ["Human", "Genome", "Sciences,", "Inc.", "and", "partner", "GlaxoSmithKline", "plc", "(GSK)", "obtained", "FDA", "approval", "for", "Benlysta", "(belimumab)", "in", "2011", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Unmet", "medical", "needs", "for", "the", "treatment", "of", "EPI", "remain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p42_s1", "idA": "1316175_14_item1_p10_s0", "sentA": "In 2012, we completed the PEARL-SC Phase 2b clinical study, which evaluated the efficacy and safety of multiple doses of subcutaneous blisibimod versus placebo in patients with active and seropositive lupus.", "sentB": "SOLUTION is a Phase 3, randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the efficacy and safety of liprotamase in patients with cystic fibrosis-related exocrine pancreatic insufficiency.", "type": 2, "words": ["<tag1>", "In", "2012,", "we", "completed", "the", "PEARL-SC", "Phase", "2b", "clinical", "study,", "which", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag2>", "SOLUTION", "is", "a", "Phase", "3,", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "liprotamase", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency.", "<tag3>"], "wordsA": ["In", "2012,", "we", "completed", "the", "PEARL-SC", "Phase", "2b", "clinical", "study,", "which", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "wordsB": ["SOLUTION", "is", "a", "Phase", "3,", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "liprotamase", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p108_s2", "idA": "1316175_14_item1_p111_s0", "sentA": "Several new biological agents under development have targeted BAFF (like Benlysta ) and other B-cell related pathways for the treatment of lupus.", "sentB": "Several other agents under development target other B-cell related pathways or other inflammatory mechanisms for the treatment of lupus.", "type": 2, "words": ["<tag1>", "Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(like", "Benlysta", ")", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Several", "other", "agents", "under", "development", "target", "other", "B-cell", "related", "pathways", "or", "other", "inflammatory", "mechanisms", "for", "the", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(like", "Benlysta", ")", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Several", "other", "agents", "under", "development", "target", "other", "B-cell", "related", "pathways", "or", "other", "inflammatory", "mechanisms", "for", "the", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p36_s0", "idA": "1316175_14_item1_p111_s0", "sentA": "Several new biological agents under development have targeted BAFF (like Benlysta ) and other B-cell related pathways for the treatment of lupus.", "sentB": "Liprotamase is a novel PERT intended for the treatment of EPI.", "type": 2, "words": ["<tag1>", "Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(like", "Benlysta", ")", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Liprotamase", "is", "a", "novel", "PERT", "intended", "for", "the", "treatment", "of", "EPI.", "<tag3>"], "wordsA": ["Several", "new", "biological", "agents", "under", "development", "have", "targeted", "BAFF", "(like", "Benlysta", ")", "and", "other", "B-cell", "related", "pathways", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Liprotamase", "is", "a", "novel", "PERT", "intended", "for", "the", "treatment", "of", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p108_s3", "idA": "1316175_14_item1_p111_s1", "sentA": "These product candidates include tabalumab (LY2127399) from Eli Lilly and Company, atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc.", "sentB": "These product candidates include atacicept, or TACI-Ig, from ZymoGenetics Inc. and epratuzumab from Immunomedics, Inc.", "type": 2, "words": ["<tag1>", "These", "product", "candidates", "include", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.", "<tag2>", "These", "product", "candidates", "include", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc.", "<tag3>"], "wordsA": ["These", "product", "candidates", "include", "tabalumab", "(LY2127399)", "from", "Eli", "Lilly", "and", "Company,", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc."], "wordsB": ["These", "product", "candidates", "include", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "epratuzumab", "from", "Immunomedics,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p108_s4", "idA": "1316175_14_item1_p111_s2", "sentA": "Other pathways targeting both B-cell and non-B-cell mechanisms are in earlier-phase clinical trials, such as Lupuzor from ImmuPharma plc; anti-inhibitors of interferon (IFN) alpha, MEDI-545 and MEDI-546 and rontalizumab; the anti-IFN gamma antibody AMG 811; toll-like receptor inhibitors; the anti-interleukin 6 antibody sirukumab; the phosphodiesterase 4 inhibitor CC-10004; the anti-CD74 monocloncal antibody milatuzumab; and inhibition of B7 related protein (B7RP-1) pathway with AMG 557.", "sentB": "Other pathways targeting both B-cell and non-B-cell mechanisms are in earlier-phase clinical trials, such as Lupuzor from ImmuPharma plc; anti-inhibitors of interferon (IFN) alpha, sifalimumab, MEDI-545 and rontalizumab; the anti-IFN gamma antibody AMG 811; toll-like receptor inhibitors; the anti-interleukin 6 antibodies sirukumab and PF-04236921; the phosphodiesterase 4 inhibitor CC-10004; the anti-CD74 monocloncal antibody milatuzumab; and inhibition of B7 related protein (B7RP-1) pathway with AMG 557.", "type": 2, "words": ["<tag1>", "Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "MEDI-545", "and", "MEDI-546", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibody", "sirukumab;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557.", "<tag2>", "Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "sifalimumab,", "MEDI-545", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibodies", "sirukumab", "and", "PF-04236921;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557.", "<tag3>"], "wordsA": ["Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "MEDI-545", "and", "MEDI-546", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibody", "sirukumab;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557."], "wordsB": ["Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "sifalimumab,", "MEDI-545", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibodies", "sirukumab", "and", "PF-04236921;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p122_s0", "idA": "1316175_14_item1_p115_s0", "sentA": "As of the date of this report, our blisibimod patent portfolio includes:", "sentB": "As of the date of this report, our liprotomase portfolio is made up of exclusively licensed patents and patent applications from Eli Lilly, including:", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "our", "liprotomase", "portfolio", "is", "made", "up", "of", "exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Eli", "Lilly,", "including:", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:"], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "our", "liprotomase", "portfolio", "is", "made", "up", "of", "exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Eli", "Lilly,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p114_s0", "idA": "1316175_14_item1_p116_s0", "sentA": "Eleven pending non-EP foreign patent applications in Brazil, Bulgaria, China, the Czech Republic, Hong Kong, Hungary, Israel, Mexico, Norway, Poland, Serbia, Montenegro and Slovakia.", "sentB": "Three pending non-EP foreign patent applications in Brazil, Mexico, and Poland.", "type": 2, "words": ["<tag1>", "Eleven", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia,", "Montenegro", "and", "Slovakia.", "<tag2>", "Three", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Mexico,", "and", "Poland.", "<tag3>"], "wordsA": ["Eleven", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia,", "Montenegro", "and", "Slovakia."], "wordsB": ["Three", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Mexico,", "and", "Poland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p123_s0", "idA": "1316175_14_item1_p116_s0", "sentA": "Eleven pending non-EP foreign patent applications in Brazil, Bulgaria, China, the Czech Republic, Hong Kong, Hungary, Israel, Mexico, Norway, Poland, Serbia, Montenegro and Slovakia.", "sentB": "One pending non-EP foreign patent application.", "type": 2, "words": ["<tag1>", "Eleven", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia,", "Montenegro", "and", "Slovakia.", "<tag2>", "One", "pending", "non-EP", "foreign", "patent", "application.", "<tag3>"], "wordsA": ["Eleven", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Bulgaria,", "China,", "the", "Czech", "Republic,", "Hong", "Kong,", "Hungary,", "Israel,", "Mexico,", "Norway,", "Poland,", "Serbia,", "Montenegro", "and", "Slovakia."], "wordsB": ["One", "pending", "non-EP", "foreign", "patent", "application."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p124_s0", "idA": "1316175_14_item1_p117_s0", "sentA": "We hold exclusive worldwide licenses from Amgen to all of these patents and patent applications.", "sentB": "We hold exclusive worldwide licenses from Eli Lilly to all of these patents and patent applications.", "type": 2, "words": ["<tag1>", "We", "hold", "exclusive", "worldwide", "licenses", "from", "Amgen", "to", "all", "of", "these", "patents", "and", "patent", "applications.", "<tag2>", "We", "hold", "exclusive", "worldwide", "licenses", "from", "Eli", "Lilly", "to", "all", "of", "these", "patents", "and", "patent", "applications.", "<tag3>"], "wordsA": ["We", "hold", "exclusive", "worldwide", "licenses", "from", "Amgen", "to", "all", "of", "these", "patents", "and", "patent", "applications."], "wordsB": ["We", "hold", "exclusive", "worldwide", "licenses", "from", "Eli", "Lilly", "to", "all", "of", "these", "patents", "and", "patent", "applications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p116_s0", "idA": "1316175_14_item1_p118_s0", "sentA": "The exclusively licensed U.S. patents are currently scheduled to expire in May 2022 and November 2023.", "sentB": "The exclusively licensed U.S. patents are currently scheduled to expire in May 2022, March 2023 and November 2023.", "type": 2, "words": ["<tag1>", "The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022", "and", "November", "2023.", "<tag2>", "The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022,", "March", "2023", "and", "November", "2023.", "<tag3>"], "wordsA": ["The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022", "and", "November", "2023."], "wordsB": ["The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022,", "March", "2023", "and", "November", "2023."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p124_s1", "idA": "1316175_14_item1_p118_s0", "sentA": "The exclusively licensed U.S. patents are currently scheduled to expire in May 2022 and November 2023.", "sentB": "The exclusively licensed U.S. patents are currently scheduled to expire in March 2025 and July 2028.", "type": 2, "words": ["<tag1>", "The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022", "and", "November", "2023.", "<tag2>", "The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "March", "2025", "and", "July", "2028.", "<tag3>"], "wordsA": ["The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022", "and", "November", "2023."], "wordsB": ["The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "March", "2025", "and", "July", "2028."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p124_s2", "idA": "1316175_14_item1_p119_s0", "sentA": "Depending upon the timing, duration and specifics of FDA approval of blisibimod, one of these U.S. patents (or another patent issuing from a related patent application) is expected to be eligible for a patent term restoration of up to five years under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act.", "sentB": "Depending upon the timing, duration and specifics of FDA approval of liprotamase, the latter of these U.S. patents may be eligible for a patent term restoration of up to five years under Hatch-Waxman Act.", "type": 2, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "blisibimod,", "one", "of", "these", "U.S.", "patents", "(or", "another", "patent", "issuing", "from", "a", "related", "patent", "application)", "is", "expected", "to", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act.", "<tag2>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "liprotamase,", "the", "latter", "of", "these", "U.S.", "patents", "may", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "Hatch-Waxman", "Act.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "blisibimod,", "one", "of", "these", "U.S.", "patents", "(or", "another", "patent", "issuing", "from", "a", "related", "patent", "application)", "is", "expected", "to", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Act."], "wordsB": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "liprotamase,", "the", "latter", "of", "these", "U.S.", "patents", "may", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "Hatch-Waxman", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p117_s2", "idA": "1316175_14_item1_p119_s2", "sentA": "This could extend the expiration date of the U.S. Patent to as late as May 2027 or November 2028, depending on which patent the term restoration is applied to.", "sentB": "This could extend the expiration date of the U.S. Patent to as late as May 2027, March 2028 or November 2028, depending on which patent the term restoration is applied to.", "type": 2, "words": ["<tag1>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag2>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027,", "March", "2028", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag3>"], "wordsA": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "wordsB": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027,", "March", "2028", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p124_s4", "idA": "1316175_14_item1_p119_s2", "sentA": "This could extend the expiration date of the U.S. Patent to as late as May 2027 or November 2028, depending on which patent the term restoration is applied to.", "sentB": "This could extend the expiration date of this U.S. Patent to as late as July 2033, depending on which patent the term restoration is applied to.", "type": 2, "words": ["<tag1>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag2>", "This", "could", "extend", "the", "expiration", "date", "of", "this", "U.S.", "Patent", "to", "as", "late", "as", "July", "2033,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag3>"], "wordsA": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "U.S.", "Patent", "to", "as", "late", "as", "May", "2027", "or", "November", "2028,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "wordsB": ["This", "could", "extend", "the", "expiration", "date", "of", "this", "U.S.", "Patent", "to", "as", "late", "as", "July", "2033,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p117_s4", "idA": "1316175_14_item1_p119_s4", "sentA": "The EP patents are currently scheduled to expire in May 2022.", "sentB": "The exclusively licensed EP patents are currently scheduled to expire in May 2022.", "type": 2, "words": ["<tag1>", "The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag2>", "The", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag3>"], "wordsA": ["The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "wordsB": ["The", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p124_s6", "idA": "1316175_14_item1_p119_s4", "sentA": "The EP patents are currently scheduled to expire in May 2022.", "sentB": "Two of the exclusively licensed EP patents are currently scheduled to expire in February 2021 and October 2025.", "type": 2, "words": ["<tag1>", "The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022.", "<tag2>", "Two", "of", "the", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "February", "2021", "and", "October", "2025.", "<tag3>"], "wordsA": ["The", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022."], "wordsB": ["Two", "of", "the", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "February", "2021", "and", "October", "2025."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p124_s7", "idA": "1316175_14_item1_p119_s5", "sentA": "One of these patents is expected to be eligible for a Supplementary Protection Certificate of up to five years, which could extend the expiration date to May 2027.", "sentB": "One of these two patents may be eligible for a Supplementary Protection Certificate of up to five years, which could extend the expiration date to February 2026 or October 2030.", "type": 2, "words": ["<tag1>", "One", "of", "these", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027.", "<tag2>", "One", "of", "these", "two", "patents", "may", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "February", "2026", "or", "October", "2030.", "<tag3>"], "wordsA": ["One", "of", "these", "patents", "is", "expected", "to", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "May", "2027."], "wordsB": ["One", "of", "these", "two", "patents", "may", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "February", "2026", "or", "October", "2030."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p125_s0", "idA": "1316175_14_item1_p124_s0", "sentA": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009 and November 2014 (as amended, the Amgen Agreement ), pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "type": 2, "words": ["<tag1>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009", "and", "November", "2014", "(as", "amended,", "the", "Amgen", "Agreement", "),", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag3>"], "wordsA": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009", "and", "November", "2014", "(as", "amended,", "the", "Amgen", "Agreement", "),", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p132_s0", "idA": "1316175_14_item1_p124_s0", "sentA": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "On December 11, 2014, we entered into the Zenyaku Agreement with Zenyaku, pursuant to which we granted Zenyaku an exclusive license to certain patent rights, know-how and other intellectual property relating to blisibimod.", "type": 2, "words": ["<tag1>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "On", "December", "11,", "2014,", "we", "entered", "into", "the", "Zenyaku", "Agreement", "with", "Zenyaku,", "pursuant", "to", "which", "we", "granted", "Zenyaku", "an", "exclusive", "license", "to", "certain", "patent", "rights,", "know-how", "and", "other", "intellectual", "property", "relating", "to", "blisibimod.", "<tag3>"], "wordsA": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["On", "December", "11,", "2014,", "we", "entered", "into", "the", "Zenyaku", "Agreement", "with", "Zenyaku,", "pursuant", "to", "which", "we", "granted", "Zenyaku", "an", "exclusive", "license", "to", "certain", "patent", "rights,", "know-how", "and", "other", "intellectual", "property", "relating", "to", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p137_s1", "idA": "1316175_14_item1_p124_s0", "sentA": "In December 2007, we entered into a license agreement with Amgen, which was amended in October 2009, pursuant to which we obtained an exclusive worldwide license to certain technology and compounds relating to blisibimod, as well as a non-exclusive worldwide license to technology relating to certain peptibody compositions of matter and formulations.", "sentB": "We delivered the closing notice and entered into a subscription agreement with Zenyaku on January 27, 2015.", "type": 2, "words": ["<tag1>", "In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations.", "<tag2>", "We", "delivered", "the", "closing", "notice", "and", "entered", "into", "a", "subscription", "agreement", "with", "Zenyaku", "on", "January", "27,", "2015.", "<tag3>"], "wordsA": ["In", "December", "2007,", "we", "entered", "into", "a", "license", "agreement", "with", "Amgen,", "which", "was", "amended", "in", "October", "2009,", "pursuant", "to", "which", "we", "obtained", "an", "exclusive", "worldwide", "license", "to", "certain", "technology", "and", "compounds", "relating", "to", "blisibimod,", "as", "well", "as", "a", "non-exclusive", "worldwide", "license", "to", "technology", "relating", "to", "certain", "peptibody", "compositions", "of", "matter", "and", "formulations."], "wordsB": ["We", "delivered", "the", "closing", "notice", "and", "entered", "into", "a", "subscription", "agreement", "with", "Zenyaku", "on", "January", "27,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p126_s0", "idA": "1316175_14_item1_p125_s0", "sentA": "Under the agreement, we obtained exclusive rights under the licensed patents and know-how to research, develop, make, have made, use, sell, offer for sale and import pharmaceutical products containing blisibimod, as well as the right to grant sublicenses.", "sentB": "Under the Amgen Agreement, we obtained exclusive rights under the licensed patents and know-how to research, develop, make, have made, use, sell, offer for sale and import pharmaceutical products containing blisibimod, as well as the right to grant sublicenses.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses.", "<tag2>", "Under", "the", "Amgen", "Agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses."], "wordsB": ["Under", "the", "Amgen", "Agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p133_s0", "idA": "1316175_14_item1_p125_s0", "sentA": "Under the agreement, we obtained exclusive rights under the licensed patents and know-how to research, develop, make, have made, use, sell, offer for sale and import pharmaceutical products containing blisibimod, as well as the right to grant sublicenses.", "sentB": "Under the agreement, Zenyaku obtained exclusive rights to develop, use, sell, have sold, offer for sale and import blisibimod and any related products containing any of blisibimod s binding domains, including but not limited to any pegylated (or otherwise chemically modified) blisibimod in Japan.", "type": 2, "words": ["<tag1>", "Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses.", "<tag2>", "Under", "the", "agreement,", "Zenyaku", "obtained", "exclusive", "rights", "to", "develop,", "use,", "sell,", "have", "sold,", "offer", "for", "sale", "and", "import", "blisibimod", "and", "any", "related", "products", "containing", "any", "of", "blisibimod", "s", "binding", "domains,", "including", "but", "not", "limited", "to", "any", "pegylated", "(or", "otherwise", "chemically", "modified)", "blisibimod", "in", "Japan.", "<tag3>"], "wordsA": ["Under", "the", "agreement,", "we", "obtained", "exclusive", "rights", "under", "the", "licensed", "patents", "and", "know-how", "to", "research,", "develop,", "make,", "have", "made,", "use,", "sell,", "offer", "for", "sale", "and", "import", "pharmaceutical", "products", "containing", "blisibimod,", "as", "well", "as", "the", "right", "to", "grant", "sublicenses."], "wordsB": ["Under", "the", "agreement,", "Zenyaku", "obtained", "exclusive", "rights", "to", "develop,", "use,", "sell,", "have", "sold,", "offer", "for", "sale", "and", "import", "blisibimod", "and", "any", "related", "products", "containing", "any", "of", "blisibimod", "s", "binding", "domains,", "including", "but", "not", "limited", "to", "any", "pegylated", "(or", "otherwise", "chemically", "modified)", "blisibimod", "in", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p128_s0", "idA": "1316175_14_item1_p127_s0", "sentA": "Pursuant to the terms of the license agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "sentB": "Pursuant to the terms of the Amgen Agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "type": 2, "words": ["<tag1>", "Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag2>", "Pursuant", "to", "the", "terms", "of", "the", "Amgen", "Agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "wordsB": ["Pursuant", "to", "the", "terms", "of", "the", "Amgen", "Agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p135_s0", "idA": "1316175_14_item1_p127_s0", "sentA": "Pursuant to the terms of the license agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "sentB": "Under the terms of the Zenyaku Agreement, Zenyaku assumed sole responsibility for the sale, marketing, promotion and commercialization of products relating to blisibimod in the licensed territory, and is obligated to use commercially reasonable efforts to market, promote, sell and commercialize licensed products in such territory.", "type": 2, "words": ["<tag1>", "Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag2>", "Under", "the", "terms", "of", "the", "Zenyaku", "Agreement,", "Zenyaku", "assumed", "sole", "responsibility", "for", "the", "sale,", "marketing,", "promotion", "and", "commercialization", "of", "products", "relating", "to", "blisibimod", "in", "the", "licensed", "territory,", "and", "is", "obligated", "to", "use", "commercially", "reasonable", "efforts", "to", "market,", "promote,", "sell", "and", "commercialize", "licensed", "products", "in", "such", "territory.", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "wordsB": ["Under", "the", "terms", "of", "the", "Zenyaku", "Agreement,", "Zenyaku", "assumed", "sole", "responsibility", "for", "the", "sale,", "marketing,", "promotion", "and", "commercialization", "of", "products", "relating", "to", "blisibimod", "in", "the", "licensed", "territory,", "and", "is", "obligated", "to", "use", "commercially", "reasonable", "efforts", "to", "market,", "promote,", "sell", "and", "commercialize", "licensed", "products", "in", "such", "territory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p137_s0", "idA": "1316175_14_item1_p127_s0", "sentA": "Pursuant to the terms of the license agreement, we have paid $6.0 million in license fees to Amgen for blisibimod.", "sentB": "Pursuant to the Zenyaku Agreement, we entered into a stock purchase agreement with Zenyaku, dated December 11, 2014, under which we were entitled to require Zenyaku to purchase up to $7.0 million of shares of our common stock at a purchase price equal to 1.3 times the volume weighted average price of our common stock for 20 trading days prior to the delivery of the closing notice (the Premium Purchase Price ).", "type": 2, "words": ["<tag1>", "Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod.", "<tag2>", "Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "entered", "into", "a", "stock", "purchase", "agreement", "with", "Zenyaku,", "dated", "December", "11,", "2014,", "under", "which", "we", "were", "entitled", "to", "require", "Zenyaku", "to", "purchase", "up", "to", "$7.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "a", "purchase", "price", "equal", "to", "1.3", "times", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "the", "delivery", "of", "the", "closing", "notice", "(the", "Premium", "Purchase", "Price", ").", "<tag3>"], "wordsA": ["Pursuant", "to", "the", "terms", "of", "the", "license", "agreement,", "we", "have", "paid", "$6.0", "million", "in", "license", "fees", "to", "Amgen", "for", "blisibimod."], "wordsB": ["Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "entered", "into", "a", "stock", "purchase", "agreement", "with", "Zenyaku,", "dated", "December", "11,", "2014,", "under", "which", "we", "were", "entitled", "to", "require", "Zenyaku", "to", "purchase", "up", "to", "$7.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "a", "purchase", "price", "equal", "to", "1.3", "times", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "the", "delivery", "of", "the", "closing", "notice", "(the", "Premium", "Purchase", "Price", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p131_s1", "idA": "1316175_14_item1_p127_s1", "sentA": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon commencement of the first Phase 3 clinical study for any blisibimod formulation in the United States, European Union or Japan.", "sentB": "Under the terms of the Lilly Agreement, we were not required to make any up-front payment but we are obligated to make milestone payments of up to $33.5 million for capsule products and $9.5 million for reformulated products upon the achievement of certain regulatory and commercial sales milestones, none of which have been achieved as of December 31, 2014.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan.", "<tag2>", "Under", "the", "terms", "of", "the", "Lilly", "Agreement,", "we", "were", "not", "required", "to", "make", "any", "up-front", "payment", "but", "we", "are", "obligated", "to", "make", "milestone", "payments", "of", "up", "to", "$33.5", "million", "for", "capsule", "products", "and", "$9.5", "million", "for", "reformulated", "products", "upon", "the", "achievement", "of", "certain", "regulatory", "and", "commercial", "sales", "milestones,", "none", "of", "which", "have", "been", "achieved", "as", "of", "December", "31,", "2014.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan."], "wordsB": ["Under", "the", "terms", "of", "the", "Lilly", "Agreement,", "we", "were", "not", "required", "to", "make", "any", "up-front", "payment", "but", "we", "are", "obligated", "to", "make", "milestone", "payments", "of", "up", "to", "$33.5", "million", "for", "capsule", "products", "and", "$9.5", "million", "for", "reformulated", "products", "upon", "the", "achievement", "of", "certain", "regulatory", "and", "commercial", "sales", "milestones,", "none", "of", "which", "have", "been", "achieved", "as", "of", "December", "31,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p138_s0", "idA": "1316175_14_item1_p127_s1", "sentA": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon commencement of the first Phase 3 clinical study for any blisibimod formulation in the United States, European Union or Japan.", "sentB": "Pursuant to the Zenyaku Agreement, we intend to enter into a loan agreement with Zenyaku for an aggregate principal amount of $7.0 million, of which $5.0 million, together with interest thereon, is forgivable upon certain achievement of the primary endpoint identified in the first Phase 3 Study for blisibimod to treat IgA nephropathy and the remaining $2.0 million, together with interest thereon, is forgivable upon the submission of the first Biologics License Application for blisibimod in the licensed territory.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan.", "<tag2>", "Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "intend", "to", "enter", "into", "a", "loan", "agreement", "with", "Zenyaku", "for", "an", "aggregate", "principal", "amount", "of", "$7.0", "million,", "of", "which", "$5.0", "million,", "together", "with", "interest", "thereon,", "is", "forgivable", "upon", "certain", "achievement", "of", "the", "primary", "endpoint", "identified", "in", "the", "first", "Phase", "3", "Study", "for", "blisibimod", "to", "treat", "IgA", "nephropathy", "and", "the", "remaining", "$2.0", "million,", "together", "with", "interest", "thereon,", "is", "forgivable", "upon", "the", "submission", "of", "the", "first", "Biologics", "License", "Application", "for", "blisibimod", "in", "the", "licensed", "territory.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan."], "wordsB": ["Pursuant", "to", "the", "Zenyaku", "Agreement,", "we", "intend", "to", "enter", "into", "a", "loan", "agreement", "with", "Zenyaku", "for", "an", "aggregate", "principal", "amount", "of", "$7.0", "million,", "of", "which", "$5.0", "million,", "together", "with", "interest", "thereon,", "is", "forgivable", "upon", "certain", "achievement", "of", "the", "primary", "endpoint", "identified", "in", "the", "first", "Phase", "3", "Study", "for", "blisibimod", "to", "treat", "IgA", "nephropathy", "and", "the", "remaining", "$2.0", "million,", "together", "with", "interest", "thereon,", "is", "forgivable", "upon", "the", "submission", "of", "the", "first", "Biologics", "License", "Application", "for", "blisibimod", "in", "the", "licensed", "territory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p136_s1", "idA": "1316175_14_item1_p127_s2", "sentA": "We are also required to pay up to $10.0 million upon achievement of certain pre-approval clinical development milestones and up to $23.0 million upon achievement of certain post-approval milestones.", "sentB": "Additionally, Zenyaku is obligated to make milestone payments of up to $22.0 million upon the achievement of certain regulatory and commercial sales milestones.", "type": 2, "words": ["<tag1>", "We", "are", "also", "required", "to", "pay", "up", "to", "$10.0", "million", "upon", "achievement", "of", "certain", "pre-approval", "clinical", "development", "milestones", "and", "up", "to", "$23.0", "million", "upon", "achievement", "of", "certain", "post-approval", "milestones.", "<tag2>", "Additionally,", "Zenyaku", "is", "obligated", "to", "make", "milestone", "payments", "of", "up", "to", "$22.0", "million", "upon", "the", "achievement", "of", "certain", "regulatory", "and", "commercial", "sales", "milestones.", "<tag3>"], "wordsA": ["We", "are", "also", "required", "to", "pay", "up", "to", "$10.0", "million", "upon", "achievement", "of", "certain", "pre-approval", "clinical", "development", "milestones", "and", "up", "to", "$23.0", "million", "upon", "achievement", "of", "certain", "post-approval", "milestones."], "wordsB": ["Additionally,", "Zenyaku", "is", "obligated", "to", "make", "milestone", "payments", "of", "up", "to", "$22.0", "million", "upon", "the", "achievement", "of", "certain", "regulatory", "and", "commercial", "sales", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p131_s2", "idA": "1316175_14_item1_p127_s3", "sentA": "Furthermore, we are required to make tiered quarterly royalty payments on net sales, which increase as a percentage from the high single digits to the low double digits as net sales increase.", "sentB": "In addition, after sales of the licensed products exceed an aggregate of $100.0 million in the United States, we are obligated to pay tiered royalties on future net sales of products, ranging from the single digits to the mid-teens for products that are developed and approved as defined in the Lilly Agreement.", "type": 2, "words": ["<tag1>", "Furthermore,", "we", "are", "required", "to", "make", "tiered", "quarterly", "royalty", "payments", "on", "net", "sales,", "which", "increase", "as", "a", "percentage", "from", "the", "high", "single", "digits", "to", "the", "low", "double", "digits", "as", "net", "sales", "increase.", "<tag2>", "In", "addition,", "after", "sales", "of", "the", "licensed", "products", "exceed", "an", "aggregate", "of", "$100.0", "million", "in", "the", "United", "States,", "we", "are", "obligated", "to", "pay", "tiered", "royalties", "on", "future", "net", "sales", "of", "products,", "ranging", "from", "the", "single", "digits", "to", "the", "mid-teens", "for", "products", "that", "are", "developed", "and", "approved", "as", "defined", "in", "the", "Lilly", "Agreement.", "<tag3>"], "wordsA": ["Furthermore,", "we", "are", "required", "to", "make", "tiered", "quarterly", "royalty", "payments", "on", "net", "sales,", "which", "increase", "as", "a", "percentage", "from", "the", "high", "single", "digits", "to", "the", "low", "double", "digits", "as", "net", "sales", "increase."], "wordsB": ["In", "addition,", "after", "sales", "of", "the", "licensed", "products", "exceed", "an", "aggregate", "of", "$100.0", "million", "in", "the", "United", "States,", "we", "are", "obligated", "to", "pay", "tiered", "royalties", "on", "future", "net", "sales", "of", "products,", "ranging", "from", "the", "single", "digits", "to", "the", "mid-teens", "for", "products", "that", "are", "developed", "and", "approved", "as", "defined", "in", "the", "Lilly", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p131_s3", "idA": "1316175_14_item1_p127_s4", "sentA": "Our royalty payment obligations for a particular product in a particular country begin on the date of the first commercial sale of the licensed product in that country, and end upon the later of 10 years from the date of first commercial sale in that country or the expiration date of the last valid claim of a licensed patent that covers the manufacture, use or sale, offer to sell or import of the product.", "sentB": "Our royalty obligations as to a particular licensed product will be payable, on a licensed product-by-licensed product basis, for the longer of (a) the date of expiration of the last to expire valid claim within the licensed patents that covers the manufacture, use or sale, offer to sell, or import of such licensed product by us or a sublicense in such country, or (b) 12 years after the first commercial sale of the applicable licensed product in the applicable country.", "type": 2, "words": ["<tag1>", "Our", "royalty", "payment", "obligations", "for", "a", "particular", "product", "in", "a", "particular", "country", "begin", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "licensed", "product", "in", "that", "country,", "and", "end", "upon", "the", "later", "of", "10", "years", "from", "the", "date", "of", "first", "commercial", "sale", "in", "that", "country", "or", "the", "expiration", "date", "of", "the", "last", "valid", "claim", "of", "a", "licensed", "patent", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell", "or", "import", "of", "the", "product.", "<tag2>", "Our", "royalty", "obligations", "as", "to", "a", "particular", "licensed", "product", "will", "be", "payable,", "on", "a", "licensed", "product-by-licensed", "product", "basis,", "for", "the", "longer", "of", "(a)", "the", "date", "of", "expiration", "of", "the", "last", "to", "expire", "valid", "claim", "within", "the", "licensed", "patents", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell,", "or", "import", "of", "such", "licensed", "product", "by", "us", "or", "a", "sublicense", "in", "such", "country,", "or", "(b)", "12", "years", "after", "the", "first", "commercial", "sale", "of", "the", "applicable", "licensed", "product", "in", "the", "applicable", "country.", "<tag3>"], "wordsA": ["Our", "royalty", "payment", "obligations", "for", "a", "particular", "product", "in", "a", "particular", "country", "begin", "on", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "licensed", "product", "in", "that", "country,", "and", "end", "upon", "the", "later", "of", "10", "years", "from", "the", "date", "of", "first", "commercial", "sale", "in", "that", "country", "or", "the", "expiration", "date", "of", "the", "last", "valid", "claim", "of", "a", "licensed", "patent", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell", "or", "import", "of", "the", "product."], "wordsB": ["Our", "royalty", "obligations", "as", "to", "a", "particular", "licensed", "product", "will", "be", "payable,", "on", "a", "licensed", "product-by-licensed", "product", "basis,", "for", "the", "longer", "of", "(a)", "the", "date", "of", "expiration", "of", "the", "last", "to", "expire", "valid", "claim", "within", "the", "licensed", "patents", "that", "covers", "the", "manufacture,", "use", "or", "sale,", "offer", "to", "sell,", "or", "import", "of", "such", "licensed", "product", "by", "us", "or", "a", "sublicense", "in", "such", "country,", "or", "(b)", "12", "years", "after", "the", "first", "commercial", "sale", "of", "the", "applicable", "licensed", "product", "in", "the", "applicable", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p129_s0", "idA": "1316175_14_item1_p128_s0", "sentA": "The license agreement will remain in effect until we elect to terminate, or until termination for material breach by either party or insolvency on our part.", "sentB": "The Amgen Agreement will remain in effect until we elect to terminate, or until termination for material breach by either party or insolvency on our part.", "type": 2, "words": ["<tag1>", "The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part.", "<tag2>", "The", "Amgen", "Agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part.", "<tag3>"], "wordsA": ["The", "license", "agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part."], "wordsB": ["The", "Amgen", "Agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s2", "idA": "1316175_14_item1_p128_s1", "sentA": "Under these terms, Amgen can terminate the agreement if we fail to meet our obligations, resulting in a loss of our exclusive rights to the licensed technology.", "sentB": "Either party may terminate the agreement if a party materially breaches the agreement.", "type": 2, "words": ["<tag1>", "Under", "these", "terms,", "Amgen", "can", "terminate", "the", "agreement", "if", "we", "fail", "to", "meet", "our", "obligations,", "resulting", "in", "a", "loss", "of", "our", "exclusive", "rights", "to", "the", "licensed", "technology.", "<tag2>", "Either", "party", "may", "terminate", "the", "agreement", "if", "a", "party", "materially", "breaches", "the", "agreement.", "<tag3>"], "wordsA": ["Under", "these", "terms,", "Amgen", "can", "terminate", "the", "agreement", "if", "we", "fail", "to", "meet", "our", "obligations,", "resulting", "in", "a", "loss", "of", "our", "exclusive", "rights", "to", "the", "licensed", "technology."], "wordsB": ["Either", "party", "may", "terminate", "the", "agreement", "if", "a", "party", "materially", "breaches", "the", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p139_s3", "idA": "1316175_14_item1_p128_s1", "sentA": "Under these terms, Amgen can terminate the agreement if we fail to meet our obligations, resulting in a loss of our exclusive rights to the licensed technology.", "sentB": "In addition, Anthera may terminate the agreement if Zenyaku challenges any Anthera patent.", "type": 2, "words": ["<tag1>", "Under", "these", "terms,", "Amgen", "can", "terminate", "the", "agreement", "if", "we", "fail", "to", "meet", "our", "obligations,", "resulting", "in", "a", "loss", "of", "our", "exclusive", "rights", "to", "the", "licensed", "technology.", "<tag2>", "In", "addition,", "Anthera", "may", "terminate", "the", "agreement", "if", "Zenyaku", "challenges", "any", "Anthera", "patent.", "<tag3>"], "wordsA": ["Under", "these", "terms,", "Amgen", "can", "terminate", "the", "agreement", "if", "we", "fail", "to", "meet", "our", "obligations,", "resulting", "in", "a", "loss", "of", "our", "exclusive", "rights", "to", "the", "licensed", "technology."], "wordsB": ["In", "addition,", "Anthera", "may", "terminate", "the", "agreement", "if", "Zenyaku", "challenges", "any", "Anthera", "patent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p140_s0", "idA": "1316175_14_item1_p129_s0", "sentA": "We currently rely on contract manufacturers to produce drug substances and drug products required for our clinical studies under current Good Manufacturing Practice ( cGMP ) with oversight by our internal managers.", "sentB": "We currently rely on contract manufacturers to produce drug substances and drug products required for our clinical studies under current GMP with oversight by our internal managers.", "type": 2, "words": ["<tag1>", "We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "Good", "Manufacturing", "Practice", "(", "cGMP", ")", "with", "oversight", "by", "our", "internal", "managers.", "<tag2>", "We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "GMP", "with", "oversight", "by", "our", "internal", "managers.", "<tag3>"], "wordsA": ["We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "Good", "Manufacturing", "Practice", "(", "cGMP", ")", "with", "oversight", "by", "our", "internal", "managers."], "wordsB": ["We", "currently", "rely", "on", "contract", "manufacturers", "to", "produce", "drug", "substances", "and", "drug", "products", "required", "for", "our", "clinical", "studies", "under", "current", "GMP", "with", "oversight", "by", "our", "internal", "managers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p140_s2", "idA": "1316175_14_item1_p129_s2", "sentA": "Should a supplier or a manufacturer on which we have relied to produce a product candidate provide us with a faulty product or such product is later recalled, we would likely experience significant delays and material additional costs.", "sentB": "Should a supplier or a manufacturer on which we have relied to produce product candidates provide us with faulty products or such products are later recalled, we would likely experience significant delays and material additional costs.", "type": 2, "words": ["<tag1>", "Should", "a", "supplier", "or", "a", "manufacturer", "on", "which", "we", "have", "relied", "to", "produce", "a", "product", "candidate", "provide", "us", "with", "a", "faulty", "product", "or", "such", "product", "is", "later", "recalled,", "we", "would", "likely", "experience", "significant", "delays", "and", "material", "additional", "costs.", "<tag2>", "Should", "a", "supplier", "or", "a", "manufacturer", "on", "which", "we", "have", "relied", "to", "produce", "product", "candidates", "provide", "us", "with", "faulty", "products", "or", "such", "products", "are", "later", "recalled,", "we", "would", "likely", "experience", "significant", "delays", "and", "material", "additional", "costs.", "<tag3>"], "wordsA": ["Should", "a", "supplier", "or", "a", "manufacturer", "on", "which", "we", "have", "relied", "to", "produce", "a", "product", "candidate", "provide", "us", "with", "a", "faulty", "product", "or", "such", "product", "is", "later", "recalled,", "we", "would", "likely", "experience", "significant", "delays", "and", "material", "additional", "costs."], "wordsB": ["Should", "a", "supplier", "or", "a", "manufacturer", "on", "which", "we", "have", "relied", "to", "produce", "product", "candidates", "provide", "us", "with", "faulty", "products", "or", "such", "products", "are", "later", "recalled,", "we", "would", "likely", "experience", "significant", "delays", "and", "material", "additional", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p9_s0", "idA": "1316175_14_item1_p12_s0", "sentA": "Our product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which we believe current treatments are either inadequate or non-existent.", "sentB": "The development program for blisibimod is focused on evaluating the efficacy and safety of blisibimod in patients with lupus, and IgA nephropathy for which we believe current treatments are either inadequate or non-existent.", "type": 2, "words": ["<tag1>", "Our", "product", "development", "program", "is", "focused", "on", "development", "of", "blisibimod", "for", "use", "as", "a", "therapeutic", "treatment", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag2>", "The", "development", "program", "for", "blisibimod", "is", "focused", "on", "evaluating", "the", "efficacy", "and", "safety", "of", "blisibimod", "in", "patients", "with", "lupus,", "and", "IgA", "nephropathy", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent.", "<tag3>"], "wordsA": ["Our", "product", "development", "program", "is", "focused", "on", "development", "of", "blisibimod", "for", "use", "as", "a", "therapeutic", "treatment", "for", "lupus", "and", "other", "serious", "autoimmune", "diseases", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "wordsB": ["The", "development", "program", "for", "blisibimod", "is", "focused", "on", "evaluating", "the", "efficacy", "and", "safety", "of", "blisibimod", "in", "patients", "with", "lupus,", "and", "IgA", "nephropathy", "for", "which", "we", "believe", "current", "treatments", "are", "either", "inadequate", "or", "non-existent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p99_s2", "idA": "1316175_14_item1_p12_s1", "sentA": "Our current plan includes continuing the ongoing CHABLIS-SC1 clinical study in patients with active lupus and the BRIGHT-SC1 clinical study in patients with IgA nephropathy, and evaluating the potential of blisibimod in additional autoimmune and hematological diseases through clinical and nonclinical investigations.", "sentB": "We currently focus our development efforts on blisibimod, which is being developed for autoimmune disease, including lupus and IgA nephropathy, and liprotamase, as an enzyme replacement therapy for EPI.", "type": 2, "words": ["<tag1>", "Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC1", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "additional", "autoimmune", "and", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations.", "<tag2>", "We", "currently", "focus", "our", "development", "efforts", "on", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy,", "and", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI.", "<tag3>"], "wordsA": ["Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC1", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "additional", "autoimmune", "and", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations."], "wordsB": ["We", "currently", "focus", "our", "development", "efforts", "on", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy,", "and", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p9_s1", "idA": "1316175_14_item1_p12_s1", "sentA": "Our current plan includes continuing the ongoing CHABLIS-SC1 clinical study in patients with active lupus and the BRIGHT-SC1 clinical study in patients with IgA nephropathy, and evaluating the potential of blisibimod in additional autoimmune and hematological diseases through clinical and nonclinical investigations.", "sentB": "Our current plan includes continuing the ongoing CHABLIS-SC1 registration clinical study in patients with active lupus and the BRIGHT-SC phase 2/3 clinical study in patients with IgA nephropathy, and evaluating the potential of blisibimod in hematological diseases through clinical and nonclinical investigations.", "type": 2, "words": ["<tag1>", "Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC1", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "additional", "autoimmune", "and", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations.", "<tag2>", "Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "registration", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC", "phase", "2/3", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations.", "<tag3>"], "wordsA": ["Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC1", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "additional", "autoimmune", "and", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations."], "wordsB": ["Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "registration", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC", "phase", "2/3", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p143_s2", "idA": "1316175_14_item1_p132_s2", "sentA": "In order to commercialize our product candidate, we must develop these capabilities internally or through collaboration with third parties.", "sentB": "In order to commercialize our product candidates, we must develop these capabilities internally or through collaboration with third parties.", "type": 2, "words": ["<tag1>", "In", "order", "to", "commercialize", "our", "product", "candidate,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties.", "<tag2>", "In", "order", "to", "commercialize", "our", "product", "candidates,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties.", "<tag3>"], "wordsA": ["In", "order", "to", "commercialize", "our", "product", "candidate,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties."], "wordsB": ["In", "order", "to", "commercialize", "our", "product", "candidates,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p143_s3", "idA": "1316175_14_item1_p132_s3", "sentA": "In selected therapeutic areas where we feel that any approved products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we may seek to commercialize the product candidate alone.", "sentB": "In selected therapeutic areas where we feel that any approved products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we may seek to commercialize the product candidates alone.", "type": 2, "words": ["<tag1>", "In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "the", "product", "candidate", "alone.", "<tag2>", "In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "the", "product", "candidates", "alone.", "<tag3>"], "wordsA": ["In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "the", "product", "candidate", "alone."], "wordsB": ["In", "selected", "therapeutic", "areas", "where", "we", "feel", "that", "any", "approved", "products", "can", "be", "commercialized", "by", "a", "specialty", "sales", "force", "that", "calls", "on", "a", "limited", "and", "focused", "group", "of", "physicians,", "we", "may", "seek", "to", "commercialize", "the", "product", "candidates", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p17_s0", "idA": "1316175_14_item1_p137_s0", "sentA": "FDA review and approval of the NDA or BLA.", "sentB": "Patient-to-patient variability in acidification of the intestine makes dissolution variable.", "type": 2, "words": ["<tag1>", "FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA.", "<tag2>", "Patient-to-patient", "variability", "in", "acidification", "of", "the", "intestine", "makes", "dissolution", "variable.", "<tag3>"], "wordsA": ["FDA", "review", "and", "approval", "of", "the", "NDA", "or", "BLA."], "wordsB": ["Patient-to-patient", "variability", "in", "acidification", "of", "the", "intestine", "makes", "dissolution", "variable."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p149_s0", "idA": "1316175_14_item1_p138_s0", "sentA": "The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidate will be granted on a timely basis, if at all.", "sentB": "The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.", "type": 2, "words": ["<tag1>", "The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidate", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all.", "<tag2>", "The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidates", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all.", "<tag3>"], "wordsA": ["The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidate", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all."], "wordsB": ["The", "testing", "and", "approval", "process", "requires", "substantial", "time,", "effort", "and", "financial", "resources", "and", "we", "cannot", "be", "certain", "that", "any", "approvals", "for", "our", "product", "candidates", "will", "be", "granted", "on", "a", "timely", "basis,", "if", "at", "all."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p150_s3", "idA": "1316175_14_item1_p139_s3", "sentA": "The sponsor will also include a protocol detailing, among other things, the objectives of the initial clinical study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical study lends itself to an efficacy evaluation.", "sentB": "The sponsor will also include a protocol detailing, among other things, the objectives of the initial clinical study, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical study lends itself to an efficacy evaluation.", "type": 2, "words": ["<tag1>", "The", "sponsor", "will", "also", "include", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation.", "<tag2>", "The", "sponsor", "will", "also", "include", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation.", "<tag3>"], "wordsA": ["The", "sponsor", "will", "also", "include", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation."], "wordsB": ["The", "sponsor", "will", "also", "include", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p10_s0", "idA": "1316175_14_item1_p13_s0", "sentA": "We have successfully manufactured blisibimod at launch scale quantities.", "sentB": "We have successfully manufactured blisibimod at launch-scale quantities.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "quantities.", "<tag2>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch-scale", "quantities.", "<tag3>"], "wordsA": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "quantities."], "wordsB": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch-scale", "quantities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p156_s0", "idA": "1316175_14_item1_p147_s0", "sentA": "Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events.", "sentB": "Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA.", "type": 2, "words": ["<tag1>", "Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA", "and", "safety", "reports", "must", "be", "submitted", "to", "the", "FDA", "and", "the", "investigators", "for", "serious", "and", "unexpected", "adverse", "events.", "<tag2>", "Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA.", "<tag3>"], "wordsA": ["Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA", "and", "safety", "reports", "must", "be", "submitted", "to", "the", "FDA", "and", "the", "investigators", "for", "serious", "and", "unexpected", "adverse", "events."], "wordsB": ["Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p156_s1", "idA": "1316175_14_item1_p147_s0", "sentA": "Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events.", "sentB": "Safety reports must be submitted to the FDA and the investigators within 15 days after the sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse reactions, findings from other studies or animal or in vitro testing that suggest a significant risk in humans, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator s brochure.", "type": 2, "words": ["<tag1>", "Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA", "and", "safety", "reports", "must", "be", "submitted", "to", "the", "FDA", "and", "the", "investigators", "for", "serious", "and", "unexpected", "adverse", "events.", "<tag2>", "Safety", "reports", "must", "be", "submitted", "to", "the", "FDA", "and", "the", "investigators", "within", "15", "days", "after", "the", "sponsor", "determines", "the", "information", "qualifies", "for", "reporting", "for", "serious", "and", "unexpected", "suspected", "adverse", "reactions,", "findings", "from", "other", "studies", "or", "animal", "or", "in", "vitro", "testing", "that", "suggest", "a", "significant", "risk", "in", "humans,", "or", "any", "clinically", "important", "increase", "in", "the", "rate", "of", "a", "serious", "suspected", "adverse", "reaction", "over", "that", "listed", "in", "the", "protocol", "or", "investigator", "s", "brochure.", "<tag3>"], "wordsA": ["Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA", "and", "safety", "reports", "must", "be", "submitted", "to", "the", "FDA", "and", "the", "investigators", "for", "serious", "and", "unexpected", "adverse", "events."], "wordsB": ["Safety", "reports", "must", "be", "submitted", "to", "the", "FDA", "and", "the", "investigators", "within", "15", "days", "after", "the", "sponsor", "determines", "the", "information", "qualifies", "for", "reporting", "for", "serious", "and", "unexpected", "suspected", "adverse", "reactions,", "findings", "from", "other", "studies", "or", "animal", "or", "in", "vitro", "testing", "that", "suggest", "a", "significant", "risk", "in", "humans,", "or", "any", "clinically", "important", "increase", "in", "the", "rate", "of", "a", "serious", "suspected", "adverse", "reaction", "over", "that", "listed", "in", "the", "protocol", "or", "investigator", "s", "brochure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p156_s4", "idA": "1316175_14_item1_p147_s2", "sentA": "The FDA or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.", "sentB": "The FDA , a data safety monitoring board, or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.", "type": 2, "words": ["<tag1>", "The", "FDA", "or", "the", "sponsor", "may", "suspend", "or", "terminate", "a", "clinical", "study", "at", "any", "time", "on", "various", "grounds,", "including", "a", "finding", "that", "the", "research", "subjects", "or", "patients", "are", "being", "exposed", "to", "an", "unacceptable", "health", "risk.", "<tag2>", "The", "FDA", ",", "a", "data", "safety", "monitoring", "board,", "or", "the", "sponsor", "may", "suspend", "or", "terminate", "a", "clinical", "study", "at", "any", "time", "on", "various", "grounds,", "including", "a", "finding", "that", "the", "research", "subjects", "or", "patients", "are", "being", "exposed", "to", "an", "unacceptable", "health", "risk.", "<tag3>"], "wordsA": ["The", "FDA", "or", "the", "sponsor", "may", "suspend", "or", "terminate", "a", "clinical", "study", "at", "any", "time", "on", "various", "grounds,", "including", "a", "finding", "that", "the", "research", "subjects", "or", "patients", "are", "being", "exposed", "to", "an", "unacceptable", "health", "risk."], "wordsB": ["The", "FDA", ",", "a", "data", "safety", "monitoring", "board,", "or", "the", "sponsor", "may", "suspend", "or", "terminate", "a", "clinical", "study", "at", "any", "time", "on", "various", "grounds,", "including", "a", "finding", "that", "the", "research", "subjects", "or", "patients", "are", "being", "exposed", "to", "an", "unacceptable", "health", "risk."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p157_s2", "idA": "1316175_14_item1_p148_s2", "sentA": "Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.", "sentB": "Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life.", "type": 2, "words": ["<tag1>", "Additionally,", "appropriate", "packaging", "must", "be", "selected", "and", "tested", "and", "stability", "studies", "must", "be", "conducted", "to", "demonstrate", "that", "the", "product", "candidate", "does", "not", "undergo", "unacceptable", "deterioration", "over", "its", "shelf", "life.", "<tag2>", "Additionally,", "appropriate", "packaging", "must", "be", "selected", "and", "tested", "and", "stability", "studies", "must", "be", "conducted", "to", "demonstrate", "that", "the", "product", "candidates", "do", "not", "undergo", "unacceptable", "deterioration", "over", "their", "shelf", "life.", "<tag3>"], "wordsA": ["Additionally,", "appropriate", "packaging", "must", "be", "selected", "and", "tested", "and", "stability", "studies", "must", "be", "conducted", "to", "demonstrate", "that", "the", "product", "candidate", "does", "not", "undergo", "unacceptable", "deterioration", "over", "its", "shelf", "life."], "wordsB": ["Additionally,", "appropriate", "packaging", "must", "be", "selected", "and", "tested", "and", "stability", "studies", "must", "be", "conducted", "to", "demonstrate", "that", "the", "product", "candidates", "do", "not", "undergo", "unacceptable", "deterioration", "over", "their", "shelf", "life."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p100_s1", "idA": "1316175_14_item1_p14_s1", "sentA": "We are actively pursuing various partnerships with major pharmaceutical and biotech companies to develop and commercialize blisibimod for both lupus and IgA nephropathy.", "sentB": "We retain full development and commercialization rights of blisibimod for all other global territories including North America and the European Union and we are actively pursuing partnerships with pharmaceutical and biotech companies to develop and commercialize blisibimod in these territories.", "type": 2, "words": ["<tag1>", "We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "IgA", "nephropathy.", "<tag2>", "We", "retain", "full", "development", "and", "commercialization", "rights", "of", "blisibimod", "for", "all", "other", "global", "territories", "including", "North", "America", "and", "the", "European", "Union", "and", "we", "are", "actively", "pursuing", "partnerships", "with", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "in", "these", "territories.", "<tag3>"], "wordsA": ["We", "are", "actively", "pursuing", "various", "partnerships", "with", "major", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "for", "both", "lupus", "and", "IgA", "nephropathy."], "wordsB": ["We", "retain", "full", "development", "and", "commercialization", "rights", "of", "blisibimod", "for", "all", "other", "global", "territories", "including", "North", "America", "and", "the", "European", "Union", "and", "we", "are", "actively", "pursuing", "partnerships", "with", "pharmaceutical", "and", "biotech", "companies", "to", "develop", "and", "commercialize", "blisibimod", "in", "these", "territories."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p24_s0", "idA": "1316175_14_item1_p153_s3", "sentA": "An advisory committee is a panel of experts who provide advice and recommendations when requested by the FDA on matters of importance that come before the agency.", "sentB": "The systemic lupus erythematosus response index is a recognized endpoint by the FDA for previously approved therapeutics.", "type": 2, "words": ["<tag1>", "An", "advisory", "committee", "is", "a", "panel", "of", "experts", "who", "provide", "advice", "and", "recommendations", "when", "requested", "by", "the", "FDA", "on", "matters", "of", "importance", "that", "come", "before", "the", "agency.", "<tag2>", "The", "systemic", "lupus", "erythematosus", "response", "index", "is", "a", "recognized", "endpoint", "by", "the", "FDA", "for", "previously", "approved", "therapeutics.", "<tag3>"], "wordsA": ["An", "advisory", "committee", "is", "a", "panel", "of", "experts", "who", "provide", "advice", "and", "recommendations", "when", "requested", "by", "the", "FDA", "on", "matters", "of", "importance", "that", "come", "before", "the", "agency."], "wordsB": ["The", "systemic", "lupus", "erythematosus", "response", "index", "is", "a", "recognized", "endpoint", "by", "the", "FDA", "for", "previously", "approved", "therapeutics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p165_s0", "idA": "1316175_14_item1_p156_s0", "sentA": "Depending upon the timing, duration and specifics of FDA approval of the use of our product candidate, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments.", "sentB": "Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act.", "type": 2, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidate,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Amendments.", "<tag2>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Hatch-Waxman", "Act.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidate,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Drug", "Price", "Competition", "and", "Patent", "Term", "Restoration", "Act", "of", "1984,", "commonly", "referred", "to", "as", "the", "Hatch-Waxman", "Amendments."], "wordsB": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Hatch-Waxman", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p165_s1", "idA": "1316175_14_item1_p156_s1", "sentA": "The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during the FDA regulatory review process.", "sentB": "The Hatch-Waxman Act permit a patent restoration term of up to five years as compensation for patent term lost during the FDA regulatory review process.", "type": 2, "words": ["<tag1>", "The", "Hatch-Waxman", "Amendments", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process.", "<tag2>", "The", "Hatch-Waxman", "Act", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process.", "<tag3>"], "wordsA": ["The", "Hatch-Waxman", "Amendments", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process."], "wordsB": ["The", "Hatch-Waxman", "Act", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p43_s1", "idA": "1316175_14_item1_p156_s4", "sentA": "Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.", "sentB": "The size of the capsule can be smaller than comparable procine-PERTs since a relatively high dose (lipase units) of non-enterically-coated liprotamase enzymes can be packed into small capsules compared to the large capsules necessary for the crude procine pancrease enterically-coated extract.", "type": 2, "words": ["<tag1>", "Only", "one", "patent", "applicable", "to", "an", "approved", "drug", "is", "eligible", "for", "the", "extension", "and", "the", "application", "for", "the", "extension", "must", "be", "submitted", "prior", "to", "the", "expiration", "of", "the", "patent.", "<tag2>", "The", "size", "of", "the", "capsule", "can", "be", "smaller", "than", "comparable", "procine-PERTs", "since", "a", "relatively", "high", "dose", "(lipase", "units)", "of", "non-enterically-coated", "liprotamase", "enzymes", "can", "be", "packed", "into", "small", "capsules", "compared", "to", "the", "large", "capsules", "necessary", "for", "the", "crude", "procine", "pancrease", "enterically-coated", "extract.", "<tag3>"], "wordsA": ["Only", "one", "patent", "applicable", "to", "an", "approved", "drug", "is", "eligible", "for", "the", "extension", "and", "the", "application", "for", "the", "extension", "must", "be", "submitted", "prior", "to", "the", "expiration", "of", "the", "patent."], "wordsB": ["The", "size", "of", "the", "capsule", "can", "be", "smaller", "than", "comparable", "procine-PERTs", "since", "a", "relatively", "high", "dose", "(lipase", "units)", "of", "non-enterically-coated", "liprotamase", "enzymes", "can", "be", "packed", "into", "small", "capsules", "compared", "to", "the", "large", "capsules", "necessary", "for", "the", "crude", "procine", "pancrease", "enterically-coated", "extract."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p26_s0", "idA": "1316175_14_item1_p15_s0", "sentA": "We are currently evaluating additional plans for the development of blisibimod as a treatment for patients with multiple myeloma.", "sentB": "We are currently investigating blisibimod as a therapy for IgA nephropathy (also known as Berger s disease).", "type": 2, "words": ["<tag1>", "We", "are", "currently", "evaluating", "additional", "plans", "for", "the", "development", "of", "blisibimod", "as", "a", "treatment", "for", "patients", "with", "multiple", "myeloma.", "<tag2>", "We", "are", "currently", "investigating", "blisibimod", "as", "a", "therapy", "for", "IgA", "nephropathy", "(also", "known", "as", "Berger", "s", "disease).", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "additional", "plans", "for", "the", "development", "of", "blisibimod", "as", "a", "treatment", "for", "patients", "with", "multiple", "myeloma."], "wordsB": ["We", "are", "currently", "investigating", "blisibimod", "as", "a", "therapy", "for", "IgA", "nephropathy", "(also", "known", "as", "Berger", "s", "disease)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p76_s2", "idA": "1316175_14_item1_p15_s0", "sentA": "We are currently evaluating additional plans for the development of blisibimod as a treatment for patients with multiple myeloma.", "sentB": "These effects meet the criteria for minimal clinically-important improvement difference of 5.9 defined by Goligher and colleagues (2008) for patients with SLE.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "evaluating", "additional", "plans", "for", "the", "development", "of", "blisibimod", "as", "a", "treatment", "for", "patients", "with", "multiple", "myeloma.", "<tag2>", "These", "effects", "meet", "the", "criteria", "for", "minimal", "clinically-important", "improvement", "difference", "of", "5.9", "defined", "by", "Goligher", "and", "colleagues", "(2008)", "for", "patients", "with", "SLE.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "additional", "plans", "for", "the", "development", "of", "blisibimod", "as", "a", "treatment", "for", "patients", "with", "multiple", "myeloma."], "wordsB": ["These", "effects", "meet", "the", "criteria", "for", "minimal", "clinically-important", "improvement", "difference", "of", "5.9", "defined", "by", "Goligher", "and", "colleagues", "(2008)", "for", "patients", "with", "SLE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p178_s0", "idA": "1316175_14_item1_p169_s0", "sentA": "The FDASIA includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy.", "sentB": "The FDA Safety and Innovation Act, or FDASIA includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy.", "type": 2, "words": ["<tag1>", "The", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag2>", "The", "FDA", "Safety", "and", "Innovation", "Act,", "or", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag3>"], "wordsA": ["The", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "wordsB": ["The", "FDA", "Safety", "and", "Innovation", "Act,", "or", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p14_s0", "idA": "1316175_14_item1_p16_s0", "sentA": "Blisibimod (also referred to as A-623) is a peptibody antagonist of the BAFF cytokine, also known as B-cell activating factor, which was initially developed as treatment for patients with severe systemic lupus.", "sentB": "Pancreatic enzyme replacement therapy is currently the mainstay of treatment for nutrient malabsorption in patients with digestive enzyme deficiencies known as exocrine pancreatic insufficiency, or EPI.", "type": 2, "words": ["<tag1>", "Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine,", "also", "known", "as", "B-cell", "activating", "factor,", "which", "was", "initially", "developed", "as", "treatment", "for", "patients", "with", "severe", "systemic", "lupus.", "<tag2>", "Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "exocrine", "pancreatic", "insufficiency,", "or", "EPI.", "<tag3>"], "wordsA": ["Blisibimod", "(also", "referred", "to", "as", "A-623)", "is", "a", "peptibody", "antagonist", "of", "the", "BAFF", "cytokine,", "also", "known", "as", "B-cell", "activating", "factor,", "which", "was", "initially", "developed", "as", "treatment", "for", "patients", "with", "severe", "systemic", "lupus."], "wordsB": ["Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "exocrine", "pancreatic", "insufficiency,", "or", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s5", "idA": "1316175_14_item1_p172_s0", "sentA": "The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market.", "sentB": "The EMA also recommended the protocol to provide information on the required duration of treatment, duration of response and need for re-treatment.", "type": 2, "words": ["<tag1>", "The", "FDA", "strictly", "regulates", "labeling,", "advertising,", "promotion", "and", "other", "types", "of", "information", "on", "products", "that", "are", "placed", "on", "the", "market.", "<tag2>", "The", "EMA", "also", "recommended", "the", "protocol", "to", "provide", "information", "on", "the", "required", "duration", "of", "treatment,", "duration", "of", "response", "and", "need", "for", "re-treatment.", "<tag3>"], "wordsA": ["The", "FDA", "strictly", "regulates", "labeling,", "advertising,", "promotion", "and", "other", "types", "of", "information", "on", "products", "that", "are", "placed", "on", "the", "market."], "wordsB": ["The", "EMA", "also", "recommended", "the", "protocol", "to", "provide", "information", "on", "the", "required", "duration", "of", "treatment,", "duration", "of", "response", "and", "need", "for", "re-treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p156_s2", "idA": "1316175_14_item1_p183_s2", "sentA": "The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application.", "sentB": "A sponsor also must notify FDA of any unexpected fatal or life-threatening suspected adverse reaction within 7 days after the sponsor s receipt of the information.", "type": 2, "words": ["<tag1>", "The", "reference", "member", "state", "prepares", "a", "draft", "assessment", "and", "drafts", "of", "the", "related", "materials", "within", "120", "days", "after", "receipt", "of", "a", "valid", "application.", "<tag2>", "A", "sponsor", "also", "must", "notify", "FDA", "of", "any", "unexpected", "fatal", "or", "life-threatening", "suspected", "adverse", "reaction", "within", "7", "days", "after", "the", "sponsor", "s", "receipt", "of", "the", "information.", "<tag3>"], "wordsA": ["The", "reference", "member", "state", "prepares", "a", "draft", "assessment", "and", "drafts", "of", "the", "related", "materials", "within", "120", "days", "after", "receipt", "of", "a", "valid", "application."], "wordsB": ["A", "sponsor", "also", "must", "notify", "FDA", "of", "any", "unexpected", "fatal", "or", "life-threatening", "suspected", "adverse", "reaction", "within", "7", "days", "after", "the", "sponsor", "s", "receipt", "of", "the", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p191_s6", "idA": "1316175_14_item1_p184_s6", "sentA": "Our product candidate may not be considered cost-effective.", "sentB": "Our product candidates may not be considered cost-effective.", "type": 2, "words": ["<tag1>", "Our", "product", "candidate", "may", "not", "be", "considered", "cost-effective.", "<tag2>", "Our", "product", "candidates", "may", "not", "be", "considered", "cost-effective.", "<tag3>"], "wordsA": ["Our", "product", "candidate", "may", "not", "be", "considered", "cost-effective."], "wordsB": ["Our", "product", "candidates", "may", "not", "be", "considered", "cost-effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p134_s0", "idA": "1316175_14_item1_p186_s6", "sentA": "Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee.", "sentB": "The development activities of both us and Zenyaku are overseen by a joint development committee.", "type": 2, "words": ["<tag1>", "Any", "formulary", "used", "by", "a", "Part", "D", "prescription", "drug", "plan", "must", "be", "developed", "and", "reviewed", "by", "a", "pharmacy", "and", "therapeutic", "committee.", "<tag2>", "The", "development", "activities", "of", "both", "us", "and", "Zenyaku", "are", "overseen", "by", "a", "joint", "development", "committee.", "<tag3>"], "wordsA": ["Any", "formulary", "used", "by", "a", "Part", "D", "prescription", "drug", "plan", "must", "be", "developed", "and", "reviewed", "by", "a", "pharmacy", "and", "therapeutic", "committee."], "wordsB": ["The", "development", "activities", "of", "both", "us", "and", "Zenyaku", "are", "overseen", "by", "a", "joint", "development", "committee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p201_s0", "idA": "1316175_14_item1_p194_s0", "sentA": "As of December 31, 2013, we had 25 employees.", "sentB": "As of December 31, 2014, we had 20 employees.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2013,", "we", "had", "25", "employees.", "<tag2>", "As", "of", "December", "31,", "2014,", "we", "had", "20", "employees.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2013,", "we", "had", "25", "employees."], "wordsB": ["As", "of", "December", "31,", "2014,", "we", "had", "20", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p130_s2", "idA": "1316175_14_item1_p195_s1", "sentA": "All references to shares of common stock outstanding and per share data for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted to reflect such reverse split.", "sentB": "We issued 420,751 shares of common stock to Amgen at $2.3767 per share on January 28, 2015 pursuant to a subscription agreement with Amgen, with the consideration paid by Amgen in the form of a waiver of a fee otherwise payable to Amgen under the Amgen Agreement.", "type": 2, "words": ["<tag1>", "All", "references", "to", "shares", "of", "common", "stock", "outstanding", "and", "per", "share", "data", "for", "all", "periods", "presented", "in", "the", "accompanying", "consolidated", "financial", "statements", "and", "notes", "thereto", "have", "been", "adjusted", "to", "reflect", "such", "reverse", "split.", "<tag2>", "We", "issued", "420,751", "shares", "of", "common", "stock", "to", "Amgen", "at", "$2.3767", "per", "share", "on", "January", "28,", "2015", "pursuant", "to", "a", "subscription", "agreement", "with", "Amgen,", "with", "the", "consideration", "paid", "by", "Amgen", "in", "the", "form", "of", "a", "waiver", "of", "a", "fee", "otherwise", "payable", "to", "Amgen", "under", "the", "Amgen", "Agreement.", "<tag3>"], "wordsA": ["All", "references", "to", "shares", "of", "common", "stock", "outstanding", "and", "per", "share", "data", "for", "all", "periods", "presented", "in", "the", "accompanying", "consolidated", "financial", "statements", "and", "notes", "thereto", "have", "been", "adjusted", "to", "reflect", "such", "reverse", "split."], "wordsB": ["We", "issued", "420,751", "shares", "of", "common", "stock", "to", "Amgen", "at", "$2.3767", "per", "share", "on", "January", "28,", "2015", "pursuant", "to", "a", "subscription", "agreement", "with", "Amgen,", "with", "the", "consideration", "paid", "by", "Amgen", "in", "the", "form", "of", "a", "waiver", "of", "a", "fee", "otherwise", "payable", "to", "Amgen", "under", "the", "Amgen", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p137_s2", "idA": "1316175_14_item1_p195_s1", "sentA": "All references to shares of common stock outstanding and per share data for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted to reflect such reverse split.", "sentB": "We issued 2,795,895 shares of our common stock at a price per share equal to $2.50367 to Zenyaku in exchange for $7.0 million in cash.", "type": 2, "words": ["<tag1>", "All", "references", "to", "shares", "of", "common", "stock", "outstanding", "and", "per", "share", "data", "for", "all", "periods", "presented", "in", "the", "accompanying", "consolidated", "financial", "statements", "and", "notes", "thereto", "have", "been", "adjusted", "to", "reflect", "such", "reverse", "split.", "<tag2>", "We", "issued", "2,795,895", "shares", "of", "our", "common", "stock", "at", "a", "price", "per", "share", "equal", "to", "$2.50367", "to", "Zenyaku", "in", "exchange", "for", "$7.0", "million", "in", "cash.", "<tag3>"], "wordsA": ["All", "references", "to", "shares", "of", "common", "stock", "outstanding", "and", "per", "share", "data", "for", "all", "periods", "presented", "in", "the", "accompanying", "consolidated", "financial", "statements", "and", "notes", "thereto", "have", "been", "adjusted", "to", "reflect", "such", "reverse", "split."], "wordsB": ["We", "issued", "2,795,895", "shares", "of", "our", "common", "stock", "at", "a", "price", "per", "share", "equal", "to", "$2.50367", "to", "Zenyaku", "in", "exchange", "for", "$7.0", "million", "in", "cash."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p137_s5", "idA": "1316175_14_item1_p196_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "All sales under the stock purchase agreement are subject to the condition that Zenyaku will not at any time be obligated to purchase such number of shares of common stock that would result in Zenyaku being the beneficial owner of more than 15% of our issued and outstanding shares of common stock.", "type": 2, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "All", "sales", "under", "the", "stock", "purchase", "agreement", "are", "subject", "to", "the", "condition", "that", "Zenyaku", "will", "not", "at", "any", "time", "be", "obligated", "to", "purchase", "such", "number", "of", "shares", "of", "common", "stock", "that", "would", "result", "in", "Zenyaku", "being", "the", "beneficial", "owner", "of", "more", "than", "15%", "of", "our", "issued", "and", "outstanding", "shares", "of", "common", "stock.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["All", "sales", "under", "the", "stock", "purchase", "agreement", "are", "subject", "to", "the", "condition", "that", "Zenyaku", "will", "not", "at", "any", "time", "be", "obligated", "to", "purchase", "such", "number", "of", "shares", "of", "common", "stock", "that", "would", "result", "in", "Zenyaku", "being", "the", "beneficial", "owner", "of", "more", "than", "15%", "of", "our", "issued", "and", "outstanding", "shares", "of", "common", "stock."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p68_s7", "idA": "1316175_14_item1_p196_s1", "sentA": "Therefore, we file periodic reports, proxy statements and other information with the Securities and Exchange Commission (SEC), which may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, NE, Washington, D.C. 20549 or by calling the SEC at 1-800-SEC-0330.", "sentB": "The information found on our website is not part of this or any other report we file or furnish with the SEC .", "type": 2, "words": ["<tag1>", "Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "Securities", "and", "Exchange", "Commission", "(SEC),", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330.", "<tag2>", "The", "information", "found", "on", "our", "website", "is", "not", "part", "of", "this", "or", "any", "other", "report", "we", "file", "or", "furnish", "with", "the", "SEC", ".", "<tag3>"], "wordsA": ["Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "Securities", "and", "Exchange", "Commission", "(SEC),", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330."], "wordsB": ["The", "information", "found", "on", "our", "website", "is", "not", "part", "of", "this", "or", "any", "other", "report", "we", "file", "or", "furnish", "with", "the", "SEC", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p80_s0", "idA": "1316175_14_item1_p196_s1", "sentA": "Therefore, we file periodic reports, proxy statements and other information with the Securities and Exchange Commission (SEC), which may be obtained by visiting the Public Reference Room of the SEC at 100 F Street, NE, Washington, D.C. 20549 or by calling the SEC at 1-800-SEC-0330.", "sentB": "The information found on our website is not part of this or any other report we file or furnish with the SEC.", "type": 2, "words": ["<tag1>", "Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "Securities", "and", "Exchange", "Commission", "(SEC),", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330.", "<tag2>", "The", "information", "found", "on", "our", "website", "is", "not", "part", "of", "this", "or", "any", "other", "report", "we", "file", "or", "furnish", "with", "the", "SEC.", "<tag3>"], "wordsA": ["Therefore,", "we", "file", "periodic", "reports,", "proxy", "statements", "and", "other", "information", "with", "the", "Securities", "and", "Exchange", "Commission", "(SEC),", "which", "may", "be", "obtained", "by", "visiting", "the", "Public", "Reference", "Room", "of", "the", "SEC", "at", "100", "F", "Street,", "NE,", "Washington,", "D.C.", "20549", "or", "by", "calling", "the", "SEC", "at", "1-800-SEC-0330."], "wordsB": ["The", "information", "found", "on", "our", "website", "is", "not", "part", "of", "this", "or", "any", "other", "report", "we", "file", "or", "furnish", "with", "the", "SEC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p203_s1", "idA": "1316175_14_item1_p197_s0", "sentA": "The mailing address of our headquarters is 25801 Industrial Blvd, Hayward, CA 94545, and our telephone number at that location is 510-856-5600.", "sentB": "T he mailing address of our headquarters is 25801 Industrial Blvd, Hayward, CA 94545, and our telephone number at that location is 510-856-5600.", "type": 2, "words": ["<tag1>", "The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600.", "<tag2>", "T", "he", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600.", "<tag3>"], "wordsA": ["The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600."], "wordsB": ["T", "he", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p0_s0", "idA": "1316175_14_item1_p1_s0", "sentA": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.", "sentB": "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs .", "type": 2, "words": ["<tag1>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation", "and", "autoimmune", "diseases.", "<tag2>", "Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "advancing", "the", "development", "and", "commercialization", "of", "innovative", "medicines", "that", "benefit", "patients", "with", "unmet", "medical", "needs", ".", "<tag3>"], "wordsA": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "developing", "and", "commercializing", "products", "to", "treat", "serious", "diseases", "associated", "with", "inflammation", "and", "autoimmune", "diseases."], "wordsB": ["Anthera", "Pharmaceuticals,", "Inc.", "is", "a", "biopharmaceutical", "company", "focused", "on", "advancing", "the", "development", "and", "commercialization", "of", "innovative", "medicines", "that", "benefit", "patients", "with", "unmet", "medical", "needs", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p62_s0", "idA": "1316175_14_item1_p22_s0", "sentA": "To date, four randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC trial.", "sentB": "To date, four randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled by our licensor, Amgen, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC study, both conducted by us.", "type": 2, "words": ["<tag1>", "To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "trial.", "<tag2>", "To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us.", "<tag3>"], "wordsA": ["To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "trial."], "wordsB": ["To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p91_s0", "idA": "1316175_14_item1_p22_s0", "sentA": "To date, four randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC trial.", "sentB": "Liprotamase was studied from 2002 to 2009 in seven clinical trials, in which a total of 492 unique subjects received at least 1 dose of liprotamase.", "type": 2, "words": ["<tag1>", "To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "trial.", "<tag2>", "Liprotamase", "was", "studied", "from", "2002", "to", "2009", "in", "seven", "clinical", "trials,", "in", "which", "a", "total", "of", "492", "unique", "subjects", "received", "at", "least", "1", "dose", "of", "liprotamase.", "<tag3>"], "wordsA": ["To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "trial."], "wordsB": ["Liprotamase", "was", "studied", "from", "2002", "to", "2009", "in", "seven", "clinical", "trials,", "in", "which", "a", "total", "of", "492", "unique", "subjects", "received", "at", "least", "1", "dose", "of", "liprotamase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p95_s2", "idA": "1316175_14_item1_p22_s1", "sentA": "As expected for a BAFF inhibitor, statistically significant reductions in total B-cells were observed in patients treated with blisibimod compared with placebo in all three of the placebo-controlled studies.", "sentB": "Pairwise comparison of the CFA values showed that statistically greater improvements were observed at the higher doses of liprotamase compared with the lowest dose of 6,500 U (Figure 14).", "type": 2, "words": ["<tag1>", "As", "expected", "for", "a", "BAFF", "inhibitor,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "in", "all", "three", "of", "the", "placebo-controlled", "studies.", "<tag2>", "Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "liprotamase", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U", "(Figure", "14).", "<tag3>"], "wordsA": ["As", "expected", "for", "a", "BAFF", "inhibitor,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "in", "all", "three", "of", "the", "placebo-controlled", "studies."], "wordsB": ["Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "liprotamase", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U", "(Figure", "14)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p63_s0", "idA": "1316175_14_item1_p23_s0", "sentA": "Based on positive results among 104 lupus patients in our licensor s Phase 1a and 1b clinical studies, we conducted PEARL-SC, a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of various subcutaneous doses of blisibimod in patients with seropositive lupus and active disease defined as SELENA-SLEDAI 6 at enrollment, which ran from mid-2010 to April 2012.", "sentB": "Based on positive results among 104 lupus patients in Amgen s Phase 1a and 1b clinical studies, we conducted the PEARL-SC study, a Phase 2b randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of various subcutaneous doses of blisibimod in patients with seropositive lupus and active disease defined as SELENA-SLEDAI 6 at enrollment, which ran from mid-2010 to April 2012.", "type": 2, "words": ["<tag1>", "Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "our", "licensor", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "PEARL-SC,", "a", "Phase", "2b", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012.", "<tag2>", "Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "Amgen", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "the", "PEARL-SC", "study,", "a", "Phase", "2b", "randomized,", "double-", "blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012.", "<tag3>"], "wordsA": ["Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "our", "licensor", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "PEARL-SC,", "a", "Phase", "2b", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012."], "wordsB": ["Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "Amgen", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "the", "PEARL-SC", "study,", "a", "Phase", "2b", "randomized,", "double-", "blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p95_s3", "idA": "1316175_14_item1_p26_s1", "sentA": "Compared with baseline, decreases in proteinuria were observed with blisibimod from Week 12 through Week 52 in the subgroup of subjects with proteinuria equivalent 1 g/24hr at enrollment (Figure 3).", "sentB": "Similar improvements in the CNA, were observed with liprotamase at the two highest dose levels.", "type": 2, "words": ["<tag1>", "Compared", "with", "baseline,", "decreases", "in", "proteinuria", "were", "observed", "with", "blisibimod", "from", "Week", "12", "through", "Week", "52", "in", "the", "subgroup", "of", "subjects", "with", "proteinuria", "equivalent", "1", "g/24hr", "at", "enrollment", "(Figure", "3).", "<tag2>", "Similar", "improvements", "in", "the", "CNA,", "were", "observed", "with", "liprotamase", "at", "the", "two", "highest", "dose", "levels.", "<tag3>"], "wordsA": ["Compared", "with", "baseline,", "decreases", "in", "proteinuria", "were", "observed", "with", "blisibimod", "from", "Week", "12", "through", "Week", "52", "in", "the", "subgroup", "of", "subjects", "with", "proteinuria", "equivalent", "1", "g/24hr", "at", "enrollment", "(Figure", "3)."], "wordsB": ["Similar", "improvements", "in", "the", "CNA,", "were", "observed", "with", "liprotamase", "at", "the", "two", "highest", "dose", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p91_s1", "idA": "1316175_14_item1_p26_s2", "sentA": "Similarly, decreases in proteinuria were observed in subjects with proteinuria equivalent 0.5 g/24hr through Week 44.", "sentB": "Three Phase 1 trials were conducted, 1 in healthy volunteers and 2 in subjects with EPI due to CF.", "type": 2, "words": ["<tag1>", "Similarly,", "decreases", "in", "proteinuria", "were", "observed", "in", "subjects", "with", "proteinuria", "equivalent", "0.5", "g/24hr", "through", "Week", "44.", "<tag2>", "Three", "Phase", "1", "trials", "were", "conducted,", "1", "in", "healthy", "volunteers", "and", "2", "in", "subjects", "with", "EPI", "due", "to", "CF.", "<tag3>"], "wordsA": ["Similarly,", "decreases", "in", "proteinuria", "were", "observed", "in", "subjects", "with", "proteinuria", "equivalent", "0.5", "g/24hr", "through", "Week", "44."], "wordsB": ["Three", "Phase", "1", "trials", "were", "conducted,", "1", "in", "healthy", "volunteers", "and", "2", "in", "subjects", "with", "EPI", "due", "to", "CF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p76_s1", "idA": "1316175_14_item1_p29_s1", "sentA": "In this severe subgroup, separation of clinical response was evident as early as Week 8 and numerical improvements relative to placebo were maintained beyond Week 24.", "sentB": "Improvements in patient self-reported fatigue were observed amongst subjects randomized to blisibimod based on the FACIT-Fatigue scale (Figure 7), especially in the 200mg QW group (N=80) where favorable effects of blisibimod compared with placebo were observed as early as Week 8, and a mean 6.9-point improvement from baseline was reported at Week 24 compared to 4.4 with placebo (N=229).", "type": 2, "words": ["<tag1>", "In", "this", "severe", "subgroup,", "separation", "of", "clinical", "response", "was", "evident", "as", "early", "as", "Week", "8", "and", "numerical", "improvements", "relative", "to", "placebo", "were", "maintained", "beyond", "Week", "24.", "<tag2>", "Improvements", "in", "patient", "self-reported", "fatigue", "were", "observed", "amongst", "subjects", "randomized", "to", "blisibimod", "based", "on", "the", "FACIT-Fatigue", "scale", "(Figure", "7),", "especially", "in", "the", "200mg", "QW", "group", "(N=80)", "where", "favorable", "effects", "of", "blisibimod", "compared", "with", "placebo", "were", "observed", "as", "early", "as", "Week", "8,", "and", "a", "mean", "6.9-point", "improvement", "from", "baseline", "was", "reported", "at", "Week", "24", "compared", "to", "4.4", "with", "placebo", "(N=229).", "<tag3>"], "wordsA": ["In", "this", "severe", "subgroup,", "separation", "of", "clinical", "response", "was", "evident", "as", "early", "as", "Week", "8", "and", "numerical", "improvements", "relative", "to", "placebo", "were", "maintained", "beyond", "Week", "24."], "wordsB": ["Improvements", "in", "patient", "self-reported", "fatigue", "were", "observed", "amongst", "subjects", "randomized", "to", "blisibimod", "based", "on", "the", "FACIT-Fatigue", "scale", "(Figure", "7),", "especially", "in", "the", "200mg", "QW", "group", "(N=80)", "where", "favorable", "effects", "of", "blisibimod", "compared", "with", "placebo", "were", "observed", "as", "early", "as", "Week", "8,", "and", "a", "mean", "6.9-point", "improvement", "from", "baseline", "was", "reported", "at", "Week", "24", "compared", "to", "4.4", "with", "placebo", "(N=229)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p91_s3", "idA": "1316175_14_item1_p29_s3", "sentA": "Significant and early decreases in proteinuria were also observed with blisibimod as early as Week 8 in subjects with baseline proteinuria equivalent 1g/24 hrs.", "sentB": "Two long-term Phase 3 safety and tolerability trials were also conducted: Study 767 in subjects with EPI due to CF and Study 810 in subjects with EPI due to CP/pancreatectomy.", "type": 2, "words": ["<tag1>", "Significant", "and", "early", "decreases", "in", "proteinuria", "were", "also", "observed", "with", "blisibimod", "as", "early", "as", "Week", "8", "in", "subjects", "with", "baseline", "proteinuria", "equivalent", "1g/24", "hrs.", "<tag2>", "Two", "long-term", "Phase", "3", "safety", "and", "tolerability", "trials", "were", "also", "conducted:", "Study", "767", "in", "subjects", "with", "EPI", "due", "to", "CF", "and", "Study", "810", "in", "subjects", "with", "EPI", "due", "to", "CP/pancreatectomy.", "<tag3>"], "wordsA": ["Significant", "and", "early", "decreases", "in", "proteinuria", "were", "also", "observed", "with", "blisibimod", "as", "early", "as", "Week", "8", "in", "subjects", "with", "baseline", "proteinuria", "equivalent", "1g/24", "hrs."], "wordsB": ["Two", "long-term", "Phase", "3", "safety", "and", "tolerability", "trials", "were", "also", "conducted:", "Study", "767", "in", "subjects", "with", "EPI", "due", "to", "CF", "and", "Study", "810", "in", "subjects", "with", "EPI", "due", "to", "CP/pancreatectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p1_s0", "idA": "1316175_14_item1_p2_s0", "sentA": "Our Phase 3 candidate, blisibimod, targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, (lupus), Immunoglobin A nephropathy (IgA nephropathy), lupus nephritis, vasculitis and others.", "sentB": "Our first Phase 3 product candidate, blisibimod, licensed from Amgen in December 2007, targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ( SLE ), or lupus, Immunoglobulin A nephropathy, or IgA nephropathy, lupus nephritis, and others.", "type": 2, "words": ["<tag1>", "Our", "Phase", "3", "candidate,", "blisibimod,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "(lupus),", "Immunoglobin", "A", "nephropathy", "(IgA", "nephropathy),", "lupus", "nephritis,", "vasculitis", "and", "others.", "<tag2>", "Our", "first", "Phase", "3", "product", "candidate,", "blisibimod,", "licensed", "from", "Amgen", "in", "December", "2007,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others.", "<tag3>"], "wordsA": ["Our", "Phase", "3", "candidate,", "blisibimod,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus,", "(lupus),", "Immunoglobin", "A", "nephropathy", "(IgA", "nephropathy),", "lupus", "nephritis,", "vasculitis", "and", "others."], "wordsB": ["Our", "first", "Phase", "3", "product", "candidate,", "blisibimod,", "licensed", "from", "Amgen", "in", "December", "2007,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p69_s0", "idA": "1316175_14_item1_p30_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, Washington DC, 2012 in Figure 1, an SRI-5 responder achieved all of the following: 5 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "sentB": "In Figure 5, an SRI-6 responder achieved all of the following: 6 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Washington", "DC,", "2012", "in", "Figure", "1,", "an", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag2>", "In", "Figure", "5,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Washington", "DC,", "2012", "in", "Figure", "1,", "an", "SRI-5", "responder", "achieved", "all", "of", "the", "following:", "5", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "wordsB": ["In", "Figure", "5,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p96_s2", "idA": "1316175_14_item1_p30_s1", "sentA": "Across all subjects enrolled in the PEARL-SC study, the percent of subjects achieving the SRI-5 at 24 weeks was higher in subjects receiving the highest dose of blisibimod (200mg QW) compared with placebo.", "sentB": "Amongst the 138 subjects enrolled in this study, treatment with liprotamase resulted in a statistically significant improvement in the change from baseline in the CFA of 21.2% with liprotamase compared with 6.0% with placebo (p = 0.0011, Figure 15).", "type": 2, "words": ["<tag1>", "Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo.", "<tag2>", "Amongst", "the", "138", "subjects", "enrolled", "in", "this", "study,", "treatment", "with", "liprotamase", "resulted", "in", "a", "statistically", "significant", "improvement", "in", "the", "change", "from", "baseline", "in", "the", "CFA", "of", "21.2%", "with", "liprotamase", "compared", "with", "6.0%", "with", "placebo", "(p", "=", "0.0011,", "Figure", "15).", "<tag3>"], "wordsA": ["Across", "all", "subjects", "enrolled", "in", "the", "PEARL-SC", "study,", "the", "percent", "of", "subjects", "achieving", "the", "SRI-5", "at", "24", "weeks", "was", "higher", "in", "subjects", "receiving", "the", "highest", "dose", "of", "blisibimod", "(200mg", "QW)", "compared", "with", "placebo."], "wordsB": ["Amongst", "the", "138", "subjects", "enrolled", "in", "this", "study,", "treatment", "with", "liprotamase", "resulted", "in", "a", "statistically", "significant", "improvement", "in", "the", "change", "from", "baseline", "in", "the", "CFA", "of", "21.2%", "with", "liprotamase", "compared", "with", "6.0%", "with", "placebo", "(p", "=", "0.0011,", "Figure", "15)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p70_s1", "idA": "1316175_14_item1_p32_s3", "sentA": "Graph shows data for blisibimod (200mg QW) and regimen matched placebo administered subcutaneously for 24 weeks.", "sentB": "The graph shows data for blisibimod (200mg QW) and regimen matched placebo administered subcutaneously for 24 weeks (Furie et al., Ann Rheum Dis . 2014).", "type": 2, "words": ["<tag1>", "Graph", "shows", "data", "for", "blisibimod", "(200mg", "QW)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks.", "<tag2>", "The", "graph", "shows", "data", "for", "blisibimod", "(200mg", "QW)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "(Furie", "et", "al.,", "Ann", "Rheum", "Dis", ".", "2014).", "<tag3>"], "wordsA": ["Graph", "shows", "data", "for", "blisibimod", "(200mg", "QW)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks."], "wordsB": ["The", "graph", "shows", "data", "for", "blisibimod", "(200mg", "QW)", "and", "regimen", "matched", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "(Furie", "et", "al.,", "Ann", "Rheum", "Dis", ".", "2014)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p74_s0", "idA": "1316175_14_item1_p36_s0", "sentA": "Graphs show data from subgroups of patients defined by baseline proteinuria for blisibimod.", "sentB": "The graph shows data from subgroups of patients defined by baseline proteinuria for blisibimod.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod.", "<tag2>", "The", "graph", "shows", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod."], "wordsB": ["The", "graph", "shows", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p94_s1", "idA": "1316175_14_item1_p37_s0", "sentA": "In this study, statistically significant reductions in total B-cells were observed in patients treated with blisibimod compared with placebo due to its mechanism of BAFF inhibition.", "sentB": "In this study, greater improvements in nutrients absorption, as measured using the percent change from baseline in the coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA), were observed at doses of 500 U per kg per meal and higher.", "type": 2, "words": ["<tag1>", "In", "this", "study,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag2>", "In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "U", "per", "kg", "per", "meal", "and", "higher.", "<tag3>"], "wordsA": ["In", "this", "study,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "wordsB": ["In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "U", "per", "kg", "per", "meal", "and", "higher."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p108_s0", "idA": "1316175_14_item1_p38_s2", "sentA": "Interim data from the combined PEARL-SC and OLE studies were presented at the 2013 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP).", "sentB": "Emerging data from 2 large Phase 3 trials with the BAFF-targeted monocloncal antibody, tabalumab, were presented by Professor David Isenberg at the American College of Rheumatology Annual Conference, Boston, MA, November 2014.", "type": 2, "words": ["<tag1>", "Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP).", "<tag2>", "Emerging", "data", "from", "2", "large", "Phase", "3", "trials", "with", "the", "BAFF-targeted", "monocloncal", "antibody,", "tabalumab,", "were", "presented", "by", "Professor", "David", "Isenberg", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston,", "MA,", "November", "2014.", "<tag3>"], "wordsA": ["Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP)."], "wordsB": ["Emerging", "data", "from", "2", "large", "Phase", "3", "trials", "with", "the", "BAFF-targeted", "monocloncal", "antibody,", "tabalumab,", "were", "presented", "by", "Professor", "David", "Isenberg", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston,", "MA,", "November", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p203_s0", "idA": "1316175_14_item1_p3_s0", "sentA": "We were incorporated as a Delaware corporation in September 2004.", "sentB": "We were incorporated in Delaware in 2004.", "type": 2, "words": ["<tag1>", "We", "were", "incorporated", "as", "a", "Delaware", "corporation", "in", "September", "2004.", "<tag2>", "We", "were", "incorporated", "in", "Delaware", "in", "2004.", "<tag3>"], "wordsA": ["We", "were", "incorporated", "as", "a", "Delaware", "corporation", "in", "September", "2004."], "wordsB": ["We", "were", "incorporated", "in", "Delaware", "in", "2004."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p109_s1", "idA": "1316175_14_item1_p40_s0", "sentA": "The data from the Phase 2 program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the Phase 2 study in patients with IgA nephropathy (BRIGHT-SC1).", "sentB": "We are also aware of companies with other products in development that are being tested for potential treatment of EPI caused by cystic fibrosis: Johnson and Johnson Research and Development LLC recently completed a Phase 3 study to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis patients with clinical symptoms of EPI; and Nordmark Arzneimittel GmbH Co. KG s compound, Burlulipase, is being tested in a Phase 3 study in patients with EPI.", "type": 2, "words": ["<tag1>", "The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1).", "<tag2>", "We", "are", "also", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "EPI", "caused", "by", "cystic", "fibrosis:", "Johnson", "and", "Johnson", "Research", "and", "Development", "LLC", "recently", "completed", "a", "Phase", "3", "study", "to", "assess", "the", "effectiveness", "and", "safety", "of", "oral", "pancrelipase", "MT", "in", "the", "treatment", "of", "adult", "and", "pediatric/adolescent", "cystic", "fibrosis", "patients", "with", "clinical", "symptoms", "of", "EPI;", "and", "Nordmark", "Arzneimittel", "GmbH", "Co.", "KG", "s", "compound,", "Burlulipase,", "is", "being", "tested", "in", "a", "Phase", "3", "study", "in", "patients", "with", "EPI.", "<tag3>"], "wordsA": ["The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1)."], "wordsB": ["We", "are", "also", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "EPI", "caused", "by", "cystic", "fibrosis:", "Johnson", "and", "Johnson", "Research", "and", "Development", "LLC", "recently", "completed", "a", "Phase", "3", "study", "to", "assess", "the", "effectiveness", "and", "safety", "of", "oral", "pancrelipase", "MT", "in", "the", "treatment", "of", "adult", "and", "pediatric/adolescent", "cystic", "fibrosis", "patients", "with", "clinical", "symptoms", "of", "EPI;", "and", "Nordmark", "Arzneimittel", "GmbH", "Co.", "KG", "s", "compound,", "Burlulipase,", "is", "being", "tested", "in", "a", "Phase", "3", "study", "in", "patients", "with", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s7", "idA": "1316175_14_item1_p40_s0", "sentA": "The data from the Phase 2 program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the Phase 2 study in patients with IgA nephropathy (BRIGHT-SC1).", "sentB": "These characteristics were associated with improved outcomes in both our previous Phase 2 clinical study as well as in two large Phase 3 studies conducted with other BAFF-inhibitors, belimumab (Benlysta) and, more recently, tabalumab.", "type": 2, "words": ["<tag1>", "The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1).", "<tag2>", "These", "characteristics", "were", "associated", "with", "improved", "outcomes", "in", "both", "our", "previous", "Phase", "2", "clinical", "study", "as", "well", "as", "in", "two", "large", "Phase", "3", "studies", "conducted", "with", "other", "BAFF-inhibitors,", "belimumab", "(Benlysta)", "and,", "more", "recently,", "tabalumab.", "<tag3>"], "wordsA": ["The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1)."], "wordsB": ["These", "characteristics", "were", "associated", "with", "improved", "outcomes", "in", "both", "our", "previous", "Phase", "2", "clinical", "study", "as", "well", "as", "in", "two", "large", "Phase", "3", "studies", "conducted", "with", "other", "BAFF-inhibitors,", "belimumab", "(Benlysta)", "and,", "more", "recently,", "tabalumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p91_s2", "idA": "1316175_14_item1_p40_s0", "sentA": "The data from the Phase 2 program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the Phase 2 study in patients with IgA nephropathy (BRIGHT-SC1).", "sentB": "Two short-term trials, the Phase 2 Study TC 2A, and the Phase 3 Study 726 evaluated the efficacy of liprotamase in subjects 7 years of age with EPI due to CF.", "type": 2, "words": ["<tag1>", "The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1).", "<tag2>", "Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC", "2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "liprotamase", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF.", "<tag3>"], "wordsA": ["The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1)."], "wordsB": ["Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC", "2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "liprotamase", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p79_s1", "idA": "1316175_14_item1_p40_s1", "sentA": "Additional information for the OLE clinical studies can be found at www.anthera.com /studies_open-label-extension-study.htm.", "sentB": "Additional information for the OLE clinical studies can be found at http://www.anthera.com/pipeline/clinical-studies/past-studies/open-label-extension-study .html.", "type": 2, "words": ["<tag1>", "Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "www.anthera.com", "/studies_open-label-extension-study.htm.", "<tag2>", "Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "http://www.anthera.com/pipeline/clinical-studies/past-studies/open-label-extension-study", ".html.", "<tag3>"], "wordsA": ["Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "www.anthera.com", "/studies_open-label-extension-study.htm."], "wordsB": ["Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "http://www.anthera.com/pipeline/clinical-studies/past-studies/open-label-extension-study", ".html."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p68_s6", "idA": "1316175_14_item1_p41_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013, in Figure 4, the significant improvements in proteinuria in patients with lupus randomized to blisibimod compared with placebo observed in the PEARL-SC study were found to be durable through their continuing exposure to blisibimod in the OLE study.", "sentB": "In addition to publications in earlier abstracts at key international rheumatology conferences, the efficacy and safety data from the PEARL-SC study were published by Dr Richard Furie and colleagues ( Ann Rheum Dis . 2014).", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study.", "<tag2>", "In", "addition", "to", "publications", "in", "earlier", "abstracts", "at", "key", "international", "rheumatology", "conferences,", "the", "efficacy", "and", "safety", "data", "from", "the", "PEARL-SC", "study", "were", "published", "by", "Dr", "Richard", "Furie", "and", "colleagues", "(", "Ann", "Rheum", "Dis", ".", "2014).", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study."], "wordsB": ["In", "addition", "to", "publications", "in", "earlier", "abstracts", "at", "key", "international", "rheumatology", "conferences,", "the", "efficacy", "and", "safety", "data", "from", "the", "PEARL-SC", "study", "were", "published", "by", "Dr", "Richard", "Furie", "and", "colleagues", "(", "Ann", "Rheum", "Dis", ".", "2014)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p76_s0", "idA": "1316175_14_item1_p41_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013, in Figure 4, the significant improvements in proteinuria in patients with lupus randomized to blisibimod compared with placebo observed in the PEARL-SC study were found to be durable through their continuing exposure to blisibimod in the OLE study.", "sentB": "The effects of blisibimod on patient-reported fatigue were evaluated in the PEARL-SC study using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, and reported by Dr Michelle Petri at the American College of Rheumatology Annual Conference, Boston MA, 2014.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study.", "<tag2>", "The", "effects", "of", "blisibimod", "on", "patient-reported", "fatigue", "were", "evaluated", "in", "the", "PEARL-SC", "study", "using", "the", "Functional", "Assessment", "of", "Chronic", "Illness", "Therapy", "(FACIT)-Fatigue", "scale,", "and", "reported", "by", "Dr", "Michelle", "Petri", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston", "MA,", "2014.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study."], "wordsB": ["The", "effects", "of", "blisibimod", "on", "patient-reported", "fatigue", "were", "evaluated", "in", "the", "PEARL-SC", "study", "using", "the", "Functional", "Assessment", "of", "Chronic", "Illness", "Therapy", "(FACIT)-Fatigue", "scale,", "and", "reported", "by", "Dr", "Michelle", "Petri", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston", "MA,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p95_s1", "idA": "1316175_14_item1_p41_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013, in Figure 4, the significant improvements in proteinuria in patients with lupus randomized to blisibimod compared with placebo observed in the PEARL-SC study were found to be durable through their continuing exposure to blisibimod in the OLE study.", "sentB": "Observed mean CFAs at the end of study were 56.2%, 67.0%, and 69.7% in the 6,500, 32,500, and 130,000 U dose groups, respectively (one-way ANOVA p = 0.0032) with significant improvements in mean changes from baseline (one-way ANOVA p = 0.0005).", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study.", "<tag2>", "Observed", "mean", "CFAs", "at", "the", "end", "of", "study", "were", "56.2%,", "67.0%,", "and", "69.7%", "in", "the", "6,500,", "32,500,", "and", "130,000", "U", "dose", "groups,", "respectively", "(one-way", "ANOVA", "p", "=", "0.0032)", "with", "significant", "improvements", "in", "mean", "changes", "from", "baseline", "(one-way", "ANOVA", "p", "=", "0.0005).", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "4,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study."], "wordsB": ["Observed", "mean", "CFAs", "at", "the", "end", "of", "study", "were", "56.2%,", "67.0%,", "and", "69.7%", "in", "the", "6,500,", "32,500,", "and", "130,000", "U", "dose", "groups,", "respectively", "(one-way", "ANOVA", "p", "=", "0.0032)", "with", "significant", "improvements", "in", "mean", "changes", "from", "baseline", "(one-way", "ANOVA", "p", "=", "0.0005)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p81_s1", "idA": "1316175_14_item1_p41_s1", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "sentB": "The graph shows data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag2>", "The", "graph", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "wordsB": ["The", "graph", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p82_s1", "idA": "1316175_14_item1_p41_s1", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "sentB": "The graphs shows data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag2>", "The", "graphs", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "wordsB": ["The", "graphs", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p82_s0", "idA": "1316175_14_item1_p42_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 5, w ith its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B-cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 9, with its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B-cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "5,", "w", "ith", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "9,", "with", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "5,", "w", "ith", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "9,", "with", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p83_s3", "idA": "1316175_14_item1_p42_s1", "sentA": "Graphs show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "sentB": "The graphs show data for blisibimod (all pooled dose levels as well as 200mg once- weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC study, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "type": 2, "words": ["<tag1>", "Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag2>", "The", "graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-", "weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "study,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag3>"], "wordsA": ["Graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "wordsB": ["The", "graphs", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-", "weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "study,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p83_s0", "idA": "1316175_14_item1_p43_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 6, s ignificant reductions in immunoglobulins IgG and IgM were observed with blisibimod compared with placebo during the placebo-controlled PEARL-SC study.", "sentB": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 10, significant reductions in immunoglobulins IgG and IgM were observed with blisibimod compared with placebo during the placebo-controlled PEARL-SC study.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "6,", "s", "ignificant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study.", "<tag2>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "10,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "6,", "s", "ignificant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study."], "wordsB": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "10,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p18_s0", "idA": "1316175_14_item1_p44_s0", "sentA": "In the third quarter of 2012 at an End of Phase 2 meeting with the United States Food and Drug Administration, or FDA, we presented the results of the PEARL-SC clinical study and our plans for Phase 3 registration studies in patients with active lupus.", "sentB": "In the third quarter of 2012 at an End of Phase 2 meeting with the United States Food and Drug Administration, or FDA, we presented the results of the PEARL-SC study and our plans for Phase 3 registration studies in patients with active lupus.", "type": 2, "words": ["<tag1>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag2>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag3>"], "wordsA": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "clinical", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "wordsB": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p18_s1", "idA": "1316175_14_item1_p44_s1", "sentA": "As a result of this meeting we initiated patient enrollment in the initial Phase 3 CHABLIS-SC1 (Figure 7) study in March 2013.", "sentB": "As a result of this meeting we initiated patient enrollment in the initial Phase 3 CHABLIS-SC1 study in March 2013.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "(Figure", "7)", "study", "in", "March", "2013.", "<tag2>", "As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "March", "2013.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "(Figure", "7)", "study", "in", "March", "2013."], "wordsB": ["As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "March", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s0", "idA": "1316175_14_item1_p45_s0", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are multicenter, randomized, double-blind, placebo-controlled studies designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with seropositive, clinically active lupus (SELENA-SLEDAI 10) who continue to have active disease despite stable corticosteroid therapy for treatment of their disease.", "sentB": "CHABLIS-SC1 is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with seropositive, clinically-active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard-of-care for treatment of their disease.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "seropositive,", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "continue", "to", "have", "active", "disease", "despite", "stable", "corticosteroid", "therapy", "for", "treatment", "of", "their", "disease.", "<tag2>", "CHABLIS-SC1", "is", "a", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "seropositive,", "clinically-active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "studies", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "seropositive,", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "continue", "to", "have", "active", "disease", "despite", "stable", "corticosteroid", "therapy", "for", "treatment", "of", "their", "disease."], "wordsB": ["CHABLIS-SC1", "is", "a", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "designed", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "seropositive,", "clinically-active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard-of-care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s2", "idA": "1316175_14_item1_p45_s1", "sentA": "Each study plans to randomize up to 400 patients to receive either 200mg of blisibimod or placebo for 52 weeks.", "sentB": "The study plans to randomize up to 400 patients to receive either 200mg of blisibimod or placebo in addition to their standard-of-care medication for 52 weeks.", "type": 2, "words": ["<tag1>", "Each", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks.", "<tag2>", "The", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "in", "addition", "to", "their", "standard-of-care", "medication", "for", "52", "weeks.", "<tag3>"], "wordsA": ["Each", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "for", "52", "weeks."], "wordsB": ["The", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "in", "addition", "to", "their", "standard-of-care", "medication", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s4", "idA": "1316175_14_item1_p45_s2", "sentA": "As agreed with the FDA, the primary endpoint of the Phase 3 studies will be clinical improvement in the SRI-8 response at 52 weeks.", "sentB": "The primary endpoint of the CHABLIS-SC1 will be clinical improvement in the SRI-6 response at 52 weeks.", "type": 2, "words": ["<tag1>", "As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks.", "<tag2>", "The", "primary", "endpoint", "of", "the", "CHABLIS-SC1", "will", "be", "clinical", "improvement", "in", "the", "SRI-6", "response", "at", "52", "weeks.", "<tag3>"], "wordsA": ["As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks."], "wordsB": ["The", "primary", "endpoint", "of", "the", "CHABLIS-SC1", "will", "be", "clinical", "improvement", "in", "the", "SRI-6", "response", "at", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p24_s1", "idA": "1316175_14_item1_p45_s2", "sentA": "As agreed with the FDA, the primary endpoint of the Phase 3 studies will be clinical improvement in the SRI-8 response at 52 weeks.", "sentB": "Prior to the interim analysis and in response to input from our Scientific Advisory Board who evaluated the published clinical data from other recent lupus studies with BAFF inhibitors, we modified the primary endpoint of CHABLIS-SC1 from a comparison of the proportion of responders to the SRI-8 responder index to a comparison of the proportion of responders to the SRI-6 responder index (previously a secondary endpoint of the study).", "type": 2, "words": ["<tag1>", "As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks.", "<tag2>", "Prior", "to", "the", "interim", "analysis", "and", "in", "response", "to", "input", "from", "our", "Scientific", "Advisory", "Board", "who", "evaluated", "the", "published", "clinical", "data", "from", "other", "recent", "lupus", "studies", "with", "BAFF", "inhibitors,", "we", "modified", "the", "primary", "endpoint", "of", "CHABLIS-SC1", "from", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-8", "responder", "index", "to", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-6", "responder", "index", "(previously", "a", "secondary", "endpoint", "of", "the", "study).", "<tag3>"], "wordsA": ["As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks."], "wordsB": ["Prior", "to", "the", "interim", "analysis", "and", "in", "response", "to", "input", "from", "our", "Scientific", "Advisory", "Board", "who", "evaluated", "the", "published", "clinical", "data", "from", "other", "recent", "lupus", "studies", "with", "BAFF", "inhibitors,", "we", "modified", "the", "primary", "endpoint", "of", "CHABLIS-SC1", "from", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-8", "responder", "index", "to", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-6", "responder", "index", "(previously", "a", "secondary", "endpoint", "of", "the", "study)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p24_s3", "idA": "1316175_14_item1_p45_s2", "sentA": "As agreed with the FDA, the primary endpoint of the Phase 3 studies will be clinical improvement in the SRI-8 response at 52 weeks.", "sentB": "Response rates to the SRI-8 responder index will remain a key secondary endpoint of the study.", "type": 2, "words": ["<tag1>", "As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks.", "<tag2>", "Response", "rates", "to", "the", "SRI-8", "responder", "index", "will", "remain", "a", "key", "secondary", "endpoint", "of", "the", "study.", "<tag3>"], "wordsA": ["As", "agreed", "with", "the", "FDA,", "the", "primary", "endpoint", "of", "the", "Phase", "3", "studies", "will", "be", "clinical", "improvement", "in", "the", "SRI-8", "response", "at", "52", "weeks."], "wordsB": ["Response", "rates", "to", "the", "SRI-8", "responder", "index", "will", "remain", "a", "key", "secondary", "endpoint", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p42_s3", "idA": "1316175_14_item1_p46_s0", "sentA": "We believe the CHABLIS development program for blisibimod may offer a number of potential opportunities for differentiation versus the currently marketed BAFF antagonist and other novel B-cell directed therapies, including:", "sentB": "We believe the SOLUTION study may offer a number of potential opportunities for differentiation versus the currently marketed PERTs, including:", "type": 2, "words": ["<tag1>", "We", "believe", "the", "CHABLIS", "development", "program", "for", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist", "and", "other", "novel", "B-cell", "directed", "therapies,", "including:", "<tag2>", "We", "believe", "the", "SOLUTION", "study", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:", "<tag3>"], "wordsA": ["We", "believe", "the", "CHABLIS", "development", "program", "for", "blisibimod", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "BAFF", "antagonist", "and", "other", "novel", "B-cell", "directed", "therapies,", "including:"], "wordsB": ["We", "believe", "the", "SOLUTION", "study", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p23_s0", "idA": "1316175_14_item1_p48_s0", "sentA": "A futility analysis of clinical study is planned to be conducted by an independent unblinded statistician in mid-2014 after a minimum of 100 subjects have completed 24 weeks of treatment to confirm the clinical and commercial assumptions of the design of this study.", "sentB": "In February 2015, an interim analysis of CHABLIS-SC1 was conducted by an independent un-blinded statistician, who evaluated at a pre-specified time point, the proportion of responders to the systemic lupus erythematous SRI-6 responder index, and recommended the study to continue to completion as planned.", "type": 2, "words": ["<tag1>", "A", "futility", "analysis", "of", "clinical", "study", "is", "planned", "to", "be", "conducted", "by", "an", "independent", "unblinded", "statistician", "in", "mid-2014", "after", "a", "minimum", "of", "100", "subjects", "have", "completed", "24", "weeks", "of", "treatment", "to", "confirm", "the", "clinical", "and", "commercial", "assumptions", "of", "the", "design", "of", "this", "study.", "<tag2>", "In", "February", "2015,", "an", "interim", "analysis", "of", "CHABLIS-SC1", "was", "conducted", "by", "an", "independent", "un-blinded", "statistician,", "who", "evaluated", "at", "a", "pre-specified", "time", "point,", "the", "proportion", "of", "responders", "to", "the", "systemic", "lupus", "erythematous", "SRI-6", "responder", "index,", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned.", "<tag3>"], "wordsA": ["A", "futility", "analysis", "of", "clinical", "study", "is", "planned", "to", "be", "conducted", "by", "an", "independent", "unblinded", "statistician", "in", "mid-2014", "after", "a", "minimum", "of", "100", "subjects", "have", "completed", "24", "weeks", "of", "treatment", "to", "confirm", "the", "clinical", "and", "commercial", "assumptions", "of", "the", "design", "of", "this", "study."], "wordsB": ["In", "February", "2015,", "an", "interim", "analysis", "of", "CHABLIS-SC1", "was", "conducted", "by", "an", "independent", "un-blinded", "statistician,", "who", "evaluated", "at", "a", "pre-specified", "time", "point,", "the", "proportion", "of", "responders", "to", "the", "systemic", "lupus", "erythematous", "SRI-6", "responder", "index,", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p23_s1", "idA": "1316175_14_item1_p48_s1", "sentA": "This futility analysis is not intended to provide any rules for stopping for overwhelming efficacy, change in study sample size, or alteration of the study design.", "sentB": "This futility analysis was not intended to provide any rules for stopping for overwhelming efficacy, for a change in study sample size, or for an alteration of the study design.", "type": 2, "words": ["<tag1>", "This", "futility", "analysis", "is", "not", "intended", "to", "provide", "any", "rules", "for", "stopping", "for", "overwhelming", "efficacy,", "change", "in", "study", "sample", "size,", "or", "alteration", "of", "the", "study", "design.", "<tag2>", "This", "futility", "analysis", "was", "not", "intended", "to", "provide", "any", "rules", "for", "stopping", "for", "overwhelming", "efficacy,", "for", "a", "change", "in", "study", "sample", "size,", "or", "for", "an", "alteration", "of", "the", "study", "design.", "<tag3>"], "wordsA": ["This", "futility", "analysis", "is", "not", "intended", "to", "provide", "any", "rules", "for", "stopping", "for", "overwhelming", "efficacy,", "change", "in", "study", "sample", "size,", "or", "alteration", "of", "the", "study", "design."], "wordsB": ["This", "futility", "analysis", "was", "not", "intended", "to", "provide", "any", "rules", "for", "stopping", "for", "overwhelming", "efficacy,", "for", "a", "change", "in", "study", "sample", "size,", "or", "for", "an", "alteration", "of", "the", "study", "design."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s6", "idA": "1316175_14_item1_p49_s0", "sentA": "Enrollment rates for the CHABLIS-SC1 study have exceeded our initial expectations.", "sentB": "To date, enrolled patient demographics and disease characteristics for the CHABLIS-SC1 study are consistent with our goal to enroll patients with higher levels of lupus activity and positive biomarkers despite the stable use of corticosteroids.", "type": 2, "words": ["<tag1>", "Enrollment", "rates", "for", "the", "CHABLIS-SC1", "study", "have", "exceeded", "our", "initial", "expectations.", "<tag2>", "To", "date,", "enrolled", "patient", "demographics", "and", "disease", "characteristics", "for", "the", "CHABLIS-SC1", "study", "are", "consistent", "with", "our", "goal", "to", "enroll", "patients", "with", "higher", "levels", "of", "lupus", "activity", "and", "positive", "biomarkers", "despite", "the", "stable", "use", "of", "corticosteroids.", "<tag3>"], "wordsA": ["Enrollment", "rates", "for", "the", "CHABLIS-SC1", "study", "have", "exceeded", "our", "initial", "expectations."], "wordsB": ["To", "date,", "enrolled", "patient", "demographics", "and", "disease", "characteristics", "for", "the", "CHABLIS-SC1", "study", "are", "consistent", "with", "our", "goal", "to", "enroll", "patients", "with", "higher", "levels", "of", "lupus", "activity", "and", "positive", "biomarkers", "despite", "the", "stable", "use", "of", "corticosteroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p2_s0", "idA": "1316175_14_item1_p4_s0", "sentA": "BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells.", "sentB": "BAFF, or B-cell Activating Factor, (also known as B lymphocyte stimulator or BLyS), is a member of a tumor necrosis family of natural human proteins and is critical to the development, maintenance and survival of multiple B-cell families as well as plasma cells all of which are critical to the human immune response.", "type": 2, "words": ["<tag1>", "BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "multiple", "B-cell", "lineages", "as", "well", "as", "plasma", "cells.", "<tag2>", "BAFF,", "or", "B-cell", "Activating", "Factor,", "(also", "known", "as", "B", "lymphocyte", "stimulator", "or", "BLyS),", "is", "a", "member", "of", "a", "tumor", "necrosis", "family", "of", "natural", "human", "proteins", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "multiple", "B-cell", "families", "as", "well", "as", "plasma", "cells", "all", "of", "which", "are", "critical", "to", "the", "human", "immune", "response.", "<tag3>"], "wordsA": ["BAFF,", "also", "known", "as", "BLyS,", "is", "a", "tumor", "necrosis", "family", "member", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "multiple", "B-cell", "lineages", "as", "well", "as", "plasma", "cells."], "wordsB": ["BAFF,", "or", "B-cell", "Activating", "Factor,", "(also", "known", "as", "B", "lymphocyte", "stimulator", "or", "BLyS),", "is", "a", "member", "of", "a", "tumor", "necrosis", "family", "of", "natural", "human", "proteins", "and", "is", "critical", "to", "the", "development,", "maintenance", "and", "survival", "of", "multiple", "B-cell", "families", "as", "well", "as", "plasma", "cells", "all", "of", "which", "are", "critical", "to", "the", "human", "immune", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p2_s1", "idA": "1316175_14_item1_p4_s1", "sentA": "B-cells and plasma cells are a vital part of the human immune system, producing natural antibody responses to invading pathogens such as viruses.", "sentB": "B-cells and plasma cells are a vital part of the human immune system, producing natural antibody responses to invading pathogens such as viruses, bacteria and other dangerous antigens.", "type": 2, "words": ["<tag1>", "B-cells", "and", "plasma", "cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system,", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses.", "<tag2>", "B-cells", "and", "plasma", "cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system,", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses,", "bacteria", "and", "other", "dangerous", "antigens.", "<tag3>"], "wordsA": ["B-cells", "and", "plasma", "cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system,", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses."], "wordsB": ["B-cells", "and", "plasma", "cells", "are", "a", "vital", "part", "of", "the", "human", "immune", "system,", "producing", "natural", "antibody", "responses", "to", "invading", "pathogens", "such", "as", "viruses,", "bacteria", "and", "other", "dangerous", "antigens."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p19_s3", "idA": "1316175_14_item1_p50_s2", "sentA": "Regardless of the outcome of the interim analysis, all patients randomized into the CHABLIS-SC1 study will be allowed to complete the full 52 weeks of blinded treatment to provide additional safety and efficacy data for future regulatory filings for other potential indications for blisibimod.", "sentB": "We expect to complete enrollment in mid-2015 and receive topline data after the last enrolled patient completes 52 weeks of treatment in mid-2016.", "type": 2, "words": ["<tag1>", "Regardless", "of", "the", "outcome", "of", "the", "interim", "analysis,", "all", "patients", "randomized", "into", "the", "CHABLIS-SC1", "study", "will", "be", "allowed", "to", "complete", "the", "full", "52", "weeks", "of", "blinded", "treatment", "to", "provide", "additional", "safety", "and", "efficacy", "data", "for", "future", "regulatory", "filings", "for", "other", "potential", "indications", "for", "blisibimod.", "<tag2>", "We", "expect", "to", "complete", "enrollment", "in", "mid-2015", "and", "receive", "topline", "data", "after", "the", "last", "enrolled", "patient", "completes", "52", "weeks", "of", "treatment", "in", "mid-2016.", "<tag3>"], "wordsA": ["Regardless", "of", "the", "outcome", "of", "the", "interim", "analysis,", "all", "patients", "randomized", "into", "the", "CHABLIS-SC1", "study", "will", "be", "allowed", "to", "complete", "the", "full", "52", "weeks", "of", "blinded", "treatment", "to", "provide", "additional", "safety", "and", "efficacy", "data", "for", "future", "regulatory", "filings", "for", "other", "potential", "indications", "for", "blisibimod."], "wordsB": ["We", "expect", "to", "complete", "enrollment", "in", "mid-2015", "and", "receive", "topline", "data", "after", "the", "last", "enrolled", "patient", "completes", "52", "weeks", "of", "treatment", "in", "mid-2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p24_s4", "idA": "1316175_14_item1_p50_s3", "sentA": "In addition to serving as a registration study for a potential lupus indication, we plan to include safety data from CHABLIS-SC1 in a potential IgA nephropathy marketing application for blisibimod.", "sentB": "In addition to serving as a registration study for a potential lupus indication, observations in this study are intended to be included in marketing applications for blisibimod in IgA nephropathy and other indications.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "serving", "as", "a", "registration", "study", "for", "a", "potential", "lupus", "indication,", "we", "plan", "to", "include", "safety", "data", "from", "CHABLIS-SC1", "in", "a", "potential", "IgA", "nephropathy", "marketing", "application", "for", "blisibimod.", "<tag2>", "In", "addition", "to", "serving", "as", "a", "registration", "study", "for", "a", "potential", "lupus", "indication,", "observations", "in", "this", "study", "are", "intended", "to", "be", "included", "in", "marketing", "applications", "for", "blisibimod", "in", "IgA", "nephropathy", "and", "other", "indications.", "<tag3>"], "wordsA": ["In", "addition", "to", "serving", "as", "a", "registration", "study", "for", "a", "potential", "lupus", "indication,", "we", "plan", "to", "include", "safety", "data", "from", "CHABLIS-SC1", "in", "a", "potential", "IgA", "nephropathy", "marketing", "application", "for", "blisibimod."], "wordsB": ["In", "addition", "to", "serving", "as", "a", "registration", "study", "for", "a", "potential", "lupus", "indication,", "observations", "in", "this", "study", "are", "intended", "to", "be", "included", "in", "marketing", "applications", "for", "blisibimod", "in", "IgA", "nephropathy", "and", "other", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p25_s0", "idA": "1316175_14_item1_p51_s0", "sentA": "Following recent input from the FDA, we submitted a second pivotal study, CHABLIS-SC2, to the FDA in the first quarter of 2014.", "sentB": "In the first quarter of 2014, we submitted the protocol to the FDA for our second lupus registration study, CHABLIS-SC2.", "type": 2, "words": ["<tag1>", "Following", "recent", "input", "from", "the", "FDA,", "we", "submitted", "a", "second", "pivotal", "study,", "CHABLIS-SC2,", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "In", "the", "first", "quarter", "of", "2014,", "we", "submitted", "the", "protocol", "to", "the", "FDA", "for", "our", "second", "lupus", "registration", "study,", "CHABLIS-SC2.", "<tag3>"], "wordsA": ["Following", "recent", "input", "from", "the", "FDA,", "we", "submitted", "a", "second", "pivotal", "study,", "CHABLIS-SC2,", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["In", "the", "first", "quarter", "of", "2014,", "we", "submitted", "the", "protocol", "to", "the", "FDA", "for", "our", "second", "lupus", "registration", "study,", "CHABLIS-SC2."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p26_s1", "idA": "1316175_14_item1_p53_s0", "sentA": "According to the National Organization of Rare Disease, or NORD, IgA nephropathy, an orphan indication, is believed to affect approximately 130,000 people annually in the United States.", "sentB": "According to the National Organization of Rare Disease, IgA nephropathy, an orphan indication, is believed to affect approximately 130,000 people annually in the United States.", "type": 2, "words": ["<tag1>", "According", "to", "the", "National", "Organization", "of", "Rare", "Disease,", "or", "NORD,", "IgA", "nephropathy,", "an", "orphan", "indication,", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "National", "Organization", "of", "Rare", "Disease,", "IgA", "nephropathy,", "an", "orphan", "indication,", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["According", "to", "the", "National", "Organization", "of", "Rare", "Disease,", "or", "NORD,", "IgA", "nephropathy,", "an", "orphan", "indication,", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "National", "Organization", "of", "Rare", "Disease,", "IgA", "nephropathy,", "an", "orphan", "indication,", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p31_s0", "idA": "1316175_14_item1_p58_s0", "sentA": "Data for the cumulative renal survival rate observed from the time of renal biopsy until a diagnosis of end-stage renal disease in 1,012 patients with IgA Nephopathy (Presented by Moriyama and colleagues at the American Society of Nephrology, 2013).", "sentB": "Figure 3 - Data for the cumulative renal survival rate observed from the time of renal biopsy until a diagnosis of end-stage renal disease in 1,012 patients with IgA nephropathy (Presented by Moriyama and colleagues at the American Society of Nephrology, 2013).", "type": 2, "words": ["<tag1>", "Data", "for", "the", "cumulative", "renal", "survival", "rate", "observed", "from", "the", "time", "of", "renal", "biopsy", "until", "a", "diagnosis", "of", "end-stage", "renal", "disease", "in", "1,012", "patients", "with", "IgA", "Nephopathy", "(Presented", "by", "Moriyama", "and", "colleagues", "at", "the", "American", "Society", "of", "Nephrology,", "2013).", "<tag2>", "Figure", "3", "-", "Data", "for", "the", "cumulative", "renal", "survival", "rate", "observed", "from", "the", "time", "of", "renal", "biopsy", "until", "a", "diagnosis", "of", "end-stage", "renal", "disease", "in", "1,012", "patients", "with", "IgA", "nephropathy", "(Presented", "by", "Moriyama", "and", "colleagues", "at", "the", "American", "Society", "of", "Nephrology,", "2013).", "<tag3>"], "wordsA": ["Data", "for", "the", "cumulative", "renal", "survival", "rate", "observed", "from", "the", "time", "of", "renal", "biopsy", "until", "a", "diagnosis", "of", "end-stage", "renal", "disease", "in", "1,012", "patients", "with", "IgA", "Nephopathy", "(Presented", "by", "Moriyama", "and", "colleagues", "at", "the", "American", "Society", "of", "Nephrology,", "2013)."], "wordsB": ["Figure", "3", "-", "Data", "for", "the", "cumulative", "renal", "survival", "rate", "observed", "from", "the", "time", "of", "renal", "biopsy", "until", "a", "diagnosis", "of", "end-stage", "renal", "disease", "in", "1,012", "patients", "with", "IgA", "nephropathy", "(Presented", "by", "Moriyama", "and", "colleagues", "at", "the", "American", "Society", "of", "Nephrology,", "2013)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p32_s0", "idA": "1316175_14_item1_p59_s0", "sentA": "Similar to patients with other autoimmune diseases such as lupus, in IgA nephropathy, elevated levels of BAFF are associated with disease activity.", "sentB": "Similar to patients with other autoimmune diseases such as lupus, in IgA nephropathy, elevated levels of BAFF are associated with severity of disease activity.", "type": 2, "words": ["<tag1>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "disease", "activity.", "<tag2>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "severity", "of", "disease", "activity.", "<tag3>"], "wordsA": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "disease", "activity."], "wordsB": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "severity", "of", "disease", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p92_s0", "idA": "1316175_14_item1_p59_s1", "sentA": "In patients with IgA nephropathy, levels of BAFF are significantly higher than in healthy patients.", "sentB": "Completed clinical trials demonstrated that dietary fat and nitrogen (protein) absorption are significantly increased in patients with cystic fibrosis and EPI who received liprotamase.", "type": 2, "words": ["<tag1>", "In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients.", "<tag2>", "Completed", "clinical", "trials", "demonstrated", "that", "dietary", "fat", "and", "nitrogen", "(protein)", "absorption", "are", "significantly", "increased", "in", "patients", "with", "cystic", "fibrosis", "and", "EPI", "who", "received", "liprotamase.", "<tag3>"], "wordsA": ["In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "patients."], "wordsB": ["Completed", "clinical", "trials", "demonstrated", "that", "dietary", "fat", "and", "nitrogen", "(protein)", "absorption", "are", "significantly", "increased", "in", "patients", "with", "cystic", "fibrosis", "and", "EPI", "who", "received", "liprotamase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p2_s2", "idA": "1316175_14_item1_p5_s0", "sentA": "Abnormal elevations in BAFF, B-cells and plasma cells have been associated with several autoimmune diseases.", "sentB": "Abnormally high elevations of BAFF, B-cells and plasma cells have been associated with several autoimmune diseases, including lupus and IgA nephropathy.", "type": 2, "words": ["<tag1>", "Abnormal", "elevations", "in", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases.", "<tag2>", "Abnormally", "high", "elevations", "of", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases,", "including", "lupus", "and", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["Abnormal", "elevations", "in", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases."], "wordsB": ["Abnormally", "high", "elevations", "of", "BAFF,", "B-cells", "and", "plasma", "cells", "have", "been", "associated", "with", "several", "autoimmune", "diseases,", "including", "lupus", "and", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s0", "idA": "1316175_14_item1_p61_s0", "sentA": "The BRIGHT-SC1 study (Figure 10) is a Phase 2/3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "sentB": "The BRIGHT-SC study is a Phase 2/3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC1", "study", "(Figure", "10)", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag2>", "The", "BRIGHT-SC", "study", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC1", "study", "(Figure", "10)", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "wordsB": ["The", "BRIGHT-SC", "study", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s1", "idA": "1316175_14_item1_p62_s0", "sentA": "Initially we intend to enroll up to 48 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "We intend to enroll up to 200 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "type": 2, "words": ["<tag1>", "Initially", "we", "intend", "to", "enroll", "up", "to", "48", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag3>"], "wordsA": ["Initially", "we", "intend", "to", "enroll", "up", "to", "48", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s2", "idA": "1316175_14_item1_p62_s1", "sentA": "We initiated our BRIGHT-SC1 study in the second quarter of 2013.", "sentB": "We initiated our BRIGHT-SC study in the second quarter of 2013.", "type": 2, "words": ["<tag1>", "We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "We", "initiated", "our", "BRIGHT-SC", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag3>"], "wordsA": ["We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["We", "initiated", "our", "BRIGHT-SC", "study", "in", "the", "second", "quarter", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s5", "idA": "1316175_14_item1_p62_s1", "sentA": "We initiated our BRIGHT-SC1 study in the second quarter of 2013.", "sentB": "We intend to expand the study in the EU, North America and Latin America in 2015 with the goal to complete enrollment by the first half of 2016.", "type": 2, "words": ["<tag1>", "We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "We", "intend", "to", "expand", "the", "study", "in", "the", "EU,", "North", "America", "and", "Latin", "America", "in", "2015", "with", "the", "goal", "to", "complete", "enrollment", "by", "the", "first", "half", "of", "2016.", "<tag3>"], "wordsA": ["We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["We", "intend", "to", "expand", "the", "study", "in", "the", "EU,", "North", "America", "and", "Latin", "America", "in", "2015", "with", "the", "goal", "to", "complete", "enrollment", "by", "the", "first", "half", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p59_s4", "idA": "1316175_14_item1_p62_s1", "sentA": "We initiated our BRIGHT-SC1 study in the second quarter of 2013.", "sentB": "The study design is expected to be finalized in the second half of 2015.", "type": 2, "words": ["<tag1>", "We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "The", "study", "design", "is", "expected", "to", "be", "finalized", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["We", "initiated", "our", "BRIGHT-SC1", "study", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["The", "study", "design", "is", "expected", "to", "be", "finalized", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s3", "idA": "1316175_14_item1_p63_s0", "sentA": "Patients will receive 300mg weekly blisibimod or placebo subcutaneously during the first 8 weeks of therapy, the induction phase, followed by 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "sentB": "Patients enrolled in the BRIGHT-SC study receive 300mg weekly blisibimod or placebo subcutaneously during the first 8 weeks of therapy, the induction phase, followed by a minimum of 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "type": 2, "words": ["<tag1>", "Patients", "will", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag2>", "Patients", "enrolled", "in", "the", "BRIGHT-SC", "study", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "a", "minimum", "of", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag3>"], "wordsA": ["Patients", "will", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "wordsB": ["Patients", "enrolled", "in", "the", "BRIGHT-SC", "study", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "a", "minimum", "of", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s6", "idA": "1316175_14_item1_p63_s1", "sentA": "When the first 48 patients have completed eight weeks of treatment we plan to conduct an interim analysis to determine the effect of blisibimod on proteinuria and other relevant renal biomarkers such as IgA and IgG levels.", "sentB": "We plan to conduct an interim futility analysis in the first quarter of 2015 to determine the effect of blisibimod on proteinuria after a minimum of eight weeks of treatment.", "type": 2, "words": ["<tag1>", "When", "the", "first", "48", "patients", "have", "completed", "eight", "weeks", "of", "treatment", "we", "plan", "to", "conduct", "an", "interim", "analysis", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "and", "other", "relevant", "renal", "biomarkers", "such", "as", "IgA", "and", "IgG", "levels.", "<tag2>", "We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment.", "<tag3>"], "wordsA": ["When", "the", "first", "48", "patients", "have", "completed", "eight", "weeks", "of", "treatment", "we", "plan", "to", "conduct", "an", "interim", "analysis", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "and", "other", "relevant", "renal", "biomarkers", "such", "as", "IgA", "and", "IgG", "levels."], "wordsB": ["We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s0", "idA": "1316175_14_item1_p64_s0", "sentA": "In May 2013, we met with the FDA to discuss the blisibimod development program for IgA nephropathy.", "sentB": "In September 2013, we met with the FDA who agreed to consider accepting proteinuria as an endpoint for Subpart E approval for blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy.", "<tag2>", "In", "September", "2013,", "we", "met", "with", "the", "FDA", "who", "agreed", "to", "consider", "accepting", "proteinuria", "as", "an", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy."], "wordsB": ["In", "September", "2013,", "we", "met", "with", "the", "FDA", "who", "agreed", "to", "consider", "accepting", "proteinuria", "as", "an", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s1", "idA": "1316175_14_item1_p64_s0", "sentA": "In May 2013, we met with the FDA to discuss the blisibimod development program for IgA nephropathy.", "sentB": "In April 2014, we met with the Japan Pharmaceuticals and Medical Devices Agency ( PMDA ) to discuss our registration program for blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy.", "<tag2>", "In", "April", "2014,", "we", "met", "with", "the", "Japan", "Pharmaceuticals", "and", "Medical", "Devices", "Agency", "(", "PMDA", ")", "to", "discuss", "our", "registration", "program", "for", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy."], "wordsB": ["In", "April", "2014,", "we", "met", "with", "the", "Japan", "Pharmaceuticals", "and", "Medical", "Devices", "Agency", "(", "PMDA", ")", "to", "discuss", "our", "registration", "program", "for", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s3", "idA": "1316175_14_item1_p64_s0", "sentA": "In May 2013, we met with the FDA to discuss the blisibimod development program for IgA nephropathy.", "sentB": "In December 2014 we met with the European Medicines Agency ( EMA ) as part of the scientific advice process for blisibimod.", "type": 2, "words": ["<tag1>", "In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy.", "<tag2>", "In", "December", "2014", "we", "met", "with", "the", "European", "Medicines", "Agency", "(", "EMA", ")", "as", "part", "of", "the", "scientific", "advice", "process", "for", "blisibimod.", "<tag3>"], "wordsA": ["In", "May", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "blisibimod", "development", "program", "for", "IgA", "nephropathy."], "wordsB": ["In", "December", "2014", "we", "met", "with", "the", "European", "Medicines", "Agency", "(", "EMA", ")", "as", "part", "of", "the", "scientific", "advice", "process", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s2", "idA": "1316175_14_item1_p64_s1", "sentA": "As a result of feedback from the FDA on the potential use proteinuria as the endpoint for Subpart E approval for blisibimod, we have amended the BRIGHT-SC study endpoints during the fourth quarter of 2013.", "sentB": "In this meeting we gained the PMDA s agreement on the acceptability of proteinuria as the primary efficacy endpoint to support marketing approval in Japan and have amended the BRIGHT-SC study to include the specific data requirements of the PMDA.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013.", "<tag2>", "In", "this", "meeting", "we", "gained", "the", "PMDA", "s", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "endpoint", "to", "support", "marketing", "approval", "in", "Japan", "and", "have", "amended", "the", "BRIGHT-SC", "study", "to", "include", "the", "specific", "data", "requirements", "of", "the", "PMDA.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013."], "wordsB": ["In", "this", "meeting", "we", "gained", "the", "PMDA", "s", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "endpoint", "to", "support", "marketing", "approval", "in", "Japan", "and", "have", "amended", "the", "BRIGHT-SC", "study", "to", "include", "the", "specific", "data", "requirements", "of", "the", "PMDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p61_s0", "idA": "1316175_14_item1_p64_s1", "sentA": "As a result of feedback from the FDA on the potential use proteinuria as the endpoint for Subpart E approval for blisibimod, we have amended the BRIGHT-SC study endpoints during the fourth quarter of 2013.", "sentB": "In 2013, our licensor, Eli Lilly, gained agreement from the FDA on the design of a Phase 3 trial that would provide adequate evaluation of efficacy and safety of liprotamase to respond to the FDA s 2011 complete response letter.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013.", "<tag2>", "In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "trial", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "liprotamase", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013."], "wordsB": ["In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "trial", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "liprotamase", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p93_s0", "idA": "1316175_14_item1_p64_s1", "sentA": "As a result of feedback from the FDA on the potential use proteinuria as the endpoint for Subpart E approval for blisibimod, we have amended the BRIGHT-SC study endpoints during the fourth quarter of 2013.", "sentB": "In 2013, Eli Lilly gained agreement from the FDA on the design of a pivotal trial that would provide adequate evaluation of efficacy and safety.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013.", "<tag2>", "In", "2013,", "Eli", "Lilly", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "pivotal", "trial", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "feedback", "from", "the", "FDA", "on", "the", "potential", "use", "proteinuria", "as", "the", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod,", "we", "have", "amended", "the", "BRIGHT-SC", "study", "endpoints", "during", "the", "fourth", "quarter", "of", "2013."], "wordsB": ["In", "2013,", "Eli", "Lilly", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "pivotal", "trial", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p34_s4", "idA": "1316175_14_item1_p64_s5", "sentA": "Additional information about the BRIGHT-SC clinical study can be found at www.anthera.com/studies_bright-sc.htm.", "sentB": "The BRIGHT-SC clinical study is currently recruiting patients primarily in Southeast Asia.", "type": 2, "words": ["<tag1>", "Additional", "information", "about", "the", "BRIGHT-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_bright-sc.htm.", "<tag2>", "The", "BRIGHT-SC", "clinical", "study", "is", "currently", "recruiting", "patients", "primarily", "in", "Southeast", "Asia.", "<tag3>"], "wordsA": ["Additional", "information", "about", "the", "BRIGHT-SC", "clinical", "study", "can", "be", "found", "at", "www.anthera.com/studies_bright-sc.htm."], "wordsB": ["The", "BRIGHT-SC", "clinical", "study", "is", "currently", "recruiting", "patients", "primarily", "in", "Southeast", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p60_s2", "idA": "1316175_14_item1_p65_s1", "sentA": "At this initial meeting, the PMDA agreed to consider a change in proteinuria as the basis for an initial approval of blisibimod for the treatment of IgA nephropathy.", "sentB": "A single pivotal study (BRIGHT-SC) evaluating the change in proteinuria as a surrogate endpoint to support an accelerated (Subpart E) or Conditional Approval in US and EU, respectively, was presented to the FDA, EMA, and PDMA.", "type": 2, "words": ["<tag1>", "At", "this", "initial", "meeting,", "the", "PMDA", "agreed", "to", "consider", "a", "change", "in", "proteinuria", "as", "the", "basis", "for", "an", "initial", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy.", "<tag2>", "A", "single", "pivotal", "study", "(BRIGHT-SC)", "evaluating", "the", "change", "in", "proteinuria", "as", "a", "surrogate", "endpoint", "to", "support", "an", "accelerated", "(Subpart", "E)", "or", "Conditional", "Approval", "in", "US", "and", "EU,", "respectively,", "was", "presented", "to", "the", "FDA,", "EMA,", "and", "PDMA.", "<tag3>"], "wordsA": ["At", "this", "initial", "meeting,", "the", "PMDA", "agreed", "to", "consider", "a", "change", "in", "proteinuria", "as", "the", "basis", "for", "an", "initial", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy."], "wordsB": ["A", "single", "pivotal", "study", "(BRIGHT-SC)", "evaluating", "the", "change", "in", "proteinuria", "as", "a", "surrogate", "endpoint", "to", "support", "an", "accelerated", "(Subpart", "E)", "or", "Conditional", "Approval", "in", "US", "and", "EU,", "respectively,", "was", "presented", "to", "the", "FDA,", "EMA,", "and", "PDMA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p60_s3", "idA": "1316175_14_item1_p65_s1", "sentA": "At this initial meeting, the PMDA agreed to consider a change in proteinuria as the basis for an initial approval of blisibimod for the treatment of IgA nephropathy.", "sentB": "Each agency provided separate concurrence on the willingness to consider proteinuria as a surrogate endpoint, with varying points of view on the degree of change in proteinuria to predict a treatment effect, and the timing for completion of enrollment of the post marketing confirmatory study.", "type": 2, "words": ["<tag1>", "At", "this", "initial", "meeting,", "the", "PMDA", "agreed", "to", "consider", "a", "change", "in", "proteinuria", "as", "the", "basis", "for", "an", "initial", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy.", "<tag2>", "Each", "agency", "provided", "separate", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "with", "varying", "points", "of", "view", "on", "the", "degree", "of", "change", "in", "proteinuria", "to", "predict", "a", "treatment", "effect,", "and", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study.", "<tag3>"], "wordsA": ["At", "this", "initial", "meeting,", "the", "PMDA", "agreed", "to", "consider", "a", "change", "in", "proteinuria", "as", "the", "basis", "for", "an", "initial", "approval", "of", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy."], "wordsB": ["Each", "agency", "provided", "separate", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "with", "varying", "points", "of", "view", "on", "the", "degree", "of", "change", "in", "proteinuria", "to", "predict", "a", "treatment", "effect,", "and", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p100_s0", "idA": "1316175_14_item1_p65_s2", "sentA": "Additional discussions with the PMDA regarding development of blisibimod in Japan are planned for the second quarter of 2014.", "sentB": "In December 2014, we entered in an exclusive license agreement with Zenyaku Kogyo Co., Ltd ( Zenyaku ) for the development and commercialization of blisibimod in Japan and potentially other countries throughout Asia ( the Zenyaku Agreement ).", "type": 2, "words": ["<tag1>", "Additional", "discussions", "with", "the", "PMDA", "regarding", "development", "of", "blisibimod", "in", "Japan", "are", "planned", "for", "the", "second", "quarter", "of", "2014.", "<tag2>", "In", "December", "2014,", "we", "entered", "in", "an", "exclusive", "license", "agreement", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd", "(", "Zenyaku", ")", "for", "the", "development", "and", "commercialization", "of", "blisibimod", "in", "Japan", "and", "potentially", "other", "countries", "throughout", "Asia", "(", "the", "Zenyaku", "Agreement", ").", "<tag3>"], "wordsA": ["Additional", "discussions", "with", "the", "PMDA", "regarding", "development", "of", "blisibimod", "in", "Japan", "are", "planned", "for", "the", "second", "quarter", "of", "2014."], "wordsB": ["In", "December", "2014,", "we", "entered", "in", "an", "exclusive", "license", "agreement", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd", "(", "Zenyaku", ")", "for", "the", "development", "and", "commercialization", "of", "blisibimod", "in", "Japan", "and", "potentially", "other", "countries", "throughout", "Asia", "(", "the", "Zenyaku", "Agreement", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p14_s1", "idA": "1316175_14_item1_p67_s0", "sentA": "We intend to study blisibimod in B-cell mediated hematologic diseases such as multiple myeloma.", "sentB": "EPI occurs when diseases such as cystic fibrosis, or CF, and chronic pancreatitis impede or destroy the exocrine function of the pancreas.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "hematologic", "diseases", "such", "as", "multiple", "myeloma.", "<tag2>", "EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis,", "or", "CF,", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas.", "<tag3>"], "wordsA": ["We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "hematologic", "diseases", "such", "as", "multiple", "myeloma."], "wordsB": ["EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis,", "or", "CF,", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p37_s1", "idA": "1316175_14_item1_p67_s0", "sentA": "We intend to study blisibimod in B-cell mediated hematologic diseases such as multiple myeloma.", "sentB": "EPI occurs when diseases such as cystic fibrosis ( CF ) and chronic pancreatitis ( CP ) impede or destroy the exocrine function of the pancreas.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "hematologic", "diseases", "such", "as", "multiple", "myeloma.", "<tag2>", "EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis", "(", "CF", ")", "and", "chronic", "pancreatitis", "(", "CP", ")", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas.", "<tag3>"], "wordsA": ["We", "intend", "to", "study", "blisibimod", "in", "B-cell", "mediated", "hematologic", "diseases", "such", "as", "multiple", "myeloma."], "wordsB": ["EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis", "(", "CF", ")", "and", "chronic", "pancreatitis", "(", "CP", ")", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p55_s0", "idA": "1316175_14_item1_p68_s0", "sentA": "According to the NORD, multiple myeloma is a rare disease that afflicted an estimated 21,700 new individuals in the United States in 2012.", "sentB": "According to IMS Health, EPI is a disease that affects an estimated 250,000 patients in the United States.", "type": 2, "words": ["<tag1>", "According", "to", "the", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "United", "States", "in", "2012.", "<tag2>", "According", "to", "IMS", "Health,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "250,000", "patients", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["According", "to", "the", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "United", "States", "in", "2012."], "wordsB": ["According", "to", "IMS", "Health,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "250,000", "patients", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p4_s0", "idA": "1316175_14_item1_p6_s2", "sentA": "Based on data from our Phase 2b clinical study, we intend to advance the clinical development of our BAFF inhibitor, blisibimod, to exploit its potential clinical utility in a number of autoimmune diseases.", "sentB": "Based on data from our Phase 2b clinical study, we have advanced the clinical development of our BAFF inhibitor, blisibimod, to exploit its potential clinical utility in a number of autoimmune diseases.", "type": 2, "words": ["<tag1>", "Based", "on", "data", "from", "our", "Phase", "2b", "clinical", "study,", "we", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases.", "<tag2>", "Based", "on", "data", "from", "our", "Phase", "2b", "clinical", "study,", "we", "have", "advanced", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Based", "on", "data", "from", "our", "Phase", "2b", "clinical", "study,", "we", "intend", "to", "advance", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases."], "wordsB": ["Based", "on", "data", "from", "our", "Phase", "2b", "clinical", "study,", "we", "have", "advanced", "the", "clinical", "development", "of", "our", "BAFF", "inhibitor,", "blisibimod,", "to", "exploit", "its", "potential", "clinical", "utility", "in", "a", "number", "of", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p25_s1", "idA": "1316175_14_item1_p73_s0", "sentA": "We plan to initiate a Phase 2 study in the second half of 2014 to evaluate the effects of blisibimod on survival, progression, and biomarkers in patients with relapsed or refractory multiple myeloma treated with at least one prior regimen.", "sentB": "In light of the emerging publication of data from completed clinical trials with SLE, the study design of the CHABLIS-SC2 study is currently being refined with a panel of lupus clinical experts and we plan to finalize the design in the second half of 2015.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen.", "<tag2>", "In", "light", "of", "the", "emerging", "publication", "of", "data", "from", "completed", "clinical", "trials", "with", "SLE,", "the", "study", "design", "of", "the", "CHABLIS-SC2", "study", "is", "currently", "being", "refined", "with", "a", "panel", "of", "lupus", "clinical", "experts", "and", "we", "plan", "to", "finalize", "the", "design", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen."], "wordsB": ["In", "light", "of", "the", "emerging", "publication", "of", "data", "from", "completed", "clinical", "trials", "with", "SLE,", "the", "study", "design", "of", "the", "CHABLIS-SC2", "study", "is", "currently", "being", "refined", "with", "a", "panel", "of", "lupus", "clinical", "experts", "and", "we", "plan", "to", "finalize", "the", "design", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p42_s0", "idA": "1316175_14_item1_p73_s0", "sentA": "We plan to initiate a Phase 2 study in the second half of 2014 to evaluate the effects of blisibimod on survival, progression, and biomarkers in patients with relapsed or refractory multiple myeloma treated with at least one prior regimen.", "sentB": "Upon completion of the development and manufacture of liprotamase in sachet formulation, we plan to initiate the SOLUTION study in the second half of 2015.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen.", "<tag2>", "Upon", "completion", "of", "the", "development", "and", "manufacture", "of", "liprotamase", "in", "sachet", "formulation,", "we", "plan", "to", "initiate", "the", "SOLUTION", "study", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen."], "wordsB": ["Upon", "completion", "of", "the", "development", "and", "manufacture", "of", "liprotamase", "in", "sachet", "formulation,", "we", "plan", "to", "initiate", "the", "SOLUTION", "study", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p96_s0", "idA": "1316175_14_item1_p73_s0", "sentA": "We plan to initiate a Phase 2 study in the second half of 2014 to evaluate the effects of blisibimod on survival, progression, and biomarkers in patients with relapsed or refractory multiple myeloma treated with at least one prior regimen.", "sentB": "Study 726, a Phase 3, placebo-controlled, parallel design, multinational clinical, evaluated the effects of a single capsule of liprotamase (containing 32,500 U lipase, with protease and amylase in fixed ratios) or placebo administered with every meal or snack on severe EPI defined as baseline CFA 40% in the absence of PERT.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen.", "<tag2>", "Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "on", "severe", "EPI", "defined", "as", "baseline", "CFA", "40%", "in", "the", "absence", "of", "PERT.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "a", "Phase", "2", "study", "in", "the", "second", "half", "of", "2014", "to", "evaluate", "the", "effects", "of", "blisibimod", "on", "survival,", "progression,", "and", "biomarkers", "in", "patients", "with", "relapsed", "or", "refractory", "multiple", "myeloma", "treated", "with", "at", "least", "one", "prior", "regimen."], "wordsB": ["Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "on", "severe", "EPI", "defined", "as", "baseline", "CFA", "40%", "in", "the", "absence", "of", "PERT."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p22_s0", "idA": "1316175_14_item1_p74_s2", "sentA": "The course of the disease is unpredictable, with periods of illness, called flares, alternating with remission.", "sentB": "An independent Data Safety Monitoring Board ( DSMB ) meets regularly over the course of the study to assess patient safety.", "type": 2, "words": ["<tag1>", "The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares,", "alternating", "with", "remission.", "<tag2>", "An", "independent", "Data", "Safety", "Monitoring", "Board", "(", "DSMB", ")", "meets", "regularly", "over", "the", "course", "of", "the", "study", "to", "assess", "patient", "safety.", "<tag3>"], "wordsA": ["The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares,", "alternating", "with", "remission."], "wordsB": ["An", "independent", "Data", "Safety", "Monitoring", "Board", "(", "DSMB", ")", "meets", "regularly", "over", "the", "course", "of", "the", "study", "to", "assess", "patient", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p45_s2", "idA": "1316175_14_item1_p74_s7", "sentA": "Based on the results from our PERAL SC study, we believe patients in the moderate to severe disease categories, which approximate 30,000 to 40,000, are likely to benefit most from treatment with blisibimod and this is the population whom we are enrolling in our Phase 3 CHABLIS-SC studies..", "sentB": "Based on the results from our PEARL-SC study, we believe patients in the moderate to severe disease categories, approximately 30,000 to 40,000 people, are likely to benefit most from treatment with blisibimod and this is the population we are enrolling in our Phase 3 CHABLIS-SC studies.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "results", "from", "our", "PERAL", "SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "which", "approximate", "30,000", "to", "40,000,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "whom", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies..", "<tag2>", "Based", "on", "the", "results", "from", "our", "PEARL-SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "approximately", "30,000", "to", "40,000", "people,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.", "<tag3>"], "wordsA": ["Based", "on", "the", "results", "from", "our", "PERAL", "SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "which", "approximate", "30,000", "to", "40,000,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "whom", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.."], "wordsB": ["Based", "on", "the", "results", "from", "our", "PEARL-SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "approximately", "30,000", "to", "40,000", "people,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p46_s0", "idA": "1316175_14_item1_p76_s0", "sentA": "Patients with active lupus may have a broad range of symptoms related to the inflammation.", "sentB": "Patients with active lupus may have a broad range of symptoms related to an abnormally active immune response in one or more organs.", "type": 2, "words": ["<tag1>", "Patients", "with", "active", "lupus", "may", "have", "a", "broad", "range", "of", "symptoms", "related", "to", "the", "inflammation.", "<tag2>", "Patients", "with", "active", "lupus", "may", "have", "a", "broad", "range", "of", "symptoms", "related", "to", "an", "abnormally", "active", "immune", "response", "in", "one", "or", "more", "organs.", "<tag3>"], "wordsA": ["Patients", "with", "active", "lupus", "may", "have", "a", "broad", "range", "of", "symptoms", "related", "to", "the", "inflammation."], "wordsB": ["Patients", "with", "active", "lupus", "may", "have", "a", "broad", "range", "of", "symptoms", "related", "to", "an", "abnormally", "active", "immune", "response", "in", "one", "or", "more", "organs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p46_s1", "idA": "1316175_14_item1_p76_s1", "sentA": "Inflammation of the brain may cause seizures and other neurologic abnormalities.", "sentB": "In the brain, lupus may cause seizures and other neurologic abnormalities.", "type": 2, "words": ["<tag1>", "Inflammation", "of", "the", "brain", "may", "cause", "seizures", "and", "other", "neurologic", "abnormalities.", "<tag2>", "In", "the", "brain,", "lupus", "may", "cause", "seizures", "and", "other", "neurologic", "abnormalities.", "<tag3>"], "wordsA": ["Inflammation", "of", "the", "brain", "may", "cause", "seizures", "and", "other", "neurologic", "abnormalities."], "wordsB": ["In", "the", "brain,", "lupus", "may", "cause", "seizures", "and", "other", "neurologic", "abnormalities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p46_s2", "idA": "1316175_14_item1_p76_s2", "sentA": "Inflammation of the heart may cause heart failure or sudden death.", "sentB": "In the heart, lupus may cause heart failure or sudden death.", "type": 2, "words": ["<tag1>", "Inflammation", "of", "the", "heart", "may", "cause", "heart", "failure", "or", "sudden", "death.", "<tag2>", "In", "the", "heart,", "lupus", "may", "cause", "heart", "failure", "or", "sudden", "death.", "<tag3>"], "wordsA": ["Inflammation", "of", "the", "heart", "may", "cause", "heart", "failure", "or", "sudden", "death."], "wordsB": ["In", "the", "heart,", "lupus", "may", "cause", "heart", "failure", "or", "sudden", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p46_s3", "idA": "1316175_14_item1_p76_s3", "sentA": "Lung inflammation may cause shortness of breath.", "sentB": "Lung inflammation in the lung may cause shortness of breath, pleurisy and chest pain.", "type": 2, "words": ["<tag1>", "Lung", "inflammation", "may", "cause", "shortness", "of", "breath.", "<tag2>", "Lung", "inflammation", "in", "the", "lung", "may", "cause", "shortness", "of", "breath,", "pleurisy", "and", "chest", "pain.", "<tag3>"], "wordsA": ["Lung", "inflammation", "may", "cause", "shortness", "of", "breath."], "wordsB": ["Lung", "inflammation", "in", "the", "lung", "may", "cause", "shortness", "of", "breath,", "pleurisy", "and", "chest", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p46_s4", "idA": "1316175_14_item1_p76_s4", "sentA": "Lupus may also cause swollen joints, proteinuria and severe rash.", "sentB": "Lupus may also cause swollen joints, arthritis, muscle aches, proteinuria, severe rash, oral ulcers and alopecia.", "type": 2, "words": ["<tag1>", "Lupus", "may", "also", "cause", "swollen", "joints,", "proteinuria", "and", "severe", "rash.", "<tag2>", "Lupus", "may", "also", "cause", "swollen", "joints,", "arthritis,", "muscle", "aches,", "proteinuria,", "severe", "rash,", "oral", "ulcers", "and", "alopecia.", "<tag3>"], "wordsA": ["Lupus", "may", "also", "cause", "swollen", "joints,", "proteinuria", "and", "severe", "rash."], "wordsB": ["Lupus", "may", "also", "cause", "swollen", "joints,", "arthritis,", "muscle", "aches,", "proteinuria,", "severe", "rash,", "oral", "ulcers", "and", "alopecia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p48_s0", "idA": "1316175_14_item1_p78_s0", "sentA": "Immunoglobulin A (IgA) is an antibody that plays a critical role in mucosal immunity.", "sentB": "Immunoglobulin A (IgA) is a human antibody that plays a critical role in mucosal immunity, which is a portion of the immune system that provides protection to an organism s various mucous membranes from invasion by infections.", "type": 2, "words": ["<tag1>", "Immunoglobulin", "A", "(IgA)", "is", "an", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity.", "<tag2>", "Immunoglobulin", "A", "(IgA)", "is", "a", "human", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity,", "which", "is", "a", "portion", "of", "the", "immune", "system", "that", "provides", "protection", "to", "an", "organism", "s", "various", "mucous", "membranes", "from", "invasion", "by", "infections.", "<tag3>"], "wordsA": ["Immunoglobulin", "A", "(IgA)", "is", "an", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity."], "wordsB": ["Immunoglobulin", "A", "(IgA)", "is", "a", "human", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity,", "which", "is", "a", "portion", "of", "the", "immune", "system", "that", "provides", "protection", "to", "an", "organism", "s", "various", "mucous", "membranes", "from", "invasion", "by", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p49_s0", "idA": "1316175_14_item1_p78_s1", "sentA": "IgA nephropathy (also known as IgA nephritis or Berger's disease) is a form of glomerulonephritis (inflammation of the glomeruli of the kidney) and a principal cause of end-stage renal disease.", "sentB": "IgA nephropathy (also known as IgA nephritis or Berger's disease) is the most common form of primary glomerulonephritis (inflammation of the glomeruli of the kidney) throughout the world and a principal cause of end-stage renal disease.", "type": 2, "words": ["<tag1>", "IgA", "nephropathy", "(also", "known", "as", "IgA", "nephritis", "or", "Berger's", "disease)", "is", "a", "form", "of", "glomerulonephritis", "(inflammation", "of", "the", "glomeruli", "of", "the", "kidney)", "and", "a", "principal", "cause", "of", "end-stage", "renal", "disease.", "<tag2>", "IgA", "nephropathy", "(also", "known", "as", "IgA", "nephritis", "or", "Berger's", "disease)", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "(inflammation", "of", "the", "glomeruli", "of", "the", "kidney)", "throughout", "the", "world", "and", "a", "principal", "cause", "of", "end-stage", "renal", "disease.", "<tag3>"], "wordsA": ["IgA", "nephropathy", "(also", "known", "as", "IgA", "nephritis", "or", "Berger's", "disease)", "is", "a", "form", "of", "glomerulonephritis", "(inflammation", "of", "the", "glomeruli", "of", "the", "kidney)", "and", "a", "principal", "cause", "of", "end-stage", "renal", "disease."], "wordsB": ["IgA", "nephropathy", "(also", "known", "as", "IgA", "nephritis", "or", "Berger's", "disease)", "is", "the", "most", "common", "form", "of", "primary", "glomerulonephritis", "(inflammation", "of", "the", "glomeruli", "of", "the", "kidney)", "throughout", "the", "world", "and", "a", "principal", "cause", "of", "end-stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p52_s0", "idA": "1316175_14_item1_p81_s0", "sentA": "According to NORD, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life and a large number of cases eventually progress to renal failure.", "sentB": "According to the National Organization for Rare Diseases, primary IgA nephropathy occurs at any age, most commonly with clinical onset in the second and third decades of life and a large number of cases eventually progress to renal failure.", "type": 2, "words": ["<tag1>", "According", "to", "NORD,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag2>", "According", "to", "the", "National", "Organization", "for", "Rare", "Diseases,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure.", "<tag3>"], "wordsA": ["According", "to", "NORD,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "wordsB": ["According", "to", "the", "National", "Organization", "for", "Rare", "Diseases,", "primary", "IgA", "nephropathy", "occurs", "at", "any", "age,", "most", "commonly", "with", "clinical", "onset", "in", "the", "second", "and", "third", "decades", "of", "life", "and", "a", "large", "number", "of", "cases", "eventually", "progress", "to", "renal", "failure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p133_s3", "idA": "1316175_14_item1_p82_s0", "sentA": "There is also a striking geographic variation in the prevalence of IgA nephropathy throughout the world.", "sentB": "We retained the right to practice and grant licenses relating to blisibimod technology in all areas outside of the licensed territory, to manufacture and have manufactured compounds and products relating to blisibimod anywhere in the world and to conduct or have conducted clinical trials and other studies of compounds and products relating to blisibimod anywhere in the world.", "type": 2, "words": ["<tag1>", "There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgA", "nephropathy", "throughout", "the", "world.", "<tag2>", "We", "retained", "the", "right", "to", "practice", "and", "grant", "licenses", "relating", "to", "blisibimod", "technology", "in", "all", "areas", "outside", "of", "the", "licensed", "territory,", "to", "manufacture", "and", "have", "manufactured", "compounds", "and", "products", "relating", "to", "blisibimod", "anywhere", "in", "the", "world", "and", "to", "conduct", "or", "have", "conducted", "clinical", "trials", "and", "other", "studies", "of", "compounds", "and", "products", "relating", "to", "blisibimod", "anywhere", "in", "the", "world.", "<tag3>"], "wordsA": ["There", "is", "also", "a", "striking", "geographic", "variation", "in", "the", "prevalence", "of", "IgA", "nephropathy", "throughout", "the", "world."], "wordsB": ["We", "retained", "the", "right", "to", "practice", "and", "grant", "licenses", "relating", "to", "blisibimod", "technology", "in", "all", "areas", "outside", "of", "the", "licensed", "territory,", "to", "manufacture", "and", "have", "manufactured", "compounds", "and", "products", "relating", "to", "blisibimod", "anywhere", "in", "the", "world", "and", "to", "conduct", "or", "have", "conducted", "clinical", "trials", "and", "other", "studies", "of", "compounds", "and", "products", "relating", "to", "blisibimod", "anywhere", "in", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p56_s1", "idA": "1316175_14_item1_p84_s0", "sentA": "According to NORD, multiple myeloma is a rare disease that afflicted an estimated 21,700 new individuals in the US in 2012.", "sentB": "In children, another common cause is Shwachman-Bodian-Diamond syndrome, a rare autosomal recessive genetic disorder resulting from mutation in the SBDS gene.", "type": 2, "words": ["<tag1>", "According", "to", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "US", "in", "2012.", "<tag2>", "In", "children,", "another", "common", "cause", "is", "Shwachman-Bodian-Diamond", "syndrome,", "a", "rare", "autosomal", "recessive", "genetic", "disorder", "resulting", "from", "mutation", "in", "the", "SBDS", "gene.", "<tag3>"], "wordsA": ["According", "to", "NORD,", "multiple", "myeloma", "is", "a", "rare", "disease", "that", "afflicted", "an", "estimated", "21,700", "new", "individuals", "in", "the", "US", "in", "2012."], "wordsB": ["In", "children,", "another", "common", "cause", "is", "Shwachman-Bodian-Diamond", "syndrome,", "a", "rare", "autosomal", "recessive", "genetic", "disorder", "resulting", "from", "mutation", "in", "the", "SBDS", "gene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p57_s0", "idA": "1316175_14_item1_p87_s0", "sentA": "In December 2011, we completed the manufacturing site transfer from Amgen Inc., or Amgen, to our contract manufacturing organization, or CMO (Fujifilm Diosynth Bioservices, or Fujifilm).", "sentB": "In December 2011, we completed the manufacturing site transfer from Amgen Inc., or Amgen, to our contract manufacturing organization ( CMO ), Fujifilm Diosynth Bioservices ( Fujifilm ).", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices,", "or", "Fujifilm).", "<tag2>", "In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization", "(", "CMO", "),", "Fujifilm", "Diosynth", "Bioservices", "(", "Fujifilm", ").", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization,", "or", "CMO", "(Fujifilm", "Diosynth", "Bioservices,", "or", "Fujifilm)."], "wordsB": ["In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization", "(", "CMO", "),", "Fujifilm", "Diosynth", "Bioservices", "(", "Fujifilm", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p57_s2", "idA": "1316175_14_item1_p87_s2", "sentA": "Two batches of blisibimod produced under U.S. and EU good manufacturing procedures, or GMPs, at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "sentB": "Two batches of blisibimod produced under U.S. and EU good manufacturing procedures ( GMPs ), at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "type": 2, "words": ["<tag1>", "Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures,", "or", "GMPs,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag2>", "Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures", "(", "GMPs", "),", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag3>"], "wordsA": ["Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures,", "or", "GMPs,", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "wordsB": ["Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures", "(", "GMPs", "),", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p22_s2", "idA": "1316175_14_item1_p88_s0", "sentA": "We have successfully manufactured blisibimod at launch scale volumes to support the CHABLIS-SC1 and BRIGHT-SC1 studies.", "sentB": "After the most recent scheduled meeting in October 2014, the DSMB recommended continuing the CHABLIS-SC1 and BRIGHT-SC clinical studies.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC1", "studies.", "<tag2>", "After", "the", "most", "recent", "scheduled", "meeting", "in", "October", "2014,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies.", "<tag3>"], "wordsA": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC1", "studies."], "wordsB": ["After", "the", "most", "recent", "scheduled", "meeting", "in", "October", "2014,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p58_s0", "idA": "1316175_14_item1_p88_s0", "sentA": "We have successfully manufactured blisibimod at launch scale volumes to support the CHABLIS-SC1 and BRIGHT-SC1 studies.", "sentB": "We have successfully manufactured blisibimod at launch scale volumes to support the CHABLIS-SC1 and BRIGHT-SC studies.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC1", "studies.", "<tag2>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies.", "<tag3>"], "wordsA": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC1", "studies."], "wordsB": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p58_s1", "idA": "1316175_14_item1_p88_s3", "sentA": "Furthermore, we plan to develop an auto injector strategy for the product presentation at launch in 2014.", "sentB": "We are currently evaluating an auto injector strategy for the product presentation.", "type": 2, "words": ["<tag1>", "Furthermore,", "we", "plan", "to", "develop", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation", "at", "launch", "in", "2014.", "<tag2>", "We", "are", "currently", "evaluating", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation.", "<tag3>"], "wordsA": ["Furthermore,", "we", "plan", "to", "develop", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation", "at", "launch", "in", "2014."], "wordsB": ["We", "are", "currently", "evaluating", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p60_s1", "idA": "1316175_14_item1_p89_s0", "sentA": "The Phase 3 program for blisibimod was presented to the European Medicines Agency (EMA, Scientific Advice) in the second quarter of 2012, to the FDA in the third quarter of 2012 (End-of-Phase 2 meeting) and to the FDA in a follow-up advice procedure in the third quarter of 2013 (Type C request to which the FDA provided written responses in lieu of a meeting).", "sentB": "The Phase 3 program for blisibimod in IgA nephropathy builds on the SLE program and the CHABLIS studies.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012,", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)", "and", "to", "the", "FDA", "in", "a", "follow-up", "advice", "procedure", "in", "the", "third", "quarter", "of", "2013", "(Type", "C", "request", "to", "which", "the", "FDA", "provided", "written", "responses", "in", "lieu", "of", "a", "meeting).", "<tag2>", "The", "Phase", "3", "program", "for", "blisibimod", "in", "IgA", "nephropathy", "builds", "on", "the", "SLE", "program", "and", "the", "CHABLIS", "studies.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "blisibimod", "was", "presented", "to", "the", "European", "Medicines", "Agency", "(EMA,", "Scientific", "Advice)", "in", "the", "second", "quarter", "of", "2012,", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2012", "(End-of-Phase", "2", "meeting)", "and", "to", "the", "FDA", "in", "a", "follow-up", "advice", "procedure", "in", "the", "third", "quarter", "of", "2013", "(Type", "C", "request", "to", "which", "the", "FDA", "provided", "written", "responses", "in", "lieu", "of", "a", "meeting)."], "wordsB": ["The", "Phase", "3", "program", "for", "blisibimod", "in", "IgA", "nephropathy", "builds", "on", "the", "SLE", "program", "and", "the", "CHABLIS", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p59_s2", "idA": "1316175_14_item1_p89_s2", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies of similar design intended to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies intended to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "of", "similar", "design", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "of", "similar", "design", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p61_s1", "idA": "1316175_14_item1_p89_s2", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies of similar design intended to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "sentB": "The Phase 3 study (SOLUTION) is a randomized, open-label, assessor-blind, non-inferiority, active-comparator study intended to evaluate the non-inferiority of liprotamase compared with another commercially available PERT.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "of", "similar", "design", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag2>", "The", "Phase", "3", "study", "(SOLUTION)", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "of", "similar", "design", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "wordsB": ["The", "Phase", "3", "study", "(SOLUTION)", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p131_s0", "idA": "1316175_14_item1_p89_s3", "sentA": "The second Phase 3 study, CHABLIS SC-2, includes modifications to enrich for the enrollment of patients with lupus and nephritis.", "sentB": "On July 11, 2014, we entered into a worldwide, exclusive license agreement with Eli Lilly (the Lilly Agreement ), to develop and commercialize liprotamase, a Phase 3 novel investigational PERT for the treatment of patients with EPI, often seen in patients with cystic fibrosis and other conditions.", "type": 2, "words": ["<tag1>", "The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis.", "<tag2>", "On", "July", "11,", "2014,", "we", "entered", "into", "a", "worldwide,", "exclusive", "license", "agreement", "with", "Eli", "Lilly", "(the", "Lilly", "Agreement", "),", "to", "develop", "and", "commercialize", "liprotamase,", "a", "Phase", "3", "novel", "investigational", "PERT", "for", "the", "treatment", "of", "patients", "with", "EPI,", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag3>"], "wordsA": ["The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis."], "wordsB": ["On", "July", "11,", "2014,", "we", "entered", "into", "a", "worldwide,", "exclusive", "license", "agreement", "with", "Eli", "Lilly", "(the", "Lilly", "Agreement", "),", "to", "develop", "and", "commercialize", "liprotamase,", "a", "Phase", "3", "novel", "investigational", "PERT", "for", "the", "treatment", "of", "patients", "with", "EPI,", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p1_s1", "idA": "1316175_14_item1_p89_s3", "sentA": "The second Phase 3 study, CHABLIS SC-2, includes modifications to enrich for the enrollment of patients with lupus and nephritis.", "sentB": "Our second Phase 3 product candidate, liprotamase, licensed from Eli Lilly Co ( Eli Lilly ) in July 2014, is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "type": 2, "words": ["<tag1>", "The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis.", "<tag2>", "Our", "second", "Phase", "3", "product", "candidate,", "liprotamase,", "licensed", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014,", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag3>"], "wordsA": ["The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis."], "wordsB": ["Our", "second", "Phase", "3", "product", "candidate,", "liprotamase,", "licensed", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014,", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p59_s3", "idA": "1316175_14_item1_p89_s3", "sentA": "The second Phase 3 study, CHABLIS SC-2, includes modifications to enrich for the enrollment of patients with lupus and nephritis.", "sentB": "The design of the second Phase 3 study, CHABLIS-SC2, will be based on input from clinical experts as well as evaluation from recently reported data with tabalumab.", "type": 2, "words": ["<tag1>", "The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis.", "<tag2>", "The", "design", "of", "the", "second", "Phase", "3", "study,", "CHABLIS-SC2,", "will", "be", "based", "on", "input", "from", "clinical", "experts", "as", "well", "as", "evaluation", "from", "recently", "reported", "data", "with", "tabalumab.", "<tag3>"], "wordsA": ["The", "second", "Phase", "3", "study,", "CHABLIS", "SC-2,", "includes", "modifications", "to", "enrich", "for", "the", "enrollment", "of", "patients", "with", "lupus", "and", "nephritis."], "wordsB": ["The", "design", "of", "the", "second", "Phase", "3", "study,", "CHABLIS-SC2,", "will", "be", "based", "on", "input", "from", "clinical", "experts", "as", "well", "as", "evaluation", "from", "recently", "reported", "data", "with", "tabalumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p35_s6", "idA": "1316175_14_item1_p89_s5", "sentA": "The statistical analysis plan for CHALIS SC-1 has been amended to reflect advice received from the FDA.", "sentB": "The BRIGHT SC protocol will be amended to reflect these recommendations from the EMA, along with other recommendations from the FDA and PMDA.", "type": 2, "words": ["<tag1>", "The", "statistical", "analysis", "plan", "for", "CHALIS", "SC-1", "has", "been", "amended", "to", "reflect", "advice", "received", "from", "the", "FDA.", "<tag2>", "The", "BRIGHT", "SC", "protocol", "will", "be", "amended", "to", "reflect", "these", "recommendations", "from", "the", "EMA,", "along", "with", "other", "recommendations", "from", "the", "FDA", "and", "PMDA.", "<tag3>"], "wordsA": ["The", "statistical", "analysis", "plan", "for", "CHALIS", "SC-1", "has", "been", "amended", "to", "reflect", "advice", "received", "from", "the", "FDA."], "wordsB": ["The", "BRIGHT", "SC", "protocol", "will", "be", "amended", "to", "reflect", "these", "recommendations", "from", "the", "EMA,", "along", "with", "other", "recommendations", "from", "the", "FDA", "and", "PMDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p60_s4", "idA": "1316175_14_item1_p89_s5", "sentA": "The statistical analysis plan for CHALIS SC-1 has been amended to reflect advice received from the FDA.", "sentB": "The BRIGHT-SC protocol has been amended to best address the recommendations of the FDA, EMA and PDMA.", "type": 2, "words": ["<tag1>", "The", "statistical", "analysis", "plan", "for", "CHALIS", "SC-1", "has", "been", "amended", "to", "reflect", "advice", "received", "from", "the", "FDA.", "<tag2>", "The", "BRIGHT-SC", "protocol", "has", "been", "amended", "to", "best", "address", "the", "recommendations", "of", "the", "FDA,", "EMA", "and", "PDMA.", "<tag3>"], "wordsA": ["The", "statistical", "analysis", "plan", "for", "CHALIS", "SC-1", "has", "been", "amended", "to", "reflect", "advice", "received", "from", "the", "FDA."], "wordsB": ["The", "BRIGHT-SC", "protocol", "has", "been", "amended", "to", "best", "address", "the", "recommendations", "of", "the", "FDA,", "EMA", "and", "PDMA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p138_s2", "idA": "1316175_14_item1_p89_s6", "sentA": "Amended CHALIS-SC1 and CHABLIS SC-2 protocols were submitted to the FDA in the first quarter of 2014.", "sentB": "The Promissory Note is planned for execution in the first half of 2015.", "type": 2, "words": ["<tag1>", "Amended", "CHALIS-SC1", "and", "CHABLIS", "SC-2", "protocols", "were", "submitted", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014.", "<tag2>", "The", "Promissory", "Note", "is", "planned", "for", "execution", "in", "the", "first", "half", "of", "2015.", "<tag3>"], "wordsA": ["Amended", "CHALIS-SC1", "and", "CHABLIS", "SC-2", "protocols", "were", "submitted", "to", "the", "FDA", "in", "the", "first", "quarter", "of", "2014."], "wordsB": ["The", "Promissory", "Note", "is", "planned", "for", "execution", "in", "the", "first", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p61_s2", "idA": "1316175_14_item1_p90_s2", "sentA": "The meeting with the FDA in May 2013 focused on the choice of primary endpoints for an approval in the post-marketing setting.", "sentB": "The SOUTION design also addresses the 2005 EMA protocol assistance comments, which were consistent with the FDA s request for an active comparator trial.", "type": 2, "words": ["<tag1>", "The", "meeting", "with", "the", "FDA", "in", "May", "2013", "focused", "on", "the", "choice", "of", "primary", "endpoints", "for", "an", "approval", "in", "the", "post-marketing", "setting.", "<tag2>", "The", "SOUTION", "design", "also", "addresses", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial.", "<tag3>"], "wordsA": ["The", "meeting", "with", "the", "FDA", "in", "May", "2013", "focused", "on", "the", "choice", "of", "primary", "endpoints", "for", "an", "approval", "in", "the", "post-marketing", "setting."], "wordsB": ["The", "SOUTION", "design", "also", "addresses", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_15_item1_p97_s0", "idA": "1316175_14_item1_p93_s1", "sentA": "Prior to our in-licensing of blisibimod, our licensor, Amgen, completed two Phase 1 clinical studies of blisibimod in lupus patients to evaluate the safety and pharmacokinetics of single and multiple doses of the drug using intravenous and subcutaneous formulations.", "sentB": "Two long-term studies were conducted to evaluate the safety and effects on nutritional status of liprotamase.", "type": 2, "words": ["<tag1>", "Prior", "to", "our", "in-licensing", "of", "blisibimod,", "our", "licensor,", "Amgen,", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations.", "<tag2>", "Two", "long-term", "studies", "were", "conducted", "to", "evaluate", "the", "safety", "and", "effects", "on", "nutritional", "status", "of", "liprotamase.", "<tag3>"], "wordsA": ["Prior", "to", "our", "in-licensing", "of", "blisibimod,", "our", "licensor,", "Amgen,", "completed", "two", "Phase", "1", "clinical", "studies", "of", "blisibimod", "in", "lupus", "patients", "to", "evaluate", "the", "safety", "and", "pharmacokinetics", "of", "single", "and", "multiple", "doses", "of", "the", "drug", "using", "intravenous", "and", "subcutaneous", "formulations."], "wordsB": ["Two", "long-term", "studies", "were", "conducted", "to", "evaluate", "the", "safety", "and", "effects", "on", "nutritional", "status", "of", "liprotamase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p37_s0", "idA": "1316175_15_item1_p100_s0", "sentA": "In December 2014, we entered in an exclusive license agreement with Zenyaku Kogyo Co., Ltd ( Zenyaku ) for the development and commercialization of blisibimod in Japan and potentially other countries throughout Asia ( the Zenyaku Agreement ).", "sentB": "We partnered our development of IgA nephropathy with Zenyaku Kogyo Co., Ltd. ( Zenyaku ) through a collaborative and license agreement executed in December 2014, which agreement was terminated effective January 7, 2016.", "type": 2, "words": ["<tag1>", "In", "December", "2014,", "we", "entered", "in", "an", "exclusive", "license", "agreement", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd", "(", "Zenyaku", ")", "for", "the", "development", "and", "commercialization", "of", "blisibimod", "in", "Japan", "and", "potentially", "other", "countries", "throughout", "Asia", "(", "the", "Zenyaku", "Agreement", ").", "<tag2>", "We", "partnered", "our", "development", "of", "IgA", "nephropathy", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd.", "(", "Zenyaku", ")", "through", "a", "collaborative", "and", "license", "agreement", "executed", "in", "December", "2014,", "which", "agreement", "was", "terminated", "effective", "January", "7,", "2016.", "<tag3>"], "wordsA": ["In", "December", "2014,", "we", "entered", "in", "an", "exclusive", "license", "agreement", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd", "(", "Zenyaku", ")", "for", "the", "development", "and", "commercialization", "of", "blisibimod", "in", "Japan", "and", "potentially", "other", "countries", "throughout", "Asia", "(", "the", "Zenyaku", "Agreement", ")."], "wordsB": ["We", "partnered", "our", "development", "of", "IgA", "nephropathy", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd.", "(", "Zenyaku", ")", "through", "a", "collaborative", "and", "license", "agreement", "executed", "in", "December", "2014,", "which", "agreement", "was", "terminated", "effective", "January", "7,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p118_s0", "idA": "1316175_15_item1_p101_s0", "sentA": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including autoimmune diseases and enzyme replacement therapies.", "sentB": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "enzyme", "replacement", "therapies.", "<tag2>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "enzyme", "replacement", "therapies", "and", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "autoimmune", "diseases", "and", "enzyme", "replacement", "therapies."], "wordsB": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "enzyme", "replacement", "therapies", "and", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p119_s1", "idA": "1316175_15_item1_p102_s0", "sentA": "We are advancing the development of blisibimod to evaluate the broad potential clinical utility of BAFF antagonism.", "sentB": "We are also advancing the development of blisibimod to evaluate the broad potential clinical utility of BAFF antagonism.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "evaluate", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism.", "<tag2>", "We", "are", "also", "advancing", "the", "development", "of", "blisibimod", "to", "evaluate", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "blisibimod", "to", "evaluate", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism."], "wordsB": ["We", "are", "also", "advancing", "the", "development", "of", "blisibimod", "to", "evaluate", "the", "broad", "potential", "clinical", "utility", "of", "BAFF", "antagonism."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p119_s0", "idA": "1316175_15_item1_p102_s2", "sentA": "We intend to initiate the development of liprotamase in a Phase 3 registration program in the second half of 2015 in patients with cystic fibrosis-related Exocrine Pancreatic Insufficiency.", "sentB": "We are advancing the development of liprotamase in a Phase 3 registration program in patients with cystic fibrosis-related EPI.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "initiate", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "the", "second", "half", "of", "2015", "in", "patients", "with", "cystic", "fibrosis-related", "Exocrine", "Pancreatic", "Insufficiency.", "<tag2>", "We", "are", "advancing", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI.", "<tag3>"], "wordsA": ["We", "intend", "to", "initiate", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "the", "second", "half", "of", "2015", "in", "patients", "with", "cystic", "fibrosis-related", "Exocrine", "Pancreatic", "Insufficiency."], "wordsB": ["We", "are", "advancing", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p119_s3", "idA": "1316175_15_item1_p102_s3", "sentA": "We may opportunistically enter into collaborations with third parties for development of blisibimod in lupus or for the development of liprotamase, including securing corporate partners whose capabilities complement ours.", "sentB": "We may opportunistically enter into collaborations with third parties for development of liprotamase and blisibimod, including securing corporate partners whose capabilities complement ours.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "for", "the", "development", "of", "liprotamase,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "liprotamase", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "blisibimod", "in", "lupus", "or", "for", "the", "development", "of", "liprotamase,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "liprotamase", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p120_s0", "idA": "1316175_15_item1_p103_s0", "sentA": "Our product candidates are focused on highly-specialized physician segments, such as rheumatologists, nephrologists and cystic fibrosis specialists.", "sentB": "Our product candidates are focused on highly-specialized physician segments, such as cystic fibrosis specialists, rheumatologists and nephrologists.", "type": 2, "words": ["<tag1>", "Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists,", "nephrologists", "and", "cystic", "fibrosis", "specialists.", "<tag2>", "Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "cystic", "fibrosis", "specialists,", "rheumatologists", "and", "nephrologists.", "<tag3>"], "wordsA": ["Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "rheumatologists,", "nephrologists", "and", "cystic", "fibrosis", "specialists."], "wordsB": ["Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "cystic", "fibrosis", "specialists,", "rheumatologists", "and", "nephrologists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p121_s2", "idA": "1316175_15_item1_p104_s2", "sentA": "Our primary competitors are described in further detail below, under Approved Categories of Drugs and B-Cell Targeting Drugs Under Late-Stage Clinical Development .", "sentB": "Our primary competitors are described in further detail below, under Approved Categories of Drugs .", "type": 2, "words": ["<tag1>", "Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", "and", "B-Cell", "Targeting", "Drugs", "Under", "Late-Stage", "Clinical", "Development", ".", "<tag2>", "Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", ".", "<tag3>"], "wordsA": ["Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", "and", "B-Cell", "Targeting", "Drugs", "Under", "Late-Stage", "Clinical", "Development", "."], "wordsB": ["Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p125_s2", "idA": "1316175_15_item1_p107_s1", "sentA": "However, use of these agents is often associated with limited efficacy or significant adverse events and broad immune suppression.", "sentB": "Other current therapies such as non-steroidal anti-inflammatory drugs, or NSAIDs, corticosteroids, anti-malarials and immunosuppressants are generally associated with limited efficacy or significant adverse events and broad immune suppression.", "type": 2, "words": ["<tag1>", "However,", "use", "of", "these", "agents", "is", "often", "associated", "with", "limited", "efficacy", "or", "significant", "adverse", "events", "and", "broad", "immune", "suppression.", "<tag2>", "Other", "current", "therapies", "such", "as", "non-steroidal", "anti-inflammatory", "drugs,", "or", "NSAIDs,", "corticosteroids,", "anti-malarials", "and", "immunosuppressants", "are", "generally", "associated", "with", "limited", "efficacy", "or", "significant", "adverse", "events", "and", "broad", "immune", "suppression.", "<tag3>"], "wordsA": ["However,", "use", "of", "these", "agents", "is", "often", "associated", "with", "limited", "efficacy", "or", "significant", "adverse", "events", "and", "broad", "immune", "suppression."], "wordsB": ["Other", "current", "therapies", "such", "as", "non-steroidal", "anti-inflammatory", "drugs,", "or", "NSAIDs,", "corticosteroids,", "anti-malarials", "and", "immunosuppressants", "are", "generally", "associated", "with", "limited", "efficacy", "or", "significant", "adverse", "events", "and", "broad", "immune", "suppression."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p126_s0", "idA": "1316175_15_item1_p108_s0", "sentA": "Emerging data from 2 large Phase 3 trials with the BAFF-targeted monocloncal antibody, tabalumab, were presented by Professor David Isenberg at the American College of Rheumatology Annual Conference, Boston, MA, November 2014.", "sentB": "Emerging data from 2 large Phase 3 trials with the BAFF-targeted monoclonal antibody, tabalumab, were presented by Professor David Isenberg at the American College of Rheumatology Annual Conference, Boston, MA, November 2014.", "type": 2, "words": ["<tag1>", "Emerging", "data", "from", "2", "large", "Phase", "3", "trials", "with", "the", "BAFF-targeted", "monocloncal", "antibody,", "tabalumab,", "were", "presented", "by", "Professor", "David", "Isenberg", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston,", "MA,", "November", "2014.", "<tag2>", "Emerging", "data", "from", "2", "large", "Phase", "3", "trials", "with", "the", "BAFF-targeted", "monoclonal", "antibody,", "tabalumab,", "were", "presented", "by", "Professor", "David", "Isenberg", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston,", "MA,", "November", "2014.", "<tag3>"], "wordsA": ["Emerging", "data", "from", "2", "large", "Phase", "3", "trials", "with", "the", "BAFF-targeted", "monocloncal", "antibody,", "tabalumab,", "were", "presented", "by", "Professor", "David", "Isenberg", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston,", "MA,", "November", "2014."], "wordsB": ["Emerging", "data", "from", "2", "large", "Phase", "3", "trials", "with", "the", "BAFF-targeted", "monoclonal", "antibody,", "tabalumab,", "were", "presented", "by", "Professor", "David", "Isenberg", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "Boston,", "MA,", "November", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p126_s3", "idA": "1316175_15_item1_p108_s4", "sentA": "Other pathways targeting both B-cell and non-B-cell mechanisms are in earlier-phase clinical trials, such as Lupuzor from ImmuPharma plc; anti-inhibitors of interferon (IFN) alpha, sifalimumab, MEDI-545 and rontalizumab; the anti-IFN gamma antibody AMG 811; toll-like receptor inhibitors; the anti-interleukin 6 antibodies sirukumab and PF-04236921; the phosphodiesterase 4 inhibitor CC-10004; the anti-CD74 monocloncal antibody milatuzumab; and inhibition of B7 related protein (B7RP-1) pathway with AMG 557.", "sentB": "These product candidates include atacicept, or TACI-Ig, from ZymoGenetics Inc. and anifrolumab from AstraZeneca, Other pathways targeting both B-cell and non-B-cell mechanisms are in earlier-phase clinical trials, such as Lupuzor from ImmuPharma plc; the anti-IFN gamma antibody AMG 811; toll-like receptor inhibitors; the anti-interleukin 6 antibodies sirukumab and PF-04236921; the phosphodiesterase 4 inhibitor CC-10004; the anti-CD74 monoclonal antibody milatuzumab; and inhibition of B7 related protein (B7RP-1) pathway with AMG 557.", "type": 2, "words": ["<tag1>", "Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "sifalimumab,", "MEDI-545", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibodies", "sirukumab", "and", "PF-04236921;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557.", "<tag2>", "These", "product", "candidates", "include", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "anifrolumab", "from", "AstraZeneca,", "Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibodies", "sirukumab", "and", "PF-04236921;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monoclonal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557.", "<tag3>"], "wordsA": ["Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "anti-inhibitors", "of", "interferon", "(IFN)", "alpha,", "sifalimumab,", "MEDI-545", "and", "rontalizumab;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibodies", "sirukumab", "and", "PF-04236921;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monocloncal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557."], "wordsB": ["These", "product", "candidates", "include", "atacicept,", "or", "TACI-Ig,", "from", "ZymoGenetics", "Inc.", "and", "anifrolumab", "from", "AstraZeneca,", "Other", "pathways", "targeting", "both", "B-cell", "and", "non-B-cell", "mechanisms", "are", "in", "earlier-phase", "clinical", "trials,", "such", "as", "Lupuzor", "from", "ImmuPharma", "plc;", "the", "anti-IFN", "gamma", "antibody", "AMG", "811;", "toll-like", "receptor", "inhibitors;", "the", "anti-interleukin", "6", "antibodies", "sirukumab", "and", "PF-04236921;", "the", "phosphodiesterase", "4", "inhibitor", "CC-10004;", "the", "anti-CD74", "monoclonal", "antibody", "milatuzumab;", "and", "inhibition", "of", "B7", "related", "protein", "(B7RP-1)", "pathway", "with", "AMG", "557."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p126_s4", "idA": "1316175_15_item1_p108_s5", "sentA": "We believe that blisibimod may offer potential differentiation from these agents, including demonstrated dosing flexibility with both subcutaneous and intravenous delivery; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; the use of a bacterial expression platform which is expected to translate to lower manufacturing costs compared with therapeutic antibodies; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen.", "sentB": "We believe that blisibimod may offer potential differentiation from these agents, including focused evaluation on the populations of lupus patients who were identified in prior trials with BAFF inhibitors to be responsive to this treatment modality; selective modulation and reduction of relevant B-cell types in lupus patients; the ability to inhibit the activity of both membrane-bound and soluble BAFF; the use of a bacterial expression platform which is expected to translate to lower manufacturing costs compared with therapeutic antibodies; and distinct patent protection based on a novel and proprietary technology developed and commercialized by Amgen.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "blisibimod", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "the", "use", "of", "a", "bacterial", "expression", "platform", "which", "is", "expected", "to", "translate", "to", "lower", "manufacturing", "costs", "compared", "with", "therapeutic", "antibodies;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen.", "<tag2>", "We", "believe", "that", "blisibimod", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "focused", "evaluation", "on", "the", "populations", "of", "lupus", "patients", "who", "were", "identified", "in", "prior", "trials", "with", "BAFF", "inhibitors", "to", "be", "responsive", "to", "this", "treatment", "modality;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "the", "use", "of", "a", "bacterial", "expression", "platform", "which", "is", "expected", "to", "translate", "to", "lower", "manufacturing", "costs", "compared", "with", "therapeutic", "antibodies;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen.", "<tag3>"], "wordsA": ["We", "believe", "that", "blisibimod", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "demonstrated", "dosing", "flexibility", "with", "both", "subcutaneous", "and", "intravenous", "delivery;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "the", "use", "of", "a", "bacterial", "expression", "platform", "which", "is", "expected", "to", "translate", "to", "lower", "manufacturing", "costs", "compared", "with", "therapeutic", "antibodies;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen."], "wordsB": ["We", "believe", "that", "blisibimod", "may", "offer", "potential", "differentiation", "from", "these", "agents,", "including", "focused", "evaluation", "on", "the", "populations", "of", "lupus", "patients", "who", "were", "identified", "in", "prior", "trials", "with", "BAFF", "inhibitors", "to", "be", "responsive", "to", "this", "treatment", "modality;", "selective", "modulation", "and", "reduction", "of", "relevant", "B-cell", "types", "in", "lupus", "patients;", "the", "ability", "to", "inhibit", "the", "activity", "of", "both", "membrane-bound", "and", "soluble", "BAFF;", "the", "use", "of", "a", "bacterial", "expression", "platform", "which", "is", "expected", "to", "translate", "to", "lower", "manufacturing", "costs", "compared", "with", "therapeutic", "antibodies;", "and", "distinct", "patent", "protection", "based", "on", "a", "novel", "and", "proprietary", "technology", "developed", "and", "commercialized", "by", "Amgen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p124_s0", "idA": "1316175_15_item1_p109_s1", "sentA": "We are also aware of companies with other products in development that are being tested for potential treatment of EPI caused by cystic fibrosis: Johnson and Johnson Research and Development LLC recently completed a Phase 3 study to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis patients with clinical symptoms of EPI; and Nordmark Arzneimittel GmbH Co. KG s compound, Burlulipase, is being tested in a Phase 3 study in patients with EPI.", "sentB": "We are aware of one company with other products in development that are being tested for potential treatment of EPI caused by cystic fibrosis: Nordmark Arzneimittel GmbH Co. KG s compound, Burlulipase (also known as NM-BL), recently completed a Phase 1/Phase 2 study in patients with EPI.", "type": 2, "words": ["<tag1>", "We", "are", "also", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "EPI", "caused", "by", "cystic", "fibrosis:", "Johnson", "and", "Johnson", "Research", "and", "Development", "LLC", "recently", "completed", "a", "Phase", "3", "study", "to", "assess", "the", "effectiveness", "and", "safety", "of", "oral", "pancrelipase", "MT", "in", "the", "treatment", "of", "adult", "and", "pediatric/adolescent", "cystic", "fibrosis", "patients", "with", "clinical", "symptoms", "of", "EPI;", "and", "Nordmark", "Arzneimittel", "GmbH", "Co.", "KG", "s", "compound,", "Burlulipase,", "is", "being", "tested", "in", "a", "Phase", "3", "study", "in", "patients", "with", "EPI.", "<tag2>", "We", "are", "aware", "of", "one", "company", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "EPI", "caused", "by", "cystic", "fibrosis:", "Nordmark", "Arzneimittel", "GmbH", "Co.", "KG", "s", "compound,", "Burlulipase", "(also", "known", "as", "NM-BL),", "recently", "completed", "a", "Phase", "1/Phase", "2", "study", "in", "patients", "with", "EPI.", "<tag3>"], "wordsA": ["We", "are", "also", "aware", "of", "companies", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "EPI", "caused", "by", "cystic", "fibrosis:", "Johnson", "and", "Johnson", "Research", "and", "Development", "LLC", "recently", "completed", "a", "Phase", "3", "study", "to", "assess", "the", "effectiveness", "and", "safety", "of", "oral", "pancrelipase", "MT", "in", "the", "treatment", "of", "adult", "and", "pediatric/adolescent", "cystic", "fibrosis", "patients", "with", "clinical", "symptoms", "of", "EPI;", "and", "Nordmark", "Arzneimittel", "GmbH", "Co.", "KG", "s", "compound,", "Burlulipase,", "is", "being", "tested", "in", "a", "Phase", "3", "study", "in", "patients", "with", "EPI."], "wordsB": ["We", "are", "aware", "of", "one", "company", "with", "other", "products", "in", "development", "that", "are", "being", "tested", "for", "potential", "treatment", "of", "EPI", "caused", "by", "cystic", "fibrosis:", "Nordmark", "Arzneimittel", "GmbH", "Co.", "KG", "s", "compound,", "Burlulipase", "(also", "known", "as", "NM-BL),", "recently", "completed", "a", "Phase", "1/Phase", "2", "study", "in", "patients", "with", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p149_s4", "idA": "1316175_15_item1_p113_s0", "sentA": "As of the date of this report, our blisibimod patent portfolio includes:", "sentB": "As of the date of termination, no patients had been enrolled in any blisibimod clinical studies in the Zenyaku territory and Zenyaku had not purchased any blisibimod product from us.", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:", "<tag2>", "As", "of", "the", "date", "of", "termination,", "no", "patients", "had", "been", "enrolled", "in", "any", "blisibimod", "clinical", "studies", "in", "the", "Zenyaku", "territory", "and", "Zenyaku", "had", "not", "purchased", "any", "blisibimod", "product", "from", "us.", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "blisibimod", "patent", "portfolio", "includes:"], "wordsB": ["As", "of", "the", "date", "of", "termination,", "no", "patients", "had", "been", "enrolled", "in", "any", "blisibimod", "clinical", "studies", "in", "the", "Zenyaku", "territory", "and", "Zenyaku", "had", "not", "purchased", "any", "blisibimod", "product", "from", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p134_s0", "idA": "1316175_15_item1_p114_s0", "sentA": "Three pending non-EP foreign patent applications in Brazil, Mexico, and Poland.", "sentB": "Four pending non-EP foreign patent applications in Brazil, Hong Kong, Mexico, and Poland.", "type": 2, "words": ["<tag1>", "Three", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Mexico,", "and", "Poland.", "<tag2>", "Four", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Hong", "Kong,", "Mexico,", "and", "Poland.", "<tag3>"], "wordsA": ["Three", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Mexico,", "and", "Poland."], "wordsB": ["Four", "pending", "non-EP", "foreign", "patent", "applications", "in", "Brazil,", "Hong", "Kong,", "Mexico,", "and", "Poland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p136_s0", "idA": "1316175_15_item1_p116_s0", "sentA": "The exclusively licensed U.S. patents are currently scheduled to expire in May 2022, March 2023 and November 2023.", "sentB": "The four exclusively licensed U.S. patents are currently scheduled to expire in May 2022, March 2023 and November 2023.", "type": 2, "words": ["<tag1>", "The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022,", "March", "2023", "and", "November", "2023.", "<tag2>", "The", "four", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022,", "March", "2023", "and", "November", "2023.", "<tag3>"], "wordsA": ["The", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022,", "March", "2023", "and", "November", "2023."], "wordsB": ["The", "four", "exclusively", "licensed", "U.S.", "patents", "are", "currently", "scheduled", "to", "expire", "in", "May", "2022,", "March", "2023", "and", "November", "2023."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p123_s1", "idA": "1316175_15_item1_p11_s0", "sentA": "The blisibimod product is designed for at-home, self-administration and is presented as a pre-filled syringe for subcutaneous administration.", "sentB": "Alcresta recently gained marketing approval for its product, Relizorb, which utilizes a digestive lipase enzyme, and is designed for use by adults on enteral tube feeding who have trouble breaking down and absorbing dietary fats.", "type": 2, "words": ["<tag1>", "The", "blisibimod", "product", "is", "designed", "for", "at-home,", "self-administration", "and", "is", "presented", "as", "a", "pre-filled", "syringe", "for", "subcutaneous", "administration.", "<tag2>", "Alcresta", "recently", "gained", "marketing", "approval", "for", "its", "product,", "Relizorb,", "which", "utilizes", "a", "digestive", "lipase", "enzyme,", "and", "is", "designed", "for", "use", "by", "adults", "on", "enteral", "tube", "feeding", "who", "have", "trouble", "breaking", "down", "and", "absorbing", "dietary", "fats.", "<tag3>"], "wordsA": ["The", "blisibimod", "product", "is", "designed", "for", "at-home,", "self-administration", "and", "is", "presented", "as", "a", "pre-filled", "syringe", "for", "subcutaneous", "administration."], "wordsB": ["Alcresta", "recently", "gained", "marketing", "approval", "for", "its", "product,", "Relizorb,", "which", "utilizes", "a", "digestive", "lipase", "enzyme,", "and", "is", "designed", "for", "use", "by", "adults", "on", "enteral", "tube", "feeding", "who", "have", "trouble", "breaking", "down", "and", "absorbing", "dietary", "fats."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p131_s0", "idA": "1316175_15_item1_p123_s0", "sentA": "One pending non-EP foreign patent application.", "sentB": "Three pending non-EP foreign patent application.", "type": 2, "words": ["<tag1>", "One", "pending", "non-EP", "foreign", "patent", "application.", "<tag2>", "Three", "pending", "non-EP", "foreign", "patent", "application.", "<tag3>"], "wordsA": ["One", "pending", "non-EP", "foreign", "patent", "application."], "wordsB": ["Three", "pending", "non-EP", "foreign", "patent", "application."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p132_s4", "idA": "1316175_15_item1_p124_s4", "sentA": "This could extend the expiration date of this U.S. Patent to as late as July 2033, depending on which patent the term restoration is applied to.", "sentB": "This could extend the expiration date of the selected U.S. Patent to as late as March 2030 or July 2033, depending on which patent the term restoration is applied to.", "type": 2, "words": ["<tag1>", "This", "could", "extend", "the", "expiration", "date", "of", "this", "U.S.", "Patent", "to", "as", "late", "as", "July", "2033,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag2>", "This", "could", "extend", "the", "expiration", "date", "of", "the", "selected", "U.S.", "Patent", "to", "as", "late", "as", "March", "2030", "or", "July", "2033,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to.", "<tag3>"], "wordsA": ["This", "could", "extend", "the", "expiration", "date", "of", "this", "U.S.", "Patent", "to", "as", "late", "as", "July", "2033,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "wordsB": ["This", "could", "extend", "the", "expiration", "date", "of", "the", "selected", "U.S.", "Patent", "to", "as", "late", "as", "March", "2030", "or", "July", "2033,", "depending", "on", "which", "patent", "the", "term", "restoration", "is", "applied", "to."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p132_s6", "idA": "1316175_15_item1_p124_s6", "sentA": "Two of the exclusively licensed EP patents are currently scheduled to expire in February 2021 and October 2025.", "sentB": "The three exclusively licensed EP patents are currently scheduled to expire between February 2021 and October 2025.", "type": 2, "words": ["<tag1>", "Two", "of", "the", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "February", "2021", "and", "October", "2025.", "<tag2>", "The", "three", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "between", "February", "2021", "and", "October", "2025.", "<tag3>"], "wordsA": ["Two", "of", "the", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "in", "February", "2021", "and", "October", "2025."], "wordsB": ["The", "three", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "between", "February", "2021", "and", "October", "2025."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p132_s7", "idA": "1316175_15_item1_p124_s7", "sentA": "One of these two patents may be eligible for a Supplementary Protection Certificate of up to five years, which could extend the expiration date to February 2026 or October 2030.", "sentB": "One of these patents may be eligible for a Supplementary Protection Certificate of up to five years, which could extend the expiration date to between February 2026 and October 2030.", "type": 2, "words": ["<tag1>", "One", "of", "these", "two", "patents", "may", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "February", "2026", "or", "October", "2030.", "<tag2>", "One", "of", "these", "patents", "may", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "between", "February", "2026", "and", "October", "2030.", "<tag3>"], "wordsA": ["One", "of", "these", "two", "patents", "may", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "February", "2026", "or", "October", "2030."], "wordsB": ["One", "of", "these", "patents", "may", "be", "eligible", "for", "a", "Supplementary", "Protection", "Certificate", "of", "up", "to", "five", "years,", "which", "could", "extend", "the", "expiration", "date", "to", "between", "February", "2026", "and", "October", "2030."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p4_s1", "idA": "1316175_15_item1_p12_s1", "sentA": "The lipase in liprotamase is more stable than the porcine derived lipase in the low pH environment of the stomach and therefore liprotamase does not have an enteric polymer coating, nor does it contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "sentB": "Through enzyme cross-linking, the lipase enzyme in liprotamase is more stable than the porcine derived lipase in the low pH environment of the stomach and therefore liprotamase does not have an enteric polymer coating.", "type": 2, "words": ["<tag1>", "The", "lipase", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating,", "nor", "does", "it", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag2>", "Through", "enzyme", "cross-linking,", "the", "lipase", "enzyme", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating.", "<tag3>"], "wordsA": ["The", "lipase", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating,", "nor", "does", "it", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "wordsB": ["Through", "enzyme", "cross-linking,", "the", "lipase", "enzyme", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p4_s2", "idA": "1316175_15_item1_p12_s1", "sentA": "The lipase in liprotamase is more stable than the porcine derived lipase in the low pH environment of the stomach and therefore liprotamase does not have an enteric polymer coating, nor does it contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "sentB": "Furthermore, since the three enzymes in liprotamase are biotechnology-derived, liprotamase does not contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "type": 2, "words": ["<tag1>", "The", "lipase", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating,", "nor", "does", "it", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag2>", "Furthermore,", "since", "the", "three", "enzymes", "in", "liprotamase", "are", "biotechnology-derived,", "liprotamase", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag3>"], "wordsA": ["The", "lipase", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating,", "nor", "does", "it", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "wordsB": ["Furthermore,", "since", "the", "three", "enzymes", "in", "liprotamase", "are", "biotechnology-derived,", "liprotamase", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p149_s3", "idA": "1316175_15_item1_p130_s0", "sentA": "In connection with the collaborative arrangement with Zenyaku, we amended the Amgen Agreement in November 2014 to (i) adjust certain royalty and milestone payment obligations payable to Amgen in light of our collaboration with Zenyaku and (ii) provide that the sublicense granted by us to Zenyaku shall survive the termination of the Amgen Agreement.", "sentB": "We did not incur any termination penalties in connection with the early termination of the Zenyaku Agreement by Zenyaku.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "the", "collaborative", "arrangement", "with", "Zenyaku,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement.", "<tag2>", "We", "did", "not", "incur", "any", "termination", "penalties", "in", "connection", "with", "the", "early", "termination", "of", "the", "Zenyaku", "Agreement", "by", "Zenyaku.", "<tag3>"], "wordsA": ["In", "connection", "with", "the", "collaborative", "arrangement", "with", "Zenyaku,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement."], "wordsB": ["We", "did", "not", "incur", "any", "termination", "penalties", "in", "connection", "with", "the", "early", "termination", "of", "the", "Zenyaku", "Agreement", "by", "Zenyaku."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p147_s1", "idA": "1316175_15_item1_p130_s1", "sentA": "Under this amendment, we also agreed to grant Amgen that number of shares of our common stock equal $1,000,000 divided by the volume weighted average price of our common stock for 20 trading days prior to issuance.", "sentB": "Under this amendment, we also agreed to grant Amgen that number of shares of our common stock equal $1 .0 million divided by the volume weighted average price of our common stock for 20 trading days prior to issuance.", "type": 2, "words": ["<tag1>", "Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1,000,000", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance.", "<tag2>", "Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1", ".0", "million", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance.", "<tag3>"], "wordsA": ["Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1,000,000", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance."], "wordsB": ["Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1", ".0", "million", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p15_s4", "idA": "1316175_15_item1_p138_s2", "sentA": "The Promissory Note is planned for execution in the first half of 2015.", "sentB": "A second, smaller Phase 3 study, SIMPLICITY, in younger pediatric subjects is planned for initiation in first half of 2016.", "type": 2, "words": ["<tag1>", "The", "Promissory", "Note", "is", "planned", "for", "execution", "in", "the", "first", "half", "of", "2015.", "<tag2>", "A", "second,", "smaller", "Phase", "3", "study,", "SIMPLICITY,", "in", "younger", "pediatric", "subjects", "is", "planned", "for", "initiation", "in", "first", "half", "of", "2016.", "<tag3>"], "wordsA": ["The", "Promissory", "Note", "is", "planned", "for", "execution", "in", "the", "first", "half", "of", "2015."], "wordsB": ["A", "second,", "smaller", "Phase", "3", "study,", "SIMPLICITY,", "in", "younger", "pediatric", "subjects", "is", "planned", "for", "initiation", "in", "first", "half", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p71_s6", "idA": "1316175_15_item1_p138_s2", "sentA": "The Promissory Note is planned for execution in the first half of 2015.", "sentB": "Data generated from the analysis of the BRIGHT-SC study in the first half of 2016, will be used to guide the final study design elements for the Phase 3 registration study protocol.", "type": 2, "words": ["<tag1>", "The", "Promissory", "Note", "is", "planned", "for", "execution", "in", "the", "first", "half", "of", "2015.", "<tag2>", "Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol.", "<tag3>"], "wordsA": ["The", "Promissory", "Note", "is", "planned", "for", "execution", "in", "the", "first", "half", "of", "2015."], "wordsB": ["Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p153_s4", "idA": "1316175_15_item1_p143_s5", "sentA": "We also plan to seek commercialization partners for products in non-specialty and international markets.", "sentB": "We also plan to seek commercialization partners for products in international markets.", "type": 2, "words": ["<tag1>", "We", "also", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "non-specialty", "and", "international", "markets.", "<tag2>", "We", "also", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "international", "markets.", "<tag3>"], "wordsA": ["We", "also", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "non-specialty", "and", "international", "markets."], "wordsB": ["We", "also", "plan", "to", "seek", "commercialization", "partners", "for", "products", "in", "international", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p154_s0", "idA": "1316175_15_item1_p144_s0", "sentA": "We intend to build the commercial infrastructure necessary to bring our product candidate to market alone or in collaboration with a co-development or co- promotion partner.", "sentB": "We intend to build the commercial infrastructure necessary to bring our product candidates to market.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidate", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-", "promotion", "partner.", "<tag2>", "We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidates", "to", "market.", "<tag3>"], "wordsA": ["We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidate", "to", "market", "alone", "or", "in", "collaboration", "with", "a", "co-development", "or", "co-", "promotion", "partner."], "wordsB": ["We", "intend", "to", "build", "the", "commercial", "infrastructure", "necessary", "to", "bring", "our", "product", "candidates", "to", "market."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p6_s0", "idA": "1316175_15_item1_p14_s0", "sentA": "Pancreatic enzyme replacement therapy is currently the mainstay of treatment for nutrient malabsorption in patients with digestive enzyme deficiencies known as exocrine pancreatic insufficiency, or EPI.", "sentB": "Pancreatic enzyme replacement therapy is currently the mainstay of treatment for nutrient malabsorption in patients with digestive enzyme deficiencies known as EPI.", "type": 2, "words": ["<tag1>", "Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "exocrine", "pancreatic", "insufficiency,", "or", "EPI.", "<tag2>", "Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "EPI.", "<tag3>"], "wordsA": ["Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "exocrine", "pancreatic", "insufficiency,", "or", "EPI."], "wordsB": ["Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p10_s1", "idA": "1316175_15_item1_p14_s1", "sentA": "EPI occurs when diseases such as cystic fibrosis, or CF, and chronic pancreatitis impede or destroy the exocrine function of the pancreas.", "sentB": "EPI occurs when diseases such as CF and chronic pancreatitis impede or destroy the exocrine function of the pancreas.", "type": 2, "words": ["<tag1>", "EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis,", "or", "CF,", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas.", "<tag2>", "EPI", "occurs", "when", "diseases", "such", "as", "CF", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas.", "<tag3>"], "wordsA": ["EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis,", "or", "CF,", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas."], "wordsB": ["EPI", "occurs", "when", "diseases", "such", "as", "CF", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p72_s0", "idA": "1316175_15_item1_p15_s1", "sentA": "Unmet medical needs for the treatment of EPI remain.", "sentB": "We continue to dose patients in our BRIGHT-SC clinical study for the treatment of patients with IgA nephropathy ( IgAN ), an orphan disease.", "type": 2, "words": ["<tag1>", "Unmet", "medical", "needs", "for", "the", "treatment", "of", "EPI", "remain.", "<tag2>", "We", "continue", "to", "dose", "patients", "in", "our", "BRIGHT-SC", "clinical", "study", "for", "the", "treatment", "of", "patients", "with", "IgA", "nephropathy", "(", "IgAN", "),", "an", "orphan", "disease.", "<tag3>"], "wordsA": ["Unmet", "medical", "needs", "for", "the", "treatment", "of", "EPI", "remain."], "wordsB": ["We", "continue", "to", "dose", "patients", "in", "our", "BRIGHT-SC", "clinical", "study", "for", "the", "treatment", "of", "patients", "with", "IgA", "nephropathy", "(", "IgAN", "),", "an", "orphan", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p8_s0", "idA": "1316175_15_item1_p16_s0", "sentA": "Since protease and lipase can become irreversibly inactivated in an acid environment, most products are provided as enteric-coated microbeads.", "sentB": "Since porcine lipase can become irreversibly deactivated in an acid environment, most products are enterically-coated.", "type": 2, "words": ["<tag1>", "Since", "protease", "and", "lipase", "can", "become", "irreversibly", "inactivated", "in", "an", "acid", "environment,", "most", "products", "are", "provided", "as", "enteric-coated", "microbeads.", "<tag2>", "Since", "porcine", "lipase", "can", "become", "irreversibly", "deactivated", "in", "an", "acid", "environment,", "most", "products", "are", "enterically-coated.", "<tag3>"], "wordsA": ["Since", "protease", "and", "lipase", "can", "become", "irreversibly", "inactivated", "in", "an", "acid", "environment,", "most", "products", "are", "provided", "as", "enteric-coated", "microbeads."], "wordsB": ["Since", "porcine", "lipase", "can", "become", "irreversibly", "deactivated", "in", "an", "acid", "environment,", "most", "products", "are", "enterically-coated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p8_s1", "idA": "1316175_15_item1_p17_s0", "sentA": "Patient-to-patient variability in acidification of the intestine makes dissolution variable.", "sentB": "Patient-to-patient differences in the acidity of the intestine makes dissolution of enterically-coated products variable, and gives rise to alterations in the rate and extent to which enzymes are released from these products.", "type": 2, "words": ["<tag1>", "Patient-to-patient", "variability", "in", "acidification", "of", "the", "intestine", "makes", "dissolution", "variable.", "<tag2>", "Patient-to-patient", "differences", "in", "the", "acidity", "of", "the", "intestine", "makes", "dissolution", "of", "enterically-coated", "products", "variable,", "and", "gives", "rise", "to", "alterations", "in", "the", "rate", "and", "extent", "to", "which", "enzymes", "are", "released", "from", "these", "products.", "<tag3>"], "wordsA": ["Patient-to-patient", "variability", "in", "acidification", "of", "the", "intestine", "makes", "dissolution", "variable."], "wordsB": ["Patient-to-patient", "differences", "in", "the", "acidity", "of", "the", "intestine", "makes", "dissolution", "of", "enterically-coated", "products", "variable,", "and", "gives", "rise", "to", "alterations", "in", "the", "rate", "and", "extent", "to", "which", "enzymes", "are", "released", "from", "these", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p149_s5", "idA": "1316175_15_item1_p18_s1", "sentA": "As a result of this meeting we initiated patient enrollment in the initial Phase 3 CHABLIS-SC1 study in March 2013.", "sentB": "As a result of the termination on January 7, 2016, we regained full worldwide rights for blisibimod.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "March", "2013.", "<tag2>", "As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "meeting", "we", "initiated", "patient", "enrollment", "in", "the", "initial", "Phase", "3", "CHABLIS-SC1", "study", "in", "March", "2013."], "wordsB": ["As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s1", "idA": "1316175_15_item1_p190_s2", "sentA": "The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application.", "sentB": "Following our receipt of a termination notice from Zenyaku and the subsequent expiration of the 120-day termination period on January 7, 2016, we elected to stop further enrollment in the BRIGHT-SC clinical study.", "type": 2, "words": ["<tag1>", "The", "reference", "member", "state", "prepares", "a", "draft", "assessment", "and", "drafts", "of", "the", "related", "materials", "within", "120", "days", "after", "receipt", "of", "a", "valid", "application.", "<tag2>", "Following", "our", "receipt", "of", "a", "termination", "notice", "from", "Zenyaku", "and", "the", "subsequent", "expiration", "of", "the", "120-day", "termination", "period", "on", "January", "7,", "2016,", "we", "elected", "to", "stop", "further", "enrollment", "in", "the", "BRIGHT-SC", "clinical", "study.", "<tag3>"], "wordsA": ["The", "reference", "member", "state", "prepares", "a", "draft", "assessment", "and", "drafts", "of", "the", "related", "materials", "within", "120", "days", "after", "receipt", "of", "a", "valid", "application."], "wordsB": ["Following", "our", "receipt", "of", "a", "termination", "notice", "from", "Zenyaku", "and", "the", "subsequent", "expiration", "of", "the", "120-day", "termination", "period", "on", "January", "7,", "2016,", "we", "elected", "to", "stop", "further", "enrollment", "in", "the", "BRIGHT-SC", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p29_s1", "idA": "1316175_15_item1_p19_s2", "sentA": "The study plans to randomize up to 400 patients to receive either 200mg of blisibimod or placebo in addition to their standard-of-care medication for 52 weeks.", "sentB": "The study enrolled 442 SLE patients to receive either 200mg of blisibimod or placebo in addition to their standard-of-care medication for 52 weeks.", "type": 2, "words": ["<tag1>", "The", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "in", "addition", "to", "their", "standard-of-care", "medication", "for", "52", "weeks.", "<tag2>", "The", "study", "enrolled", "442", "SLE", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "in", "addition", "to", "their", "standard-of-care", "medication", "for", "52", "weeks.", "<tag3>"], "wordsA": ["The", "study", "plans", "to", "randomize", "up", "to", "400", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "in", "addition", "to", "their", "standard-of-care", "medication", "for", "52", "weeks."], "wordsB": ["The", "study", "enrolled", "442", "SLE", "patients", "to", "receive", "either", "200mg", "of", "blisibimod", "or", "placebo", "in", "addition", "to", "their", "standard-of-care", "medication", "for", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p29_s2", "idA": "1316175_15_item1_p19_s3", "sentA": "We expect to complete enrollment in mid-2015 and receive topline data after the last enrolled patient completes 52 weeks of treatment in mid-2016.", "sentB": "Topline data is expected after the last enrolled patient completes 52 weeks of treatment around the third quarter of 2016.", "type": 2, "words": ["<tag1>", "We", "expect", "to", "complete", "enrollment", "in", "mid-2015", "and", "receive", "topline", "data", "after", "the", "last", "enrolled", "patient", "completes", "52", "weeks", "of", "treatment", "in", "mid-2016.", "<tag2>", "Topline", "data", "is", "expected", "after", "the", "last", "enrolled", "patient", "completes", "52", "weeks", "of", "treatment", "around", "the", "third", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["We", "expect", "to", "complete", "enrollment", "in", "mid-2015", "and", "receive", "topline", "data", "after", "the", "last", "enrolled", "patient", "completes", "52", "weeks", "of", "treatment", "in", "mid-2016."], "wordsB": ["Topline", "data", "is", "expected", "after", "the", "last", "enrolled", "patient", "completes", "52", "weeks", "of", "treatment", "around", "the", "third", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p30_s0", "idA": "1316175_15_item1_p19_s4", "sentA": "The primary endpoint of the CHABLIS-SC1 will be clinical improvement in the SRI-6 response at 52 weeks.", "sentB": "The primary endpoint of the CHABLIS-SC1 will be clinical improvement in the SLE Responder Index-6 (SRI-6) response at 52 weeks.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "CHABLIS-SC1", "will", "be", "clinical", "improvement", "in", "the", "SRI-6", "response", "at", "52", "weeks.", "<tag2>", "The", "primary", "endpoint", "of", "the", "CHABLIS-SC1", "will", "be", "clinical", "improvement", "in", "the", "SLE", "Responder", "Index-6", "(SRI-6)", "response", "at", "52", "weeks.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "CHABLIS-SC1", "will", "be", "clinical", "improvement", "in", "the", "SRI-6", "response", "at", "52", "weeks."], "wordsB": ["The", "primary", "endpoint", "of", "the", "CHABLIS-SC1", "will", "be", "clinical", "improvement", "in", "the", "SLE", "Responder", "Index-6", "(SRI-6)", "response", "at", "52", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p30_s1", "idA": "1316175_15_item1_p19_s5", "sentA": "Key secondary outcomes from the study, including SRI-8, reduction in the number of lupus flares and steroid use, are intended to further differentiate blisibimod from currently available therapies.", "sentB": "Key secondary outcomes from the study, including SRI-8, reduction in the number of lupus flares and steroid use, are intended to provide more insight into blisibimod s efficacy, and further differentiate blisibimod from currently available therapies.", "type": 2, "words": ["<tag1>", "Key", "secondary", "outcomes", "from", "the", "study,", "including", "SRI-8,", "reduction", "in", "the", "number", "of", "lupus", "flares", "and", "steroid", "use,", "are", "intended", "to", "further", "differentiate", "blisibimod", "from", "currently", "available", "therapies.", "<tag2>", "Key", "secondary", "outcomes", "from", "the", "study,", "including", "SRI-8,", "reduction", "in", "the", "number", "of", "lupus", "flares", "and", "steroid", "use,", "are", "intended", "to", "provide", "more", "insight", "into", "blisibimod", "s", "efficacy,", "and", "further", "differentiate", "blisibimod", "from", "currently", "available", "therapies.", "<tag3>"], "wordsA": ["Key", "secondary", "outcomes", "from", "the", "study,", "including", "SRI-8,", "reduction", "in", "the", "number", "of", "lupus", "flares", "and", "steroid", "use,", "are", "intended", "to", "further", "differentiate", "blisibimod", "from", "currently", "available", "therapies."], "wordsB": ["Key", "secondary", "outcomes", "from", "the", "study,", "including", "SRI-8,", "reduction", "in", "the", "number", "of", "lupus", "flares", "and", "steroid", "use,", "are", "intended", "to", "provide", "more", "insight", "into", "blisibimod", "s", "efficacy,", "and", "further", "differentiate", "blisibimod", "from", "currently", "available", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p30_s2", "idA": "1316175_15_item1_p19_s6", "sentA": "To date, enrolled patient demographics and disease characteristics for the CHABLIS-SC1 study are consistent with our goal to enroll patients with higher levels of lupus activity and positive biomarkers despite the stable use of corticosteroids.", "sentB": "The demographics and disease characteristics of the patients enrolled in the CHABLIS-SC1 study are consistent with our goal to enroll patients with higher levels of lupus activity and positive biomarkers despite the stable use of corticosteroids.", "type": 2, "words": ["<tag1>", "To", "date,", "enrolled", "patient", "demographics", "and", "disease", "characteristics", "for", "the", "CHABLIS-SC1", "study", "are", "consistent", "with", "our", "goal", "to", "enroll", "patients", "with", "higher", "levels", "of", "lupus", "activity", "and", "positive", "biomarkers", "despite", "the", "stable", "use", "of", "corticosteroids.", "<tag2>", "The", "demographics", "and", "disease", "characteristics", "of", "the", "patients", "enrolled", "in", "the", "CHABLIS-SC1", "study", "are", "consistent", "with", "our", "goal", "to", "enroll", "patients", "with", "higher", "levels", "of", "lupus", "activity", "and", "positive", "biomarkers", "despite", "the", "stable", "use", "of", "corticosteroids.", "<tag3>"], "wordsA": ["To", "date,", "enrolled", "patient", "demographics", "and", "disease", "characteristics", "for", "the", "CHABLIS-SC1", "study", "are", "consistent", "with", "our", "goal", "to", "enroll", "patients", "with", "higher", "levels", "of", "lupus", "activity", "and", "positive", "biomarkers", "despite", "the", "stable", "use", "of", "corticosteroids."], "wordsB": ["The", "demographics", "and", "disease", "characteristics", "of", "the", "patients", "enrolled", "in", "the", "CHABLIS-SC1", "study", "are", "consistent", "with", "our", "goal", "to", "enroll", "patients", "with", "higher", "levels", "of", "lupus", "activity", "and", "positive", "biomarkers", "despite", "the", "stable", "use", "of", "corticosteroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p30_s3", "idA": "1316175_15_item1_p19_s7", "sentA": "These characteristics were associated with improved outcomes in both our previous Phase 2 clinical study as well as in two large Phase 3 studies conducted with other BAFF-inhibitors, belimumab (Benlysta) and, more recently, tabalumab.", "sentB": "These characteristics were associated with improved outcomes in both our previous Phase 2 clinical study as well as in large Phase 3 studies conducted with other BAFF-inhibitors, belimumab (Benlysta) and tabalumab.", "type": 2, "words": ["<tag1>", "These", "characteristics", "were", "associated", "with", "improved", "outcomes", "in", "both", "our", "previous", "Phase", "2", "clinical", "study", "as", "well", "as", "in", "two", "large", "Phase", "3", "studies", "conducted", "with", "other", "BAFF-inhibitors,", "belimumab", "(Benlysta)", "and,", "more", "recently,", "tabalumab.", "<tag2>", "These", "characteristics", "were", "associated", "with", "improved", "outcomes", "in", "both", "our", "previous", "Phase", "2", "clinical", "study", "as", "well", "as", "in", "large", "Phase", "3", "studies", "conducted", "with", "other", "BAFF-inhibitors,", "belimumab", "(Benlysta)", "and", "tabalumab.", "<tag3>"], "wordsA": ["These", "characteristics", "were", "associated", "with", "improved", "outcomes", "in", "both", "our", "previous", "Phase", "2", "clinical", "study", "as", "well", "as", "in", "two", "large", "Phase", "3", "studies", "conducted", "with", "other", "BAFF-inhibitors,", "belimumab", "(Benlysta)", "and,", "more", "recently,", "tabalumab."], "wordsB": ["These", "characteristics", "were", "associated", "with", "improved", "outcomes", "in", "both", "our", "previous", "Phase", "2", "clinical", "study", "as", "well", "as", "in", "large", "Phase", "3", "studies", "conducted", "with", "other", "BAFF-inhibitors,", "belimumab", "(Benlysta)", "and", "tabalumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p3_s0", "idA": "1316175_15_item1_p1_s0", "sentA": "Our first Phase 3 product candidate, blisibimod, licensed from Amgen in December 2007, targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ( SLE ), or lupus, Immunoglobulin A nephropathy, or IgA nephropathy, lupus nephritis, and others.", "sentB": "Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ( SLE ), or lupus, Immunoglobulin A nephropathy, or IgA nephropathy, lupus nephritis, and others.", "type": 2, "words": ["<tag1>", "Our", "first", "Phase", "3", "product", "candidate,", "blisibimod,", "licensed", "from", "Amgen", "in", "December", "2007,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others.", "<tag2>", "Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others.", "<tag3>"], "wordsA": ["Our", "first", "Phase", "3", "product", "candidate,", "blisibimod,", "licensed", "from", "Amgen", "in", "December", "2007,", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others."], "wordsB": ["Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p0_s2", "idA": "1316175_15_item1_p1_s1", "sentA": "Our second Phase 3 product candidate, liprotamase, licensed from Eli Lilly Co ( Eli Lilly ) in July 2014, is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "sentB": "We licensed liprotamase from Eli Lilly Co ( Eli Lilly ) in July 2014.", "type": 2, "words": ["<tag1>", "Our", "second", "Phase", "3", "product", "candidate,", "liprotamase,", "licensed", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014,", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag2>", "We", "licensed", "liprotamase", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014.", "<tag3>"], "wordsA": ["Our", "second", "Phase", "3", "product", "candidate,", "liprotamase,", "licensed", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014,", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "wordsB": ["We", "licensed", "liprotamase", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p1_s0", "idA": "1316175_15_item1_p1_s1", "sentA": "Our second Phase 3 product candidate, liprotamase, licensed from Eli Lilly Co ( Eli Lilly ) in July 2014, is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "sentB": "Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "type": 2, "words": ["<tag1>", "Our", "second", "Phase", "3", "product", "candidate,", "liprotamase,", "licensed", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014,", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag2>", "Sollpura", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag3>"], "wordsA": ["Our", "second", "Phase", "3", "product", "candidate,", "liprotamase,", "licensed", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014,", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "wordsB": ["Sollpura", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p211_s0", "idA": "1316175_15_item1_p201_s0", "sentA": "As of December 31, 2014, we had 20 employees.", "sentB": "As of December 31, 2015, we had 25 employees.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2014,", "we", "had", "20", "employees.", "<tag2>", "As", "of", "December", "31,", "2015,", "we", "had", "25", "employees.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2014,", "we", "had", "20", "employees."], "wordsB": ["As", "of", "December", "31,", "2015,", "we", "had", "25", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p213_s1", "idA": "1316175_15_item1_p203_s1", "sentA": "T he mailing address of our headquarters is 25801 Industrial Blvd, Hayward, CA 94545, and our telephone number at that location is 510-856-5600.", "sentB": "The mailing address of our headquarters is 25801 Industrial Blvd, Hayward, CA 94545, and our telephone number at that location is 510-856-5600.", "type": 2, "words": ["<tag1>", "T", "he", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600.", "<tag2>", "The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600.", "<tag3>"], "wordsA": ["T", "he", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600."], "wordsB": ["The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p33_s2", "idA": "1316175_15_item1_p22_s2", "sentA": "After the most recent scheduled meeting in October 2014, the DSMB recommended continuing the CHABLIS-SC1 and BRIGHT-SC clinical studies.", "sentB": "After the most recent scheduled meeting in November 2015, the DSMB recommended continuing the CHABLIS-SC1 and BRIGHT-SC clinical studies.", "type": 2, "words": ["<tag1>", "After", "the", "most", "recent", "scheduled", "meeting", "in", "October", "2014,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies.", "<tag2>", "After", "the", "most", "recent", "scheduled", "meeting", "in", "November", "2015,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies.", "<tag3>"], "wordsA": ["After", "the", "most", "recent", "scheduled", "meeting", "in", "October", "2014,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies."], "wordsB": ["After", "the", "most", "recent", "scheduled", "meeting", "in", "November", "2015,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p49_s0", "idA": "1316175_15_item1_p23_s0", "sentA": "In February 2015, an interim analysis of CHABLIS-SC1 was conducted by an independent un-blinded statistician, who evaluated at a pre-specified time point, the proportion of responders to the systemic lupus erythematous SRI-6 responder index, and recommended the study to continue to completion as planned.", "sentB": "In March 2015, an interim futility analysis of BRIGHT-SC study was conducted by an independent unblinded statistician, who evaluated several important biomarkers of renal disease in patients who had completed at least 8 weeks of treatment and recommended the study to continue to completion as planned.", "type": 2, "words": ["<tag1>", "In", "February", "2015,", "an", "interim", "analysis", "of", "CHABLIS-SC1", "was", "conducted", "by", "an", "independent", "un-blinded", "statistician,", "who", "evaluated", "at", "a", "pre-specified", "time", "point,", "the", "proportion", "of", "responders", "to", "the", "systemic", "lupus", "erythematous", "SRI-6", "responder", "index,", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned.", "<tag2>", "In", "March", "2015,", "an", "interim", "futility", "analysis", "of", "BRIGHT-SC", "study", "was", "conducted", "by", "an", "independent", "unblinded", "statistician,", "who", "evaluated", "several", "important", "biomarkers", "of", "renal", "disease", "in", "patients", "who", "had", "completed", "at", "least", "8", "weeks", "of", "treatment", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned.", "<tag3>"], "wordsA": ["In", "February", "2015,", "an", "interim", "analysis", "of", "CHABLIS-SC1", "was", "conducted", "by", "an", "independent", "un-blinded", "statistician,", "who", "evaluated", "at", "a", "pre-specified", "time", "point,", "the", "proportion", "of", "responders", "to", "the", "systemic", "lupus", "erythematous", "SRI-6", "responder", "index,", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned."], "wordsB": ["In", "March", "2015,", "an", "interim", "futility", "analysis", "of", "BRIGHT-SC", "study", "was", "conducted", "by", "an", "independent", "unblinded", "statistician,", "who", "evaluated", "several", "important", "biomarkers", "of", "renal", "disease", "in", "patients", "who", "had", "completed", "at", "least", "8", "weeks", "of", "treatment", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p79_s2", "idA": "1316175_15_item1_p23_s2", "sentA": "Rather, the analysis suggests that the observed data conforms with the assumptions upon which the trial was designed.", "sentB": "The median body weight of subjects in this trial was 50 kg, for which the corresponding liprotamase dose was 650 U lipase/kg/meal or snack.", "type": 2, "words": ["<tag1>", "Rather,", "the", "analysis", "suggests", "that", "the", "observed", "data", "conforms", "with", "the", "assumptions", "upon", "which", "the", "trial", "was", "designed.", "<tag2>", "The", "median", "body", "weight", "of", "subjects", "in", "this", "trial", "was", "50", "kg,", "for", "which", "the", "corresponding", "liprotamase", "dose", "was", "650", "U", "lipase/kg/meal", "or", "snack.", "<tag3>"], "wordsA": ["Rather,", "the", "analysis", "suggests", "that", "the", "observed", "data", "conforms", "with", "the", "assumptions", "upon", "which", "the", "trial", "was", "designed."], "wordsB": ["The", "median", "body", "weight", "of", "subjects", "in", "this", "trial", "was", "50", "kg,", "for", "which", "the", "corresponding", "liprotamase", "dose", "was", "650", "U", "lipase/kg/meal", "or", "snack."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p35_s1", "idA": "1316175_15_item1_p24_s1", "sentA": "Prior to the interim analysis and in response to input from our Scientific Advisory Board who evaluated the published clinical data from other recent lupus studies with BAFF inhibitors, we modified the primary endpoint of CHABLIS-SC1 from a comparison of the proportion of responders to the SRI-8 responder index to a comparison of the proportion of responders to the SRI-6 responder index (previously a secondary endpoint of the study).", "sentB": "Prior to the interim analysis and on the advice of our Scientific Advisory Board who evaluated the published clinical data from other recent lupus studies with BAFF inhibitors, we modified the primary endpoint of CHABLIS-SC1 from a comparison of the proportion of responders to the SRI-8 responder index to a comparison of the proportion of responders to the SRI-6 responder index (previously a secondary endpoint of the study) as data, including emerging observations with tabalumab (Isenberg et al ., Annual Meeting of the American College of Rheumatology, November 2014), suggest that SRI-6 responder rates are consistent and stable across multiple trials.", "type": 2, "words": ["<tag1>", "Prior", "to", "the", "interim", "analysis", "and", "in", "response", "to", "input", "from", "our", "Scientific", "Advisory", "Board", "who", "evaluated", "the", "published", "clinical", "data", "from", "other", "recent", "lupus", "studies", "with", "BAFF", "inhibitors,", "we", "modified", "the", "primary", "endpoint", "of", "CHABLIS-SC1", "from", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-8", "responder", "index", "to", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-6", "responder", "index", "(previously", "a", "secondary", "endpoint", "of", "the", "study).", "<tag2>", "Prior", "to", "the", "interim", "analysis", "and", "on", "the", "advice", "of", "our", "Scientific", "Advisory", "Board", "who", "evaluated", "the", "published", "clinical", "data", "from", "other", "recent", "lupus", "studies", "with", "BAFF", "inhibitors,", "we", "modified", "the", "primary", "endpoint", "of", "CHABLIS-SC1", "from", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-8", "responder", "index", "to", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-6", "responder", "index", "(previously", "a", "secondary", "endpoint", "of", "the", "study)", "as", "data,", "including", "emerging", "observations", "with", "tabalumab", "(Isenberg", "et", "al", ".,", "Annual", "Meeting", "of", "the", "American", "College", "of", "Rheumatology,", "November", "2014),", "suggest", "that", "SRI-6", "responder", "rates", "are", "consistent", "and", "stable", "across", "multiple", "trials.", "<tag3>"], "wordsA": ["Prior", "to", "the", "interim", "analysis", "and", "in", "response", "to", "input", "from", "our", "Scientific", "Advisory", "Board", "who", "evaluated", "the", "published", "clinical", "data", "from", "other", "recent", "lupus", "studies", "with", "BAFF", "inhibitors,", "we", "modified", "the", "primary", "endpoint", "of", "CHABLIS-SC1", "from", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-8", "responder", "index", "to", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-6", "responder", "index", "(previously", "a", "secondary", "endpoint", "of", "the", "study)."], "wordsB": ["Prior", "to", "the", "interim", "analysis", "and", "on", "the", "advice", "of", "our", "Scientific", "Advisory", "Board", "who", "evaluated", "the", "published", "clinical", "data", "from", "other", "recent", "lupus", "studies", "with", "BAFF", "inhibitors,", "we", "modified", "the", "primary", "endpoint", "of", "CHABLIS-SC1", "from", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-8", "responder", "index", "to", "a", "comparison", "of", "the", "proportion", "of", "responders", "to", "the", "SRI-6", "responder", "index", "(previously", "a", "secondary", "endpoint", "of", "the", "study)", "as", "data,", "including", "emerging", "observations", "with", "tabalumab", "(Isenberg", "et", "al", ".,", "Annual", "Meeting", "of", "the", "American", "College", "of", "Rheumatology,", "November", "2014),", "suggest", "that", "SRI-6", "responder", "rates", "are", "consistent", "and", "stable", "across", "multiple", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p36_s0", "idA": "1316175_15_item1_p25_s0", "sentA": "In the first quarter of 2014, we submitted the protocol to the FDA for our second lupus registration study, CHABLIS-SC2.", "sentB": "We submitted a study protocol for our second lupus study, CHABLIS 7.5 (formerly named CHABLIS-SC2), to the FDA in the third quarter of 2015.", "type": 2, "words": ["<tag1>", "In", "the", "first", "quarter", "of", "2014,", "we", "submitted", "the", "protocol", "to", "the", "FDA", "for", "our", "second", "lupus", "registration", "study,", "CHABLIS-SC2.", "<tag2>", "We", "submitted", "a", "study", "protocol", "for", "our", "second", "lupus", "study,", "CHABLIS", "7.5", "(formerly", "named", "CHABLIS-SC2),", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2015.", "<tag3>"], "wordsA": ["In", "the", "first", "quarter", "of", "2014,", "we", "submitted", "the", "protocol", "to", "the", "FDA", "for", "our", "second", "lupus", "registration", "study,", "CHABLIS-SC2."], "wordsB": ["We", "submitted", "a", "study", "protocol", "for", "our", "second", "lupus", "study,", "CHABLIS", "7.5", "(formerly", "named", "CHABLIS-SC2),", "to", "the", "FDA", "in", "the", "third", "quarter", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p38_s1", "idA": "1316175_15_item1_p26_s3", "sentA": "In Asia, routine urinalyses are often performed for school children, and renal biopsies are performed for any patients with asymptomatic hematuria, thus raising the reported prevalence of the disease.", "sentB": "In Asia, a higher reported prevalence is attributed to the routine urinalyses that are often performed for school children, and renal biopsies are performed for any patients with asymptomatic hematuria.", "type": 2, "words": ["<tag1>", "In", "Asia,", "routine", "urinalyses", "are", "often", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "any", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease.", "<tag2>", "In", "Asia,", "a", "higher", "reported", "prevalence", "is", "attributed", "to", "the", "routine", "urinalyses", "that", "are", "often", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "any", "patients", "with", "asymptomatic", "hematuria.", "<tag3>"], "wordsA": ["In", "Asia,", "routine", "urinalyses", "are", "often", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "any", "patients", "with", "asymptomatic", "hematuria,", "thus", "raising", "the", "reported", "prevalence", "of", "the", "disease."], "wordsB": ["In", "Asia,", "a", "higher", "reported", "prevalence", "is", "attributed", "to", "the", "routine", "urinalyses", "that", "are", "often", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "any", "patients", "with", "asymptomatic", "hematuria."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p43_s0", "idA": "1316175_15_item1_p32_s0", "sentA": "Similar to patients with other autoimmune diseases such as lupus, in IgA nephropathy, elevated levels of BAFF are associated with severity of disease activity.", "sentB": "Similar to patients with other autoimmune diseases such as lupus, in IgA nephropathy, elevated levels of BAFF are associated with histological severity of disease in kidney tissue.", "type": 2, "words": ["<tag1>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "severity", "of", "disease", "activity.", "<tag2>", "Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "histological", "severity", "of", "disease", "in", "kidney", "tissue.", "<tag3>"], "wordsA": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "severity", "of", "disease", "activity."], "wordsB": ["Similar", "to", "patients", "with", "other", "autoimmune", "diseases", "such", "as", "lupus,", "in", "IgA", "nephropathy,", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "histological", "severity", "of", "disease", "in", "kidney", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p45_s0", "idA": "1316175_15_item1_p34_s0", "sentA": "The BRIGHT-SC study is a Phase 2/3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "sentB": "The BRIGHT-SC study is a Phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "study", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag2>", "The", "BRIGHT-SC", "study", "is", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "study", "is", "a", "Phase", "2/3", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "wordsB": ["The", "BRIGHT-SC", "study", "is", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p45_s1", "idA": "1316175_15_item1_p34_s1", "sentA": "We intend to enroll up to 200 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "Enrollment criteria are biopsy-proven IgA nephropathy and proteinuria greater than one gram per 24 hours (1g/24hr).", "type": 2, "words": ["<tag1>", "We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "Enrollment", "criteria", "are", "biopsy-proven", "IgA", "nephropathy", "and", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr).", "<tag3>"], "wordsA": ["We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["Enrollment", "criteria", "are", "biopsy-proven", "IgA", "nephropathy", "and", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p46_s0", "idA": "1316175_15_item1_p34_s1", "sentA": "We intend to enroll up to 200 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "Patients must be receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "Patients", "must", "be", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag3>"], "wordsA": ["We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["Patients", "must", "be", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s0", "idA": "1316175_15_item1_p34_s1", "sentA": "We intend to enroll up to 200 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "Following results from previous studies in SLE, namely the PEARL-SC phase 2 clinical study, where patients, with baseline urinary protein excretion ( UPE ) of greater than one gram per 24 hours, demonstrated statistically significant reductions in urinary protein after 24 weeks, we initiated the BRIGHT-SC clinical study to evaluate the effects of blisibimod treatment in patients with IgAN.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "Following", "results", "from", "previous", "studies", "in", "SLE,", "namely", "the", "PEARL-SC", "phase", "2", "clinical", "study,", "where", "patients,", "with", "baseline", "urinary", "protein", "excretion", "(", "UPE", ")", "of", "greater", "than", "one", "gram", "per", "24", "hours,", "demonstrated", "statistically", "significant", "reductions", "in", "urinary", "protein", "after", "24", "weeks,", "we", "initiated", "the", "BRIGHT-SC", "clinical", "study", "to", "evaluate", "the", "effects", "of", "blisibimod", "treatment", "in", "patients", "with", "IgAN.", "<tag3>"], "wordsA": ["We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["Following", "results", "from", "previous", "studies", "in", "SLE,", "namely", "the", "PEARL-SC", "phase", "2", "clinical", "study,", "where", "patients,", "with", "baseline", "urinary", "protein", "excretion", "(", "UPE", ")", "of", "greater", "than", "one", "gram", "per", "24", "hours,", "demonstrated", "statistically", "significant", "reductions", "in", "urinary", "protein", "after", "24", "weeks,", "we", "initiated", "the", "BRIGHT-SC", "clinical", "study", "to", "evaluate", "the", "effects", "of", "blisibimod", "treatment", "in", "patients", "with", "IgAN."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s5", "idA": "1316175_15_item1_p34_s1", "sentA": "We intend to enroll up to 200 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "CR is defined as the proportion of patients with baseline UPE of greater than two grams per 24 hours, achieving UPE of less than one gram per 24 hours or a 50% reduction in UPE from baseline, and the proportion of patients with baseline UPE between one and two grams per 24 hours, achieving UPE of less than one gram per 24 hours and a 50% reduction from baseline.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "CR", "is", "defined", "as", "the", "proportion", "of", "patients", "with", "baseline", "UPE", "of", "greater", "than", "two", "grams", "per", "24", "hours,", "achieving", "UPE", "of", "less", "than", "one", "gram", "per", "24", "hours", "or", "a", "50%", "reduction", "in", "UPE", "from", "baseline,", "and", "the", "proportion", "of", "patients", "with", "baseline", "UPE", "between", "one", "and", "two", "grams", "per", "24", "hours,", "achieving", "UPE", "of", "less", "than", "one", "gram", "per", "24", "hours", "and", "a", "50%", "reduction", "from", "baseline.", "<tag3>"], "wordsA": ["We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["CR", "is", "defined", "as", "the", "proportion", "of", "patients", "with", "baseline", "UPE", "of", "greater", "than", "two", "grams", "per", "24", "hours,", "achieving", "UPE", "of", "less", "than", "one", "gram", "per", "24", "hours", "or", "a", "50%", "reduction", "in", "UPE", "from", "baseline,", "and", "the", "proportion", "of", "patients", "with", "baseline", "UPE", "between", "one", "and", "two", "grams", "per", "24", "hours,", "achieving", "UPE", "of", "less", "than", "one", "gram", "per", "24", "hours", "and", "a", "50%", "reduction", "from", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s6", "idA": "1316175_15_item1_p34_s1", "sentA": "We intend to enroll up to 200 patients with biopsy-proven IgA nephropathy who have proteinuria greater than one gram per 24 hours (1g/24hr) and are receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "PR is defined as the proportion of patients achieving urinary protein excretion ( UPE ) of less than or equal to one gram per 24 hours.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "PR", "is", "defined", "as", "the", "proportion", "of", "patients", "achieving", "urinary", "protein", "excretion", "(", "UPE", ")", "of", "less", "than", "or", "equal", "to", "one", "gram", "per", "24", "hours.", "<tag3>"], "wordsA": ["We", "intend", "to", "enroll", "up", "to", "200", "patients", "with", "biopsy-proven", "IgA", "nephropathy", "who", "have", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)", "and", "are", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["PR", "is", "defined", "as", "the", "proportion", "of", "patients", "achieving", "urinary", "protein", "excretion", "(", "UPE", ")", "of", "less", "than", "or", "equal", "to", "one", "gram", "per", "24", "hours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p15_s0", "idA": "1316175_15_item1_p34_s2", "sentA": "We initiated our BRIGHT-SC study in the second quarter of 2013.", "sentB": "We initiated the SOLUTION study in the third quarter of 2015.", "type": 2, "words": ["<tag1>", "We", "initiated", "our", "BRIGHT-SC", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "We", "initiated", "the", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015.", "<tag3>"], "wordsA": ["We", "initiated", "our", "BRIGHT-SC", "study", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["We", "initiated", "the", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p47_s0", "idA": "1316175_15_item1_p34_s2", "sentA": "We initiated our BRIGHT-SC study in the second quarter of 2013.", "sentB": "The BRIGHT-SC study was initiated in the second quarter of 2013.", "type": 2, "words": ["<tag1>", "We", "initiated", "our", "BRIGHT-SC", "study", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "The", "BRIGHT-SC", "study", "was", "initiated", "in", "the", "second", "quarter", "of", "2013.", "<tag3>"], "wordsA": ["We", "initiated", "our", "BRIGHT-SC", "study", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["The", "BRIGHT-SC", "study", "was", "initiated", "in", "the", "second", "quarter", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p48_s0", "idA": "1316175_15_item1_p34_s4", "sentA": "The BRIGHT-SC clinical study is currently recruiting patients primarily in Southeast Asia.", "sentB": "The BRIGHT-SC clinical study has enrolled patients in Southeast Asia, the European Union ( EU ) and Eastern Europe.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "clinical", "study", "is", "currently", "recruiting", "patients", "primarily", "in", "Southeast", "Asia.", "<tag2>", "The", "BRIGHT-SC", "clinical", "study", "has", "enrolled", "patients", "in", "Southeast", "Asia,", "the", "European", "Union", "(", "EU", ")", "and", "Eastern", "Europe.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "clinical", "study", "is", "currently", "recruiting", "patients", "primarily", "in", "Southeast", "Asia."], "wordsB": ["The", "BRIGHT-SC", "clinical", "study", "has", "enrolled", "patients", "in", "Southeast", "Asia,", "the", "European", "Union", "(", "EU", ")", "and", "Eastern", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p36_s4", "idA": "1316175_15_item1_p34_s5", "sentA": "We intend to expand the study in the EU, North America and Latin America in 2015 with the goal to complete enrollment by the first half of 2016.", "sentB": "We plan to initiate the CHABLIS 7.5 study in the first half of 2016.", "type": 2, "words": ["<tag1>", "We", "intend", "to", "expand", "the", "study", "in", "the", "EU,", "North", "America", "and", "Latin", "America", "in", "2015", "with", "the", "goal", "to", "complete", "enrollment", "by", "the", "first", "half", "of", "2016.", "<tag2>", "We", "plan", "to", "initiate", "the", "CHABLIS", "7.5", "study", "in", "the", "first", "half", "of", "2016.", "<tag3>"], "wordsA": ["We", "intend", "to", "expand", "the", "study", "in", "the", "EU,", "North", "America", "and", "Latin", "America", "in", "2015", "with", "the", "goal", "to", "complete", "enrollment", "by", "the", "first", "half", "of", "2016."], "wordsB": ["We", "plan", "to", "initiate", "the", "CHABLIS", "7.5", "study", "in", "the", "first", "half", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p36_s2", "idA": "1316175_15_item1_p34_s6", "sentA": "We plan to conduct an interim futility analysis in the first quarter of 2015 to determine the effect of blisibimod on proteinuria after a minimum of eight weeks of treatment.", "sentB": "This study will evaluate the effect of blisibimod on top of standard-of-care medication in patients with severe, seropositive SLE that is inadequately controlled with corticosteroids.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment.", "<tag2>", "This", "study", "will", "evaluate", "the", "effect", "of", "blisibimod", "on", "top", "of", "standard-of-care", "medication", "in", "patients", "with", "severe,", "seropositive", "SLE", "that", "is", "inadequately", "controlled", "with", "corticosteroids.", "<tag3>"], "wordsA": ["We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment."], "wordsB": ["This", "study", "will", "evaluate", "the", "effect", "of", "blisibimod", "on", "top", "of", "standard-of-care", "medication", "in", "patients", "with", "severe,", "seropositive", "SLE", "that", "is", "inadequately", "controlled", "with", "corticosteroids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p49_s1", "idA": "1316175_15_item1_p34_s6", "sentA": "We plan to conduct an interim futility analysis in the first quarter of 2015 to determine the effect of blisibimod on proteinuria after a minimum of eight weeks of treatment.", "sentB": "We plan to conduct an analysis of the clinical data in the first half of 2016 when more than 40 patients have completed 6 months of treatment, followed by a longer-term treatment data in the second half of 2016 when a majority of the patients have completed one year of treatment.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment.", "<tag2>", "We", "plan", "to", "conduct", "an", "analysis", "of", "the", "clinical", "data", "in", "the", "first", "half", "of", "2016", "when", "more", "than", "40", "patients", "have", "completed", "6", "months", "of", "treatment,", "followed", "by", "a", "longer-term", "treatment", "data", "in", "the", "second", "half", "of", "2016", "when", "a", "majority", "of", "the", "patients", "have", "completed", "one", "year", "of", "treatment.", "<tag3>"], "wordsA": ["We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment."], "wordsB": ["We", "plan", "to", "conduct", "an", "analysis", "of", "the", "clinical", "data", "in", "the", "first", "half", "of", "2016", "when", "more", "than", "40", "patients", "have", "completed", "6", "months", "of", "treatment,", "followed", "by", "a", "longer-term", "treatment", "data", "in", "the", "second", "half", "of", "2016", "when", "a", "majority", "of", "the", "patients", "have", "completed", "one", "year", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s3", "idA": "1316175_15_item1_p34_s6", "sentA": "We plan to conduct an interim futility analysis in the first quarter of 2015 to determine the effect of blisibimod on proteinuria after a minimum of eight weeks of treatment.", "sentB": "We plan to conduct a proof-of-concept efficacy analysis when substantially all patients have received a minimum of six months of therapy in Q2 2016.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment.", "<tag2>", "We", "plan", "to", "conduct", "a", "proof-of-concept", "efficacy", "analysis", "when", "substantially", "all", "patients", "have", "received", "a", "minimum", "of", "six", "months", "of", "therapy", "in", "Q2", "2016.", "<tag3>"], "wordsA": ["We", "plan", "to", "conduct", "an", "interim", "futility", "analysis", "in", "the", "first", "quarter", "of", "2015", "to", "determine", "the", "effect", "of", "blisibimod", "on", "proteinuria", "after", "a", "minimum", "of", "eight", "weeks", "of", "treatment."], "wordsB": ["We", "plan", "to", "conduct", "a", "proof-of-concept", "efficacy", "analysis", "when", "substantially", "all", "patients", "have", "received", "a", "minimum", "of", "six", "months", "of", "therapy", "in", "Q2", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p13_s0", "idA": "1316175_15_item1_p40_s0", "sentA": "We believe liprotamase is potentially the first soluble, stable and non-porcine derived enzyme product to offer a novel solution to patients who are unable to maintain appropriate nutritional health with existing enzyme therapies.", "sentB": "We believe liprotamase is potentially the first soluble, stable and non-porcine derived enzyme product to offer a novel solution to patients who are unable to maintain appropriate nutritional health.", "type": 2, "words": ["<tag1>", "We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health", "with", "existing", "enzyme", "therapies.", "<tag2>", "We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health.", "<tag3>"], "wordsA": ["We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health", "with", "existing", "enzyme", "therapies."], "wordsB": ["We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p14_s0", "idA": "1316175_15_item1_p41_s0", "sentA": "Liprotamase s chemical characteristics, unlike currently available PERTs, make it ideal for powder formulation as either a capsule or sachet product, which can be conveniently co-administered with a small volume of water.", "sentB": "Liprotamase s chemical characteristics, unlike currently available PERTs, make it ideal for powder formulation as either a capsule, or sachet of powder for oral solution which can be conveniently administered in solution in a small volume of water.", "type": 2, "words": ["<tag1>", "Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule", "or", "sachet", "product,", "which", "can", "be", "conveniently", "co-administered", "with", "a", "small", "volume", "of", "water.", "<tag2>", "Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule,", "or", "sachet", "of", "powder", "for", "oral", "solution", "which", "can", "be", "conveniently", "administered", "in", "solution", "in", "a", "small", "volume", "of", "water.", "<tag3>"], "wordsA": ["Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule", "or", "sachet", "product,", "which", "can", "be", "conveniently", "co-administered", "with", "a", "small", "volume", "of", "water."], "wordsB": ["Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule,", "or", "sachet", "of", "powder", "for", "oral", "solution", "which", "can", "be", "conveniently", "administered", "in", "solution", "in", "a", "small", "volume", "of", "water."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p15_s2", "idA": "1316175_15_item1_p42_s2", "sentA": "This pivotal study is intended to evaluate the non-inferiority of liprotamase compared with other commercially available PERT in a population enriched for PERT responders.", "sentB": "This pivotal study is intended to evaluate the non-inferiority of liprotamase compared with another commercially available PERT in a population enriched for PERT responders and will enroll up to 150 patients in the United States and Europe.", "type": 2, "words": ["<tag1>", "This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "other", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders.", "<tag2>", "This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders", "and", "will", "enroll", "up", "to", "150", "patients", "in", "the", "United", "States", "and", "Europe.", "<tag3>"], "wordsA": ["This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "other", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders."], "wordsB": ["This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders", "and", "will", "enroll", "up", "to", "150", "patients", "in", "the", "United", "States", "and", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p15_s3", "idA": "1316175_15_item1_p42_s3", "sentA": "We believe the SOLUTION study may offer a number of potential opportunities for differentiation versus the currently marketed PERTs, including:", "sentB": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "type": 2, "words": ["<tag1>", "We", "believe", "the", "SOLUTION", "study", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:", "<tag2>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag3>"], "wordsA": ["We", "believe", "the", "SOLUTION", "study", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:"], "wordsB": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p15_s6", "idA": "1316175_15_item1_p42_s3", "sentA": "We believe the SOLUTION study may offer a number of potential opportunities for differentiation versus the currently marketed PERTs, including:", "sentB": "We believe the SOLUTION and SIMPLICITY studies may offer a number of potential opportunities for differentiation versus the currently marketed PERTs, including:", "type": 2, "words": ["<tag1>", "We", "believe", "the", "SOLUTION", "study", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:", "<tag2>", "We", "believe", "the", "SOLUTION", "and", "SIMPLICITY", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:", "<tag3>"], "wordsA": ["We", "believe", "the", "SOLUTION", "study", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:"], "wordsB": ["We", "believe", "the", "SOLUTION", "and", "SIMPLICITY", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p52_s2", "idA": "1316175_15_item1_p44_s2", "sentA": "The course of the disease is unpredictable, with periods of illness, called flares, alternating with remission.", "sentB": "The course of the disease is unpredictable, with periods of disease worsening, called flares.", "type": 2, "words": ["<tag1>", "The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares,", "alternating", "with", "remission.", "<tag2>", "The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "disease", "worsening,", "called", "flares.", "<tag3>"], "wordsA": ["The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "illness,", "called", "flares,", "alternating", "with", "remission."], "wordsB": ["The", "course", "of", "the", "disease", "is", "unpredictable,", "with", "periods", "of", "disease", "worsening,", "called", "flares."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p54_s1", "idA": "1316175_15_item1_p45_s2", "sentA": "Based on the results from our PEARL-SC study, we believe patients in the moderate to severe disease categories, approximately 30,000 to 40,000 people, are likely to benefit most from treatment with blisibimod and this is the population we are enrolling in our Phase 3 CHABLIS-SC studies.", "sentB": "Based on the results from our PEARL-SC study, we believe patients in the moderate-to-severe lupus, approximately 30,000 to 40,000 people, are likely to benefit most from treatment with blisibimod.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "results", "from", "our", "PEARL-SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "approximately", "30,000", "to", "40,000", "people,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.", "<tag2>", "Based", "on", "the", "results", "from", "our", "PEARL-SC", "study,", "we", "believe", "patients", "in", "the", "moderate-to-severe", "lupus,", "approximately", "30,000", "to", "40,000", "people,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod.", "<tag3>"], "wordsA": ["Based", "on", "the", "results", "from", "our", "PEARL-SC", "study,", "we", "believe", "patients", "in", "the", "moderate", "to", "severe", "disease", "categories,", "approximately", "30,000", "to", "40,000", "people,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod", "and", "this", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies."], "wordsB": ["Based", "on", "the", "results", "from", "our", "PEARL-SC", "study,", "we", "believe", "patients", "in", "the", "moderate-to-severe", "lupus,", "approximately", "30,000", "to", "40,000", "people,", "are", "likely", "to", "benefit", "most", "from", "treatment", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p57_s0", "idA": "1316175_15_item1_p47_s1", "sentA": "Evidence has emerged that over-expression of BAFF plays an important role in this disease process.", "sentB": "Evidence has emerged that over-expression of BAFF correlates with disease severity in patients (Petri M .", "type": 2, "words": ["<tag1>", "Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "plays", "an", "important", "role", "in", "this", "disease", "process.", "<tag2>", "Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "correlates", "with", "disease", "severity", "in", "patients", "(Petri", "M", ".", "<tag3>"], "wordsA": ["Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "plays", "an", "important", "role", "in", "this", "disease", "process."], "wordsB": ["Evidence", "has", "emerged", "that", "over-expression", "of", "BAFF", "correlates", "with", "disease", "severity", "in", "patients", "(Petri", "M", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p58_s1", "idA": "1316175_15_item1_p47_s3", "sentA": "In addition, treatment of lupus-prone mice with blisibimod ameliorates the disease.", "sentB": "In addition, treatment of lupus-prone mice with blisibimod ameliorates the disease (Hsu H, Khare S.D., Lee F, Miner K, Hu YL, Stolina M., Hawkins N., Chen Q., Ho S.Y., Min H., Xiong F., Boone T., Zack D.J., A Novel Modality of BAFF-Specific Inhibitor AMG623 Peptibody Reduces B-cell Number and Improves Outcomes in Murine Models of Autoimmune Disease . 2012, Clinical and Experimental Rheumatology, 30(2): 197-201).", "type": 2, "words": ["<tag1>", "In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease.", "<tag2>", "In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease", "(Hsu", "H,", "Khare", "S.D.,", "Lee", "F,", "Miner", "K,", "Hu", "YL,", "Stolina", "M.,", "Hawkins", "N.,", "Chen", "Q.,", "Ho", "S.Y.,", "Min", "H.,", "Xiong", "F.,", "Boone", "T.,", "Zack", "D.J.,", "A", "Novel", "Modality", "of", "BAFF-Specific", "Inhibitor", "AMG623", "Peptibody", "Reduces", "B-cell", "Number", "and", "Improves", "Outcomes", "in", "Murine", "Models", "of", "Autoimmune", "Disease", ".", "2012,", "Clinical", "and", "Experimental", "Rheumatology,", "30(2):", "197-201).", "<tag3>"], "wordsA": ["In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease."], "wordsB": ["In", "addition,", "treatment", "of", "lupus-prone", "mice", "with", "blisibimod", "ameliorates", "the", "disease", "(Hsu", "H,", "Khare", "S.D.,", "Lee", "F,", "Miner", "K,", "Hu", "YL,", "Stolina", "M.,", "Hawkins", "N.,", "Chen", "Q.,", "Ho", "S.Y.,", "Min", "H.,", "Xiong", "F.,", "Boone", "T.,", "Zack", "D.J.,", "A", "Novel", "Modality", "of", "BAFF-Specific", "Inhibitor", "AMG623", "Peptibody", "Reduces", "B-cell", "Number", "and", "Improves", "Outcomes", "in", "Murine", "Models", "of", "Autoimmune", "Disease", ".", "2012,", "Clinical", "and", "Experimental", "Rheumatology,", "30(2):", "197-201)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p64_s1", "idA": "1316175_15_item1_p53_s1", "sentA": "In the United States, IgA nephropathy is considered an orphan disease as it is believed to affect approximately 130,000 people annually, although this number might prove to be higher with more robust screening.", "sentB": "In the United States, IgA nephropathy is considered an orphan disease as it is believed to affect approximately 130,000 people annually.", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually,", "although", "this", "number", "might", "prove", "to", "be", "higher", "with", "more", "robust", "screening.", "<tag2>", "In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually,", "although", "this", "number", "might", "prove", "to", "be", "higher", "with", "more", "robust", "screening."], "wordsB": ["In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p66_s0", "idA": "1316175_15_item1_p57_s0", "sentA": "In December 2011, we completed the manufacturing site transfer from Amgen Inc., or Amgen, to our contract manufacturing organization ( CMO ), Fujifilm Diosynth Bioservices ( Fujifilm ).", "sentB": "In December 2011, we completed the manufacturing site transfer from Amgen to our contract manufacturing organization ( CMO ), Fujifilm Diosynth Bioservices ( Fujifilm ).", "type": 2, "words": ["<tag1>", "In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization", "(", "CMO", "),", "Fujifilm", "Diosynth", "Bioservices", "(", "Fujifilm", ").", "<tag2>", "In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "to", "our", "contract", "manufacturing", "organization", "(", "CMO", "),", "Fujifilm", "Diosynth", "Bioservices", "(", "Fujifilm", ").", "<tag3>"], "wordsA": ["In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "Inc.,", "or", "Amgen,", "to", "our", "contract", "manufacturing", "organization", "(", "CMO", "),", "Fujifilm", "Diosynth", "Bioservices", "(", "Fujifilm", ")."], "wordsB": ["In", "December", "2011,", "we", "completed", "the", "manufacturing", "site", "transfer", "from", "Amgen", "to", "our", "contract", "manufacturing", "organization", "(", "CMO", "),", "Fujifilm", "Diosynth", "Bioservices", "(", "Fujifilm", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p66_s2", "idA": "1316175_15_item1_p57_s2", "sentA": "Two batches of blisibimod produced under U.S. and EU good manufacturing procedures ( GMPs ), at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "sentB": "Three batches of blisibimod produced under U.S. and EU good manufacturing procedures ( GMPs ), at the 3,000 liter scale passed all physical quality specifications and comparability assessments.", "type": 2, "words": ["<tag1>", "Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures", "(", "GMPs", "),", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag2>", "Three", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures", "(", "GMPs", "),", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments.", "<tag3>"], "wordsA": ["Two", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures", "(", "GMPs", "),", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "wordsB": ["Three", "batches", "of", "blisibimod", "produced", "under", "U.S.", "and", "EU", "good", "manufacturing", "procedures", "(", "GMPs", "),", "at", "the", "3,000", "liter", "scale", "passed", "all", "physical", "quality", "specifications", "and", "comparability", "assessments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p67_s0", "idA": "1316175_15_item1_p58_s0", "sentA": "We have successfully manufactured blisibimod at launch scale volumes to support the CHABLIS-SC1 and BRIGHT-SC studies.", "sentB": "We have successfully manufactured blisibimod at launch scale volumes to support the CHABLIS-SC1, CHABLIS-7.5 and BRIGHT-SC studies.", "type": 2, "words": ["<tag1>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies.", "<tag2>", "We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1,", "CHABLIS-7.5", "and", "BRIGHT-SC", "studies.", "<tag3>"], "wordsA": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "studies."], "wordsB": ["We", "have", "successfully", "manufactured", "blisibimod", "at", "launch", "scale", "volumes", "to", "support", "the", "CHABLIS-SC1,", "CHABLIS-7.5", "and", "BRIGHT-SC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p67_s1", "idA": "1316175_15_item1_p58_s1", "sentA": "We are currently evaluating an auto injector strategy for the product presentation.", "sentB": "We are currently evaluating an auto injector strategy for use with the subcutaneous product presentation of blisibimod.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "evaluating", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation.", "<tag2>", "We", "are", "currently", "evaluating", "an", "auto", "injector", "strategy", "for", "use", "with", "the", "subcutaneous", "product", "presentation", "of", "blisibimod.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "an", "auto", "injector", "strategy", "for", "the", "product", "presentation."], "wordsB": ["We", "are", "currently", "evaluating", "an", "auto", "injector", "strategy", "for", "use", "with", "the", "subcutaneous", "product", "presentation", "of", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p70_s2", "idA": "1316175_15_item1_p59_s2", "sentA": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) are planned to be multicenter, placebo-controlled, randomized, double-blind studies intended to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "sentB": "The Phase 3 studies (CHABLIS-SC1 and CHABLIS7.5) are planned to be multicenter, placebo-controlled, randomized, double-blind studies intended to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active lupus (SELENA-SLEDAI 10) who require corticosteroid therapy in addition to standard of care for treatment of their disease.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag2>", "The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS7.5)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease.", "<tag3>"], "wordsA": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS-SC2)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "wordsB": ["The", "Phase", "3", "studies", "(CHABLIS-SC1", "and", "CHABLIS7.5)", "are", "planned", "to", "be", "multicenter,", "placebo-controlled,", "randomized,", "double-blind", "studies", "intended", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "patients", "with", "clinically", "active", "lupus", "(SELENA-SLEDAI", "10)", "who", "require", "corticosteroid", "therapy", "in", "addition", "to", "standard", "of", "care", "for", "treatment", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p70_s3", "idA": "1316175_15_item1_p59_s3", "sentA": "The design of the second Phase 3 study, CHABLIS-SC2, will be based on input from clinical experts as well as evaluation from recently reported data with tabalumab.", "sentB": "The design of the second Phase 3 study, CHABLIS-7.5, will be based on input advice from clinical experts as well as learnings from recently reported data from clinical trials in SLE.", "type": 2, "words": ["<tag1>", "The", "design", "of", "the", "second", "Phase", "3", "study,", "CHABLIS-SC2,", "will", "be", "based", "on", "input", "from", "clinical", "experts", "as", "well", "as", "evaluation", "from", "recently", "reported", "data", "with", "tabalumab.", "<tag2>", "The", "design", "of", "the", "second", "Phase", "3", "study,", "CHABLIS-7.5,", "will", "be", "based", "on", "input", "advice", "from", "clinical", "experts", "as", "well", "as", "learnings", "from", "recently", "reported", "data", "from", "clinical", "trials", "in", "SLE.", "<tag3>"], "wordsA": ["The", "design", "of", "the", "second", "Phase", "3", "study,", "CHABLIS-SC2,", "will", "be", "based", "on", "input", "from", "clinical", "experts", "as", "well", "as", "evaluation", "from", "recently", "reported", "data", "with", "tabalumab."], "wordsB": ["The", "design", "of", "the", "second", "Phase", "3", "study,", "CHABLIS-7.5,", "will", "be", "based", "on", "input", "advice", "from", "clinical", "experts", "as", "well", "as", "learnings", "from", "recently", "reported", "data", "from", "clinical", "trials", "in", "SLE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p70_s4", "idA": "1316175_15_item1_p59_s4", "sentA": "The study design is expected to be finalized in the second half of 2015.", "sentB": "The CHABLIS-SC1 study has completed enrollment of 442 patients, and the CHABLIS 7.5 protocol was submitted to the FDA in the second half of 2015.", "type": 2, "words": ["<tag1>", "The", "study", "design", "is", "expected", "to", "be", "finalized", "in", "the", "second", "half", "of", "2015.", "<tag2>", "The", "CHABLIS-SC1", "study", "has", "completed", "enrollment", "of", "442", "patients,", "and", "the", "CHABLIS", "7.5", "protocol", "was", "submitted", "to", "the", "FDA", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["The", "study", "design", "is", "expected", "to", "be", "finalized", "in", "the", "second", "half", "of", "2015."], "wordsB": ["The", "CHABLIS-SC1", "study", "has", "completed", "enrollment", "of", "442", "patients,", "and", "the", "CHABLIS", "7.5", "protocol", "was", "submitted", "to", "the", "FDA", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s7", "idA": "1316175_15_item1_p60_s2", "sentA": "A single pivotal study (BRIGHT-SC) evaluating the change in proteinuria as a surrogate endpoint to support an accelerated (Subpart E) or Conditional Approval in US and EU, respectively, was presented to the FDA, EMA, and PDMA.", "sentB": "Based on our previous discussions with regulatory authorities, we believe an evaluation of the change in proteinuria could serve as a surrogate endpoint to support an accelerated or conditional approval in various key commercial geographies.", "type": 2, "words": ["<tag1>", "A", "single", "pivotal", "study", "(BRIGHT-SC)", "evaluating", "the", "change", "in", "proteinuria", "as", "a", "surrogate", "endpoint", "to", "support", "an", "accelerated", "(Subpart", "E)", "or", "Conditional", "Approval", "in", "US", "and", "EU,", "respectively,", "was", "presented", "to", "the", "FDA,", "EMA,", "and", "PDMA.", "<tag2>", "Based", "on", "our", "previous", "discussions", "with", "regulatory", "authorities,", "we", "believe", "an", "evaluation", "of", "the", "change", "in", "proteinuria", "could", "serve", "as", "a", "surrogate", "endpoint", "to", "support", "an", "accelerated", "or", "conditional", "approval", "in", "various", "key", "commercial", "geographies.", "<tag3>"], "wordsA": ["A", "single", "pivotal", "study", "(BRIGHT-SC)", "evaluating", "the", "change", "in", "proteinuria", "as", "a", "surrogate", "endpoint", "to", "support", "an", "accelerated", "(Subpart", "E)", "or", "Conditional", "Approval", "in", "US", "and", "EU,", "respectively,", "was", "presented", "to", "the", "FDA,", "EMA,", "and", "PDMA."], "wordsB": ["Based", "on", "our", "previous", "discussions", "with", "regulatory", "authorities,", "we", "believe", "an", "evaluation", "of", "the", "change", "in", "proteinuria", "could", "serve", "as", "a", "surrogate", "endpoint", "to", "support", "an", "accelerated", "or", "conditional", "approval", "in", "various", "key", "commercial", "geographies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s8", "idA": "1316175_15_item1_p60_s3", "sentA": "Each agency provided separate concurrence on the willingness to consider proteinuria as a surrogate endpoint, with varying points of view on the degree of change in proteinuria to predict a treatment effect, and the timing for completion of enrollment of the post marketing confirmatory study.", "sentB": "Following the completion of the BRIGHT-SC study we intend to explore a Special Protocol Assessment from the US FDA to ensure final concurrence on the willingness to consider proteinuria as a surrogate endpoint, the timing for completion of enrollment of the post marketing confirmatory study and blisibimod s eligibility to receive orphan designation.", "type": 2, "words": ["<tag1>", "Each", "agency", "provided", "separate", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "with", "varying", "points", "of", "view", "on", "the", "degree", "of", "change", "in", "proteinuria", "to", "predict", "a", "treatment", "effect,", "and", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study.", "<tag2>", "Following", "the", "completion", "of", "the", "BRIGHT-SC", "study", "we", "intend", "to", "explore", "a", "Special", "Protocol", "Assessment", "from", "the", "US", "FDA", "to", "ensure", "final", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study", "and", "blisibimod", "s", "eligibility", "to", "receive", "orphan", "designation.", "<tag3>"], "wordsA": ["Each", "agency", "provided", "separate", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "with", "varying", "points", "of", "view", "on", "the", "degree", "of", "change", "in", "proteinuria", "to", "predict", "a", "treatment", "effect,", "and", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study."], "wordsB": ["Following", "the", "completion", "of", "the", "BRIGHT-SC", "study", "we", "intend", "to", "explore", "a", "Special", "Protocol", "Assessment", "from", "the", "US", "FDA", "to", "ensure", "final", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study", "and", "blisibimod", "s", "eligibility", "to", "receive", "orphan", "designation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p82_s0", "idA": "1316175_15_item1_p62_s0", "sentA": "To date, four randomized, placebo-controlled clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled by our licensor, Amgen, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC study, both conducted by us.", "sentB": "To date, four randomized, clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled by our licensor, Amgen, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study (PEARL-SC) in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC study, both conducted by us.", "type": 2, "words": ["<tag1>", "To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us.", "<tag2>", "To", "date,", "four", "randomized,", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "(PEARL-SC)", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us.", "<tag3>"], "wordsA": ["To", "date,", "four", "randomized,", "placebo-controlled", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us."], "wordsB": ["To", "date,", "four", "randomized,", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "(PEARL-SC)", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p83_s0", "idA": "1316175_15_item1_p63_s0", "sentA": "Based on positive results among 104 lupus patients in Amgen s Phase 1a and 1b clinical studies, we conducted the PEARL-SC study, a Phase 2b randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of various subcutaneous doses of blisibimod in patients with seropositive lupus and active disease defined as SELENA-SLEDAI 6 at enrollment, which ran from mid-2010 to April 2012.", "sentB": "Based on positive safety and pharmacodynamics results among 118 lupus patients in Amgen s Phase 1a and 1b clinical studies, we conducted the PEARL-SC study, a Phase 2b randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of various subcutaneous doses of blisibimod in patients with seropositive lupus and active disease defined as SELENA-SLEDAI 6 at enrollment, which ran from mid-2010 to April 2012.", "type": 2, "words": ["<tag1>", "Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "Amgen", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "the", "PEARL-SC", "study,", "a", "Phase", "2b", "randomized,", "double-", "blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012.", "<tag2>", "Based", "on", "positive", "safety", "and", "pharmacodynamics", "results", "among", "118", "lupus", "patients", "in", "Amgen", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "the", "PEARL-SC", "study,", "a", "Phase", "2b", "randomized,", "double-", "blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012.", "<tag3>"], "wordsA": ["Based", "on", "positive", "results", "among", "104", "lupus", "patients", "in", "Amgen", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "the", "PEARL-SC", "study,", "a", "Phase", "2b", "randomized,", "double-", "blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012."], "wordsB": ["Based", "on", "positive", "safety", "and", "pharmacodynamics", "results", "among", "118", "lupus", "patients", "in", "Amgen", "s", "Phase", "1a", "and", "1b", "clinical", "studies,", "we", "conducted", "the", "PEARL-SC", "study,", "a", "Phase", "2b", "randomized,", "double-", "blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "various", "subcutaneous", "doses", "of", "blisibimod", "in", "patients", "with", "seropositive", "lupus", "and", "active", "disease", "defined", "as", "SELENA-SLEDAI", "6", "at", "enrollment,", "which", "ran", "from", "mid-2010", "to", "April", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s2", "idA": "1316175_15_item1_p67_s0", "sentA": "In June of 2012 we completed dosing in the PEARL-SC study.", "sentB": "We have enrolled 57 patients, 45 of which remained in the study.", "type": 2, "words": ["<tag1>", "In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study.", "<tag2>", "We", "have", "enrolled", "57", "patients,", "45", "of", "which", "remained", "in", "the", "study.", "<tag3>"], "wordsA": ["In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study."], "wordsB": ["We", "have", "enrolled", "57", "patients,", "45", "of", "which", "remained", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p97_s2", "idA": "1316175_15_item1_p67_s0", "sentA": "In June of 2012 we completed dosing in the PEARL-SC study.", "sentB": "Lupus biomarker observations from the PEARL-SC trial are summarized in the next section, Open-Label Extension Study in Patients Enrolled in PEARL-SC Study , along with data from the open-label extension study.", "type": 2, "words": ["<tag1>", "In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study.", "<tag2>", "Lupus", "biomarker", "observations", "from", "the", "PEARL-SC", "trial", "are", "summarized", "in", "the", "next", "section,", "Open-Label", "Extension", "Study", "in", "Patients", "Enrolled", "in", "PEARL-SC", "Study", ",", "along", "with", "data", "from", "the", "open-label", "extension", "study.", "<tag3>"], "wordsA": ["In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study."], "wordsB": ["Lupus", "biomarker", "observations", "from", "the", "PEARL-SC", "trial", "are", "summarized", "in", "the", "next", "section,", "Open-Label", "Extension", "Study", "in", "Patients", "Enrolled", "in", "PEARL-SC", "Study", ",", "along", "with", "data", "from", "the", "open-label", "extension", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p88_s0", "idA": "1316175_15_item1_p68_s0", "sentA": "Using a higher treatment threshold of an eight-point reduction in the SELENA-SLEDAI, or an SRI-8 endpoint, in this enhanced subgroup population, the 200mg blisibimod treatment group demonstrated a 15.6% treatment difference compared to pooled placebo (41.7% versus 26.1%, p 0.05) and 31.1% treatment difference compare to regimen-matched placebo (41.7% versus 10.6%, p 0.001) at 24 weeks.", "sentB": "Using a higher treatment threshold of an six-point reduction in the SELENA-SLEDAI, or an SRI-6 endpoint, in this enhanced subgroup population, the 200mg blisibimod treatment group demonstrated a 15.9% treatment difference compared to regimen-matched placebo (54.2% versus 46.4%, p=0.12).", "type": 2, "words": ["<tag1>", "Using", "a", "higher", "treatment", "threshold", "of", "an", "eight-point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "regimen-matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks.", "<tag2>", "Using", "a", "higher", "treatment", "threshold", "of", "an", "six-point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-6", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.9%", "treatment", "difference", "compared", "to", "regimen-matched", "placebo", "(54.2%", "versus", "46.4%,", "p=0.12).", "<tag3>"], "wordsA": ["Using", "a", "higher", "treatment", "threshold", "of", "an", "eight-point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-8", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.6%", "treatment", "difference", "compared", "to", "pooled", "placebo", "(41.7%", "versus", "26.1%,", "p", "0.05)", "and", "31.1%", "treatment", "difference", "compare", "to", "regimen-matched", "placebo", "(41.7%", "versus", "10.6%,", "p", "0.001)", "at", "24", "weeks."], "wordsB": ["Using", "a", "higher", "treatment", "threshold", "of", "an", "six-point", "reduction", "in", "the", "SELENA-SLEDAI,", "or", "an", "SRI-6", "endpoint,", "in", "this", "enhanced", "subgroup", "population,", "the", "200mg", "blisibimod", "treatment", "group", "demonstrated", "a", "15.9%", "treatment", "difference", "compared", "to", "regimen-matched", "placebo", "(54.2%", "versus", "46.4%,", "p=0.12)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p54_s2", "idA": "1316175_15_item1_p68_s2", "sentA": "This severe subgroup is the population that we believe will benefit most from treatment with blisibimod, and is the population we are enrolling in our Phase 3 CHABLIS-SC studies.", "sentB": "This is the population we are enrolling in our Phase 3 CHABLIS-SC studies.", "type": 2, "words": ["<tag1>", "This", "severe", "subgroup", "is", "the", "population", "that", "we", "believe", "will", "benefit", "most", "from", "treatment", "with", "blisibimod,", "and", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.", "<tag2>", "This", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies.", "<tag3>"], "wordsA": ["This", "severe", "subgroup", "is", "the", "population", "that", "we", "believe", "will", "benefit", "most", "from", "treatment", "with", "blisibimod,", "and", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies."], "wordsB": ["This", "is", "the", "population", "we", "are", "enrolling", "in", "our", "Phase", "3", "CHABLIS-SC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p88_s4", "idA": "1316175_15_item1_p68_s4", "sentA": "All doses of blisibimod demonstrated consistent serological response including reductions of B-cells, double-stranded-DNA antibodies and improvement in complement levels.", "sentB": "Consistent pharmacodynamics responses were noted with blisibimod including reductions of B-cells, double-stranded-DNA antibodies and increases in complement C3 and C4.", "type": 2, "words": ["<tag1>", "All", "doses", "of", "blisibimod", "demonstrated", "consistent", "serological", "response", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "improvement", "in", "complement", "levels.", "<tag2>", "Consistent", "pharmacodynamics", "responses", "were", "noted", "with", "blisibimod", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "increases", "in", "complement", "C3", "and", "C4.", "<tag3>"], "wordsA": ["All", "doses", "of", "blisibimod", "demonstrated", "consistent", "serological", "response", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "improvement", "in", "complement", "levels."], "wordsB": ["Consistent", "pharmacodynamics", "responses", "were", "noted", "with", "blisibimod", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "increases", "in", "complement", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p89_s1", "idA": "1316175_15_item1_p68_s6", "sentA": "In addition to publications in earlier abstracts at key international rheumatology conferences, the efficacy and safety data from the PEARL-SC study were published by Dr Richard Furie and colleagues ( Ann Rheum Dis . 2014).", "sentB": "In addition to publications in earlier abstracts at key international rheumatology conferences, the efficacy and safety data from the PEARL-SC study were published by Dr. Richard Furie and colleagues ( Ann Rheum Dis . 2015), and Dr. Scheinberg ( International Journal of Clinical Rheumatology , 2014).", "type": 2, "words": ["<tag1>", "In", "addition", "to", "publications", "in", "earlier", "abstracts", "at", "key", "international", "rheumatology", "conferences,", "the", "efficacy", "and", "safety", "data", "from", "the", "PEARL-SC", "study", "were", "published", "by", "Dr", "Richard", "Furie", "and", "colleagues", "(", "Ann", "Rheum", "Dis", ".", "2014).", "<tag2>", "In", "addition", "to", "publications", "in", "earlier", "abstracts", "at", "key", "international", "rheumatology", "conferences,", "the", "efficacy", "and", "safety", "data", "from", "the", "PEARL-SC", "study", "were", "published", "by", "Dr.", "Richard", "Furie", "and", "colleagues", "(", "Ann", "Rheum", "Dis", ".", "2015),", "and", "Dr.", "Scheinberg", "(", "International", "Journal", "of", "Clinical", "Rheumatology", ",", "2014).", "<tag3>"], "wordsA": ["In", "addition", "to", "publications", "in", "earlier", "abstracts", "at", "key", "international", "rheumatology", "conferences,", "the", "efficacy", "and", "safety", "data", "from", "the", "PEARL-SC", "study", "were", "published", "by", "Dr", "Richard", "Furie", "and", "colleagues", "(", "Ann", "Rheum", "Dis", ".", "2014)."], "wordsB": ["In", "addition", "to", "publications", "in", "earlier", "abstracts", "at", "key", "international", "rheumatology", "conferences,", "the", "efficacy", "and", "safety", "data", "from", "the", "PEARL-SC", "study", "were", "published", "by", "Dr.", "Richard", "Furie", "and", "colleagues", "(", "Ann", "Rheum", "Dis", ".", "2015),", "and", "Dr.", "Scheinberg", "(", "International", "Journal", "of", "Clinical", "Rheumatology", ",", "2014)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p91_s0", "idA": "1316175_15_item1_p69_s0", "sentA": "In Figure 5, an SRI-6 responder achieved all of the following: 6 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "sentB": "In the above figure, an SRI-6 responder achieved all of the following: 6 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "In", "Figure", "5,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag2>", "In", "the", "above", "figure,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["In", "Figure", "5,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "wordsB": ["In", "the", "above", "figure,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p95_s0", "idA": "1316175_15_item1_p73_s0", "sentA": "In subjects with baseline urinary protein excretion equivalent to 1-6g/24hrs, treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "sentB": "In subjects with baseline urinary protein excretion equivalent to 1-6g/24hrs (measured as urinary protein:creatinine ratio 1-6 mg/mg), treatment with blisibimod resulted in significantly greater reductions in proteinuria compared to placebo from Week 8 through Week 24.", "type": 2, "words": ["<tag1>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag2>", "In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6g/24hrs", "(measured", "as", "urinary", "protein:creatinine", "ratio", "1-6", "mg/mg),", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24.", "<tag3>"], "wordsA": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6g/24hrs,", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "wordsB": ["In", "subjects", "with", "baseline", "urinary", "protein", "excretion", "equivalent", "to", "1-6g/24hrs", "(measured", "as", "urinary", "protein:creatinine", "ratio", "1-6", "mg/mg),", "treatment", "with", "blisibimod", "resulted", "in", "significantly", "greater", "reductions", "in", "proteinuria", "compared", "to", "placebo", "from", "Week", "8", "through", "Week", "24."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p95_s1", "idA": "1316175_15_item1_p73_s1", "sentA": "Furthermore, the observed treatment-related decreases in proteinuria resulted in near normalization of the proteinuria to 1g/24hrs in those subjects receiving blisibimod.", "sentB": "Furthermore, the observed treatment-related decreases in proteinuria resulted in near normalization of the proteinuria to 1g/24hrs in those subjects receiving blisibimod, and were durable through 52 weeks of continuous blisibimod dosing in the PEARL-SC and open-label extension studies.", "type": 2, "words": ["<tag1>", "Furthermore,", "the", "observed", "treatment-related", "decreases", "in", "proteinuria", "resulted", "in", "near", "normalization", "of", "the", "proteinuria", "to", "1g/24hrs", "in", "those", "subjects", "receiving", "blisibimod.", "<tag2>", "Furthermore,", "the", "observed", "treatment-related", "decreases", "in", "proteinuria", "resulted", "in", "near", "normalization", "of", "the", "proteinuria", "to", "1g/24hrs", "in", "those", "subjects", "receiving", "blisibimod,", "and", "were", "durable", "through", "52", "weeks", "of", "continuous", "blisibimod", "dosing", "in", "the", "PEARL-SC", "and", "open-label", "extension", "studies.", "<tag3>"], "wordsA": ["Furthermore,", "the", "observed", "treatment-related", "decreases", "in", "proteinuria", "resulted", "in", "near", "normalization", "of", "the", "proteinuria", "to", "1g/24hrs", "in", "those", "subjects", "receiving", "blisibimod."], "wordsB": ["Furthermore,", "the", "observed", "treatment-related", "decreases", "in", "proteinuria", "resulted", "in", "near", "normalization", "of", "the", "proteinuria", "to", "1g/24hrs", "in", "those", "subjects", "receiving", "blisibimod,", "and", "were", "durable", "through", "52", "weeks", "of", "continuous", "blisibimod", "dosing", "in", "the", "PEARL-SC", "and", "open-label", "extension", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p96_s0", "idA": "1316175_15_item1_p74_s0", "sentA": "The graph shows data from subgroups of patients defined by baseline proteinuria for blisibimod.", "sentB": "Figure 4 shows data from subgroups of patients defined by baseline proteinuria for blisibimod.", "type": 2, "words": ["<tag1>", "The", "graph", "shows", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod.", "<tag2>", "Figure", "4", "shows", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod.", "<tag3>"], "wordsA": ["The", "graph", "shows", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod."], "wordsB": ["Figure", "4", "shows", "data", "from", "subgroups", "of", "patients", "defined", "by", "baseline", "proteinuria", "for", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p98_s0", "idA": "1316175_15_item1_p75_s2", "sentA": "Blisibimod was safe and well-tolerated at all dose levels evaluated in this study, with no meaningful imbalances in serious adverse events or infections compared with placebo (see Table 2 in the next section).", "sentB": "Blisibimod was safe and well-tolerated at all dose levels evaluated in this study, with no meaningful imbalances in serious adverse events or infections compared with placebo.", "type": 2, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section).", "<tag2>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo.", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo", "(see", "Table", "2", "in", "the", "next", "section)."], "wordsB": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "evaluated", "in", "this", "study,", "with", "no", "meaningful", "imbalances", "in", "serious", "adverse", "events", "or", "infections", "compared", "with", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p100_s0", "idA": "1316175_15_item1_p77_s0", "sentA": "In order to evaluate longer-term safety of blisibimod, patients with lupus who completed the PEARL-SC study were able to participate in an OLE study in which they were treated with an active drug (blisibimod).", "sentB": "In order to evaluate longer-term safety of blisibimod, patients with lupus who completed the PEARL-SC study were able to participate in an OLE study in which they were treated with blisibimod.", "type": 2, "words": ["<tag1>", "In", "order", "to", "evaluate", "longer-term", "safety", "of", "blisibimod,", "patients", "with", "lupus", "who", "completed", "the", "PEARL-SC", "study", "were", "able", "to", "participate", "in", "an", "OLE", "study", "in", "which", "they", "were", "treated", "with", "an", "active", "drug", "(blisibimod).", "<tag2>", "In", "order", "to", "evaluate", "longer-term", "safety", "of", "blisibimod,", "patients", "with", "lupus", "who", "completed", "the", "PEARL-SC", "study", "were", "able", "to", "participate", "in", "an", "OLE", "study", "in", "which", "they", "were", "treated", "with", "blisibimod.", "<tag3>"], "wordsA": ["In", "order", "to", "evaluate", "longer-term", "safety", "of", "blisibimod,", "patients", "with", "lupus", "who", "completed", "the", "PEARL-SC", "study", "were", "able", "to", "participate", "in", "an", "OLE", "study", "in", "which", "they", "were", "treated", "with", "an", "active", "drug", "(blisibimod)."], "wordsB": ["In", "order", "to", "evaluate", "longer-term", "safety", "of", "blisibimod,", "patients", "with", "lupus", "who", "completed", "the", "PEARL-SC", "study", "were", "able", "to", "participate", "in", "an", "OLE", "study", "in", "which", "they", "were", "treated", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p100_s1", "idA": "1316175_15_item1_p77_s1", "sentA": "The OLE study was opened in Q2 2012 and closed in Q2 2013 after subjects had completed a minimum of one year of continuous therapy with blisibimod.", "sentB": "The OLE study was opened in the second quarter of 2011 and closed in the second quarter of 2013 after subjects had completed a minimum of one year of continuous therapy with blisibimod.", "type": 2, "words": ["<tag1>", "The", "OLE", "study", "was", "opened", "in", "Q2", "2012", "and", "closed", "in", "Q2", "2013", "after", "subjects", "had", "completed", "a", "minimum", "of", "one", "year", "of", "continuous", "therapy", "with", "blisibimod.", "<tag2>", "The", "OLE", "study", "was", "opened", "in", "the", "second", "quarter", "of", "2011", "and", "closed", "in", "the", "second", "quarter", "of", "2013", "after", "subjects", "had", "completed", "a", "minimum", "of", "one", "year", "of", "continuous", "therapy", "with", "blisibimod.", "<tag3>"], "wordsA": ["The", "OLE", "study", "was", "opened", "in", "Q2", "2012", "and", "closed", "in", "Q2", "2013", "after", "subjects", "had", "completed", "a", "minimum", "of", "one", "year", "of", "continuous", "therapy", "with", "blisibimod."], "wordsB": ["The", "OLE", "study", "was", "opened", "in", "the", "second", "quarter", "of", "2011", "and", "closed", "in", "the", "second", "quarter", "of", "2013", "after", "subjects", "had", "completed", "a", "minimum", "of", "one", "year", "of", "continuous", "therapy", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p73_s4", "idA": "1316175_15_item1_p78_s0", "sentA": "The emerging data for the OLE study corroborate the effects of 24-week therapy with blisibimod observed in the PEARL-SC study.", "sentB": "This analysis will examine the effects of blisibimod versus placebo in the proportion of qualifying patients who achieve a complete response ( CR ) and a partial response ( PR ) at six months.", "type": 2, "words": ["<tag1>", "The", "emerging", "data", "for", "the", "OLE", "study", "corroborate", "the", "effects", "of", "24-week", "therapy", "with", "blisibimod", "observed", "in", "the", "PEARL-SC", "study.", "<tag2>", "This", "analysis", "will", "examine", "the", "effects", "of", "blisibimod", "versus", "placebo", "in", "the", "proportion", "of", "qualifying", "patients", "who", "achieve", "a", "complete", "response", "(", "CR", ")", "and", "a", "partial", "response", "(", "PR", ")", "at", "six", "months.", "<tag3>"], "wordsA": ["The", "emerging", "data", "for", "the", "OLE", "study", "corroborate", "the", "effects", "of", "24-week", "therapy", "with", "blisibimod", "observed", "in", "the", "PEARL-SC", "study."], "wordsB": ["This", "analysis", "will", "examine", "the", "effects", "of", "blisibimod", "versus", "placebo", "in", "the", "proportion", "of", "qualifying", "patients", "who", "achieve", "a", "complete", "response", "(", "CR", ")", "and", "a", "partial", "response", "(", "PR", ")", "at", "six", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p101_s1", "idA": "1316175_15_item1_p78_s1", "sentA": "Specifically, the improvements in proteinuria observed in the subgroup of patients with abnormal proteinuria at enrollment (Figure 8), were maintained over 52 weeks of continuous blisibimod therapy.", "sentB": "Specifically, the improvements in proteinuria observed in the subgroup of patients with abnormal proteinuria at enrollment were maintained over 52 weeks of continuous blisibimod therapy.", "type": 2, "words": ["<tag1>", "Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "(Figure", "8),", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy.", "<tag2>", "Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy.", "<tag3>"], "wordsA": ["Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "(Figure", "8),", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy."], "wordsB": ["Specifically,", "the", "improvements", "in", "proteinuria", "observed", "in", "the", "subgroup", "of", "patients", "with", "abnormal", "proteinuria", "at", "enrollment", "were", "maintained", "over", "52", "weeks", "of", "continuous", "blisibimod", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p101_s3", "idA": "1316175_15_item1_p78_s3", "sentA": "Blisibimod was safe and well-tolerated at all dose levels through the PEARL-SC and OLE studies, with no associated increase in risk of severe infection (Table 2).", "sentB": "Blisibimod was safe and well-tolerated at all dose levels through the PEARL-SC and OLE studies, with no associated increase in risk of severe infection as illustrated in the following table.", "type": 2, "words": ["<tag1>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "through", "the", "PEARL-SC", "and", "OLE", "studies,", "with", "no", "associated", "increase", "in", "risk", "of", "severe", "infection", "(Table", "2).", "<tag2>", "Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "through", "the", "PEARL-SC", "and", "OLE", "studies,", "with", "no", "associated", "increase", "in", "risk", "of", "severe", "infection", "as", "illustrated", "in", "the", "following", "table.", "<tag3>"], "wordsA": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "through", "the", "PEARL-SC", "and", "OLE", "studies,", "with", "no", "associated", "increase", "in", "risk", "of", "severe", "infection", "(Table", "2)."], "wordsB": ["Blisibimod", "was", "safe", "and", "well-tolerated", "at", "all", "dose", "levels", "through", "the", "PEARL-SC", "and", "OLE", "studies,", "with", "no", "associated", "increase", "in", "risk", "of", "severe", "infection", "as", "illustrated", "in", "the", "following", "table."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p102_s0", "idA": "1316175_15_item1_p79_s0", "sentA": "The data from the Phase 2 program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the Phase 2 study in patients with IgA nephropathy (BRIGHT-SC1).", "sentB": "The data from the Phase 2b (PEARL-SC) clinical program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the clinical study in patients with IgA nephropathy (BRIGHT-SC).", "type": 2, "words": ["<tag1>", "The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1).", "<tag2>", "The", "data", "from", "the", "Phase", "2b", "(PEARL-SC)", "clinical", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC).", "<tag3>"], "wordsA": ["The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1)."], "wordsB": ["The", "data", "from", "the", "Phase", "2b", "(PEARL-SC)", "clinical", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p36_s3", "idA": "1316175_15_item1_p79_s0", "sentA": "The data from the Phase 2 program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the Phase 2 study in patients with IgA nephropathy (BRIGHT-SC1).", "sentB": "Patient eligibility for this study is informed by responder traits identified in the Phase 2 trial with blisibimod as well as the large Phase 3 programs with other BAFF inhibitors, belimumab and tabalumab.", "type": 2, "words": ["<tag1>", "The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1).", "<tag2>", "Patient", "eligibility", "for", "this", "study", "is", "informed", "by", "responder", "traits", "identified", "in", "the", "Phase", "2", "trial", "with", "blisibimod", "as", "well", "as", "the", "large", "Phase", "3", "programs", "with", "other", "BAFF", "inhibitors,", "belimumab", "and", "tabalumab.", "<tag3>"], "wordsA": ["The", "data", "from", "the", "Phase", "2", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "Phase", "2", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC1)."], "wordsB": ["Patient", "eligibility", "for", "this", "study", "is", "informed", "by", "responder", "traits", "identified", "in", "the", "Phase", "2", "trial", "with", "blisibimod", "as", "well", "as", "the", "large", "Phase", "3", "programs", "with", "other", "BAFF", "inhibitors,", "belimumab", "and", "tabalumab."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p89_s2", "idA": "1316175_15_item1_p79_s1", "sentA": "Additional information for the OLE clinical studies can be found at http://www.anthera.com/pipeline/clinical-studies/past-studies/open-label-extension-study .html.", "sentB": "Additional information and publications from the PEARL-SC study can be found at http://www.anthera.com/pipeline/clinical-studies/past-studies/pearl-sc.html.", "type": 2, "words": ["<tag1>", "Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "http://www.anthera.com/pipeline/clinical-studies/past-studies/open-label-extension-study", ".html.", "<tag2>", "Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "study", "can", "be", "found", "at", "http://www.anthera.com/pipeline/clinical-studies/past-studies/pearl-sc.html.", "<tag3>"], "wordsA": ["Additional", "information", "for", "the", "OLE", "clinical", "studies", "can", "be", "found", "at", "http://www.anthera.com/pipeline/clinical-studies/past-studies/open-label-extension-study", ".html."], "wordsB": ["Additional", "information", "and", "publications", "from", "the", "PEARL-SC", "study", "can", "be", "found", "at", "http://www.anthera.com/pipeline/clinical-studies/past-studies/pearl-sc.html."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p104_s0", "idA": "1316175_15_item1_p81_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013, in Figure 11, the significant improvements in proteinuria in patients with lupus randomized to blisibimod compared with placebo observed in the PEARL-SC study were found to be durable through their continuing exposure to blisibimod in the OLE study.", "sentB": "The significant improvements in proteinuria in patients with lupus randomized to blisibimod compared with placebo observed in the PEARL-SC study were found to be durable through their continuing exposure to blisibimod in the OLE study.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "11,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study.", "<tag2>", "The", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013,", "in", "Figure", "11,", "the", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study."], "wordsB": ["The", "significant", "improvements", "in", "proteinuria", "in", "patients", "with", "lupus", "randomized", "to", "blisibimod", "compared", "with", "placebo", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "through", "their", "continuing", "exposure", "to", "blisibimod", "in", "the", "OLE", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p107_s0", "idA": "1316175_15_item1_p81_s1", "sentA": "The graph shows data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "sentB": "Figure 7 show data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52 (interim data presented by Dr. Furie at the American College of Rheumatology Annual Conference, San Diego 2013).", "type": 2, "words": ["<tag1>", "The", "graph", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag2>", "Figure", "7", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52", "(interim", "data", "presented", "by", "Dr.", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013).", "<tag3>"], "wordsA": ["The", "graph", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "wordsB": ["Figure", "7", "show", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52", "(interim", "data", "presented", "by", "Dr.", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p106_s0", "idA": "1316175_15_item1_p82_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 9, with its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B-cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "sentB": "As expected for its mechanism of BAFF inhibition, blisibimod treatment was associated with significant reductions in the numbers of total B-cells, anti-dsDNA antibodies, as well as significant increases in complement components C3 and C4.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "9,", "with", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag2>", "As", "expected", "for", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "9,", "with", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "wordsB": ["As", "expected", "for", "its", "mechanism", "of", "BAFF", "inhibition,", "blisibimod", "treatment", "was", "associated", "with", "significant", "reductions", "in", "the", "numbers", "of", "total", "B-cells,", "anti-dsDNA", "antibodies,", "as", "well", "as", "significant", "increases", "in", "complement", "components", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p105_s0", "idA": "1316175_15_item1_p82_s1", "sentA": "The graphs shows data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52.", "sentB": "Figure 6 shows data for blisibimod (all pooled dose levels as well as 200mg once-weekly) and placebo administered subcutaneously for 24 weeks in the PEARL-SC trial, and interim data for subjects who continued to receive blisibimod through the OLE trial are presented through Week 52 (presented by Dr. Furie at the American College of Rheumatology Annual Conference, San Diego, 2013).", "type": 2, "words": ["<tag1>", "The", "graphs", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52.", "<tag2>", "Figure", "6", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52", "(presented", "by", "Dr.", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego,", "2013).", "<tag3>"], "wordsA": ["The", "graphs", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52."], "wordsB": ["Figure", "6", "shows", "data", "for", "blisibimod", "(all", "pooled", "dose", "levels", "as", "well", "as", "200mg", "once-weekly)", "and", "placebo", "administered", "subcutaneously", "for", "24", "weeks", "in", "the", "PEARL-SC", "trial,", "and", "interim", "data", "for", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "trial", "are", "presented", "through", "Week", "52", "(presented", "by", "Dr.", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego,", "2013)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p106_s1", "idA": "1316175_15_item1_p83_s0", "sentA": "According to data presented by Dr. Richard Furie at the American College of Rheumatology Annual Conference, San Diego 2013 in Figure 10, significant reductions in immunoglobulins IgG and IgM were observed with blisibimod compared with placebo during the placebo-controlled PEARL-SC study.", "sentB": "In addition, significant reductions in immunoglobulins IgG and IgM were observed with blisibimod compared with placebo during the placebo-controlled PEARL-SC study.", "type": 2, "words": ["<tag1>", "According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "10,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study.", "<tag2>", "In", "addition,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study.", "<tag3>"], "wordsA": ["According", "to", "data", "presented", "by", "Dr.", "Richard", "Furie", "at", "the", "American", "College", "of", "Rheumatology", "Annual", "Conference,", "San", "Diego", "2013", "in", "Figure", "10,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study."], "wordsB": ["In", "addition,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p106_s2", "idA": "1316175_15_item1_p83_s1", "sentA": "These effects were found to be durable in subjects who continued to receive blisibimod through the OLE study.", "sentB": "The effects of blisibimod on lupus biomarkers and serum immunoglobulins observed in the PEARL-SC study were found to be durable in subjects who continued to receive blisibimod through the OLE study.", "type": 2, "words": ["<tag1>", "These", "effects", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study.", "<tag2>", "The", "effects", "of", "blisibimod", "on", "lupus", "biomarkers", "and", "serum", "immunoglobulins", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study.", "<tag3>"], "wordsA": ["These", "effects", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study."], "wordsB": ["The", "effects", "of", "blisibimod", "on", "lupus", "biomarkers", "and", "serum", "immunoglobulins", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p108_s2", "idA": "1316175_15_item1_p84_s2", "sentA": "The randomized, placebo-controlled, dose-escalation Phase 1a clinical study evaluated blisibimod as a single intravenous or subcutaneous therapy among 56 lupus patients.", "sentB": "The randomized, placebo-controlled, dose-escalation Phase 1a clinical study evaluated blisibimod or placebo as a single intravenous or subcutaneous therapy among 54 lupus patients.", "type": 2, "words": ["<tag1>", "The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "blisibimod", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "56", "lupus", "patients.", "<tag2>", "The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "blisibimod", "or", "placebo", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "54", "lupus", "patients.", "<tag3>"], "wordsA": ["The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "blisibimod", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "56", "lupus", "patients."], "wordsB": ["The", "randomized,", "placebo-controlled,", "dose-escalation", "Phase", "1a", "clinical", "study", "evaluated", "blisibimod", "or", "placebo", "as", "a", "single", "intravenous", "or", "subcutaneous", "therapy", "among", "54", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p113_s0", "idA": "1316175_15_item1_p88_s5", "sentA": "Results showed that multiple doses of blisibimod exhibited dose-proportional pharmacokinetics after both intravenous and subcutaneous administration.", "sentB": "Blisibimod exhibited dose-proportional pharmacokinetics after repeat intravenous and subcutaneous administration.", "type": 2, "words": ["<tag1>", "Results", "showed", "that", "multiple", "doses", "of", "blisibimod", "exhibited", "dose-proportional", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration.", "<tag2>", "Blisibimod", "exhibited", "dose-proportional", "pharmacokinetics", "after", "repeat", "intravenous", "and", "subcutaneous", "administration.", "<tag3>"], "wordsA": ["Results", "showed", "that", "multiple", "doses", "of", "blisibimod", "exhibited", "dose-proportional", "pharmacokinetics", "after", "both", "intravenous", "and", "subcutaneous", "administration."], "wordsB": ["Blisibimod", "exhibited", "dose-proportional", "pharmacokinetics", "after", "repeat", "intravenous", "and", "subcutaneous", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p113_s1", "idA": "1316175_15_item1_p88_s6", "sentA": "Further, results demonstrated a significant decrease in total B-cells as early as 15 days after beginning treatment, and total B-cell reduction (up to approximately 60-70% of baseline) reached its nadir after about 160 days of therapy.", "sentB": "Further, a significant decrease in total B-cells as early as 15 days after beginning treatment, and total B-cell reduction (up to approximately 60-70% of baseline) reached its nadir after about 160 days of therapy.", "type": 2, "words": ["<tag1>", "Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "after", "beginning", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy.", "<tag2>", "Further,", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "after", "beginning", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy.", "<tag3>"], "wordsA": ["Further,", "results", "demonstrated", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "after", "beginning", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy."], "wordsB": ["Further,", "a", "significant", "decrease", "in", "total", "B-cells", "as", "early", "as", "15", "days", "after", "beginning", "treatment,", "and", "total", "B-cell", "reduction", "(up", "to", "approximately", "60-70%", "of", "baseline)", "reached", "its", "nadir", "after", "about", "160", "days", "of", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p113_s3", "idA": "1316175_15_item1_p88_s8", "sentA": "Further analyses of B-cell subsets found that na ve B-cells and activated B-cells were significantly decreased while memory B-cells were transiently significantly increased following treatment with blisibimod, consistent with a correction of the B-cell abnormalities reported in lupus patients.", "sentB": "Further analyses of B-cell subsets found that naive B-cells and activated B-cells were significantly decreased while memory B-cells were transiently significantly increased following treatment with blisibimod.", "type": 2, "words": ["<tag1>", "Further", "analyses", "of", "B-cell", "subsets", "found", "that", "na", "ve", "B-cells", "and", "activated", "B-cells", "were", "significantly", "decreased", "while", "memory", "B-cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B-cell", "abnormalities", "reported", "in", "lupus", "patients.", "<tag2>", "Further", "analyses", "of", "B-cell", "subsets", "found", "that", "naive", "B-cells", "and", "activated", "B-cells", "were", "significantly", "decreased", "while", "memory", "B-cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod.", "<tag3>"], "wordsA": ["Further", "analyses", "of", "B-cell", "subsets", "found", "that", "na", "ve", "B-cells", "and", "activated", "B-cells", "were", "significantly", "decreased", "while", "memory", "B-cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod,", "consistent", "with", "a", "correction", "of", "the", "B-cell", "abnormalities", "reported", "in", "lupus", "patients."], "wordsB": ["Further", "analyses", "of", "B-cell", "subsets", "found", "that", "naive", "B-cells", "and", "activated", "B-cells", "were", "significantly", "decreased", "while", "memory", "B-cells", "were", "transiently", "significantly", "increased", "following", "treatment", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p79_s0", "idA": "1316175_15_item1_p96_s0", "sentA": "Study 726, a Phase 3, placebo-controlled, parallel design, multinational clinical, evaluated the effects of a single capsule of liprotamase (containing 32,500 U lipase, with protease and amylase in fixed ratios) or placebo administered with every meal or snack on severe EPI defined as baseline CFA 40% in the absence of PERT.", "sentB": "Study 726, a Phase 3, placebo-controlled, parallel design, multinational clinical, evaluated the effects of a single capsule of liprotamase (containing 32,500 U lipase, with protease and amylase in fixed ratios) or placebo administered with every meal or snack in subjects with cystic fibrosis-related EPI.", "type": 2, "words": ["<tag1>", "Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "on", "severe", "EPI", "defined", "as", "baseline", "CFA", "40%", "in", "the", "absence", "of", "PERT.", "<tag2>", "Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "in", "subjects", "with", "cystic", "fibrosis-related", "EPI.", "<tag3>"], "wordsA": ["Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "on", "severe", "EPI", "defined", "as", "baseline", "CFA", "40%", "in", "the", "absence", "of", "PERT."], "wordsB": ["Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "in", "subjects", "with", "cystic", "fibrosis-related", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p117_s0", "idA": "1316175_15_item1_p99_s0", "sentA": "Since our inception in 2004, we have focused primarily on developing our product candidates, blisibimod, liprotamase, varespladib and varespladib sodium.", "sentB": "Since our inception in 2004, we have focused primarily on developing our product candidates, which currently include liprotamase and blisibimod.", "type": 2, "words": ["<tag1>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "blisibimod,", "liprotamase,", "varespladib", "and", "varespladib", "sodium.", "<tag2>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "liprotamase", "and", "blisibimod.", "<tag3>"], "wordsA": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "blisibimod,", "liprotamase,", "varespladib", "and", "varespladib", "sodium."], "wordsB": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "liprotamase", "and", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p117_s1", "idA": "1316175_15_item1_p99_s2", "sentA": "We currently focus our development efforts on blisibimod, which is being developed for autoimmune disease, including lupus and IgA nephropathy, and liprotamase, as an enzyme replacement therapy for EPI.", "sentB": "We currently focus our clinical development and research efforts on liprotamase, as an enzyme replacement therapy for EPI, and blisibimod, which is being developed for autoimmune disease, including lupus and IgA nephropathy.", "type": 2, "words": ["<tag1>", "We", "currently", "focus", "our", "development", "efforts", "on", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy,", "and", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI.", "<tag2>", "We", "currently", "focus", "our", "clinical", "development", "and", "research", "efforts", "on", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI,", "and", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["We", "currently", "focus", "our", "development", "efforts", "on", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy,", "and", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI."], "wordsB": ["We", "currently", "focus", "our", "clinical", "development", "and", "research", "efforts", "on", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI,", "and", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p117_s2", "idA": "1316175_15_item1_p99_s3", "sentA": "In the years ended December 31, 2014, 2013 and 2012, we incurred $21.8 million, $21.7 million and $49.2 million, respectively, of research and development expense.", "sentB": "In the years ended December 31, 2015, 2014 and 2013, we incurred $33.6 million, $21.8 million and $21.7 million, respectively, of research and development expense.", "type": 2, "words": ["<tag1>", "In", "the", "years", "ended", "December", "31,", "2014,", "2013", "and", "2012,", "we", "incurred", "$21.8", "million,", "$21.7", "million", "and", "$49.2", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag2>", "In", "the", "years", "ended", "December", "31,", "2015,", "2014", "and", "2013,", "we", "incurred", "$33.6", "million,", "$21.8", "million", "and", "$21.7", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag3>"], "wordsA": ["In", "the", "years", "ended", "December", "31,", "2014,", "2013", "and", "2012,", "we", "incurred", "$21.8", "million,", "$21.7", "million", "and", "$49.2", "million,", "respectively,", "of", "research", "and", "development", "expense."], "wordsB": ["In", "the", "years", "ended", "December", "31,", "2015,", "2014", "and", "2013,", "we", "incurred", "$33.6", "million,", "$21.8", "million", "and", "$21.7", "million,", "respectively,", "of", "research", "and", "development", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_16_item1_p25_s1", "idA": "1316175_15_item1_p9_s1", "sentA": "Our current plan includes continuing the ongoing CHABLIS-SC1 registration clinical study in patients with active lupus and the BRIGHT-SC phase 2/3 clinical study in patients with IgA nephropathy, and evaluating the potential of blisibimod in hematological diseases through clinical and nonclinical investigations.", "sentB": "Our current plan includes continuing the ongoing CHABLIS-SC1 registration clinical study in patients with active lupus and the BRIGHT-SC phase 2 clinical study in patients with IgA nephropathy, initiating CHABLIS-SC 7.5, and evaluating the potential of blisibimod in hematological diseases through clinical and nonclinical investigations.", "type": 2, "words": ["<tag1>", "Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "registration", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC", "phase", "2/3", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations.", "<tag2>", "Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "registration", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC", "phase", "2", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "initiating", "CHABLIS-SC", "7.5,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations.", "<tag3>"], "wordsA": ["Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "registration", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC", "phase", "2/3", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations."], "wordsB": ["Our", "current", "plan", "includes", "continuing", "the", "ongoing", "CHABLIS-SC1", "registration", "clinical", "study", "in", "patients", "with", "active", "lupus", "and", "the", "BRIGHT-SC", "phase", "2", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy,", "initiating", "CHABLIS-SC", "7.5,", "and", "evaluating", "the", "potential", "of", "blisibimod", "in", "hematological", "diseases", "through", "clinical", "and", "nonclinical", "investigations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p0_s1", "idA": "1316175_16_item1_p0_s1", "sentA": "We currently have two Phase 3 product candidates, liprotamase also known as Sollpura TM and blisibimod.", "sentB": "We currently have two product candidates, Sollpura, formally known as liprotamase, and blisibimod.", "type": 2, "words": ["<tag1>", "We", "currently", "have", "two", "Phase", "3", "product", "candidates,", "liprotamase", "also", "known", "as", "Sollpura", "TM", "and", "blisibimod.", "<tag2>", "We", "currently", "have", "two", "product", "candidates,", "Sollpura,", "formally", "known", "as", "liprotamase,", "and", "blisibimod.", "<tag3>"], "wordsA": ["We", "currently", "have", "two", "Phase", "3", "product", "candidates,", "liprotamase", "also", "known", "as", "Sollpura", "TM", "and", "blisibimod."], "wordsB": ["We", "currently", "have", "two", "product", "candidates,", "Sollpura,", "formally", "known", "as", "liprotamase,", "and", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p0_s2", "idA": "1316175_16_item1_p0_s2", "sentA": "We licensed liprotamase from Eli Lilly Co ( Eli Lilly ) in July 2014.", "sentB": "We licensed Sollpura from Eli Lilly Co ( Eli Lilly ) in July 2014.", "type": 2, "words": ["<tag1>", "We", "licensed", "liprotamase", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014.", "<tag2>", "We", "licensed", "Sollpura", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014.", "<tag3>"], "wordsA": ["We", "licensed", "liprotamase", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014."], "wordsB": ["We", "licensed", "Sollpura", "from", "Eli", "Lilly", "Co", "(", "Eli", "Lilly", ")", "in", "July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s7", "idA": "1316175_16_item1_p100_s2", "sentA": "Interim data from the combined PEARL-SC and OLE studies were presented at the 2013 Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP).", "sentB": "We expect to release data from the extension phase of the study towards the end of first quarter of 2017.", "type": 2, "words": ["<tag1>", "Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP).", "<tag2>", "We", "expect", "to", "release", "data", "from", "the", "extension", "phase", "of", "the", "study", "towards", "the", "end", "of", "first", "quarter", "of", "2017.", "<tag3>"], "wordsA": ["Interim", "data", "from", "the", "combined", "PEARL-SC", "and", "OLE", "studies", "were", "presented", "at", "the", "2013", "Annual", "Scientific", "Meeting", "of", "the", "American", "College", "of", "Rheumatology", "and", "Association", "of", "Rheumatology", "Health", "Professionals", "(ACR/ARHP)."], "wordsB": ["We", "expect", "to", "release", "data", "from", "the", "extension", "phase", "of", "the", "study", "towards", "the", "end", "of", "first", "quarter", "of", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p64_s4", "idA": "1316175_16_item1_p102_s0", "sentA": "The data from the Phase 2b (PEARL-SC) clinical program with blisibimod support the ongoing exploration of blisibimod s efficacy and safety in the Phase 3 study in patients with lupus (CHABLIS-SC1) as well as the clinical study in patients with IgA nephropathy (BRIGHT-SC).", "sentB": "We believe the latter effects support the ongoing research with blisibimod into IgA nephropathy.", "type": 2, "words": ["<tag1>", "The", "data", "from", "the", "Phase", "2b", "(PEARL-SC)", "clinical", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC).", "<tag2>", "We", "believe", "the", "latter", "effects", "support", "the", "ongoing", "research", "with", "blisibimod", "into", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["The", "data", "from", "the", "Phase", "2b", "(PEARL-SC)", "clinical", "program", "with", "blisibimod", "support", "the", "ongoing", "exploration", "of", "blisibimod", "s", "efficacy", "and", "safety", "in", "the", "Phase", "3", "study", "in", "patients", "with", "lupus", "(CHABLIS-SC1)", "as", "well", "as", "the", "clinical", "study", "in", "patients", "with", "IgA", "nephropathy", "(BRIGHT-SC)."], "wordsB": ["We", "believe", "the", "latter", "effects", "support", "the", "ongoing", "research", "with", "blisibimod", "into", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s4", "idA": "1316175_16_item1_p106_s1", "sentA": "In addition, significant reductions in immunoglobulins IgG and IgM were observed with blisibimod compared with placebo during the placebo-controlled PEARL-SC study.", "sentB": "However, a tendency toward slowing proteinuria progression was again observed with blisibimod.", "type": 2, "words": ["<tag1>", "In", "addition,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study.", "<tag2>", "However,", "a", "tendency", "toward", "slowing", "proteinuria", "progression", "was", "again", "observed", "with", "blisibimod.", "<tag3>"], "wordsA": ["In", "addition,", "significant", "reductions", "in", "immunoglobulins", "IgG", "and", "IgM", "were", "observed", "with", "blisibimod", "compared", "with", "placebo", "during", "the", "placebo-controlled", "PEARL-SC", "study."], "wordsB": ["However,", "a", "tendency", "toward", "slowing", "proteinuria", "progression", "was", "again", "observed", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s7", "idA": "1316175_16_item1_p106_s2", "sentA": "The effects of blisibimod on lupus biomarkers and serum immunoglobulins observed in the PEARL-SC study were found to be durable in subjects who continued to receive blisibimod through the OLE study.", "sentB": "Given the positive effect observed in this analysis, Anthera plans to continue to follow the subjects enrolled in the BRIGHT study to gain more understanding of the long-term effects of blisibimod on disease progression.", "type": 2, "words": ["<tag1>", "The", "effects", "of", "blisibimod", "on", "lupus", "biomarkers", "and", "serum", "immunoglobulins", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study.", "<tag2>", "Given", "the", "positive", "effect", "observed", "in", "this", "analysis,", "Anthera", "plans", "to", "continue", "to", "follow", "the", "subjects", "enrolled", "in", "the", "BRIGHT", "study", "to", "gain", "more", "understanding", "of", "the", "long-term", "effects", "of", "blisibimod", "on", "disease", "progression.", "<tag3>"], "wordsA": ["The", "effects", "of", "blisibimod", "on", "lupus", "biomarkers", "and", "serum", "immunoglobulins", "observed", "in", "the", "PEARL-SC", "study", "were", "found", "to", "be", "durable", "in", "subjects", "who", "continued", "to", "receive", "blisibimod", "through", "the", "OLE", "study."], "wordsB": ["Given", "the", "positive", "effect", "observed", "in", "this", "analysis,", "Anthera", "plans", "to", "continue", "to", "follow", "the", "subjects", "enrolled", "in", "the", "BRIGHT", "study", "to", "gain", "more", "understanding", "of", "the", "long-term", "effects", "of", "blisibimod", "on", "disease", "progression."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s5", "idA": "1316175_16_item1_p109_s2", "sentA": "Results from this clinical study indicated the safety and tolerability of blisibimod administered as a single intravenous or subcutaneous dose were comparable to placebo.", "sentB": "In contrast, over the same period the mean PCR worsened by almost 1.5 g/g in subjects randomized to placebo.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "were", "comparable", "to", "placebo.", "<tag2>", "In", "contrast,", "over", "the", "same", "period", "the", "mean", "PCR", "worsened", "by", "almost", "1.5", "g/g", "in", "subjects", "randomized", "to", "placebo.", "<tag3>"], "wordsA": ["Results", "from", "this", "clinical", "study", "indicated", "the", "safety", "and", "tolerability", "of", "blisibimod", "administered", "as", "a", "single", "intravenous", "or", "subcutaneous", "dose", "were", "comparable", "to", "placebo."], "wordsB": ["In", "contrast,", "over", "the", "same", "period", "the", "mean", "PCR", "worsened", "by", "almost", "1.5", "g/g", "in", "subjects", "randomized", "to", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p65_s0", "idA": "1316175_16_item1_p117_s0", "sentA": "Since our inception in 2004, we have focused primarily on developing our product candidates, which currently include liprotamase and blisibimod.", "sentB": "Since our inception in 2004, we have focused primarily on developing our product candidates, which currently include Sollpura and blisibimod.", "type": 2, "words": ["<tag1>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "liprotamase", "and", "blisibimod.", "<tag2>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "Sollpura", "and", "blisibimod.", "<tag3>"], "wordsA": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "liprotamase", "and", "blisibimod."], "wordsB": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "Sollpura", "and", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p65_s1", "idA": "1316175_16_item1_p117_s1", "sentA": "We currently focus our clinical development and research efforts on liprotamase, as an enzyme replacement therapy for EPI, and blisibimod, which is being developed for autoimmune disease, including lupus and IgA nephropathy.", "sentB": "We currently focus our clinical development and research efforts on Sollpura, as an enzyme replacement therapy for EPI, and blisibimod, which is being developed for a renal disease, IgA nephropathy.", "type": 2, "words": ["<tag1>", "We", "currently", "focus", "our", "clinical", "development", "and", "research", "efforts", "on", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI,", "and", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy.", "<tag2>", "We", "currently", "focus", "our", "clinical", "development", "and", "research", "efforts", "on", "Sollpura,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI,", "and", "blisibimod,", "which", "is", "being", "developed", "for", "a", "renal", "disease,", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["We", "currently", "focus", "our", "clinical", "development", "and", "research", "efforts", "on", "liprotamase,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI,", "and", "blisibimod,", "which", "is", "being", "developed", "for", "autoimmune", "disease,", "including", "lupus", "and", "IgA", "nephropathy."], "wordsB": ["We", "currently", "focus", "our", "clinical", "development", "and", "research", "efforts", "on", "Sollpura,", "as", "an", "enzyme", "replacement", "therapy", "for", "EPI,", "and", "blisibimod,", "which", "is", "being", "developed", "for", "a", "renal", "disease,", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p65_s2", "idA": "1316175_16_item1_p117_s2", "sentA": "In the years ended December 31, 2015, 2014 and 2013, we incurred $33.6 million, $21.8 million and $21.7 million, respectively, of research and development expense.", "sentB": "In the years ended December 31, 2016, 2015 and 2014, we incurred $46.5 million, $33.6 million and $21.8 million, respectively, of research and development expense.", "type": 2, "words": ["<tag1>", "In", "the", "years", "ended", "December", "31,", "2015,", "2014", "and", "2013,", "we", "incurred", "$33.6", "million,", "$21.8", "million", "and", "$21.7", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag2>", "In", "the", "years", "ended", "December", "31,", "2016,", "2015", "and", "2014,", "we", "incurred", "$46.5", "million,", "$33.6", "million", "and", "$21.8", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag3>"], "wordsA": ["In", "the", "years", "ended", "December", "31,", "2015,", "2014", "and", "2013,", "we", "incurred", "$33.6", "million,", "$21.8", "million", "and", "$21.7", "million,", "respectively,", "of", "research", "and", "development", "expense."], "wordsB": ["In", "the", "years", "ended", "December", "31,", "2016,", "2015", "and", "2014,", "we", "incurred", "$46.5", "million,", "$33.6", "million", "and", "$21.8", "million,", "respectively,", "of", "research", "and", "development", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p66_s0", "idA": "1316175_16_item1_p118_s0", "sentA": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases.", "sentB": "Our objective is to develop and commercialize our product candidates to treat serious diseases associated with inflammation, including enzyme replacement therapies and renal disease.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "enzyme", "replacement", "therapies", "and", "autoimmune", "diseases.", "<tag2>", "Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "enzyme", "replacement", "therapies", "and", "renal", "disease.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "enzyme", "replacement", "therapies", "and", "autoimmune", "diseases."], "wordsB": ["Our", "objective", "is", "to", "develop", "and", "commercialize", "our", "product", "candidates", "to", "treat", "serious", "diseases", "associated", "with", "inflammation,", "including", "enzyme", "replacement", "therapies", "and", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p67_s0", "idA": "1316175_16_item1_p119_s0", "sentA": "We are advancing the development of liprotamase in a Phase 3 registration program in patients with cystic fibrosis-related EPI.", "sentB": "We are advancing the development of Sollpura in a Phase 3 registration program in patients with cystic fibrosis-related EPI.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI.", "<tag2>", "We", "are", "advancing", "the", "development", "of", "Sollpura", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "liprotamase", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI."], "wordsB": ["We", "are", "advancing", "the", "development", "of", "Sollpura", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p67_s2", "idA": "1316175_16_item1_p119_s3", "sentA": "We may opportunistically enter into collaborations with third parties for development of liprotamase and blisibimod, including securing corporate partners whose capabilities complement ours.", "sentB": "We may opportunistically enter into collaborations with third parties for development of Sollpura and blisibimod, including securing corporate partners whose capabilities complement ours.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "liprotamase", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "Sollpura", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "liprotamase", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "Sollpura", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p7_s0", "idA": "1316175_16_item1_p11_s0", "sentA": "A reduction in, or absence of the normally secreted pancreatic digestive enzymes, causes lipids, proteins, and carbohydrates to enter the distal gastrointestinal ( GI ) tract in unabsorbable forms, leading to GI pain and distention, maldigestion, and steatorrhea.", "sentB": "A reduction in, or absence of the normally secreted pancreatic digestive enzymes, causes lipids, proteins, and carbohydrates to enter the distal gastrointestinal ( GI ) tract in un-absorbable forms, leading to GI pain and distention, mal-digestion, and steatorrhea.", "type": 2, "words": ["<tag1>", "A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "unabsorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "maldigestion,", "and", "steatorrhea.", "<tag2>", "A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "un-absorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "mal-digestion,", "and", "steatorrhea.", "<tag3>"], "wordsA": ["A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "unabsorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "maldigestion,", "and", "steatorrhea."], "wordsB": ["A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "un-absorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "mal-digestion,", "and", "steatorrhea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p68_s0", "idA": "1316175_16_item1_p120_s0", "sentA": "Our product candidates are focused on highly-specialized physician segments, such as cystic fibrosis specialists, rheumatologists and nephrologists.", "sentB": "Our product candidates are focused on highly-specialized physician segments, such as cystic fibrosis specialists and nephrologists.", "type": 2, "words": ["<tag1>", "Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "cystic", "fibrosis", "specialists,", "rheumatologists", "and", "nephrologists.", "<tag2>", "Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "cystic", "fibrosis", "specialists", "and", "nephrologists.", "<tag3>"], "wordsA": ["Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "cystic", "fibrosis", "specialists,", "rheumatologists", "and", "nephrologists."], "wordsB": ["Our", "product", "candidates", "are", "focused", "on", "highly-specialized", "physician", "segments,", "such", "as", "cystic", "fibrosis", "specialists", "and", "nephrologists."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p71_s0", "idA": "1316175_16_item1_p123_s0", "sentA": "There are currently several marketed products for EPI caused by cystic fibrosis, including Creon marketed by AbbVie, Inc., Pancreaze by Janssen Pharmaceuticals, Inc., Pertzye by Cornestone Therapeutics, Inc., and Ultresa and Zenpep by Aptalis Pharma US.", "sentB": "There are currently several marketed products for EPI caused by cystic fibrosis, including Creon marketed by AbbVie, Inc., Pancreaze by Janssen Pharmaceuticals, Inc., Pertzye by Cornerstone Therapeutics, Inc., and Ultresa and Zenpep by Aptalis Pharma US.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "several", "marketed", "products", "for", "EPI", "caused", "by", "cystic", "fibrosis,", "including", "Creon", "marketed", "by", "AbbVie,", "Inc.,", "Pancreaze", "by", "Janssen", "Pharmaceuticals,", "Inc.,", "Pertzye", "by", "Cornestone", "Therapeutics,", "Inc.,", "and", "Ultresa", "and", "Zenpep", "by", "Aptalis", "Pharma", "US.", "<tag2>", "There", "are", "currently", "several", "marketed", "products", "for", "EPI", "caused", "by", "cystic", "fibrosis,", "including", "Creon", "marketed", "by", "AbbVie,", "Inc.,", "Pancreaze", "by", "Janssen", "Pharmaceuticals,", "Inc.,", "Pertzye", "by", "Cornerstone", "Therapeutics,", "Inc.,", "and", "Ultresa", "and", "Zenpep", "by", "Aptalis", "Pharma", "US.", "<tag3>"], "wordsA": ["There", "are", "currently", "several", "marketed", "products", "for", "EPI", "caused", "by", "cystic", "fibrosis,", "including", "Creon", "marketed", "by", "AbbVie,", "Inc.,", "Pancreaze", "by", "Janssen", "Pharmaceuticals,", "Inc.,", "Pertzye", "by", "Cornestone", "Therapeutics,", "Inc.,", "and", "Ultresa", "and", "Zenpep", "by", "Aptalis", "Pharma", "US."], "wordsB": ["There", "are", "currently", "several", "marketed", "products", "for", "EPI", "caused", "by", "cystic", "fibrosis,", "including", "Creon", "marketed", "by", "AbbVie,", "Inc.,", "Pancreaze", "by", "Janssen", "Pharmaceuticals,", "Inc.,", "Pertzye", "by", "Cornerstone", "Therapeutics,", "Inc.,", "and", "Ultresa", "and", "Zenpep", "by", "Aptalis", "Pharma", "US."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p63_s3", "idA": "1316175_16_item1_p126_s2", "sentA": "Several other agents under development target other B-cell related pathways or other inflammatory mechanisms for the treatment of lupus.", "sentB": "Both studies failed to meet the primary endpoints and we elected to stop further development of blisibimod for the treatment of lupus.", "type": 2, "words": ["<tag1>", "Several", "other", "agents", "under", "development", "target", "other", "B-cell", "related", "pathways", "or", "other", "inflammatory", "mechanisms", "for", "the", "treatment", "of", "lupus.", "<tag2>", "Both", "studies", "failed", "to", "meet", "the", "primary", "endpoints", "and", "we", "elected", "to", "stop", "further", "development", "of", "blisibimod", "for", "the", "treatment", "of", "lupus.", "<tag3>"], "wordsA": ["Several", "other", "agents", "under", "development", "target", "other", "B-cell", "related", "pathways", "or", "other", "inflammatory", "mechanisms", "for", "the", "treatment", "of", "lupus."], "wordsB": ["Both", "studies", "failed", "to", "meet", "the", "primary", "endpoints", "and", "we", "elected", "to", "stop", "further", "development", "of", "blisibimod", "for", "the", "treatment", "of", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p76_s0", "idA": "1316175_16_item1_p130_s0", "sentA": "As of the date of this report, our liprotomase portfolio is made up of exclusively licensed patents and patent applications from Eli Lilly, including:", "sentB": "As of the date of this report, our Sollpura portfolio is made up of exclusively licensed patents and patent applications from Eli Lilly, including:", "type": 2, "words": ["<tag1>", "As", "of", "the", "date", "of", "this", "report,", "our", "liprotomase", "portfolio", "is", "made", "up", "of", "exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Eli", "Lilly,", "including:", "<tag2>", "As", "of", "the", "date", "of", "this", "report,", "our", "Sollpura", "portfolio", "is", "made", "up", "of", "exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Eli", "Lilly,", "including:", "<tag3>"], "wordsA": ["As", "of", "the", "date", "of", "this", "report,", "our", "liprotomase", "portfolio", "is", "made", "up", "of", "exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Eli", "Lilly,", "including:"], "wordsB": ["As", "of", "the", "date", "of", "this", "report,", "our", "Sollpura", "portfolio", "is", "made", "up", "of", "exclusively", "licensed", "patents", "and", "patent", "applications", "from", "Eli", "Lilly,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p78_s2", "idA": "1316175_16_item1_p132_s2", "sentA": "Depending upon the timing, duration and specifics of FDA approval of liprotamase, one of these U.S. patents may be eligible for a patent term restoration of up to five years under Hatch-Waxman Act.", "sentB": "Depending upon the timing, duration and specifics of FDA approval of Sollpura, one of these U.S. patents may be eligible for a patent term restoration of up to five years under Hatch-Waxman Act.", "type": 2, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "liprotamase,", "one", "of", "these", "U.S.", "patents", "may", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "Hatch-Waxman", "Act.", "<tag2>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "Sollpura,", "one", "of", "these", "U.S.", "patents", "may", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "Hatch-Waxman", "Act.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "liprotamase,", "one", "of", "these", "U.S.", "patents", "may", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "Hatch-Waxman", "Act."], "wordsB": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "Sollpura,", "one", "of", "these", "U.S.", "patents", "may", "be", "eligible", "for", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "under", "Hatch-Waxman", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p81_s1", "idA": "1316175_16_item1_p135_s1", "sentA": "In addition, we hold a non-exclusive worldwide license to one pending U.S. non-provisional patent application, one EP patent, one pending EP patent application, and over 50 non-EP foreign patents and pending patent applications relating to general peptibody compositions and formulations.", "sentB": "In addition, we hold a non-exclusive worldwide license to one issued U.S. patent, one pending U.S. non-provisional patent application, one EP patent, one pending EP patent application, and over 50 non-EP foreign patents and pending patent applications relating to general peptibody compositions and formulations.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "and", "over", "50", "non-EP", "foreign", "patents", "and", "pending", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations.", "<tag2>", "In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "issued", "U.S.", "patent,", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "and", "over", "50", "non-EP", "foreign", "patents", "and", "pending", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations.", "<tag3>"], "wordsA": ["In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "and", "over", "50", "non-EP", "foreign", "patents", "and", "pending", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations."], "wordsB": ["In", "addition,", "we", "hold", "a", "non-exclusive", "worldwide", "license", "to", "one", "issued", "U.S.", "patent,", "one", "pending", "U.S.", "non-provisional", "patent", "application,", "one", "EP", "patent,", "one", "pending", "EP", "patent", "application,", "and", "over", "50", "non-EP", "foreign", "patents", "and", "pending", "patent", "applications", "relating", "to", "general", "peptibody", "compositions", "and", "formulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p12_s0", "idA": "1316175_16_item1_p13_s0", "sentA": "We believe liprotamase is potentially the first soluble, stable and non-porcine derived enzyme product to offer a novel solution to patients who are unable to maintain appropriate nutritional health.", "sentB": "We believe Sollpura is potentially the first soluble, stable and non-porcine derived enzyme product to offer a novel solution to patients who are unable to maintain appropriate nutritional health.", "type": 2, "words": ["<tag1>", "We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health.", "<tag2>", "We", "believe", "Sollpura", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health.", "<tag3>"], "wordsA": ["We", "believe", "liprotamase", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health."], "wordsB": ["We", "believe", "Sollpura", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p87_s0", "idA": "1316175_16_item1_p141_s0", "sentA": "We are aware of two families of third-party U.S. patents and pending foreign applications that contain broad claims related to BLyS or BAFF binding polypeptides.", "sentB": "We are aware of two third-party issued U.S. patents that contain broad claims related to BLyS or BAFF binding polypeptides.", "type": 2, "words": ["<tag1>", "We", "are", "aware", "of", "two", "families", "of", "third-party", "U.S.", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides.", "<tag2>", "We", "are", "aware", "of", "two", "third-party", "issued", "U.S.", "patents", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides.", "<tag3>"], "wordsA": ["We", "are", "aware", "of", "two", "families", "of", "third-party", "U.S.", "patents", "and", "pending", "foreign", "applications", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides."], "wordsB": ["We", "are", "aware", "of", "two", "third-party", "issued", "U.S.", "patents", "that", "contain", "broad", "claims", "related", "to", "BLyS", "or", "BAFF", "binding", "polypeptides."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p87_s2", "idA": "1316175_16_item1_p141_s2", "sentA": "If we were to challenge the validity of any issued U.S. patent in court, we would need to overcome the presumption of validity that attaches to every U.S. patent by presenting clear and convincing evidence as to the invalidity of the patent s claims.", "sentB": "If we were to challenge the validity of either of these issued U.S. patents in court, we would need to overcome the presumption of validity that attaches to every U.S. patent by presenting clear and convincing evidence as to the invalidity of the patent s claims.", "type": 2, "words": ["<tag1>", "If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "U.S.", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "U.S.", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims.", "<tag2>", "If", "we", "were", "to", "challenge", "the", "validity", "of", "either", "of", "these", "issued", "U.S.", "patents", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "U.S.", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims.", "<tag3>"], "wordsA": ["If", "we", "were", "to", "challenge", "the", "validity", "of", "any", "issued", "U.S.", "patent", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "U.S.", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims."], "wordsB": ["If", "we", "were", "to", "challenge", "the", "validity", "of", "either", "of", "these", "issued", "U.S.", "patents", "in", "court,", "we", "would", "need", "to", "overcome", "the", "presumption", "of", "validity", "that", "attaches", "to", "every", "U.S.", "patent", "by", "presenting", "clear", "and", "convincing", "evidence", "as", "to", "the", "invalidity", "of", "the", "patent", "s", "claims."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p93_s0", "idA": "1316175_16_item1_p147_s0", "sentA": "In connection with the collaborative arrangement with Zenyaku, we amended the Amgen Agreement in November 2014 to (i) adjust certain royalty and milestone payment obligations payable to Amgen in light of our collaboration with Zenyaku and (ii) provide that the sublicense granted by us to Zenyaku shall survive the termination of the Amgen Agreement.", "sentB": "In connection with a collaborative arrangement with Zenyaku for the development of IgA nephropathy that was executed in December 2014 and terminated in January 2016, we amended the Amgen Agreement in November 2014 to (i) adjust certain royalty and milestone payment obligations payable to Amgen in light of our collaboration with Zenyaku and (ii) provide that the sublicense granted by us to Zenyaku shall survive the termination of the Amgen Agreement.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "the", "collaborative", "arrangement", "with", "Zenyaku,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement.", "<tag2>", "In", "connection", "with", "a", "collaborative", "arrangement", "with", "Zenyaku", "for", "the", "development", "of", "IgA", "nephropathy", "that", "was", "executed", "in", "December", "2014", "and", "terminated", "in", "January", "2016,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement.", "<tag3>"], "wordsA": ["In", "connection", "with", "the", "collaborative", "arrangement", "with", "Zenyaku,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement."], "wordsB": ["In", "connection", "with", "a", "collaborative", "arrangement", "with", "Zenyaku", "for", "the", "development", "of", "IgA", "nephropathy", "that", "was", "executed", "in", "December", "2014", "and", "terminated", "in", "January", "2016,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p93_s1", "idA": "1316175_16_item1_p147_s1", "sentA": "Under this amendment, we also agreed to grant Amgen that number of shares of our common stock equal $1 .0 million divided by the volume weighted average price of our common stock for 20 trading days prior to issuance.", "sentB": "Under this amendment, we also agreed to grant Amgen that number of shares of our common stock equal to $1.0 million divided by the volume weighted average price of our common stock for 20 trading days prior to issuance.", "type": 2, "words": ["<tag1>", "Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1", ".0", "million", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance.", "<tag2>", "Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "to", "$1.0", "million", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance.", "<tag3>"], "wordsA": ["Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "$1", ".0", "million", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance."], "wordsB": ["Under", "this", "amendment,", "we", "also", "agreed", "to", "grant", "Amgen", "that", "number", "of", "shares", "of", "our", "common", "stock", "equal", "to", "$1.0", "million", "divided", "by", "the", "volume", "weighted", "average", "price", "of", "our", "common", "stock", "for", "20", "trading", "days", "prior", "to", "issuance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p94_s0", "idA": "1316175_16_item1_p148_s0", "sentA": "On July 11, 2014, we entered into a worldwide, exclusive license agreement with Eli Lilly (the Lilly Agreement ), to develop and commercialize liprotamase, a Phase 3 novel investigational PERT for the treatment of patients with EPI, often seen in patients with cystic fibrosis and other conditions.", "sentB": "On July 11, 2014, we entered into a worldwide, exclusive license agreement with Eli Lilly (the Lilly Agreement ), to develop and commercialize Sollpura, a Phase 3 novel investigational PERT for the treatment of patients with EPI, often seen in patients with cystic fibrosis and other conditions.", "type": 2, "words": ["<tag1>", "On", "July", "11,", "2014,", "we", "entered", "into", "a", "worldwide,", "exclusive", "license", "agreement", "with", "Eli", "Lilly", "(the", "Lilly", "Agreement", "),", "to", "develop", "and", "commercialize", "liprotamase,", "a", "Phase", "3", "novel", "investigational", "PERT", "for", "the", "treatment", "of", "patients", "with", "EPI,", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag2>", "On", "July", "11,", "2014,", "we", "entered", "into", "a", "worldwide,", "exclusive", "license", "agreement", "with", "Eli", "Lilly", "(the", "Lilly", "Agreement", "),", "to", "develop", "and", "commercialize", "Sollpura,", "a", "Phase", "3", "novel", "investigational", "PERT", "for", "the", "treatment", "of", "patients", "with", "EPI,", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag3>"], "wordsA": ["On", "July", "11,", "2014,", "we", "entered", "into", "a", "worldwide,", "exclusive", "license", "agreement", "with", "Eli", "Lilly", "(the", "Lilly", "Agreement", "),", "to", "develop", "and", "commercialize", "liprotamase,", "a", "Phase", "3", "novel", "investigational", "PERT", "for", "the", "treatment", "of", "patients", "with", "EPI,", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "wordsB": ["On", "July", "11,", "2014,", "we", "entered", "into", "a", "worldwide,", "exclusive", "license", "agreement", "with", "Eli", "Lilly", "(the", "Lilly", "Agreement", "),", "to", "develop", "and", "commercialize", "Sollpura,", "a", "Phase", "3", "novel", "investigational", "PERT", "for", "the", "treatment", "of", "patients", "with", "EPI,", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p54_s3", "idA": "1316175_16_item1_p149_s5", "sentA": "As a result of the termination on January 7, 2016, we regained full worldwide rights for blisibimod.", "sentB": "As a result of the narrow miss we intend to initiate a new Phase 3 study, RESULT, incorporating the learnings from the SOLUTION study.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod.", "<tag2>", "As", "a", "result", "of", "the", "narrow", "miss", "we", "intend", "to", "initiate", "a", "new", "Phase", "3", "study,", "RESULT,", "incorporating", "the", "learnings", "from", "the", "SOLUTION", "study.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod."], "wordsB": ["As", "a", "result", "of", "the", "narrow", "miss", "we", "intend", "to", "initiate", "a", "new", "Phase", "3", "study,", "RESULT,", "incorporating", "the", "learnings", "from", "the", "SOLUTION", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p56_s1", "idA": "1316175_16_item1_p149_s5", "sentA": "As a result of the termination on January 7, 2016, we regained full worldwide rights for blisibimod.", "sentB": "As a result of the proteinuria effect after 48 weeks of dosing, and the demonstration of blisibimod s effect on immunological markers relevant to IgA nephropathy including reductions of B cells, and immunoglobulins including IgA, IgG and IgM, we plan to continue the study until the majority of subjects have had the opportunity to complete two years of treatment.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod.", "<tag2>", "As", "a", "result", "of", "the", "proteinuria", "effect", "after", "48", "weeks", "of", "dosing,", "and", "the", "demonstration", "of", "blisibimod", "s", "effect", "on", "immunological", "markers", "relevant", "to", "IgA", "nephropathy", "including", "reductions", "of", "B", "cells,", "and", "immunoglobulins", "including", "IgA,", "IgG", "and", "IgM,", "we", "plan", "to", "continue", "the", "study", "until", "the", "majority", "of", "subjects", "have", "had", "the", "opportunity", "to", "complete", "two", "years", "of", "treatment.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod."], "wordsB": ["As", "a", "result", "of", "the", "proteinuria", "effect", "after", "48", "weeks", "of", "dosing,", "and", "the", "demonstration", "of", "blisibimod", "s", "effect", "on", "immunological", "markers", "relevant", "to", "IgA", "nephropathy", "including", "reductions", "of", "B", "cells,", "and", "immunoglobulins", "including", "IgA,", "IgG", "and", "IgM,", "we", "plan", "to", "continue", "the", "study", "until", "the", "majority", "of", "subjects", "have", "had", "the", "opportunity", "to", "complete", "two", "years", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p64_s5", "idA": "1316175_16_item1_p149_s5", "sentA": "As a result of the termination on January 7, 2016, we regained full worldwide rights for blisibimod.", "sentB": "As a result of the outcomes of the CHABLIS-SC1 trial, at the end of 2016, we elected to discontinue the Phase 3 CHABLIS-7.5 study, which was initiated in June 2016.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod.", "<tag2>", "As", "a", "result", "of", "the", "outcomes", "of", "the", "CHABLIS-SC1", "trial,", "at", "the", "end", "of", "2016,", "we", "elected", "to", "discontinue", "the", "Phase", "3", "CHABLIS-7.5", "study,", "which", "was", "initiated", "in", "June", "2016.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "termination", "on", "January", "7,", "2016,", "we", "regained", "full", "worldwide", "rights", "for", "blisibimod."], "wordsB": ["As", "a", "result", "of", "the", "outcomes", "of", "the", "CHABLIS-SC1", "trial,", "at", "the", "end", "of", "2016,", "we", "elected", "to", "discontinue", "the", "Phase", "3", "CHABLIS-7.5", "study,", "which", "was", "initiated", "in", "June", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p13_s0", "idA": "1316175_16_item1_p14_s0", "sentA": "Liprotamase s chemical characteristics, unlike currently available PERTs, make it ideal for powder formulation as either a capsule, or sachet of powder for oral solution which can be conveniently administered in solution in a small volume of water.", "sentB": "Sollpura s chemical characteristics, unlike currently available PERTs, make it ideal for powder formulation as either a capsule, or sachet of powder for oral solution which can be conveniently administered in solution in a small volume of water.", "type": 2, "words": ["<tag1>", "Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule,", "or", "sachet", "of", "powder", "for", "oral", "solution", "which", "can", "be", "conveniently", "administered", "in", "solution", "in", "a", "small", "volume", "of", "water.", "<tag2>", "Sollpura", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule,", "or", "sachet", "of", "powder", "for", "oral", "solution", "which", "can", "be", "conveniently", "administered", "in", "solution", "in", "a", "small", "volume", "of", "water.", "<tag3>"], "wordsA": ["Liprotamase", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule,", "or", "sachet", "of", "powder", "for", "oral", "solution", "which", "can", "be", "conveniently", "administered", "in", "solution", "in", "a", "small", "volume", "of", "water."], "wordsB": ["Sollpura", "s", "chemical", "characteristics,", "unlike", "currently", "available", "PERTs,", "make", "it", "ideal", "for", "powder", "formulation", "as", "either", "a", "capsule,", "or", "sachet", "of", "powder", "for", "oral", "solution", "which", "can", "be", "conveniently", "administered", "in", "solution", "in", "a", "small", "volume", "of", "water."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p19_s2", "idA": "1316175_16_item1_p150_s1", "sentA": "We plan to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our product candidates if and when approved for marketing by the FDA.", "sentB": "We currently plan to continue the EASY study until the BLA for Sollpura is approved by the FDA.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA.", "<tag2>", "We", "currently", "plan", "to", "continue", "the", "EASY", "study", "until", "the", "BLA", "for", "Sollpura", "is", "approved", "by", "the", "FDA.", "<tag3>"], "wordsA": ["We", "plan", "to", "continue", "to", "rely", "upon", "contract", "manufacturers", "and,", "potentially,", "collaboration", "partners", "to", "manufacture", "commercial", "quantities", "of", "our", "product", "candidates", "if", "and", "when", "approved", "for", "marketing", "by", "the", "FDA."], "wordsB": ["We", "currently", "plan", "to", "continue", "the", "EASY", "study", "until", "the", "BLA", "for", "Sollpura", "is", "approved", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p101_s1", "idA": "1316175_16_item1_p155_s1", "sentA": "Our product candidates must be approved by the FDA through the new drug application, or NDA, process, and our biological product candidate, blisibimod, must be approved by the FDA through the biologics license application, or BLA, process before they may legally be marketed in the United States.", "sentB": "Our product candidates must be approved by the FDA through either the new drug application, or NDA, process, or the biologics license application, or BLA, process before they may legally be marketed in the United States.", "type": 2, "words": ["<tag1>", "Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process,", "and", "our", "biological", "product", "candidate,", "blisibimod,", "must", "be", "approved", "by", "the", "FDA", "through", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States.", "<tag2>", "Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "either", "the", "new", "drug", "application,", "or", "NDA,", "process,", "or", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "the", "new", "drug", "application,", "or", "NDA,", "process,", "and", "our", "biological", "product", "candidate,", "blisibimod,", "must", "be", "approved", "by", "the", "FDA", "through", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States."], "wordsB": ["Our", "product", "candidates", "must", "be", "approved", "by", "the", "FDA", "through", "either", "the", "new", "drug", "application,", "or", "NDA,", "process,", "or", "the", "biologics", "license", "application,", "or", "BLA,", "process", "before", "they", "may", "legally", "be", "marketed", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s0", "idA": "1316175_16_item1_p15_s0", "sentA": "We initiated the SOLUTION study in the third quarter of 2015.", "sentB": "We initiated the Phase 3 SOLUTION study in the third quarter of 2015.", "type": 2, "words": ["<tag1>", "We", "initiated", "the", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015.", "<tag2>", "We", "initiated", "the", "Phase", "3", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015.", "<tag3>"], "wordsA": ["We", "initiated", "the", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015."], "wordsB": ["We", "initiated", "the", "Phase", "3", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p19_s0", "idA": "1316175_16_item1_p15_s0", "sentA": "We initiated the SOLUTION study in the third quarter of 2015.", "sentB": "During the third quarter of 2016, we initiated the EASY study, which provides continued access to Sollpura for patients who completed the SOLUTION study.", "type": 2, "words": ["<tag1>", "We", "initiated", "the", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015.", "<tag2>", "During", "the", "third", "quarter", "of", "2016,", "we", "initiated", "the", "EASY", "study,", "which", "provides", "continued", "access", "to", "Sollpura", "for", "patients", "who", "completed", "the", "SOLUTION", "study.", "<tag3>"], "wordsA": ["We", "initiated", "the", "SOLUTION", "study", "in", "the", "third", "quarter", "of", "2015."], "wordsB": ["During", "the", "third", "quarter", "of", "2016,", "we", "initiated", "the", "EASY", "study,", "which", "provides", "continued", "access", "to", "Sollpura", "for", "patients", "who", "completed", "the", "SOLUTION", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s1", "idA": "1316175_16_item1_p15_s1", "sentA": "SOLUTION is a Phase 3, randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the efficacy and safety of liprotamase in patients with cystic fibrosis-related exocrine pancreatic insufficiency.", "sentB": "SOLUTION is a randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the efficacy and safety of Sollpura in patients with cystic fibrosis-related exocrine pancreatic insufficiency.", "type": 2, "words": ["<tag1>", "SOLUTION", "is", "a", "Phase", "3,", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "liprotamase", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency.", "<tag2>", "SOLUTION", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "Sollpura", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency.", "<tag3>"], "wordsA": ["SOLUTION", "is", "a", "Phase", "3,", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "liprotamase", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency."], "wordsB": ["SOLUTION", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "Sollpura", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s2", "idA": "1316175_16_item1_p15_s2", "sentA": "This pivotal study is intended to evaluate the non-inferiority of liprotamase compared with another commercially available PERT in a population enriched for PERT responders and will enroll up to 150 patients in the United States and Europe.", "sentB": "This pivotal study enrolled 128 patients in North America, Europe and Israel to evaluate the non-inferiority of Sollpura compared with another commercially available PERT in a population of porcine-derived PERT responders.", "type": 2, "words": ["<tag1>", "This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders", "and", "will", "enroll", "up", "to", "150", "patients", "in", "the", "United", "States", "and", "Europe.", "<tag2>", "This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders.", "<tag3>"], "wordsA": ["This", "pivotal", "study", "is", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "enriched", "for", "PERT", "responders", "and", "will", "enroll", "up", "to", "150", "patients", "in", "the", "United", "States", "and", "Europe."], "wordsB": ["This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s0", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "Because the SOLUTION study failed to achieve its primary endpoint by only one 1%, we plan to initiate a new Phase 3 study, informed by the SOLUTION study data, which we refer to as the RESULT study.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "Because", "the", "SOLUTION", "study", "failed", "to", "achieve", "its", "primary", "endpoint", "by", "only", "one", "1%,", "we", "plan", "to", "initiate", "a", "new", "Phase", "3", "study,", "informed", "by", "the", "SOLUTION", "study", "data,", "which", "we", "refer", "to", "as", "the", "RESULT", "study.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["Because", "the", "SOLUTION", "study", "failed", "to", "achieve", "its", "primary", "endpoint", "by", "only", "one", "1%,", "we", "plan", "to", "initiate", "a", "new", "Phase", "3", "study,", "informed", "by", "the", "SOLUTION", "study", "data,", "which", "we", "refer", "to", "as", "the", "RESULT", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s3", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "Approximately 150 cystic fibrosis patients who are porcine PERT responders will be enrolled in similar geographies as the SOLUTION study.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "Approximately", "150", "cystic", "fibrosis", "patients", "who", "are", "porcine", "PERT", "responders", "will", "be", "enrolled", "in", "similar", "geographies", "as", "the", "SOLUTION", "study.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["Approximately", "150", "cystic", "fibrosis", "patients", "who", "are", "porcine", "PERT", "responders", "will", "be", "enrolled", "in", "similar", "geographies", "as", "the", "SOLUTION", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s5", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "We believe that efficacy in the SOLUTION study was limited by a restrictive dose optimization paradigm in a population whose dose of lipase at baseline had been optimized for porcine PERTs (but not Sollpura) and that modification of the dosing paradigm may allow for success in the RESULT study.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "We", "believe", "that", "efficacy", "in", "the", "SOLUTION", "study", "was", "limited", "by", "a", "restrictive", "dose", "optimization", "paradigm", "in", "a", "population", "whose", "dose", "of", "lipase", "at", "baseline", "had", "been", "optimized", "for", "porcine", "PERTs", "(but", "not", "Sollpura)", "and", "that", "modification", "of", "the", "dosing", "paradigm", "may", "allow", "for", "success", "in", "the", "RESULT", "study.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["We", "believe", "that", "efficacy", "in", "the", "SOLUTION", "study", "was", "limited", "by", "a", "restrictive", "dose", "optimization", "paradigm", "in", "a", "population", "whose", "dose", "of", "lipase", "at", "baseline", "had", "been", "optimized", "for", "porcine", "PERTs", "(but", "not", "Sollpura)", "and", "that", "modification", "of", "the", "dosing", "paradigm", "may", "allow", "for", "success", "in", "the", "RESULT", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p18_s0", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "Based on the data produced by the SOLUTION study, we plan to amend the SIMPLICITY study to follow similar dosing paradigm as the RESULT study.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "Based", "on", "the", "data", "produced", "by", "the", "SOLUTION", "study,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "similar", "dosing", "paradigm", "as", "the", "RESULT", "study.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["Based", "on", "the", "data", "produced", "by", "the", "SOLUTION", "study,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "similar", "dosing", "paradigm", "as", "the", "RESULT", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p4_s0", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "* Continued access study provided to patients who previously completed the SOLUTION study.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "*", "Continued", "access", "study", "provided", "to", "patients", "who", "previously", "completed", "the", "SOLUTION", "study.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["*", "Continued", "access", "study", "provided", "to", "patients", "who", "previously", "completed", "the", "SOLUTION", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p54_s1", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "We completed the SOLUTION study and reported topline data in December 2016.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "We", "completed", "the", "SOLUTION", "study", "and", "reported", "topline", "data", "in", "December", "2016.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["We", "completed", "the", "SOLUTION", "study", "and", "reported", "topline", "data", "in", "December", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p54_s2", "idA": "1316175_16_item1_p15_s3", "sentA": "Liprotamase will be supplied in capsule form for the SOLUTION study.", "sentB": "The SOLUTION study narrowly missed the primary endpoint by one percent.", "type": 2, "words": ["<tag1>", "Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study.", "<tag2>", "The", "SOLUTION", "study", "narrowly", "missed", "the", "primary", "endpoint", "by", "one", "percent.", "<tag3>"], "wordsA": ["Liprotamase", "will", "be", "supplied", "in", "capsule", "form", "for", "the", "SOLUTION", "study."], "wordsB": ["The", "SOLUTION", "study", "narrowly", "missed", "the", "primary", "endpoint", "by", "one", "percent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p16_s1", "idA": "1316175_16_item1_p15_s5", "sentA": "The SIMPLICITY study will utilize sachets containing liprotamase powder for oral solution for ease of administration and will enroll approximately 60 patients.", "sentB": "The SIMPLICITY study utilizes sachets containing Sollpura powder for oral solution.", "type": 2, "words": ["<tag1>", "The", "SIMPLICITY", "study", "will", "utilize", "sachets", "containing", "liprotamase", "powder", "for", "oral", "solution", "for", "ease", "of", "administration", "and", "will", "enroll", "approximately", "60", "patients.", "<tag2>", "The", "SIMPLICITY", "study", "utilizes", "sachets", "containing", "Sollpura", "powder", "for", "oral", "solution.", "<tag3>"], "wordsA": ["The", "SIMPLICITY", "study", "will", "utilize", "sachets", "containing", "liprotamase", "powder", "for", "oral", "solution", "for", "ease", "of", "administration", "and", "will", "enroll", "approximately", "60", "patients."], "wordsB": ["The", "SIMPLICITY", "study", "utilizes", "sachets", "containing", "Sollpura", "powder", "for", "oral", "solution."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p18_s1", "idA": "1316175_16_item1_p15_s5", "sentA": "The SIMPLICITY study will utilize sachets containing liprotamase powder for oral solution for ease of administration and will enroll approximately 60 patients.", "sentB": "Part B of SIMPLICITY study will commence enrollment towards the middle of 2017.", "type": 2, "words": ["<tag1>", "The", "SIMPLICITY", "study", "will", "utilize", "sachets", "containing", "liprotamase", "powder", "for", "oral", "solution", "for", "ease", "of", "administration", "and", "will", "enroll", "approximately", "60", "patients.", "<tag2>", "Part", "B", "of", "SIMPLICITY", "study", "will", "commence", "enrollment", "towards", "the", "middle", "of", "2017.", "<tag3>"], "wordsA": ["The", "SIMPLICITY", "study", "will", "utilize", "sachets", "containing", "liprotamase", "powder", "for", "oral", "solution", "for", "ease", "of", "administration", "and", "will", "enroll", "approximately", "60", "patients."], "wordsB": ["Part", "B", "of", "SIMPLICITY", "study", "will", "commence", "enrollment", "towards", "the", "middle", "of", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p19_s1", "idA": "1316175_16_item1_p15_s6", "sentA": "We believe the SOLUTION and SIMPLICITY studies may offer a number of potential opportunities for differentiation versus the currently marketed PERTs, including:", "sentB": "The EASY study will also be offered to patients completing RESULT and SIMPLICITY studies.", "type": 2, "words": ["<tag1>", "We", "believe", "the", "SOLUTION", "and", "SIMPLICITY", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:", "<tag2>", "The", "EASY", "study", "will", "also", "be", "offered", "to", "patients", "completing", "RESULT", "and", "SIMPLICITY", "studies.", "<tag3>"], "wordsA": ["We", "believe", "the", "SOLUTION", "and", "SIMPLICITY", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:"], "wordsB": ["The", "EASY", "study", "will", "also", "be", "offered", "to", "patients", "completing", "RESULT", "and", "SIMPLICITY", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p20_s0", "idA": "1316175_16_item1_p15_s6", "sentA": "We believe the SOLUTION and SIMPLICITY studies may offer a number of potential opportunities for differentiation versus the currently marketed PERTs, including:", "sentB": "We believe our Sollpura studies may offer a number of potential opportunities for differentiation versus the currently marketed porcine-derived PERTs, including:", "type": 2, "words": ["<tag1>", "We", "believe", "the", "SOLUTION", "and", "SIMPLICITY", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:", "<tag2>", "We", "believe", "our", "Sollpura", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "porcine-derived", "PERTs,", "including:", "<tag3>"], "wordsA": ["We", "believe", "the", "SOLUTION", "and", "SIMPLICITY", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "PERTs,", "including:"], "wordsB": ["We", "believe", "our", "Sollpura", "studies", "may", "offer", "a", "number", "of", "potential", "opportunities", "for", "differentiation", "versus", "the", "currently", "marketed", "porcine-derived", "PERTs,", "including:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p56_s3", "idA": "1316175_16_item1_p166_s0", "sentA": "Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA.", "sentB": "In December 2016, we submitted an orphan designation request to the US FDA.", "type": 2, "words": ["<tag1>", "Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA.", "<tag2>", "In", "December", "2016,", "we", "submitted", "an", "orphan", "designation", "request", "to", "the", "US", "FDA.", "<tag3>"], "wordsA": ["Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "studies", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA."], "wordsB": ["In", "December", "2016,", "we", "submitted", "an", "orphan", "designation", "request", "to", "the", "US", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s6", "idA": "1316175_16_item1_p179_s2", "sentA": "This six-month exclusivity, which runs from the end of other exclusivity protection or patent delay, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued Written Request for such a study.", "sentB": "Topline data from the RESULT study is expected towards the end of 2017 or in early 2018.", "type": 2, "words": ["<tag1>", "This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study.", "<tag2>", "Topline", "data", "from", "the", "RESULT", "study", "is", "expected", "towards", "the", "end", "of", "2017", "or", "in", "early", "2018.", "<tag3>"], "wordsA": ["This", "six-month", "exclusivity,", "which", "runs", "from", "the", "end", "of", "other", "exclusivity", "protection", "or", "patent", "delay,", "may", "be", "granted", "based", "on", "the", "voluntary", "completion", "of", "a", "pediatric", "study", "in", "accordance", "with", "an", "FDA-issued", "Written", "Request", "for", "such", "a", "study."], "wordsB": ["Topline", "data", "from", "the", "RESULT", "study", "is", "expected", "towards", "the", "end", "of", "2017", "or", "in", "early", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p23_s0", "idA": "1316175_16_item1_p17_s0", "sentA": "a sachet formulation containing liprotamase power for oral solution which can be easily dissolved into water, and finally provides patients, especially young pediatric patients, with an easy-to-swallow dosing option.", "sentB": "a sachet formulation containing Sollpura power for oral solution which can be easily dissolved into water, and finally provides patients, especially young pediatric patients, with an easy-to-swallow dosing option.", "type": 2, "words": ["<tag1>", "a", "sachet", "formulation", "containing", "liprotamase", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option.", "<tag2>", "a", "sachet", "formulation", "containing", "Sollpura", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option.", "<tag3>"], "wordsA": ["a", "sachet", "formulation", "containing", "liprotamase", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option."], "wordsB": ["a", "sachet", "formulation", "containing", "Sollpura", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p1_s0", "idA": "1316175_16_item1_p1_s0", "sentA": "Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "sentB": "Sollpura TM is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "type": 2, "words": ["<tag1>", "Sollpura", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag2>", "Sollpura", "TM", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag3>"], "wordsA": ["Sollpura", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "wordsB": ["Sollpura", "TM", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p157_s0", "idA": "1316175_16_item1_p211_s0", "sentA": "As of December 31, 2015, we had 25 employees.", "sentB": "As of December 31, 2016, we had 33 employees.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2015,", "we", "had", "25", "employees.", "<tag2>", "As", "of", "December", "31,", "2016,", "we", "had", "33", "employees.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2015,", "we", "had", "25", "employees."], "wordsB": ["As", "of", "December", "31,", "2016,", "we", "had", "33", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p157_s1", "idA": "1316175_16_item1_p211_s1", "sentA": "All of our employees are engaged in administration, finance, clinical, regulatory and business development functions.", "sentB": "All of our employees are engaged in administration, finance, clinical, manufacturing, regulatory and business development functions.", "type": 2, "words": ["<tag1>", "All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "regulatory", "and", "business", "development", "functions.", "<tag2>", "All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "manufacturing,", "regulatory", "and", "business", "development", "functions.", "<tag3>"], "wordsA": ["All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "regulatory", "and", "business", "development", "functions."], "wordsB": ["All", "of", "our", "employees", "are", "engaged", "in", "administration,", "finance,", "clinical,", "manufacturing,", "regulatory", "and", "business", "development", "functions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p5_s1", "idA": "1316175_16_item1_p212_s2", "sentA": "In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically.", "sentB": "In addition, the pancreas secretes bicarbonate into the duodenum to neutralize the very high acidity of stomach contents.", "type": 2, "words": ["<tag1>", "In", "addition,", "the", "SEC", "maintains", "a", "website", "(www.sec.gov)", "that", "contains", "reports,", "proxy", "and", "information", "statements,", "and", "other", "information", "regarding", "issuers", "that", "file", "electronically.", "<tag2>", "In", "addition,", "the", "pancreas", "secretes", "bicarbonate", "into", "the", "duodenum", "to", "neutralize", "the", "very", "high", "acidity", "of", "stomach", "contents.", "<tag3>"], "wordsA": ["In", "addition,", "the", "SEC", "maintains", "a", "website", "(www.sec.gov)", "that", "contains", "reports,", "proxy", "and", "information", "statements,", "and", "other", "information", "regarding", "issuers", "that", "file", "electronically."], "wordsB": ["In", "addition,", "the", "pancreas", "secretes", "bicarbonate", "into", "the", "duodenum", "to", "neutralize", "the", "very", "high", "acidity", "of", "stomach", "contents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p63_s1", "idA": "1316175_16_item1_p23_s0", "sentA": "In 2012, we completed the PEARL-SC Phase 2b clinical study, which evaluated the efficacy and safety of multiple doses of subcutaneous blisibimod versus placebo in patients with active and seropositive lupus.", "sentB": "All five clinical studies evaluated the efficacy and safety of multiple doses of subcutaneous blisibimod versus placebo in patients with active and seropositive lupus.", "type": 2, "words": ["<tag1>", "In", "2012,", "we", "completed", "the", "PEARL-SC", "Phase", "2b", "clinical", "study,", "which", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag2>", "All", "five", "clinical", "studies", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus.", "<tag3>"], "wordsA": ["In", "2012,", "we", "completed", "the", "PEARL-SC", "Phase", "2b", "clinical", "study,", "which", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "wordsB": ["All", "five", "clinical", "studies", "evaluated", "the", "efficacy", "and", "safety", "of", "multiple", "doses", "of", "subcutaneous", "blisibimod", "versus", "placebo", "in", "patients", "with", "active", "and", "seropositive", "lupus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s5", "idA": "1316175_16_item1_p28_s0", "sentA": "In the third quarter of 2012 at an End of Phase 2 meeting with the United States Food and Drug Administration, or FDA, we presented the results of the PEARL-SC study and our plans for Phase 3 registration studies in patients with active lupus.", "sentB": "CNA is a measure of protein digestion and absorption and is a key requirement of our planned United States Food and Drug Administration ( FDA ) regulatory submission.", "type": 2, "words": ["<tag1>", "In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus.", "<tag2>", "CNA", "is", "a", "measure", "of", "protein", "digestion", "and", "absorption", "and", "is", "a", "key", "requirement", "of", "our", "planned", "United", "States", "Food", "and", "Drug", "Administration", "(", "FDA", ")", "regulatory", "submission.", "<tag3>"], "wordsA": ["In", "the", "third", "quarter", "of", "2012", "at", "an", "End", "of", "Phase", "2", "meeting", "with", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "we", "presented", "the", "results", "of", "the", "PEARL-SC", "study", "and", "our", "plans", "for", "Phase", "3", "registration", "studies", "in", "patients", "with", "active", "lupus."], "wordsB": ["CNA", "is", "a", "measure", "of", "protein", "digestion", "and", "absorption", "and", "is", "a", "key", "requirement", "of", "our", "planned", "United", "States", "Food", "and", "Drug", "Administration", "(", "FDA", ")", "regulatory", "submission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p17_s1", "idA": "1316175_16_item1_p33_s0", "sentA": "An independent Data Safety Monitoring Board ( DSMB ) meets regularly over the course of the study to assess patient safety.", "sentB": "An independent Data Monitoring Committee (the DMC ) evaluated the data from Part A and in its determination that it is safe to proceed with enrolling pediatric subjects less than 7 years of age in Part B of the study, unanimously approved the initiation of Part B of the study.", "type": 2, "words": ["<tag1>", "An", "independent", "Data", "Safety", "Monitoring", "Board", "(", "DSMB", ")", "meets", "regularly", "over", "the", "course", "of", "the", "study", "to", "assess", "patient", "safety.", "<tag2>", "An", "independent", "Data", "Monitoring", "Committee", "(the", "DMC", ")", "evaluated", "the", "data", "from", "Part", "A", "and", "in", "its", "determination", "that", "it", "is", "safe", "to", "proceed", "with", "enrolling", "pediatric", "subjects", "less", "than", "7", "years", "of", "age", "in", "Part", "B", "of", "the", "study,", "unanimously", "approved", "the", "initiation", "of", "Part", "B", "of", "the", "study.", "<tag3>"], "wordsA": ["An", "independent", "Data", "Safety", "Monitoring", "Board", "(", "DSMB", ")", "meets", "regularly", "over", "the", "course", "of", "the", "study", "to", "assess", "patient", "safety."], "wordsB": ["An", "independent", "Data", "Monitoring", "Committee", "(the", "DMC", ")", "evaluated", "the", "data", "from", "Part", "A", "and", "in", "its", "determination", "that", "it", "is", "safe", "to", "proceed", "with", "enrolling", "pediatric", "subjects", "less", "than", "7", "years", "of", "age", "in", "Part", "B", "of", "the", "study,", "unanimously", "approved", "the", "initiation", "of", "Part", "B", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p63_s2", "idA": "1316175_16_item1_p33_s2", "sentA": "After the most recent scheduled meeting in November 2015, the DSMB recommended continuing the CHABLIS-SC1 and BRIGHT-SC clinical studies.", "sentB": "The PEARL-SC study was completed in June 2012 and the CHABLIS-SC1 study was completed in November 2016.", "type": 2, "words": ["<tag1>", "After", "the", "most", "recent", "scheduled", "meeting", "in", "November", "2015,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies.", "<tag2>", "The", "PEARL-SC", "study", "was", "completed", "in", "June", "2012", "and", "the", "CHABLIS-SC1", "study", "was", "completed", "in", "November", "2016.", "<tag3>"], "wordsA": ["After", "the", "most", "recent", "scheduled", "meeting", "in", "November", "2015,", "the", "DSMB", "recommended", "continuing", "the", "CHABLIS-SC1", "and", "BRIGHT-SC", "clinical", "studies."], "wordsB": ["The", "PEARL-SC", "study", "was", "completed", "in", "June", "2012", "and", "the", "CHABLIS-SC1", "study", "was", "completed", "in", "November", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s4", "idA": "1316175_16_item1_p35_s2", "sentA": "Response rates to the SRI-8 responder index will remain a key secondary endpoint of the study.", "sentB": "Based on data from the SOLUTION study, the planned RESULT study s design is being modified to (1) start Sollpura dosing as 125% of the pre-study PERT dose, and (2) allow for a more liberal dose titration, as needed, based on signs and symptoms throughout the primary treatment phase of the study.", "type": 2, "words": ["<tag1>", "Response", "rates", "to", "the", "SRI-8", "responder", "index", "will", "remain", "a", "key", "secondary", "endpoint", "of", "the", "study.", "<tag2>", "Based", "on", "data", "from", "the", "SOLUTION", "study,", "the", "planned", "RESULT", "study", "s", "design", "is", "being", "modified", "to", "(1)", "start", "Sollpura", "dosing", "as", "125%", "of", "the", "pre-study", "PERT", "dose,", "and", "(2)", "allow", "for", "a", "more", "liberal", "dose", "titration,", "as", "needed,", "based", "on", "signs", "and", "symptoms", "throughout", "the", "primary", "treatment", "phase", "of", "the", "study.", "<tag3>"], "wordsA": ["Response", "rates", "to", "the", "SRI-8", "responder", "index", "will", "remain", "a", "key", "secondary", "endpoint", "of", "the", "study."], "wordsB": ["Based", "on", "data", "from", "the", "SOLUTION", "study,", "the", "planned", "RESULT", "study", "s", "design", "is", "being", "modified", "to", "(1)", "start", "Sollpura", "dosing", "as", "125%", "of", "the", "pre-study", "PERT", "dose,", "and", "(2)", "allow", "for", "a", "more", "liberal", "dose", "titration,", "as", "needed,", "based", "on", "signs", "and", "symptoms", "throughout", "the", "primary", "treatment", "phase", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s1", "idA": "1316175_16_item1_p36_s4", "sentA": "We plan to initiate the CHABLIS 7.5 study in the first half of 2016.", "sentB": "The RESULT study is expected to commence in the first half of 2017.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "the", "CHABLIS", "7.5", "study", "in", "the", "first", "half", "of", "2016.", "<tag2>", "The", "RESULT", "study", "is", "expected", "to", "commence", "in", "the", "first", "half", "of", "2017.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "the", "CHABLIS", "7.5", "study", "in", "the", "first", "half", "of", "2016."], "wordsB": ["The", "RESULT", "study", "is", "expected", "to", "commence", "in", "the", "first", "half", "of", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p17_s0", "idA": "1316175_16_item1_p36_s4", "sentA": "We plan to initiate the CHABLIS 7.5 study in the first half of 2016.", "sentB": "Part A of the SIMPLICITY study, which evaluated the safety and general usability of the Sollpura powder for oral solution in 15 patients aged 7 years or older, was completed in the fourth quarter of 2016.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "initiate", "the", "CHABLIS", "7.5", "study", "in", "the", "first", "half", "of", "2016.", "<tag2>", "Part", "A", "of", "the", "SIMPLICITY", "study,", "which", "evaluated", "the", "safety", "and", "general", "usability", "of", "the", "Sollpura", "powder", "for", "oral", "solution", "in", "15", "patients", "aged", "7", "years", "or", "older,", "was", "completed", "in", "the", "fourth", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "the", "CHABLIS", "7.5", "study", "in", "the", "first", "half", "of", "2016."], "wordsB": ["Part", "A", "of", "the", "SIMPLICITY", "study,", "which", "evaluated", "the", "safety", "and", "general", "usability", "of", "the", "Sollpura", "powder", "for", "oral", "solution", "in", "15", "patients", "aged", "7", "years", "or", "older,", "was", "completed", "in", "the", "fourth", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p3_s0", "idA": "1316175_16_item1_p3_s0", "sentA": "Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ( SLE ), or lupus, Immunoglobulin A nephropathy, or IgA nephropathy, lupus nephritis, and others.", "sentB": "Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy, systemic lupus erythematosus ( SLE ), or lupus, lupus nephritis, and others.", "type": 2, "words": ["<tag1>", "Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others.", "<tag2>", "Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "lupus", "nephritis,", "and", "others.", "<tag3>"], "wordsA": ["Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "lupus", "nephritis,", "and", "others."], "wordsB": ["Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "lupus", "nephritis,", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p32_s1", "idA": "1316175_16_item1_p41_s1", "sentA": "These IgA deposits build up inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "sentB": "These IgA containing immune complexes deposit in the mesangium of glomeruli in the kidney and are proinflammatory.", "type": 2, "words": ["<tag1>", "These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag2>", "These", "IgA", "containing", "immune", "complexes", "deposit", "in", "the", "mesangium", "of", "glomeruli", "in", "the", "kidney", "and", "are", "proinflammatory.", "<tag3>"], "wordsA": ["These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "wordsB": ["These", "IgA", "containing", "immune", "complexes", "deposit", "in", "the", "mesangium", "of", "glomeruli", "in", "the", "kidney", "and", "are", "proinflammatory."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p32_s2", "idA": "1316175_16_item1_p41_s1", "sentA": "These IgA deposits build up inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "sentB": "As a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "type": 2, "words": ["<tag1>", "These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag2>", "As", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag3>"], "wordsA": ["These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "wordsB": ["As", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p47_s1", "idA": "1316175_16_item1_p41_s1", "sentA": "These IgA deposits build up inside the small blood vessels of the kidney and as a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "sentB": "As a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "type": 2, "words": ["<tag1>", "These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag2>", "As", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag3>"], "wordsA": ["These", "IgA", "deposits", "build", "up", "inside", "the", "small", "blood", "vessels", "of", "the", "kidney", "and", "as", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "wordsB": ["As", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p34_s0", "idA": "1316175_16_item1_p43_s1", "sentA": "In patients with IgA nephropathy, levels of BAFF are significantly higher than in healthy individuals.", "sentB": "In patients with IgA nephropathy, levels of BAFF are significantly higher than in healthy individuals, and elevated levels of BAFF are associated with histological severity of disease in kidney tissue.", "type": 2, "words": ["<tag1>", "In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "individuals.", "<tag2>", "In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "individuals,", "and", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "histological", "severity", "of", "disease", "in", "kidney", "tissue.", "<tag3>"], "wordsA": ["In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "individuals."], "wordsB": ["In", "patients", "with", "IgA", "nephropathy,", "levels", "of", "BAFF", "are", "significantly", "higher", "than", "in", "healthy", "individuals,", "and", "elevated", "levels", "of", "BAFF", "are", "associated", "with", "histological", "severity", "of", "disease", "in", "kidney", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p35_s2", "idA": "1316175_16_item1_p44_s2", "sentA": "In our PEARL-SC Phase 2b study, significant reductions in total B-cells as well as significant improvements in proteinuria and increases in complement C3 were observed with blisibimod in lupus patients.", "sentB": "In our PEARL-SC Phase 2b study and our CHABLIS-SC1 Phase 3 study, significant reductions in total B-cells as well as significant improvements in proteinuria and increases in complement C3 were observed with blisibimod in lupus patients.", "type": 2, "words": ["<tag1>", "In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients.", "<tag2>", "In", "our", "PEARL-SC", "Phase", "2b", "study", "and", "our", "CHABLIS-SC1", "Phase", "3", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients.", "<tag3>"], "wordsA": ["In", "our", "PEARL-SC", "Phase", "2b", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients."], "wordsB": ["In", "our", "PEARL-SC", "Phase", "2b", "study", "and", "our", "CHABLIS-SC1", "Phase", "3", "study,", "significant", "reductions", "in", "total", "B-cells", "as", "well", "as", "significant", "improvements", "in", "proteinuria", "and", "increases", "in", "complement", "C3", "were", "observed", "with", "blisibimod", "in", "lupus", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p16_s0", "idA": "1316175_16_item1_p47_s0", "sentA": "The BRIGHT-SC study was initiated in the second quarter of 2013.", "sentB": "A second, smaller Phase 3 study, SIMPLICITY, was initiated in the second quarter of 2016.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "study", "was", "initiated", "in", "the", "second", "quarter", "of", "2013.", "<tag2>", "A", "second,", "smaller", "Phase", "3", "study,", "SIMPLICITY,", "was", "initiated", "in", "the", "second", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "study", "was", "initiated", "in", "the", "second", "quarter", "of", "2013."], "wordsB": ["A", "second,", "smaller", "Phase", "3", "study,", "SIMPLICITY,", "was", "initiated", "in", "the", "second", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p10_s0", "idA": "1316175_16_item1_p4_s0", "sentA": "Liprotamase is a novel non-porcine PERT that contains three biotechnology-derived digestive enzymes: a lipase, a protease and an amylase.", "sentB": "Sollpura is a novel non-porcine PERT that contains three biotechnology-derived digestive enzymes: a lipase, a protease and an amylase.", "type": 2, "words": ["<tag1>", "Liprotamase", "is", "a", "novel", "non-porcine", "PERT", "that", "contains", "three", "biotechnology-derived", "digestive", "enzymes:", "a", "lipase,", "a", "protease", "and", "an", "amylase.", "<tag2>", "Sollpura", "is", "a", "novel", "non-porcine", "PERT", "that", "contains", "three", "biotechnology-derived", "digestive", "enzymes:", "a", "lipase,", "a", "protease", "and", "an", "amylase.", "<tag3>"], "wordsA": ["Liprotamase", "is", "a", "novel", "non-porcine", "PERT", "that", "contains", "three", "biotechnology-derived", "digestive", "enzymes:", "a", "lipase,", "a", "protease", "and", "an", "amylase."], "wordsB": ["Sollpura", "is", "a", "novel", "non-porcine", "PERT", "that", "contains", "three", "biotechnology-derived", "digestive", "enzymes:", "a", "lipase,", "a", "protease", "and", "an", "amylase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p10_s1", "idA": "1316175_16_item1_p4_s1", "sentA": "Through enzyme cross-linking, the lipase enzyme in liprotamase is more stable than the porcine derived lipase in the low pH environment of the stomach and therefore liprotamase does not have an enteric polymer coating.", "sentB": "Through enzyme cross-linking, the lipase enzyme in Sollpura is more stable than the porcine derived lipase in the low pH environment of the stomach and therefore Sollpura does not have an enteric polymer coating.", "type": 2, "words": ["<tag1>", "Through", "enzyme", "cross-linking,", "the", "lipase", "enzyme", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating.", "<tag2>", "Through", "enzyme", "cross-linking,", "the", "lipase", "enzyme", "in", "Sollpura", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "Sollpura", "does", "not", "have", "an", "enteric", "polymer", "coating.", "<tag3>"], "wordsA": ["Through", "enzyme", "cross-linking,", "the", "lipase", "enzyme", "in", "liprotamase", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "liprotamase", "does", "not", "have", "an", "enteric", "polymer", "coating."], "wordsB": ["Through", "enzyme", "cross-linking,", "the", "lipase", "enzyme", "in", "Sollpura", "is", "more", "stable", "than", "the", "porcine", "derived", "lipase", "in", "the", "low", "pH", "environment", "of", "the", "stomach", "and", "therefore", "Sollpura", "does", "not", "have", "an", "enteric", "polymer", "coating."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p10_s2", "idA": "1316175_16_item1_p4_s2", "sentA": "Furthermore, since the three enzymes in liprotamase are biotechnology-derived, liprotamase does not contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "sentB": "Furthermore, since the three enzymes in Sollpura are biotechnology-derived, Sollpura does not contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "type": 2, "words": ["<tag1>", "Furthermore,", "since", "the", "three", "enzymes", "in", "liprotamase", "are", "biotechnology-derived,", "liprotamase", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag2>", "Furthermore,", "since", "the", "three", "enzymes", "in", "Sollpura", "are", "biotechnology-derived,", "Sollpura", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag3>"], "wordsA": ["Furthermore,", "since", "the", "three", "enzymes", "in", "liprotamase", "are", "biotechnology-derived,", "liprotamase", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "wordsB": ["Furthermore,", "since", "the", "three", "enzymes", "in", "Sollpura", "are", "biotechnology-derived,", "Sollpura", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s4", "idA": "1316175_16_item1_p4_s2", "sentA": "Furthermore, since the three enzymes in liprotamase are biotechnology-derived, liprotamase does not contain porcine proteins or purines that may be associated with a risk of viral transmission or allergic reaction to proteins of porcine origin.", "sentB": "The study also confirmed that the ratio of the three enzymes in Sollpura demonstrated an appropriate response in the Coefficient of Nitrogen Absorption (CNA).", "type": 2, "words": ["<tag1>", "Furthermore,", "since", "the", "three", "enzymes", "in", "liprotamase", "are", "biotechnology-derived,", "liprotamase", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin.", "<tag2>", "The", "study", "also", "confirmed", "that", "the", "ratio", "of", "the", "three", "enzymes", "in", "Sollpura", "demonstrated", "an", "appropriate", "response", "in", "the", "Coefficient", "of", "Nitrogen", "Absorption", "(CNA).", "<tag3>"], "wordsA": ["Furthermore,", "since", "the", "three", "enzymes", "in", "liprotamase", "are", "biotechnology-derived,", "liprotamase", "does", "not", "contain", "porcine", "proteins", "or", "purines", "that", "may", "be", "associated", "with", "a", "risk", "of", "viral", "transmission", "or", "allergic", "reaction", "to", "proteins", "of", "porcine", "origin."], "wordsB": ["The", "study", "also", "confirmed", "that", "the", "ratio", "of", "the", "three", "enzymes", "in", "Sollpura", "demonstrated", "an", "appropriate", "response", "in", "the", "Coefficient", "of", "Nitrogen", "Absorption", "(CNA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p43_s0", "idA": "1316175_16_item1_p50_s0", "sentA": "According to IMS Health, EPI is a disease that affects an estimated 250,000 patients in the United States.", "sentB": "According to our estimate, EPI is a disease that affects an estimated 130,000 patients in the United States.", "type": 2, "words": ["<tag1>", "According", "to", "IMS", "Health,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "250,000", "patients", "in", "the", "United", "States.", "<tag2>", "According", "to", "our", "estimate,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "130,000", "patients", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["According", "to", "IMS", "Health,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "250,000", "patients", "in", "the", "United", "States."], "wordsB": ["According", "to", "our", "estimate,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "130,000", "patients", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p45_s0", "idA": "1316175_16_item1_p59_s0", "sentA": "Immunoglobulin A (IgA) is a human antibody that plays a critical role in mucosal immunity, which is a portion of the immune system that provides protection to an organism s various mucous membranes from invasion by infections.", "sentB": "Immunoglobulin A (IgA) is a human antibody that plays a critical role in mucosal immunity, which provides protection to an organism s various mucous membranes from invasion by infections.", "type": 2, "words": ["<tag1>", "Immunoglobulin", "A", "(IgA)", "is", "a", "human", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity,", "which", "is", "a", "portion", "of", "the", "immune", "system", "that", "provides", "protection", "to", "an", "organism", "s", "various", "mucous", "membranes", "from", "invasion", "by", "infections.", "<tag2>", "Immunoglobulin", "A", "(IgA)", "is", "a", "human", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity,", "which", "provides", "protection", "to", "an", "organism", "s", "various", "mucous", "membranes", "from", "invasion", "by", "infections.", "<tag3>"], "wordsA": ["Immunoglobulin", "A", "(IgA)", "is", "a", "human", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity,", "which", "is", "a", "portion", "of", "the", "immune", "system", "that", "provides", "protection", "to", "an", "organism", "s", "various", "mucous", "membranes", "from", "invasion", "by", "infections."], "wordsB": ["Immunoglobulin", "A", "(IgA)", "is", "a", "human", "antibody", "that", "plays", "a", "critical", "role", "in", "mucosal", "immunity,", "which", "provides", "protection", "to", "an", "organism", "s", "various", "mucous", "membranes", "from", "invasion", "by", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p11_s0", "idA": "1316175_16_item1_p5_s0", "sentA": "The individual enzyme components of liprotamase are formulated at a fixed ratio of lipase, protease, and amylase.", "sentB": "The individual enzyme components of Sollpura are formulated at a fixed ratio of lipase, protease, and amylase.", "type": 2, "words": ["<tag1>", "The", "individual", "enzyme", "components", "of", "liprotamase", "are", "formulated", "at", "a", "fixed", "ratio", "of", "lipase,", "protease,", "and", "amylase.", "<tag2>", "The", "individual", "enzyme", "components", "of", "Sollpura", "are", "formulated", "at", "a", "fixed", "ratio", "of", "lipase,", "protease,", "and", "amylase.", "<tag3>"], "wordsA": ["The", "individual", "enzyme", "components", "of", "liprotamase", "are", "formulated", "at", "a", "fixed", "ratio", "of", "lipase,", "protease,", "and", "amylase."], "wordsB": ["The", "individual", "enzyme", "components", "of", "Sollpura", "are", "formulated", "at", "a", "fixed", "ratio", "of", "lipase,", "protease,", "and", "amylase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p11_s1", "idA": "1316175_16_item1_p5_s1", "sentA": "The liprotamase enzyme dose ratio was selected from preclinical efficacy studies conducted using a canine model of pancreatic insufficiency which demonstrated that the lipase enzyme in liprotamase was efficacious when administered at 500 units/kg per meal, and the protease doses 1000 units/kg per meal (Borowitz et al . 2006).", "sentB": "The Sollpura enzyme dose ratio was selected from preclinical efficacy studies conducted using a canine model of pancreatic insufficiency which demonstrated that the lipase enzyme in Sollpura was efficacious when administered at 500 units/kg per meal, and the protease doses 1000 units/kg per meal.", "type": 2, "words": ["<tag1>", "The", "liprotamase", "enzyme", "dose", "ratio", "was", "selected", "from", "preclinical", "efficacy", "studies", "conducted", "using", "a", "canine", "model", "of", "pancreatic", "insufficiency", "which", "demonstrated", "that", "the", "lipase", "enzyme", "in", "liprotamase", "was", "efficacious", "when", "administered", "at", "500", "units/kg", "per", "meal,", "and", "the", "protease", "doses", "1000", "units/kg", "per", "meal", "(Borowitz", "et", "al", ".", "2006).", "<tag2>", "The", "Sollpura", "enzyme", "dose", "ratio", "was", "selected", "from", "preclinical", "efficacy", "studies", "conducted", "using", "a", "canine", "model", "of", "pancreatic", "insufficiency", "which", "demonstrated", "that", "the", "lipase", "enzyme", "in", "Sollpura", "was", "efficacious", "when", "administered", "at", "500", "units/kg", "per", "meal,", "and", "the", "protease", "doses", "1000", "units/kg", "per", "meal.", "<tag3>"], "wordsA": ["The", "liprotamase", "enzyme", "dose", "ratio", "was", "selected", "from", "preclinical", "efficacy", "studies", "conducted", "using", "a", "canine", "model", "of", "pancreatic", "insufficiency", "which", "demonstrated", "that", "the", "lipase", "enzyme", "in", "liprotamase", "was", "efficacious", "when", "administered", "at", "500", "units/kg", "per", "meal,", "and", "the", "protease", "doses", "1000", "units/kg", "per", "meal", "(Borowitz", "et", "al", ".", "2006)."], "wordsB": ["The", "Sollpura", "enzyme", "dose", "ratio", "was", "selected", "from", "preclinical", "efficacy", "studies", "conducted", "using", "a", "canine", "model", "of", "pancreatic", "insufficiency", "which", "demonstrated", "that", "the", "lipase", "enzyme", "in", "Sollpura", "was", "efficacious", "when", "administered", "at", "500", "units/kg", "per", "meal,", "and", "the", "protease", "doses", "1000", "units/kg", "per", "meal."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p11_s2", "idA": "1316175_16_item1_p5_s2", "sentA": "This finding is further supported by the similar efficacy observed between liprotamase and Creon in pigs with surgically-induced pancreatic insufficiency.", "sentB": "This finding is further supported by the similar efficacy observed between Sollpura and Creon in pigs with surgically-induced pancreatic insufficiency.", "type": 2, "words": ["<tag1>", "This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "liprotamase", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency.", "<tag2>", "This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "Sollpura", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency.", "<tag3>"], "wordsA": ["This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "liprotamase", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency."], "wordsB": ["This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "Sollpura", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p47_s0", "idA": "1316175_16_item1_p61_s0", "sentA": "IgA nephropathy occurs when too much of this protein, especially aberrant and immunogenic forms of IgA, is deposited in the kidneys.", "sentB": "IgA nephropathy occurs when too much of this protein, especially aberrant and immunogenic forms of IgA, are recognized by other immunoglobulins, forming proinflammatory immune complexes which are deposited in the kidney.", "type": 2, "words": ["<tag1>", "IgA", "nephropathy", "occurs", "when", "too", "much", "of", "this", "protein,", "especially", "aberrant", "and", "immunogenic", "forms", "of", "IgA,", "is", "deposited", "in", "the", "kidneys.", "<tag2>", "IgA", "nephropathy", "occurs", "when", "too", "much", "of", "this", "protein,", "especially", "aberrant", "and", "immunogenic", "forms", "of", "IgA,", "are", "recognized", "by", "other", "immunoglobulins,", "forming", "proinflammatory", "immune", "complexes", "which", "are", "deposited", "in", "the", "kidney.", "<tag3>"], "wordsA": ["IgA", "nephropathy", "occurs", "when", "too", "much", "of", "this", "protein,", "especially", "aberrant", "and", "immunogenic", "forms", "of", "IgA,", "is", "deposited", "in", "the", "kidneys."], "wordsB": ["IgA", "nephropathy", "occurs", "when", "too", "much", "of", "this", "protein,", "especially", "aberrant", "and", "immunogenic", "forms", "of", "IgA,", "are", "recognized", "by", "other", "immunoglobulins,", "forming", "proinflammatory", "immune", "complexes", "which", "are", "deposited", "in", "the", "kidney."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p48_s0", "idA": "1316175_16_item1_p62_s0", "sentA": "The classic presentation (in 40-50% of the cases) of signs and symptoms in patients with IgA nephropathy is episodic frank hematuria which usually starts within a day or two of a non-specific upper respiratory tract infection or (less commonly) gastrointestinal or urinary infection.", "sentB": "The classic presentation (in 40-50% of the cases) is episodic frank hematuria which usually starts within a day or two of a non-specific upper respiratory tract infection or (less commonly) gastrointestinal or urinary infection.", "type": 2, "words": ["<tag1>", "The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgA", "nephropathy", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection.", "<tag2>", "The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection.", "<tag3>"], "wordsA": ["The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "of", "signs", "and", "symptoms", "in", "patients", "with", "IgA", "nephropathy", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection."], "wordsB": ["The", "classic", "presentation", "(in", "40-50%", "of", "the", "cases)", "is", "episodic", "frank", "hematuria", "which", "usually", "starts", "within", "a", "day", "or", "two", "of", "a", "non-specific", "upper", "respiratory", "tract", "infection", "or", "(less", "commonly)", "gastrointestinal", "or", "urinary", "infection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p52_s0", "idA": "1316175_16_item1_p68_s0", "sentA": "Technology transfer to commercial scale active pharmaceutical ingredients, or API and drug product manufacturing CMOs was initiated in 2015 and is ongoing.", "sentB": "Technology transfer to commercial scale active pharmaceutical ingredient (API) manufacturing and drug product manufacturing CMOs was initiated in 2015 and completed in late 2016.", "type": 2, "words": ["<tag1>", "Technology", "transfer", "to", "commercial", "scale", "active", "pharmaceutical", "ingredients,", "or", "API", "and", "drug", "product", "manufacturing", "CMOs", "was", "initiated", "in", "2015", "and", "is", "ongoing.", "<tag2>", "Technology", "transfer", "to", "commercial", "scale", "active", "pharmaceutical", "ingredient", "(API)", "manufacturing", "and", "drug", "product", "manufacturing", "CMOs", "was", "initiated", "in", "2015", "and", "completed", "in", "late", "2016.", "<tag3>"], "wordsA": ["Technology", "transfer", "to", "commercial", "scale", "active", "pharmaceutical", "ingredients,", "or", "API", "and", "drug", "product", "manufacturing", "CMOs", "was", "initiated", "in", "2015", "and", "is", "ongoing."], "wordsB": ["Technology", "transfer", "to", "commercial", "scale", "active", "pharmaceutical", "ingredient", "(API)", "manufacturing", "and", "drug", "product", "manufacturing", "CMOs", "was", "initiated", "in", "2015", "and", "completed", "in", "late", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p52_s1", "idA": "1316175_16_item1_p68_s1", "sentA": "The large scale fermentation and the associated down-stream processing for all three enzyme APIs are anticipated to be complete through process validation in 2016.", "sentB": "The large scale fermentation and the associated down-stream process validation activities for all three enzyme APIs are anticipated to be complete in late 2017 to early 2018.", "type": 2, "words": ["<tag1>", "The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "processing", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "through", "process", "validation", "in", "2016.", "<tag2>", "The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "process", "validation", "activities", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "in", "late", "2017", "to", "early", "2018.", "<tag3>"], "wordsA": ["The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "processing", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "through", "process", "validation", "in", "2016."], "wordsB": ["The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "process", "validation", "activities", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "in", "late", "2017", "to", "early", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p52_s2", "idA": "1316175_16_item1_p68_s2", "sentA": "In parallel, commercial scale capsule and sachet manufacturing are also being established at respective product CMOs.", "sentB": "In parallel, commercial scale capsule and sachet drug product manufacturing process validation is anticipated to be completed in late 2017 to early 2018.", "type": 2, "words": ["<tag1>", "In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "manufacturing", "are", "also", "being", "established", "at", "respective", "product", "CMOs.", "<tag2>", "In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "drug", "product", "manufacturing", "process", "validation", "is", "anticipated", "to", "be", "completed", "in", "late", "2017", "to", "early", "2018.", "<tag3>"], "wordsA": ["In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "manufacturing", "are", "also", "being", "established", "at", "respective", "product", "CMOs."], "wordsB": ["In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "drug", "product", "manufacturing", "process", "validation", "is", "anticipated", "to", "be", "completed", "in", "late", "2017", "to", "early", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p54_s0", "idA": "1316175_16_item1_p69_s0", "sentA": "In 2013, our licensor, Eli Lilly, gained agreement from the FDA on the design of a Phase 3 trial that would provide adequate evaluation of efficacy and safety of liprotamase to respond to the FDA s 2011 complete response letter.", "sentB": "In 2013, our licensor, Eli Lilly, gained agreement from the FDA on the design of a Phase 3 clinical study (SOLUTION) that would provide adequate evaluation of efficacy and safety of Sollpura to respond to the FDA s 2011 complete response letter.", "type": 2, "words": ["<tag1>", "In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "trial", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "liprotamase", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter.", "<tag2>", "In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "clinical", "study", "(SOLUTION)", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "Sollpura", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter.", "<tag3>"], "wordsA": ["In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "trial", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "liprotamase", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter."], "wordsB": ["In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "clinical", "study", "(SOLUTION)", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "Sollpura", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p15_s2", "idA": "1316175_16_item1_p69_s1", "sentA": "The Phase 3 study (SOLUTION) is a randomized, open-label, assessor-blind, non-inferiority, active-comparator study intended to evaluate the non-inferiority of liprotamase compared with another commercially available PERT.", "sentB": "Similar to the SOLUTION study, the RESULT study will also be a randomized, open-label, assessor- blind, non-inferiority, active-comparator study.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "study", "(SOLUTION)", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT.", "<tag2>", "Similar", "to", "the", "SOLUTION", "study,", "the", "RESULT", "study", "will", "also", "be", "a", "randomized,", "open-label,", "assessor-", "blind,", "non-inferiority,", "active-comparator", "study.", "<tag3>"], "wordsA": ["The", "Phase", "3", "study", "(SOLUTION)", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "intended", "to", "evaluate", "the", "non-inferiority", "of", "liprotamase", "compared", "with", "another", "commercially", "available", "PERT."], "wordsB": ["Similar", "to", "the", "SOLUTION", "study,", "the", "RESULT", "study", "will", "also", "be", "a", "randomized,", "open-label,", "assessor-", "blind,", "non-inferiority,", "active-comparator", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p54_s4", "idA": "1316175_16_item1_p69_s2", "sentA": "The SOUTION design also addresses the 2005 EMA protocol assistance comments, which were consistent with the FDA s request for an active comparator trial.", "sentB": "The RESULT study should also address the 2005 EMA protocol assistance comments, which were consistent with the FDA s request for an active comparator trial.", "type": 2, "words": ["<tag1>", "The", "SOUTION", "design", "also", "addresses", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial.", "<tag2>", "The", "RESULT", "study", "should", "also", "address", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial.", "<tag3>"], "wordsA": ["The", "SOUTION", "design", "also", "addresses", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial."], "wordsB": ["The", "RESULT", "study", "should", "also", "address", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p8_s0", "idA": "1316175_16_item1_p6_s0", "sentA": "Pancreatic enzyme replacement therapy is currently the mainstay of treatment for nutrient malabsorption in patients with digestive enzyme deficiencies known as EPI.", "sentB": "PERT is currently the mainstay of treatment for nutrient malabsorption in patients with digestive enzyme deficiencies known as EPI and orally delivered porcine PERTs have been available for many years for its treatment.", "type": 2, "words": ["<tag1>", "Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "EPI.", "<tag2>", "PERT", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "EPI", "and", "orally", "delivered", "porcine", "PERTs", "have", "been", "available", "for", "many", "years", "for", "its", "treatment.", "<tag3>"], "wordsA": ["Pancreatic", "enzyme", "replacement", "therapy", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "EPI."], "wordsB": ["PERT", "is", "currently", "the", "mainstay", "of", "treatment", "for", "nutrient", "malabsorption", "in", "patients", "with", "digestive", "enzyme", "deficiencies", "known", "as", "EPI", "and", "orally", "delivered", "porcine", "PERTs", "have", "been", "available", "for", "many", "years", "for", "its", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s0", "idA": "1316175_16_item1_p71_s6", "sentA": "Data generated from the analysis of the BRIGHT-SC study in the first half of 2016, will be used to guide the final study design elements for the Phase 3 registration study protocol.", "sentB": "In December 2016, an additional interim analysis of the BRIGHT-SC study was reported.", "type": 2, "words": ["<tag1>", "Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol.", "<tag2>", "In", "December", "2016,", "an", "additional", "interim", "analysis", "of", "the", "BRIGHT-SC", "study", "was", "reported.", "<tag3>"], "wordsA": ["Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol."], "wordsB": ["In", "December", "2016,", "an", "additional", "interim", "analysis", "of", "the", "BRIGHT-SC", "study", "was", "reported."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p42_s0", "idA": "1316175_16_item1_p71_s6", "sentA": "Data generated from the analysis of the BRIGHT-SC study in the first half of 2016, will be used to guide the final study design elements for the Phase 3 registration study protocol.", "sentB": "Effects of Blisibimod on Proteinuria in Subjects with IgA Nephropathy in the BRIGHT-SC Study:", "type": 2, "words": ["<tag1>", "Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol.", "<tag2>", "Effects", "of", "Blisibimod", "on", "Proteinuria", "in", "Subjects", "with", "IgA", "Nephropathy", "in", "the", "BRIGHT-SC", "Study:", "<tag3>"], "wordsA": ["Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol."], "wordsB": ["Effects", "of", "Blisibimod", "on", "Proteinuria", "in", "Subjects", "with", "IgA", "Nephropathy", "in", "the", "BRIGHT-SC", "Study:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p55_s6", "idA": "1316175_16_item1_p71_s6", "sentA": "Data generated from the analysis of the BRIGHT-SC study in the first half of 2016, will be used to guide the final study design elements for the Phase 3 registration study protocol.", "sentB": "Data generated from the analyses of the BRIGHT-SC study at week 24 and 48 will be used to guide the final study design elements for the Phase 3 registration study protocol.", "type": 2, "words": ["<tag1>", "Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol.", "<tag2>", "Data", "generated", "from", "the", "analyses", "of", "the", "BRIGHT-SC", "study", "at", "week", "24", "and", "48", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol.", "<tag3>"], "wordsA": ["Data", "generated", "from", "the", "analysis", "of", "the", "BRIGHT-SC", "study", "in", "the", "first", "half", "of", "2016,", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol."], "wordsB": ["Data", "generated", "from", "the", "analyses", "of", "the", "BRIGHT-SC", "study", "at", "week", "24", "and", "48", "will", "be", "used", "to", "guide", "the", "final", "study", "design", "elements", "for", "the", "Phase", "3", "registration", "study", "protocol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p56_s0", "idA": "1316175_16_item1_p72_s0", "sentA": "We continue to dose patients in our BRIGHT-SC clinical study for the treatment of patients with IgA nephropathy ( IgAN ), an orphan disease.", "sentB": "We continue to dose patients in our Phase 2 BRIGHT-SC clinical study for the treatment of patients with IgA nephropathy, an orphan disease.", "type": 2, "words": ["<tag1>", "We", "continue", "to", "dose", "patients", "in", "our", "BRIGHT-SC", "clinical", "study", "for", "the", "treatment", "of", "patients", "with", "IgA", "nephropathy", "(", "IgAN", "),", "an", "orphan", "disease.", "<tag2>", "We", "continue", "to", "dose", "patients", "in", "our", "Phase", "2", "BRIGHT-SC", "clinical", "study", "for", "the", "treatment", "of", "patients", "with", "IgA", "nephropathy,", "an", "orphan", "disease.", "<tag3>"], "wordsA": ["We", "continue", "to", "dose", "patients", "in", "our", "BRIGHT-SC", "clinical", "study", "for", "the", "treatment", "of", "patients", "with", "IgA", "nephropathy", "(", "IgAN", "),", "an", "orphan", "disease."], "wordsB": ["We", "continue", "to", "dose", "patients", "in", "our", "Phase", "2", "BRIGHT-SC", "clinical", "study", "for", "the", "treatment", "of", "patients", "with", "IgA", "nephropathy,", "an", "orphan", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p16_s2", "idA": "1316175_16_item1_p73_s2", "sentA": "We have enrolled 57 patients, 45 of which remained in the study.", "sentB": "We expect to enroll approximately 46 patients in the two parts of the study (Part A and Part B).", "type": 2, "words": ["<tag1>", "We", "have", "enrolled", "57", "patients,", "45", "of", "which", "remained", "in", "the", "study.", "<tag2>", "We", "expect", "to", "enroll", "approximately", "46", "patients", "in", "the", "two", "parts", "of", "the", "study", "(Part", "A", "and", "Part", "B).", "<tag3>"], "wordsA": ["We", "have", "enrolled", "57", "patients,", "45", "of", "which", "remained", "in", "the", "study."], "wordsB": ["We", "expect", "to", "enroll", "approximately", "46", "patients", "in", "the", "two", "parts", "of", "the", "study", "(Part", "A", "and", "Part", "B)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p56_s5", "idA": "1316175_16_item1_p73_s8", "sentA": "Following the completion of the BRIGHT-SC study we intend to explore a Special Protocol Assessment from the US FDA to ensure final concurrence on the willingness to consider proteinuria as a surrogate endpoint, the timing for completion of enrollment of the post marketing confirmatory study and blisibimod s eligibility to receive orphan designation.", "sentB": "Following the completion of the BRIGHT-SC study we intend to explore a Special Protocol Assessment from the US FDA to ensure final concurrence on the willingness to consider proteinuria as a surrogate endpoint, the timing for completion of enrollment of the post marketing confirmatory study.", "type": 2, "words": ["<tag1>", "Following", "the", "completion", "of", "the", "BRIGHT-SC", "study", "we", "intend", "to", "explore", "a", "Special", "Protocol", "Assessment", "from", "the", "US", "FDA", "to", "ensure", "final", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study", "and", "blisibimod", "s", "eligibility", "to", "receive", "orphan", "designation.", "<tag2>", "Following", "the", "completion", "of", "the", "BRIGHT-SC", "study", "we", "intend", "to", "explore", "a", "Special", "Protocol", "Assessment", "from", "the", "US", "FDA", "to", "ensure", "final", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study.", "<tag3>"], "wordsA": ["Following", "the", "completion", "of", "the", "BRIGHT-SC", "study", "we", "intend", "to", "explore", "a", "Special", "Protocol", "Assessment", "from", "the", "US", "FDA", "to", "ensure", "final", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study", "and", "blisibimod", "s", "eligibility", "to", "receive", "orphan", "designation."], "wordsB": ["Following", "the", "completion", "of", "the", "BRIGHT-SC", "study", "we", "intend", "to", "explore", "a", "Special", "Protocol", "Assessment", "from", "the", "US", "FDA", "to", "ensure", "final", "concurrence", "on", "the", "willingness", "to", "consider", "proteinuria", "as", "a", "surrogate", "endpoint,", "the", "timing", "for", "completion", "of", "enrollment", "of", "the", "post", "marketing", "confirmatory", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p57_s0", "idA": "1316175_16_item1_p74_s0", "sentA": "Liprotamase was studied from 2002 to 2009 in seven clinical trials, in which a total of 492 unique subjects received at least 1 dose of liprotamase.", "sentB": "Sollpura was studied from 2002 to 2009 in seven clinical trials, in which a total of 492 unique subjects received at least 1 dose of Sollpura.", "type": 2, "words": ["<tag1>", "Liprotamase", "was", "studied", "from", "2002", "to", "2009", "in", "seven", "clinical", "trials,", "in", "which", "a", "total", "of", "492", "unique", "subjects", "received", "at", "least", "1", "dose", "of", "liprotamase.", "<tag2>", "Sollpura", "was", "studied", "from", "2002", "to", "2009", "in", "seven", "clinical", "trials,", "in", "which", "a", "total", "of", "492", "unique", "subjects", "received", "at", "least", "1", "dose", "of", "Sollpura.", "<tag3>"], "wordsA": ["Liprotamase", "was", "studied", "from", "2002", "to", "2009", "in", "seven", "clinical", "trials,", "in", "which", "a", "total", "of", "492", "unique", "subjects", "received", "at", "least", "1", "dose", "of", "liprotamase."], "wordsB": ["Sollpura", "was", "studied", "from", "2002", "to", "2009", "in", "seven", "clinical", "trials,", "in", "which", "a", "total", "of", "492", "unique", "subjects", "received", "at", "least", "1", "dose", "of", "Sollpura."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p14_s6", "idA": "1316175_16_item1_p74_s1", "sentA": "Three Phase 1 trials were conducted, 1 in healthy volunteers and 2 in subjects with EPI due to CF.", "sentB": "Data from the SOLUTION study identified that, for some patients, higher doses may be necessary to compensate for the lower solubility of Sollpura under the acidic upper small intestinal conditions found in many patients with EPI due to CF.", "type": 2, "words": ["<tag1>", "Three", "Phase", "1", "trials", "were", "conducted,", "1", "in", "healthy", "volunteers", "and", "2", "in", "subjects", "with", "EPI", "due", "to", "CF.", "<tag2>", "Data", "from", "the", "SOLUTION", "study", "identified", "that,", "for", "some", "patients,", "higher", "doses", "may", "be", "necessary", "to", "compensate", "for", "the", "lower", "solubility", "of", "Sollpura", "under", "the", "acidic", "upper", "small", "intestinal", "conditions", "found", "in", "many", "patients", "with", "EPI", "due", "to", "CF.", "<tag3>"], "wordsA": ["Three", "Phase", "1", "trials", "were", "conducted,", "1", "in", "healthy", "volunteers", "and", "2", "in", "subjects", "with", "EPI", "due", "to", "CF."], "wordsB": ["Data", "from", "the", "SOLUTION", "study", "identified", "that,", "for", "some", "patients,", "higher", "doses", "may", "be", "necessary", "to", "compensate", "for", "the", "lower", "solubility", "of", "Sollpura", "under", "the", "acidic", "upper", "small", "intestinal", "conditions", "found", "in", "many", "patients", "with", "EPI", "due", "to", "CF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p57_s2", "idA": "1316175_16_item1_p74_s2", "sentA": "Two short-term trials, the Phase 2 Study TC-2A, and the Phase 3 Study 726 evaluated the efficacy of liprotamase in subjects 7 years of age with EPI due to CF.", "sentB": "Two short-term trials, the Phase 2 Study TC-2A, and the Phase 3 Study 726 evaluated the efficacy of Sollpura in subjects 7 years of age with EPI due to CF.", "type": 2, "words": ["<tag1>", "Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC-2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "liprotamase", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF.", "<tag2>", "Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC-2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "Sollpura", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF.", "<tag3>"], "wordsA": ["Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC-2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "liprotamase", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF."], "wordsB": ["Two", "short-term", "trials,", "the", "Phase", "2", "Study", "TC-2A,", "and", "the", "Phase", "3", "Study", "726", "evaluated", "the", "efficacy", "of", "Sollpura", "in", "subjects", "7", "years", "of", "age", "with", "EPI", "due", "to", "CF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p57_s3", "idA": "1316175_16_item1_p74_s3", "sentA": "Two long-term Phase 3 safety and tolerability trials were also conducted: Study 767 in subjects with EPI due to CF and Study 810 in subjects with EPI due to CP/pancreatectomy.", "sentB": "Two long-term Phase 3 safety and tolerability trials were also conducted: Study 767 in subjects with EPI due to CF and Study 810 in subjects with EPI due to chronic pancreatitis/pancreatectomy.", "type": 2, "words": ["<tag1>", "Two", "long-term", "Phase", "3", "safety", "and", "tolerability", "trials", "were", "also", "conducted:", "Study", "767", "in", "subjects", "with", "EPI", "due", "to", "CF", "and", "Study", "810", "in", "subjects", "with", "EPI", "due", "to", "CP/pancreatectomy.", "<tag2>", "Two", "long-term", "Phase", "3", "safety", "and", "tolerability", "trials", "were", "also", "conducted:", "Study", "767", "in", "subjects", "with", "EPI", "due", "to", "CF", "and", "Study", "810", "in", "subjects", "with", "EPI", "due", "to", "chronic", "pancreatitis/pancreatectomy.", "<tag3>"], "wordsA": ["Two", "long-term", "Phase", "3", "safety", "and", "tolerability", "trials", "were", "also", "conducted:", "Study", "767", "in", "subjects", "with", "EPI", "due", "to", "CF", "and", "Study", "810", "in", "subjects", "with", "EPI", "due", "to", "CP/pancreatectomy."], "wordsB": ["Two", "long-term", "Phase", "3", "safety", "and", "tolerability", "trials", "were", "also", "conducted:", "Study", "767", "in", "subjects", "with", "EPI", "due", "to", "CF", "and", "Study", "810", "in", "subjects", "with", "EPI", "due", "to", "chronic", "pancreatitis/pancreatectomy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p57_s4", "idA": "1316175_16_item1_p75_s0", "sentA": "Completed clinical trials demonstrated that dietary fat and nitrogen (protein) absorption are significantly increased in patients with cystic fibrosis and EPI who received liprotamase.", "sentB": "Completed clinical trials demonstrated that dietary fat and nitrogen (protein) absorption are significantly increased in patients with cystic fibrosis and EPI who received Sollpura.", "type": 2, "words": ["<tag1>", "Completed", "clinical", "trials", "demonstrated", "that", "dietary", "fat", "and", "nitrogen", "(protein)", "absorption", "are", "significantly", "increased", "in", "patients", "with", "cystic", "fibrosis", "and", "EPI", "who", "received", "liprotamase.", "<tag2>", "Completed", "clinical", "trials", "demonstrated", "that", "dietary", "fat", "and", "nitrogen", "(protein)", "absorption", "are", "significantly", "increased", "in", "patients", "with", "cystic", "fibrosis", "and", "EPI", "who", "received", "Sollpura.", "<tag3>"], "wordsA": ["Completed", "clinical", "trials", "demonstrated", "that", "dietary", "fat", "and", "nitrogen", "(protein)", "absorption", "are", "significantly", "increased", "in", "patients", "with", "cystic", "fibrosis", "and", "EPI", "who", "received", "liprotamase."], "wordsB": ["Completed", "clinical", "trials", "demonstrated", "that", "dietary", "fat", "and", "nitrogen", "(protein)", "absorption", "are", "significantly", "increased", "in", "patients", "with", "cystic", "fibrosis", "and", "EPI", "who", "received", "Sollpura."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p59_s0", "idA": "1316175_16_item1_p77_s0", "sentA": "The dose-ranging Phase 1 study TC-1B evaluated five dose levels across a 50-fold range, from 100-to-5000 units (U) per kg per meal in CF-EPI subjects.", "sentB": "The dose-ranging Phase 1 study TC-1B evaluated five dose levels across a 50-fold range, from 100-to-5000 lipase units (U) per kg per meal in CF-EPI subjects.", "type": 2, "words": ["<tag1>", "The", "dose-ranging", "Phase", "1", "study", "TC-1B", "evaluated", "five", "dose", "levels", "across", "a", "50-fold", "range,", "from", "100-to-5000", "units", "(U)", "per", "kg", "per", "meal", "in", "CF-EPI", "subjects.", "<tag2>", "The", "dose-ranging", "Phase", "1", "study", "TC-1B", "evaluated", "five", "dose", "levels", "across", "a", "50-fold", "range,", "from", "100-to-5000", "lipase", "units", "(U)", "per", "kg", "per", "meal", "in", "CF-EPI", "subjects.", "<tag3>"], "wordsA": ["The", "dose-ranging", "Phase", "1", "study", "TC-1B", "evaluated", "five", "dose", "levels", "across", "a", "50-fold", "range,", "from", "100-to-5000", "units", "(U)", "per", "kg", "per", "meal", "in", "CF-EPI", "subjects."], "wordsB": ["The", "dose-ranging", "Phase", "1", "study", "TC-1B", "evaluated", "five", "dose", "levels", "across", "a", "50-fold", "range,", "from", "100-to-5000", "lipase", "units", "(U)", "per", "kg", "per", "meal", "in", "CF-EPI", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p59_s1", "idA": "1316175_16_item1_p77_s1", "sentA": "In this study, greater improvements in nutrients absorption, as measured using the percent change from baseline in the coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA), were observed at doses of 500 U per kg per meal and higher.", "sentB": "In this study, greater improvements in nutrients absorption, as measured using the percent change from baseline in the coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA), were observed at doses of 500 lipase U per kg per meal and higher.", "type": 2, "words": ["<tag1>", "In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "U", "per", "kg", "per", "meal", "and", "higher.", "<tag2>", "In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "lipase", "U", "per", "kg", "per", "meal", "and", "higher.", "<tag3>"], "wordsA": ["In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "U", "per", "kg", "per", "meal", "and", "higher."], "wordsB": ["In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "lipase", "U", "per", "kg", "per", "meal", "and", "higher."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p60_s0", "idA": "1316175_16_item1_p78_s0", "sentA": "Study TC-2A, a Phase 2, randomized, double-blind, parallel group, dose-finding trial, was conducted in 125 pediatric and adult subjects with CF-related EPI who were treated with liprotamase in one of three dosing regimens containing 6,500 U, 32,500 U, and 130,000 U lipase administered per meal or snack.", "sentB": "Study TC-2A, a Phase 2, randomized, double-blind, parallel group, dose-finding trial, was conducted in 125 pediatric and adult subjects with CF-related EPI who were treated with Sollpura in one of three dosing regimens containing 6,500 U, 32,500 U, and 130,000 U lipase administered per meal or snack.", "type": 2, "words": ["<tag1>", "Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "liprotamase", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack.", "<tag2>", "Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "Sollpura", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack.", "<tag3>"], "wordsA": ["Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "liprotamase", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack."], "wordsB": ["Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "Sollpura", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p60_s2", "idA": "1316175_16_item1_p78_s2", "sentA": "Pairwise comparison of the CFA values showed that statistically greater improvements were observed at the higher doses of liprotamase compared with the lowest dose of 6,500 U (Figure 1).", "sentB": "Pairwise comparison of the CFA values showed that statistically greater improvements were observed at the higher doses of Sollpura compared with the lowest dose of 6,500 U. Similar improvements in the CNA, were observed with Sollpura at the two highest dose levels.", "type": 2, "words": ["<tag1>", "Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "liprotamase", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U", "(Figure", "1).", "<tag2>", "Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "Sollpura", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U.", "Similar", "improvements", "in", "the", "CNA,", "were", "observed", "with", "Sollpura", "at", "the", "two", "highest", "dose", "levels.", "<tag3>"], "wordsA": ["Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "liprotamase", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U", "(Figure", "1)."], "wordsB": ["Pairwise", "comparison", "of", "the", "CFA", "values", "showed", "that", "statistically", "greater", "improvements", "were", "observed", "at", "the", "higher", "doses", "of", "Sollpura", "compared", "with", "the", "lowest", "dose", "of", "6,500", "U.", "Similar", "improvements", "in", "the", "CNA,", "were", "observed", "with", "Sollpura", "at", "the", "two", "highest", "dose", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p61_s0", "idA": "1316175_16_item1_p79_s0", "sentA": "Study 726, a Phase 3, placebo-controlled, parallel design, multinational clinical, evaluated the effects of a single capsule of liprotamase (containing 32,500 U lipase, with protease and amylase in fixed ratios) or placebo administered with every meal or snack in subjects with cystic fibrosis-related EPI.", "sentB": "Study 726, a Phase 3, placebo-controlled, parallel design, multinational clinical, evaluated the effects of a single capsule of Sollpura (containing 32,500 U lipase, with protease and amylase in fixed ratios) or placebo administered with every meal or snack in subjects with cystic fibrosis-related EPI.", "type": 2, "words": ["<tag1>", "Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "in", "subjects", "with", "cystic", "fibrosis-related", "EPI.", "<tag2>", "Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "Sollpura", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "in", "subjects", "with", "cystic", "fibrosis-related", "EPI.", "<tag3>"], "wordsA": ["Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "liprotamase", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "in", "subjects", "with", "cystic", "fibrosis-related", "EPI."], "wordsB": ["Study", "726,", "a", "Phase", "3,", "placebo-controlled,", "parallel", "design,", "multinational", "clinical,", "evaluated", "the", "effects", "of", "a", "single", "capsule", "of", "Sollpura", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "or", "placebo", "administered", "with", "every", "meal", "or", "snack", "in", "subjects", "with", "cystic", "fibrosis-related", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p61_s1", "idA": "1316175_16_item1_p79_s1", "sentA": "Amongst the 138 subjects enrolled in this study, treatment with liprotamase resulted in a statistically significant improvement in the change from baseline in the CFA of 21.2% with liprotamase compared with 6.0% with placebo (p = 0.0011) (Figure 2).", "sentB": "Among the 138 subjects enrolled in this study, treatment with Sollpura resulted in a statistically significant improvement in the change from baseline in the CFA of 21.2% with Sollpura compared with 6.0% with placebo (p = 0.0011).", "type": 2, "words": ["<tag1>", "Amongst", "the", "138", "subjects", "enrolled", "in", "this", "study,", "treatment", "with", "liprotamase", "resulted", "in", "a", "statistically", "significant", "improvement", "in", "the", "change", "from", "baseline", "in", "the", "CFA", "of", "21.2%", "with", "liprotamase", "compared", "with", "6.0%", "with", "placebo", "(p", "=", "0.0011)", "(Figure", "2).", "<tag2>", "Among", "the", "138", "subjects", "enrolled", "in", "this", "study,", "treatment", "with", "Sollpura", "resulted", "in", "a", "statistically", "significant", "improvement", "in", "the", "change", "from", "baseline", "in", "the", "CFA", "of", "21.2%", "with", "Sollpura", "compared", "with", "6.0%", "with", "placebo", "(p", "=", "0.0011).", "<tag3>"], "wordsA": ["Amongst", "the", "138", "subjects", "enrolled", "in", "this", "study,", "treatment", "with", "liprotamase", "resulted", "in", "a", "statistically", "significant", "improvement", "in", "the", "change", "from", "baseline", "in", "the", "CFA", "of", "21.2%", "with", "liprotamase", "compared", "with", "6.0%", "with", "placebo", "(p", "=", "0.0011)", "(Figure", "2)."], "wordsB": ["Among", "the", "138", "subjects", "enrolled", "in", "this", "study,", "treatment", "with", "Sollpura", "resulted", "in", "a", "statistically", "significant", "improvement", "in", "the", "change", "from", "baseline", "in", "the", "CFA", "of", "21.2%", "with", "Sollpura", "compared", "with", "6.0%", "with", "placebo", "(p", "=", "0.0011)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p61_s2", "idA": "1316175_16_item1_p79_s2", "sentA": "The median body weight of subjects in this trial was 50 kg, for which the corresponding liprotamase dose was 650 U lipase/kg/meal or snack.", "sentB": "The median body weight of subjects in this trial was 50 kg, for which the corresponding Sollpura dose was 650 U lipase/kg/meal or snack.", "type": 2, "words": ["<tag1>", "The", "median", "body", "weight", "of", "subjects", "in", "this", "trial", "was", "50", "kg,", "for", "which", "the", "corresponding", "liprotamase", "dose", "was", "650", "U", "lipase/kg/meal", "or", "snack.", "<tag2>", "The", "median", "body", "weight", "of", "subjects", "in", "this", "trial", "was", "50", "kg,", "for", "which", "the", "corresponding", "Sollpura", "dose", "was", "650", "U", "lipase/kg/meal", "or", "snack.", "<tag3>"], "wordsA": ["The", "median", "body", "weight", "of", "subjects", "in", "this", "trial", "was", "50", "kg,", "for", "which", "the", "corresponding", "liprotamase", "dose", "was", "650", "U", "lipase/kg/meal", "or", "snack."], "wordsB": ["The", "median", "body", "weight", "of", "subjects", "in", "this", "trial", "was", "50", "kg,", "for", "which", "the", "corresponding", "Sollpura", "dose", "was", "650", "U", "lipase/kg/meal", "or", "snack."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p8_s1", "idA": "1316175_16_item1_p7_s2", "sentA": "For example, as the porcine-derived proteins contained in the PERTs pass through the low pH environment of the stomach, enzyme activity rapidly diminishes and, as a consequence, large doses of porcine enzymes are often required.", "sentB": "As the porcine-derived proteins contained in the PERTs pass through the low pH environment of the stomach, they are protected by the enteric coating until they reach a pH of approximately 5.6 or greater in the duodenum and then are rapidly released.", "type": 2, "words": ["<tag1>", "For", "example,", "as", "the", "porcine-derived", "proteins", "contained", "in", "the", "PERTs", "pass", "through", "the", "low", "pH", "environment", "of", "the", "stomach,", "enzyme", "activity", "rapidly", "diminishes", "and,", "as", "a", "consequence,", "large", "doses", "of", "porcine", "enzymes", "are", "often", "required.", "<tag2>", "As", "the", "porcine-derived", "proteins", "contained", "in", "the", "PERTs", "pass", "through", "the", "low", "pH", "environment", "of", "the", "stomach,", "they", "are", "protected", "by", "the", "enteric", "coating", "until", "they", "reach", "a", "pH", "of", "approximately", "5.6", "or", "greater", "in", "the", "duodenum", "and", "then", "are", "rapidly", "released.", "<tag3>"], "wordsA": ["For", "example,", "as", "the", "porcine-derived", "proteins", "contained", "in", "the", "PERTs", "pass", "through", "the", "low", "pH", "environment", "of", "the", "stomach,", "enzyme", "activity", "rapidly", "diminishes", "and,", "as", "a", "consequence,", "large", "doses", "of", "porcine", "enzymes", "are", "often", "required."], "wordsB": ["As", "the", "porcine-derived", "proteins", "contained", "in", "the", "PERTs", "pass", "through", "the", "low", "pH", "environment", "of", "the", "stomach,", "they", "are", "protected", "by", "the", "enteric", "coating", "until", "they", "reach", "a", "pH", "of", "approximately", "5.6", "or", "greater", "in", "the", "duodenum", "and", "then", "are", "rapidly", "released."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p62_s0", "idA": "1316175_16_item1_p80_s0", "sentA": "Two long-term studies were conducted to evaluate the safety and effects on nutritional status of liprotamase.", "sentB": "Two one-year studies were conducted to evaluate the safety and effects on nutritional status of Sollpura.", "type": 2, "words": ["<tag1>", "Two", "long-term", "studies", "were", "conducted", "to", "evaluate", "the", "safety", "and", "effects", "on", "nutritional", "status", "of", "liprotamase.", "<tag2>", "Two", "one-year", "studies", "were", "conducted", "to", "evaluate", "the", "safety", "and", "effects", "on", "nutritional", "status", "of", "Sollpura.", "<tag3>"], "wordsA": ["Two", "long-term", "studies", "were", "conducted", "to", "evaluate", "the", "safety", "and", "effects", "on", "nutritional", "status", "of", "liprotamase."], "wordsB": ["Two", "one-year", "studies", "were", "conducted", "to", "evaluate", "the", "safety", "and", "effects", "on", "nutritional", "status", "of", "Sollpura."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p62_s2", "idA": "1316175_16_item1_p81_s0", "sentA": "Amongst the 214 subjects who were treated, an average dose of 5.5 capsules (containing 32,500 U lipase, with protease and amylase in fixed ratios) of liprotamase per day maintained nutritional status as assessed by serial measurement of height and weight, including age-appropriate growth and weight gain in children.", "sentB": "Among the 214 subjects who were treated, an average dose of 5.5 capsules (containing 32,500 U lipase, with protease and amylase in fixed ratios) of Sollpura per day maintained nutritional status as assessed by serial measurement of height and weight, including age-appropriate growth and weight gain in children.", "type": 2, "words": ["<tag1>", "Amongst", "the", "214", "subjects", "who", "were", "treated,", "an", "average", "dose", "of", "5.5", "capsules", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "of", "liprotamase", "per", "day", "maintained", "nutritional", "status", "as", "assessed", "by", "serial", "measurement", "of", "height", "and", "weight,", "including", "age-appropriate", "growth", "and", "weight", "gain", "in", "children.", "<tag2>", "Among", "the", "214", "subjects", "who", "were", "treated,", "an", "average", "dose", "of", "5.5", "capsules", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "of", "Sollpura", "per", "day", "maintained", "nutritional", "status", "as", "assessed", "by", "serial", "measurement", "of", "height", "and", "weight,", "including", "age-appropriate", "growth", "and", "weight", "gain", "in", "children.", "<tag3>"], "wordsA": ["Amongst", "the", "214", "subjects", "who", "were", "treated,", "an", "average", "dose", "of", "5.5", "capsules", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "of", "liprotamase", "per", "day", "maintained", "nutritional", "status", "as", "assessed", "by", "serial", "measurement", "of", "height", "and", "weight,", "including", "age-appropriate", "growth", "and", "weight", "gain", "in", "children."], "wordsB": ["Among", "the", "214", "subjects", "who", "were", "treated,", "an", "average", "dose", "of", "5.5", "capsules", "(containing", "32,500", "U", "lipase,", "with", "protease", "and", "amylase", "in", "fixed", "ratios)", "of", "Sollpura", "per", "day", "maintained", "nutritional", "status", "as", "assessed", "by", "serial", "measurement", "of", "height", "and", "weight,", "including", "age-appropriate", "growth", "and", "weight", "gain", "in", "children."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p63_s0", "idA": "1316175_16_item1_p82_s0", "sentA": "To date, four randomized, clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies in which a total of 104 patients were enrolled by our licensor, Amgen, a Phase 2b double-blind placebo-controlled dose-ranging clinical outcomes study (PEARL-SC) in which 547 subjects were enrolled, and a Phase 2 Open-Label Extension study (OLE) which evaluated the long-term safety of blisibimod in subjects previously enrolled in the Phase 2b PEARL-SC study, both conducted by us.", "sentB": "To date, five randomized, clinical studies have been conducted with blisibimod in patients with lupus: two Phase 1 dose-ranging studies by our licensor, Amgen, two double-blind, placebo-controlled dose-ranging clinical outcomes studies, PEARL-SC (Phase 2b) and CHABLIS-SC1 (Phase 3), and a Phase 2 Open-Label Extension study (OLE).", "type": 2, "words": ["<tag1>", "To", "date,", "four", "randomized,", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "(PEARL-SC)", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us.", "<tag2>", "To", "date,", "five", "randomized,", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "by", "our", "licensor,", "Amgen,", "two", "double-blind,", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "studies,", "PEARL-SC", "(Phase", "2b)", "and", "CHABLIS-SC1", "(Phase", "3),", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE).", "<tag3>"], "wordsA": ["To", "date,", "four", "randomized,", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "in", "which", "a", "total", "of", "104", "patients", "were", "enrolled", "by", "our", "licensor,", "Amgen,", "a", "Phase", "2b", "double-blind", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "study", "(PEARL-SC)", "in", "which", "547", "subjects", "were", "enrolled,", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)", "which", "evaluated", "the", "long-term", "safety", "of", "blisibimod", "in", "subjects", "previously", "enrolled", "in", "the", "Phase", "2b", "PEARL-SC", "study,", "both", "conducted", "by", "us."], "wordsB": ["To", "date,", "five", "randomized,", "clinical", "studies", "have", "been", "conducted", "with", "blisibimod", "in", "patients", "with", "lupus:", "two", "Phase", "1", "dose-ranging", "studies", "by", "our", "licensor,", "Amgen,", "two", "double-blind,", "placebo-controlled", "dose-ranging", "clinical", "outcomes", "studies,", "PEARL-SC", "(Phase", "2b)", "and", "CHABLIS-SC1", "(Phase", "3),", "and", "a", "Phase", "2", "Open-Label", "Extension", "study", "(OLE)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s3", "idA": "1316175_16_item1_p85_s0", "sentA": "The primary endpoint of the PEARL-SC study was a clinical improvement at the lupus responder index, or SRI-5, at week 24 for the pooled blisibimod dose groups versus placebo groups.", "sentB": "As with the analysis in June 2016, the numerical reduction in proteinuria in blisibimod versus placebo treated patients at Week 48 did not meet the predefined statistical primary endpoint of complete or partial response.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "lupus", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "blisibimod", "dose", "groups", "versus", "placebo", "groups.", "<tag2>", "As", "with", "the", "analysis", "in", "June", "2016,", "the", "numerical", "reduction", "in", "proteinuria", "in", "blisibimod", "versus", "placebo", "treated", "patients", "at", "Week", "48", "did", "not", "meet", "the", "predefined", "statistical", "primary", "endpoint", "of", "complete", "or", "partial", "response.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "PEARL-SC", "study", "was", "a", "clinical", "improvement", "at", "the", "lupus", "responder", "index,", "or", "SRI-5,", "at", "week", "24", "for", "the", "pooled", "blisibimod", "dose", "groups", "versus", "placebo", "groups."], "wordsB": ["As", "with", "the", "analysis", "in", "June", "2016,", "the", "numerical", "reduction", "in", "proteinuria", "in", "blisibimod", "versus", "placebo", "treated", "patients", "at", "Week", "48", "did", "not", "meet", "the", "predefined", "statistical", "primary", "endpoint", "of", "complete", "or", "partial", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p64_s2", "idA": "1316175_16_item1_p85_s2", "sentA": "The primary endpoint of this study was not met due to the lack of efficacy in the two lowest dose groups.", "sentB": "However, this effect was not statistically significant at the primary endpoint analysis at Week 52.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups.", "<tag2>", "However,", "this", "effect", "was", "not", "statistically", "significant", "at", "the", "primary", "endpoint", "analysis", "at", "Week", "52.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "this", "study", "was", "not", "met", "due", "to", "the", "lack", "of", "efficacy", "in", "the", "two", "lowest", "dose", "groups."], "wordsB": ["However,", "this", "effect", "was", "not", "statistically", "significant", "at", "the", "primary", "endpoint", "analysis", "at", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p64_s1", "idA": "1316175_16_item1_p85_s8", "sentA": "Compared with baseline, decreases in proteinuria were observed with blisibimod from Week 12 through Week 52 in the subgroup of subjects with proteinuria equivalent 1 g/24hr at enrollment (Figure 4).", "sentB": "Compared with placebo, a higher proportion of subjects on blisibimod met the SRI-6 criteria from Week 16 through Week 52.", "type": 2, "words": ["<tag1>", "Compared", "with", "baseline,", "decreases", "in", "proteinuria", "were", "observed", "with", "blisibimod", "from", "Week", "12", "through", "Week", "52", "in", "the", "subgroup", "of", "subjects", "with", "proteinuria", "equivalent", "1", "g/24hr", "at", "enrollment", "(Figure", "4).", "<tag2>", "Compared", "with", "placebo,", "a", "higher", "proportion", "of", "subjects", "on", "blisibimod", "met", "the", "SRI-6", "criteria", "from", "Week", "16", "through", "Week", "52.", "<tag3>"], "wordsA": ["Compared", "with", "baseline,", "decreases", "in", "proteinuria", "were", "observed", "with", "blisibimod", "from", "Week", "12", "through", "Week", "52", "in", "the", "subgroup", "of", "subjects", "with", "proteinuria", "equivalent", "1", "g/24hr", "at", "enrollment", "(Figure", "4)."], "wordsB": ["Compared", "with", "placebo,", "a", "higher", "proportion", "of", "subjects", "on", "blisibimod", "met", "the", "SRI-6", "criteria", "from", "Week", "16", "through", "Week", "52."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p36_s0", "idA": "1316175_16_item1_p87_s0", "sentA": "In June of 2012 we completed dosing in the PEARL-SC study.", "sentB": "In June 2013, we initiated a Phase 2 clinical study, BRIGHT-SC study.", "type": 2, "words": ["<tag1>", "In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study.", "<tag2>", "In", "June", "2013,", "we", "initiated", "a", "Phase", "2", "clinical", "study,", "BRIGHT-SC", "study.", "<tag3>"], "wordsA": ["In", "June", "of", "2012", "we", "completed", "dosing", "in", "the", "PEARL-SC", "study."], "wordsB": ["In", "June", "2013,", "we", "initiated", "a", "Phase", "2", "clinical", "study,", "BRIGHT-SC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p64_s3", "idA": "1316175_16_item1_p88_s4", "sentA": "Consistent pharmacodynamics responses were noted with blisibimod including reductions of B-cells, double-stranded-DNA antibodies and increases in complement C3 and C4.", "sentB": "Significant changes in SLE-relevant disease markers were observed with blisibimod, including reductions in urinary protein:creatinine ratio, peripheral B cell lineages, anti-dsDNA, anti-phospholipid antibodies, and serum immunoglobulins, and significant increases in complement C3 and C4.", "type": 2, "words": ["<tag1>", "Consistent", "pharmacodynamics", "responses", "were", "noted", "with", "blisibimod", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "increases", "in", "complement", "C3", "and", "C4.", "<tag2>", "Significant", "changes", "in", "SLE-relevant", "disease", "markers", "were", "observed", "with", "blisibimod,", "including", "reductions", "in", "urinary", "protein:creatinine", "ratio,", "peripheral", "B", "cell", "lineages,", "anti-dsDNA,", "anti-phospholipid", "antibodies,", "and", "serum", "immunoglobulins,", "and", "significant", "increases", "in", "complement", "C3", "and", "C4.", "<tag3>"], "wordsA": ["Consistent", "pharmacodynamics", "responses", "were", "noted", "with", "blisibimod", "including", "reductions", "of", "B-cells,", "double-stranded-DNA", "antibodies", "and", "increases", "in", "complement", "C3", "and", "C4."], "wordsB": ["Significant", "changes", "in", "SLE-relevant", "disease", "markers", "were", "observed", "with", "blisibimod,", "including", "reductions", "in", "urinary", "protein:creatinine", "ratio,", "peripheral", "B", "cell", "lineages,", "anti-dsDNA,", "anti-phospholipid", "antibodies,", "and", "serum", "immunoglobulins,", "and", "significant", "increases", "in", "complement", "C3", "and", "C4."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p9_s0", "idA": "1316175_16_item1_p8_s1", "sentA": "Patient-to-patient differences in the acidity of the intestine makes dissolution of enterically-coated products variable, and gives rise to alterations in the rate and extent to which enzymes are released from these products.", "sentB": "Patient-to-patient differences in the acidity of the upper intestine makes dissolution of enterically-coated products variable, and gives rise to alterations in the rate and extent to which enzymes are released from these products.", "type": 2, "words": ["<tag1>", "Patient-to-patient", "differences", "in", "the", "acidity", "of", "the", "intestine", "makes", "dissolution", "of", "enterically-coated", "products", "variable,", "and", "gives", "rise", "to", "alterations", "in", "the", "rate", "and", "extent", "to", "which", "enzymes", "are", "released", "from", "these", "products.", "<tag2>", "Patient-to-patient", "differences", "in", "the", "acidity", "of", "the", "upper", "intestine", "makes", "dissolution", "of", "enterically-coated", "products", "variable,", "and", "gives", "rise", "to", "alterations", "in", "the", "rate", "and", "extent", "to", "which", "enzymes", "are", "released", "from", "these", "products.", "<tag3>"], "wordsA": ["Patient-to-patient", "differences", "in", "the", "acidity", "of", "the", "intestine", "makes", "dissolution", "of", "enterically-coated", "products", "variable,", "and", "gives", "rise", "to", "alterations", "in", "the", "rate", "and", "extent", "to", "which", "enzymes", "are", "released", "from", "these", "products."], "wordsB": ["Patient-to-patient", "differences", "in", "the", "acidity", "of", "the", "upper", "intestine", "makes", "dissolution", "of", "enterically-coated", "products", "variable,", "and", "gives", "rise", "to", "alterations", "in", "the", "rate", "and", "extent", "to", "which", "enzymes", "are", "released", "from", "these", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p64_s0", "idA": "1316175_16_item1_p91_s0", "sentA": "In the above figure, an SRI-6 responder achieved all of the following: 6 point improvement in SELENA-SLEDAI, and no new BILAG 1A or 2B organ domain scores, and no worsening ( 0.3 increase) in Physician s Global Assessment.", "sentB": "In the CHABLIS-SC1 study, the primary endpoint compared the effects of blisibimod and placebo at Week 52 using the SLE Responder Index-6 (SRI-6): 6-point improvement in SELENA-SLEDAI, no new BILAG 1A or 2B domain scores, and 0.3-point increase in Physician s Global Assessment.", "type": 2, "words": ["<tag1>", "In", "the", "above", "figure,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment.", "<tag2>", "In", "the", "CHABLIS-SC1", "study,", "the", "primary", "endpoint", "compared", "the", "effects", "of", "blisibimod", "and", "placebo", "at", "Week", "52", "using", "the", "SLE", "Responder", "Index-6", "(SRI-6):", "6-point", "improvement", "in", "SELENA-SLEDAI,", "no", "new", "BILAG", "1A", "or", "2B", "domain", "scores,", "and", "0.3-point", "increase", "in", "Physician", "s", "Global", "Assessment.", "<tag3>"], "wordsA": ["In", "the", "above", "figure,", "an", "SRI-6", "responder", "achieved", "all", "of", "the", "following:", "6", "point", "improvement", "in", "SELENA-SLEDAI,", "and", "no", "new", "BILAG", "1A", "or", "2B", "organ", "domain", "scores,", "and", "no", "worsening", "(", "0.3", "increase)", "in", "Physician", "s", "Global", "Assessment."], "wordsB": ["In", "the", "CHABLIS-SC1", "study,", "the", "primary", "endpoint", "compared", "the", "effects", "of", "blisibimod", "and", "placebo", "at", "Week", "52", "using", "the", "SLE", "Responder", "Index-6", "(SRI-6):", "6-point", "improvement", "in", "SELENA-SLEDAI,", "no", "new", "BILAG", "1A", "or", "2B", "domain", "scores,", "and", "0.3-point", "increase", "in", "Physician", "s", "Global", "Assessment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s6", "idA": "1316175_16_item1_p97_s0", "sentA": "In this study, statistically significant reductions in total B-cells were observed in patients treated with blisibimod compared with placebo due to its mechanism of BAFF inhibition.", "sentB": "Concomitant decreases were observed in B cells and immunoglobulins with blisibimod compared with placebo which supports the hypothesized mechanism of action that blisibimod-mediated BAFF inhibition acts to reduce peripheral B cells and immunoglobulins, and may prevent deterioration of PCR levels in IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "this", "study,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition.", "<tag2>", "Concomitant", "decreases", "were", "observed", "in", "B", "cells", "and", "immunoglobulins", "with", "blisibimod", "compared", "with", "placebo", "which", "supports", "the", "hypothesized", "mechanism", "of", "action", "that", "blisibimod-mediated", "BAFF", "inhibition", "acts", "to", "reduce", "peripheral", "B", "cells", "and", "immunoglobulins,", "and", "may", "prevent", "deterioration", "of", "PCR", "levels", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "this", "study,", "statistically", "significant", "reductions", "in", "total", "B-cells", "were", "observed", "in", "patients", "treated", "with", "blisibimod", "compared", "with", "placebo", "due", "to", "its", "mechanism", "of", "BAFF", "inhibition."], "wordsB": ["Concomitant", "decreases", "were", "observed", "in", "B", "cells", "and", "immunoglobulins", "with", "blisibimod", "compared", "with", "placebo", "which", "supports", "the", "hypothesized", "mechanism", "of", "action", "that", "blisibimod-mediated", "BAFF", "inhibition", "acts", "to", "reduce", "peripheral", "B", "cells", "and", "immunoglobulins,", "and", "may", "prevent", "deterioration", "of", "PCR", "levels", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_17_item1_p41_s1", "idA": "1316175_16_item1_p97_s2", "sentA": "Lupus biomarker observations from the PEARL-SC trial are summarized in the next section, Open-Label Extension Study in Patients Enrolled in PEARL-SC Study , along with data from the open-label extension study.", "sentB": "This analysis, which was conducted when the last subject enrolled had completed the Week 48 assessments, confirmed and extended the observations from the analysis in June 2016 with more subjects contributing to the later timepoint in the analysis.", "type": 2, "words": ["<tag1>", "Lupus", "biomarker", "observations", "from", "the", "PEARL-SC", "trial", "are", "summarized", "in", "the", "next", "section,", "Open-Label", "Extension", "Study", "in", "Patients", "Enrolled", "in", "PEARL-SC", "Study", ",", "along", "with", "data", "from", "the", "open-label", "extension", "study.", "<tag2>", "This", "analysis,", "which", "was", "conducted", "when", "the", "last", "subject", "enrolled", "had", "completed", "the", "Week", "48", "assessments,", "confirmed", "and", "extended", "the", "observations", "from", "the", "analysis", "in", "June", "2016", "with", "more", "subjects", "contributing", "to", "the", "later", "timepoint", "in", "the", "analysis.", "<tag3>"], "wordsA": ["Lupus", "biomarker", "observations", "from", "the", "PEARL-SC", "trial", "are", "summarized", "in", "the", "next", "section,", "Open-Label", "Extension", "Study", "in", "Patients", "Enrolled", "in", "PEARL-SC", "Study", ",", "along", "with", "data", "from", "the", "open-label", "extension", "study."], "wordsB": ["This", "analysis,", "which", "was", "conducted", "when", "the", "last", "subject", "enrolled", "had", "completed", "the", "Week", "48", "assessments,", "confirmed", "and", "extended", "the", "observations", "from", "the", "analysis", "in", "June", "2016", "with", "more", "subjects", "contributing", "to", "the", "later", "timepoint", "in", "the", "analysis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p0_s1", "idA": "1316175_17_item1_p0_s1", "sentA": "We currently have two product candidates, Sollpura, formally known as liprotamase, and blisibimod.", "sentB": "We currently have two compounds in development, Sollpura and blisibimod.", "type": 2, "words": ["<tag1>", "We", "currently", "have", "two", "product", "candidates,", "Sollpura,", "formally", "known", "as", "liprotamase,", "and", "blisibimod.", "<tag2>", "We", "currently", "have", "two", "compounds", "in", "development,", "Sollpura", "and", "blisibimod.", "<tag3>"], "wordsA": ["We", "currently", "have", "two", "product", "candidates,", "Sollpura,", "formally", "known", "as", "liprotamase,", "and", "blisibimod."], "wordsB": ["We", "currently", "have", "two", "compounds", "in", "development,", "Sollpura", "and", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p82_s2", "idA": "1316175_17_item1_p100_s2", "sentA": "We may also choose to employ medical sales liaisons personnel to support the product.", "sentB": "We may also choose to employ medical sales liaisons personnel to support our products.", "type": 2, "words": ["<tag1>", "We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "the", "product.", "<tag2>", "We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "our", "products.", "<tag3>"], "wordsA": ["We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "the", "product."], "wordsB": ["We", "may", "also", "choose", "to", "employ", "medical", "sales", "liaisons", "personnel", "to", "support", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p84_s3", "idA": "1316175_17_item1_p102_s3", "sentA": "These sanctions could include the FDA s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.", "sentB": "These sanctions could include the FDA s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.", "type": 2, "words": ["<tag1>", "These", "sanctions", "could", "include", "the", "FDA", "s", "refusal", "to", "approve", "pending", "applications,", "withdrawal", "of", "an", "approval,", "a", "clinical", "hold,", "untitled", "or", "warning", "letters,", "product", "recalls,", "product", "seizures,", "total", "or", "partial", "suspension", "of", "production", "or", "distribution,", "injunctions,", "fines,", "refusals", "of", "government", "contracts,", "restitution,", "disgorgement", "or", "civil", "or", "criminal", "penalties.", "<tag2>", "These", "sanctions", "could", "include", "the", "FDA", "s", "refusal", "to", "approve", "pending", "applications,", "withdrawal", "of", "an", "approval,", "license", "revocation,", "a", "clinical", "hold,", "untitled", "or", "warning", "letters,", "product", "recalls,", "product", "seizures,", "total", "or", "partial", "suspension", "of", "production", "or", "distribution,", "injunctions,", "fines,", "refusals", "of", "government", "contracts,", "restitution,", "disgorgement", "or", "civil", "or", "criminal", "penalties.", "<tag3>"], "wordsA": ["These", "sanctions", "could", "include", "the", "FDA", "s", "refusal", "to", "approve", "pending", "applications,", "withdrawal", "of", "an", "approval,", "a", "clinical", "hold,", "untitled", "or", "warning", "letters,", "product", "recalls,", "product", "seizures,", "total", "or", "partial", "suspension", "of", "production", "or", "distribution,", "injunctions,", "fines,", "refusals", "of", "government", "contracts,", "restitution,", "disgorgement", "or", "civil", "or", "criminal", "penalties."], "wordsB": ["These", "sanctions", "could", "include", "the", "FDA", "s", "refusal", "to", "approve", "pending", "applications,", "withdrawal", "of", "an", "approval,", "license", "revocation,", "a", "clinical", "hold,", "untitled", "or", "warning", "letters,", "product", "recalls,", "product", "seizures,", "total", "or", "partial", "suspension", "of", "production", "or", "distribution,", "injunctions,", "fines,", "refusals", "of", "government", "contracts,", "restitution,", "disgorgement", "or", "civil", "or", "criminal", "penalties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p88_s1", "idA": "1316175_17_item1_p106_s1", "sentA": "Preclinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies to assess its potential safety and efficacy.", "sentB": "Nonclinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies to assess its potential safety and efficacy.", "type": 2, "words": ["<tag1>", "Preclinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies", "to", "assess", "its", "potential", "safety", "and", "efficacy.", "<tag2>", "Nonclinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies", "to", "assess", "its", "potential", "safety", "and", "efficacy.", "<tag3>"], "wordsA": ["Preclinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies", "to", "assess", "its", "potential", "safety", "and", "efficacy."], "wordsB": ["Nonclinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity,", "formulation", "and", "stability,", "as", "well", "as", "animal", "studies", "to", "assess", "its", "potential", "safety", "and", "efficacy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p88_s3", "idA": "1316175_17_item1_p106_s3", "sentA": "The sponsor will also include a protocol detailing, among other things, the objectives of the initial clinical study, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical study lends itself to an efficacy evaluation.", "sentB": "The sponsor includes a protocol detailing, among other things, the objectives of the initial clinical study, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the initial clinical study lends itself to an efficacy evaluation.", "type": 2, "words": ["<tag1>", "The", "sponsor", "will", "also", "include", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation.", "<tag2>", "The", "sponsor", "includes", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation.", "<tag3>"], "wordsA": ["The", "sponsor", "will", "also", "include", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation."], "wordsB": ["The", "sponsor", "includes", "a", "protocol", "detailing,", "among", "other", "things,", "the", "objectives", "of", "the", "initial", "clinical", "study,", "dosing", "procedures,", "subject", "selection", "and", "exclusion", "criteria,", "the", "parameters", "to", "be", "used", "in", "monitoring", "safety", "and", "the", "effectiveness", "criteria", "to", "be", "evaluated", "if", "the", "initial", "clinical", "study", "lends", "itself", "to", "an", "efficacy", "evaluation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p89_s0", "idA": "1316175_17_item1_p106_s4", "sentA": "Some preclinical testing may continue even after the IND is submitted.", "sentB": "Some nonclinical testing may continue even after the IND is submitted.", "type": 2, "words": ["<tag1>", "Some", "preclinical", "testing", "may", "continue", "even", "after", "the", "IND", "is", "submitted.", "<tag2>", "Some", "nonclinical", "testing", "may", "continue", "even", "after", "the", "IND", "is", "submitted.", "<tag3>"], "wordsA": ["Some", "preclinical", "testing", "may", "continue", "even", "after", "the", "IND", "is", "submitted."], "wordsB": ["Some", "nonclinical", "testing", "may", "continue", "even", "after", "the", "IND", "is", "submitted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p145_s2", "idA": "1316175_17_item1_p106_s7", "sentA": "Clinical holds may also be imposed by the FDA at any time before or during clinical studies due to safety concerns or non-compliance.", "sentB": "Coverage policies and third-party reimbursement rates may change at any time.", "type": 2, "words": ["<tag1>", "Clinical", "holds", "may", "also", "be", "imposed", "by", "the", "FDA", "at", "any", "time", "before", "or", "during", "clinical", "studies", "due", "to", "safety", "concerns", "or", "non-compliance.", "<tag2>", "Coverage", "policies", "and", "third-party", "reimbursement", "rates", "may", "change", "at", "any", "time.", "<tag3>"], "wordsA": ["Clinical", "holds", "may", "also", "be", "imposed", "by", "the", "FDA", "at", "any", "time", "before", "or", "during", "clinical", "studies", "due", "to", "safety", "concerns", "or", "non-compliance."], "wordsB": ["Coverage", "policies", "and", "third-party", "reimbursement", "rates", "may", "change", "at", "any", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p98_s0", "idA": "1316175_17_item1_p115_s0", "sentA": "In addition, under the Pediatric Research Equity Act of 2003, or PREA, which was reauthorized under the Food and Drug Administration Amendments Act of 2007, an NDA or BLA or supplement to an NDA or BLA must contain data to assess the safety and effectiveness of the drug or biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.", "sentB": "In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended, an NDA or BLA or supplement to an NDA or BLA must contain data to assess the safety and effectiveness of the drug or biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.", "type": 2, "words": ["<tag1>", "In", "addition,", "under", "the", "Pediatric", "Research", "Equity", "Act", "of", "2003,", "or", "PREA,", "which", "was", "reauthorized", "under", "the", "Food", "and", "Drug", "Administration", "Amendments", "Act", "of", "2007,", "an", "NDA", "or", "BLA", "or", "supplement", "to", "an", "NDA", "or", "BLA", "must", "contain", "data", "to", "assess", "the", "safety", "and", "effectiveness", "of", "the", "drug", "or", "biological", "product", "for", "the", "claimed", "indications", "in", "all", "relevant", "pediatric", "subpopulations", "and", "to", "support", "dosing", "and", "administration", "for", "each", "pediatric", "subpopulation", "for", "which", "the", "product", "is", "safe", "and", "effective.", "<tag2>", "In", "addition,", "under", "the", "Pediatric", "Research", "Equity", "Act", "of", "2003,", "or", "PREA,", "as", "amended,", "an", "NDA", "or", "BLA", "or", "supplement", "to", "an", "NDA", "or", "BLA", "must", "contain", "data", "to", "assess", "the", "safety", "and", "effectiveness", "of", "the", "drug", "or", "biological", "product", "for", "the", "claimed", "indications", "in", "all", "relevant", "pediatric", "subpopulations", "and", "to", "support", "dosing", "and", "administration", "for", "each", "pediatric", "subpopulation", "for", "which", "the", "product", "is", "safe", "and", "effective.", "<tag3>"], "wordsA": ["In", "addition,", "under", "the", "Pediatric", "Research", "Equity", "Act", "of", "2003,", "or", "PREA,", "which", "was", "reauthorized", "under", "the", "Food", "and", "Drug", "Administration", "Amendments", "Act", "of", "2007,", "an", "NDA", "or", "BLA", "or", "supplement", "to", "an", "NDA", "or", "BLA", "must", "contain", "data", "to", "assess", "the", "safety", "and", "effectiveness", "of", "the", "drug", "or", "biological", "product", "for", "the", "claimed", "indications", "in", "all", "relevant", "pediatric", "subpopulations", "and", "to", "support", "dosing", "and", "administration", "for", "each", "pediatric", "subpopulation", "for", "which", "the", "product", "is", "safe", "and", "effective."], "wordsB": ["In", "addition,", "under", "the", "Pediatric", "Research", "Equity", "Act", "of", "2003,", "or", "PREA,", "as", "amended,", "an", "NDA", "or", "BLA", "or", "supplement", "to", "an", "NDA", "or", "BLA", "must", "contain", "data", "to", "assess", "the", "safety", "and", "effectiveness", "of", "the", "drug", "or", "biological", "product", "for", "the", "claimed", "indications", "in", "all", "relevant", "pediatric", "subpopulations", "and", "to", "support", "dosing", "and", "administration", "for", "each", "pediatric", "subpopulation", "for", "which", "the", "product", "is", "safe", "and", "effective."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p12_s2", "idA": "1316175_17_item1_p11_s2", "sentA": "This finding is further supported by the similar efficacy observed between Sollpura and Creon in pigs with surgically-induced pancreatic insufficiency.", "sentB": "The suitability of the enzyme ratio in Sollpura is further supported by the observation that Sollpura and Creon were equi-effective in pigs with surgically-induced pancreatic insufficiency.", "type": 2, "words": ["<tag1>", "This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "Sollpura", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency.", "<tag2>", "The", "suitability", "of", "the", "enzyme", "ratio", "in", "Sollpura", "is", "further", "supported", "by", "the", "observation", "that", "Sollpura", "and", "Creon", "were", "equi-effective", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency.", "<tag3>"], "wordsA": ["This", "finding", "is", "further", "supported", "by", "the", "similar", "efficacy", "observed", "between", "Sollpura", "and", "Creon", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency."], "wordsB": ["The", "suitability", "of", "the", "enzyme", "ratio", "in", "Sollpura", "is", "further", "supported", "by", "the", "observation", "that", "Sollpura", "and", "Creon", "were", "equi-effective", "in", "pigs", "with", "surgically-induced", "pancreatic", "insufficiency."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p106_s0", "idA": "1316175_17_item1_p121_s0", "sentA": "Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act.", "sentB": "Depending upon the timing, duration and specifics of FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendment.", "type": 2, "words": ["<tag1>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Hatch-Waxman", "Act.", "<tag2>", "Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Hatch-Waxman", "Amendment.", "<tag3>"], "wordsA": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Hatch-Waxman", "Act."], "wordsB": ["Depending", "upon", "the", "timing,", "duration", "and", "specifics", "of", "FDA", "approval", "of", "the", "use", "of", "our", "product", "candidates,", "some", "of", "our", "U.S.", "patents", "may", "be", "eligible", "for", "limited", "patent", "term", "extension", "under", "the", "Hatch-Waxman", "Amendment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p106_s1", "idA": "1316175_17_item1_p121_s1", "sentA": "The Hatch-Waxman Act permit a patent restoration term of up to five years as compensation for patent term lost during the FDA regulatory review process.", "sentB": "The Hatch-Waxman Amendment permits a patent term restoration of up to five years as compensation for patent term lost during the FDA regulatory review process.", "type": 2, "words": ["<tag1>", "The", "Hatch-Waxman", "Act", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process.", "<tag2>", "The", "Hatch-Waxman", "Amendment", "permits", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process.", "<tag3>"], "wordsA": ["The", "Hatch-Waxman", "Act", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process."], "wordsB": ["The", "Hatch-Waxman", "Amendment", "permits", "a", "patent", "term", "restoration", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p153_s1", "idA": "1316175_17_item1_p121_s1", "sentA": "The Hatch-Waxman Act permit a patent restoration term of up to five years as compensation for patent term lost during the FDA regulatory review process.", "sentB": "Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs.", "type": 2, "words": ["<tag1>", "The", "Hatch-Waxman", "Act", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process.", "<tag2>", "Violations", "of", "this", "law", "are", "punishable", "by", "up", "to", "five", "years", "in", "prison,", "criminal", "fines,", "administrative", "civil", "money", "penalties", "and", "exclusion", "from", "participation", "in", "federal", "healthcare", "programs.", "<tag3>"], "wordsA": ["The", "Hatch-Waxman", "Act", "permit", "a", "patent", "restoration", "term", "of", "up", "to", "five", "years", "as", "compensation", "for", "patent", "term", "lost", "during", "the", "FDA", "regulatory", "review", "process."], "wordsB": ["Violations", "of", "this", "law", "are", "punishable", "by", "up", "to", "five", "years", "in", "prison,", "criminal", "fines,", "administrative", "civil", "money", "penalties", "and", "exclusion", "from", "participation", "in", "federal", "healthcare", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p106_s3", "idA": "1316175_17_item1_p121_s3", "sentA": "The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application.", "sentB": "The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA and the approval of that application.", "type": 2, "words": ["<tag1>", "The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "the", "time", "between", "the", "effective", "date", "of", "an", "IND", "and", "the", "submission", "date", "of", "an", "NDA", "plus", "the", "time", "between", "the", "submission", "date", "of", "an", "NDA", "and", "the", "approval", "of", "that", "application.", "<tag2>", "The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "the", "time", "between", "the", "effective", "date", "of", "an", "IND", "and", "the", "submission", "date", "of", "an", "NDA", "or", "BLA", "plus", "the", "time", "between", "the", "submission", "date", "of", "an", "NDA", "and", "the", "approval", "of", "that", "application.", "<tag3>"], "wordsA": ["The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "the", "time", "between", "the", "effective", "date", "of", "an", "IND", "and", "the", "submission", "date", "of", "an", "NDA", "plus", "the", "time", "between", "the", "submission", "date", "of", "an", "NDA", "and", "the", "approval", "of", "that", "application."], "wordsB": ["The", "patent", "term", "restoration", "period", "is", "generally", "one-half", "the", "time", "between", "the", "effective", "date", "of", "an", "IND", "and", "the", "submission", "date", "of", "an", "NDA", "or", "BLA", "plus", "the", "time", "between", "the", "submission", "date", "of", "an", "NDA", "and", "the", "approval", "of", "that", "application."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p106_s6", "idA": "1316175_17_item1_p121_s6", "sentA": "In the future, we intend to apply for restorations of patent terms for some of our currently owned or licensed patents to add patent life beyond their current expiration dates, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant NDA.", "sentB": "In the future, we intend to apply for restorations of patent terms for some of our currently owned or licensed patents to add patent life beyond their current expiration dates, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant NDA or BLA.", "type": 2, "words": ["<tag1>", "In", "the", "future,", "we", "intend", "to", "apply", "for", "restorations", "of", "patent", "terms", "for", "some", "of", "our", "currently", "owned", "or", "licensed", "patents", "to", "add", "patent", "life", "beyond", "their", "current", "expiration", "dates,", "depending", "on", "the", "expected", "length", "of", "the", "clinical", "studies", "and", "other", "factors", "involved", "in", "the", "filing", "of", "the", "relevant", "NDA.", "<tag2>", "In", "the", "future,", "we", "intend", "to", "apply", "for", "restorations", "of", "patent", "terms", "for", "some", "of", "our", "currently", "owned", "or", "licensed", "patents", "to", "add", "patent", "life", "beyond", "their", "current", "expiration", "dates,", "depending", "on", "the", "expected", "length", "of", "the", "clinical", "studies", "and", "other", "factors", "involved", "in", "the", "filing", "of", "the", "relevant", "NDA", "or", "BLA.", "<tag3>"], "wordsA": ["In", "the", "future,", "we", "intend", "to", "apply", "for", "restorations", "of", "patent", "terms", "for", "some", "of", "our", "currently", "owned", "or", "licensed", "patents", "to", "add", "patent", "life", "beyond", "their", "current", "expiration", "dates,", "depending", "on", "the", "expected", "length", "of", "the", "clinical", "studies", "and", "other", "factors", "involved", "in", "the", "filing", "of", "the", "relevant", "NDA."], "wordsB": ["In", "the", "future,", "we", "intend", "to", "apply", "for", "restorations", "of", "patent", "terms", "for", "some", "of", "our", "currently", "owned", "or", "licensed", "patents", "to", "add", "patent", "life", "beyond", "their", "current", "expiration", "dates,", "depending", "on", "the", "expected", "length", "of", "the", "clinical", "studies", "and", "other", "factors", "involved", "in", "the", "filing", "of", "the", "relevant", "NDA", "or", "BLA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p109_s0", "idA": "1316175_17_item1_p124_s0", "sentA": "HR 3590 provides 12 years of data exclusivity for innovator biologics.", "sentB": "The Patient Protection and Affordable Care Act provides 12 years of data exclusivity for innovator biologics.", "type": 2, "words": ["<tag1>", "HR", "3590", "provides", "12", "years", "of", "data", "exclusivity", "for", "innovator", "biologics.", "<tag2>", "The", "Patient", "Protection", "and", "Affordable", "Care", "Act", "provides", "12", "years", "of", "data", "exclusivity", "for", "innovator", "biologics.", "<tag3>"], "wordsA": ["HR", "3590", "provides", "12", "years", "of", "data", "exclusivity", "for", "innovator", "biologics."], "wordsB": ["The", "Patient", "Protection", "and", "Affordable", "Care", "Act", "provides", "12", "years", "of", "data", "exclusivity", "for", "innovator", "biologics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p145_s1", "idA": "1316175_17_item1_p125_s0", "sentA": "Pediatric exclusivity is another type of exclusivity in the United States.", "sentB": "We expect that an increasing emphasis on cost containment measures in the United States will continue to increase the pressure on pharmaceutical pricing.", "type": 2, "words": ["<tag1>", "Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States.", "<tag2>", "We", "expect", "that", "an", "increasing", "emphasis", "on", "cost", "containment", "measures", "in", "the", "United", "States", "will", "continue", "to", "increase", "the", "pressure", "on", "pharmaceutical", "pricing.", "<tag3>"], "wordsA": ["Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States."], "wordsB": ["We", "expect", "that", "an", "increasing", "emphasis", "on", "cost", "containment", "measures", "in", "the", "United", "States", "will", "continue", "to", "increase", "the", "pressure", "on", "pharmaceutical", "pricing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s9", "idA": "1316175_17_item1_p125_s0", "sentA": "Pediatric exclusivity is another type of exclusivity in the United States.", "sentB": "m 2 with placebo as seen in the graph below.", "type": 2, "words": ["<tag1>", "Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States.", "<tag2>", "m", "2", "with", "placebo", "as", "seen", "in", "the", "graph", "below.", "<tag3>"], "wordsA": ["Pediatric", "exclusivity", "is", "another", "type", "of", "exclusivity", "in", "the", "United", "States."], "wordsB": ["m", "2", "with", "placebo", "as", "seen", "in", "the", "graph", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p112_s0", "idA": "1316175_17_item1_p127_s0", "sentA": "If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication, except in very limited circumstances, for seven years.", "sentB": "If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication, except in very limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or by providing a major contribution to patient care, for seven years.", "type": 2, "words": ["<tag1>", "If", "a", "product", "that", "has", "orphan", "designation", "subsequently", "receives", "the", "first", "FDA", "approval", "for", "the", "disease", "or", "condition", "for", "which", "it", "has", "such", "designation,", "the", "product", "is", "entitled", "to", "orphan", "product", "exclusivity,", "which", "means", "that", "the", "FDA", "may", "not", "approve", "any", "other", "applications", "to", "market", "the", "same", "drug", "or", "biological", "product", "for", "the", "same", "indication,", "except", "in", "very", "limited", "circumstances,", "for", "seven", "years.", "<tag2>", "If", "a", "product", "that", "has", "orphan", "designation", "subsequently", "receives", "the", "first", "FDA", "approval", "for", "the", "disease", "or", "condition", "for", "which", "it", "has", "such", "designation,", "the", "product", "is", "entitled", "to", "orphan", "product", "exclusivity,", "which", "means", "that", "the", "FDA", "may", "not", "approve", "any", "other", "applications", "to", "market", "the", "same", "drug", "or", "biological", "product", "for", "the", "same", "indication,", "except", "in", "very", "limited", "circumstances,", "such", "as", "a", "showing", "of", "clinical", "superiority", "to", "the", "product", "with", "orphan", "exclusivity", "by", "means", "of", "greater", "effectiveness,", "greater", "safety,", "or", "by", "providing", "a", "major", "contribution", "to", "patient", "care,", "for", "seven", "years.", "<tag3>"], "wordsA": ["If", "a", "product", "that", "has", "orphan", "designation", "subsequently", "receives", "the", "first", "FDA", "approval", "for", "the", "disease", "or", "condition", "for", "which", "it", "has", "such", "designation,", "the", "product", "is", "entitled", "to", "orphan", "product", "exclusivity,", "which", "means", "that", "the", "FDA", "may", "not", "approve", "any", "other", "applications", "to", "market", "the", "same", "drug", "or", "biological", "product", "for", "the", "same", "indication,", "except", "in", "very", "limited", "circumstances,", "for", "seven", "years."], "wordsB": ["If", "a", "product", "that", "has", "orphan", "designation", "subsequently", "receives", "the", "first", "FDA", "approval", "for", "the", "disease", "or", "condition", "for", "which", "it", "has", "such", "designation,", "the", "product", "is", "entitled", "to", "orphan", "product", "exclusivity,", "which", "means", "that", "the", "FDA", "may", "not", "approve", "any", "other", "applications", "to", "market", "the", "same", "drug", "or", "biological", "product", "for", "the", "same", "indication,", "except", "in", "very", "limited", "circumstances,", "such", "as", "a", "showing", "of", "clinical", "superiority", "to", "the", "product", "with", "orphan", "exclusivity", "by", "means", "of", "greater", "effectiveness,", "greater", "safety,", "or", "by", "providing", "a", "major", "contribution", "to", "patient", "care,", "for", "seven", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p139_s0", "idA": "1316175_17_item1_p127_s1", "sentA": "Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product, but for a different indication for which the orphan product has exclusivity.", "sentB": "The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness.", "type": 2, "words": ["<tag1>", "Competitors,", "however,", "may", "receive", "approval", "of", "different", "products", "for", "the", "indication", "for", "which", "the", "orphan", "product", "has", "exclusivity", "or", "obtain", "approval", "for", "the", "same", "product,", "but", "for", "a", "different", "indication", "for", "which", "the", "orphan", "product", "has", "exclusivity.", "<tag2>", "The", "American", "Recovery", "and", "Reinvestment", "Act", "of", "2009", "provides", "funding", "for", "the", "federal", "government", "to", "compare", "the", "effectiveness", "of", "different", "treatments", "for", "the", "same", "illness.", "<tag3>"], "wordsA": ["Competitors,", "however,", "may", "receive", "approval", "of", "different", "products", "for", "the", "indication", "for", "which", "the", "orphan", "product", "has", "exclusivity", "or", "obtain", "approval", "for", "the", "same", "product,", "but", "for", "a", "different", "indication", "for", "which", "the", "orphan", "product", "has", "exclusivity."], "wordsB": ["The", "American", "Recovery", "and", "Reinvestment", "Act", "of", "2009", "provides", "funding", "for", "the", "federal", "government", "to", "compare", "the", "effectiveness", "of", "different", "treatments", "for", "the", "same", "illness."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p138_s0", "idA": "1316175_17_item1_p128_s1", "sentA": "A product does not have to be designated as an orphan product to be eligible for the grant program.", "sentB": "For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program.", "type": 2, "words": ["<tag1>", "A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program.", "<tag2>", "For", "a", "drug", "product", "to", "receive", "federal", "reimbursement", "under", "the", "Medicaid", "or", "Medicare", "Part", "B", "programs", "or", "to", "be", "sold", "directly", "to", "U.S.", "government", "agencies,", "the", "manufacturer", "must", "extend", "discounts", "to", "entities", "eligible", "to", "participate", "in", "the", "340B", "drug", "pricing", "program.", "<tag3>"], "wordsA": ["A", "product", "does", "not", "have", "to", "be", "designated", "as", "an", "orphan", "product", "to", "be", "eligible", "for", "the", "grant", "program."], "wordsB": ["For", "a", "drug", "product", "to", "receive", "federal", "reimbursement", "under", "the", "Medicaid", "or", "Medicare", "Part", "B", "programs", "or", "to", "be", "sold", "directly", "to", "U.S.", "government", "agencies,", "the", "manufacturer", "must", "extend", "discounts", "to", "entities", "eligible", "to", "participate", "in", "the", "340B", "drug", "pricing", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p13_s0", "idA": "1316175_17_item1_p12_s0", "sentA": "We believe Sollpura is potentially the first soluble, stable and non-porcine derived enzyme product to offer a novel solution to patients who are unable to maintain appropriate nutritional health.", "sentB": "We believe Sollpura has the potential to become the first soluble, stable and non-porcine derived enzyme product and offer a novel solution to patients who are unable to maintain appropriate nutritional health.", "type": 2, "words": ["<tag1>", "We", "believe", "Sollpura", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health.", "<tag2>", "We", "believe", "Sollpura", "has", "the", "potential", "to", "become", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "and", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health.", "<tag3>"], "wordsA": ["We", "believe", "Sollpura", "is", "potentially", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "to", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health."], "wordsB": ["We", "believe", "Sollpura", "has", "the", "potential", "to", "become", "the", "first", "soluble,", "stable", "and", "non-porcine", "derived", "enzyme", "product", "and", "offer", "a", "novel", "solution", "to", "patients", "who", "are", "unable", "to", "maintain", "appropriate", "nutritional", "health."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p115_s0", "idA": "1316175_17_item1_p130_s1", "sentA": "Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition.", "sentB": "The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition.", "type": 2, "words": ["<tag1>", "Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition.", "<tag2>", "The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "intended", "to", "expedite", "or", "facilitate", "the", "process", "for", "reviewing", "new", "drugs", "and", "biological", "products", "that", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition.", "<tag3>"], "wordsA": ["Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition."], "wordsB": ["The", "FDA", "has", "a", "fast", "track", "program", "that", "is", "intended", "to", "expedite", "or", "facilitate", "the", "process", "for", "reviewing", "new", "drugs", "and", "biological", "products", "that", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p139_s2", "idA": "1316175_17_item1_p130_s1", "sentA": "Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition.", "sentB": "Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our drug candidates, if any such drug or the condition that they are intended to treat are the subject of a trial.", "type": 2, "words": ["<tag1>", "Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition.", "<tag2>", "Although", "the", "results", "of", "the", "comparative", "effectiveness", "studies", "are", "not", "intended", "to", "mandate", "coverage", "policies", "for", "public", "or", "private", "payors,", "it", "is", "not", "clear", "what", "effect,", "if", "any,", "the", "research", "will", "have", "on", "the", "sales", "of", "our", "drug", "candidates,", "if", "any", "such", "drug", "or", "the", "condition", "that", "they", "are", "intended", "to", "treat", "are", "the", "subject", "of", "a", "trial.", "<tag3>"], "wordsA": ["Specifically,", "new", "drugs", "and", "biological", "products", "are", "eligible", "for", "fast", "track", "designation", "if", "they", "are", "intended", "to", "treat", "a", "serious", "or", "life-threatening", "condition", "and", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs", "for", "the", "condition."], "wordsB": ["Although", "the", "results", "of", "the", "comparative", "effectiveness", "studies", "are", "not", "intended", "to", "mandate", "coverage", "policies", "for", "public", "or", "private", "payors,", "it", "is", "not", "clear", "what", "effect,", "if", "any,", "the", "research", "will", "have", "on", "the", "sales", "of", "our", "drug", "candidates,", "if", "any", "such", "drug", "or", "the", "condition", "that", "they", "are", "intended", "to", "treat", "are", "the", "subject", "of", "a", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p118_s0", "idA": "1316175_17_item1_p134_s0", "sentA": "The FDA Safety and Innovation Act, or FDASIA includes a provision that allows sponsors to request that their drug be designated as a Breakthrough Therapy.", "sentB": "Sponsors may request that their drug be designated as a Breakthrough Therapy.", "type": 2, "words": ["<tag1>", "The", "FDA", "Safety", "and", "Innovation", "Act,", "or", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag2>", "Sponsors", "may", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy.", "<tag3>"], "wordsA": ["The", "FDA", "Safety", "and", "Innovation", "Act,", "or", "FDASIA", "includes", "a", "provision", "that", "allows", "sponsors", "to", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "wordsB": ["Sponsors", "may", "request", "that", "their", "drug", "be", "designated", "as", "a", "Breakthrough", "Therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p99_s2", "idA": "1316175_17_item1_p136_s0", "sentA": "The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market.", "sentB": "The FDA and the sponsor must reach agreement on the PSP.", "type": 2, "words": ["<tag1>", "The", "FDA", "strictly", "regulates", "labeling,", "advertising,", "promotion", "and", "other", "types", "of", "information", "on", "products", "that", "are", "placed", "on", "the", "market.", "<tag2>", "The", "FDA", "and", "the", "sponsor", "must", "reach", "agreement", "on", "the", "PSP.", "<tag3>"], "wordsA": ["The", "FDA", "strictly", "regulates", "labeling,", "advertising,", "promotion", "and", "other", "types", "of", "information", "on", "products", "that", "are", "placed", "on", "the", "market."], "wordsB": ["The", "FDA", "and", "the", "sponsor", "must", "reach", "agreement", "on", "the", "PSP."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p132_s0", "idA": "1316175_17_item1_p147_s0", "sentA": "Sales of pharmaceutical products depend significantly on the availability of third-party reimbursement.", "sentB": "Sales of pharmaceutical products depend significantly on the availability and adequacy of third-party reimbursement.", "type": 2, "words": ["<tag1>", "Sales", "of", "pharmaceutical", "products", "depend", "significantly", "on", "the", "availability", "of", "third-party", "reimbursement.", "<tag2>", "Sales", "of", "pharmaceutical", "products", "depend", "significantly", "on", "the", "availability", "and", "adequacy", "of", "third-party", "reimbursement.", "<tag3>"], "wordsA": ["Sales", "of", "pharmaceutical", "products", "depend", "significantly", "on", "the", "availability", "of", "third-party", "reimbursement."], "wordsB": ["Sales", "of", "pharmaceutical", "products", "depend", "significantly", "on", "the", "availability", "and", "adequacy", "of", "third-party", "reimbursement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p132_s2", "idA": "1316175_17_item1_p147_s2", "sentA": "We anticipate third-party payors will provide reimbursement for our product.", "sentB": "We anticipate third-party payors will provide reimbursement for our product although we cannot predict the level of reimbursement such third-party payors will provide for our products.", "type": 2, "words": ["<tag1>", "We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product.", "<tag2>", "We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product", "although", "we", "cannot", "predict", "the", "level", "of", "reimbursement", "such", "third-party", "payors", "will", "provide", "for", "our", "products.", "<tag3>"], "wordsA": ["We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product."], "wordsB": ["We", "anticipate", "third-party", "payors", "will", "provide", "reimbursement", "for", "our", "product", "although", "we", "cannot", "predict", "the", "level", "of", "reimbursement", "such", "third-party", "payors", "will", "provide", "for", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p132_s3", "idA": "1316175_17_item1_p147_s3", "sentA": "However, these third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services.", "sentB": "Third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services.", "type": 2, "words": ["<tag1>", "However,", "these", "third-party", "payors", "are", "increasingly", "challenging", "the", "price", "and", "examining", "the", "cost-effectiveness", "of", "medical", "products", "and", "services.", "<tag2>", "Third-party", "payors", "are", "increasingly", "challenging", "the", "price", "and", "examining", "the", "cost-effectiveness", "of", "medical", "products", "and", "services.", "<tag3>"], "wordsA": ["However,", "these", "third-party", "payors", "are", "increasingly", "challenging", "the", "price", "and", "examining", "the", "cost-effectiveness", "of", "medical", "products", "and", "services."], "wordsB": ["Third-party", "payors", "are", "increasingly", "challenging", "the", "price", "and", "examining", "the", "cost-effectiveness", "of", "medical", "products", "and", "services."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p9_s0", "idA": "1316175_17_item1_p147_s5", "sentA": "We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products.", "sentB": "Due to the bulk imposed by the enteric coating, most patients have to take 10-20 capsules per day in order to maintain their nutritional requirement.", "type": 2, "words": ["<tag1>", "We", "may", "need", "to", "conduct", "expensive", "pharmacoeconomic", "studies", "in", "order", "to", "demonstrate", "the", "cost-effectiveness", "of", "our", "products.", "<tag2>", "Due", "to", "the", "bulk", "imposed", "by", "the", "enteric", "coating,", "most", "patients", "have", "to", "take", "10-20", "capsules", "per", "day", "in", "order", "to", "maintain", "their", "nutritional", "requirement.", "<tag3>"], "wordsA": ["We", "may", "need", "to", "conduct", "expensive", "pharmacoeconomic", "studies", "in", "order", "to", "demonstrate", "the", "cost-effectiveness", "of", "our", "products."], "wordsB": ["Due", "to", "the", "bulk", "imposed", "by", "the", "enteric", "coating,", "most", "patients", "have", "to", "take", "10-20", "capsules", "per", "day", "in", "order", "to", "maintain", "their", "nutritional", "requirement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p139_s4", "idA": "1316175_17_item1_p147_s8", "sentA": "Reimbursement may not be available or sufficient to allow us to sell our product on a competitive and profitable basis.", "sentB": "If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis.", "type": 2, "words": ["<tag1>", "Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "product", "on", "a", "competitive", "and", "profitable", "basis.", "<tag2>", "If", "third-party", "payors", "do", "not", "consider", "our", "drugs", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "our", "drugs", "after", "approval", "as", "a", "benefit", "under", "their", "plans", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "drugs", "on", "a", "profitable", "basis.", "<tag3>"], "wordsA": ["Reimbursement", "may", "not", "be", "available", "or", "sufficient", "to", "allow", "us", "to", "sell", "our", "product", "on", "a", "competitive", "and", "profitable", "basis."], "wordsB": ["If", "third-party", "payors", "do", "not", "consider", "our", "drugs", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "our", "drugs", "after", "approval", "as", "a", "benefit", "under", "their", "plans", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "drugs", "on", "a", "profitable", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p133_s1", "idA": "1316175_17_item1_p148_s1", "sentA": "For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, and the associated reconciliation bill, which we refer to collectively as the Health Care Reform Law, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.", "sentB": "For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, and mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies share of sales to federal health care programs.", "type": 2, "words": ["<tag1>", "For", "example,", "in", "March", "2010,", "President", "Obama", "signed", "into", "law", "the", "Patient", "Protection", "and", "Affordable", "Care", "Act,", "and", "the", "associated", "reconciliation", "bill,", "which", "we", "refer", "to", "collectively", "as", "the", "Health", "Care", "Reform", "Law,", "a", "sweeping", "law", "intended", "to", "broaden", "access", "to", "health", "insurance,", "reduce", "or", "constrain", "the", "growth", "of", "healthcare", "spending,", "enhance", "remedies", "against", "fraud", "and", "abuse,", "add", "new", "transparency", "requirements", "for", "healthcare", "and", "health", "insurance", "industries,", "impose", "new", "taxes", "and", "fees", "on", "the", "health", "industry", "and", "impose", "additional", "health", "policy", "reforms.", "<tag2>", "For", "example,", "the", "Patient", "Protection", "and", "Affordable", "Care", "Act,", "as", "amended", "by", "the", "Health", "Care", "and", "Education", "Reconciliation", "Act", "of", "2010,", "or", "collectively", "the", "ACA,", "contains", "provisions", "that", "may", "reduce", "the", "profitability", "of", "drug", "products", "through", "increased", "rebates", "for", "drugs", "reimbursed", "by", "Medicaid", "programs,", "extension", "of", "Medicaid", "rebates", "to", "Medicaid", "managed", "care", "plans,", "and", "mandatory", "discounts", "for", "certain", "Medicare", "Part", "D", "beneficiaries", "and", "annual", "fees", "based", "on", "pharmaceutical", "companies", "share", "of", "sales", "to", "federal", "health", "care", "programs.", "<tag3>"], "wordsA": ["For", "example,", "in", "March", "2010,", "President", "Obama", "signed", "into", "law", "the", "Patient", "Protection", "and", "Affordable", "Care", "Act,", "and", "the", "associated", "reconciliation", "bill,", "which", "we", "refer", "to", "collectively", "as", "the", "Health", "Care", "Reform", "Law,", "a", "sweeping", "law", "intended", "to", "broaden", "access", "to", "health", "insurance,", "reduce", "or", "constrain", "the", "growth", "of", "healthcare", "spending,", "enhance", "remedies", "against", "fraud", "and", "abuse,", "add", "new", "transparency", "requirements", "for", "healthcare", "and", "health", "insurance", "industries,", "impose", "new", "taxes", "and", "fees", "on", "the", "health", "industry", "and", "impose", "additional", "health", "policy", "reforms."], "wordsB": ["For", "example,", "the", "Patient", "Protection", "and", "Affordable", "Care", "Act,", "as", "amended", "by", "the", "Health", "Care", "and", "Education", "Reconciliation", "Act", "of", "2010,", "or", "collectively", "the", "ACA,", "contains", "provisions", "that", "may", "reduce", "the", "profitability", "of", "drug", "products", "through", "increased", "rebates", "for", "drugs", "reimbursed", "by", "Medicaid", "programs,", "extension", "of", "Medicaid", "rebates", "to", "Medicaid", "managed", "care", "plans,", "and", "mandatory", "discounts", "for", "certain", "Medicare", "Part", "D", "beneficiaries", "and", "annual", "fees", "based", "on", "pharmaceutical", "companies", "share", "of", "sales", "to", "federal", "health", "care", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p136_s0", "idA": "1316175_17_item1_p149_s0", "sentA": "The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries, and included a major expansion of the prescription drug benefit under a new Medicare Part D. Medicare Part D went into effect on January 1, 2006.", "sentB": "The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries, and included a major expansion of the prescription drug benefit under a new Medicare Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that will provide coverage of outpatient prescription drugs.", "type": 2, "words": ["<tag1>", "The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Medicare", "Part", "D", "went", "into", "effect", "on", "January", "1,", "2006.", "<tag2>", "The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Under", "Part", "D,", "Medicare", "beneficiaries", "may", "enroll", "in", "prescription", "drug", "plans", "offered", "by", "private", "entities", "that", "will", "provide", "coverage", "of", "outpatient", "prescription", "drugs.", "<tag3>"], "wordsA": ["The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Medicare", "Part", "D", "went", "into", "effect", "on", "January", "1,", "2006."], "wordsB": ["The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposed", "new", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries,", "and", "included", "a", "major", "expansion", "of", "the", "prescription", "drug", "benefit", "under", "a", "new", "Medicare", "Part", "D.", "Under", "Part", "D,", "Medicare", "beneficiaries", "may", "enroll", "in", "prescription", "drug", "plans", "offered", "by", "private", "entities", "that", "will", "provide", "coverage", "of", "outpatient", "prescription", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p136_s1", "idA": "1316175_17_item1_p149_s2", "sentA": "Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans.", "sentB": "Part D prescription drug plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans.", "type": 2, "words": ["<tag1>", "Part", "D", "plans", "include", "both", "stand-alone", "prescription", "drug", "benefit", "plans", "and", "prescription", "drug", "coverage", "as", "a", "supplement", "to", "Medicare", "Advantage", "plans.", "<tag2>", "Part", "D", "prescription", "drug", "plans", "include", "both", "stand-alone", "prescription", "drug", "benefit", "plans", "and", "prescription", "drug", "coverage", "as", "a", "supplement", "to", "Medicare", "Advantage", "plans.", "<tag3>"], "wordsA": ["Part", "D", "plans", "include", "both", "stand-alone", "prescription", "drug", "benefit", "plans", "and", "prescription", "drug", "coverage", "as", "a", "supplement", "to", "Medicare", "Advantage", "plans."], "wordsB": ["Part", "D", "prescription", "drug", "plans", "include", "both", "stand-alone", "prescription", "drug", "benefit", "plans", "and", "prescription", "drug", "coverage", "as", "a", "supplement", "to", "Medicare", "Advantage", "plans."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p136_s4", "idA": "1316175_17_item1_p149_s4", "sentA": "Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.", "sentB": "While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.", "type": 2, "words": ["<tag1>", "Part", "D", "prescription", "drug", "plan", "sponsors", "are", "not", "required", "to", "pay", "for", "all", "covered", "Part", "D", "drugs,", "and", "each", "drug", "plan", "can", "develop", "its", "own", "drug", "formulary", "that", "identifies", "which", "drugs", "it", "will", "cover", "and", "at", "what", "tier", "or", "level.", "<tag2>", "While", "all", "Medicare", "drug", "plans", "must", "give", "at", "least", "a", "standard", "level", "of", "coverage", "set", "by", "Medicare,", "Part", "D", "prescription", "drug", "plan", "sponsors", "are", "not", "required", "to", "pay", "for", "all", "covered", "Part", "D", "drugs,", "and", "each", "drug", "plan", "can", "develop", "its", "own", "drug", "formulary", "that", "identifies", "which", "drugs", "it", "will", "cover", "and", "at", "what", "tier", "or", "level.", "<tag3>"], "wordsA": ["Part", "D", "prescription", "drug", "plan", "sponsors", "are", "not", "required", "to", "pay", "for", "all", "covered", "Part", "D", "drugs,", "and", "each", "drug", "plan", "can", "develop", "its", "own", "drug", "formulary", "that", "identifies", "which", "drugs", "it", "will", "cover", "and", "at", "what", "tier", "or", "level."], "wordsB": ["While", "all", "Medicare", "drug", "plans", "must", "give", "at", "least", "a", "standard", "level", "of", "coverage", "set", "by", "Medicare,", "Part", "D", "prescription", "drug", "plan", "sponsors", "are", "not", "required", "to", "pay", "for", "all", "covered", "Part", "D", "drugs,", "and", "each", "drug", "plan", "can", "develop", "its", "own", "drug", "formulary", "that", "identifies", "which", "drugs", "it", "will", "cover", "and", "at", "what", "tier", "or", "level."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p20_s1", "idA": "1316175_17_item1_p14_s1", "sentA": "SOLUTION is a randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the efficacy and safety of Sollpura in patients with cystic fibrosis-related exocrine pancreatic insufficiency.", "sentB": "The SOLUTION study was also a randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the efficacy and safety of Sollpura.", "type": 2, "words": ["<tag1>", "SOLUTION", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "Sollpura", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency.", "<tag2>", "The", "SOLUTION", "study", "was", "also", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "Sollpura.", "<tag3>"], "wordsA": ["SOLUTION", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "Sollpura", "in", "patients", "with", "cystic", "fibrosis-related", "exocrine", "pancreatic", "insufficiency."], "wordsB": ["The", "SOLUTION", "study", "was", "also", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "Sollpura."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p15_s1", "idA": "1316175_17_item1_p14_s2", "sentA": "This pivotal study enrolled 128 patients in North America, Europe and Israel to evaluate the non-inferiority of Sollpura compared with another commercially available PERT in a population of porcine-derived PERT responders.", "sentB": "The RESULT study is a randomized, open-label, assessor-blind, non-inferiority, active-comparator study evaluating the non-inferiority of Sollpura with respect to Coefficient of Fat Absorption ( CFA ) compared to a commercially available PERT in a population of porcine-derived PERT responders.", "type": 2, "words": ["<tag1>", "This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders.", "<tag2>", "The", "RESULT", "study", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "non-inferiority", "of", "Sollpura", "with", "respect", "to", "Coefficient", "of", "Fat", "Absorption", "(", "CFA", ")", "compared", "to", "a", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders.", "<tag3>"], "wordsA": ["This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders."], "wordsB": ["The", "RESULT", "study", "is", "a", "randomized,", "open-label,", "assessor-blind,", "non-inferiority,", "active-comparator", "study", "evaluating", "the", "non-inferiority", "of", "Sollpura", "with", "respect", "to", "Coefficient", "of", "Fat", "Absorption", "(", "CFA", ")", "compared", "to", "a", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p16_s0", "idA": "1316175_17_item1_p14_s2", "sentA": "This pivotal study enrolled 128 patients in North America, Europe and Israel to evaluate the non-inferiority of Sollpura compared with another commercially available PERT in a population of porcine-derived PERT responders.", "sentB": "The RESULT study enrolled 140 patients in North America, Eastern and Western Europe and Israel.", "type": 2, "words": ["<tag1>", "This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders.", "<tag2>", "The", "RESULT", "study", "enrolled", "140", "patients", "in", "North", "America,", "Eastern", "and", "Western", "Europe", "and", "Israel.", "<tag3>"], "wordsA": ["This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders."], "wordsB": ["The", "RESULT", "study", "enrolled", "140", "patients", "in", "North", "America,", "Eastern", "and", "Western", "Europe", "and", "Israel."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p20_s2", "idA": "1316175_17_item1_p14_s2", "sentA": "This pivotal study enrolled 128 patients in North America, Europe and Israel to evaluate the non-inferiority of Sollpura compared with another commercially available PERT in a population of porcine-derived PERT responders.", "sentB": "This pivotal study enrolled 128 patients in North America, Europe and Israel.", "type": 2, "words": ["<tag1>", "This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders.", "<tag2>", "This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel.", "<tag3>"], "wordsA": ["This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel", "to", "evaluate", "the", "non-inferiority", "of", "Sollpura", "compared", "with", "another", "commercially", "available", "PERT", "in", "a", "population", "of", "porcine-derived", "PERT", "responders."], "wordsB": ["This", "pivotal", "study", "enrolled", "128", "patients", "in", "North", "America,", "Europe", "and", "Israel."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p20_s3", "idA": "1316175_17_item1_p14_s3", "sentA": "Topline data announced in December 2016 showed that the study narrowly missed the Coefficient of Fat Absorption ( CFA ) non-inferiority margin of the primary modified Intent to Treat population (mITT) analysis by 1%; however, by additional pre-specified analyses of CFA (mITT-Baseline Observation Carried Forward and Per Protocol), Sollpura met the non-inferiority criterion.", "sentB": "Top line data announced in December 2016 showed that the study narrowly missed the CFA non-inferiority margin of the primary mITT analysis by one percent; however, by additional pre-specified analyses of CFA (mITT-Baseline Observation Carried Forward and Per Protocol), Sollpura met the non-inferiority criterion.", "type": 2, "words": ["<tag1>", "Topline", "data", "announced", "in", "December", "2016", "showed", "that", "the", "study", "narrowly", "missed", "the", "Coefficient", "of", "Fat", "Absorption", "(", "CFA", ")", "non-inferiority", "margin", "of", "the", "primary", "modified", "Intent", "to", "Treat", "population", "(mITT)", "analysis", "by", "1%;", "however,", "by", "additional", "pre-specified", "analyses", "of", "CFA", "(mITT-Baseline", "Observation", "Carried", "Forward", "and", "Per", "Protocol),", "Sollpura", "met", "the", "non-inferiority", "criterion.", "<tag2>", "Top", "line", "data", "announced", "in", "December", "2016", "showed", "that", "the", "study", "narrowly", "missed", "the", "CFA", "non-inferiority", "margin", "of", "the", "primary", "mITT", "analysis", "by", "one", "percent;", "however,", "by", "additional", "pre-specified", "analyses", "of", "CFA", "(mITT-Baseline", "Observation", "Carried", "Forward", "and", "Per", "Protocol),", "Sollpura", "met", "the", "non-inferiority", "criterion.", "<tag3>"], "wordsA": ["Topline", "data", "announced", "in", "December", "2016", "showed", "that", "the", "study", "narrowly", "missed", "the", "Coefficient", "of", "Fat", "Absorption", "(", "CFA", ")", "non-inferiority", "margin", "of", "the", "primary", "modified", "Intent", "to", "Treat", "population", "(mITT)", "analysis", "by", "1%;", "however,", "by", "additional", "pre-specified", "analyses", "of", "CFA", "(mITT-Baseline", "Observation", "Carried", "Forward", "and", "Per", "Protocol),", "Sollpura", "met", "the", "non-inferiority", "criterion."], "wordsB": ["Top", "line", "data", "announced", "in", "December", "2016", "showed", "that", "the", "study", "narrowly", "missed", "the", "CFA", "non-inferiority", "margin", "of", "the", "primary", "mITT", "analysis", "by", "one", "percent;", "however,", "by", "additional", "pre-specified", "analyses", "of", "CFA", "(mITT-Baseline", "Observation", "Carried", "Forward", "and", "Per", "Protocol),", "Sollpura", "met", "the", "non-inferiority", "criterion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p20_s4", "idA": "1316175_17_item1_p14_s4", "sentA": "The study also confirmed that the ratio of the three enzymes in Sollpura demonstrated an appropriate response in the Coefficient of Nitrogen Absorption (CNA).", "sentB": "The study also demonstrated that the ratio of the three enzymes in Sollpura provided an appropriate response in coefficient of nitrogen absorption ( CNA\").", "type": 2, "words": ["<tag1>", "The", "study", "also", "confirmed", "that", "the", "ratio", "of", "the", "three", "enzymes", "in", "Sollpura", "demonstrated", "an", "appropriate", "response", "in", "the", "Coefficient", "of", "Nitrogen", "Absorption", "(CNA).", "<tag2>", "The", "study", "also", "demonstrated", "that", "the", "ratio", "of", "the", "three", "enzymes", "in", "Sollpura", "provided", "an", "appropriate", "response", "in", "coefficient", "of", "nitrogen", "absorption", "(", "CNA\").", "<tag3>"], "wordsA": ["The", "study", "also", "confirmed", "that", "the", "ratio", "of", "the", "three", "enzymes", "in", "Sollpura", "demonstrated", "an", "appropriate", "response", "in", "the", "Coefficient", "of", "Nitrogen", "Absorption", "(CNA)."], "wordsB": ["The", "study", "also", "demonstrated", "that", "the", "ratio", "of", "the", "three", "enzymes", "in", "Sollpura", "provided", "an", "appropriate", "response", "in", "coefficient", "of", "nitrogen", "absorption", "(", "CNA\")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p15_s4", "idA": "1316175_17_item1_p14_s5", "sentA": "CNA is a measure of protein digestion and absorption and is a key requirement of our planned United States Food and Drug Administration ( FDA ) regulatory submission.", "sentB": "The RESULT study design was discussed with the United States Food and Drug Administration ( FDA ) prior to initiation.", "type": 2, "words": ["<tag1>", "CNA", "is", "a", "measure", "of", "protein", "digestion", "and", "absorption", "and", "is", "a", "key", "requirement", "of", "our", "planned", "United", "States", "Food", "and", "Drug", "Administration", "(", "FDA", ")", "regulatory", "submission.", "<tag2>", "The", "RESULT", "study", "design", "was", "discussed", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "(", "FDA", ")", "prior", "to", "initiation.", "<tag3>"], "wordsA": ["CNA", "is", "a", "measure", "of", "protein", "digestion", "and", "absorption", "and", "is", "a", "key", "requirement", "of", "our", "planned", "United", "States", "Food", "and", "Drug", "Administration", "(", "FDA", ")", "regulatory", "submission."], "wordsB": ["The", "RESULT", "study", "design", "was", "discussed", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "(", "FDA", ")", "prior", "to", "initiation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p20_s5", "idA": "1316175_17_item1_p14_s7", "sentA": "We expect to release data from the extension phase of the study towards the end of first quarter of 2017.", "sentB": "In March 2017, we announced data from the extension phase of the study, which showed that Sollpura demonstrated comparable maintenance in key measurements of height, weight, and body mass index in addition to being well tolerated throughout the 12-week extension period.", "type": 2, "words": ["<tag1>", "We", "expect", "to", "release", "data", "from", "the", "extension", "phase", "of", "the", "study", "towards", "the", "end", "of", "first", "quarter", "of", "2017.", "<tag2>", "In", "March", "2017,", "we", "announced", "data", "from", "the", "extension", "phase", "of", "the", "study,", "which", "showed", "that", "Sollpura", "demonstrated", "comparable", "maintenance", "in", "key", "measurements", "of", "height,", "weight,", "and", "body", "mass", "index", "in", "addition", "to", "being", "well", "tolerated", "throughout", "the", "12-week", "extension", "period.", "<tag3>"], "wordsA": ["We", "expect", "to", "release", "data", "from", "the", "extension", "phase", "of", "the", "study", "towards", "the", "end", "of", "first", "quarter", "of", "2017."], "wordsB": ["In", "March", "2017,", "we", "announced", "data", "from", "the", "extension", "phase", "of", "the", "study,", "which", "showed", "that", "Sollpura", "demonstrated", "comparable", "maintenance", "in", "key", "measurements", "of", "height,", "weight,", "and", "body", "mass", "index", "in", "addition", "to", "being", "well", "tolerated", "throughout", "the", "12-week", "extension", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p145_s0", "idA": "1316175_17_item1_p150_s0", "sentA": "Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval.", "sentB": "As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement.", "type": 2, "words": ["<tag1>", "Government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval.", "<tag2>", "As", "noted", "above,", "the", "marketability", "of", "any", "products", "for", "which", "we", "receive", "regulatory", "approval", "for", "commercial", "sale", "may", "suffer", "if", "the", "government", "and", "third-party", "payors", "fail", "to", "provide", "adequate", "coverage", "and", "reimbursement.", "<tag3>"], "wordsA": ["Government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval."], "wordsB": ["As", "noted", "above,", "the", "marketability", "of", "any", "products", "for", "which", "we", "receive", "regulatory", "approval", "for", "commercial", "sale", "may", "suffer", "if", "the", "government", "and", "third-party", "payors", "fail", "to", "provide", "adequate", "coverage", "and", "reimbursement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p145_s3", "idA": "1316175_17_item1_p150_s0", "sentA": "Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval.", "sentB": "Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.", "type": 2, "words": ["<tag1>", "Government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval.", "<tag2>", "Even", "if", "favorable", "coverage", "and", "reimbursement", "status", "is", "attained", "for", "one", "or", "more", "products", "for", "which", "we", "receive", "regulatory", "approval,", "less", "favorable", "coverage", "policies", "and", "reimbursement", "rates", "may", "be", "implemented", "in", "the", "future.", "<tag3>"], "wordsA": ["Government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval."], "wordsB": ["Even", "if", "favorable", "coverage", "and", "reimbursement", "status", "is", "attained", "for", "one", "or", "more", "products", "for", "which", "we", "receive", "regulatory", "approval,", "less", "favorable", "coverage", "policies", "and", "reimbursement", "rates", "may", "be", "implemented", "in", "the", "future."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p152_s0", "idA": "1316175_17_item1_p150_s0", "sentA": "Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval.", "sentB": "For our product and any product candidates which may obtain regulatory approval and are marketed in the United States, our arrangements with third-party payors, healthcare providers, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval.", "type": 2, "words": ["<tag1>", "Government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval.", "<tag2>", "For", "our", "product", "and", "any", "product", "candidates", "which", "may", "obtain", "regulatory", "approval", "and", "are", "marketed", "in", "the", "United", "States,", "our", "arrangements", "with", "third-party", "payors,", "healthcare", "providers,", "and", "customers", "may", "expose", "us", "to", "broadly", "applicable", "fraud", "and", "abuse", "and", "other", "healthcare", "laws", "and", "regulations", "that", "may", "constrain", "the", "business", "or", "financial", "arrangements", "and", "relationships", "through", "which", "we", "market,", "sell", "and", "distribute", "any", "products", "for", "which", "we", "obtain", "marketing", "approval.", "<tag3>"], "wordsA": ["Government", "payment", "for", "some", "of", "the", "costs", "of", "prescription", "drugs", "may", "increase", "demand", "for", "products", "for", "which", "we", "receive", "marketing", "approval."], "wordsB": ["For", "our", "product", "and", "any", "product", "candidates", "which", "may", "obtain", "regulatory", "approval", "and", "are", "marketed", "in", "the", "United", "States,", "our", "arrangements", "with", "third-party", "payors,", "healthcare", "providers,", "and", "customers", "may", "expose", "us", "to", "broadly", "applicable", "fraud", "and", "abuse", "and", "other", "healthcare", "laws", "and", "regulations", "that", "may", "constrain", "the", "business", "or", "financial", "arrangements", "and", "relationships", "through", "which", "we", "market,", "sell", "and", "distribute", "any", "products", "for", "which", "we", "obtain", "marketing", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p163_s4", "idA": "1316175_17_item1_p151_s1", "sentA": "For example, a company may be debarred from participation if it is found to have violated federal anti-kickback laws, which could have a significant effect on a company s ability to operate its business.", "sentB": "Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company s attention from the business.", "type": 2, "words": ["<tag1>", "For", "example,", "a", "company", "may", "be", "debarred", "from", "participation", "if", "it", "is", "found", "to", "have", "violated", "federal", "anti-kickback", "laws,", "which", "could", "have", "a", "significant", "effect", "on", "a", "company", "s", "ability", "to", "operate", "its", "business.", "<tag2>", "Ensuring", "business", "arrangements", "comply", "with", "applicable", "healthcare", "laws,", "as", "well", "as", "responding", "to", "possible", "investigations", "by", "government", "authorities,", "can", "be", "time-", "and", "resource-consuming", "and", "can", "divert", "a", "company", "s", "attention", "from", "the", "business.", "<tag3>"], "wordsA": ["For", "example,", "a", "company", "may", "be", "debarred", "from", "participation", "if", "it", "is", "found", "to", "have", "violated", "federal", "anti-kickback", "laws,", "which", "could", "have", "a", "significant", "effect", "on", "a", "company", "s", "ability", "to", "operate", "its", "business."], "wordsB": ["Ensuring", "business", "arrangements", "comply", "with", "applicable", "healthcare", "laws,", "as", "well", "as", "responding", "to", "possible", "investigations", "by", "government", "authorities,", "can", "be", "time-", "and", "resource-consuming", "and", "can", "divert", "a", "company", "s", "attention", "from", "the", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p163_s0", "idA": "1316175_17_item1_p152_s2", "sentA": "Indeed, we expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs.", "sentB": "Federal and state enforcement bodies have scrutinized interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.", "type": 2, "words": ["<tag1>", "Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs.", "<tag2>", "Federal", "and", "state", "enforcement", "bodies", "have", "scrutinized", "interactions", "between", "healthcare", "companies", "and", "healthcare", "providers,", "which", "has", "led", "to", "a", "number", "of", "investigations,", "prosecutions,", "convictions", "and", "settlements", "in", "the", "healthcare", "industry.", "<tag3>"], "wordsA": ["Indeed,", "we", "expect", "that", "there", "will", "continue", "to", "be", "a", "number", "of", "federal", "and", "state", "proposals", "to", "implement", "governmental", "pricing", "controls", "and", "limit", "the", "growth", "of", "healthcare", "costs,", "including", "the", "cost", "of", "prescription", "drugs."], "wordsB": ["Federal", "and", "state", "enforcement", "bodies", "have", "scrutinized", "interactions", "between", "healthcare", "companies", "and", "healthcare", "providers,", "which", "has", "led", "to", "a", "number", "of", "investigations,", "prosecutions,", "convictions", "and", "settlements", "in", "the", "healthcare", "industry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p164_s0", "idA": "1316175_17_item1_p157_s0", "sentA": "As of December 31, 2016, we had 33 employees.", "sentB": "As of December 31, 2017, we had 21 employees.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2016,", "we", "had", "33", "employees.", "<tag2>", "As", "of", "December", "31,", "2017,", "we", "had", "21", "employees.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2016,", "we", "had", "33", "employees."], "wordsB": ["As", "of", "December", "31,", "2017,", "we", "had", "21", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p135_s3", "idA": "1316175_17_item1_p158_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990.", "type": 2, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "Pricing", "and", "rebate", "programs", "must", "also", "comply", "with", "the", "Medicaid", "rebate", "requirements", "of", "the", "U.S.", "Omnibus", "Budget", "Reconciliation", "Act", "of", "1990.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["Pricing", "and", "rebate", "programs", "must", "also", "comply", "with", "the", "Medicaid", "rebate", "requirements", "of", "the", "U.S.", "Omnibus", "Budget", "Reconciliation", "Act", "of", "1990."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p156_s0", "idA": "1316175_17_item1_p158_s0", "sentA": "We are subject to the information requirements of the Exchange Act.", "sentB": "Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act.", "type": 2, "words": ["<tag1>", "We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act.", "<tag2>", "Claims", "which", "include", "items", "or", "services", "resulting", "from", "a", "violation", "of", "the", "federal", "Anti-Kickback", "Statute", "are", "false", "or", "fraudulent", "claims", "for", "purposes", "of", "the", "False", "Claims", "Act.", "<tag3>"], "wordsA": ["We", "are", "subject", "to", "the", "information", "requirements", "of", "the", "Exchange", "Act."], "wordsB": ["Claims", "which", "include", "items", "or", "services", "resulting", "from", "a", "violation", "of", "the", "federal", "Anti-Kickback", "Statute", "are", "false", "or", "fraudulent", "claims", "for", "purposes", "of", "the", "False", "Claims", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p166_s1", "idA": "1316175_17_item1_p159_s1", "sentA": "The mailing address of our headquarters is 25801 Industrial Blvd, Hayward, CA 94545, and our telephone number at that location is 510-856-5600.", "sentB": "The mailing address of our headquarters is 25801 Industrial Blvd, Suite B, Hayward, CA 94545, and our telephone number at that location is 510-856-5600.", "type": 2, "words": ["<tag1>", "The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600.", "<tag2>", "The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Suite", "B,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600.", "<tag3>"], "wordsA": ["The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600."], "wordsB": ["The", "mailing", "address", "of", "our", "headquarters", "is", "25801", "Industrial", "Blvd,", "Suite", "B,", "Hayward,", "CA", "94545,", "and", "our", "telephone", "number", "at", "that", "location", "is", "510-856-5600."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p15_s2", "idA": "1316175_17_item1_p15_s4", "sentA": "Based on data from the SOLUTION study, the planned RESULT study s design is being modified to (1) start Sollpura dosing as 125% of the pre-study PERT dose, and (2) allow for a more liberal dose titration, as needed, based on signs and symptoms throughout the primary treatment phase of the study.", "sentB": "The RESULT study s design is modified from a previous Phase 3 study s ( SOLUTION ) design to account for the design limitations in the SOLUTION study by 1) starting Sollpura dosing as 125% of the pre-study PERT dose, 2) allowing for a more real life dose adjustment, as needed, based on signs and symptoms throughout the primary treatment phase of the study, and 3) a shorter treatment duration of 4 weeks, with 3 weeks of dose optimization and 1 week of stable dosing.", "type": 2, "words": ["<tag1>", "Based", "on", "data", "from", "the", "SOLUTION", "study,", "the", "planned", "RESULT", "study", "s", "design", "is", "being", "modified", "to", "(1)", "start", "Sollpura", "dosing", "as", "125%", "of", "the", "pre-study", "PERT", "dose,", "and", "(2)", "allow", "for", "a", "more", "liberal", "dose", "titration,", "as", "needed,", "based", "on", "signs", "and", "symptoms", "throughout", "the", "primary", "treatment", "phase", "of", "the", "study.", "<tag2>", "The", "RESULT", "study", "s", "design", "is", "modified", "from", "a", "previous", "Phase", "3", "study", "s", "(", "SOLUTION", ")", "design", "to", "account", "for", "the", "design", "limitations", "in", "the", "SOLUTION", "study", "by", "1)", "starting", "Sollpura", "dosing", "as", "125%", "of", "the", "pre-study", "PERT", "dose,", "2)", "allowing", "for", "a", "more", "real", "life", "dose", "adjustment,", "as", "needed,", "based", "on", "signs", "and", "symptoms", "throughout", "the", "primary", "treatment", "phase", "of", "the", "study,", "and", "3)", "a", "shorter", "treatment", "duration", "of", "4", "weeks,", "with", "3", "weeks", "of", "dose", "optimization", "and", "1", "week", "of", "stable", "dosing.", "<tag3>"], "wordsA": ["Based", "on", "data", "from", "the", "SOLUTION", "study,", "the", "planned", "RESULT", "study", "s", "design", "is", "being", "modified", "to", "(1)", "start", "Sollpura", "dosing", "as", "125%", "of", "the", "pre-study", "PERT", "dose,", "and", "(2)", "allow", "for", "a", "more", "liberal", "dose", "titration,", "as", "needed,", "based", "on", "signs", "and", "symptoms", "throughout", "the", "primary", "treatment", "phase", "of", "the", "study."], "wordsB": ["The", "RESULT", "study", "s", "design", "is", "modified", "from", "a", "previous", "Phase", "3", "study", "s", "(", "SOLUTION", ")", "design", "to", "account", "for", "the", "design", "limitations", "in", "the", "SOLUTION", "study", "by", "1)", "starting", "Sollpura", "dosing", "as", "125%", "of", "the", "pre-study", "PERT", "dose,", "2)", "allowing", "for", "a", "more", "real", "life", "dose", "adjustment,", "as", "needed,", "based", "on", "signs", "and", "symptoms", "throughout", "the", "primary", "treatment", "phase", "of", "the", "study,", "and", "3)", "a", "shorter", "treatment", "duration", "of", "4", "weeks,", "with", "3", "weeks", "of", "dose", "optimization", "and", "1", "week", "of", "stable", "dosing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p16_s2", "idA": "1316175_17_item1_p15_s6", "sentA": "Topline data from the RESULT study is expected towards the end of 2017 or in early 2018.", "sentB": "We expect to report topline data from the RESULT study in March 2018.", "type": 2, "words": ["<tag1>", "Topline", "data", "from", "the", "RESULT", "study", "is", "expected", "towards", "the", "end", "of", "2017", "or", "in", "early", "2018.", "<tag2>", "We", "expect", "to", "report", "topline", "data", "from", "the", "RESULT", "study", "in", "March", "2018.", "<tag3>"], "wordsA": ["Topline", "data", "from", "the", "RESULT", "study", "is", "expected", "towards", "the", "end", "of", "2017", "or", "in", "early", "2018."], "wordsB": ["We", "expect", "to", "report", "topline", "data", "from", "the", "RESULT", "study", "in", "March", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p17_s0", "idA": "1316175_17_item1_p16_s0", "sentA": "A second, smaller Phase 3 study, SIMPLICITY, was initiated in the second quarter of 2016.", "sentB": "A second, smaller Phase 3 study ( SIMPLICITY ) aimed at expanding the treatment age of patients to include patients age 28 days to seven years old, and enabling potential marketing approval for the sachet presentation of Sollpura, was initiated in the second quarter of 2016.", "type": 2, "words": ["<tag1>", "A", "second,", "smaller", "Phase", "3", "study,", "SIMPLICITY,", "was", "initiated", "in", "the", "second", "quarter", "of", "2016.", "<tag2>", "A", "second,", "smaller", "Phase", "3", "study", "(", "SIMPLICITY", ")", "aimed", "at", "expanding", "the", "treatment", "age", "of", "patients", "to", "include", "patients", "age", "28", "days", "to", "seven", "years", "old,", "and", "enabling", "potential", "marketing", "approval", "for", "the", "sachet", "presentation", "of", "Sollpura,", "was", "initiated", "in", "the", "second", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["A", "second,", "smaller", "Phase", "3", "study,", "SIMPLICITY,", "was", "initiated", "in", "the", "second", "quarter", "of", "2016."], "wordsB": ["A", "second,", "smaller", "Phase", "3", "study", "(", "SIMPLICITY", ")", "aimed", "at", "expanding", "the", "treatment", "age", "of", "patients", "to", "include", "patients", "age", "28", "days", "to", "seven", "years", "old,", "and", "enabling", "potential", "marketing", "approval", "for", "the", "sachet", "presentation", "of", "Sollpura,", "was", "initiated", "in", "the", "second", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p18_s0", "idA": "1316175_17_item1_p16_s2", "sentA": "We expect to enroll approximately 46 patients in the two parts of the study (Part A and Part B).", "sentB": "The study is designed in two parts (Part A and Part B).", "type": 2, "words": ["<tag1>", "We", "expect", "to", "enroll", "approximately", "46", "patients", "in", "the", "two", "parts", "of", "the", "study", "(Part", "A", "and", "Part", "B).", "<tag2>", "The", "study", "is", "designed", "in", "two", "parts", "(Part", "A", "and", "Part", "B).", "<tag3>"], "wordsA": ["We", "expect", "to", "enroll", "approximately", "46", "patients", "in", "the", "two", "parts", "of", "the", "study", "(Part", "A", "and", "Part", "B)."], "wordsB": ["The", "study", "is", "designed", "in", "two", "parts", "(Part", "A", "and", "Part", "B)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p18_s1", "idA": "1316175_17_item1_p17_s0", "sentA": "Part A of the SIMPLICITY study, which evaluated the safety and general usability of the Sollpura powder for oral solution in 15 patients aged 7 years or older, was completed in the fourth quarter of 2016.", "sentB": "Part A which evaluated the safety and general usability of Sollpura powder for oral solution in 15 patients 7 years of age, was completed in the fourth quarter of 2016.", "type": 2, "words": ["<tag1>", "Part", "A", "of", "the", "SIMPLICITY", "study,", "which", "evaluated", "the", "safety", "and", "general", "usability", "of", "the", "Sollpura", "powder", "for", "oral", "solution", "in", "15", "patients", "aged", "7", "years", "or", "older,", "was", "completed", "in", "the", "fourth", "quarter", "of", "2016.", "<tag2>", "Part", "A", "which", "evaluated", "the", "safety", "and", "general", "usability", "of", "Sollpura", "powder", "for", "oral", "solution", "in", "15", "patients", "7", "years", "of", "age,", "was", "completed", "in", "the", "fourth", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["Part", "A", "of", "the", "SIMPLICITY", "study,", "which", "evaluated", "the", "safety", "and", "general", "usability", "of", "the", "Sollpura", "powder", "for", "oral", "solution", "in", "15", "patients", "aged", "7", "years", "or", "older,", "was", "completed", "in", "the", "fourth", "quarter", "of", "2016."], "wordsB": ["Part", "A", "which", "evaluated", "the", "safety", "and", "general", "usability", "of", "Sollpura", "powder", "for", "oral", "solution", "in", "15", "patients", "7", "years", "of", "age,", "was", "completed", "in", "the", "fourth", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p18_s2", "idA": "1316175_17_item1_p17_s1", "sentA": "An independent Data Monitoring Committee (the DMC ) evaluated the data from Part A and in its determination that it is safe to proceed with enrolling pediatric subjects less than 7 years of age in Part B of the study, unanimously approved the initiation of Part B of the study.", "sentB": "On December 9, 2016, an independent Data Monitoring Committee evaluated the data from Part A and approved progression to Part B, which will enroll pediatric subjects below 7 years of age.", "type": 2, "words": ["<tag1>", "An", "independent", "Data", "Monitoring", "Committee", "(the", "DMC", ")", "evaluated", "the", "data", "from", "Part", "A", "and", "in", "its", "determination", "that", "it", "is", "safe", "to", "proceed", "with", "enrolling", "pediatric", "subjects", "less", "than", "7", "years", "of", "age", "in", "Part", "B", "of", "the", "study,", "unanimously", "approved", "the", "initiation", "of", "Part", "B", "of", "the", "study.", "<tag2>", "On", "December", "9,", "2016,", "an", "independent", "Data", "Monitoring", "Committee", "evaluated", "the", "data", "from", "Part", "A", "and", "approved", "progression", "to", "Part", "B,", "which", "will", "enroll", "pediatric", "subjects", "below", "7", "years", "of", "age.", "<tag3>"], "wordsA": ["An", "independent", "Data", "Monitoring", "Committee", "(the", "DMC", ")", "evaluated", "the", "data", "from", "Part", "A", "and", "in", "its", "determination", "that", "it", "is", "safe", "to", "proceed", "with", "enrolling", "pediatric", "subjects", "less", "than", "7", "years", "of", "age", "in", "Part", "B", "of", "the", "study,", "unanimously", "approved", "the", "initiation", "of", "Part", "B", "of", "the", "study."], "wordsB": ["On", "December", "9,", "2016,", "an", "independent", "Data", "Monitoring", "Committee", "evaluated", "the", "data", "from", "Part", "A", "and", "approved", "progression", "to", "Part", "B,", "which", "will", "enroll", "pediatric", "subjects", "below", "7", "years", "of", "age."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p18_s3", "idA": "1316175_17_item1_p18_s0", "sentA": "Based on the data produced by the SOLUTION study, we plan to amend the SIMPLICITY study to follow similar dosing paradigm as the RESULT study.", "sentB": "Before we proceed with Part B, we plan to amend the SIMPLICITY study to follow a similar dosing approach as in the RESULT study and initiate enrollment in Part B in the second quarter of 2018.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "data", "produced", "by", "the", "SOLUTION", "study,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "similar", "dosing", "paradigm", "as", "the", "RESULT", "study.", "<tag2>", "Before", "we", "proceed", "with", "Part", "B,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "a", "similar", "dosing", "approach", "as", "in", "the", "RESULT", "study", "and", "initiate", "enrollment", "in", "Part", "B", "in", "the", "second", "quarter", "of", "2018.", "<tag3>"], "wordsA": ["Based", "on", "the", "data", "produced", "by", "the", "SOLUTION", "study,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "similar", "dosing", "paradigm", "as", "the", "RESULT", "study."], "wordsB": ["Before", "we", "proceed", "with", "Part", "B,", "we", "plan", "to", "amend", "the", "SIMPLICITY", "study", "to", "follow", "a", "similar", "dosing", "approach", "as", "in", "the", "RESULT", "study", "and", "initiate", "enrollment", "in", "Part", "B", "in", "the", "second", "quarter", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p19_s0", "idA": "1316175_17_item1_p19_s0", "sentA": "During the third quarter of 2016, we initiated the EASY study, which provides continued access to Sollpura for patients who completed the SOLUTION study.", "sentB": "Furthermore, during the third quarter of 2016, we initiated the EASY study, which provides continued access to Sollpura for patients in the Sollpura arm who completed the SOLUTION study.", "type": 2, "words": ["<tag1>", "During", "the", "third", "quarter", "of", "2016,", "we", "initiated", "the", "EASY", "study,", "which", "provides", "continued", "access", "to", "Sollpura", "for", "patients", "who", "completed", "the", "SOLUTION", "study.", "<tag2>", "Furthermore,", "during", "the", "third", "quarter", "of", "2016,", "we", "initiated", "the", "EASY", "study,", "which", "provides", "continued", "access", "to", "Sollpura", "for", "patients", "in", "the", "Sollpura", "arm", "who", "completed", "the", "SOLUTION", "study.", "<tag3>"], "wordsA": ["During", "the", "third", "quarter", "of", "2016,", "we", "initiated", "the", "EASY", "study,", "which", "provides", "continued", "access", "to", "Sollpura", "for", "patients", "who", "completed", "the", "SOLUTION", "study."], "wordsB": ["Furthermore,", "during", "the", "third", "quarter", "of", "2016,", "we", "initiated", "the", "EASY", "study,", "which", "provides", "continued", "access", "to", "Sollpura", "for", "patients", "in", "the", "Sollpura", "arm", "who", "completed", "the", "SOLUTION", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p1_s0", "idA": "1316175_17_item1_p1_s0", "sentA": "Sollpura TM is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "sentB": "Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy ( PERT ) intended for the treatment of patients with Exocrine Pancreatic Insufficiency ( EPI ), often seen in patients with cystic fibrosis and other conditions.", "type": 2, "words": ["<tag1>", "Sollpura", "TM", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag2>", "Sollpura", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions.", "<tag3>"], "wordsA": ["Sollpura", "TM", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "wordsB": ["Sollpura", "is", "a", "novel", "non-porcine", "investigational", "Pancreatic", "Enzyme", "Replacement", "Therapy", "(", "PERT", ")", "intended", "for", "the", "treatment", "of", "patients", "with", "Exocrine", "Pancreatic", "Insufficiency", "(", "EPI", "),", "often", "seen", "in", "patients", "with", "cystic", "fibrosis", "and", "other", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p22_s0", "idA": "1316175_17_item1_p23_s0", "sentA": "a sachet formulation containing Sollpura power for oral solution which can be easily dissolved into water, and finally provides patients, especially young pediatric patients, with an easy-to-swallow dosing option.", "sentB": "a sachet formulation containing Sollpura powder for oral solution which can be easily dissolved into water, and finally provides patients, especially young pediatric patients, with an easy-to-swallow dosing option.", "type": 2, "words": ["<tag1>", "a", "sachet", "formulation", "containing", "Sollpura", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option.", "<tag2>", "a", "sachet", "formulation", "containing", "Sollpura", "powder", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option.", "<tag3>"], "wordsA": ["a", "sachet", "formulation", "containing", "Sollpura", "power", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option."], "wordsB": ["a", "sachet", "formulation", "containing", "Sollpura", "powder", "for", "oral", "solution", "which", "can", "be", "easily", "dissolved", "into", "water,", "and", "finally", "provides", "patients,", "especially", "young", "pediatric", "patients,", "with", "an", "easy-to-swallow", "dosing", "option."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p29_s0", "idA": "1316175_17_item1_p32_s0", "sentA": "IgA nephropathy may occur when plasma B-cells express excessive amounts of abnormal IgA and subsequent immune complexes containing this immunogenic protein are deposited in the kidneys.", "sentB": "IgA nephropathy may occur when plasma cells express excessive amounts of under-glycosylated IgA and subsequent immune complexes containing this immunogenic protein are deposited in the kidneys.", "type": 2, "words": ["<tag1>", "IgA", "nephropathy", "may", "occur", "when", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "subsequent", "immune", "complexes", "containing", "this", "immunogenic", "protein", "are", "deposited", "in", "the", "kidneys.", "<tag2>", "IgA", "nephropathy", "may", "occur", "when", "plasma", "cells", "express", "excessive", "amounts", "of", "under-glycosylated", "IgA", "and", "subsequent", "immune", "complexes", "containing", "this", "immunogenic", "protein", "are", "deposited", "in", "the", "kidneys.", "<tag3>"], "wordsA": ["IgA", "nephropathy", "may", "occur", "when", "plasma", "B-cells", "express", "excessive", "amounts", "of", "abnormal", "IgA", "and", "subsequent", "immune", "complexes", "containing", "this", "immunogenic", "protein", "are", "deposited", "in", "the", "kidneys."], "wordsB": ["IgA", "nephropathy", "may", "occur", "when", "plasma", "cells", "express", "excessive", "amounts", "of", "under-glycosylated", "IgA", "and", "subsequent", "immune", "complexes", "containing", "this", "immunogenic", "protein", "are", "deposited", "in", "the", "kidneys."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p31_s0", "idA": "1316175_17_item1_p35_s0", "sentA": "In IgA nephropathy, increased plasma B-cells express immunogenic IgA that forms immune complexes that deposit in renal tissue and lead to renal inflammation and damage that can progress to renal failure and end-stage renal disease.", "sentB": "In IgA nephropathy, plasma cells express immunogenic IgA that forms immune complexes that deposit in renal tissue and lead to renal inflammation and damage that can progress to renal failure and end-stage renal disease.", "type": 2, "words": ["<tag1>", "In", "IgA", "nephropathy,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease.", "<tag2>", "In", "IgA", "nephropathy,", "plasma", "cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease.", "<tag3>"], "wordsA": ["In", "IgA", "nephropathy,", "increased", "plasma", "B-cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease."], "wordsB": ["In", "IgA", "nephropathy,", "plasma", "cells", "express", "immunogenic", "IgA", "that", "forms", "immune", "complexes", "that", "deposit", "in", "renal", "tissue", "and", "lead", "to", "renal", "inflammation", "and", "damage", "that", "can", "progress", "to", "renal", "failure", "and", "end-stage", "renal", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p32_s0", "idA": "1316175_17_item1_p35_s1", "sentA": "Significant reductions in plasma B-cells were observed in previous clinical studies of patients with lupus with another BAFF inhibitor antibody, belimumab.", "sentB": "Significant reductions in B-cell counts were observed in clinical studies of patients with lupus with blisibimod with concomitant decreases in proteinuria, serum immunoglobulins and autoantibodies, and increases in complement C3.", "type": 2, "words": ["<tag1>", "Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "patients", "with", "lupus", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab.", "<tag2>", "Significant", "reductions", "in", "B-cell", "counts", "were", "observed", "in", "clinical", "studies", "of", "patients", "with", "lupus", "with", "blisibimod", "with", "concomitant", "decreases", "in", "proteinuria,", "serum", "immunoglobulins", "and", "autoantibodies,", "and", "increases", "in", "complement", "C3.", "<tag3>"], "wordsA": ["Significant", "reductions", "in", "plasma", "B-cells", "were", "observed", "in", "previous", "clinical", "studies", "of", "patients", "with", "lupus", "with", "another", "BAFF", "inhibitor", "antibody,", "belimumab."], "wordsB": ["Significant", "reductions", "in", "B-cell", "counts", "were", "observed", "in", "clinical", "studies", "of", "patients", "with", "lupus", "with", "blisibimod", "with", "concomitant", "decreases", "in", "proteinuria,", "serum", "immunoglobulins", "and", "autoantibodies,", "and", "increases", "in", "complement", "C3."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p32_s1", "idA": "1316175_17_item1_p35_s3", "sentA": "We believe inhibition of BAFF may reduce proliferative B-cells and plasma B-cells, reduce serum levels of IgA and therefore reduce progressive renal damage in patients with IgA nephropathy.", "sentB": "We believe inhibition of BAFF may reduce B-cell proliferation, maturation, and survival, thereby reducing serum levels of IgA and targeting antibodies, and therefore reduce progressive renal damage in patients with IgA nephropathy.", "type": 2, "words": ["<tag1>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgA", "nephropathy.", "<tag2>", "We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "B-cell", "proliferation,", "maturation,", "and", "survival,", "thereby", "reducing", "serum", "levels", "of", "IgA", "and", "targeting", "antibodies,", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "proliferative", "B-cells", "and", "plasma", "B-cells,", "reduce", "serum", "levels", "of", "IgA", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgA", "nephropathy."], "wordsB": ["We", "believe", "inhibition", "of", "BAFF", "may", "reduce", "B-cell", "proliferation,", "maturation,", "and", "survival,", "thereby", "reducing", "serum", "levels", "of", "IgA", "and", "targeting", "antibodies,", "and", "therefore", "reduce", "progressive", "renal", "damage", "in", "patients", "with", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s0", "idA": "1316175_17_item1_p36_s0", "sentA": "In June 2013, we initiated a Phase 2 clinical study, BRIGHT-SC study.", "sentB": "In June 2013, we initiated a Phase 2 clinical study, ( BRIGHT-SC ) of patients with IgA nephropathy in Asia and Eastern Europe.", "type": 2, "words": ["<tag1>", "In", "June", "2013,", "we", "initiated", "a", "Phase", "2", "clinical", "study,", "BRIGHT-SC", "study.", "<tag2>", "In", "June", "2013,", "we", "initiated", "a", "Phase", "2", "clinical", "study,", "(", "BRIGHT-SC", ")", "of", "patients", "with", "IgA", "nephropathy", "in", "Asia", "and", "Eastern", "Europe.", "<tag3>"], "wordsA": ["In", "June", "2013,", "we", "initiated", "a", "Phase", "2", "clinical", "study,", "BRIGHT-SC", "study."], "wordsB": ["In", "June", "2013,", "we", "initiated", "a", "Phase", "2", "clinical", "study,", "(", "BRIGHT-SC", ")", "of", "patients", "with", "IgA", "nephropathy", "in", "Asia", "and", "Eastern", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s1", "idA": "1316175_17_item1_p36_s1", "sentA": "The BRIGHT-SC study is a Phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "sentB": "The BRIGHT-SC study was a Phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "study", "is", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag2>", "The", "BRIGHT-SC", "study", "was", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "study", "is", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "wordsB": ["The", "BRIGHT-SC", "study", "was", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s5", "idA": "1316175_17_item1_p36_s1", "sentA": "The BRIGHT-SC study is a Phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in IgA nephropathy.", "sentB": "The BRIGHT-SC study enrolled 58 patients.", "type": 2, "words": ["<tag1>", "The", "BRIGHT-SC", "study", "is", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy.", "<tag2>", "The", "BRIGHT-SC", "study", "enrolled", "58", "patients.", "<tag3>"], "wordsA": ["The", "BRIGHT-SC", "study", "is", "a", "Phase", "2", "multicenter,", "randomized,", "double-blind,", "placebo-controlled", "study", "to", "evaluate", "the", "efficacy,", "safety,", "tolerability", "and", "immunogenicity", "of", "blisibimod", "in", "IgA", "nephropathy."], "wordsB": ["The", "BRIGHT-SC", "study", "enrolled", "58", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s2", "idA": "1316175_17_item1_p36_s2", "sentA": "Enrollment criteria are biopsy-proven IgA nephropathy and proteinuria greater than one gram per 24 hours (1g/24hr).", "sentB": "Enrollment criteria included biopsy-proven IgA nephropathy and proteinuria greater than one gram but less than six grams per 24 hours (1g-6g/24hr).", "type": 2, "words": ["<tag1>", "Enrollment", "criteria", "are", "biopsy-proven", "IgA", "nephropathy", "and", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr).", "<tag2>", "Enrollment", "criteria", "included", "biopsy-proven", "IgA", "nephropathy", "and", "proteinuria", "greater", "than", "one", "gram", "but", "less", "than", "six", "grams", "per", "24", "hours", "(1g-6g/24hr).", "<tag3>"], "wordsA": ["Enrollment", "criteria", "are", "biopsy-proven", "IgA", "nephropathy", "and", "proteinuria", "greater", "than", "one", "gram", "per", "24", "hours", "(1g/24hr)."], "wordsB": ["Enrollment", "criteria", "included", "biopsy-proven", "IgA", "nephropathy", "and", "proteinuria", "greater", "than", "one", "gram", "but", "less", "than", "six", "grams", "per", "24", "hours", "(1g-6g/24hr)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s3", "idA": "1316175_17_item1_p37_s0", "sentA": "Patients must be receiving standard of care medication including angiotensin converting enzyme inhibitors and angiotensin receptor blockers.", "sentB": "Patients must have been receiving standard of care medication including angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers.", "type": 2, "words": ["<tag1>", "Patients", "must", "be", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers.", "<tag2>", "Patients", "must", "have", "been", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and/or", "angiotensin", "receptor", "blockers.", "<tag3>"], "wordsA": ["Patients", "must", "be", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and", "angiotensin", "receptor", "blockers."], "wordsB": ["Patients", "must", "have", "been", "receiving", "standard", "of", "care", "medication", "including", "angiotensin", "converting", "enzyme", "inhibitors", "and/or", "angiotensin", "receptor", "blockers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s4", "idA": "1316175_17_item1_p38_s0", "sentA": "Patients enrolled in the BRIGHT-SC study receive 300mg weekly blisibimod or placebo subcutaneously during the first 8 weeks of therapy, the induction phase, followed by a minimum of 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "sentB": "Patients enrolled in the BRIGHT-SC study received 300mg weekly blisibimod or placebo subcutaneously during the first 8 weeks of therapy, the induction phase, followed by a minimum of 24 weeks of 200mg weekly blisibimod or placebo, the maintenance phase.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "the", "BRIGHT-SC", "study", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "a", "minimum", "of", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag2>", "Patients", "enrolled", "in", "the", "BRIGHT-SC", "study", "received", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "a", "minimum", "of", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "the", "BRIGHT-SC", "study", "receive", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "a", "minimum", "of", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "wordsB": ["Patients", "enrolled", "in", "the", "BRIGHT-SC", "study", "received", "300mg", "weekly", "blisibimod", "or", "placebo", "subcutaneously", "during", "the", "first", "8", "weeks", "of", "therapy,", "the", "induction", "phase,", "followed", "by", "a", "minimum", "of", "24", "weeks", "of", "200mg", "weekly", "blisibimod", "or", "placebo,", "the", "maintenance", "phase."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p3_s0", "idA": "1316175_17_item1_p3_s0", "sentA": "Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy, systemic lupus erythematosus ( SLE ), or lupus, lupus nephritis, and others.", "sentB": "Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy.", "type": 2, "words": ["<tag1>", "Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "lupus", "nephritis,", "and", "others.", "<tag2>", "Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy,", "systemic", "lupus", "erythematosus", "(", "SLE", "),", "or", "lupus,", "lupus", "nephritis,", "and", "others."], "wordsB": ["Blisibimod", "targets", "B-cell", "activating", "factor,", "or", "BAFF,", "which", "has", "been", "shown", "to", "be", "elevated", "in", "a", "variety", "of", "B-cell", "mediated", "autoimmune", "diseases,", "including", "Immunoglobulin", "A", "nephropathy,", "or", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p16_s1", "idA": "1316175_17_item1_p40_s0", "sentA": "In March 2015, an interim futility analysis of BRIGHT-SC study was conducted by an independent unblinded statistician, who evaluated several important biomarkers of renal disease in patients who had completed at least 8 weeks of treatment and recommended the study to continue to completion as planned.", "sentB": "In December 2017 and January 2018, pre-specified interim futility analyses of the RESULT study were conducted by a Data Monitoring Committee ( DMC ) comprised of experts appointed by the CFFTDN when approximately 25% and 50% of patients had completed the 4-week treatment period; in each instance, the committee recommended the study to continue to completion as planned.", "type": 2, "words": ["<tag1>", "In", "March", "2015,", "an", "interim", "futility", "analysis", "of", "BRIGHT-SC", "study", "was", "conducted", "by", "an", "independent", "unblinded", "statistician,", "who", "evaluated", "several", "important", "biomarkers", "of", "renal", "disease", "in", "patients", "who", "had", "completed", "at", "least", "8", "weeks", "of", "treatment", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned.", "<tag2>", "In", "December", "2017", "and", "January", "2018,", "pre-specified", "interim", "futility", "analyses", "of", "the", "RESULT", "study", "were", "conducted", "by", "a", "Data", "Monitoring", "Committee", "(", "DMC", ")", "comprised", "of", "experts", "appointed", "by", "the", "CFFTDN", "when", "approximately", "25%", "and", "50%", "of", "patients", "had", "completed", "the", "4-week", "treatment", "period;", "in", "each", "instance,", "the", "committee", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned.", "<tag3>"], "wordsA": ["In", "March", "2015,", "an", "interim", "futility", "analysis", "of", "BRIGHT-SC", "study", "was", "conducted", "by", "an", "independent", "unblinded", "statistician,", "who", "evaluated", "several", "important", "biomarkers", "of", "renal", "disease", "in", "patients", "who", "had", "completed", "at", "least", "8", "weeks", "of", "treatment", "and", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned."], "wordsB": ["In", "December", "2017", "and", "January", "2018,", "pre-specified", "interim", "futility", "analyses", "of", "the", "RESULT", "study", "were", "conducted", "by", "a", "Data", "Monitoring", "Committee", "(", "DMC", ")", "comprised", "of", "experts", "appointed", "by", "the", "CFFTDN", "when", "approximately", "25%", "and", "50%", "of", "patients", "had", "completed", "the", "4-week", "treatment", "period;", "in", "each", "instance,", "the", "committee", "recommended", "the", "study", "to", "continue", "to", "completion", "as", "planned."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p42_s0", "idA": "1316175_17_item1_p41_s7", "sentA": "Given the positive effect observed in this analysis, Anthera plans to continue to follow the subjects enrolled in the BRIGHT study to gain more understanding of the long-term effects of blisibimod on disease progression.", "sentB": "Given the observed effects of blisibimod on proteinuria in patients with lupus, we are currently evaluating our options for investigating the effects of blisibimod in B-cell associated glomerulonephritides.", "type": 2, "words": ["<tag1>", "Given", "the", "positive", "effect", "observed", "in", "this", "analysis,", "Anthera", "plans", "to", "continue", "to", "follow", "the", "subjects", "enrolled", "in", "the", "BRIGHT", "study", "to", "gain", "more", "understanding", "of", "the", "long-term", "effects", "of", "blisibimod", "on", "disease", "progression.", "<tag2>", "Given", "the", "observed", "effects", "of", "blisibimod", "on", "proteinuria", "in", "patients", "with", "lupus,", "we", "are", "currently", "evaluating", "our", "options", "for", "investigating", "the", "effects", "of", "blisibimod", "in", "B-cell", "associated", "glomerulonephritides.", "<tag3>"], "wordsA": ["Given", "the", "positive", "effect", "observed", "in", "this", "analysis,", "Anthera", "plans", "to", "continue", "to", "follow", "the", "subjects", "enrolled", "in", "the", "BRIGHT", "study", "to", "gain", "more", "understanding", "of", "the", "long-term", "effects", "of", "blisibimod", "on", "disease", "progression."], "wordsB": ["Given", "the", "observed", "effects", "of", "blisibimod", "on", "proteinuria", "in", "patients", "with", "lupus,", "we", "are", "currently", "evaluating", "our", "options", "for", "investigating", "the", "effects", "of", "blisibimod", "in", "B-cell", "associated", "glomerulonephritides."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s8", "idA": "1316175_17_item1_p43_s0", "sentA": "According to our estimate, EPI is a disease that affects an estimated 130,000 patients in the United States.", "sentB": "Specifically, in patients treated with blisibimod, the mean change in proteinuria was stable to trending slightly downward, whereas the mean levels increased for patients in the placebo arm.", "type": 2, "words": ["<tag1>", "According", "to", "our", "estimate,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "130,000", "patients", "in", "the", "United", "States.", "<tag2>", "Specifically,", "in", "patients", "treated", "with", "blisibimod,", "the", "mean", "change", "in", "proteinuria", "was", "stable", "to", "trending", "slightly", "downward,", "whereas", "the", "mean", "levels", "increased", "for", "patients", "in", "the", "placebo", "arm.", "<tag3>"], "wordsA": ["According", "to", "our", "estimate,", "EPI", "is", "a", "disease", "that", "affects", "an", "estimated", "130,000", "patients", "in", "the", "United", "States."], "wordsB": ["Specifically,", "in", "patients", "treated", "with", "blisibimod,", "the", "mean", "change", "in", "proteinuria", "was", "stable", "to", "trending", "slightly", "downward,", "whereas", "the", "mean", "levels", "increased", "for", "patients", "in", "the", "placebo", "arm."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p37_s2", "idA": "1316175_17_item1_p46_s1", "sentA": "The prevalence of IgA nephropathy varies throughout the world, with the highest prevalence in Asia (Singapore, Japan and China), Australia, Finland and southern Europe (20 to 40% of all glomerulonephritis).", "sentB": "In August 2017, the FDA granted orphan drug designation for blisibimod for the treatment of IgA. The prevalence of IgA nephropathy varies throughout the world, with the highest prevalence in Asia (Singapore, Japan and China), Australia, Finland and southern Europe (20 to 40% of all glomerulonephritis).", "type": 2, "words": ["<tag1>", "The", "prevalence", "of", "IgA", "nephropathy", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan", "and", "China),", "Australia,", "Finland", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulonephritis).", "<tag2>", "In", "August", "2017,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "blisibimod", "for", "the", "treatment", "of", "IgA.", "The", "prevalence", "of", "IgA", "nephropathy", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan", "and", "China),", "Australia,", "Finland", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulonephritis).", "<tag3>"], "wordsA": ["The", "prevalence", "of", "IgA", "nephropathy", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan", "and", "China),", "Australia,", "Finland", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulonephritis)."], "wordsB": ["In", "August", "2017,", "the", "FDA", "granted", "orphan", "drug", "designation", "for", "blisibimod", "for", "the", "treatment", "of", "IgA.", "The", "prevalence", "of", "IgA", "nephropathy", "varies", "throughout", "the", "world,", "with", "the", "highest", "prevalence", "in", "Asia", "(Singapore,", "Japan", "and", "China),", "Australia,", "Finland", "and", "southern", "Europe", "(20", "to", "40%", "of", "all", "glomerulonephritis)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p29_s2", "idA": "1316175_17_item1_p47_s1", "sentA": "As a result kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "sentB": "As a result, kidney glomeruli become inflamed and damaged, leading to leakage of blood and protein into urine.", "type": 2, "words": ["<tag1>", "As", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag2>", "As", "a", "result,", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine.", "<tag3>"], "wordsA": ["As", "a", "result", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "wordsB": ["As", "a", "result,", "kidney", "glomeruli", "become", "inflamed", "and", "damaged,", "leading", "to", "leakage", "of", "blood", "and", "protein", "into", "urine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p19_s1", "idA": "1316175_17_item1_p4_s1", "sentA": "We plan to modifiy the study to allow patients completing future studies (e.g., RESULT or SIMPLICITY Part B) to have continued access and continue the EASY study until the Biologic License Application ( BLA ) for Sollpura is approved by the U.S. Food and Drug Administration ( FDA ).", "sentB": "We have amended this study to also allow Sollpura-assigned patients completing the RESULT study at a lipase dose greater than 10,000 units/kg/day to have continued access until the Biological License Application ( BLA ) for Sollpura is approved by the FDA.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "modifiy", "the", "study", "to", "allow", "patients", "completing", "future", "studies", "(e.g.,", "RESULT", "or", "SIMPLICITY", "Part", "B)", "to", "have", "continued", "access", "and", "continue", "the", "EASY", "study", "until", "the", "Biologic", "License", "Application", "(", "BLA", ")", "for", "Sollpura", "is", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(", "FDA", ").", "<tag2>", "We", "have", "amended", "this", "study", "to", "also", "allow", "Sollpura-assigned", "patients", "completing", "the", "RESULT", "study", "at", "a", "lipase", "dose", "greater", "than", "10,000", "units/kg/day", "to", "have", "continued", "access", "until", "the", "Biological", "License", "Application", "(", "BLA", ")", "for", "Sollpura", "is", "approved", "by", "the", "FDA.", "<tag3>"], "wordsA": ["We", "plan", "to", "modifiy", "the", "study", "to", "allow", "patients", "completing", "future", "studies", "(e.g.,", "RESULT", "or", "SIMPLICITY", "Part", "B)", "to", "have", "continued", "access", "and", "continue", "the", "EASY", "study", "until", "the", "Biologic", "License", "Application", "(", "BLA", ")", "for", "Sollpura", "is", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(", "FDA", ")."], "wordsB": ["We", "have", "amended", "this", "study", "to", "also", "allow", "Sollpura-assigned", "patients", "completing", "the", "RESULT", "study", "at", "a", "lipase", "dose", "greater", "than", "10,000", "units/kg/day", "to", "have", "continued", "access", "until", "the", "Biological", "License", "Application", "(", "BLA", ")", "for", "Sollpura", "is", "approved", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p152_s2", "idA": "1316175_17_item1_p50_s1", "sentA": "In the United States, IgA nephropathy is considered an orphan disease as it is believed to affect approximately 130,000 people annually.", "sentB": "In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below:", "type": 2, "words": ["<tag1>", "In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually.", "<tag2>", "In", "the", "United", "States,", "these", "laws", "include,", "without", "limitation,", "state", "and", "federal", "anti-kickback,", "false", "claims,", "physician", "transparency,", "and", "patient", "data", "privacy", "and", "security", "laws", "and", "regulations,", "including", "but", "not", "limited", "to", "those", "described", "below:", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "IgA", "nephropathy", "is", "considered", "an", "orphan", "disease", "as", "it", "is", "believed", "to", "affect", "approximately", "130,000", "people", "annually."], "wordsB": ["In", "the", "United", "States,", "these", "laws", "include,", "without", "limitation,", "state", "and", "federal", "anti-kickback,", "false", "claims,", "physician", "transparency,", "and", "patient", "data", "privacy", "and", "security", "laws", "and", "regulations,", "including", "but", "not", "limited", "to", "those", "described", "below:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p37_s3", "idA": "1316175_17_item1_p50_s2", "sentA": "In Asia, routine urinalyses are performed for school children, and renal biopsies are performed for patients with asymptomatic hematuria and the reported prevalence of the disease is much higher.", "sentB": "In Asia, routine urinalyses are performed for school children and renal biopsies for patients with asymptomatic hematuria, and the reported prevalence of the disease is much higher.", "type": 2, "words": ["<tag1>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria", "and", "the", "reported", "prevalence", "of", "the", "disease", "is", "much", "higher.", "<tag2>", "In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children", "and", "renal", "biopsies", "for", "patients", "with", "asymptomatic", "hematuria,", "and", "the", "reported", "prevalence", "of", "the", "disease", "is", "much", "higher.", "<tag3>"], "wordsA": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children,", "and", "renal", "biopsies", "are", "performed", "for", "patients", "with", "asymptomatic", "hematuria", "and", "the", "reported", "prevalence", "of", "the", "disease", "is", "much", "higher."], "wordsB": ["In", "Asia,", "routine", "urinalyses", "are", "performed", "for", "school", "children", "and", "renal", "biopsies", "for", "patients", "with", "asymptomatic", "hematuria,", "and", "the", "reported", "prevalence", "of", "the", "disease", "is", "much", "higher."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p39_s0", "idA": "1316175_17_item1_p52_s1", "sentA": "The large scale fermentation and the associated down-stream process validation activities for all three enzyme APIs are anticipated to be complete in late 2017 to early 2018.", "sentB": "We completed technology transfer for pharmaceutical ingredient ( API ) manufacturing and drug product manufacturing in 2016, and estimate that we will complete process validation for the fermentation and associated down-stream purification for all three enzyme APIs in 2019.", "type": 2, "words": ["<tag1>", "The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "process", "validation", "activities", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "in", "late", "2017", "to", "early", "2018.", "<tag2>", "We", "completed", "technology", "transfer", "for", "pharmaceutical", "ingredient", "(", "API", ")", "manufacturing", "and", "drug", "product", "manufacturing", "in", "2016,", "and", "estimate", "that", "we", "will", "complete", "process", "validation", "for", "the", "fermentation", "and", "associated", "down-stream", "purification", "for", "all", "three", "enzyme", "APIs", "in", "2019.", "<tag3>"], "wordsA": ["The", "large", "scale", "fermentation", "and", "the", "associated", "down-stream", "process", "validation", "activities", "for", "all", "three", "enzyme", "APIs", "are", "anticipated", "to", "be", "complete", "in", "late", "2017", "to", "early", "2018."], "wordsB": ["We", "completed", "technology", "transfer", "for", "pharmaceutical", "ingredient", "(", "API", ")", "manufacturing", "and", "drug", "product", "manufacturing", "in", "2016,", "and", "estimate", "that", "we", "will", "complete", "process", "validation", "for", "the", "fermentation", "and", "associated", "down-stream", "purification", "for", "all", "three", "enzyme", "APIs", "in", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p39_s1", "idA": "1316175_17_item1_p52_s2", "sentA": "In parallel, commercial scale capsule and sachet drug product manufacturing process validation is anticipated to be completed in late 2017 to early 2018.", "sentB": "In parallel, commercial scale capsule and sachet drug product manufacturing process validation is anticipated to be completed in 2019.", "type": 2, "words": ["<tag1>", "In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "drug", "product", "manufacturing", "process", "validation", "is", "anticipated", "to", "be", "completed", "in", "late", "2017", "to", "early", "2018.", "<tag2>", "In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "drug", "product", "manufacturing", "process", "validation", "is", "anticipated", "to", "be", "completed", "in", "2019.", "<tag3>"], "wordsA": ["In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "drug", "product", "manufacturing", "process", "validation", "is", "anticipated", "to", "be", "completed", "in", "late", "2017", "to", "early", "2018."], "wordsB": ["In", "parallel,", "commercial", "scale", "capsule", "and", "sachet", "drug", "product", "manufacturing", "process", "validation", "is", "anticipated", "to", "be", "completed", "in", "2019."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p40_s1", "idA": "1316175_17_item1_p54_s0", "sentA": "In 2013, our licensor, Eli Lilly, gained agreement from the FDA on the design of a Phase 3 clinical study (SOLUTION) that would provide adequate evaluation of efficacy and safety of Sollpura to respond to the FDA s 2011 complete response letter.", "sentB": "We believe that the design of RESULT provides adequate evaluation of efficacy and safety of Sollpura to respond to the FDA s 2011 complete response letter.", "type": 2, "words": ["<tag1>", "In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "clinical", "study", "(SOLUTION)", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "Sollpura", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter.", "<tag2>", "We", "believe", "that", "the", "design", "of", "RESULT", "provides", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "Sollpura", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter.", "<tag3>"], "wordsA": ["In", "2013,", "our", "licensor,", "Eli", "Lilly,", "gained", "agreement", "from", "the", "FDA", "on", "the", "design", "of", "a", "Phase", "3", "clinical", "study", "(SOLUTION)", "that", "would", "provide", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "Sollpura", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter."], "wordsB": ["We", "believe", "that", "the", "design", "of", "RESULT", "provides", "adequate", "evaluation", "of", "efficacy", "and", "safety", "of", "Sollpura", "to", "respond", "to", "the", "FDA", "s", "2011", "complete", "response", "letter."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p40_s0", "idA": "1316175_17_item1_p54_s4", "sentA": "The RESULT study should also address the 2005 EMA protocol assistance comments, which were consistent with the FDA s request for an active comparator trial.", "sentB": "The RESULT study protocol has been reviewed by the FDA prior to initiation.", "type": 2, "words": ["<tag1>", "The", "RESULT", "study", "should", "also", "address", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial.", "<tag2>", "The", "RESULT", "study", "protocol", "has", "been", "reviewed", "by", "the", "FDA", "prior", "to", "initiation.", "<tag3>"], "wordsA": ["The", "RESULT", "study", "should", "also", "address", "the", "2005", "EMA", "protocol", "assistance", "comments,", "which", "were", "consistent", "with", "the", "FDA", "s", "request", "for", "an", "active", "comparator", "trial."], "wordsB": ["The", "RESULT", "study", "protocol", "has", "been", "reviewed", "by", "the", "FDA", "prior", "to", "initiation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p41_s0", "idA": "1316175_17_item1_p55_s0", "sentA": "In September 2013, we met with the FDA who agreed to consider accepting proteinuria as an endpoint for Subpart E approval for blisibimod in IgA nephropathy.", "sentB": "In September 2013, we met with the FDA who agreed to consider accepting proteinuria as a surrogate endpoint under a Subpart E approval for blisibimod for treatment of IgA nephropathy.", "type": 2, "words": ["<tag1>", "In", "September", "2013,", "we", "met", "with", "the", "FDA", "who", "agreed", "to", "consider", "accepting", "proteinuria", "as", "an", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod", "in", "IgA", "nephropathy.", "<tag2>", "In", "September", "2013,", "we", "met", "with", "the", "FDA", "who", "agreed", "to", "consider", "accepting", "proteinuria", "as", "a", "surrogate", "endpoint", "under", "a", "Subpart", "E", "approval", "for", "blisibimod", "for", "treatment", "of", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["In", "September", "2013,", "we", "met", "with", "the", "FDA", "who", "agreed", "to", "consider", "accepting", "proteinuria", "as", "an", "endpoint", "for", "Subpart", "E", "approval", "for", "blisibimod", "in", "IgA", "nephropathy."], "wordsB": ["In", "September", "2013,", "we", "met", "with", "the", "FDA", "who", "agreed", "to", "consider", "accepting", "proteinuria", "as", "a", "surrogate", "endpoint", "under", "a", "Subpart", "E", "approval", "for", "blisibimod", "for", "treatment", "of", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p41_s2", "idA": "1316175_17_item1_p55_s2", "sentA": "In this meeting we gained the PMDA s agreement on the acceptability of proteinuria as the primary efficacy endpoint to support marketing approval in Japan and have amended the BRIGHT-SC study to include the specific data requirements of the PMDA.", "sentB": "In this meeting we gained the PMDA s agreement on the acceptability of proteinuria as the primary efficacy endpoint to support marketing approval in Japan.", "type": 2, "words": ["<tag1>", "In", "this", "meeting", "we", "gained", "the", "PMDA", "s", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "endpoint", "to", "support", "marketing", "approval", "in", "Japan", "and", "have", "amended", "the", "BRIGHT-SC", "study", "to", "include", "the", "specific", "data", "requirements", "of", "the", "PMDA.", "<tag2>", "In", "this", "meeting", "we", "gained", "the", "PMDA", "s", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "endpoint", "to", "support", "marketing", "approval", "in", "Japan.", "<tag3>"], "wordsA": ["In", "this", "meeting", "we", "gained", "the", "PMDA", "s", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "endpoint", "to", "support", "marketing", "approval", "in", "Japan", "and", "have", "amended", "the", "BRIGHT-SC", "study", "to", "include", "the", "specific", "data", "requirements", "of", "the", "PMDA."], "wordsB": ["In", "this", "meeting", "we", "gained", "the", "PMDA", "s", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "endpoint", "to", "support", "marketing", "approval", "in", "Japan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p41_s3", "idA": "1316175_17_item1_p55_s4", "sentA": "We reached an agreement with the EMA on the acceptability of proteinuria as the primary efficacy variable as well as the requirement for a single study to support a Conditional Marketing Authorization Application ( CMAA ) provided that confirmatory evidence from a second study, would be available post approval.", "sentB": "In December 2014 we met with the European Medicines Agency ( EMA ) as part of the scientific advice process for blisibimod, and reached agreement on the acceptability of proteinuria as the primary efficacy variable, as well as the sufficiency of a single study to support a Conditional Marketing Authorization Application ( CMAA ) provided that confirmatory evidence from a second study would be available post approval.", "type": 2, "words": ["<tag1>", "We", "reached", "an", "agreement", "with", "the", "EMA", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "variable", "as", "well", "as", "the", "requirement", "for", "a", "single", "study", "to", "support", "a", "Conditional", "Marketing", "Authorization", "Application", "(", "CMAA", ")", "provided", "that", "confirmatory", "evidence", "from", "a", "second", "study,", "would", "be", "available", "post", "approval.", "<tag2>", "In", "December", "2014", "we", "met", "with", "the", "European", "Medicines", "Agency", "(", "EMA", ")", "as", "part", "of", "the", "scientific", "advice", "process", "for", "blisibimod,", "and", "reached", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "variable,", "as", "well", "as", "the", "sufficiency", "of", "a", "single", "study", "to", "support", "a", "Conditional", "Marketing", "Authorization", "Application", "(", "CMAA", ")", "provided", "that", "confirmatory", "evidence", "from", "a", "second", "study", "would", "be", "available", "post", "approval.", "<tag3>"], "wordsA": ["We", "reached", "an", "agreement", "with", "the", "EMA", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "variable", "as", "well", "as", "the", "requirement", "for", "a", "single", "study", "to", "support", "a", "Conditional", "Marketing", "Authorization", "Application", "(", "CMAA", ")", "provided", "that", "confirmatory", "evidence", "from", "a", "second", "study,", "would", "be", "available", "post", "approval."], "wordsB": ["In", "December", "2014", "we", "met", "with", "the", "European", "Medicines", "Agency", "(", "EMA", ")", "as", "part", "of", "the", "scientific", "advice", "process", "for", "blisibimod,", "and", "reached", "agreement", "on", "the", "acceptability", "of", "proteinuria", "as", "the", "primary", "efficacy", "variable,", "as", "well", "as", "the", "sufficiency", "of", "a", "single", "study", "to", "support", "a", "Conditional", "Marketing", "Authorization", "Application", "(", "CMAA", ")", "provided", "that", "confirmatory", "evidence", "from", "a", "second", "study", "would", "be", "available", "post", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p41_s4", "idA": "1316175_17_item1_p55_s5", "sentA": "The EMA also recommended the protocol to provide information on the required duration of treatment, duration of response and need for re-treatment.", "sentB": "The EMA also recommended that the protocol provide information on the required duration of treatment, duration of response and need for re-treatment.", "type": 2, "words": ["<tag1>", "The", "EMA", "also", "recommended", "the", "protocol", "to", "provide", "information", "on", "the", "required", "duration", "of", "treatment,", "duration", "of", "response", "and", "need", "for", "re-treatment.", "<tag2>", "The", "EMA", "also", "recommended", "that", "the", "protocol", "provide", "information", "on", "the", "required", "duration", "of", "treatment,", "duration", "of", "response", "and", "need", "for", "re-treatment.", "<tag3>"], "wordsA": ["The", "EMA", "also", "recommended", "the", "protocol", "to", "provide", "information", "on", "the", "required", "duration", "of", "treatment,", "duration", "of", "response", "and", "need", "for", "re-treatment."], "wordsB": ["The", "EMA", "also", "recommended", "that", "the", "protocol", "provide", "information", "on", "the", "required", "duration", "of", "treatment,", "duration", "of", "response", "and", "need", "for", "re-treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p33_s6", "idA": "1316175_17_item1_p56_s1", "sentA": "As a result of the proteinuria effect after 48 weeks of dosing, and the demonstration of blisibimod s effect on immunological markers relevant to IgA nephropathy including reductions of B cells, and immunoglobulins including IgA, IgG and IgM, we plan to continue the study until the majority of subjects have had the opportunity to complete two years of treatment.", "sentB": "In August 2017, we reported top line data from the completed extension of the BRIGHT-SC study in which all patients had the opportunity to complete at least 60 weeks of treatment and some patients were treated for up to two years.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "the", "proteinuria", "effect", "after", "48", "weeks", "of", "dosing,", "and", "the", "demonstration", "of", "blisibimod", "s", "effect", "on", "immunological", "markers", "relevant", "to", "IgA", "nephropathy", "including", "reductions", "of", "B", "cells,", "and", "immunoglobulins", "including", "IgA,", "IgG", "and", "IgM,", "we", "plan", "to", "continue", "the", "study", "until", "the", "majority", "of", "subjects", "have", "had", "the", "opportunity", "to", "complete", "two", "years", "of", "treatment.", "<tag2>", "In", "August", "2017,", "we", "reported", "top", "line", "data", "from", "the", "completed", "extension", "of", "the", "BRIGHT-SC", "study", "in", "which", "all", "patients", "had", "the", "opportunity", "to", "complete", "at", "least", "60", "weeks", "of", "treatment", "and", "some", "patients", "were", "treated", "for", "up", "to", "two", "years.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "the", "proteinuria", "effect", "after", "48", "weeks", "of", "dosing,", "and", "the", "demonstration", "of", "blisibimod", "s", "effect", "on", "immunological", "markers", "relevant", "to", "IgA", "nephropathy", "including", "reductions", "of", "B", "cells,", "and", "immunoglobulins", "including", "IgA,", "IgG", "and", "IgM,", "we", "plan", "to", "continue", "the", "study", "until", "the", "majority", "of", "subjects", "have", "had", "the", "opportunity", "to", "complete", "two", "years", "of", "treatment."], "wordsB": ["In", "August", "2017,", "we", "reported", "top", "line", "data", "from", "the", "completed", "extension", "of", "the", "BRIGHT-SC", "study", "in", "which", "all", "patients", "had", "the", "opportunity", "to", "complete", "at", "least", "60", "weeks", "of", "treatment", "and", "some", "patients", "were", "treated", "for", "up", "to", "two", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p45_s1", "idA": "1316175_17_item1_p59_s1", "sentA": "In this study, greater improvements in nutrients absorption, as measured using the percent change from baseline in the coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA), were observed at doses of 500 lipase U per kg per meal and higher.", "sentB": "In this study, greater improvements in nutrients absorption, as measured using the percent change from baseline in the coefficient of fat absorption (CFA) and CNA, were observed at doses of 500 lipase U per kg per meal and higher.", "type": 2, "words": ["<tag1>", "In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "lipase", "U", "per", "kg", "per", "meal", "and", "higher.", "<tag2>", "In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "CNA,", "were", "observed", "at", "doses", "of", "500", "lipase", "U", "per", "kg", "per", "meal", "and", "higher.", "<tag3>"], "wordsA": ["In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "coefficient", "of", "nitrogen", "absorption", "(CNA),", "were", "observed", "at", "doses", "of", "500", "lipase", "U", "per", "kg", "per", "meal", "and", "higher."], "wordsB": ["In", "this", "study,", "greater", "improvements", "in", "nutrients", "absorption,", "as", "measured", "using", "the", "percent", "change", "from", "baseline", "in", "the", "coefficient", "of", "fat", "absorption", "(CFA)", "and", "CNA,", "were", "observed", "at", "doses", "of", "500", "lipase", "U", "per", "kg", "per", "meal", "and", "higher."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p46_s0", "idA": "1316175_17_item1_p60_s0", "sentA": "Study TC-2A, a Phase 2, randomized, double-blind, parallel group, dose-finding trial, was conducted in 125 pediatric and adult subjects with CF-related EPI who were treated with Sollpura in one of three dosing regimens containing 6,500 U, 32,500 U, and 130,000 U lipase administered per meal or snack.", "sentB": "Study TC-2A, a Phase 2, randomized, double-blind, parallel group, dose-finding trial, was conducted in 125 pediatric and adult subjects with CF-related EPI who were treated with Sollpura for 28 days in one of three dosing regimens containing 6,500 U, 32,500 U, and 130,000 U lipase administered per meal or snack.", "type": 2, "words": ["<tag1>", "Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "Sollpura", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack.", "<tag2>", "Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "Sollpura", "for", "28", "days", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack.", "<tag3>"], "wordsA": ["Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "Sollpura", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack."], "wordsB": ["Study", "TC-2A,", "a", "Phase", "2,", "randomized,", "double-blind,", "parallel", "group,", "dose-finding", "trial,", "was", "conducted", "in", "125", "pediatric", "and", "adult", "subjects", "with", "CF-related", "EPI", "who", "were", "treated", "with", "Sollpura", "for", "28", "days", "in", "one", "of", "three", "dosing", "regimens", "containing", "6,500", "U,", "32,500", "U,", "and", "130,000", "U", "lipase", "administered", "per", "meal", "or", "snack."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p46_s1", "idA": "1316175_17_item1_p60_s1", "sentA": "Observed mean CFAs at the end of study were 56.2%, 67.0%, and 69.7% in the 6,500, 32,500, and 130,000 U dose groups, respectively (one-way ANOVA p = 0.0032) with significant improvements in mean changes from baseline (one-way ANOVA p = 0.0005).", "sentB": "Observed mean CFAs at the end of study were 56.2%, 67.0%, and 69.7% in the 6,500, 32,500, and 130,000 U dose groups, respectively (one-way ANOVA p = 0.0032) with significant improvements in mean changes from baseline (one-way ANOVA p = 0.0005) and mean changes from baseline off-enzyme CFA to on treatment were 1.2%, 11.4% and 17.3%, respectively (1-way ANOVA p=0.0005).", "type": 2, "words": ["<tag1>", "Observed", "mean", "CFAs", "at", "the", "end", "of", "study", "were", "56.2%,", "67.0%,", "and", "69.7%", "in", "the", "6,500,", "32,500,", "and", "130,000", "U", "dose", "groups,", "respectively", "(one-way", "ANOVA", "p", "=", "0.0032)", "with", "significant", "improvements", "in", "mean", "changes", "from", "baseline", "(one-way", "ANOVA", "p", "=", "0.0005).", "<tag2>", "Observed", "mean", "CFAs", "at", "the", "end", "of", "study", "were", "56.2%,", "67.0%,", "and", "69.7%", "in", "the", "6,500,", "32,500,", "and", "130,000", "U", "dose", "groups,", "respectively", "(one-way", "ANOVA", "p", "=", "0.0032)", "with", "significant", "improvements", "in", "mean", "changes", "from", "baseline", "(one-way", "ANOVA", "p", "=", "0.0005)", "and", "mean", "changes", "from", "baseline", "off-enzyme", "CFA", "to", "on", "treatment", "were", "1.2%,", "11.4%", "and", "17.3%,", "respectively", "(1-way", "ANOVA", "p=0.0005).", "<tag3>"], "wordsA": ["Observed", "mean", "CFAs", "at", "the", "end", "of", "study", "were", "56.2%,", "67.0%,", "and", "69.7%", "in", "the", "6,500,", "32,500,", "and", "130,000", "U", "dose", "groups,", "respectively", "(one-way", "ANOVA", "p", "=", "0.0032)", "with", "significant", "improvements", "in", "mean", "changes", "from", "baseline", "(one-way", "ANOVA", "p", "=", "0.0005)."], "wordsB": ["Observed", "mean", "CFAs", "at", "the", "end", "of", "study", "were", "56.2%,", "67.0%,", "and", "69.7%", "in", "the", "6,500,", "32,500,", "and", "130,000", "U", "dose", "groups,", "respectively", "(one-way", "ANOVA", "p", "=", "0.0032)", "with", "significant", "improvements", "in", "mean", "changes", "from", "baseline", "(one-way", "ANOVA", "p", "=", "0.0005)", "and", "mean", "changes", "from", "baseline", "off-enzyme", "CFA", "to", "on", "treatment", "were", "1.2%,", "11.4%", "and", "17.3%,", "respectively", "(1-way", "ANOVA", "p=0.0005)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p55_s0", "idA": "1316175_17_item1_p63_s3", "sentA": "Both studies failed to meet the primary endpoints and we elected to stop further development of blisibimod for the treatment of lupus.", "sentB": "We have received orphan drug designation for blisibimod for the treatment of IgA nephropathy.", "type": 2, "words": ["<tag1>", "Both", "studies", "failed", "to", "meet", "the", "primary", "endpoints", "and", "we", "elected", "to", "stop", "further", "development", "of", "blisibimod", "for", "the", "treatment", "of", "lupus.", "<tag2>", "We", "have", "received", "orphan", "drug", "designation", "for", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy.", "<tag3>"], "wordsA": ["Both", "studies", "failed", "to", "meet", "the", "primary", "endpoints", "and", "we", "elected", "to", "stop", "further", "development", "of", "blisibimod", "for", "the", "treatment", "of", "lupus."], "wordsB": ["We", "have", "received", "orphan", "drug", "designation", "for", "blisibimod", "for", "the", "treatment", "of", "IgA", "nephropathy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p51_s1", "idA": "1316175_17_item1_p64_s3", "sentA": "Significant changes in SLE-relevant disease markers were observed with blisibimod, including reductions in urinary protein:creatinine ratio, peripheral B cell lineages, anti-dsDNA, anti-phospholipid antibodies, and serum immunoglobulins, and significant increases in complement C3 and C4.", "sentB": "In subjects with baseline urinary protein:creatinine ratio (UPCR) 0.5 g/g, significantly higher proportions of blisibimod subjects achieved 50% reduction in UPCR, and/or UPCR 0.5 g/g. Reductions in SLE autoantibodies and B cells, and increases in complement C3 and C4 were observed with blisibimod.", "type": 2, "words": ["<tag1>", "Significant", "changes", "in", "SLE-relevant", "disease", "markers", "were", "observed", "with", "blisibimod,", "including", "reductions", "in", "urinary", "protein:creatinine", "ratio,", "peripheral", "B", "cell", "lineages,", "anti-dsDNA,", "anti-phospholipid", "antibodies,", "and", "serum", "immunoglobulins,", "and", "significant", "increases", "in", "complement", "C3", "and", "C4.", "<tag2>", "In", "subjects", "with", "baseline", "urinary", "protein:creatinine", "ratio", "(UPCR)", "0.5", "g/g,", "significantly", "higher", "proportions", "of", "blisibimod", "subjects", "achieved", "50%", "reduction", "in", "UPCR,", "and/or", "UPCR", "0.5", "g/g.", "Reductions", "in", "SLE", "autoantibodies", "and", "B", "cells,", "and", "increases", "in", "complement", "C3", "and", "C4", "were", "observed", "with", "blisibimod.", "<tag3>"], "wordsA": ["Significant", "changes", "in", "SLE-relevant", "disease", "markers", "were", "observed", "with", "blisibimod,", "including", "reductions", "in", "urinary", "protein:creatinine", "ratio,", "peripheral", "B", "cell", "lineages,", "anti-dsDNA,", "anti-phospholipid", "antibodies,", "and", "serum", "immunoglobulins,", "and", "significant", "increases", "in", "complement", "C3", "and", "C4."], "wordsB": ["In", "subjects", "with", "baseline", "urinary", "protein:creatinine", "ratio", "(UPCR)", "0.5", "g/g,", "significantly", "higher", "proportions", "of", "blisibimod", "subjects", "achieved", "50%", "reduction", "in", "UPCR,", "and/or", "UPCR", "0.5", "g/g.", "Reductions", "in", "SLE", "autoantibodies", "and", "B", "cells,", "and", "increases", "in", "complement", "C3", "and", "C4", "were", "observed", "with", "blisibimod."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p51_s2", "idA": "1316175_17_item1_p64_s4", "sentA": "We believe the latter effects support the ongoing research with blisibimod into IgA nephropathy.", "sentB": "We believe that these data support the further research with blisibimod patients with B-cell associated glomerulonephritides including IgA nephropathy, lupus with renal manifestations, and membranous glomerulonephritis.", "type": 2, "words": ["<tag1>", "We", "believe", "the", "latter", "effects", "support", "the", "ongoing", "research", "with", "blisibimod", "into", "IgA", "nephropathy.", "<tag2>", "We", "believe", "that", "these", "data", "support", "the", "further", "research", "with", "blisibimod", "patients", "with", "B-cell", "associated", "glomerulonephritides", "including", "IgA", "nephropathy,", "lupus", "with", "renal", "manifestations,", "and", "membranous", "glomerulonephritis.", "<tag3>"], "wordsA": ["We", "believe", "the", "latter", "effects", "support", "the", "ongoing", "research", "with", "blisibimod", "into", "IgA", "nephropathy."], "wordsB": ["We", "believe", "that", "these", "data", "support", "the", "further", "research", "with", "blisibimod", "patients", "with", "B-cell", "associated", "glomerulonephritides", "including", "IgA", "nephropathy,", "lupus", "with", "renal", "manifestations,", "and", "membranous", "glomerulonephritis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p52_s0", "idA": "1316175_17_item1_p65_s0", "sentA": "Since our inception in 2004, we have focused primarily on developing our product candidates, which currently include Sollpura and blisibimod.", "sentB": "Since our inception in 2004, we have focused primarily on developing our product candidates, which currently include Sollpura for EPI and blisibimod for IgA nephropathy and potentially other glomerulonephritides.", "type": 2, "words": ["<tag1>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "Sollpura", "and", "blisibimod.", "<tag2>", "Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "Sollpura", "for", "EPI", "and", "blisibimod", "for", "IgA", "nephropathy", "and", "potentially", "other", "glomerulonephritides.", "<tag3>"], "wordsA": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "Sollpura", "and", "blisibimod."], "wordsB": ["Since", "our", "inception", "in", "2004,", "we", "have", "focused", "primarily", "on", "developing", "our", "product", "candidates,", "which", "currently", "include", "Sollpura", "for", "EPI", "and", "blisibimod", "for", "IgA", "nephropathy", "and", "potentially", "other", "glomerulonephritides."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p52_s1", "idA": "1316175_17_item1_p65_s2", "sentA": "In the years ended December 31, 2016, 2015 and 2014, we incurred $46.5 million, $33.6 million and $21.8 million, respectively, of research and development expense.", "sentB": "In the years ended December 31, 2017, 2016, and 2015, we incurred $28.6 million, $46.5 million and $33.5 million, respectively, of research and development expense.", "type": 2, "words": ["<tag1>", "In", "the", "years", "ended", "December", "31,", "2016,", "2015", "and", "2014,", "we", "incurred", "$46.5", "million,", "$33.6", "million", "and", "$21.8", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag2>", "In", "the", "years", "ended", "December", "31,", "2017,", "2016,", "and", "2015,", "we", "incurred", "$28.6", "million,", "$46.5", "million", "and", "$33.5", "million,", "respectively,", "of", "research", "and", "development", "expense.", "<tag3>"], "wordsA": ["In", "the", "years", "ended", "December", "31,", "2016,", "2015", "and", "2014,", "we", "incurred", "$46.5", "million,", "$33.6", "million", "and", "$21.8", "million,", "respectively,", "of", "research", "and", "development", "expense."], "wordsB": ["In", "the", "years", "ended", "December", "31,", "2017,", "2016,", "and", "2015,", "we", "incurred", "$28.6", "million,", "$46.5", "million", "and", "$33.5", "million,", "respectively,", "of", "research", "and", "development", "expense."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p15_s0", "idA": "1316175_17_item1_p67_s0", "sentA": "We are advancing the development of Sollpura in a Phase 3 registration program in patients with cystic fibrosis-related EPI.", "sentB": "We initiated a Phase 3 study of Sollpura (\"RESULT\") in patients with EPI due to cystic fibrosis in May 2017.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "Sollpura", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI.", "<tag2>", "We", "initiated", "a", "Phase", "3", "study", "of", "Sollpura", "(\"RESULT\")", "in", "patients", "with", "EPI", "due", "to", "cystic", "fibrosis", "in", "May", "2017.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "Sollpura", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI."], "wordsB": ["We", "initiated", "a", "Phase", "3", "study", "of", "Sollpura", "(\"RESULT\")", "in", "patients", "with", "EPI", "due", "to", "cystic", "fibrosis", "in", "May", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p20_s0", "idA": "1316175_17_item1_p67_s0", "sentA": "We are advancing the development of Sollpura in a Phase 3 registration program in patients with cystic fibrosis-related EPI.", "sentB": "Lastly, prior to the RESULT study, we conducted another Phase 3 study ( SOLUTION ) in patients with EPI.", "type": 2, "words": ["<tag1>", "We", "are", "advancing", "the", "development", "of", "Sollpura", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI.", "<tag2>", "Lastly,", "prior", "to", "the", "RESULT", "study,", "we", "conducted", "another", "Phase", "3", "study", "(", "SOLUTION", ")", "in", "patients", "with", "EPI.", "<tag3>"], "wordsA": ["We", "are", "advancing", "the", "development", "of", "Sollpura", "in", "a", "Phase", "3", "registration", "program", "in", "patients", "with", "cystic", "fibrosis-related", "EPI."], "wordsB": ["Lastly,", "prior", "to", "the", "RESULT", "study,", "we", "conducted", "another", "Phase", "3", "study", "(", "SOLUTION", ")", "in", "patients", "with", "EPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p54_s1", "idA": "1316175_17_item1_p67_s2", "sentA": "We may opportunistically enter into collaborations with third parties for development of Sollpura and blisibimod, including securing corporate partners whose capabilities complement ours.", "sentB": "If our Phase 3 clinical study is successful, we intend to commercialize Sollpura in the U.S. and seek strategic corporate partners whose capabilities complement ours to launch Sollpura outside of U.S.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "Sollpura", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "If", "our", "Phase", "3", "clinical", "study", "is", "successful,", "we", "intend", "to", "commercialize", "Sollpura", "in", "the", "U.S.", "and", "seek", "strategic", "corporate", "partners", "whose", "capabilities", "complement", "ours", "to", "launch", "Sollpura", "outside", "of", "U.S.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "Sollpura", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["If", "our", "Phase", "3", "clinical", "study", "is", "successful,", "we", "intend", "to", "commercialize", "Sollpura", "in", "the", "U.S.", "and", "seek", "strategic", "corporate", "partners", "whose", "capabilities", "complement", "ours", "to", "launch", "Sollpura", "outside", "of", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p55_s1", "idA": "1316175_17_item1_p67_s2", "sentA": "We may opportunistically enter into collaborations with third parties for development of Sollpura and blisibimod, including securing corporate partners whose capabilities complement ours.", "sentB": "We plan to opportunistically enter into collaborations with third parties for the development of blisibimod in renal disease and other B-cell associated glomerulonephritides.", "type": 2, "words": ["<tag1>", "We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "Sollpura", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours.", "<tag2>", "We", "plan", "to", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "the", "development", "of", "blisibimod", "in", "renal", "disease", "and", "other", "B-cell", "associated", "glomerulonephritides.", "<tag3>"], "wordsA": ["We", "may", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "development", "of", "Sollpura", "and", "blisibimod,", "including", "securing", "corporate", "partners", "whose", "capabilities", "complement", "ours."], "wordsB": ["We", "plan", "to", "opportunistically", "enter", "into", "collaborations", "with", "third", "parties", "for", "the", "development", "of", "blisibimod", "in", "renal", "disease", "and", "other", "B-cell", "associated", "glomerulonephritides."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p162_s0", "idA": "1316175_17_item1_p69_s0", "sentA": "Our industry is highly competitive and subject to rapid and significant technological change.", "sentB": "The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations.", "type": 2, "words": ["<tag1>", "Our", "industry", "is", "highly", "competitive", "and", "subject", "to", "rapid", "and", "significant", "technological", "change.", "<tag2>", "The", "scope", "and", "enforcement", "of", "each", "of", "these", "laws", "is", "uncertain", "and", "subject", "to", "rapid", "change", "in", "the", "current", "environment", "of", "healthcare", "reform,", "especially", "in", "light", "of", "the", "lack", "of", "applicable", "precedent", "and", "regulations.", "<tag3>"], "wordsA": ["Our", "industry", "is", "highly", "competitive", "and", "subject", "to", "rapid", "and", "significant", "technological", "change."], "wordsB": ["The", "scope", "and", "enforcement", "of", "each", "of", "these", "laws", "is", "uncertain", "and", "subject", "to", "rapid", "change", "in", "the", "current", "environment", "of", "healthcare", "reform,", "especially", "in", "light", "of", "the", "lack", "of", "applicable", "precedent", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p57_s2", "idA": "1316175_17_item1_p69_s2", "sentA": "Our primary competitors are described in further detail below, under Approved Categories of Drugs .", "sentB": "Our primary competitors who market PERTs approved in the U.S. or are developing PERTs in the U.S. are described in further detail below.", "type": 2, "words": ["<tag1>", "Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", ".", "<tag2>", "Our", "primary", "competitors", "who", "market", "PERTs", "approved", "in", "the", "U.S.", "or", "are", "developing", "PERTs", "in", "the", "U.S.", "are", "described", "in", "further", "detail", "below.", "<tag3>"], "wordsA": ["Our", "primary", "competitors", "are", "described", "in", "further", "detail", "below,", "under", "Approved", "Categories", "of", "Drugs", "."], "wordsB": ["Our", "primary", "competitors", "who", "market", "PERTs", "approved", "in", "the", "U.S.", "or", "are", "developing", "PERTs", "in", "the", "U.S.", "are", "described", "in", "further", "detail", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p5_s0", "idA": "1316175_17_item1_p6_s0", "sentA": "EPI occurs when diseases such as CF and chronic pancreatitis impede or destroy the exocrine function of the pancreas.", "sentB": "EPI occurs when diseases such as cystic fibrosis ( CF ) and chronic pancreatitis ( CP ) impede or destroy the exocrine function of the pancreas.", "type": 2, "words": ["<tag1>", "EPI", "occurs", "when", "diseases", "such", "as", "CF", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas.", "<tag2>", "EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis", "(", "CF", ")", "and", "chronic", "pancreatitis", "(", "CP", ")", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas.", "<tag3>"], "wordsA": ["EPI", "occurs", "when", "diseases", "such", "as", "CF", "and", "chronic", "pancreatitis", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas."], "wordsB": ["EPI", "occurs", "when", "diseases", "such", "as", "cystic", "fibrosis", "(", "CF", ")", "and", "chronic", "pancreatitis", "(", "CP", ")", "impede", "or", "destroy", "the", "exocrine", "function", "of", "the", "pancreas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p152_s1", "idA": "1316175_17_item1_p73_s1", "sentA": "We also rely on trade secrets that may be important to the development of our business.", "sentB": "In addition, we may be subject to health information privacy and security regulation by U.S. federal and state governments and foreign jurisdictions in which we conduct our business.", "type": 2, "words": ["<tag1>", "We", "also", "rely", "on", "trade", "secrets", "that", "may", "be", "important", "to", "the", "development", "of", "our", "business.", "<tag2>", "In", "addition,", "we", "may", "be", "subject", "to", "health", "information", "privacy", "and", "security", "regulation", "by", "U.S.", "federal", "and", "state", "governments", "and", "foreign", "jurisdictions", "in", "which", "we", "conduct", "our", "business.", "<tag3>"], "wordsA": ["We", "also", "rely", "on", "trade", "secrets", "that", "may", "be", "important", "to", "the", "development", "of", "our", "business."], "wordsB": ["In", "addition,", "we", "may", "be", "subject", "to", "health", "information", "privacy", "and", "security", "regulation", "by", "U.S.", "federal", "and", "state", "governments", "and", "foreign", "jurisdictions", "in", "which", "we", "conduct", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p62_s0", "idA": "1316175_17_item1_p77_s0", "sentA": "Three pending non-EP foreign patent application.", "sentB": "One pending non-EP foreign patent application.", "type": 2, "words": ["<tag1>", "Three", "pending", "non-EP", "foreign", "patent", "application.", "<tag2>", "One", "pending", "non-EP", "foreign", "patent", "application.", "<tag3>"], "wordsA": ["Three", "pending", "non-EP", "foreign", "patent", "application."], "wordsB": ["One", "pending", "non-EP", "foreign", "patent", "application."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p63_s6", "idA": "1316175_17_item1_p78_s6", "sentA": "The three exclusively licensed EP patents are currently scheduled to expire between February 2021 and October 2025.", "sentB": "The four exclusively licensed EP patents are currently scheduled to expire between February 2021 and October 2025.", "type": 2, "words": ["<tag1>", "The", "three", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "between", "February", "2021", "and", "October", "2025.", "<tag2>", "The", "four", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "between", "February", "2021", "and", "October", "2025.", "<tag3>"], "wordsA": ["The", "three", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "between", "February", "2021", "and", "October", "2025."], "wordsB": ["The", "four", "exclusively", "licensed", "EP", "patents", "are", "currently", "scheduled", "to", "expire", "between", "February", "2021", "and", "October", "2025."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p6_s0", "idA": "1316175_17_item1_p7_s0", "sentA": "A reduction in, or absence of the normally secreted pancreatic digestive enzymes, causes lipids, proteins, and carbohydrates to enter the distal gastrointestinal ( GI ) tract in un-absorbable forms, leading to GI pain and distention, mal-digestion, and steatorrhea.", "sentB": "A reduction in, or absence of, the normally secreted pancreatic digestive enzymes causes lipids, proteins, and carbohydrates to enter the distal gastrointestinal ( GI ) tract in un-absorbable forms, leading to GI pain and distention, mal-digestion, and steatorrhea.", "type": 2, "words": ["<tag1>", "A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "un-absorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "mal-digestion,", "and", "steatorrhea.", "<tag2>", "A", "reduction", "in,", "or", "absence", "of,", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "un-absorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "mal-digestion,", "and", "steatorrhea.", "<tag3>"], "wordsA": ["A", "reduction", "in,", "or", "absence", "of", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes,", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "un-absorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "mal-digestion,", "and", "steatorrhea."], "wordsB": ["A", "reduction", "in,", "or", "absence", "of,", "the", "normally", "secreted", "pancreatic", "digestive", "enzymes", "causes", "lipids,", "proteins,", "and", "carbohydrates", "to", "enter", "the", "distal", "gastrointestinal", "(", "GI", ")", "tract", "in", "un-absorbable", "forms,", "leading", "to", "GI", "pain", "and", "distention,", "mal-digestion,", "and", "steatorrhea."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p141_s0", "idA": "1316175_17_item1_p85_s1", "sentA": "Provisional applications are often used, among other things, to establish an early filing date for a subsequent non-provisional patent application.", "sentB": "The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress.", "type": 2, "words": ["<tag1>", "Provisional", "applications", "are", "often", "used,", "among", "other", "things,", "to", "establish", "an", "early", "filing", "date", "for", "a", "subsequent", "non-provisional", "patent", "application.", "<tag2>", "The", "Budget", "Control", "Act", "of", "2011,", "among", "other", "things,", "created", "measures", "for", "spending", "reductions", "by", "Congress.", "<tag3>"], "wordsA": ["Provisional", "applications", "are", "often", "used,", "among", "other", "things,", "to", "establish", "an", "early", "filing", "date", "for", "a", "subsequent", "non-provisional", "patent", "application."], "wordsB": ["The", "Budget", "Control", "Act", "of", "2011,", "among", "other", "things,", "created", "measures", "for", "spending", "reductions", "by", "Congress."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p75_s1", "idA": "1316175_17_item1_p91_s1", "sentA": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon commencement of the first Phase 3 clinical study for any blisibimod formulation in the United States, European Union or Japan.", "sentB": "In addition, we are required to make various milestone payments upon the achievement of certain development, regulatory and commercial objectives, including payment upon commencement of the first Phase 3 clinical study for any blisibimod formulation in the United States or European Union.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan.", "<tag2>", "In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States", "or", "European", "Union.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States,", "European", "Union", "or", "Japan."], "wordsB": ["In", "addition,", "we", "are", "required", "to", "make", "various", "milestone", "payments", "upon", "the", "achievement", "of", "certain", "development,", "regulatory", "and", "commercial", "objectives,", "including", "payment", "upon", "commencement", "of", "the", "first", "Phase", "3", "clinical", "study", "for", "any", "blisibimod", "formulation", "in", "the", "United", "States", "or", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p141_s2", "idA": "1316175_17_item1_p92_s0", "sentA": "The Amgen Agreement will remain in effect until we elect to terminate, or until termination for material breach by either party or insolvency on our part.", "sentB": "These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2025 unless additional Congressional action is taken.", "type": 2, "words": ["<tag1>", "The", "Amgen", "Agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part.", "<tag2>", "These", "changes", "included", "aggregate", "reductions", "to", "Medicare", "payments", "to", "providers", "of", "up", "to", "2%", "per", "fiscal", "year,", "which", "went", "into", "effect", "in", "April", "2013", "and", "will", "remain", "in", "effect", "through", "2025", "unless", "additional", "Congressional", "action", "is", "taken.", "<tag3>"], "wordsA": ["The", "Amgen", "Agreement", "will", "remain", "in", "effect", "until", "we", "elect", "to", "terminate,", "or", "until", "termination", "for", "material", "breach", "by", "either", "party", "or", "insolvency", "on", "our", "part."], "wordsB": ["These", "changes", "included", "aggregate", "reductions", "to", "Medicare", "payments", "to", "providers", "of", "up", "to", "2%", "per", "fiscal", "year,", "which", "went", "into", "effect", "in", "April", "2013", "and", "will", "remain", "in", "effect", "through", "2025", "unless", "additional", "Congressional", "action", "is", "taken."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p77_s0", "idA": "1316175_17_item1_p93_s0", "sentA": "In connection with a collaborative arrangement with Zenyaku for the development of IgA nephropathy that was executed in December 2014 and terminated in January 2016, we amended the Amgen Agreement in November 2014 to (i) adjust certain royalty and milestone payment obligations payable to Amgen in light of our collaboration with Zenyaku and (ii) provide that the sublicense granted by us to Zenyaku shall survive the termination of the Amgen Agreement.", "sentB": "In connection with a collaborative arrangement with Zenyaku Kogyo Co., Ltd ( Zenyaku ) for the development of IgA nephropathy that was executed in December 2014 and terminated in January 2016, we amended the Amgen Agreement in November 2014 to (i) adjust certain royalty and milestone payment obligations payable to Amgen in light of our collaboration with Zenyaku and (ii) provide that the sublicense granted by us to Zenyaku shall survive the termination of the Amgen Agreement.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "a", "collaborative", "arrangement", "with", "Zenyaku", "for", "the", "development", "of", "IgA", "nephropathy", "that", "was", "executed", "in", "December", "2014", "and", "terminated", "in", "January", "2016,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement.", "<tag2>", "In", "connection", "with", "a", "collaborative", "arrangement", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd", "(", "Zenyaku", ")", "for", "the", "development", "of", "IgA", "nephropathy", "that", "was", "executed", "in", "December", "2014", "and", "terminated", "in", "January", "2016,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement.", "<tag3>"], "wordsA": ["In", "connection", "with", "a", "collaborative", "arrangement", "with", "Zenyaku", "for", "the", "development", "of", "IgA", "nephropathy", "that", "was", "executed", "in", "December", "2014", "and", "terminated", "in", "January", "2016,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement."], "wordsB": ["In", "connection", "with", "a", "collaborative", "arrangement", "with", "Zenyaku", "Kogyo", "Co.,", "Ltd", "(", "Zenyaku", ")", "for", "the", "development", "of", "IgA", "nephropathy", "that", "was", "executed", "in", "December", "2014", "and", "terminated", "in", "January", "2016,", "we", "amended", "the", "Amgen", "Agreement", "in", "November", "2014", "to", "(i)", "adjust", "certain", "royalty", "and", "milestone", "payment", "obligations", "payable", "to", "Amgen", "in", "light", "of", "our", "collaboration", "with", "Zenyaku", "and", "(ii)", "provide", "that", "the", "sublicense", "granted", "by", "us", "to", "Zenyaku", "shall", "survive", "the", "termination", "of", "the", "Amgen", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p157_s0", "idA": "1316175_17_item1_p98_s1", "sentA": "Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials.", "sentB": "Our future marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our product and any future product candidates, are subject to scrutiny under this law.", "type": 2, "words": ["<tag1>", "Accordingly,", "we", "are", "subject", "to", "federal,", "state", "and", "local", "laws", "governing", "the", "use,", "handling", "and", "disposal", "of", "these", "materials.", "<tag2>", "Our", "future", "marketing", "and", "activities", "relating", "to", "the", "reporting", "of", "wholesaler", "or", "estimated", "retail", "prices", "for", "our", "products,", "the", "reporting", "of", "prices", "used", "to", "calculate", "Medicaid", "rebate", "information", "and", "other", "information", "affecting", "federal,", "state", "and", "third-party", "reimbursement", "for", "our", "products,", "and", "the", "sale", "and", "marketing", "of", "our", "product", "and", "any", "future", "product", "candidates,", "are", "subject", "to", "scrutiny", "under", "this", "law.", "<tag3>"], "wordsA": ["Accordingly,", "we", "are", "subject", "to", "federal,", "state", "and", "local", "laws", "governing", "the", "use,", "handling", "and", "disposal", "of", "these", "materials."], "wordsB": ["Our", "future", "marketing", "and", "activities", "relating", "to", "the", "reporting", "of", "wholesaler", "or", "estimated", "retail", "prices", "for", "our", "products,", "the", "reporting", "of", "prices", "used", "to", "calculate", "Medicaid", "rebate", "information", "and", "other", "information", "affecting", "federal,", "state", "and", "third-party", "reimbursement", "for", "our", "products,", "and", "the", "sale", "and", "marketing", "of", "our", "product", "and", "any", "future", "product", "candidates,", "are", "subject", "to", "scrutiny", "under", "this", "law."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1316175_18_item1_p81_s2", "idA": "1316175_17_item1_p99_s2", "sentA": "In order to commercialize our product candidates, we must develop these capabilities internally or through collaboration with third parties.", "sentB": "In order to commercialize our product candidates, we plan to develop these capabilities internally or through collaboration with third parties.", "type": 2, "words": ["<tag1>", "In", "order", "to", "commercialize", "our", "product", "candidates,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties.", "<tag2>", "In", "order", "to", "commercialize", "our", "product", "candidates,", "we", "plan", "to", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties.", "<tag3>"], "wordsA": ["In", "order", "to", "commercialize", "our", "product", "candidates,", "we", "must", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties."], "wordsB": ["In", "order", "to", "commercialize", "our", "product", "candidates,", "we", "plan", "to", "develop", "these", "capabilities", "internally", "or", "through", "collaboration", "with", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
